metformin has been researched along with Insulin Sensitivity in 1550 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The rationale for adding metformin in these cases is that it can reduce insulin resistance." | 10.19 | [Combination treatment with insulin and metformin in type 2 diabetes. Improves glycemic control and prevents weight gain]. ( Hermann, LS; Melander, A, 1999) |
| "Short-term combined treatment with beinaglutide and metformin appears superior to metformin monotherapy in lowering body weight, BMI, WC,WHtR and improving insulin sensitivity and androgen excess in women with PCOS and obesity, with tolerable adverse events." | 9.69 | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. ( Chen, Q; Chen, Y; Fang, S; Liang, Y; Tian, Y; Wen, Q; Yuan, J, 2023) |
| "To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI)." | 9.51 | The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. ( Bjekić-Macut, J; Livadas, S; Macut, D; Malešević, G; Mastorakos, G; Micić, D; Ognjanović, S; Popović-Pejičić, S; Prtina, A; Soldat-Stanković, V; Stanković, S, 2022) |
| "To determine the safety and efficacy of canagliflozin in comparison to metformin in polycystic ovary syndrome (PCOS) patients with insulin resistance (IR)." | 9.51 | Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial. ( Cai, M; Dilimulati, D; Gao, X; Qu, S; Shao, X; Xing, F; Zeng, Q; Zhang, M; Zhang, Y, 2022) |
| "The antidiabetic medication metformin has been proposed to be the first drug tested to target aging and extend healthspan in humans." | 9.51 | Antecedent Metabolic Health and Metformin (ANTHEM) Aging Study: Rationale and Study Design for a Randomized Controlled Trial. ( Bubak, MT; Davidyan, A; Elliehausen, CJ; Karaman, R; Konopka, AR; Kuhn, KG; Kumari, S; Miller, BF; Schoenberg, HM; Scofield, RH; VanWagoner, TM, 2022) |
| "Among men with obesity and low testosterone concentrations, the combination of metformin plus testosterone, metformin only, and testosterone only, compared to placebo, reduced insulin resistance with no evidence of additive benefit." | 9.51 | Metformin, testosterone, or both in men with obesity and low testosterone: A double-blind, parallel-group, randomized controlled trial. ( Asenjo-Plaza, M; Barrios-Rodríguez, R; Fernández-García, JC; Guzmán-Guzmán, A; Jiménez-Moleón, JJ; Martínez-González, MÁ; Molina-Vega, M; Moreno-León, L; Ramos-Molina, B; Rius-Díaz, F; Tinahones, FJ; Valdés, S; Yubero-Serrano, EM, 2022) |
| " This randomized controlled trial compared the efficacy and safety of CANA and metformin (MET) combination therapy and MET monotherapy in endocrine and metabolic profiles of overweight and obese women with polycystic ovary syndrome (PCOS)." | 9.51 | Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. ( Cheng, X; He, B; Xing, C; Zhang, J, 2022) |
| "Available evidence has shown that metformin improves insulin sensitivity and weight management in polycystic ovary syndrome (PCOS)." | 9.41 | The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Alesi, S; Forslund, M; Melin, J; Mousa, A; Pena, A; Piltonen, T; Romualdi, D; Spritzer, PM; Tay, CT; Teede, H; Witchel, SF, 2023) |
| "This is the first meta-analysis of the available literature about the efficacy of metformin exclusively in pediatric patients with non-alcoholic fatty liver disease (NAFLD)." | 9.41 | The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. ( Cheirakis, K; Christakopoulos, A; Fotoulaki, M; Gkiourtzis, N; Glava, A; Michou, P; Moutafi, M; Vouksinou, E, 2023) |
| "The glucose-lowering drug metformin has recently been shown to reduce myocardial oxygen consumption and increase myocardial efficiency in chronic heart failure (HF) patients without diabetes." | 9.41 | Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study. ( Brøsen, K; Bøtker, HE; Dollerup, OL; Frøkiær, J; Hansson, NH; Jespersen, NR; Jessen, N; Larsen, AH; Møller, N; Nørrelund, H; Wiggers, H, 2021) |
| " Adolescents (aged 12-18 years) with obesity, insulin resistance (IR), and a family history of type 2 diabetes mellitus (T2DM) will receive either metformin (850 mg p." | 9.41 | Efficacy of metformin and fermentable fiber combination therapy in adolescents with severe obesity and insulin resistance: study protocol for a double-blind randomized controlled trial. ( Ball, GDC; Colin-Ramirez, E; Deehan, EC; Dinu, I; Field, CJ; Freemark, M; Haqq, AM; Madsen, KL; Newgard, CB; Orsso, C; Pakseresht, M; Prado, CM; Rubin, D; Sharma, AM; Tan, Q; Triador, L; Tun, H; Walter, J; Wine, E, 2021) |
| " Whether metformin improves hepatic, muscle or adipose tissue insulin sensitivity has not been studied in adults with Type 1 diabetes." | 9.41 | Insulin resistance in type 1 diabetes managed with metformin (INTIMET): Study protocol of a double-blind placebo-controlled, randomised trial. ( Bruce, C; Evans, J; Greenfield, JR; Holmes-Walker, DJ; Kowalski, G; Liu, Z; Samocha-Bonet, D; Snaith, JR, 2021) |
| "Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility, for which the insulin sensitizer metformin has been used therapeutically." | 9.41 | Therapeutic Effect of Curcumin in Women with Polycystic Ovary Syndrome Receiving Metformin: A Randomized Controlled Trial. ( Atkin, SL; Azarpazhooh, MR; Heydari, B; Karimi-Zarchi, M; Sahebkar, A; Simental-Mendía, LE; Sohrevardi, SM; Teymourzadeh, M, 2021) |
| "To compare the effects of metformin, rosiglitazone, and their combination in obese polycystic ovary syndrome (PCOS) patients with insulin resistance." | 9.34 | Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. ( Duan, C; Hu, Y; Huang, W; Li, Y; Tan, J; Wang, Q, 2020) |
| " Metformin was able to stabilise insulin sensitivity in every stratified sub-cohort except one." | 9.34 | Metformin use in prediabetes: is earlier intervention better? ( Fleet, R; Pumpa, K; Somerset, S; Warrilow, A, 2020) |
| "OCP resulted in a higher reduction in serum luteinizing hormone (LH) and androgens whereas metformin resulted in significant reduction in BMI, waist circumference, and insulin resistance." | 9.30 | Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial. ( Mohanty, J; Nagy, A; Sahu, A; Tripathy, P, 2019) |
| "This study provides evidence that, compared to glimepiride, saxagliptin more effectively achieves a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in T2D patients who are inadequately controlled with metformin monotherapy, especially in overweight patients with moderate hyperglycaemia and a relatively short duration of diabetes." | 9.30 | Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr ( Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L, 2019) |
| " Therefore, we here aim to investigate if acupuncture treatment or metformin together with lifestyle or lifestyle management alone improves insulin sensitivity and related symptoms in overweight/obese women with PCOS." | 9.30 | Acupuncture or metformin to improve insulin resistance in women with polycystic ovary syndrome: study protocol of a combined multinational cross sectional case-control study and a randomised controlled trial. ( Chang, C; Friden, C; Huo, Z; Ji, X; Li, D; Li, R; Li, S; Linden-Hirschberg, A; Qiao, J; Stener-Victorin, E; Wang, H; Wang, W; Zhang, H, 2019) |
| " The current study investigated the effects of vildagliptin, DPP-4 inhibitor, compared to metformin on endothelial function and blood pressure through vascular endothelial growth factor (VEGF) modulation in patients with T2DM and hypertension." | 9.30 | The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients. ( Abdel-Latif, H; Bassyouni, A; El-Naggar, AR; Elyamany, M; Hassanin, S; Zaafar, D, 2019) |
| "Measure peripheral, hepatic, and adipose insulin sensitivity before and after metformin or placebo therapy in youth with obesity with type 1 diabetes." | 9.30 | Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes. ( Bergman, BC; Cengiz, E; Cree-Green, M; Fox, LA; Hannon, TS; Kahn, D; Libman, I; Miller, K; Nadeau, KJ; Nathan, B; Pyle, L; Tansey, M; Tichy, E; Tsalikian, E, 2019) |
| "Metformin treatment significantly reduced LVMI, LVM, office systolic BP, body weight, and oxidative stress." | 9.30 | A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. ( Al-Talabany, S; Baig, F; Bhalraam, U; Choy, AM; Gandy, SJ; George, J; Houston, JG; Hussain, MS; Khan, F; Lang, CC; Matthew, S; McKinnie, A; Mohan, M; Mordi, IR; Singh, JSS; Struthers, AD, 2019) |
| "Though most of the observational studies have shown that metformin can reduce serum thyroid stimulating hormone (TSH) level in patients of hypothyroidism with diabetes or polycystic ovarian disease, randomised controlled trials are sparse." | 9.30 | Effect of metformin on thyroid function tests in patients with subclinical hypothyroidism: an open-label randomised controlled trial. ( Durgia, H; Kamalanathan, S; Kar, SS; Palui, R; Patil, M; Raj, H; Sahoo, J; Sridharan, K, 2019) |
| "The aim of this study was to analyze the efficacy, insulin sensitivity and safety in the event of administering sulfonylurea-based drugs and metformin in combination with basal insulin." | 9.30 | A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy. ( Chun, SW; Hong, JH; Kim, SJ; Lee, JM; Lim, DM; Park, KS; Park, KY; Yu, HM, 2019) |
| " PCOS is associated with obesity, dyslipidaemia and insulin resistance, and metformin treatment may improve such metabolic features." | 9.27 | The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial. ( Andersen, M; Christensen, MMH; Glintborg, D; Pedersen, AJT; Stage, TB, 2018) |
| "To evaluate whether metformin can reduce TSH levels in subjects with subclinical hypothyroidism." | 9.27 | Metformin effect on TSH in subclinical hypothyroidism: randomized, double-blind, placebo-controlled clinical trial. ( Antonio Naujorks, A; Correa Junior, V; Dornelles Severo, M; Gus, M; Schaan, BD; Stürmer Andrade, T, 2018) |
| "We aimed to assess the use of metformin (MTF) in the prevention of gestational diabetes mellitus (GDM) in patients with pregestational insulin resistance (PIR)." | 9.27 | Metformin as a prophylactic treatment of gestational diabetes in pregnant patients with pregestational insulin resistance: A randomized study. ( Abusada, N; Candia, P; Cuellar, E; Manukian, B; Orellana, R; Sepúlveda-Martínez, A; Valdés, E, 2018) |
| "To study the effectiveness of exenatide with metformin and sequential treatment with exenatide and glargine added to metformin and their influence on insulin sensitivity and adipose distribution." | 9.27 | Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance. ( Du, X; Hu, C; Lu, W; Lu, Z; Shao, X; Shi, B, 2018) |
| "To evaluate the effect of Diane-35, alone or in combination with orlistat or metformin, on androgen and body fat percentage parameters in Chinese overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance." | 9.27 | Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| "Worldwide, metformin is prescribed to improve pregnancy outcome in polycystic ovary syndrome (PCOS)." | 9.27 | Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS? ( Andersen, MS; Høgetveit, K; Oppen, IH; Stridsklev, S; Underdal, MO; Vanky, E, 2018) |
| " The RISE Pediatric Medication Study compared two approaches-glargine followed by metformin and metformin alone-in preserving or improving β-cell function in youth with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes during and after therapy withdrawal." | 9.27 | Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. ( , 2018) |
| " The BetaFat study compared gastric banding and metformin for their impact on β-cell function in adults with moderate obesity and impaired glucose tolerance (IGT) or recently diagnosed, mild T2D." | 9.27 | Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. ( Beale, E; Buchanan, TA; Chow, T; Hendee, F; Katkhouda, N; Martinez, M; Montgomery, C; Nayak, KS; Trigo, E; Wang, X; Wu, J; Xiang, AH, 2018) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 9.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "Steady-state population pharmacokinetics of a noncommercial immediate-release metformin (hydrochloride) drug product were characterized in 28 severely obese children with insulin resistance." | 9.24 | Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. ( Alfaro, RM; Calis, KA; Hon, YY; Reynolds, JC; Roza, O; Sam, WJ; Yanovski, JA, 2017) |
| "This study aimed to evaluate the effects of metformin and conjugated linoleic acid (CLA) on insulin sensitivity, measured via euglycemic-hyperinsulinemic clamp technique and insulin pathway expression molecules in muscle biopsies of children with obesity." | 9.24 | Effects of Conjugated Linoleic Acid and Metformin on Insulin Sensitivity in Obese Children: Randomized Clinical Trial. ( Alvarez, F; Bustos, M; Cuevas, S; Duggirala, R; Fonseca-Sánchez, M; Garibay-Nieto, N; Jalife, A; Laresgoiti-Servitje, E; León, M; López-Alvarenga, JC; Macías, T; Queipo-García, G; Ramírez, F; Serratos, F; Villanueva, E, 2017) |
| "To improve insulin sensitivity, insulin-sensitizing drugs such as metformin are commonly used in overweight and obese T1D patients." | 9.24 | A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. ( Defeudis, G; Del Toro, R; Fioriti, E; Guglielmi, C; Kyanvash, S; Maggi, D; Manfrini, S; Maurizi, AR; Menduni, M; Pantano, AL; Pozzilli, P, 2017) |
| "The aim of this randomized clinical trial (RCT) was to evaluate the effect of vitamin D supplementation in obese, insulin-resistant (IR) and vitamin D-deficient polycystic ovary syndrome (PCOS) women on metabolic abnormalities in comparison to the effect of metformin or combined metformin plus vitamin D therapy." | 9.24 | The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J, 2017) |
| "Using the terms "metformin" and "polycystic ovary syndrome," we conducted a search the PubMed, EMBASE, and Google Scholar databases." | 9.22 | The use of metformin in women with polycystic ovary syndrome: an updated review. ( Neto, FTL; Notaro, ALG, 2022) |
| "Metformin is the most commonly used treatment to increase insulin sensitivity in insulin-resistant (IR) conditions such as diabetes, prediabetes, polycystic ovary syndrome, and obesity." | 9.22 | Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport. ( Dolžan, V; Herman, R; Janež, A; Jensterle, M; Kravos, NA, 2022) |
| "Based on the results of this study, compared with metformin alone, acupuncture combined with metformin has a positive effect on pregnancy rate, ovulation rate, and insulin resistance in PCOS." | 9.22 | Acupuncture combined with metformin versus metformin alone to improve pregnancy rate in polycystic ovary syndrome: A systematic review and meta-analysis. ( Chen, X; Lan, Y; Li, H; Li, Z; Liu, Y; Long, C; Wang, M; Wu, J; Xie, Q; Yang, L; Zhao, Y; Zhu, X, 2022) |
| "The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)." | 9.22 | Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016) |
| "To determine serum vascular endothelial growth factor B (VEGF-B) levels in polycystic ovary syndrome, their association with insulin resistance and β-cell dysfunction, and the effect of metformin on serum VEGF-B levels." | 9.22 | Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment. ( Chen, C; Cheng, F; Huang, T; Jia, F; Liu, D; Wu, J; Wu, Y; Yang, G; Zhang, Z; Zhao, L, 2016) |
| " We assessed the efficacy of metformin in preventing recurrence after medroxyprogesterone acetate (MPA) as fertility-sparing treatment for atypical endometrial hyperplasia (AEH) and EC." | 9.22 | Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. ( Hanaoka, H; Kiyokawa, T; Koshizaka, M; Mitsuhashi, A; Sato, Y; Shozu, M, 2016) |
| "In subjects with insulin resistance, metformin therapy significantly decreased thyroid volume and nodule size." | 9.22 | Metformin Decreases Thyroid Volume and Nodule Size in Subjects with Insulin Resistance: A Preliminary Study. ( Anil, C; Atesagaoglu, B; Bascil Tutuncu, N; Gursoy, A; Kut, A; Nar, A, 2016) |
| "Weight loss and metformin are hypothesized to improve breast cancer outcomes; however the joint impacts of these treatments have not been investigated." | 9.22 | Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors. ( Cadmus-Bertram, L; Flatt, SW; Godbole, S; Hartman, SJ; Kerr, J; Li, H; Marinac, CR; Natarajan, L; Oratowski-Coleman, J; Parker, B; Patterson, RE; Villaseñor, A, 2016) |
| "In combination with a novel carbohydrate modified diet, metformin enhanced 12-month weight loss and improved body composition in ethnically diverse normoglycemic, hyperinsulinemic women with midlife weight gain." | 9.22 | METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN. ( Freeman, R; Mogul, H; Nguyen, K, 2016) |
| " In this study, data were pooled from two randomized, placebo-controlled trials, which were originally designed to examine the efficacy of metformin in treating antipsychotic-induced weight gain and other metabolic abnormalities." | 9.22 | Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. ( Chan, PK; Gao, KM; Guo, WB; Jin, H; Ou, JJ; Shao, P; Wu, RR; Zhang, FY; Zhao, JP, 2016) |
| " Metformin was found to improve insulin sensitivity in hepatitis C patients, as well as to reduce elevated thyrotropin levels in patients with hypothyroidism." | 9.22 | The Effect of Metformin on Hypothalamic-Pituitary-Thyroid Axis Activity in Women with Interferon-Induced Hypothyroidism: A Pilot Study. ( Krysiak, R; Okopien, B; Szkrobka, W, 2016) |
| "Our results show that Metformin and acupuncture combined therapy significantly improves body weight, body mass index (BMI), fasting blood sugar (FBS), fasting insulin (FINS), homeostasis model assessment (HOMA) index, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), leptin, adiponectin, glucagon-like peptide-1 (GLP-1), resistin, serotonin, free fatty acids (FFAs), triglyceride (TG), low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc) and ceramides." | 9.22 | Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients. ( Firouzjaei, A; Li, GC; Liu, WX; Wang, N; Zhu, BM, 2016) |
| "To evaluate the effect of testosterone replacement therapy (TRT) on body composition, insulin sensitivity, oxidative metabolism and glycaemic control in aging men with lowered bioavailable testosterone (BioT) levels and type 2 diabetes mellitus (T2D) controlled on metformin monotherapy." | 9.22 | Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy. ( Andersen, M; Glintborg, D; Hermann, P; Hougaard, DM; Højlund, K; Magnussen, LV, 2016) |
| "Aim of this study was to evaluate the effect of vitamin D supplementation in obese, insulin resistant and vitamin D deficient PCOS women on biochemical and clinical hyperandrogenism and menstrual irregularity in comparison to effect of metformin or combined metformin plus vitamin D therapy." | 9.22 | The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J; Vaľková, M, 2016) |
| "Metformin has been used for alleviating metabolic abnormalities in patients with schizophrenia." | 9.22 | Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. ( Chen, CH; Chen, PY; Chiu, CC; Huang, MC; Lin, SK; Lin, YK; Lu, ML, 2016) |
| "This research was carried out to evaluate the chemopreventive effects of different doses of metformin treatment for 6 months on rectal aberrant crypt foci (ACF) in patients with impaired glucose tolerance (IGT)." | 9.20 | Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance. ( Chen, M; Chen, Y; Dai, Y; Li, Y; Wang, Y; Xie, H; Zhao, X, 2015) |
| "To compare the therapeutic effects of metformin (Met) and laparoscopic ovarian drilling (LOD) in clomiphene and insulin-resistant patients with polycystic ovary syndrome (CIRPCOS)." | 9.20 | Therapeutic effects of metformin and laparoscopic ovarian drilling in treatment of clomiphene and insulin-resistant polycystic ovary syndrome. ( Huang, LP; Wang, JQ; Wang, XH; Xu, Y, 2015) |
| " The diabetic medication, Metformin, reduces IR and aids weight loss and may therefore regress LVH." | 9.20 | Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study. ( Baig, F; Lang, CC; McSwiggan, S; Mohan, M; Rutherford, L, 2015) |
| "In individuals with prediabetes, metformin ameliorated effector pathways that have been shown to regulate longevity in animal models." | 9.20 | Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. ( Avogaro, A; Bacalini, MG; Borelli, V; Cattelan, A; Ceolotto, G; de Kreutzenberg, SV; Fadini, GP; Franceschi, C; Garagnani, P; Mazzucato, M; Pagnin, E, 2015) |
| " This study was conducted as an exploratory analysis to clarify the effects of liraglutide, a GLP-1RA, on beta cell function, fat distribution and pancreas volume compared with metformin in Japanese overweight/obese patients with T2DM." | 9.20 | Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. ( Cobelli, C; Irie, J; Itoh, H; Jinzaki, M; Kawai, T; Manesso, E; Meguro, S; Saisho, Y; Sugiura, H; Tanaka, K; Tanaka, M, 2015) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 9.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "This randomized, double-blind, placebo-controlled parallel-group study assessed the effects of sodium glucose cotransporter 2 inhibition by dapagliflozin on insulin sensitivity and secretion in subjects with type 2 diabetes mellitus (T2DM), who had inadequate glycemic control with metformin (with or without an insulin secretagogue)." | 9.19 | Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. ( Boden, G; Chalamandaris, AG; Duchesne, D; Henry, RR; Iqbal, N; List, J; Mudaliar, S; Smith, S, 2014) |
| "Although metformin is widely used to improve insulin resistance in women with polycystic ovary syndrome (PCOS), its mechanism of action is complex, with inconsistent effects on insulin sensitivity and variability in treatment response." | 9.19 | Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. ( Duran, J; Keefe, C; Pau, CT; Welt, CK, 2014) |
| "Combining metformin and exercise is recommended for the treatment of insulin resistance." | 9.19 | Metformin does not attenuate the acute insulin-sensitizing effect of a single bout of exercise in individuals with insulin resistance. ( de Prada, MV; Fernández-Elías, VE; Hamouti, N; Martínez-Vizcaíno, V; Mora-Rodríguez, R; Ortega, JF, 2014) |
| "To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia." | 9.19 | Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014) |
| "Insulin resistance (IR) affects sustained virological response (SVR) to peginterferon alfa plus ribavirin (PR) in patients with chronic hepatitis C (CHC)." | 9.19 | A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. ( Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Lin, HH; Tseng, TC; Wang, CC, 2014) |
| "Treatment of diabetics with metformin is associated with decreased breast cancer risk in observational studies, but it remains unclear if this drug has clinical antineoplastic activity." | 9.19 | Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. ( Aristarco, V; Bassi, F; Bonanni, B; Cazzaniga, M; DeCensi, A; Gandini, S; Guerrieri-Gonzaga, A; Hofmann, U; Johansson, HA; Lazzeroni, M; Luini, A; Macis, D; Mora, S; Pollak, MN; Pruneri, G; Puntoni, M; Schwab, M; Serrano, D, 2014) |
| "To study the effect of metformin on metabolic parameters, body weight (BW), and waist circumference (WC) in patients with abdominal obesity (AO)." | 9.19 | [Efficacy of metformin in abdominal obesity]. ( Kichigin, VA; Markova, TN; Mkrtumian, AM; Podachina, SV; Zhuchkova, SM, 2014) |
| "Our study included 41 fenofibrate-treated patients with impaired glucose tolerance allocated to either metformin (3 g daily) or placebo." | 9.17 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "During the first 6 months, metformin plus rosiglitazone exhibited a significantly greater improvement in insulin sensitivity and oDI versus metformin alone and versus metformin plus lifestyle; these improvements were sustained over 48 months of TODAY." | 9.17 | Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. ( , 2013) |
| "To improve the treatment outcomes in women with polycystic ovary syndrome (PCOS), various drugs like glitazones, oral contraceptive pills, or antiandrogens have been combined with metformin." | 9.17 | Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. ( Ganie, MA; Gupta, N; Khurana, ML; Kulshrestha, B; Mir, FA; Mudasir, S; Nisar, S; Shah, PA; Shah, ZA; Taing, S; Wani, TA; Zargar, MA, 2013) |
| " We conducted the present study to compare the antidepressant efficacy of pioglitazone with another insulin-sensitizer, metformin, in obese patients with concomitant polycystic ovarian syndrome (PCOS) and major depressive disorder (MDD)." | 9.17 | Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. ( Akhondzadeh, S; Ashrafi, M; Farazmand, B; Kashani, L; Modabbernia, A; Omidvar, T; Ramzanzadeh, F; Tabrizi, M; Tehraninejad, ES, 2013) |
| "The aim of the present study was to investigate the efficacy of Metformin compared with a hypocaloric diet on C-reactive protein (CRP) level and markers of insulin resistance in obese and overweight women with polycystic ovary syndrome (PCOS)." | 9.17 | Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. ( Esfahanian, F; Heshmat, R; Moini nia, F; Zamani, MM, 2013) |
| "Metformin may be an effective therapeutic option for insulin-resistant (I-R) horses/ponies because, in humans, it reportedly enhances insulin sensitivity (SI) of peripheral tissues without stimulating insulin secretion." | 9.16 | The effect of oral metformin on insulin sensitivity in insulin-resistant ponies. ( Boston, RC; Harris, PA; Noble, GK; Raidal, SL; Sillence, MN; Tinworth, KD, 2012) |
| "Physical activity or metformin enhances insulin sensitivity and opposes the progression from prediabetes to type 2 diabetes." | 9.16 | Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. ( Braun, B; Chipkin, SR; Gerber, R; Malin, SK, 2012) |
| " The body weight, body mass index, fasting insulin and insulin resistance index decreased significantly in the metformin group, but increased in the placebo group during the 12-week follow-up period." | 9.16 | Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. ( Liang, GM; Tong, JH; Wang, M; Wang, XZ; Yan, HF; Zhu, G, 2012) |
| "these results suggest pioglitazone is as effective as metformin in improving insulin sensitivity and some cardiovascular risk biomarkers but it has no significant effect on reducing BMI and body weight." | 9.16 | Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome. ( Abedini, A; Ghorbani, A; Hashemipour, S; Karimzadeh, T; Oveisi, S; Ziaee, A, 2012) |
| "A combination of metformin, peginterferon alfa-2a, and ribavirin improved insulin sensitivity and increased the SVR rate of patients with hepatitis C genotype 1 and IR, with a good safety profile." | 9.16 | The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. ( Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH, 2012) |
| "Metformin is associated with reduced breast cancer risk in observational studies in patients with diabetes, but clinical evidence for antitumor activity is unclear." | 9.16 | Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. ( Aristarco, V; Bassi, F; Bonanni, B; Bruzzi, P; Cazzaniga, M; Decensi, A; Galimberti, V; Gennari, A; Guerrieri-Gonzaga, A; Johansson, H; Lazzeroni, M; Luini, A; Pruneri, G; Puntoni, M; Serrano, D; Trabacca, MS; Varricchio, C; Veronesi, P; Viale, G, 2012) |
| "To compare serum concentrations of inflammatory cytokines, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), adiponectin, and tumor necrosis factor alpha (TNFalpha), before and after 3 months treatment with metformin in obese adolescents with insulin resistance (IR)." | 9.16 | The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. ( Apolinar-Jiménez, E; Evia-Viscarra, ML; Figueroa-Barrón, M; García-Morales, LM; Leaños-Pérez, C; Muñoz-Noriega, N; Reyes-García, JG; Rodea-Montero, ER; Sánchez-Fierros, D, 2012) |
| "This is a randomized controlled trial to test the effect of different doses of metformin in patients with breast cancer and without diabetes, with the aim of modifying the hormonal and metabolic parameters linked to breast cancer prognosis." | 9.16 | Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. ( Abbà, C; Ambroggio, S; Berrino, F; Biglia, N; Brucato, T; Campagnoli, C; Colombero, R; Danese, S; Donadio, M; Pasanisi, P; Venturelli, E; Zito, G, 2012) |
| "To evaluate the impact on glycemic control, insulin resistance, and insulin secretion of sitagliptin+metformin compared to metformin in type 2 diabetic patients." | 9.16 | Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Franzetti, I; Maffioli, P; Querci, F; Romano, D, 2012) |
| "Eighty-four women (ages 18-40 years) with first-episode schizophrenia who suffered from amenorrhea during antipsychotic treatment were randomly assigned, in a double-blind study design, to receive 1000 mg/day of metformin or placebo in addition to their antipsychotic treatment for 6 months." | 9.16 | Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. ( Chan, PK; Davis, JM; Gao, K; Guo, XF; Jin, H; Ou, JJ; Shao, P; Twamley, EW; Wang, J; Wu, RR; Zhao, JP, 2012) |
| "Twelve weeks of atorvastatin led to a significant reduction in oxidative stress as determined by MDA concentrations among patients with polycystic ovary syndrome that was independently predicted by changes in testosterone, 25OHD, and high-sensitivity C-reactive protein." | 9.16 | Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. ( Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Shepherd, J, 2012) |
| "This study evaluated the effect of metformin glycinate on glycated hemoglobin A1c (A1C) concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus (T2DM)." | 9.16 | Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus. ( Barrera-Durán, C; González-Canudas, J; González-Ortiz, M; Martínez-Abundis, E; Ramos-Zavala, MG; Robles-Cervantes, JA, 2012) |
| "In young women with PCOS, treatment with metformin or pioglitazone for 6 months induces a similar beneficial effect on endothelial function; this may be partially attributed to an improvement in insulin resistance." | 9.15 | Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. ( Bechlioulis, A; Calis, KA; Chrousos, GP; Kalantaridou, SN; Katsouras, CS; Kazakos, N; Kravariti, M; Makrigiannakis, A; Michalis, LK; Naka, KK; Tsatsoulis, A, 2011) |
| "To assess the impact of metformin and of two different oral contraceptives (OCs) containing cyproterone acetate and drospirenone, on serum anti-Müllerian hormone (AMH) levels, in a cohort of women with polycystic ovary syndrome (PCOS) with hyperandrogenism." | 9.15 | The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. ( Decavalas, G; Diamanti-Kandarakis, E; Georgopoulos, NA; Katsikis, I; Panidis, D; Piouka, A; Saltamavros, AD, 2011) |
| " ADMA, homocysteine, high sensitive C-reactive protein (hs-CRP) and homeostasis model assessment estimate of insulin resistance (HOMA-IR) were investigated." | 9.15 | Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. ( Aydin, M; Batioglu, S; Erdogan, G; Kilic, S; Yilmaz, N; Zulfikaroglu, E, 2011) |
| "To examine the appropriate treatment of oligo-terato-asthenozoospermic patients with metabolic syndrome, 45 patients were treated with metformin for 6 months." | 9.15 | Metformin improves semen characteristics of oligo-terato-asthenozoospermic men with metabolic syndrome. ( De Leo, V; Morgante, G; Musacchio, MC; Orvieto, R; Piomboni, P; Tosti, C, 2011) |
| "Metformin had modest but favorable effects on body weight, body composition, and glucose homeostasis in obese insulin-resistant children participating in a low-intensity weight-reduction program." | 9.15 | Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. ( Brady, SM; Calis, KA; Kozlosky, M; Krakoff, J; McDuffie, JR; Reynolds, JC; Salaita, CG; Sebring, NG; Yanovski, JA, 2011) |
| "There is no benefit from increased doses of metformin in PCOS but reduction of insulin resistance is more significant in those patients with a lower insulin sensitivity at baseline." | 9.15 | Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome. ( Balen, AH; Barth, J; Glanville, J; Yasmin, E, 2011) |
| "Measures of β-cell function and insulin sensitivity from an OGTT showed more favorable changes over time with rosiglitazone versus metformin or glyburide." | 9.15 | Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. ( Aftring, RP; Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Zinman, B, 2011) |
| "To compare the efficacy of 1000 mg and 1700 mg of metformin on ovulation induction in polycystic ovary syndrome (PCOS) women." | 9.15 | Randomized controlled trial of different doses of metformin for ovulation induction in infertile women with polycystic ovary syndrome. ( Jultanmas, R; Leelaphiwat, S; Lertvikool, S; Satirapot, C; Sophonsritsuk, A; Weerakiet, S, 2011) |
| "Metformin can improve insulin resistance and imbalance of endocrine hormones." | 9.15 | Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. ( Dong, JJ; Liao, L; Tian, YJ; Xin, Y; Xing, HY; Zhao, JJ, 2011) |
| "The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin." | 9.15 | Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. ( Bonaventura, A; Bossi, AC; Derosa, G; Fogari, E; Franzetti, IG; Guazzini, B; Maffioli, P; Putignano, P; Querci, F; Testori, G, 2011) |
| "Metformin and rosiglitazone combination therapy is known to improve insulin resistance and postpone diabetes mellitus development in subjects with impaired glucose tolerance." | 9.15 | Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: a double-blind, randomized, controlled study. ( Li, D; Li, X; Li, Y; Ming, J; Shi, Y; Xie, Y; Zhang, N, 2011) |
| "In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10)." | 9.15 | Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. ( Adawadkar, SS; Arrowood, JA; Cheang, KI; Essah, PA; Nestler, JE; Stovall, DW, 2011) |
| " The metformin therapy improved insulin sensitivity as evidenced by an increase in ISI by 41." | 9.15 | [Effects of metformin therapy on markers of coagulation disorders in hyperinsulinemic women with polycystic ovary syndrome]. ( Banaszewska, B; Pawelczyk, L; Serdyńska-Szuster, M; Spaczyński, R, 2011) |
| "To evaluate the clinical, endocrine and metabolic effects of metformin and N-acetyl-cysteine (NAC) in patients with polycystic ovary syndrome (PCOS)." | 9.15 | Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. ( Muderris, II; Oner, G, 2011) |
| "This randomized controlled study investigated metformin and fenofibrate, compared with metformin alone, for the treatment of peripheral insulin resistance in patients with simple obesity with hyperinsulinaemia but not diabetes." | 9.15 | Combination therapy with metformin and fenofibrate for insulin resistance in obesity. ( Li, XM; Li, Y; Shi, YQ; Xie, YH; Zhang, NN, 2011) |
| "Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study." | 9.14 | Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. ( Atkin, SL; Cho, LW; Coady, AM; Keevil, BG; Kilpatrick, ES, 2009) |
| " Hirsutism was significantly better controlled in the metformin group (p = 0." | 9.14 | Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome. ( Adibi, N; Asilian, A; Kachuei, A; Rezvanian, H; Shojaee-Moradie, F; Siavash, M, 2009) |
| "Rimonabant has been shown to reduce weight, free androgen index (FAI) and insulin resistance in obese patients with polycystic ovary syndrome (PCOS) compared to metformin." | 9.14 | Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). ( Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T, 2009) |
| "There were no adverse effects of short-term cyclic MPA plus metformin treatment on metabolic parameters or insulin resistance in patients with PCOS over a 3-month treatment period." | 9.14 | Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome. ( Bagis, T; Haydardedeoglu, B; Kilicdag, EB; Simsek, E, 2009) |
| "Circulating levels of interleukin-6 (IL-6) and C-reactive protein (CRP) were determined in 59 women with polycystic ovary syndrome, of whom 37 were retested after receiving metformin for 6 weeks and 6 months, to ascertain the response of these inflammatory markers to weight loss and insulin sensitization." | 9.14 | Determinants of interleukin-6 and C-reactive protein vary in polycystic ovary syndrome, as do effects of short- and long-term metformin therapy. ( Conway, GS; Mohamed-Ali, V; Tsilchorozidou, T, 2009) |
| " Total renin, aldosterone, androgen levels and insulin sensitivity indices were significantly improved after 6 months on metformin treatment." | 9.14 | Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. ( Diamanti-Kandarakis, E; Economou, FN; Livadas, S; Panidis, D; Papavassiliou, AG; Piperi, C; Tantalaki, E, 2009) |
| "This study assessed the efficacy of adding metformin to a structured lifestyle intervention in reducing BMI in obese adolescents with insulin resistance." | 9.14 | Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. ( Baker, JE; Clark, HE; Clarson, CL; Hill, DJ; Mahmud, FH; McKay, WM; Schauteet, VD, 2009) |
| "The aim of this randomized, placebo-controlled study was to explore the effect of metformin in children with a neurogenic or myogenic motor deficit, who are therefore prone to develop overweight, adiposity, and insulin resistance." | 9.14 | Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit. ( Casteels, K; Coudyzer, W; de Zegher, F; Fieuws, S; Goemans, N; Loeckx, D; van Helvoirt, M; Verpoorten, C, 2010) |
| " To elucidate the dynamics of FSH, LH, prolactin (PRL), TSH and insulin secretion in women with polycystic ovarian syndrome (PCOS) treated with metformin (MET)." | 9.14 | Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. ( Adamopoulos, DA; Antsaklis, A; Billa, E; Kapolla, N; Koukkou, E; Milingos, S; Nicopoulou, SC; Venaki, E, 2009) |
| "To evaluate the effect of a short-course pretreatment with metformin on hyperandrogenism, insulin resistance, cervical scores, and pregnancy rates in women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS)." | 9.14 | Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. ( Ghaffarpasand, F; Kazerooni, M; Kazerooni, T; Kazerooni, Y; Setoodeh, S, 2009) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 9.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| "Adding metformin to peginterferon and ribavirin was safe and improved insulin sensitivity." | 9.14 | Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. ( Andrade, RJ; Calleja, JL; De la Mata, M; Diago, M; Durán, S; Fernández-Rodríguez, CM; García-Samaniego, J; Herrerías, JM; Moreno-Otero, R; Nuñez, O; Olveira, A; Planas, R; Romero-Gómez, M; Salmerón, J; Solà, R, 2009) |
| "To compare the hormonal-metabolic profiles and reproductive outcomes in clomiphene-resistant patients with polycystic ovary syndrome and insulin resistance between women receiving metformin and those undergoing laparoscopic ovarian drilling." | 9.14 | Metformin versus laparoscopic ovarian drilling in clomiphene- and insulin-resistant women with polycystic ovary syndrome. ( Ahmed, MA; Ahmed, OG; Hamed, HO; Hasan, AF, 2010) |
| " The aim of this study was to determine leptin concentrations in PCOS patients before and after metformin treatment depending on BMI, insulin resistance calculated on the basis of the Homeostasis Model Assessment (HOMA) index, as well as concentrations of androgens: testosterone and androstendion." | 9.14 | Leptin concentrations in patients with polycystic ovary syndrome before and after met-formin treatment depending on insulin resistance, body mass index and androgen con-centrations--introductory report. ( Brodowska, A; Marciniak, A; Nawrocka-Rutkowska, J; Sienkiewicz, R; Starczewski, A; Szydłowska, I, 2009) |
| " Metformin improves insulin sensitivity and circulating markers of cardiovascular risk in patients with PCOS, but it is unclear whether this translates into improvements in vascular function." | 9.14 | Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. ( Agarwal, N; Bolusani, H; Dunseath, G; Ludgate, M; Luzio, SD; Rees, DA; Rice, SP, 2010) |
| "The aim of this study was to evaluate long-term changes in endocrine and metabolic parameters and body mass index in women with polycystic ovary syndrome (PCOS) who were treated with metformin over 2 years without caloric restriction." | 9.14 | The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome. ( Beckmann, MW; Cupisti, S; Dittrich, R; Jentsch, K; Kronawitter, D; Mueller, A; Oppelt, PG; Reissmann, C, 2010) |
| " 'Cases' were women with PCOS who conceived while taking Metformin and it whom it was continued throughout pregnancy." | 9.14 | Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome. ( Nawaz, FH; Rizvi, J, 2010) |
| "This report has demonstrated that the combination of metformin and simvastatin could lead to a better reduction of T and LH levels and thus reversing the LH:FSH ratio, lipid profile, and insulin resistance in patients with PCOS and may be an appropriate management option for patients with PCOS." | 9.14 | Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. ( Asadi, N; Dehbashi, S; Ghaffarpasand, F; Kazerooni, T; Kazerooni, Y; Shojaei-Baghini, A, 2010) |
| "Study the effects of exenatide (EXE) plus rosiglitazone (ROSI) on beta-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type 2 diabetes on metformin." | 9.14 | Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. ( DeFronzo, RA; Glass, LC; Lewis, MS; Maggs, D; Qu, Y; Triplitt, C, 2010) |
| "Metformin has been proffered as a therapy for adolescent obesity, although long-term controlled studies have not been reported." | 9.14 | Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. ( Abrams, SH; Aye, T; Feldman, HA; Lee, PD; Lenders, C; Lustig, RH; Osganian, SV; Wilson, DM, 2010) |
| "The aim of this study was to evaluate the effects of metformin in addition to diet and exercise on endocrine and metabolic disturbances in women with polycystic ovary syndrome (PCOS) in a prospective, double-blind, randomized, placebo (PBO) control trial." | 9.14 | Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. ( Fux Otta, C; Gaido, MI; Iraci, GS; Kaplan, R; Torres, D; Wior, M; Wyse, EP, 2010) |
| " Metformin had no effect on adiponectin in spite of significant decreases in weight, fasting glucose, and insulin resistance." | 9.14 | Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study. ( Flyvbjerg, A; Frystyk, J; Lauszus, FF; Trolle, B, 2010) |
| " We aimed to study if the changes observed in the insulin sensitivity of PCOS patients during treatment with oral contraceptives or metformin associate changes in the serum inflammatory markers interleukin-6 (IL-6) and interleukin-18 (IL-18)." | 9.14 | Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations. ( Escobar-Morreale, HF; Luque-Ramírez, M, 2010) |
| "To determine the effects of metformin treatment on serum androgen levels ahead of and during the IVF cycle in infertile polycystic ovary syndrome (PCOS) women." | 9.14 | Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome. ( Carlsen, SM; Kjøtrød, SB; Sunde, A; von Düring, V, 2009) |
| "Our first specific aim in an observational study of 431 nondiabetic women with polycystic ovary syndrome (PCOS), aged >or=20 years and with >or=11 months follow-up on metformin diet, was to prospectively assess relationships between pretreatment glucose and insulin resistance (IR) and the development of type 2 diabetes mellitus (T2DM) or gestational diabetes (GD)." | 9.13 | An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet. ( Glueck, CJ; Goldenberg, N; Sieve, L; Wang, P, 2008) |
| "One hundred forty-two nondiabetic women with polycystic ovary syndrome (PCOS) who had at least one live-birth (LB) pregnancy on metformin diet (172 pregnancies, 180 LBs)." | 9.13 | Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. ( Aregawi, D; Glueck, CJ; Pranikoff, J; Wang, P, 2008) |
| "To test the efficacy of lifestyle intervention and metformin alone and in combination for antipsychotic-induced weight gain and abnormalities in insulin sensitivity." | 9.13 | Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. ( Chen, JD; Fang, MS; Guo, XF; He, YQ; Jin, H; Li, LH; Liu, YJ; Shao, P; Wu, RR; Zhao, JP, 2008) |
| "Six hundred and ninety-four consecutive overweight and obese type 2 diabetic patients were evaluated and 56 patients were intolerant to metformin at maximum dosage." | 9.13 | Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Piccinni, MN; Ragonesi, PD; Salvadeo, SA, 2008) |
| "To compare the effects of insulin sensitization with metformin to weight reduction by rimonabant on biochemical hyperandrogenaemia and insulin resistance in patients with PCOS." | 9.13 | A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. ( Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T, 2008) |
| "In a randomized double-blind placebo controlled trial, 85 adolescents with insulin resistance were randomized to receive metformin (70%) or placebo (30%), along with monthly goal setting for diet and exercise modification." | 9.13 | Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. ( Love-Osborne, K; Sheeder, J; Zeitler, P, 2008) |
| " Metformin, which is widely prescribed for type 2 diabetes mellitus (T2DM) patients, regulates blood sugar by inhibiting hepatic gluconeogenesis and promoting insulin sensitivity to facilitate glucose uptake by cells." | 9.12 | New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Cancer: Nonapoptotic Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway. ( Cheng, KC; Chiu, CC; Hsu, SK; Lin, YH; Mgbeahuruike, MO; Sheu, SJ; Wang, HD; Wu, CY; Yen, CH, 2021) |
| "The main mechanism of gestational diabetes mellitus (GDM) is insulin resistance, therefore using metformin as a medicine reducing insulin resistance appears to be promising." | 9.12 | Metformin administration during pregnancy - current insight. ( Cypryk, K; Krekora, M; Skibinska, M; Zurawska-Klis, M, 2021) |
| "To improve insulin action, most clinicians prescribe Metformin in patients with insulin resistance (IR)." | 9.12 | Metformin does not improve insulin sensitivity over hypocaloric diets in women with polycystic ovary syndrome: a systematic review of 12 studies. ( Garcia-Hernandez, SC; Gonzalez-Mejia, ME; López-Bayghen, E; Pacheco-Soto, BT; Porchia, LM, 2021) |
| "It has been reported that women with polycystic ovary syndrome (PCOS) benefit from metformin therapy." | 9.12 | Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. ( Balen, AH; Barth, JH; Glanville, J; Hayden, CJ; Tang, T; White, D, 2006) |
| " Much better decrease in the level of testosterone and free androgen index was established in group treated with metformin, while the indices of insulin resistance were better influenced in the group treated with rosiglitazone." | 9.12 | Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. ( Mitkov, M; Pehlivanov, B; Terzieva, D, 2006) |
| "Metformin significantly lowered total testosterone concentrations, increased the likelihood of menses, and improved high-density lipoprotein cholesterol levels without affecting measures of insulin sensitivity or body weight." | 9.12 | Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. ( Baltzer, F; Bridger, T; MacDonald, S; Rodd, C, 2006) |
| " Fasting plasma glucose, A1C, HOMA-IR for insulin resistance, lipid profile, and plasma beta-endorphin-like immunoreactivity (BER) were measured before treatment and weekly at the end of each dosing period." | 9.12 | Metformin increases insulin sensitivity and plasma beta-endorphin in human subjects. ( Cheng, JT; Ou, HY; Wu, TJ; Yu, EH, 2006) |
| "We assessed the effect of metformin on body composition and insulin sensitivity in pediatric subjects with exogenous obesity." | 9.12 | Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. ( Ambler, GR; Baur, LA; Cowell, CT; Garnett, SP; Srinivasan, S; Tepsa, M; Ward, GM; Yap, F, 2006) |
| "To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine." | 9.12 | Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. ( Arapé, Y; Baptista, T; Beaulieu, S; de Mendoza, S; Hernández, L; Lacruz, A; Martínez, J; Martinez, M; Rangel, N; Serrano, A; Teneud, L, 2006) |
| "To evaluate the effects of metformin on insulin resistance, androgen concentration, ovulation rates and pregnancy rates in infertile women with polycystic ovary syndrome (PCOS)." | 9.12 | Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. ( Kocak, I; Ustün, C, 2006) |
| "To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome." | 9.12 | Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. ( Almazov, VA; Chazova, I; Shlyakhto, E, 2006) |
| "The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome." | 9.12 | Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. ( Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A, 2006) |
| "8 kg/m2, we assessed effeicacy of metformin-diet for 1 year for reduction of weight, insulin, HOMA insulin resistance (IR), cholesterol, triglycerides, and resumption of regular menses." | 9.12 | Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Luo, G; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "This study was designed to assess the usefulness of a model-based index of insulin sensitivity during an oral glucose tolerance test (OGTT) in the identification of possible changes in this metabolic parameter produced by pharmacological agents known to be potent insulin sensitizers, that is metformin (M) and thiazolidinedione (T)." | 9.12 | Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. ( Hanusch-Enserer, U; Kautzky-Willer, A; Ludvik, B; Pacini, G; Prager, R; Tura, A; Wagner, OF; Winzer, C, 2006) |
| "Metformin therapy is safe and effective in abrogating weight gain, decreased insulin sensitivity, and abnormal glucose metabolism resulting from treatment of children and adolescents with atypicals." | 9.12 | A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. ( Barton, BA; Cottingham, EM; Klein, DJ; Morrison, JA; Sorter, M, 2006) |
| "to compare the clinical, hormonal and biochemical changes after the application of the two ways of influence upon insulin resistance in women with PCOS - reduction of weight and application of metformin." | 9.12 | [Clinical, hormonal and biochemical changes after treatment with metformin and weight reduction in women with polycystic ovary syndrome]. ( Kavŭrdzhikova, S; Mitkov, M; Pekhlivanov, B, 2006) |
| "Adjuvant metformin can improve QOL, insulin sensitivity and glycaemic control in overweight adults with T1DM." | 9.12 | The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. ( Bascombe, LA; Holt, RI; Moon, RJ, 2007) |
| "One hundred and two women with insulin-resistant polycystic ovary syndrome were randomized to treatment with a vitamin B preparation, metformin, or both, in conjunction with standard infertility treatment." | 9.12 | Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. ( Friedler, S; Raziel, A; Ron-El, R; Rotem, C; Schachter, M; Strassburger, D, 2007) |
| "Impaired glucose tolerance (IGT) is associated with cardiovascular risk factors, but the effects of pioglitazone and metformin on IGT are not well described." | 9.12 | Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. ( Eguchi, K; Fukuda, T; Hoshide, S; Ishikawa, J; Kario, K; Numao, T; Shimada, K; Tomizawa, H, 2007) |
| "Metformin may safely assist olanzapine-treated patients in body weight and carbohydrate metabolism control." | 9.12 | Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. ( Baptista, T; Beaulieu, S; Carrizo, E; Connell, L; Dávila, A; de Baptista, EA; El Fakih, Y; Fernández, V; Galeazzi, T; Gutiérrez, MA; Rangel, N; Serrano, A; Servigna, M; Uzcátegui, E; Uzcátegui, M, 2007) |
| "The objective of the study was to evaluate the effects of metformin suspension on insulin sensitivity in PCOS patients." | 9.12 | Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. ( De Feo, P; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2007) |
| "To study the effect of simvastatin and metformin on insulin sensitivity and inflammatory markers." | 9.12 | Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. ( Bulcão, C; Ribeiro-Filho, FF; Roberta Ferreira, SG; Sañudo, A, 2007) |
| " Through its effect on RBP4 expression in adipocytes, metformin may improve total insulin sensitivity in obese individuals including those with MS and delay the onset of manifest DM." | 9.12 | [Serum level of retinol-binding protein 4 in obese patients with insulin resistance and in patients with type 2 diabetes treated with metformin]. ( Donicová, V; Ivancová, G; Petrovicová, J; Semanová, Z; Tajtáková, M; Zemberová, E, 2007) |
| "To evaluate and compare effects of 48-week treatment with rosiglitazone and metformin on insulin resistance in patients infected with Human Immunodeficiency Virus (HIV) receiving highly active antiretroviral therapy (HAART), containing a protease inhibitor." | 9.12 | Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial. ( Janez, A; Karner, P; Maticic, M; Sharma, P; Silic, A; Tomazic, J; Vidmar, L, 2007) |
| "Based on the known effect of metformin (MET) in improving insulin sensitivity in type 2 diabetes, with the scope to focus the effects on glycaemic and free fatty acids (FFA) levels, we studied the effects of a short-term treatment with this drug in obese subjects and obese patients with diabetes or family history of diabetes (FHD)." | 9.11 | Effects of short-term metformin treatment on insulin sensitivity of blood glucose and free fatty acids. ( Belfiore, F; Bellomia, D; Camuto, M; Cavaleri, A; Iannello, S; Milazzo, P; Pisano, MG, 2004) |
| "To determine the clinical, hormonal, and biochemical effects of metformin therapy in obese and nonobese patients with polycystic ovary syndrome (PCOS)." | 9.11 | Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. ( Abi Haidar, M; Alves da Motta, EL; Baracat, EC; de Lima, GR; Maciel, GA; Soares Júnior, JM, 2004) |
| "The data suggest that improvement of the insulin sensitivity with metformin may improve the liver disease in patients with non-alcoholic steatohepatitis." | 9.11 | Metformin in the treatment of patients with non-alcoholic steatohepatitis. ( Dagalp, K; Deveci, S; Gulsen, M; Isik, AT; Kadayifci, A; Ozgurtas, T; Tuzun, A; Uygun, A; Yesilova, Z, 2004) |
| "In a prospective observational study of 42 pregnancies in 39 Caucasian women (age 30 +/- 4 years) with polycystic ovary syndrome (PCOS), we examined effects of metformin on maternal insulin, insulin resistance (IR), insulin secretion (IS), weight gain, development of gestational diabetes (GD), testosterone and plasminogen activator inhibitor activity." | 9.11 | Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout preg ( Glueck, CJ; Goldenberg, N; Loftspring, M; Sherman, A; Wang, P, 2004) |
| "To evaluate the effects of metformin on insulin resistance, ovarian androgen production, and clomiphene-induced ovulation and pregnancy rates in infertile women with polycystic ovary syndrome (PCOS)." | 9.11 | The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. ( Aygen, E; Keleştimur, F; Sahin, Y; Yirmibeş, U, 2004) |
| "103 PCOS women (age 18-40) were treated, according to their body weight, with either 1000 mg or 1700 mg metformin per day after assessment of insulin resistance." | 9.11 | [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome]. ( Elsenbruch, S; Finke, R; Gärtner, R; Hahn, S; Janssen, OE; Mann, K; Quadbeck, B, 2004) |
| "To evaluate the effect of PIO monotherapy and in combination therapy with sulfonylurea (SU) or metformin (MET) on insulin sensitivity as assessed by HOMA-S and QUICKI in a large group of patients (approximately 1000)." | 9.11 | Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. ( Gilmore, KJ; Glazer, NB; Johns, D; Tan, MH; Widel, M, 2004) |
| "Combination of orlistat with metformin did not result in an additional effect on weight loss and insulin resistance when compared to orlistat alone in our study." | 9.11 | Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. ( Balci, MK; Coban, E; Sari, R; Yazicioglu, G, 2004) |
| "To assess the effects of 6 months of metformin therapy on clinical and biochemical parameters in polycystic ovary syndrome (PCOS) and to evaluate those parameters in responders and nonresponders to identify the subjects who respond to an insulin sensitizer in PCOS." | 9.11 | Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. ( Agarwal, N; Kriplani, A, 2004) |
| "Both rosiglitazone and metformin increase hepatic insulin sensitivity, but their mechanism of action has not been compared in humans." | 9.11 | Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. ( Häkkinen, AM; Korsheninnikova, E; Mäkimattila, S; Nyman, T; Tiikkainen, M; Yki-Järvinen, H, 2004) |
| "The aim of this study was to evaluate the effects of metformin and acarbose on insulin resistance, hormone profiles and ovulation rates in patients with clomiphene citrate-resistant polycystic ovary syndrome (PCOS)." | 9.11 | Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. ( Akgün, A; Koç, S; Ozcan, J; Savan, K; Sönmez, AS; Sut, N; Toklar, A; Yasar, L; Yazicioğu, F, 2005) |
| " metformin on the hormonal and biochemical features of patients with polycystic ovarian syndrome (PCOS)." | 9.11 | Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. ( Atkin, SL; Holding, S; Jayagopal, V; Jennings, PE; Kilpatrick, ES, 2005) |
| "Adding metformin slightly modified the treatment effect of COC, causing a more significant decrease in the free androgen index but having no additional positive impact on lipids, insulin sensitivity, SHBG or testosterone." | 9.11 | The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. ( Cibula, D; Dvorakova, K; Fanta, M; Hill, M; Skrenkova, J; Skrha, J; Stanicka, S; Vrbikova, J; Zivny, J, 2005) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 9.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| " Although long-term treatment with metformin can increase Hcy levels in patients with type II diabetes mellitus or coronary heart disease, it is becoming an increasingly accepted and widespread medication in polycystic ovary syndrome (PCOS)." | 9.11 | Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. ( Aslan, E; Bagis, T; Erkanli, S; Haydardedeoglu, B; Kilicdag, EB; Tarim, E; Zeyneloglu, HB, 2005) |
| " This study was designed to determine whether the insulin sensitizer drugs pioglitazone and metformin would improve glucose intolerance and insulin sensitivity by decreasing IMCL." | 9.11 | Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. ( Di Gregorio, GB; Elbein, SC; Kern, PA; Lu, T; Miles, LM; Rasouli, N; Raue, U, 2005) |
| "Much better and faster decrease in the level of testosterone and free androgen index in group with combined use of metformin and Diane35 was established, without deterioration of the anthropometric and biochemical indices and insulin sensitivity." | 9.11 | Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. ( Mitkov, M; Pehlivanov, B; Terzieva, D, 2005) |
| "We aimed to investigate whether metformin would reverse the endocrinopathy of polycystic ovary syndrome (PCOS), allowing resumption of cyclic ovulation and regular menses, and whether metformin causes any change in the serum concentration of insulin-like growth factor-I (IGF-I) in patients with PCOS." | 9.11 | Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy. ( Berker, B; Corapcioglu, D; Demirel, C; Emral, R; Kose, K; Unlu, C, 2004) |
| "Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated." | 9.11 | A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. ( Bugianesi, E; David, E; Gentilcore, E; Manini, R; Marchesini, G; Natale, S; Rizzetto, M; Vanni, E; Villanova, N, 2005) |
| "The aim of this study was to investigate the endothelial status in young women with polycystic ovary syndrome (PCOS), using a simple and easily reproducible hemodynamic method combined with a biological marker and to evaluate the effect of metformin treatment on these parameters." | 9.11 | Metformin administration improves endothelial function in women with polycystic ovary syndrome. ( Aessopos, A; Alexandraki, K; Diamanti-Kandarakis, E; Lekakis, J; Mavrikakis, M; Papamichael, C; Piperi, C; Protogerou, A, 2005) |
| "Weight loss is a feature of protracted metformin therapy in obese women with PCOS, with greater weight reduction potentially achievable with higher doses." | 9.11 | Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. ( Fleming, R; Harborne, LR; Norman, JE; Sattar, N, 2005) |
| "Despite their comparable glycaemic effects in patients with Type 2 diabetes mellitus (T2DM), pioglitazone and metformin may have different effects on insulin sensitivity because they have different mechanisms of action." | 9.11 | Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. ( Johns, D; Laakso, M; Mariz, S; Richardson, C; Roden, M; Tan, MH; Urquhart, R; Widel, M, 2005) |
| "Metformin improves both endothelial function and insulin resistance in patients with MS." | 9.11 | Metformin improves endothelial function in patients with metabolic syndrome. ( Cornoldi, A; Fini, M; Mercuro, G; Rosano, GM; Vitale, C; Volterrani, M, 2005) |
| "In order to explore the effects of metformin combined with cyproterone acetate (CPA) on the clinical features, endocrine and metabolism of the patients with polycystic ovarian syndrome (PCOS), 50 cases of non-obese PCOS were randomly subjected to CPA (CPA treatment group, n = 25) and CPA+ metformin (n = 25) treatment for 6 months." | 9.11 | Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. ( Liu, Y; Lv, L; Sun, Y; Tan, K, 2005) |
| " The aim of this study was to assess the effects of rosiglitazone and metformin on cardiovascular disease risk factors such as insulin resistance, oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome (PCOS)." | 9.11 | The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bukan, N; Cakir, N; Karakoç, A; Törüner, F; Yilmaz, M, 2005) |
| "Adolescents with PCOS treated with metformin or OCP experienced similar beneficial outcomes including reduction in androgen levels, weight loss, and increased insulin sensitivity." | 9.11 | Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. ( Allen, HF; Heptulla, RA; Koenigs, L; Mazzoni, C; Miller, N; Murray, MA; Reiter, EO, 2005) |
| "The primary aim of the present study was to compare the effect of long-term (12-month) combination treatment with glimepiride or rosiglitazone plus metformin on blood pressure in patients with type 2 diabetes mellitus (DM-2) and the metabolic syndrome." | 9.11 | Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S, 2005) |
| "To evaluate metformin efficacy and safety in patients with gout and insulin resistance (IR)." | 9.11 | [Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)]. ( Barskova, VG; Eliseev, MS; Iakunina, IA; Il'inykh, EV; Kudaeva, FM; Nasonov, EL; Tsapina, TN; Volkov, AV; Zilov, AV, 2005) |
| "To evaluate whether, in adolescents with type 1 diabetes, the addition of metformin to insulin and standard diabetes management results in 1) higher insulin sensitivity and 2) lower HbA1c, fasting glucose, insulin dosage (units per kilogram per day) and BMI." | 9.10 | Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. ( Cummings, E; Daneman, D; Finegood, D; Hamilton, J; Zdravkovic, V, 2003) |
| "Pioglitazone, a thiazolidinedione, improves glycemic control primarily by increasing peripheral insulin sensitivity in patients with type 2 diabetes, whereas metformin, a biguanide, exerts its effect primarily by decreasing hepatic glucose output." | 9.10 | Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. ( Festa, A; Gyimesi, A; Herz, M; Jermendy, G; Johns, D; Kerenyi, Z; Pavo, I; Schluchter, BJ; Shestakova, M; Shoustov, S; Tan, MH; Varkonyi, TT, 2003) |
| "Metformin effectively restores insulin sensitivity in insulin-resistant women with polycystic ovary syndrome (PCOS)." | 9.10 | The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. ( Abyholm, T; Dale, PO; Fedorcsák, P; Storeng, R; Tanbo, T, 2003) |
| "This study aims to evaluate the impact of metformin on ovarian response when co-administered during recombinant (r)FSH using the low-dose step-up protocol in clomiphene citrate-resistant polycystic ovarian syndrome (PCOS) patients with normal glucose tolerance." | 9.10 | Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. ( Bükülmez, O; Demirol, A; Koray, Z; Yarali, H; Yiğit, N; Yildiz, BO; Zeyneloğlu, HB, 2002) |
| " After treatment, women in the OC + metformin group had significant decreases in BMI and WHR, and a significant increase in insulin sensitivity, in contrast to those in the OC group, who had insignificant changes in these parameters." | 9.10 | Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. ( Durmusoglu, F; Elter, K; Imir, G, 2002) |
| "Nineteen obese patients with impaired glucose tolerance (IGT) were treated with either metformin or placebo in a randomized, double-blind, placebo-controlled, cross-over study." | 9.09 | Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. ( Golay, A; Lehmann, T; Morel, Y; Pasik, C; Perneger, T; Reaven, GM; Vadas, L, 1999) |
| "This study suggests that a relatively low dosage of metformin reduces insulin resistance and related cardiovascular risk parameters in HIV-infected patients with lipodystrophy." | 9.09 | Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. ( Basgoz, N; Corcoran, C; Davis, B; Grinspoon, S; Hadigan, C; Sax, P, 2000) |
| "Metformin, a biguanide antihyperglycemic drug, has been shown to improve ovarian function and glucose metabolism in women with polycystic ovary syndrome (PCOS), but results concerning its effects on insulin sensitivity are controversial." | 9.09 | Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tapanainen, JS; Vauhkonen, I, 2000) |
| "To determine the clinical, hormonal and biochemical effect of 4-5 months of insulin-sensitizing therapy (hypocaloric diet+metformin) in obese patients with polycystic ovary syndrome (PCOS)." | 9.09 | Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. ( Kinalska, I; Kinalski, M; Kowalska, I; Straczkowski, M; Wolczyski, S, 2001) |
| "Since metformin improves insulin sensitivity, it has been indicated for patients with diabetes and hypertension, which are insulin-resistant conditions." | 9.09 | Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. ( Ferreira, SR; Kohlmann, NE; Uehara, MH; Zanella, MT, 2001) |
| "Metformin effects on insulin resistance and insulin/glucose relationships during an oral glucose tolerance test (OGTT) were investigated in 60 non-diabetic male patients previously treated with coronary artery bypass surgery or angioplasty in an open, 12 week prospective study." | 9.08 | Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease. ( Carlsen, SM; Følling, I; Grill, V, 1998) |
| "To investigate the effects of metformin on glycemic control, insulin resistance, and risk factors for cardiovascular disease in NIDDM subjects from two ethnic groups (Caucasian and Asian) with different risks of cardiovascular disease." | 9.07 | Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. ( Nagi, DK; Yudkin, JS, 1993) |
| "The effects of metformin on glycaemia, insulin and c-peptide levels, hepatic glucose production and insulin sensitivity (using the euglycaemic, hyperinsulinaemic clamp) were evaluated at fortnightly intervals in 9 Type 2 diabetic patients using a stepwise dosing protocol: Stage 1--no metformin for four weeks; stage 2--metformin 500mg mane; stage 3--metformin 500mg thrice daily; stage 4--metformin 1000mg thrice daily." | 9.07 | Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. ( Bird, DM; Cameron, DP; Ma, A; McIntyre, HD; Paterson, CA; Ravenscroft, PJ, 1991) |
| "The aim of this study was to review TZD and metformin as pharmacological treatments for insulin resistance associated with obesity and cancer." | 9.05 | Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin. ( Biondo, LA; de O S Ferreira, KC; Neto, JCR; Teixeira, AAS, 2020) |
| "Breast cancer patients receiving metformin as treatment for diabetes showed significant reduction in levels of insulin, fasting glucose, CRP, HOMA, leptin, BMI, and Ki-67." | 9.05 | The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials. ( Chhabra, M; Clark, C; Gudi, SK; Manzari, N; Mousavi, SM; Naik, G; Rahmani, J; Thompson, J; Varkaneh, HK; Zhang, Y, 2020) |
| " The aim of this was to measure the effect of metformin (850 mg/twice daily) on insulin sensitivity." | 9.05 | Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. ( Aubertin, J; Brottier, E; Gin, H; Messerchmitt, C, 1985) |
| "Metformin induces reductions in thyroid nodule size and TSH and HOMA-IR levels in patients with thyroid nodules and insulin resistance." | 9.01 | Role of Metformin in the Treatment of Patients with Thyroid Nodules and Insulin Resistance: A Systematic Review and Meta-Analysis. ( He, X; Hu, C; Liu, C; Liu, Y; Tang, W; Wu, D; Xu, B; Xu, T, 2019) |
| "Metformin has shown its effectiveness in reducing body mass index (BMI) in obese children and adolescents, but relevant evidence for improving insulin resistance in overweight or obese children and adolescents is inconclusive." | 9.01 | The effects of metformin on insulin resistance in overweight or obese children and adolescents: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. ( He, H; Sun, J; Wang, Y; Zhang, X, 2019) |
| "To perform meta-analyses of studies evaluating the risk of pre-eclampsia in high-risk insulin-resistant women taking metformin prior to, or during pregnancy." | 8.98 | Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. ( Alqudah, A; Graham, U; Lyons, TJ; McClements, L; McKinley, MC; McNally, R; Watson, CJ, 2018) |
| "In September 2018, we searched PubMed, Embase, and the Cochrane Library for studies published in English using the keywords metformin, obesity/overweight, and weight loss." | 8.98 | Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review. ( Knibbe, CAJ; Lentferink, YE; van der Vorst, MMJ, 2018) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 8.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| "For several years there is an evidence for a relationship between the polycystic ovary syndrome (PCOS) and of insulin resistance; therefore metformin, an insulin sensitizer, is used for the treatment for more than 10 years." | 8.93 | [Metformin for the treatment of polycystic ovary syndrome]. ( Bekes, I; Gundelach, T; Hancke, K; Janni, W; Rodewald, M, 2016) |
| "Combined statin and metformin therapy can improve lipid and inflammation parameters, but cannot effectively improve insulin sensitivity and reduce hyperandrogenism in women with PCOS." | 8.91 | An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials. ( Cai, R; Huang, R; Sun, H; Sun, J; Wang, P; Wang, S; Xia, W; Yuan, Y; Zhou, Y, 2015) |
| "Despite the known glucose-lowering effects of metformin, more recent clinical interest lies in its potential as a weight loss drug." | 8.90 | Effects of metformin on weight loss: potential mechanisms. ( Kashyap, SR; Malin, SK, 2014) |
| "Metformin is an effective oral anti-hyperglycemic agent that is widely used to manage diabetes mellitus type 2 in the general population and more recently, in pregnancy." | 8.89 | Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. ( Goulis, DG; Lautatzis, ME; Vrontakis, M, 2013) |
| " Antidiabetic biguanides such as metformin, which reduce hyperglycemia and hyperinsulinemia by decreasing insulin resistance, extend lifespan, and inhibit carcinogenesis in rodents." | 8.89 | Metformin: do we finally have an anti-aging drug? ( Anisimov, VN, 2013) |
| "Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)." | 8.88 | A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012) |
| "In agreement with the previous review, metformin was associated with improved clinical pregnancy but there was no evidence that metformin improves live birth rates whether it is used alone or in combination with clomiphene, or when compared with clomiphene." | 8.88 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2012) |
| "Compared to metformin, TZDs had the same effectiveness in treating insulin sensitivity and lowering androgen in PCOS patients, but the effect on weight loss was not as good as metformin." | 8.88 | Comparative efficacy of thiazolidinediones and metformin for polycystic ovary syndrome. ( Du, Q; Wang, YJ, 2012) |
| "In agreement with the previous review, metformin is still of benefit in improving clinical pregnancy and ovulation rates." | 8.86 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2010) |
| " However, the antihyperglycaemic agent metformin appears promising in some recent studies and we review the literature that evaluates metformin for limiting or reversing atypical antipsychotic drug-induced weight gain and glucose metabolism dysregulation." | 8.86 | Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. ( Fredrickson, SK; Hasnain, M; Vieweg, WV, 2010) |
| " While metformin has been shown to attenuate weight gain and insulin resistance, not all studies have shown a benefit in the reduction of antipsychotic-induced weight gain and insulin resistance." | 8.86 | The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. ( Coleman, CI; Ehret, M; Goethe, J; Lanosa, M, 2010) |
| " The biguanide, N, N' dimethyl-biguanide: Metformin is an antidiabetic drug that increases glucose utilization in insulin-sensitive tissues and is useful in the reduction of both insulin resistance and circulating androgens as well as restoring ovulation." | 8.84 | Metformin in the treatment of polycystic ovary syndrome. ( Motta, DA, 2008) |
| " Reduction of hyperinsulinism and improvement of insulin sensitivity with metformin has been reported to ameliorate these abnormalities in many, but not all studies, with few adverse effects." | 8.84 | Metformin and polycystic ovary syndrome. ( Lebinger, TG, 2007) |
| " We included randomized trials of at least 8 weeks duration that compared metformin with placebo or no treatment in persons without diabetes and evaluated body mass index, fasting glucose, fasting insulin, calculated insulin resistance, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and the incidence of new-onset diabetes." | 8.84 | Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. ( Buckley, NS; Kahn, JA; Salpeter, EE; Salpeter, SR, 2008) |
| "Metformin is an insulin sensitizer currently used for treating type-2 diabetes mellitus and recently administered for inducing ovulatory menstrual cycles in oligo-amenorrhoeic patients with polycystic ovary syndrome (PCOS)." | 8.84 | Outlook: metformin use in infertile patients with polycystic ovary syndrome: an evidence-based overview. ( Oppedisano, R; Orio, F; Palomba, S; Tolino, A; Zullo, F, 2008) |
| "The debate on metformin use in polycystic ovary syndrome (PCOS) has mainly focused on its treatment for infertility in ovulation induction and menstrual cyclicity." | 8.81 | Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction. ( Oehninger, S; Stadtmauer, LA; Wong, BC, 2002) |
| "Low birth weight (LBW) followed by a rapid postnatal catch-up in weight predisposes individuals to a central distribution of body fat, which is reverted by metformin." | 8.31 | Circulating GDF15 concentrations in girls with low birth weight: effects of prolonged metformin treatment. ( Bassols, J; Carreras-Badosa, G; de Zegher, F; Díaz, M; Gavaldà-Navarro, A; Ibáñez, L; López-Bermejo, A; Villarroya, F; Villarroya, J, 2023) |
| "To study the effectiveness of metformin treatment in patients with acne but who do not have PCOS and to understand the mechanisms of action of metformin in acne not related to PCOS." | 8.31 | Effects of metformin on clinical, hormonal and relevant gene expression parameters in patients with acne: an observational study. ( De, D; Dutta, P; Handa, S; Kamboj, P; Kaushik, A; Pal, A; Saikia, UN, 2023) |
| " We compared the clinical pregnancy rate (primary outcome) and controlled ovarian stimulation (COS)-related parameters (secondary outcomes) between patients with and without metformin pre-treatment for all PCOS patients not grouped by HOMA-IR, PCOS patients with HOMA-IR < 2." | 8.31 | The homeostasis model assessment of insulin resistance is a judgment criterion for metformin pre-treatment before IVF/ICSI and embryo transfer cycles in patients with polycystic ovarian syndrome. ( Gao, R; Li, Z; Min, W; Qin, L, 2023) |
| "The high-fat diet-induced mouse model of obesity and insulin resistance of both sexes was developed in a randomized block experiment and bulk RNA-Seq of the ileum tissue was the method of choice for comparative transcriptional profiling after metformin intervention for ten weeks." | 8.31 | Metformin targets intestinal immune system signaling pathways in a high-fat diet-induced mouse model of obesity and insulin resistance. ( Ansone, L; Birzniece, L; Brīvība, M; Elbere, I; Jagare, L; Kalniņa, I; Kloviņš, J; Silamiķele, L; Silamiķelis, I, 2023) |
| "Twelve-month metformin treatment reduced fat content, waist circumference, glycated hemoglobin, glucose and triglycerides, as well as improved insulin sensitivity." | 8.12 | Impaired metabolic effects of metformin in men with early-onset androgenic alopecia. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "The current study was to evaluate the effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes." | 8.12 | Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes. ( Hao, Z; Li, G; Liu, Y; Shen, Y; Sun, Y; Wen, Y, 2022) |
| " Both metformin and myo-inositol were found to improve insulin sensitivity and to reduce thyrotropin levels in individuals with hypothyroidism." | 8.12 | Differences in levothyroxine action on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity between metformin- and myo-inositol-treated women with autoimmune subclinical hypothyroidism. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| " The present study compared the impact of low-grade systemic inflammation and insulin resistance on levothyroxine action in subjects with this disorder." | 8.12 | Thyroid Antibody Titers and Hypothalamic-Pituitary-Thyroid Axis Activity in Levothyroxine-Treated Women With Autoimmune Subclinical Hypothyroidism Receiving Atorvastatin or Metformin. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "Of those prescribed metformin, 83% were overweight or obese and 72% had elevated HOMA2-IR scores." | 8.12 | Metabolic and clinical profiles of young people with mood or psychotic disorders who are prescribed metformin in an inpatient setting. ( Carpenter, J; Hickie, IB; McHugh, C; Park, S; Scott, EM; Wilson, C, 2022) |
| "Metformin, a drug widely used to treat insulin resistance, and training that combines aerobic and strength exercise modalities (i." | 8.12 | Overweight and Obese Adult Patients Show Larger Benefits from Concurrent Training Compared with Pharmacological Metformin Treatment on Insulin Resistance and Fat Oxidation. ( Afonso, J; Azócar-Gallardo, J; García-García, JM; González-Rojas, L; Granacher, U; Ojeda-Aravena, A; Ramirez-Campillo, R; Sá, M, 2022) |
| "The results showed that CGA decreased body weight and improved glucose tolerance and insulin resistance, and these effects were similar to those of metformin." | 8.12 | Chlorogenic acid improves glucose tolerance, lipid metabolism, inflammation and microbiota composition in diabetic db/db mice. ( Guo, K; Li, Q; Shen, L; Yan, Y; Zhou, X, 2022) |
| "This study aimed to investigate the effects of metformin on gingival wound healing in insulin-resistant prediabetes." | 8.12 | Metformin accelerates wound healing by Akt phosphorylation of gingival fibroblasts in insulin-resistant prediabetes mice. ( Buranasin, P; Iwata, T; Kido, D; Kominato, H; Mikami, R; Mizutani, K; Nagasawa, T; Nakagawa, K; Saito, N; Takeda, K; Takemura, S, 2022) |
| " After metformin and exenatide supplementation, body weight, chow intake and ovarian morphology were observed." | 8.02 | Metformin and exenatide upregulate hepatocyte nuclear factor-4α, sex hormone binding globulin levels and improve hepatic triglyceride deposition in polycystic ovary syndrome with insulin resistance rats. ( He, B; Li, X; Lv, B; Wang, D; Xing, C; Zhao, H, 2021) |
| "The beneficial effects of metformin, especially its capacity to ameliorate insulin resistance (IR) in polycystic ovary syndrome (PCOS), explains why it is widely prescribed." | 8.02 | Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance. ( Li, S; Xiao, L; Xie, Y, 2021) |
| "Resveratrol (RSV) and metformin (MET) play a role in the treatment of diabetes; however, the mechanisms through which they mediate insulin resistance by regulating long non‑coding RNAs (lncRNAs) remain unknown." | 8.02 | Comparative analysis of long non‑coding RNA expression profiles induced by resveratrol and metformin treatment for hepatic insulin resistance. ( Hou, X; Ma, H; Shu, L; Song, G; Wang, C, 2021) |
| "The present study aimed to investigate the possible effects of metformin on the olanzapine-induced insulin resistance in rats." | 8.02 | Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats. ( Guo, C; Li, H; Liu, J, 2021) |
| " Insulin and C-peptide responses and insulin sensitivity were calculated from 2-h oral glucose tolerance tests." | 8.02 | Association of glycemia with insulin sensitivity and β-cell function in adults with early type 2 diabetes on metformin alone. ( Banerji, MA; Barzilay, J; Cohen, RM; Gonzalez, EV; Ismail-Beigi, F; Kahn, SE; Lachin, JM; Mather, KJ; Raskin, P; Rasouli, N; Utzschneider, KM; Wexler, DJ; Younes, N, 2021) |
| "High uric acid (HUA) is associated with insulin resistance (IR) in cardiomyocytes." | 8.02 | Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo. ( Chen, Y; Jiao, Z; Li, Y; Li, Z; Xie, Y, 2021) |
| " Metformin increases insulin sensitivity, but it is associated with unsatisfied benefits of weight loss." | 8.02 | The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis. ( Deng, Y; Ding, X; Ma, R; Sun, A; Wang, Y, 2021) |
| "Metformin with lifestyle interventions significantly reduced weight, BMI, and BMI z score in pediatric patients with obesity and insulin resistance up to 24 months, compared with intensive and routine counseling alone." | 8.02 | Metformin for pediatric obesity and insulin resistance: a retrospective study within an integrated health care system. ( Concepcion, JQ; Huang, K; Tucker, LY, 2021) |
| " In both groups, metformin reduced glucose levels, homeostasis model assessment 1 of insulin resistance index (HOMA1-IR), thyrotropin levels and Jostel's thyrotropin index, as well as increased SPINA-GT." | 7.96 | The impact of oral hormonal contraception on metformin action on hypothalamic-pituitary-thyroid axis activity in women with diabetes and prediabetes: A pilot study. ( Kowalcze, K; Krysiak, R; Okopień, B; Wolnowska, M, 2020) |
| "Our data suggest a potential use of treprostinil as an early treatment for mild metabolic syndrome-associated PH-HFpEF and that combined treatment with treprostinil and metformin may improve hyperglycemia and cardiac function in a more severe disease." | 7.96 | Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. ( Avolio, T; Bachman, TN; Bai, Y; Baust, JJ; Bonetto, A; Considine, RV; Cook, T; Fisher, A; Gladwin, MT; Goncharov, DA; Goncharova, EA; Halliday, G; Hu, J; Huot, JR; Lai, YC; Machado, RF; McTiernan, CF; Mora, AL; Satoh, T; Sebastiani, A; Tan, J; Vanderpool, RR; Wang, L, 2020) |
| "To describe the composition of jejunal microbiota in morbidly obese patients, as well as its link with insulin resistance and metformin treatment." | 7.96 | Mucosa-associated microbiota in the jejunum of patients with morbid obesity: alterations in states of insulin resistance and metformin treatment. ( García-Fuentes, E; Gonzalo, M; Gutiérrez-Repiso, C; Ho-Plágaro, A; Martín-Núñez, GM; Moreno-Indias, I; Rodríguez-Cañete, A; Tinahones, FJ, 2020) |
| "After six months, the fasting insulin, glucose/insulin ratio, and homeostatic model assessment estimates for insulin resistance were significantly improved in metformin group." | 7.96 | Metformin metabolic and vascular effects in normal weight hyperinsulinemic polycystic ovary syndrome patients treated with contraceptive vaginal ring. A pilot study. ( Artini, PG; Battaglia, B; Battaglia, C; Casadio, P; Rizzo, R, 2020) |
| " This study was set out to explore the molecular mechanism of metformin in the treatment of T1D insulin resistance." | 7.96 | Metformin Decreases Insulin Resistance in Type 1 Diabetes Through Regulating p53 and RAP2A in vitro and in vivo. ( Jiao, PF; Ma, XJ; Ren, GF; Xiao, LL; Yan, YS, 2020) |
| "The aim of this study was to investigate the effects of metformin supplementation on metabolic dysfunction, testicular antioxidant capacity, apoptosis, inflammation and spermatogenesis in male mice with high-fat and high-cholesterol diet-induced obesity." | 7.96 | Metformin Ameliorates Testicular Function and Spermatogenesis in Male Mice with High-Fat and High-Cholesterol Diet-Induced Obesity. ( Cha, TL; Chang, TC; Lin, SH; Liu, CY; Tsao, CW; Wu, ST, 2020) |
| " In both study arms, metformin reduced plasma glucose levels and improved insulin sensitivity but this effect was stronger in subjects receiving vitamin D." | 7.96 | The impact of combination therapy with metformin and exogenous vitamin D on hypothalamic-pituitary-thyroid axis activity in women with autoimmune thyroiditis and high-normal thyrotropin levels. ( Kowalcze, K; Krysiak, R; Okopień, B, 2020) |
| "This study aims to demonstrate the effects of metformin on epicardial adipose tissue and electromechanical delay in patients using metformin for insulin resistance." | 7.96 | Effects of metformin on epicardial adipose tissue and atrial electromechanical delay of obese children with insulin resistance. ( Çelik, E; Güneş, H; Özmen, Ş; Temiz, F, 2020) |
| " Metformin reduced glucose levels and glycated haemoglobin, improved insulin sensitivity and decreased thyrotrophin levels." | 7.96 | Different effects of metformin on hypothalamic-pituitary-thyroid axis activity in levothyroxine-treated and levothyroxine-naïve women with non-autoimmune hypothyroidism. ( Kowalcze, K; Krysiak, R; Okopień, B, 2020) |
| "Although the results of our and other studies show that baicalin can enhance glucose uptake and insulin sensitivity in skeletal muscle and adipocytes of mice, the specific metabolic contribution of baicalin on hepatic insulin resistance and gluconeogenic activity is still unclear." | 7.91 | Baicalin ameliorates hepatic insulin resistance and gluconeogenic activity through inhibition of p38 MAPK/PGC-1α pathway. ( Bo, P; Bu, L; Fang, P; Gu, X; Shi, M; Sun, Y; Zhang, Z, 2019) |
| " Metformin is commonly used to treat insulin resistance-glucose intolerance, and flutamide, an androgen receptor (AR) antagonist, is used to target hyperandrogenemia and dyslipidemia." | 7.91 | Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. ( Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R, 2019) |
| "We examine the effects of metformin on insulin resistance (IR) and mood including in adolescent and adult women with polycystic ovary syndrome (PCOS)." | 7.91 | A pilot trial of metformin for insulin resistance and mood disturbances in adolescent and adult women with polycystic ovary syndrome. ( Aghamohammadzadeh, N; Erensoy, H; Ghafarzadeh, S; Nader, ND; Niafar, M, 2019) |
| "Background Whether metformin might affect the risk of benign nodular goiter in patients with type 2 diabetes mellitus has not been investigated." | 7.91 | Metformin reduces risk of benign nodular goiter in patients with type 2 diabetes mellitus. ( Tseng, CH, 2019) |
| "Metformin with reduction of ECM component as collagen VI, MMP2 and MMP9, integrin/ERK pathway, necrosis markers as RIPK1, RIPK3 and MLKL, and apoptosis markers including DAP, DAPK1, DAPK3 and SIVA effects on fibrosis in insulin resistant and hypertrophied adipocytes in vitro." | 7.91 | Metformin reduces fibrosis factors in insulin resistant and hypertrophied adipocyte via integrin/ERK, collagen VI, apoptosis, and necrosis reduction. ( Malekpour-Dehkordi, Z; Mohiti-Ardakani, J; Naghiaee, Y; Nourbakhsh, M; Sharifi, R; Teimourian, S, 2019) |
| "The aim of this study was to evaluate the effect of orlistat or metformin combined with Diane-35 on anthropometric, hormonal and metabolic parameters in overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance (fasting insulin > 10 mIU/L)." | 7.88 | Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| " The aim of the current work was to investigate the effect of metformin versus vitamin D (and also simultaneous administration) therapy in type 2 diabetic (T2D) rats on the state of the muscle and insulin sensitivity." | 7.88 | Synergistic actions of vitamin D and metformin on skeletal muscles and insulin resistance of type 2 diabetic rats. ( Amin, SN; Hassan, SS; Hussein, UK; Rashed, LA; Yassa, HD, 2018) |
| " The aim of present study was to investigate the therapeutic potentials of resveratrol (RSV) alone and/or in combination with vitamin-E (Vit-E) against hyperglycemia-induced modulations using experimentally alloxan-induced diabetic animal model." | 7.88 | Resveratrol regulates hyperglycemia-induced modulations in experimental diabetic animal model. ( Akash, MSH; Munawar, SM; Rehman, K; Saeed, K, 2018) |
| "The aim of this study was to evaluate the risk of major birth defects and spontaneous abortion after metformin use during the first trimester of pregnancy." | 7.88 | Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study. ( Beck, E; Grupe, K; Schaefer, C; Scherneck, S; Schlinke, N; Weber-Schoendorfer, C, 2018) |
| " Ursolic acid, metformin, gliclazide and their combinations when administered daily for 30 days significantly improved insulin sensitivity apart from behavioral and biochemical alterations in stressed mice." | 7.88 | Synergistic action of ursolic acid and metformin in experimental model of insulin resistance and related behavioral alterations. ( Ahuja, S; Akhtar, A; Kumar, A; Mourya, A; Sah, SP, 2018) |
| "Metformin treatment significantly improved IR but had no effect on peak VO(2), the primary endpoint of our study." | 7.86 | The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. ( AlZadjali, MA; Ang, DS; Choy, A; Lang, CC; Ogston, S; Petrie, JR; Struthers, AD; Symon, R; Wong, AK, 2012) |
| "An extensive body of literature indicates a relationship between insulin resistance and the up-regulation of the kynurenine pathway, i." | 7.85 | Successful metformin treatment of insulin resistance is associated with down-regulation of the kynurenine pathway. ( Burghardt, P; Kumar, A; Muzik, O; Seyoum, B; Yi, Z, 2017) |
| "The present investigation was designed to explore the effectiveness of pterostilbene (PT) on insulin resistance, metabolic syndrome and oxidative stress in fructose-fed insulin resistant rats." | 7.85 | Pterostilbene ameliorates insulin sensitivity, glycemic control and oxidative stress in fructose-fed diabetic rats. ( Kosuru, R; Singh, S, 2017) |
| " In the present study, we investigated the potential therapeutic effects of metformin (Met) and saxagliptin (Saxa), as insulin sensitizing agents, in a rat model of brain aging and AD using D-galactose (D-gal, 150 mg/kg/day, s." | 7.85 | Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. ( Attia, A; El-Shenawy, S; Gomaa, N; Hassan, A; Hegazy, R; Kenawy, S; Zaki, H, 2017) |
| "To compare metformin and pioglitazone with standard interferon and ribavirin in achieving sustained virological response in chronic hepatitis C patients." | 7.85 | Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study. ( Butt, NF; Hamid, S; Khan, IM; Malik, BR; Malik, U; Randhawa, FA, 2017) |
| "BMI in overweight patients were significantly improved with metformin treatment duration (p < 0." | 7.85 | Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome. ( Chen, PC; Ou, HT; Wu, MH, 2017) |
| "To compare the therapeutic potential of TP-113, a unique molecular entity linking DHA with metformin, for alleviating insulin resistance in obese diabetic mice through the PDX/IL-6 pathway." | 7.85 | Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice. ( Barbier, O; Lachance, D; Marette, A; Mitchell, PL; Nachbar, R; St-Pierre, P; Trottier, J, 2017) |
| "Metformin increased insulin sensitivity, but did not affect neointimal thickness in either the normal fat or high fat diet-fed rats." | 7.85 | High-dose metformin (420mg/kg daily p.o.) increases insulin sensitivity but does not affect neointimal thickness in the rat carotid balloon injury model of restenosis. ( Breen, DM; Dalvi, P; Dolinsky, VW; Giacca, A; Guo, J; Lam, L; Pereira, TJ; Swain, N; Yeung, LSN, 2017) |
| " In patients with untreated amiodarone-induced hypothyroidism, but not in the other groups of patients, metformin reduced serum levels of thyrotropin and this effect correlated weakly with its action on insulin sensitivity." | 7.83 | The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and amiodarone-induced hypothyroidism. ( Gilowska, M; Krysiak, R; Okopień, B; Szkróbka, W, 2016) |
| "To compare the efficacy of acarbose and metformin in overweight and/or obese patients with newly diagnosed type 2 diabetes mellitus (T2DM)." | 7.83 | Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity. ( Chen, J; Liao, L; Sun, W; Wang, Y; Zeng, C, 2016) |
| "This substudy of the AWARD-3 trial evaluated the effects of the once-weekly glucagon-like peptide-1 receptor agonist, dulaglutide, versus metformin on glucose control, pancreatic function and insulin sensitivity, after standardized test meals in patients with type 2 diabetes." | 7.83 | Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes. ( de la Peña, A; Del Prato, S; Karanikas, CA; Ludvik, B; Mari, A; Milicevic, Z; Pechtner, V; Shurzinske, L, 2016) |
| "Metformin administration attenuates endotoxemia and enhances insulin signaling in high-fat fed mice, which contributes to its anti-diabetic effects." | 7.83 | Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling. ( Chai, DD; Ren, LW; Yang, HY; Yu, ZW; Zhan, P; Zhou, ZY, 2016) |
| " Here we show that treatment with the antidiabetic drug metformin inhibits excessive ECM deposition in WAT of ob/ob mice and mice with diet-induced obesity, as evidenced by decreased collagen deposition surrounding adipocytes and expression of fibrotic genes including the collagen cross-linking regulator LOX Inhibition of interstitial fibrosis by metformin is likely attributable to the activation of AMPK and the suppression of transforming growth factor-β1 (TGF-β1)/Smad3 signaling, leading to enhanced systemic insulin sensitivity." | 7.83 | AMPK Activation by Metformin Suppresses Abnormal Extracellular Matrix Remodeling in Adipose Tissue and Ameliorates Insulin Resistance in Obesity. ( Fry, J; Han, J; Jiang, B; Li, Q; Luo, T; Nocon, A; Rui, X; Sherban, A; Xu, XJ; Yan, Y; Yang, Q; Zang, M, 2016) |
| " The present study aimed to evaluate the comparative effects of sodium butyrate (NaB) and metformin on the glucose homeostasis, insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat." | 7.83 | Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: A comparative study with metformin. ( Jena, G; Khan, S, 2016) |
| "This study aims to investigate the effects of metformin and resveratrol on muscle insulin resistance with emphasis on the regulation of lipolysis in hypoxic adipose tissue." | 7.83 | Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. ( Feng, X; Hou, T; Li, A; Liu, B; Liu, K; Zhang, N; Zhao, W, 2016) |
| "We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats." | 7.83 | Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016) |
| " TZDs are commonly prescribed in combination with metformin (MET) and thus we sought to examine the combined effects of RSV and MET in treating insulin resistance." | 7.83 | Beneficial effects of combined resveratrol and metformin therapy in treating diet-induced insulin resistance. ( Frendo-Cumbo, S; MacPherson, RE; Wright, DC, 2016) |
| "To evaluate effects of metformin on endocrine, metabolic parameters and endometrial androgen receptor (AR) expression in polycystic ovary syndrome (PCOS)." | 7.81 | Effects of metformin on endocrine, metabolic milieus and endometrial expression of androgen receptor in patients with polycystic ovary syndrome. ( Fujimori, K; Hashimoto, S; Ito-Yamaguchi, A; Kumagami, A; Suganuma, R; Yoshida-Komiya, H, 2015) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 7.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| " Metformin has been introduced in the treatment of PCOS to manage insulin resistance and hyperglycemia." | 7.81 | Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model. ( Abramovich, D; Bas, D; Bianchi, MS; Di Pietro, M; Irusta, G; Parborell, F; Pascuali, N; Tesone, M, 2015) |
| "Our findings suggest that the loss-of-function variant OCT2-T201M (rs145450955) contribute to changes in insulin resistance and beta cell activity in patients with T2D treated with metformin." | 7.81 | The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin. ( Alizadeh, A; Bahar, A; Hashemi-Soteh, MB; Kashi, Z; Mahrooz, A; Masoumi, P, 2015) |
| " Leucine (Leu) activates Sirt1 by lowering its Km for NAD(+) and potentiates other sirtuin/AMPK-activators, resulting in improvement of insulin sensitivity." | 7.81 | Leucine amplifies the effects of metformin on insulin sensitivity and glycemic control in diet-induced obese mice. ( Bruckbauer, A; Cao, Q; Cui, X; Fu, L; Li, F; Shi, H; Wu, R; Xue, B; Zemel, MB, 2015) |
| " L6 muscle cells were incubated with palmitic acid (PA) to induce insulin resistance and then treated with metformin and/or the AMPK inhibitor, compound C." | 7.81 | Metformin attenuates palmitic acid-induced insulin resistance in L6 cells through the AMP-activated protein kinase/sterol regulatory element-binding protein-1c pathway. ( Bi, Y; Bu, R; Cao, S; Shi, J; Tang, S; Wu, W; Yin, W; Zhu, D, 2015) |
| "To examine, in an animal study, whether EA combined with metformin (EA-metformin) results in a better glucose-lowering effect and greater insulin sensitivity than metformin alone in steroid-induced insulin-resistant rats." | 7.81 | Electroacupuncture plus metformin lowers glucose levels and facilitates insulin sensitivity by activating MAPK in steroid-induced insulin-resistant rats. ( Chang, SL; Lee, YC; Liao, HY; Lin, JG; Sun, MF, 2015) |
| "To evaluate the effects of treatment with metformin on a murine model of obesity-associated erectile dysfunction." | 7.81 | Treatment With Metformin Improves Erectile Dysfunction in a Murine Model of Obesity Associated With Insulin Resistance. ( Alexandre, EC; Antunes, E; Calixto, MC; Calmasini, FB; Silva, FH, 2015) |
| "The aim of this study was to determine the relevance of apelin and insulin resistance (IR) with polycystic ovary syndrome (PCOS) and to assess the possible therapeutic effect of the combined therapy of drospirenone-ethinylestradiol (DRSP-EE) combined with metformin." | 7.81 | Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin. ( Sun, X; Wu, X; Yu, X; Zhang, W; Zhou, Y, 2015) |
| "Sixty six adult patients with schizophrenia or schizoaffective disorder treated, with atypical antipsychotics, and who had increased by more than 10% their pre treatment body weight, were randomly assigned to receive metformin or placebo in a double-blind study." | 7.81 | Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. ( Dayabandara, M; de Silva, VA; Gunewardena, H; Hanwella, R; Henegama, T; Suraweera, C; Wijesundara, H, 2015) |
| " The aim of this study was to assess the effects of metformin on insulin resistance, oxidant-antioxidant status, endothelial dysfunction, lipid metabolism and their contribution to the risks of cardiovascular disease in women with PCOS." | 7.80 | The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. ( Bayram, F; Diri, H; Kocer, D, 2014) |
| "Insulin-sensitizer treatment with metformin is common in polycystic ovary syndrome (PCOS)." | 7.80 | Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism. ( Lerchbaum, E; Obermayer-Pietsch, B; Pieber, T; Schweighofer, N; Schwetz, V; Trummer, O, 2014) |
| " To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity." | 7.80 | Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. ( An, X; Botchlett, R; Chen, L; Guo, T; Guo, X; Hu, X; Huo, Y; Li, H; Li, Q; Pei, Y; Qi, T; Woo, SL; Wu, C; Xiao, X; Xu, H; Xu, Y; Zhao, J; Zhao, Y; Zheng, J, 2014) |
| "Metformin and swimming exercise improved lipid profile, and increased insulin sensitivity and body weight reduction were observed." | 7.80 | Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats. ( Gao, Y; Luo, L; Pan, T; Wang, C, 2014) |
| "To study the effect of Mudan Granule (MD) on the glucose metabolism and beta cell function in monosodium glutamate (MSG) induced obese mice with insulin resistance (IR)." | 7.80 | [Effect of Mudan Granule on islets beta cell function in monosodium glutamate induced obese mice with insulin resistance: an experimental study]. ( Hou, SC; Liu, Q; Liu, SN; Shen, ZF; Sun, SJ, 2014) |
| "To investigate the therapeutical effects of visfatin and metformin on insulin resistance and reproductive endocrine disorder in rats with polycystic ovary syndrome (PCOS)." | 7.80 | [Effects of visfatin and metformin on insulin resistance and reproductive endocrine in rats with polycystic ovary syndrome]. ( Gu, J; Li, T; Su, S; Wan, J; Zhang, T; Zou, X, 2014) |
| "To analyze the level of serum leptin and its relations with insulin resistance in patients with polycystic ovary syndrome (PCOS) so as to investigate the clinical effect of aciesis in PCOS under treatment of metformin." | 7.80 | [Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome]. ( Cheng, X; Guo, J; Xie, J, 2014) |
| "Women with anovulatory polycystic ovary syndrome (PCOS) are generally insulin-resistant and as a consequence are often treated with the biguanide metformin." | 7.79 | Metformin inhibits follicle-stimulating hormone (FSH) action in human granulosa cells: relevance to polycystic ovary syndrome. ( Elia, A; Jawad, Z; Mason, HD; Pellatt, L; Rice, S, 2013) |
| "Metformin treatment enhances both adiponectin activity and insulin sensitivity, resulting in a less hyperandrogenic state in patients with PCOS." | 7.79 | Role of adiponectin and its receptor in prediction of reproductive outcome of metformin treatment in patients with polycystic ovarian syndrome. ( Hamed, HO, 2013) |
| " The secondary objective was to evaluate changes in body mass index (BMI), waist-to-hip ratio (WHR), and insulin sensitivity after 3 months of metformin therapy." | 7.79 | Insulin resistance assessment in patients with polycystic ovary syndrome using different diagnostic criteria--impact of metformin treatment. ( Brodowska, A; Ciećwież, S; Kotlega, D; Marciniak, A; Nawrocka-Rutkowska, J; Starczewski, A; Wiśniewska, B, 2013) |
| " The AMP-activated protein kinase (AMPK) activator metformin reverses obesity-associated insulin resistance (IR) and inhibits different types of inflammatory responses." | 7.79 | Metformin attenuates the exacerbation of the allergic eosinophilic inflammation in high fat-diet-induced obesity in mice. ( André, DM; Anhê, GF; Antunes, E; Bordin, S; Calixto, MC; Ferreira, D; Landgraf, RG; Leiria, LO; Lellis-Santos, C; Lintomen, L, 2013) |
| "The efficacy of metformin for the treatment of obesity has been evaluated in few clinical trials with inconclusive results." | 7.79 | Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. ( Schehler, B; Schneider, HJ; Seifarth, C, 2013) |
| "We investigated metformin-mediated SHP production improved insulin resistance through the regulation of an IL-6-dependent pathway (involving signal transducer and activator of transcription 3 [STAT3] and suppressor of cytokine signalling 3 [SOCS3]) in both Shp knockdown and Shp null mice." | 7.78 | Metformin ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models. ( Ahn, SW; Chanda, D; Cho, YM; Choi, HS; Kim, DK; Kim, YD; Kim, YH; Lee, CH; Lee, JM; Shong, M, 2012) |
| "Serum hsCRP improved with lifestyle modification and metformin therapy for 3 months in overweight subjects from India with PCOS, along with serum total cholesterol, triglycerides, and HDL-C." | 7.78 | Effect of lifestyle modification and metformin therapy on emerging cardiovascular risk factors in overweight Indian women with polycystic ovary syndrome. ( Bitla, A; P V L N Rao, S; Rajagopal, G; Reddy, AP; Sachan, A; Suresh, V; Venkata Harinarayan, C, 2012) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 7.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| " At the end of the feeding schedule, Dia group had insulin resistance along with increased blood glucose, triglyceride, uric acid and nitric oxide (NO) levels." | 7.78 | Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. ( Bagul, PK; Banerjee, SK; Bastia, T; Chakravarty, S; Madhusudana, K; Matapally, S; Middela, H; Padiya, R; Reddy, BR, 2012) |
| " In contrast, glyburide failed to reverse the glucose intolerance caused by olanzapine despite increasing insulin levels." | 7.78 | Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. ( Barr, AM; Boyda, HN; Hawkes, E; Honer, WG; Jin, CH; Pang, CC; Procyshyn, RM; Tse, L, 2012) |
| " We hypothesised that intervention with metformin would diminish the HF-feeding-evoked cognitive deficit by improving insulin sensitivity." | 7.78 | A high-fat-diet-induced cognitive deficit in rats that is not prevented by improving insulin sensitivity with metformin. ( Balfour, DJ; McNeilly, AD; Stewart, CA; Sutherland, C; Williamson, R, 2012) |
| "Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women." | 7.77 | Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. ( Aboul Foutouh, I; Ashmawi, HS; Khattab, S; Mohsen, IA; Mohsen, MN; van der Veen, F; van Wely, M; Youssef, MA, 2011) |
| "To investigate the potential preventive effects of metformin on non-alcoholic fatty liver disease (NAFLD) and roles of phospholipase A2/lysophosphatidylcholine pathway in hepatocyte lipoapoptosis in a rat NAFLD model induced by high-fat diet." | 7.77 | [Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes]. ( Fu, JF; Huang, Y; Liu, LR; Shi, HB, 2011) |
| " During the first year of treatment, exenatide, in combination with metformin and repaglinide, led to a weight loss of 14 kg and fat mass and waist circumference were respectively reduced from 31 to 25." | 7.77 | Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. ( Buysschaert, M; de la Tribonnière, X; Hermans, MP; Oriot, P; Selvais, P, 2011) |
| "In the Canadian Normoglycemia Outcome Evaluation (CANOE) trial, low-dose rosiglitazone/metformin reduced the risk of diabetes in subjects with impaired glucose tolerance by 66% over a median of 3." | 7.77 | Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. ( Hanley, AJ; Harris, SB; Qi, Y; Retnakaran, R; Zinman, B, 2011) |
| " Moreover, in comparingson of changes in HOMA among the groups, the metformin- treated group showed significantly improved metabolic control and insulin sensitivity (HOMA) at the end of the study." | 7.77 | Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. ( Akcam, M; Boyaci, A; Dundar, BN; Kaya, S; Pirgon, O; Uysal, S, 2011) |
| "To evaluate serum visfatin levels and to determine the effects of metformin treatment on visfatin levels in patients with polycystic ovary syndrome (PCOS)." | 7.76 | Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. ( Cakal, E; Engin-Ustun, Y; Ozkaya, M; Ustun, Y, 2010) |
| "Several data have demonstrated the efficacy of metformin in inducing ovulation in patients with polycystic ovary syndrome (PCOS), however, the exact mechanism by which this drug acts remains unknown." | 7.76 | Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2010) |
| " We tested the hypothesis that a gene variant in STK11 contributes to variation in insulin sensitivity and metformin efficacy." | 7.76 | A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Morán, E, 2010) |
| "A whole new area of investigation has emerged recently with regards to the anti-diabetic drug metformin and breast cancer." | 7.76 | Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. ( Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2010) |
| " Pioglitazone was added to her treatment, and follow-up showed improvement of metabolic control 7 months after introducing pioglitazone, and improvement of insulin sensitivity 2 years later." | 7.75 | Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report. ( Beressi, JP; Billon-Bancel, A; Collet-Gaudillat, C, 2009) |
| "Metformin attenuated oxidative stress-induced cardiomyocyte apoptosis and prevented the progression of heart failure in dogs, along with activation of AMPK." | 7.75 | Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. ( Asakura, M; Asanuma, H; Fujita, M; Ito, S; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Mochizuki, N; Ogai, A; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2009) |
| "The aim of this prospective study was to evaluate results of metformin (MF) therapy during 1 year of uric acid (UA) metabolism and the clinical course of gout with insulin resistance (IR)." | 7.75 | [Effect of metformin on the clinical course of gout and insulin resistance]. ( Aleksandrova, EN; Barskova, VG; Eliseev, MS; Kudaeva, FM; Nasonov, EL; Nasonova, VA; Volkov, AV, 2009) |
| "To study insulin sensitivity, as well as the effects of estrogen, metformin and GnRHa treatment on glucose homeostasis, in an aromatase-deficient girl." | 7.75 | Metformin, estrogen replacement therapy and gonadotropin inhibition fail to improve insulin sensitivity in a girl with aromatase deficiency. ( Belgorosky, A; Di Palma, MI; Guercio, G; Mazza, C; Pepe, C; Prieto, M; Rivarola, MA; Saraco, NI; Saure, C, 2009) |
| "This study aimed to assess the perinatal outcome, especially foetal growth, following the continuation of metformin during the first trimester of pregnancy." | 7.75 | Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity. ( Bolton, S; Cleary, B; Dempsey, E; Turner, MJ; Walsh, J, 2009) |
| "Most research confirms that metformin therapy has a positive influence on cardiovascular risk factors (CVRF) such as dyslipidemia, insulin resistance and hyperandrogenism in polycystic ovary syndrome (PCOS)." | 7.74 | Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. ( Bednarek-Tupikowska, G; Bohdanowicz-Pawlak, A; Demissie, M; Jakubowska, J; Milewicz, A; Szymczak, J, 2008) |
| "05) were higher on the IL/H study day than on the glycerol study day, indicating persistence of NEFA-induced insulin resistance." | 7.74 | Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes. ( Basu, A; Basu, R; Chandramouli, V; Cohen, O; Dicke, B; Landau, BR; Norby, B; Rizza, RA; Shah, P, 2008) |
| "To evaluate the acute effects of metformin therapy on biochemical markers and polycystic ovarian morphology among insulin-resistant (IR) and noninsulin-resistant (NIR) patients with polycystic ovary syndrome (PCOS)." | 7.74 | Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. ( Bayrak, A; Mor, E; Paulson, RJ; Stanczyk, FZ; Terbell, H; Urwitz-Lane, R, 2007) |
| "In the present study, we investigated the effect of an association of micronutrients (zinc (Zn), selenium (Se) and vitamin E (vit E)) on insulin activity and antioxidant status in an animal model of insulin resistance, the high-fructose-fed rat." | 7.74 | Comparison of the effects of zinc alone and zinc associated with selenium and vitamin E on insulin sensitivity and oxidative stress in high-fructose-fed rats. ( Barclay, D; Faure, P; Halimi, S; Joyeux-Faure, M, 2007) |
| "Before and 3 months after low-dose metformin therapy, eight overweight/obese Japanese subjects [body mass index (BMI) >25 kg/m2] were studied with blood sampling, measurement of IHL and IMCL by 1H magnetic resonance spectroscopy and glucose infusion rate (GIR) during euglycaemic-hyperinsulinaemic clamp as an index of peripheral insulin sensitivity." | 7.74 | Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects. ( Hirose, T; Kawamori, R; Kumashiro, N; Sakurai, Y; Sato, F; Tamura, Y; Tanaka, Y; Watada, H, 2008) |
| "Here we investigate the effect of rosiglitazone (RSG), metformin (MET) and glyburide (GLIB) on plasma glucose levels, beta-cell mass, function and insulin sensitivity in 10-week-old diabetic male Zucker diabetic fatty (mZDF) rats using quantitative morphometry and a mathematical model beta-cell mass, insulin and glucose kinetics (betaIG)." | 7.74 | Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats. ( Atkinson, LL; Benkoczi, C; Finegood, DT; McDonald-Dyck, C, 2008) |
| "The effect of 6 months of metformin treatment was prospectively assessed in 188 PCOS patients, divided into three groups according to body mass index (BMI; lean: BMI<25 kg/m2, overweight: BMI 25-29 kg/m2, and obese: BMI30 kg/m2)." | 7.74 | Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. ( Benson, S; Dietz, T; Elsenbruch, S; Hahn, S; Janssen, OE; Kimmig, R; Lahner, H; Mann, K; Moeller, LC; Schmidt, M; Tan, S, 2007) |
| "A 2-hour oral glucose tolerance test (OGTT) and a rapid intravenous glucose tolerance test (IVGTT) were performed before treatment was initiated, after treatment with metformin and at the end of 1 year of combination therapy with metformin and rosiglitazone to calculate quantitative insulin sensitivity check index (QUICKI) and acute insulin response (AIR)." | 7.74 | Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome. ( Anhalt, H; Bhangoo, A; Collin, GB; Maclaren, N; Marshall, JD; Naggert, JK; Sinha, SK; Ten, S, 2007) |
| " In this study, therefore, we aimed (1) to determine the circulating ADMA concentrations in 44 women with PCOS and 22 age- and BMI-matched healthy controls, (2) to evaluate its correlations with insulin resistance, gonadotrophins, and androgen secretion, and (3) to compare effects of metformin and ethinyl estradiol-cyproterone acetate (EE/CPA) treatments on circulating ADMA concentrations." | 7.74 | Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). ( Baser, I; Dede, M; Erbil, MK; Kenar, L; Oktenli, C; Ozgurtas, T; Sanisoglu, SY; Tapan, S; Yenen, MC; Yesilova, Z, 2008) |
| "We prospectively assessed whether metabolic and menstrual benefits of metformin-diet were equally realized in women with polycystic ovary syndrome (PCOS), categorized by pretreatment top (n = 32) and bottom (n = 35) quintile homeostasis model assessment insulin resistance (IR)." | 7.73 | Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. ( Glueck, CJ; Goldenberg, N; Loftspring, M; Sherman, A; Wang, P, 2005) |
| "Metformin had differential effects on fasting insulin levels, insulin resistance as demonstrated by homeostasis model assessment (HOMA), LH, total testosterone, dehydroepiandrosterone sulphate and free testosterone index on the basis of IRS genotype." | 7.73 | The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome. ( Aktas, A; Dilek, S; Erdal, EM; Ertunc, D; Tok, EC, 2005) |
| "Based on the favourable international experience with metformin in the most common female endocrine disease, the polycystic ovary syndrome, which has insulin resistance in the background, the author's treatment advice has been this in such cases since early 2002: for sexually active women who do not want to become pregnant for the time being, anti-androgenic contraceptive pill; for those who do not want to take contraceptives, contraceptives are contraindicated, or who do want to conceive, metformin." | 7.73 | [Treatment experience with metformin in polycystic ovary syndrome]. ( Petrányi, G, 2005) |
| "Recent data indicate that women affected by the polycystic ovary syndrome (PCOS) are at greater risk for cardiovascular disease and that metformin may improve the metabolic alterations in these patients." | 7.73 | Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. ( Azziz, R; Cascella, T; Colao, A; De Simone, B; Lombardi, G; Manguso, F; Orio, F; Palomba, S; Russo, T; Savastano, S; Tolino, A; Zullo, F, 2005) |
| "To investigate the effects of metformin on fatty livers in insulin-resistant rats." | 7.73 | [Effects of metformin on fatty liver in insulin-resistant rats]. ( Chen, SQ; Deng, JC; Liu, Q; Sun, H; Tang, L, 2005) |
| "Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well." | 7.73 | The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M, 2005) |
| "Plasma androgen levels were decreased significantly by metformin treatment, as were plasma LH and allopregnanolone levels and insulin resistance." | 7.73 | Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. ( Baraldi, E; Casarosa, E; Genazzani, AD; Genazzani, AR; Lanzoni, C; Luisi, M; Mehmeti, H; Ricchieri, F; Strucchi, C, 2006) |
| " Metformin therapy reduces whole-body insulin resistance (IR) in patients with type-2 diabetes mellitus (DM)." | 7.73 | Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance. ( Caliskan, M; Erdogan, D; Gullu, H; Muderrisoglu, H; Ozcimen, EE; Tok, D; Topcu, S; Uckuyu, A; Zeyneloglu, H, 2006) |
| "To determine whether women with polycystic ovary syndrome (PCOS) and abnormal insulin levels treated with metformin had different rates of ovulation and pregnancy from women with PCOS and normal insulin levels." | 7.73 | Use of metformin for ovulation induction in women who have polycystic ovary syndrome with or without evidence of insulin resistance. ( Liu, KE; Sagle, M; Tataryn, IV, 2006) |
| " However, obese mares exhibited a significantly longer duration of the oestrous cycle, significant increases in circulating concentrations of leptin and insulin, and decreased insulin sensitivity and concentrations of thyroxine compared with feed-restricted mares throughout the experiment." | 7.73 | Obesity is associated with altered metabolic and reproductive activity in the mare: effects of metformin on insulin sensitivity and reproductive cyclicity. ( Fitzgerald, BP; Kennedy, EL; Murphy, BA; Reedy, SE; Sessions, DR; Vick, MM, 2006) |
| "In 74 women with polycystic ovary syndrome, treated for 4 years with metformin (MET) and diet, we prospectively assessed whether, and to what degree, weight loss, reduction of insulin resistance, and amelioration of coronary heart disease risk factors could be sustained." | 7.73 | Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "The purpose of this review is to provide a critical summary of recent studies on the clinical effects of metformin in polycystic ovary syndrome." | 7.72 | The role of metformin in the management of polycystic ovary syndrome. ( Prelevic, GM; Tsilchorozidou, T, 2003) |
| "(1) High-fat diet induces insulin resistance in SD rats; this was associated with an increase in visceral fat and a decrease in the level of adiponectin; (2) Metformin treatment improved insulin sensitivity accompanied by a decrease in body weight and TG level; (3) Rosiglitazone treatment ameliorates IR in a greater extent and is accompanied by a reduction of FFA, TG and an increase of adiponectin levels." | 7.72 | [Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats]. ( Bu, S; Chen, XP; Liu, XL; Wang, N; Xiao, JZ; Yang, WY; Zhao, WH, 2004) |
| "Rosiglitazone and metformin prevented fatty-acid-induced insulin resistance (reduced clamp glucose infusion rate)." | 7.72 | Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. ( Cleasby, ME; Cooney, GJ; Dzamko, N; Furler, SM; Hegarty, BD; Kraegen, EW; Ye, JM, 2004) |
| "The aim of the present study was to evaluate the effect of metformin on body weight, body fat mass, waist circumference, lipid parameters, insulin secretion and insulin resistance in obese subjects with normal glucose tolerance." | 7.72 | Metformin in the treatment of obesity in subjects with normal glucose tolerance. ( Dakovska, L; Kirilov, G; Koev, D; Tankova, T, 2003) |
| "The present study represents a new insight into the Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 study population at inclusion." | 7.71 | Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study. ( André, P; Bard, JM; Charles, MA; Eschwege, E; Fruchart, JC; Juhan-Vague, I; Safar, M; Vague, P, 2001) |
| "Long-term metformin treatment reduced various steroid enzymatic activities both in the ovary and the adrenal glands, without apparent changes in basal steroid levels and in insulin sensitivity." | 7.71 | The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. ( Bendlová, B; Cibula, D; Hill, M; Snajderová, M; Stárka, L; Sulcová, J; Vondra, K; Vrbíková, J, 2001) |
| "Both metformin and troglitazone were comparably effective in reducing insulin resistance." | 7.71 | Comparison of the metabolic effects of metformin and troglitazone on fructose-induced insulin resistance in male Sprague-Dawley rats. ( Chang, CT; Chen, CC; Chen, RH; Sheen, LY; Shih, HC; Wang, HJ; Wang, TY, 2001) |
| " Metformin, an oral hypoglycaemic agent that increases insulin sensitivity, has been shown to reduce serum concentrations of insulin and androgens, to reduce hirsutism, and to improve ovulation rates." | 7.71 | Metformin and intervention in polycystic ovary syndrome. Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group. ( Cuneo, RC; Kidson, WJ; Norman, RJ; Zacharin, MR, 2001) |
| "The aim of the present study was to investigate the steroidogenic response pattern to HCG in obese women with polycystic ovary syndrome (PCOS) and the possible effects of metformin treatment on it." | 7.71 | Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tapanainen, JS, 2001) |
| "Long-term therapy with metformin led to the improvement in menstrual cyclicity, without significant change in basal steroid levels or parameters of insulin resistance." | 7.71 | [Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome]. ( Bendlová, B; Cibula, D; Hill, M; Snajderová, M; Stárka, L; Sulcová, J; Vondra, K; Vrbíková, J, 2001) |
| "Before metformin therapy, after covariance adjustment for age, the two cohorts did not differ in height, weight, basal metabolic index, insulin, insulin resistance, or insulin secretion." | 7.71 | Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. ( Glueck, CJ; Kobayashi, S; Phillips, H; Sieve-Smith, L; Wang, P, 2002) |
| " In the present study we tested the hypothesis that metformin therapy in obese adolescents with PCOS will attenuate the adrenal steroidogenic response to ACTH, with reduction of insulin resistance/insulinemia." | 7.71 | Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. ( Arslanian, SA; Danadian, K; Lewy, V; Saad, R, 2002) |
| "The objective of the study was to find predictors of a successful therapy with metformin in polycystic ovary syndrome." | 7.71 | Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome. ( Hill, M; Stárka, L; Vondra, K; Vrbíková, J, 2002) |
| "We investigated the role of glucose-6 phosphatase (Glc6Pase), glucokinase (GK), and glucose-6 phosphate (Glc6P) in liver insulin resistance, an early characteristic of type 2 diabetes, and its correction by metformin." | 7.70 | Role of glucose-6 phosphatase, glucokinase, and glucose-6 phosphate in liver insulin resistance and its correction by metformin. ( Minassian, C; Mithieux, G; Tarpin, S, 1998) |
| "This study investigates the effect of the antidiabetic drug metformin on dexamethasone-induced hyperglycaemia and insulin resistance in mice." | 7.70 | Prevention of dexamethasone-induced insulin resistance by metformin. ( Bailey, CJ; Jefferson, WH; Thomas, CR; Turner, SL, 1998) |
| " Metformin therapy improved menstrual disturbances in 25% of the women with PCOS and also resulted in some improvement in insulin sensitivity and reduced basal and post glucose load insulin levels." | 7.70 | The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. ( Bayram, F; Keleştimur, F; Sahin, Y; Tutuş, A; Unlühizarci, K, 1999) |
| " Metformin, a medication that improves insulin sensitivity and decreases serum insulin levels, restores menstrual cyclicity and ovulatory function and may improve fertility rates in women with PCOS." | 7.70 | Association of metformin and pregnancy in the polycystic ovary syndrome. A report of three cases. ( Neal, GS; Robinson, RD; Seale, FG, 2000) |
| "Metformin treatment prevented the development of fructose-induced insulin resistance, hyperinsulinaemia and hypertension." | 7.70 | Metformin treatment corrects vascular insulin resistance in hypertension. ( Dumont, AS; McNeill, JH; Verma, S; Yao, L, 2000) |
| "The aim of this study was to determine the distribution of plasma total homocysteine (tHcy) concentrations in type 2 diabetic patients and to assess whether high tHcy values were related to chronic complications (particularly macroangiopathy and nephropathy) and/or the degree of insulin resistance." | 7.70 | Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. ( Buysschaert, M; Dramais, AS; Hermans, MP; Wallemacq, PE, 2000) |
| "Using polycystic ovary syndrome (PCOS) as a model of insulin resistance and hyperandrogenism, our specific aim was to assess the effect of Metformin on lipoproteins, sex hormones, gonadotropins, and blood pressure in 26 women with PCOS who were studied at baseline, received Metformin 1." | 7.69 | Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. ( Glueck, CJ; Hamer, T; Mendoza, S; Sosa, F; Velazquez, EM, 1994) |
| "Insulin sensitivity, the mean fasting serum levels of glucose, insulin, total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total T, free T, androstenedione, DHEAS, and LH:FSH ratio, and the areas under the curve for plasma glucose and insulin during OGTT were not changed by either placebo or metformin treatment." | 7.69 | Can metformin reduce insulin resistance in polycystic ovary syndrome? ( Açbay, O; Gündoğdu, S, 1996) |
| "To determine whether improvement of insulin resistance decreases blood pressure as well as obesity, metformin (100 mg/kg/d) or vehicle was administered for 20 weeks to 12-week-old male Otsuka Long-Evans Tokushima Fatty (OLETF) rats (n = 10 each), a newly developed animal model of non-insulin-dependent diabetes mellitus (NIDDM) with mild obesity, hyperinsulinemia, and hypertriglyceridemia." | 7.69 | Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. ( Inukai, K; Ishii, J; Kashiwabara, H; Katayama, S; Kikuchi, C; Kosegawa, I; Negishi, K; Oka, Y, 1996) |
| "To assess the effects of metformin on tissue insulin sensitivity in obese and hyperandrogenic women." | 7.69 | [Effects of metformin on insulin resistance in obese and hyperandrogenic women]. ( Calvillán, M; Castillo, T; López, G; Muñoz, S; Sir, T, 1997) |
| "To examine the cellular mechanism of the antihyperglycemic action of in vivo metformin (M) we used an animal model of severe insulin resistance, the genetically obese (fa/fa) Zucker rat." | 7.68 | In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. ( Benecke, H; Greten, H; Hamann, A; Häring, HU; Klein, HH; Matthaei, S; Reibold, JP, 1993) |
| "The effect of metformin on insulin binding and insulin action in the presence of anti-insulin receptor antibodies was investigated in a case of type B extreme insulin resistance." | 7.68 | Metformin ameliorates extreme insulin resistance in a patient with anti-insulin receptor antibodies: description of insulin receptor and postreceptor effects in vivo and in vitro. ( Di Paolo, S, 1992) |
| "We have evaluated the effect of metformin on haemorheology, lipid levels and insulin resistance in insulin-dependent diabetic patients over a 6-week period." | 7.68 | Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). ( De Leeuw, I; Janssen, M; Rillaerts, E, 1991) |
| "Metformin treatment was associated with a significant decrease in HOMA-IR." | 7.01 | Metformin in non-diabetic patients with metabolic syndrome and diastolic dysfunction: the MET-DIME randomized trial. ( Bettencourt, N; Braga, P; Fontes-Carvalho, R; Gama, V; Ladeiras-Lopes, R; Leite, S; Leite-Moreira, A; Sampaio, F; Santos-Ferreira, D; Vilela, E, 2021) |
| "Patients with schizophrenia have exceedingly high rates of metabolic comorbidity including type 2 diabetes and lose 15-20 years of life due to cardiovascular diseases, with early accrual of cardiometabolic disease." | 7.01 | Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial. ( Agarwal, SM; Caravaggio, F; Chintoh, AF; Costa-Dookhan, KA; Graff-Guerrero, A; Hahn, MK; Hashim, E; Kirpalani, A; Kramer, CK; Leung, G; MacKenzie, NE; Matheson, K; Panda, R; Remington, GJ; Treen, QC; Voineskos, AN, 2021) |
| "Treatment with metformin is associated with a time-dependent decrease in mtDNA-CN in patients with PCOS who are treated over the course of one year." | 6.94 | Changes in peripheral mitochondrial DNA copy number in metformin-treated women with polycystic ovary syndrome: a longitudinal study. ( Chang, CH; Chen, MJ; Chen, SU; Chou, CH; Ho, HN; Yang, PK, 2020) |
| "Improving insulin sensitivity is one of many proven favourable effects of metformin." | 6.84 | Protocol for a pilot randomised controlled trial of metformin in pre-diabetes after kidney transplantation: the Transplantation and Diabetes (Transdiab) study. ( Alnasrallah, B; Manley, P; Pilmore, H, 2017) |
| "Acne is a common and complex skin disease, with a very complex pathogenesis." | 6.82 | Low glycaemic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments. ( Colao, A; Del Prete, M; Donnarumma, M; Fabbrocini, G; Faggiano, A; Izzo, R; Marasca, C; Marciello, F; Monfrecola, G; Savastano, R, 2016) |
| " This study aimed to compare the different effects of drospirenone (DRP)-containing COCs with cyproterone acetate (CPA)-containing COCs, combined with metformin and lifestyle modifications in women with PCOS and metabolic disorders." | 6.82 | Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial. ( Feng, GM; Huang, W; Song, Y; Wang, QS; Wang, QY; Xiao, L, 2016) |
| "Secondary outcomes include changes in liver fibrosis using AST to platelet ratio index, changes in glucose and lipid levels, anthropometric measures, changes in alpha-fetoprotein levels, patient acceptability, and changes in dietary and physical activity parameters." | 6.82 | Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. ( Cooper, C; Doyle, MA; Lee, T; Muir, M; Singer, J, 2016) |
| "Pioglitazone-treated patients showed a significant increase in HDL-C compared to placebo group (6." | 6.78 | Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients. ( Bravi, F; Brunetti, P; Chinea, B; Comaschi, M; Cucinotta, D; Di Pietro, C; Egan, CG; Genovese, S; Passaro, A, 2013) |
| "Chronic low-grade inflammation is a common feature of insulin resistant states, including obesity and type 2 diabetes." | 6.78 | Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. ( Aroda, V; Ciaraldi, TP; Henry, RR; Mudaliar, SR, 2013) |
| "Berberine (BBR) is an isoquinoline derivative alkaloid extracted from Chinese medicinal herbs that has been used as an insulin sensitizer." | 6.77 | A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. ( Deng, H; Guan, Y; Liang, K; Ma, Y; Sui, M; Wang, A; Wei, W; Zhang, H; Zhang, Y; Zhao, H, 2012) |
| "Dyslipidemia in patients with type 2 diabetes is characterized by elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and a predominance of small dense low-density lipoprotein (LDL) particles." | 6.76 | PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011) |
| "Both pioglitazone and metformin treatment were associated with significant reductions in hyperglycemia, HOMA-IR and HbA1c levels." | 6.75 | Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes. ( Adachi, T; Fujinami, A; Fukui, M; Hara, H; Hasegawa, G; Ishihara, K; Kitagawa, Y; Nakamura, N; Nakano, K; Obayashi, H; Ogata, M; Ohta, M; Takashima, T; Yamasaki, M, 2010) |
| "They confirm that treatment of insulin resistance decreases T production in this population and demonstrate that pharmacologic lowering of T does not affect insulin resistance." | 6.75 | Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial. ( Basu, A; Cappola, AR; Fuller, C; Iqbal, N; Kaul, S; Patel, SM; Ratcliffe, SJ; Reilly, MP; Rickels, MR; Scattergood, T, 2010) |
| "Insulin resistance is a major feature of type 2 diabetes mellitus, obesity and nonalcoholic fatty liver disease (NAFLD)." | 6.74 | The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. ( Gedik, O; Nar, A, 2009) |
| "Nonalcoholic fatty liver disease (NAFLD) is one of the most common reasons for the increase in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels." | 6.72 | The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis. ( Hu, H; Li, X; Meng, J; Shen, L; Shi, D; Wang, J, 2021) |
| "Obesity is often accompanied by insulin resistance and/or hyperinsulinemia." | 6.72 | Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study. ( Bellot-Rojas, P; Caracas-Portilla, N; Cardoso-Saldaña, G; Jurado-Santacruz, F; Posadas-Romero, C; Posadas-Sanchez, R; Zamora-Gonzalez, J, 2006) |
| "Flutamide-metformin treatment (n = 30) was followed within 3 months by marked decreases in hirsutism score and serum androgens, by a more than 50% increase in insulin sensitivity and by a less atherogenic lipid profile (all P < 0." | 6.71 | Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2003) |
| "Hirsutism is a common and distressing symptom frequently encountered in women with polycystic ovary syndrome (PCOS), who also show relative insulin resistance." | 6.71 | Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. ( Fleming, R; Harborne, L; Lyall, H; Norman, J; Sattar, N, 2003) |
| "A total of 34 subjects with type 2 diabetes (17 men and 17 women, aged 54+/-2 years and body mass index (BMI) 26." | 6.71 | Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. ( Ishibashi, S; Ishikawa, SE; Kusaka, I; Nagasaka, S; Nakamura, T; Yatagai, T; Yoshitaka, A, 2004) |
| "Metformin treatment was associated with only a transient improvement in liver chemistries." | 6.71 | Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. ( Diehl, AM; Farr, GH; Nair, S; Perrillo, RP; Wiseman, M, 2004) |
| "In conclusion, metformin treatment improved insulin sensitivity and decreased androgen levels, and flutamide decreased androgen levels but failed to improve insulin sensitivity in the non-obese women with PCOS." | 6.71 | Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. ( Aral, Y; Culha, C; Demirbas, B; Karakurt, F; Kosar, F; Sahin, I; Serter, R; Taskapan, C, 2004) |
| "Metformin was well tolerated and no one discontinued treatment due to side effects." | 6.70 | Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. ( Grinspoon, S; Hadigan, C; Rabe, J, 2002) |
| "Metformin was well tolerated except for one case of flatulence." | 6.69 | Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. ( Bergiele, A; Diamanti-Kandarakis, E; Kouli, C; Tsianateli, T, 1998) |
| "Metformin is a widely used drug in the treatment of type 2 diabetes mellitus (T2DM)." | 6.52 | Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease. ( Bettencourt, N; Fontes-Carvalho, R; Gama, V; Ladeiras-Lopes, R; Leite-Moreira, A; Sampaio, F, 2015) |
| "The key histologic feature of nonalcoholic steatohepatitis (NASH) is hepatocellular ballooning (HB)." | 6.50 | Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). ( Doycheva, I; Loomba, R, 2014) |
| "Metformin was effective in reducing enzyme levels in the short period, but very limited and controversial information are available on liver histology." | 6.50 | Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. ( Abenavoli, L; Milic, N; Rouabhia, S, 2014) |
| " Currently, there is no evidence that cardiovascular morbidity is decreased by long-term use of insulin sensitizers in PCOS women." | 6.50 | Metformin and other insulin sensitizers in polycystic ovary syndrome. ( Bhagavath, B; Hoeger, K; Queenan, J; Vitek, W, 2014) |
| "Metformin is an oral insulin-sensitizing anti-diabetic drug." | 6.50 | [Metformin in pregnancy]. ( Bijok, J; Bińkowska, M; Jakiel, G, 2014) |
| "Obesity and insulin resistance have been associated with breast cancer risk, and breast cancer outcomes." | 6.47 | Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin. ( Goodwin, PJ; Stambolic, V, 2011) |
| "Nonalcoholic steatohepatitis (NASH), which is considered the hepatic manifestation of the metabolic syndrome is an increasingly cause of chronic liver disease in Japan." | 6.43 | [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. ( Kawaguchi, K; Korenaga, K; Korenaga, M; Sakaida, I; Uchida, K, 2006) |
| "Insulin resistance has a complex etiology, with multiple manifestations across the organ systems involved in glucose homeostasis." | 6.43 | Metformin and pioglitazone: Effectively treating insulin resistance. ( Staels, B, 2006) |
| "Insulin resistance is an important pathophysiological feature of the polycystic ovary syndrome (PCOS)." | 6.43 | Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? ( Cheang, KI; Nestler, JE; Sharma, ST, 2006) |
| "Polycystic ovary syndrome is a frequent endocrine disorder often associated with insulin resistance and hyperinsulinaemia which may play a role in hyperandrogenism and anovulation." | 6.42 | [Should infertile women with polycystic ovarian syndrome be treated with metformine?]. ( Basille, C; Bry-Gauillard, H; Cédrin-Durnerin, I; Galey, J; Hugues, JN; Massin, N; Théron-Gérard, L, 2003) |
| "Metformin has beneficial effects on endothelial function which appear to be mediated through its effects to improve insulin resistance." | 6.42 | Insulin resistance as a therapeutic target for improved endothelial function: metformin. ( Anderson, T; Brame, L; Lteif, A; Mather, K; Verma, S, 2004) |
| "Insulin resistance is a major endocrinopathy underlying the development of hyperglycaemia and cardiovascular disease in type 2 diabetes." | 6.42 | Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes. ( Bailey, CJ; Day, C, 2004) |
| "Insulin resistance is a prominent feature of polycystic ovarian syndrome (PCOS), and women with the disorder are at increased risk for the development of other diseases that have been linked to insulin resistance-namely, type 2 diabetes and cardiovascular disease." | 6.41 | Should patients with polycystic ovarian syndrome be treated with metformin?: an enthusiastic endorsement. ( Nestler, JE, 2002) |
| "Lactic acidosis is a rare, serious adverse effect of metformin, which can be prevented by carefully observing the contra-indications." | 6.41 | [Metformin efficacious in poorly controlled diabetes mellitus type 2]. ( Hoekstra, JB; Holleman, F; Stades, AM, 2000) |
| " Careful selection of most relevant data in terms of dosage prompted this original review, largely devoted to the drug action at the cell level and whose hypotheses/conclusions are tentatively interpreted according to corresponding basic scientific knowledge." | 6.40 | Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. ( Wiernsperger, NF, 1999) |
| " They also suggest that long term administration of metformin might be helpful in treating insulin resistance, thus reducing risks of type 2 (non-insulin-dependent) diabetes and cardiovascular disease in these patients." | 6.40 | Insulin resistance, polycystic ovary syndrome and metformin. ( Ducluzeau, PH; Pugeat, M, 1999) |
| " The rationale for adding metformin in these cases is that it can reduce insulin resistance." | 6.19 | [Combination treatment with insulin and metformin in type 2 diabetes. Improves glycemic control and prevents weight gain]. ( Hermann, LS; Melander, A, 1999) |
| "Metformin was used as a positive control." | 5.91 | Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α. ( He, B; Lv, B; Wang, D; Wang, X; Xing, C; Zhao, H, 2023) |
| "Metformin is a commonly used drug of PCOS but few studies on whether metformin can improve the follicle development and ovarian function in PCOS." | 5.91 | Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis. ( Chang, Q; Chen, X; He, R; Hei, C; Li, G; Liang, X; Liu, H; Liu, X; Ouyang, J; Peng, Q; Ren, S; Sun, M; Sun, Y; Wang, C; Wang, Q; Wu, X; Xie, H, 2023) |
| "Metformin is a widely used drug for treating type 2 diabetes and is also used for delaying sexual maturation in girls with precocious puberty." | 5.72 | Metformin treatment of juvenile mice alters aging-related developmental and metabolic phenotypes. ( Bartke, A; Fang, Y; Medina, D; Yuan, R; Zhu, Y, 2022) |
| "Microvascular insulin resistance is present in metabolic syndrome and may contribute to increased cardiovascular disease risk and the impaired metabolic response to insulin observed." | 5.72 | Metformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome. ( Barrett, EJ; Hartline, L; Jahn, LA; Liu, Z, 2022) |
| "Metformin (MTF) treatment improves insulin signaling in endometrial tissues, but its mechanism is not fully understood." | 5.72 | Metformin Treatment Regulates the Expression of Molecules Involved in Adiponectin and Insulin Signaling Pathways in Endometria from Women with Obesity-Associated Insulin Resistance and PCOS. ( Astorga, I; Carvajal, R; García, V; Oróstica, ML; Plaza-Parrochia, F; Poblete, C; Romero, C; Vega, M, 2022) |
| "Metformin treatment may protect men with early-onset androgenic alopecia against the development of gonadotroph hyperplasia and/or focal testicular changes." | 5.72 | Pituitary Effects of Metformin in Men With Early-Onset Androgenic Alopecia. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "Metformin alone reduced hyperinsulinemia and circulating c-reactive protein, but exacerbated nephropathy." | 5.72 | Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice. ( Calcutt, NA; Doty, R; Flurkey, K; Harrison, DE; Koza, RA; Reifsnyder, PC, 2022) |
| "Metformin is a well-known AMPK activator widely used for the treatment of metabolic syndrome, while the mechanism of AMPK activation remains unclear." | 5.72 | Metformin alleviates long-term high-fructose diet-induced skeletal muscle insulin resistance in rats by regulating purine nucleotide cycle. ( Chen, J; Cheng, J; Guan, F; Huang, X; Li, M; Li, Y; Lin, G; Liu, Y; Ma, X; Su, Z; Xie, J; Xu, L; Yu, Q, 2022) |
| "Metformin is a first-line antidiabetic drug for the treatment of type 2 diabetes mellitus (DM2); its molecular target is AMP-activated protein kinase (AMPK), which is involved in many metabolic processes." | 5.72 | [Metformin and malignant neoplasms: a possible mechanism of antitumor action and prospects for use in practice]. ( Frolova, YS; Gaimakova, DV; Galimova, AM; Islamgulov, AH; Karimova, AR; Kuznetsov, KO; Nazmieva, KA; Oganesyan, IY; Rizvanova, EV; Sadertdinova, AG; Safina, ER, 2022) |
| "Janagliflozin 25 or 50 mg once-daily added to metformin therapy significantly improved glycaemic control, reduced body weight and systolic blood pressure, improved high-density lipoprotein cholesterol and insulin sensitivity, and was generally well-tolerated by Chinese T2D patients who had poor glycaemic control with metformin monotherapy." | 5.69 | Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. ( Chen, L; Chen, X; Cheng, Z; Gao, L; Guo, Y; Ji, L; Li, J; Liao, L; Pang, S; Song, W; Su, B; Su, X; Sun, J; Tan, X; Wang, K; Wang, Y; Xu, F; Ye, J, 2023) |
| "Short-term combined treatment with beinaglutide and metformin appears superior to metformin monotherapy in lowering body weight, BMI, WC,WHtR and improving insulin sensitivity and androgen excess in women with PCOS and obesity, with tolerable adverse events." | 5.69 | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. ( Chen, Q; Chen, Y; Fang, S; Liang, Y; Tian, Y; Wen, Q; Yuan, J, 2023) |
| "Aging is associated with central fat redistribution and insulin resistance." | 5.62 | Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. ( Atlan, M; Auclair, M; Bereziat, V; Capeau, J; Fève, B; Foresti, R; Gorwood, J; Laforge, M; Lagathu, C; Le Pelletier, L; Mantecon, M; Motterlini, R, 2021) |
| "Insulin resistance was induced by HFrHFD feeding for 16 weeks." | 5.62 | Propranolol and low-dose isoproterenol ameliorate insulin resistance, enhance β-arrestin2 signaling, and reduce cardiac remodeling in high-fructose, high-fat diet-fed mice: Comparative study with metformin. ( Ahmed, HMS; Ibrahim, IAAE; Ibrahim, WS; Mahmoud, AAA; Mahmoud, MF, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) has become an important health problem in the world." | 5.62 | Combination of metformin and chlorogenic acid attenuates hepatic steatosis and inflammation in high-fat diet fed mice. ( Aliabadi, M; Emamgholipour, S; Ghasempour, G; Hashemnia, SMR; Meshkani, R; Zamani-Garmsiri, F, 2021) |
| "A rat model of PCOS-IR was established using a high-fat diet (49 d) combined with letrozole (1 mg/kg·d, for 28 d)." | 5.62 | Effects of total flavonoids from Eucommia ulmoides Oliv. leaves on polycystic ovary syndrome with insulin resistance model rats induced by letrozole combined with a high-fat diet. ( Li, CX; Li, M; Miao, MS; Peng, MF; Ren, Z; Song, YG; Tian, S, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) is one of the primary causes of chronic liver disease and is closely linked to insulin resistance, type 2 diabetes mellitus (T2DM), and dyslipidemia." | 5.62 | Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats. ( Gu, X; Li, X; Zhang, C; Zhu, H; Zou, W, 2021) |
| "Metformin treatment elevates serum MANF levels and alleviates insulin resistance and hyperandrogenism in PCOS women." | 5.56 | Decreased Circulating MANF in Women with PCOS is Elevated by Metformin Therapy and is Inversely Correlated with Insulin Resistance and Hyperandrogenism. ( Deng, W; Jia, Y; Li, Y; Liu, D; Long, M; Wang, C; Wei, J; Yang, G, 2020) |
| "To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI)." | 5.51 | The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. ( Bjekić-Macut, J; Livadas, S; Macut, D; Malešević, G; Mastorakos, G; Micić, D; Ognjanović, S; Popović-Pejičić, S; Prtina, A; Soldat-Stanković, V; Stanković, S, 2022) |
| "To determine the safety and efficacy of canagliflozin in comparison to metformin in polycystic ovary syndrome (PCOS) patients with insulin resistance (IR)." | 5.51 | Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial. ( Cai, M; Dilimulati, D; Gao, X; Qu, S; Shao, X; Xing, F; Zeng, Q; Zhang, M; Zhang, Y, 2022) |
| "The antidiabetic medication metformin has been proposed to be the first drug tested to target aging and extend healthspan in humans." | 5.51 | Antecedent Metabolic Health and Metformin (ANTHEM) Aging Study: Rationale and Study Design for a Randomized Controlled Trial. ( Bubak, MT; Davidyan, A; Elliehausen, CJ; Karaman, R; Konopka, AR; Kuhn, KG; Kumari, S; Miller, BF; Schoenberg, HM; Scofield, RH; VanWagoner, TM, 2022) |
| "Twelve weeks of treatment with metformin resulted in a significant reduction in body weight and improved insulin sensitivity, but IHTG content and FA oxidation remained unchanged." | 5.51 | Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis. ( Charlton, C; Cornfield, T; Green, CJ; Hazlehurst, JM; Hodson, L; Marjot, T; McCullagh, J; Moolla, A; Pinnick, KE; Tomlinson, JW; Walsby-Tickle, J; Westcott, F, 2022) |
| "This study aimed to determine the separated and combined effects of metformin and resistance exercise on glycemic control, insulin sensitivity, and insulin-like growth factor 1 (IGF-1) in overweight/obese individuals with prediabetes and type 2 diabetes mellitus." | 5.51 | One Bout of Resistance Training Does Not Enhance Metformin Actions in Prediabetic and Diabetic Individuals. ( Alvarez-Jimenez, L; Mora-Rodriguez, R; Morales-Palomo, F; Moreno-Cabañas, A; Ortega, JF; Ramirez-Jimenez, M, 2022) |
| "Among men with obesity and low testosterone concentrations, the combination of metformin plus testosterone, metformin only, and testosterone only, compared to placebo, reduced insulin resistance with no evidence of additive benefit." | 5.51 | Metformin, testosterone, or both in men with obesity and low testosterone: A double-blind, parallel-group, randomized controlled trial. ( Asenjo-Plaza, M; Barrios-Rodríguez, R; Fernández-García, JC; Guzmán-Guzmán, A; Jiménez-Moleón, JJ; Martínez-González, MÁ; Molina-Vega, M; Moreno-León, L; Ramos-Molina, B; Rius-Díaz, F; Tinahones, FJ; Valdés, S; Yubero-Serrano, EM, 2022) |
| " This randomized controlled trial compared the efficacy and safety of CANA and metformin (MET) combination therapy and MET monotherapy in endocrine and metabolic profiles of overweight and obese women with polycystic ovary syndrome (PCOS)." | 5.51 | Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. ( Cheng, X; He, B; Xing, C; Zhang, J, 2022) |
| "Recent studies have shown that fecal microbiota transplantation (FMT) improved the metabolic profiles of patients with type 2 diabetes mellitus (T2DM), yet the effectiveness in reversing insulin resistance and increasing metformin sensitivity in T2DM patients have not been reported." | 5.51 | Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: A randomized, controlled, prospective study. ( Chen, B; Chen, F; Chen, Y; Hou, D; Hou, K; Li, X; Lin, A; Wu, Z; Xia, R; Zhang, B; Zhang, S; Zheng, C; Zhu, D, 2022) |
| "Podocyte insulin sensitivity is critical for glomerular function, and the loss of appropriate insulin signaling leads to alterations and disorders featuring diabetic nephropathy." | 5.48 | Metformin overcomes high glucose-induced insulin resistance of podocytes by pleiotropic effects on SIRT1 and AMPK. ( Angielski, S; Audzeyenka, I; Piwkowska, A; Rachubik, P; Rogacka, D; Rychłowski, M; Szrejder, M, 2018) |
| "Metformin was found to reduce elevated serum thyrotropin levels, and this effect was partially determined by endogenous dopaminergic tone." | 5.48 | Effect of Metformin on Hypothalamic-Pituitary-Thyroid Axis Activity in Elderly Antipsychotic-Treated Women With Type 2 Diabetes and Subclinical Hypothyroidism: A Preliminary Study. ( Krysiak, R; Okopień, B; Szkróbka, W, 2018) |
| "Metformin has been widely used for the treatment of type 2 diabetes." | 5.46 | Effects of metformin on compensatory pancreatic β-cell hyperplasia in mice fed a high-fat diet. ( Kyohara, M; Okuyama, T; Shirakawa, J; Tajima, K; Terauchi, Y; Togashi, Y; Yamazaki, S, 2017) |
| "Metformin was originally shown to lower testosterone levels in women with PCOS in the 1990s, an effect presumably related to its insulin sensitising actions." | 5.46 | Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. ( Ehrmann, DA; Sam, S, 2017) |
| "Metformin has outstanding utility in reducing insulin resistance and preventing type-2-diabetes mellitus, but has not been studied for statin-associated muscle symptom rescue or prevention." | 5.46 | Pleiotropic effects of metformin to rescue statin-induced muscle injury and insulin resistance: A proposed mechanism and potential clinical implications. ( Carris, NW; Chapalamadugu, KC; Magness, DJ; Magness, RR; Tipparaju, SM, 2017) |
| "Osteoprotegerin has been shown to be increased in cardiovascular disorders and type 2 diabetes mellitus." | 5.46 | Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes. ( Arslan, MS; Biyikli Gencturk, Z; Cakal, E; Delibasi, T; Karakose, M; Ozbek, M; Ozturk, G; Sahin, M; Tutal, E; Ucan, B, 2017) |
| " The mice fed with HFD were dosed with metformin (200 mg/kg) or thymol (20, 40 mg/kg) daily." | 5.46 | Thymol improves high-fat diet-induced cognitive deficits in mice via ameliorating brain insulin resistance and upregulating NRF2/HO-1 pathway. ( Li, H; Li, M; Ma, S; Qin, T, 2017) |
| "102 women with newly diagnosed breast cancer were divided into 2 main groups, a control group and a metformin group." | 5.43 | Metformin may protect nondiabetic breast cancer women from metastasis. ( El-Bassiouny, NA; El-Haggar, SM; El-Shitany, NA; Mostafa, MF, 2016) |
| "Melatonin treatment alone improved circadian activity rhythms, attenuated induction of β-cell failure, and enhanced glucose tolerance." | 5.43 | Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats. ( Hoang, J; Matveyenko, AV; Nguyen, A; Rakshit, K; Thomas, AP; Vongbunyong, K, 2016) |
| "Metformin is the mainstay therapy for type 2 diabetes (T2D) and many patients also take salicylate-based drugs [i." | 5.42 | Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. ( Blümer, RM; Bujak, AL; Crane, JD; Day, EA; Ford, RJ; Fullerton, MD; Gerstein, HC; Kemp, BE; Marcinko, K; Oakhill, JS; Pinkosky, SL; Scott, JW; Smith, BK; Steinberg, GR, 2015) |
| "The metformin treatment of Wistar rats with obesity induced by high-fat diet was carried out for 2 months (daily dose of 200 mg/kg)." | 5.42 | [THE EFFECTS OF LONG-TERM METFORMIN TREATMENT ON THE ACTIVITY OF ADENYLYL CYCLASE SYSTEM AND NO-SYNTHASES IN THE BRAIN AND THE MYOCARDIUM OF RATS WITH OBESITY]. ( Bondareva, VM; Derkach, KV; Ignatieva, PA; Kuznetsova, LA; Sharova, TS; Shpakov, AO, 2015) |
| "During hyperinsulinemia, glucose infusion rate (GINF) to maintain euglycemia (reflective of whole-body insulin sensitivity) was higher in Veh/Veh vs other groups." | 5.42 | Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance. ( Ahsan, Z; Chintoh, A; Giacca, A; Guenette, M; Hahn, MK; Remington, GJ; Teo, C; Wilson, V, 2015) |
| "Metformin treatment can improve NAFLD and decrease the level of chemerin." | 5.42 | Therapeutic Effect of Metformin on Chemerin in Non-Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). ( Jiang, D; Li, L; Li, X; Lou, F; Lou, N; Pan, Z; Sun, A; Sun, F; Zhang, L; Zhuang, X, 2015) |
| "Available evidence has shown that metformin improves insulin sensitivity and weight management in polycystic ovary syndrome (PCOS)." | 5.41 | The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Alesi, S; Forslund, M; Melin, J; Mousa, A; Pena, A; Piltonen, T; Romualdi, D; Spritzer, PM; Tay, CT; Teede, H; Witchel, SF, 2023) |
| "This is the first meta-analysis of the available literature about the efficacy of metformin exclusively in pediatric patients with non-alcoholic fatty liver disease (NAFLD)." | 5.41 | The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. ( Cheirakis, K; Christakopoulos, A; Fotoulaki, M; Gkiourtzis, N; Glava, A; Michou, P; Moutafi, M; Vouksinou, E, 2023) |
| "The potential application of metformin contains three directions: Firstly, improvement of metabolic factors associated with treatment effects, such as insulin resistance and peripheral neuropathy." | 5.41 | Current status and frontier tracking of clinical trials on Metformin for cancer treatment. ( Wang, W; Wei, L; Wu, Z; Zhu, S, 2023) |
| "The glucose-lowering drug metformin has recently been shown to reduce myocardial oxygen consumption and increase myocardial efficiency in chronic heart failure (HF) patients without diabetes." | 5.41 | Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study. ( Brøsen, K; Bøtker, HE; Dollerup, OL; Frøkiær, J; Hansson, NH; Jespersen, NR; Jessen, N; Larsen, AH; Møller, N; Nørrelund, H; Wiggers, H, 2021) |
| " Adolescents (aged 12-18 years) with obesity, insulin resistance (IR), and a family history of type 2 diabetes mellitus (T2DM) will receive either metformin (850 mg p." | 5.41 | Efficacy of metformin and fermentable fiber combination therapy in adolescents with severe obesity and insulin resistance: study protocol for a double-blind randomized controlled trial. ( Ball, GDC; Colin-Ramirez, E; Deehan, EC; Dinu, I; Field, CJ; Freemark, M; Haqq, AM; Madsen, KL; Newgard, CB; Orsso, C; Pakseresht, M; Prado, CM; Rubin, D; Sharma, AM; Tan, Q; Triador, L; Tun, H; Walter, J; Wine, E, 2021) |
| "Evaluate the impact of metformin treatment during puberty, a critical window of cardiometabolic change, on insulin sensitivity (Si) and compensatory β-cell response in youth with obesity." | 5.41 | Two-Year Treatment With Metformin During Puberty Does Not Preserve β-Cell Function in Youth With Obesity. ( Hilkin, A; Kelsey, MM; Nadeau, KJ; Pyle, L; Severn, C; Utzschneider, K; Van Pelt, RE; Zeitler, PS, 2021) |
| " Whether metformin improves hepatic, muscle or adipose tissue insulin sensitivity has not been studied in adults with Type 1 diabetes." | 5.41 | Insulin resistance in type 1 diabetes managed with metformin (INTIMET): Study protocol of a double-blind placebo-controlled, randomised trial. ( Bruce, C; Evans, J; Greenfield, JR; Holmes-Walker, DJ; Kowalski, G; Liu, Z; Samocha-Bonet, D; Snaith, JR, 2021) |
| "Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility, for which the insulin sensitizer metformin has been used therapeutically." | 5.41 | Therapeutic Effect of Curcumin in Women with Polycystic Ovary Syndrome Receiving Metformin: A Randomized Controlled Trial. ( Atkin, SL; Azarpazhooh, MR; Heydari, B; Karimi-Zarchi, M; Sahebkar, A; Simental-Mendía, LE; Sohrevardi, SM; Teymourzadeh, M, 2021) |
| "We conclude that addition of ALC therapy is superior to metformin plus pioglitazone in ameliorating insulin resistance, polycystic ovaries, menstrual irregularities, and hypoadiponectinemia in women with PCOS." | 5.41 | Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial. ( Badshah, H; Ehtesham, E; Habib, SH; Israr, M; Malik, MO; Rauf, B; Raza, MA; Shah, FA; Shah, I; Shah, M; Tauqir, S; Usman, M, 2021) |
| "Treatment with metformin attenuated the severity of liver injury, restored AMPK activity and normalized the expression of acetyl-CoA carboxylase and fatty acid synthase." | 5.40 | Involvement of insulin resistance in the protective effect of metformin against alcoholic liver injury. ( Jiang, Z; Nanji, AA; Wang, W; Zhao, C; Zhen, Z; Zhou, D; Zhou, J; Zhu, Z, 2014) |
| " These results indicated that chronic administration of Met regulated pancreatic inflammation generation, ion and hormone homeostasis and improved β cell function of diabetic KKAy mice." | 5.40 | [Metformin ameliorates β-cell dysfunction by regulating inflammation production, ion and hormone homeostasis of pancreas in diabetic KKAy mice]. ( Hou, SC; Liu, Q; Liu, SN; Shen, ZF; Sun, SJ; Wang, Y, 2014) |
| "Treatment with metformin significantly attenuates neointimal hyperplasia through inhibition of smooth muscle cell proliferation, migration, and inflammation as well as by improvement of the insulin signaling pathway." | 5.39 | The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats. ( Adeli, K; Ji, J; Jiang, B; Liu, L; Lu, J; Meng, H; Meng, QH; Randell, E; Wang, D, 2013) |
| "Metformin treatment after 6 and 12 months significantly reduced weight, BMI, waist circumference, insulin and HOMA-IR (p=0." | 5.39 | Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment. ( Velija-Ašimi, Z, 2013) |
| "Metformin treatment, lead to a significant decrease in serum insulin (p = 0." | 5.39 | Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. ( Ferriani, RA; Japur de Sá Rosa-e-Silva, AC; Nascimento, AD; Reis, RM; Silva Lara, LA, 2013) |
| "Insulin resistance is a recently identified mechanism involved in the pathophysiology of chronic heart failure (CHF)." | 5.38 | Metformin prevents the development of chronic heart failure in the SHHF rat model. ( Aimaretti, G; Cittadini, A; Isgaard, J; Longobardi, S; Monti, MG; Napoli, R; Netti, PA; Rea, D; Saccà, L; Samà, M; Walser, M, 2012) |
| "Insulin resistance has been shown to be associated with cardiac sympathovagal imbalance, myocardial dysfunction, and cardiac mitochondrial dysfunction." | 5.38 | Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet. ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H, 2012) |
| "Metformin treatment decreases serum ASAA in these women." | 5.37 | The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis. ( Adya, R; Aghilla, M; Keay, SD; Lehnert, H; Randeva, HS; Shan, X; Tan, BK, 2011) |
| "Treatment with metformin sensitized the impaired insulin actions and also prevented appearance of molecular and pathological characteristics observed in AD." | 5.37 | Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. ( Bisht, B; Dey, CS; Gupta, A, 2011) |
| "Sixty women with gestational and type 2 diabetes were enrolled, 30 each for metformin and insulin." | 5.35 | Metformin--a convenient alternative to insulin for Indian women with diabetes in pregnancy. ( Kamath, A; Meenakshi, D; Rai, L, 2009) |
| "Insulin resistance is a central feature of the PCOS and may increase cardiovascular risk." | 5.35 | Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. ( Best, AM; Cheang, KI; Essah, PA; Huszar, JM; Nestler, JE; Sharma, S, 2009) |
| "Metformin treatment led to improvement of hormonal and metabolic parameters and decreased ADMA levels possibly independent of BMI and metabolic changes." | 5.35 | Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. ( Heutling, D; Kaltwasser, P; Kleinstein, J; Krzyzanowska, K; Lehnert, H; Mittermayer, F; Nickel, I; Randeva, H; Schernthaner, G; Schulz, H; Westphal, S; Wolzt, M, 2008) |
| "Twenty-one patients with type 2 diabetes mellitus were observed for more than 6 months after treatment with pioglitazone, and 31 patients with type 2 diabetes mellitus were observed for more than 6 months after the treatment with metformin." | 5.35 | The ratio of leptin to adiponectin can be used as an index of insulin resistance. ( Fujita, T; Hayakawa, N; Horikawa, Y; Imamura, S; Inagaki, K; Itoh, M; Kakizawa, H; Oda, N; Suzuki, A; Takeda, J; Uchida, Y, 2008) |
| " Further studies are required to define appropriate selection of subjects warranting therapy, dosing schedule and pharmacokinetics." | 5.35 | The effect of metformin on measurements of insulin sensitivity and beta cell response in 18 horses and ponies with insulin resistance. ( Durham, AE; Newton, JE; Rendle, DI, 2008) |
| "The aim of this study was to compare the efficacy and safety of adding metformin or spironolactone to rosiglitazone in women with polycystic ovary syndrome (PCOS)." | 5.34 | Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS. ( Bhat, D; Butt, TP; Choh, N; Ganie, MA; Gupta, N; Masoodi, SR; Nisar, S; Rashid, A; Sofi, NY; Sood, M; Wani, IA, 2020) |
| "To compare the effects of metformin, rosiglitazone, and their combination in obese polycystic ovary syndrome (PCOS) patients with insulin resistance." | 5.34 | Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. ( Duan, C; Hu, Y; Huang, W; Li, Y; Tan, J; Wang, Q, 2020) |
| "Gestational diabetes mellitus is a condition similar to type 2 diabetes mellitus (T2DM) in that patients are unable to compensate for the degree of insulin resistance, and both conditions are often treated with metformin." | 5.34 | Pharmacodynamics of Metformin in Pregnant Women With Gestational Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes Mellitus. ( Ahmed, MS; Brown, Z; Caritis, S; Clark, S; Easterling, TR; Flood Nichols, SK; Haas, DM; Haneline, LS; Hebert, MF; Ma, X; Manuck, TA; Morris Brown, L; Quinney, SK; Ren, Z; Shen, DD; Shireman, LM; Shuster, DL; Thummel, KE; Tita, AT; Venkataramanan, R, 2020) |
| "To determine the separated and combined effects of metformin and exercise on insulin sensitivity and free-living glycemic control in overweight individuals with prediabetes/type 2 diabetes (T2DM)." | 5.34 | Exercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks. ( Mora-Rodríguez, R; Morales-Palomo, F; Moreno-Cabañas, A; Ortega, JF; Ramirez-Jimenez, M, 2020) |
| " This study aims to compare the impact on beta-cell function and insulin resistance of prednisone 40 mg between adults with newly diagnosed T2DM and healthy adults." | 5.34 | Effect of short-term prednisone on beta-cell function in subjects with type 2 diabetes mellitus and healthy subjects. ( Adel, MM; Fogelfeld, L; Guerra, Y; Shah, M; Tahsin, B, 2020) |
| " Metformin was able to stabilise insulin sensitivity in every stratified sub-cohort except one." | 5.34 | Metformin use in prediabetes: is earlier intervention better? ( Fleet, R; Pumpa, K; Somerset, S; Warrilow, A, 2020) |
| "Metformin treatment for one year improved HbA1c in both groups (with and without type-1 LADA)." | 5.34 | [Detection of LADA-type diabetes in overweight diabetic patients. Is treatment with metformin suitable?]. ( Arroyo Bros, J; Campos Bonilla, B; Granada Ybern, ML; Lóriz Peralta, O; Sanmartí Sala, A, 2007) |
| "Treatment with metformin or rosiglitazone prevents excess adrenal androgen synthesis." | 5.34 | Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. ( Bahtiyar, G; Sacerdote, AS; Weiss, K, 2007) |
| "It is important to choose the optimal treatment for DM in myotonic dystrophy, because the patients have hyperinsulinemia caused by specific mechanism and could not reduce the insulin resistance." | 5.33 | Low-dose metformin improves hyperglycaemia related to myotonic dystrophy. ( Komiya, I; Kouki, T; Nakachi, A; Takasu, N; Tamanaha, T; Tawata, M, 2005) |
| "A patient with type 2 diabetes and hypothalamic damage due to a suprasellar tumor developed impaired glycemic control and central obesity." | 5.33 | Markedly improved glycemic control and enhanced insulin sensitivity in a patient with type 2 diabetes complicated by a suprasellar tumor treated with pioglitazone and metformin. ( Goto, T; Igaki, N; Tanaka, M, 2005) |
| "Metformin is a logical treatment in these circumstances but there has always been concern about its safety for the fetus, particularly as it crosses the placenta and it may increase the risk of teratogenesis." | 5.33 | Metformin use and diabetic pregnancy-has its time come? ( Hawthorne, G, 2006) |
| "Metformin vs placebo treatment of diabetic pigs (twice 1." | 5.33 | Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model. ( Ackermans, M; Corbijn, H; Dekker, R; Koopmans, SJ; Mroz, Z; Sauerwein, H, 2006) |
| "Metformin or vehicle was administered to rats daily for 1 week." | 5.32 | Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms. ( Cleasby, ME; Cooney, GJ; Dzamko, N; Hegarty, BD; Kraegen, EW; Ye, JM, 2004) |
| "Metformin was then administered." | 5.32 | Metformin use in an obese diabetic patient from weeks 1 to 21 of pregnancy. ( Imamura, M; Mori, M; Nagai, T, 2003) |
| "There is no known treatment for fatty liver, a ubiquitous cause of chronic liver disease." | 5.31 | Metformin reverses fatty liver disease in obese, leptin-deficient mice. ( Chuckaree, C; Diehl, AM; Kuhajda, F; Lin, HZ; Ronnet, G; Yang, SQ, 2000) |
| "Polycystic ovary syndrome is considered the most frequent endocrine abnormality during the fertile age." | 5.31 | [Effects of metformin on insulin resistance and on ovarian steroidogenesis in women with polycystic ovary syndrome]. ( De Conciliis, B; Passannanti, G; Romano, L; Santarpia, R, 2001) |
| "OCP resulted in a higher reduction in serum luteinizing hormone (LH) and androgens whereas metformin resulted in significant reduction in BMI, waist circumference, and insulin resistance." | 5.30 | Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial. ( Mohanty, J; Nagy, A; Sahu, A; Tripathy, P, 2019) |
| "This study provides evidence that, compared to glimepiride, saxagliptin more effectively achieves a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in T2D patients who are inadequately controlled with metformin monotherapy, especially in overweight patients with moderate hyperglycaemia and a relatively short duration of diabetes." | 5.30 | Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr ( Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L, 2019) |
| "Metformin and exercise independently improve insulin sensitivity and decrease the risk of diabetes." | 5.30 | Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. ( Bailey, SM; Biela, LM; Castor, WM; Hamilton, KL; Konopka, AR; Laurin, JL; Linden, MA; Miller, BF; Musci, RV; Reid, JJ; Safairad, OD; Schoenberg, HM; Wolff, CA, 2019) |
| " Therefore, we here aim to investigate if acupuncture treatment or metformin together with lifestyle or lifestyle management alone improves insulin sensitivity and related symptoms in overweight/obese women with PCOS." | 5.30 | Acupuncture or metformin to improve insulin resistance in women with polycystic ovary syndrome: study protocol of a combined multinational cross sectional case-control study and a randomised controlled trial. ( Chang, C; Friden, C; Huo, Z; Ji, X; Li, D; Li, R; Li, S; Linden-Hirschberg, A; Qiao, J; Stener-Victorin, E; Wang, H; Wang, W; Zhang, H, 2019) |
| "To determine the feasibility of a metformin- versus-placebo definitive randomized clinical trial in women with low milk production and signs of insulin resistance." | 5.30 | Feasibility and Acceptability of Metformin to Augment Low Milk Supply: A Pilot Randomized Controlled Trial. ( King, E; Nommsen-Rivers, L; Riddle, S; Thompson, A; Wagner, E; Ward, L, 2019) |
| " The current study investigated the effects of vildagliptin, DPP-4 inhibitor, compared to metformin on endothelial function and blood pressure through vascular endothelial growth factor (VEGF) modulation in patients with T2DM and hypertension." | 5.30 | The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients. ( Abdel-Latif, H; Bassyouni, A; El-Naggar, AR; Elyamany, M; Hassanin, S; Zaafar, D, 2019) |
| "To evaluate the reproductive and metabolic effects of L-carnitine plus metformin in clomiphene citrate (CC) resistant obese polycystic ovary syndrome (PCOS) women." | 5.30 | l-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial. ( El Sharkwy, I; Sharaf El-Din, M, 2019) |
| "Measure peripheral, hepatic, and adipose insulin sensitivity before and after metformin or placebo therapy in youth with obesity with type 1 diabetes." | 5.30 | Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes. ( Bergman, BC; Cengiz, E; Cree-Green, M; Fox, LA; Hannon, TS; Kahn, D; Libman, I; Miller, K; Nadeau, KJ; Nathan, B; Pyle, L; Tansey, M; Tichy, E; Tsalikian, E, 2019) |
| "Metformin treatment significantly reduced LVMI, LVM, office systolic BP, body weight, and oxidative stress." | 5.30 | A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. ( Al-Talabany, S; Baig, F; Bhalraam, U; Choy, AM; Gandy, SJ; George, J; Houston, JG; Hussain, MS; Khan, F; Lang, CC; Matthew, S; McKinnie, A; Mohan, M; Mordi, IR; Singh, JSS; Struthers, AD, 2019) |
| "Though most of the observational studies have shown that metformin can reduce serum thyroid stimulating hormone (TSH) level in patients of hypothyroidism with diabetes or polycystic ovarian disease, randomised controlled trials are sparse." | 5.30 | Effect of metformin on thyroid function tests in patients with subclinical hypothyroidism: an open-label randomised controlled trial. ( Durgia, H; Kamalanathan, S; Kar, SS; Palui, R; Patil, M; Raj, H; Sahoo, J; Sridharan, K, 2019) |
| "The aim of this study was to analyze the efficacy, insulin sensitivity and safety in the event of administering sulfonylurea-based drugs and metformin in combination with basal insulin." | 5.30 | A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy. ( Chun, SW; Hong, JH; Kim, SJ; Lee, JM; Lim, DM; Park, KS; Park, KY; Yu, HM, 2019) |
| " PCOS is associated with obesity, dyslipidaemia and insulin resistance, and metformin treatment may improve such metabolic features." | 5.27 | The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial. ( Andersen, M; Christensen, MMH; Glintborg, D; Pedersen, AJT; Stage, TB, 2018) |
| "To evaluate whether metformin can reduce TSH levels in subjects with subclinical hypothyroidism." | 5.27 | Metformin effect on TSH in subclinical hypothyroidism: randomized, double-blind, placebo-controlled clinical trial. ( Antonio Naujorks, A; Correa Junior, V; Dornelles Severo, M; Gus, M; Schaan, BD; Stürmer Andrade, T, 2018) |
| "We aimed to assess the use of metformin (MTF) in the prevention of gestational diabetes mellitus (GDM) in patients with pregestational insulin resistance (PIR)." | 5.27 | Metformin as a prophylactic treatment of gestational diabetes in pregnant patients with pregestational insulin resistance: A randomized study. ( Abusada, N; Candia, P; Cuellar, E; Manukian, B; Orellana, R; Sepúlveda-Martínez, A; Valdés, E, 2018) |
| "To study the effectiveness of exenatide with metformin and sequential treatment with exenatide and glargine added to metformin and their influence on insulin sensitivity and adipose distribution." | 5.27 | Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance. ( Du, X; Hu, C; Lu, W; Lu, Z; Shao, X; Shi, B, 2018) |
| "To evaluate the effect of Diane-35, alone or in combination with orlistat or metformin, on androgen and body fat percentage parameters in Chinese overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance." | 5.27 | Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| "Worldwide, metformin is prescribed to improve pregnancy outcome in polycystic ovary syndrome (PCOS)." | 5.27 | Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS? ( Andersen, MS; Høgetveit, K; Oppen, IH; Stridsklev, S; Underdal, MO; Vanky, E, 2018) |
| "In this randomized, prospective, controlled study, 87 non-obese (18-30 BMI) women of reproductive age (18-39) with polycystic ovary syndrome (PCOS) were assigned to control (n = 17), OC (n = 21), combination (n = 20) and metformin (n = 29) therapy groups." | 5.27 | The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study. ( Bodur, S; Dundar, O; Kanat-Pektas, M; Kinci, MF; Tutuncu, L, 2018) |
| " The RISE Pediatric Medication Study compared two approaches-glargine followed by metformin and metformin alone-in preserving or improving β-cell function in youth with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes during and after therapy withdrawal." | 5.27 | Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. ( , 2018) |
| "We investigated whether metformin prevents tamoxifen-induced endometrial changes and insulin resistance (IR) after a diagnosis of breast cancer." | 5.27 | The benefits of adding metformin to tamoxifen to protect the endometrium-A randomized placebo-controlled trial. ( Bell, RJ; Brown, KA; Chipman, M; Davis, SR; Edwards, A; Jane, F; McNeilage, J; Piessens, S; Robinson, PJ; White, S; Woinarski, J, 2018) |
| " The BetaFat study compared gastric banding and metformin for their impact on β-cell function in adults with moderate obesity and impaired glucose tolerance (IGT) or recently diagnosed, mild T2D." | 5.27 | Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. ( Beale, E; Buchanan, TA; Chow, T; Hendee, F; Katkhouda, N; Martinez, M; Montgomery, C; Nayak, KS; Trigo, E; Wang, X; Wu, J; Xiang, AH, 2018) |
| "To determine the relationship between the serum fetuin and insulin resistance in Type 1 diabetes subjects and the effect of short-term Metformin therapy on this relationship." | 5.27 | Effect of Metformin Therapy on Serum Fetuin Levels in Insulin Resistant Type 1 Diabetics. ( Abdelsalam, MM; Ahmed, IZ; Eid, YM; Mahdy, MM; Mansour, HK; Sheriba, NA, 2018) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 5.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "Steady-state population pharmacokinetics of a noncommercial immediate-release metformin (hydrochloride) drug product were characterized in 28 severely obese children with insulin resistance." | 5.24 | Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. ( Alfaro, RM; Calis, KA; Hon, YY; Reynolds, JC; Roza, O; Sam, WJ; Yanovski, JA, 2017) |
| "This study aimed to evaluate the effects of metformin and conjugated linoleic acid (CLA) on insulin sensitivity, measured via euglycemic-hyperinsulinemic clamp technique and insulin pathway expression molecules in muscle biopsies of children with obesity." | 5.24 | Effects of Conjugated Linoleic Acid and Metformin on Insulin Sensitivity in Obese Children: Randomized Clinical Trial. ( Alvarez, F; Bustos, M; Cuevas, S; Duggirala, R; Fonseca-Sánchez, M; Garibay-Nieto, N; Jalife, A; Laresgoiti-Servitje, E; León, M; López-Alvarenga, JC; Macías, T; Queipo-García, G; Ramírez, F; Serratos, F; Villanueva, E, 2017) |
| "To improve insulin sensitivity, insulin-sensitizing drugs such as metformin are commonly used in overweight and obese T1D patients." | 5.24 | A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. ( Defeudis, G; Del Toro, R; Fioriti, E; Guglielmi, C; Kyanvash, S; Maggi, D; Manfrini, S; Maurizi, AR; Menduni, M; Pantano, AL; Pozzilli, P, 2017) |
| "The aim of this randomized clinical trial (RCT) was to evaluate the effect of vitamin D supplementation in obese, insulin-resistant (IR) and vitamin D-deficient polycystic ovary syndrome (PCOS) women on metabolic abnormalities in comparison to the effect of metformin or combined metformin plus vitamin D therapy." | 5.24 | The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J, 2017) |
| "This study will investigate the effects of acupuncture on the insulin sensitivity of PCOS and IR women compared with metformin and sham acupuncture." | 5.24 | Acupuncture treatment for insulin sensitivity of women with polycystic ovary syndrome and insulin resistance: a study protocol for a randomized controlled trial. ( Hu, Z; Lai, M; Li, J; Li, M; Liu, J; Ma, H; Ng, EH; Shao, X; Stener-Victorin, E; Su, N; Wang, H; Wu, T; Xie, C; Yu, C, 2017) |
| " A significant reduction in homoeostatic model assessment of insulin resistance (HOMA-IR) was seen with exenatide versus metformin (MD: -0." | 5.22 | Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. ( Abdalla, MA; Al-Rifai, RH; Atkin, SL; Deshmukh, H; Östlundh, L; Sahebkar, A; Sathyapalan, T; Shah, N, 2022) |
| " Indeed, metformin has been involved in repair mitochondrial dysfunction, decrease of oxidative stress, reduction of androgens levels and the enhancing of insulin sensitivity." | 5.22 | Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance. ( Barrera, D; Echeverría, O; Escobar, L; Espinoza-Simón, E; González, J; Hernández-Jiménez, JL; Ortíz-Hernández, R; Torres-Ramírez, N, 2022) |
| "Using the terms "metformin" and "polycystic ovary syndrome," we conducted a search the PubMed, EMBASE, and Google Scholar databases." | 5.22 | The use of metformin in women with polycystic ovary syndrome: an updated review. ( Neto, FTL; Notaro, ALG, 2022) |
| "Metformin is the most commonly used treatment to increase insulin sensitivity in insulin-resistant (IR) conditions such as diabetes, prediabetes, polycystic ovary syndrome, and obesity." | 5.22 | Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport. ( Dolžan, V; Herman, R; Janež, A; Jensterle, M; Kravos, NA, 2022) |
| "Metformin is a synthetic biguanide that improves insulin sensitivity and reduces hepatic gluconeogenesis." | 5.22 | Metformin in Differentiated Thyroid Cancer: Molecular Pathways and Its Clinical Implications. ( Ferreira-Hermosillo, A; García-Sáenz, M; Lobaton-Ginsberg, M, 2022) |
| " Many studies have reported improvement in insulin resistance and thereby intracellular glucose uptake after myo-inositol treatment in PCOS patients, but these studies have a small sample size, varying methodology, and outcome analysis." | 5.22 | Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial. ( Deshpande, S; Gajjar, N; Jethaliya, H; Patel, R; Patel, V, 2022) |
| "Based on the results of this study, compared with metformin alone, acupuncture combined with metformin has a positive effect on pregnancy rate, ovulation rate, and insulin resistance in PCOS." | 5.22 | Acupuncture combined with metformin versus metformin alone to improve pregnancy rate in polycystic ovary syndrome: A systematic review and meta-analysis. ( Chen, X; Lan, Y; Li, H; Li, Z; Liu, Y; Long, C; Wang, M; Wu, J; Xie, Q; Yang, L; Zhao, Y; Zhu, X, 2022) |
| "The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)." | 5.22 | Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016) |
| "To determine serum vascular endothelial growth factor B (VEGF-B) levels in polycystic ovary syndrome, their association with insulin resistance and β-cell dysfunction, and the effect of metformin on serum VEGF-B levels." | 5.22 | Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment. ( Chen, C; Cheng, F; Huang, T; Jia, F; Liu, D; Wu, J; Wu, Y; Yang, G; Zhang, Z; Zhao, L, 2016) |
| " We assessed the efficacy of metformin in preventing recurrence after medroxyprogesterone acetate (MPA) as fertility-sparing treatment for atypical endometrial hyperplasia (AEH) and EC." | 5.22 | Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. ( Hanaoka, H; Kiyokawa, T; Koshizaka, M; Mitsuhashi, A; Sato, Y; Shozu, M, 2016) |
| "In subjects with insulin resistance, metformin therapy significantly decreased thyroid volume and nodule size." | 5.22 | Metformin Decreases Thyroid Volume and Nodule Size in Subjects with Insulin Resistance: A Preliminary Study. ( Anil, C; Atesagaoglu, B; Bascil Tutuncu, N; Gursoy, A; Kut, A; Nar, A, 2016) |
| "Weight loss and metformin are hypothesized to improve breast cancer outcomes; however the joint impacts of these treatments have not been investigated." | 5.22 | Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors. ( Cadmus-Bertram, L; Flatt, SW; Godbole, S; Hartman, SJ; Kerr, J; Li, H; Marinac, CR; Natarajan, L; Oratowski-Coleman, J; Parker, B; Patterson, RE; Villaseñor, A, 2016) |
| "In combination with a novel carbohydrate modified diet, metformin enhanced 12-month weight loss and improved body composition in ethnically diverse normoglycemic, hyperinsulinemic women with midlife weight gain." | 5.22 | METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN. ( Freeman, R; Mogul, H; Nguyen, K, 2016) |
| " In this study, data were pooled from two randomized, placebo-controlled trials, which were originally designed to examine the efficacy of metformin in treating antipsychotic-induced weight gain and other metabolic abnormalities." | 5.22 | Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. ( Chan, PK; Gao, KM; Guo, WB; Jin, H; Ou, JJ; Shao, P; Wu, RR; Zhang, FY; Zhao, JP, 2016) |
| "In the Carotid Atherosclerosis: Metformin for Insulin Resistance (CAMERA) study (NCT00723307), 173 individuals without Type 2 diabetes, but with coronary disease, were randomized to metformin (n=86) or placebo (n=87) for 18 months." | 5.22 | Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study. ( Ala-Korpela, M; Holman, RR; Kangas, AJ; Preiss, D; Rankin, N; Sattar, N; Soininen, P; Welsh, P; Würtz, P, 2016) |
| " Metformin was found to improve insulin sensitivity in hepatitis C patients, as well as to reduce elevated thyrotropin levels in patients with hypothyroidism." | 5.22 | The Effect of Metformin on Hypothalamic-Pituitary-Thyroid Axis Activity in Women with Interferon-Induced Hypothyroidism: A Pilot Study. ( Krysiak, R; Okopien, B; Szkrobka, W, 2016) |
| "Our results show that Metformin and acupuncture combined therapy significantly improves body weight, body mass index (BMI), fasting blood sugar (FBS), fasting insulin (FINS), homeostasis model assessment (HOMA) index, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), leptin, adiponectin, glucagon-like peptide-1 (GLP-1), resistin, serotonin, free fatty acids (FFAs), triglyceride (TG), low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc) and ceramides." | 5.22 | Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients. ( Firouzjaei, A; Li, GC; Liu, WX; Wang, N; Zhu, BM, 2016) |
| "To evaluate the effect of testosterone replacement therapy (TRT) on body composition, insulin sensitivity, oxidative metabolism and glycaemic control in aging men with lowered bioavailable testosterone (BioT) levels and type 2 diabetes mellitus (T2D) controlled on metformin monotherapy." | 5.22 | Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy. ( Andersen, M; Glintborg, D; Hermann, P; Hougaard, DM; Højlund, K; Magnussen, LV, 2016) |
| "Severely burned adult patients with burns over 20% total body surface area (TBSA) burn were prospectively randomized in this Phase II clinical trial to either metformin or insulin (standard of care) treatment." | 5.22 | Glucose Control in Severely Burned Patients Using Metformin: An Interim Safety and Efficacy Analysis of a Phase II Randomized Controlled Trial. ( Abdullahi, A; Burnett, M; Jeschke, MG; Rehou, S; Stanojcic, M, 2016) |
| "Aim of this study was to evaluate the effect of vitamin D supplementation in obese, insulin resistant and vitamin D deficient PCOS women on biochemical and clinical hyperandrogenism and menstrual irregularity in comparison to effect of metformin or combined metformin plus vitamin D therapy." | 5.22 | The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J; Vaľková, M, 2016) |
| "As adolescents with obesity and insulin resistance may be refractory to lifestyle intervention therapy alone, additional off-label metformin therapy is often used." | 5.22 | Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. ( Elst, MA; Knibbe, CA; van de Garde, EM; van der Aa, MP; van der Vorst, MM; van Mil, EG, 2016) |
| "To determine whether resveratrol supplementation can improve insulin sensitivity and promote overall metabolic health on top of standard diabetes care." | 5.22 | Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial. ( de Ligt, M; Hansen, J; Hesselink, MK; Kunz, I; Moonen-Kornips, E; Phielix, E; Schaart, G; Schrauwen, P; Schrauwen-Hinderling, VB; Timmers, S; van de Weijer, T, 2016) |
| "Metformin has been used for alleviating metabolic abnormalities in patients with schizophrenia." | 5.22 | Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. ( Chen, CH; Chen, PY; Chiu, CC; Huang, MC; Lin, SK; Lin, YK; Lu, ML, 2016) |
| " This study aimed to explore the association between the estimated insulin demand of the diet, as measured by glycemic and insulin load, weight loss, percentage body fat and insulin sensitivity index (ISI) in obese adolescents with clinical features of insulin resistance and/or prediabetes after a 3 month lifestyle and metformin intervention." | 5.20 | Dietary glycemic load, insulin load, and weight loss in obese, insulin resistant adolescents: RESIST study. ( Buyken, AE; Cowell, CT; Garnett, SP; Goletzke, J; Gow, M; Halim, J; Ho, M; Joslowski, G; Louie, JC, 2015) |
| " Metformin, typically used in type 2 diabetes mellitus (T2DM), is a possible adjunct therapy in T1DM to help improve glycemic control and insulin sensitivity." | 5.20 | Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study. ( Alam, S; Campbell, S; Chow, K; Klingensmith, G; Lindquist, K; McFann, K; Nadeau, KJ; Walravens, P, 2015) |
| "This research was carried out to evaluate the chemopreventive effects of different doses of metformin treatment for 6 months on rectal aberrant crypt foci (ACF) in patients with impaired glucose tolerance (IGT)." | 5.20 | Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance. ( Chen, M; Chen, Y; Dai, Y; Li, Y; Wang, Y; Xie, H; Zhao, X, 2015) |
| "To compare the therapeutic effects of metformin (Met) and laparoscopic ovarian drilling (LOD) in clomiphene and insulin-resistant patients with polycystic ovary syndrome (CIRPCOS)." | 5.20 | Therapeutic effects of metformin and laparoscopic ovarian drilling in treatment of clomiphene and insulin-resistant polycystic ovary syndrome. ( Huang, LP; Wang, JQ; Wang, XH; Xu, Y, 2015) |
| "Prepubertal intervention with metformin reduces central adiposity and improves insulin sensitivity in non-obese catch-up SGA children." | 5.20 | Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo-controlled pilot study in prepubertal children. ( Bassols, J; de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A, 2015) |
| "This study was undertaken to determine whether metformin would ameliorate insulin resistance, reduce weight and waist circumference and improve lipids in obese, but not morbidly obese, euglycemic women." | 5.20 | Metformin for overweight women at midlife: a double-blind, randomized, controlled trial. ( Bell, RJ; Davis, SR; Jane, F; Robinson, PJ; Worsley, R, 2015) |
| " The diabetic medication, Metformin, reduces IR and aids weight loss and may therefore regress LVH." | 5.20 | Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study. ( Baig, F; Lang, CC; McSwiggan, S; Mohan, M; Rutherford, L, 2015) |
| " We present a protocol for a study to test the hypothesis that metformin will improve insulin sensitivity in obese pregnant women, thereby reducing the incidence of high birthweight babies and other pregnancy complications." | 5.20 | Efficacy of metformin in pregnant obese women: a randomised controlled trial. ( Chiswick, CA; Denison, FC; Drake, AJ; Forbes, S; Murray, GD; Newby, DE; Norman, JE; Quenby, S; Reynolds, RM; Walker, BR; Whyte, SA; Wray, S, 2015) |
| "Development of aleglitazar was halted because of a lack of cardiovascular efficacy and peroxisome proliferator-activated receptor-related side effects in patients with type 2 diabetes post-acute coronary syndrome; however, in the present studies, aleglitazar was well tolerated and effective in improving HbA1c, insulin resistance and lipid variables." | 5.20 | Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials. ( Andjelkovic, M; Buse, JB; Durrwell, L; El Azzouzi, B; Henry, RR; Herz, M; Jaekel, K; Mingrino, R; Wu, H, 2015) |
| "In individuals with prediabetes, metformin ameliorated effector pathways that have been shown to regulate longevity in animal models." | 5.20 | Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. ( Avogaro, A; Bacalini, MG; Borelli, V; Cattelan, A; Ceolotto, G; de Kreutzenberg, SV; Fadini, GP; Franceschi, C; Garagnani, P; Mazzucato, M; Pagnin, E, 2015) |
| " This study was conducted as an exploratory analysis to clarify the effects of liraglutide, a GLP-1RA, on beta cell function, fat distribution and pancreas volume compared with metformin in Japanese overweight/obese patients with T2DM." | 5.20 | Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. ( Cobelli, C; Irie, J; Itoh, H; Jinzaki, M; Kawai, T; Manesso, E; Meguro, S; Saisho, Y; Sugiura, H; Tanaka, K; Tanaka, M, 2015) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 5.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "Primary outcomes are clamp-derived glucose-stimulated C-peptide secretion and maximal C-peptide response to arginine during hyperglycemia." | 5.19 | Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span. ( , 2014) |
| "Adding metformin to insulin therapy in women with insulin-resistant diabetes mellitus with pregnancy seems to be effective in proper glycemic control in a considerable proportion of women, along with benefits of reduced hospital stay, reduced frequency of maternal hypoglycemia as well as reduced frequency of neonatal hypoglycemia, NICU admission and neonatal respiratory distress syndrome." | 5.19 | The role of adding metformin in insulin-resistant diabetic pregnant women: a randomized controlled trial. ( Anwar, M; Faris, M; Hamdy, A; Ibrahim, MI; Shafik, A; Taha, S, 2014) |
| "This randomized, double-blind, placebo-controlled parallel-group study assessed the effects of sodium glucose cotransporter 2 inhibition by dapagliflozin on insulin sensitivity and secretion in subjects with type 2 diabetes mellitus (T2DM), who had inadequate glycemic control with metformin (with or without an insulin secretagogue)." | 5.19 | Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. ( Boden, G; Chalamandaris, AG; Duchesne, D; Henry, RR; Iqbal, N; List, J; Mudaliar, S; Smith, S, 2014) |
| " Using stored samples from this resource, we measured BMI, waist circumference (WC), an insulin sensitivity index (ISI; [1/HOMA-IR]) and NT-proBNP at baseline and at 2 years of follow-up in participants randomised to placebo (n = 692), intensive lifestyle intervention (n = 832) or metformin (n = 887)." | 5.19 | Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. ( Barrett-Connor, E; Christophi, CA; Davis, J; Florez, JC; Goldberg, RB; Horton, E; Jarolim, P; Ma, Y; Mather, KJ; Walford, GA; Wang, TJ, 2014) |
| "Although metformin is widely used to improve insulin resistance in women with polycystic ovary syndrome (PCOS), its mechanism of action is complex, with inconsistent effects on insulin sensitivity and variability in treatment response." | 5.19 | Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. ( Duran, J; Keefe, C; Pau, CT; Welt, CK, 2014) |
| "Combining metformin and exercise is recommended for the treatment of insulin resistance." | 5.19 | Metformin does not attenuate the acute insulin-sensitizing effect of a single bout of exercise in individuals with insulin resistance. ( de Prada, MV; Fernández-Elías, VE; Hamouti, N; Martínez-Vizcaíno, V; Mora-Rodríguez, R; Ortega, JF, 2014) |
| " We evaluated the following variables: BMI; glycaemic control; fasting plasma insulin; homeostatic model assessment of insulin resistance index; fasting plasma proinsulin; glucagon; lipid profile; adiponectin; high-sensitivity C-reactive protein; interleukin-6; and tumour necrosis factor-α." | 5.19 | Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014) |
| "To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia." | 5.19 | Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014) |
| " The end points for β- and α-cell function were change from baseline in C-peptide, insulin, and glucagon areas under the curve from 0 to 180 min (AUC0-180), insulinogenic index, and insulin sensitivity from Matsuda index after a mixed meal." | 5.19 | Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes. ( Hirshberg, B; Iqbal, N; Lu, J; Sjöstrand, M, 2014) |
| "Insulin resistance (IR) affects sustained virological response (SVR) to peginterferon alfa plus ribavirin (PR) in patients with chronic hepatitis C (CHC)." | 5.19 | A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. ( Chen, DS; Hsu, CS; Hsu, SJ; Kao, JH; Lin, HH; Tseng, TC; Wang, CC, 2014) |
| "Treatment of diabetics with metformin is associated with decreased breast cancer risk in observational studies, but it remains unclear if this drug has clinical antineoplastic activity." | 5.19 | Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. ( Aristarco, V; Bassi, F; Bonanni, B; Cazzaniga, M; DeCensi, A; Gandini, S; Guerrieri-Gonzaga, A; Hofmann, U; Johansson, HA; Lazzeroni, M; Luini, A; Macis, D; Mora, S; Pollak, MN; Pruneri, G; Puntoni, M; Schwab, M; Serrano, D, 2014) |
| "To study the effect of metformin on metabolic parameters, body weight (BW), and waist circumference (WC) in patients with abdominal obesity (AO)." | 5.19 | [Efficacy of metformin in abdominal obesity]. ( Kichigin, VA; Markova, TN; Mkrtumian, AM; Podachina, SV; Zhuchkova, SM, 2014) |
| "To assess the effect of metformin (Met) or omega-3 (ω-3) polyunsaturated fatty acids (PUFA) on the homeostasis model assessment-estimated insulin resistance (HOMA-IR) index, lipid profile, and body mass index (BMI) of obese children." | 5.17 | Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents. ( Flores-Huerta, S; Juárez-López, C; Klünder-Klünder, M; Madrigal-Azcárate, A, 2013) |
| "Our study included 41 fenofibrate-treated patients with impaired glucose tolerance allocated to either metformin (3 g daily) or placebo." | 5.17 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "Abdominal acupuncture and metformin improved the endocrine and metabolic function of patients with obesity-type PCOS." | 5.17 | Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial. ( Lai, MH; Liu, H; Ma, HX; Wang, XH; Yao, H; Zheng, YH, 2013) |
| "During the first 6 months, metformin plus rosiglitazone exhibited a significantly greater improvement in insulin sensitivity and oDI versus metformin alone and versus metformin plus lifestyle; these improvements were sustained over 48 months of TODAY." | 5.17 | Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. ( , 2013) |
| " Patients also underwent a combined euglycemic, hyperinsulinemic, and hyperglycemic clamp with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion." | 5.17 | Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial. ( Carbone, A; Ciccarelli, L; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F, 2013) |
| "To improve the treatment outcomes in women with polycystic ovary syndrome (PCOS), various drugs like glitazones, oral contraceptive pills, or antiandrogens have been combined with metformin." | 5.17 | Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. ( Ganie, MA; Gupta, N; Khurana, ML; Kulshrestha, B; Mir, FA; Mudasir, S; Nisar, S; Shah, PA; Shah, ZA; Taing, S; Wani, TA; Zargar, MA, 2013) |
| " Metformin is an insulin sensitising agent which is known to improve vascular health outcomes in type 2 diabetes (T2D) and other individuals with insulin resistance." | 5.17 | Does metformin improve vascular health in children with type 1 diabetes? Protocol for a one year, double blind, randomised, placebo controlled trial. ( Anderson, J; Coppin, B; Couper, J; D'Arcy, B; Gent, R; Olds, T; Peña, AS; Sullivan, T, 2013) |
| "These results show that in obese patients with type 2 diabetes, DPP-4 inhibitors treatment in combination with metformin was associated with improvements in glycaemic control, and a reduction in body weight." | 5.17 | The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes. ( Coric, J; Dizdarevic-Bostandzic, A; Djelilovic-Vranic, J; Izetbegovic, S; Karamehic, J; Macic-Dzankovic, A; Panjeta, M; Velija-Asimi, Z, 2013) |
| " We conducted the present study to compare the antidepressant efficacy of pioglitazone with another insulin-sensitizer, metformin, in obese patients with concomitant polycystic ovarian syndrome (PCOS) and major depressive disorder (MDD)." | 5.17 | Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. ( Akhondzadeh, S; Ashrafi, M; Farazmand, B; Kashani, L; Modabbernia, A; Omidvar, T; Ramzanzadeh, F; Tabrizi, M; Tehraninejad, ES, 2013) |
| "The aim of the present study was to investigate the efficacy of Metformin compared with a hypocaloric diet on C-reactive protein (CRP) level and markers of insulin resistance in obese and overweight women with polycystic ovary syndrome (PCOS)." | 5.17 | Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. ( Esfahanian, F; Heshmat, R; Moini nia, F; Zamani, MM, 2013) |
| "Metformin may be an effective therapeutic option for insulin-resistant (I-R) horses/ponies because, in humans, it reportedly enhances insulin sensitivity (SI) of peripheral tissues without stimulating insulin secretion." | 5.16 | The effect of oral metformin on insulin sensitivity in insulin-resistant ponies. ( Boston, RC; Harris, PA; Noble, GK; Raidal, SL; Sillence, MN; Tinworth, KD, 2012) |
| "To investigate the effects of metformin and lifestyle changes on the development of androgen deprivation therapy (ADT)-related metabolic syndrome." | 5.16 | A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. ( Klopper, T; Laing, RW; Langley, SE; Nobes, JP; Russell-Jones, D, 2012) |
| "Physical activity or metformin enhances insulin sensitivity and opposes the progression from prediabetes to type 2 diabetes." | 5.16 | Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. ( Braun, B; Chipkin, SR; Gerber, R; Malin, SK, 2012) |
| "In youth with recent-onset T2DM treated with metformin, glycemic control, as measured by HbA1c, appears to be associated with residual β-cell function and not insulin sensitivity." | 5.16 | Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study. ( Arslanian, S; Bacha, F; Caprio, S; Cuttler, L; Goland, R; Haymond, M; Levitsky, L; Lynch, J; Nadeau, K; Pyle, L; Weinstock, RS; White, NH, 2012) |
| " The body weight, body mass index, fasting insulin and insulin resistance index decreased significantly in the metformin group, but increased in the placebo group during the 12-week follow-up period." | 5.16 | Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. ( Liang, GM; Tong, JH; Wang, M; Wang, XZ; Yan, HF; Zhu, G, 2012) |
| "these results suggest pioglitazone is as effective as metformin in improving insulin sensitivity and some cardiovascular risk biomarkers but it has no significant effect on reducing BMI and body weight." | 5.16 | Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome. ( Abedini, A; Ghorbani, A; Hashemipour, S; Karimzadeh, T; Oveisi, S; Ziaee, A, 2012) |
| "A combination of metformin, peginterferon alfa-2a, and ribavirin improved insulin sensitivity and increased the SVR rate of patients with hepatitis C genotype 1 and IR, with a good safety profile." | 5.16 | The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. ( Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH, 2012) |
| "The addition of vildagliptin to metformin gave a better improvement of glycemic control, insulin resistance, and β-cell function compared with metformin alone." | 5.16 | Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. ( Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD; Romano, D, 2012) |
| "Metformin is associated with reduced breast cancer risk in observational studies in patients with diabetes, but clinical evidence for antitumor activity is unclear." | 5.16 | Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. ( Aristarco, V; Bassi, F; Bonanni, B; Bruzzi, P; Cazzaniga, M; Decensi, A; Galimberti, V; Gennari, A; Guerrieri-Gonzaga, A; Johansson, H; Lazzeroni, M; Luini, A; Pruneri, G; Puntoni, M; Serrano, D; Trabacca, MS; Varricchio, C; Veronesi, P; Viale, G, 2012) |
| "To compare serum concentrations of inflammatory cytokines, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), adiponectin, and tumor necrosis factor alpha (TNFalpha), before and after 3 months treatment with metformin in obese adolescents with insulin resistance (IR)." | 5.16 | The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. ( Apolinar-Jiménez, E; Evia-Viscarra, ML; Figueroa-Barrón, M; García-Morales, LM; Leaños-Pérez, C; Muñoz-Noriega, N; Reyes-García, JG; Rodea-Montero, ER; Sánchez-Fierros, D, 2012) |
| "This is a randomized controlled trial to test the effect of different doses of metformin in patients with breast cancer and without diabetes, with the aim of modifying the hormonal and metabolic parameters linked to breast cancer prognosis." | 5.16 | Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. ( Abbà, C; Ambroggio, S; Berrino, F; Biglia, N; Brucato, T; Campagnoli, C; Colombero, R; Danese, S; Donadio, M; Pasanisi, P; Venturelli, E; Zito, G, 2012) |
| "To evaluate the impact on glycemic control, insulin resistance, and insulin secretion of sitagliptin+metformin compared to metformin in type 2 diabetic patients." | 5.16 | Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Franzetti, I; Maffioli, P; Querci, F; Romano, D, 2012) |
| "Eighty-four women (ages 18-40 years) with first-episode schizophrenia who suffered from amenorrhea during antipsychotic treatment were randomly assigned, in a double-blind study design, to receive 1000 mg/day of metformin or placebo in addition to their antipsychotic treatment for 6 months." | 5.16 | Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. ( Chan, PK; Davis, JM; Gao, K; Guo, XF; Jin, H; Ou, JJ; Shao, P; Twamley, EW; Wang, J; Wu, RR; Zhao, JP, 2012) |
| "Twelve weeks of atorvastatin led to a significant reduction in oxidative stress as determined by MDA concentrations among patients with polycystic ovary syndrome that was independently predicted by changes in testosterone, 25OHD, and high-sensitivity C-reactive protein." | 5.16 | Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. ( Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Shepherd, J, 2012) |
| "Exenatide demonstrated more beneficial effects on HbA(1C), weight reduction and insulin resistance during 26 weeks of treatment, but there were more hypoglycemic events and mild-to-moderate nausea compared with metformin." | 5.16 | Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study. ( Gao, Y; Guo, XH; Huang, YY; Song, WL; Yuan, GH, 2012) |
| "This study evaluated the effect of metformin glycinate on glycated hemoglobin A1c (A1C) concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus (T2DM)." | 5.16 | Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus. ( Barrera-Durán, C; González-Canudas, J; González-Ortiz, M; Martínez-Abundis, E; Ramos-Zavala, MG; Robles-Cervantes, JA, 2012) |
| "To evaluate the impact on glycemic control, insulin secretion and on insulin resistance of a sitagliptin + metformin combination compared to metformin monotherapy in type 2 diabetic, naïve to treatment, patients." | 5.16 | A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2012) |
| " Weight, body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR) index as well as serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), insulin, total and direct bilirubin, fasting blood sugar (FBS), glycated hemoglobin (HbA1c), uric acid, albumin and lipid profile were evaluated at baseline and at the end of trial." | 5.16 | Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. ( Beiraghdar, F; Ghamarchehreh, ME; Jalalian, HR; Panahi, Y; Sahebkar, A; Zare, R, 2012) |
| "To evaluate sCD40L levels in women with polycystic ovary syndrome (PCOS) who use combination therapy with metformin and oral contraceptives." | 5.15 | Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients. ( Bilgir, O; Bozkaya, G; Kebapcilar, AG; Kebapcilar, L; Sari, I; Taner, CE; Yildiz, Y, 2011) |
| "In young women with PCOS, treatment with metformin or pioglitazone for 6 months induces a similar beneficial effect on endothelial function; this may be partially attributed to an improvement in insulin resistance." | 5.15 | Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. ( Bechlioulis, A; Calis, KA; Chrousos, GP; Kalantaridou, SN; Katsouras, CS; Kazakos, N; Kravariti, M; Makrigiannakis, A; Michalis, LK; Naka, KK; Tsatsoulis, A, 2011) |
| "To assess the impact of metformin and of two different oral contraceptives (OCs) containing cyproterone acetate and drospirenone, on serum anti-Müllerian hormone (AMH) levels, in a cohort of women with polycystic ovary syndrome (PCOS) with hyperandrogenism." | 5.15 | The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. ( Decavalas, G; Diamanti-Kandarakis, E; Georgopoulos, NA; Katsikis, I; Panidis, D; Piouka, A; Saltamavros, AD, 2011) |
| " Metformin did not affect postprandial lipemia and could be used to treat insulin resistance in this population." | 5.15 | Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy. ( Cabezas, MC; Dallinga-Thie, G; de Koning, EJ; Hoepelman, AI; Rabelink, TJ; van Wijk, JP, 2011) |
| "Both rosiglitazone/metformin combination therapy and metformin monotherapy decreased serum vaspin levels through glucose and insulin sensitivity regulation, while they exerted differential effects on adiponectin, IL-6 and other cardiovascular risk factors in drug-naïve patients with T2DM." | 5.15 | Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes. ( Kadoglou, NP; Kapelouzou, A; Liapis, CD; Sailer, N; Tsanikidis, H; Vitta, I, 2011) |
| " ADMA, homocysteine, high sensitive C-reactive protein (hs-CRP) and homeostasis model assessment estimate of insulin resistance (HOMA-IR) were investigated." | 5.15 | Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. ( Aydin, M; Batioglu, S; Erdogan, G; Kilic, S; Yilmaz, N; Zulfikaroglu, E, 2011) |
| "To examine the appropriate treatment of oligo-terato-asthenozoospermic patients with metabolic syndrome, 45 patients were treated with metformin for 6 months." | 5.15 | Metformin improves semen characteristics of oligo-terato-asthenozoospermic men with metabolic syndrome. ( De Leo, V; Morgante, G; Musacchio, MC; Orvieto, R; Piomboni, P; Tosti, C, 2011) |
| "Metformin had modest but favorable effects on body weight, body composition, and glucose homeostasis in obese insulin-resistant children participating in a low-intensity weight-reduction program." | 5.15 | Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. ( Brady, SM; Calis, KA; Kozlosky, M; Krakoff, J; McDuffie, JR; Reynolds, JC; Salaita, CG; Sebring, NG; Yanovski, JA, 2011) |
| "There is no benefit from increased doses of metformin in PCOS but reduction of insulin resistance is more significant in those patients with a lower insulin sensitivity at baseline." | 5.15 | Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome. ( Balen, AH; Barth, J; Glanville, J; Yasmin, E, 2011) |
| "Measures of β-cell function and insulin sensitivity from an OGTT showed more favorable changes over time with rosiglitazone versus metformin or glyburide." | 5.15 | Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. ( Aftring, RP; Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Zinman, B, 2011) |
| "To compare the efficacy of 1000 mg and 1700 mg of metformin on ovulation induction in polycystic ovary syndrome (PCOS) women." | 5.15 | Randomized controlled trial of different doses of metformin for ovulation induction in infertile women with polycystic ovary syndrome. ( Jultanmas, R; Leelaphiwat, S; Lertvikool, S; Satirapot, C; Sophonsritsuk, A; Weerakiet, S, 2011) |
| "Metformin can improve insulin resistance and imbalance of endocrine hormones." | 5.15 | Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. ( Dong, JJ; Liao, L; Tian, YJ; Xin, Y; Xing, HY; Zhao, JJ, 2011) |
| "The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin." | 5.15 | Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. ( Bonaventura, A; Bossi, AC; Derosa, G; Fogari, E; Franzetti, IG; Guazzini, B; Maffioli, P; Putignano, P; Querci, F; Testori, G, 2011) |
| "Metformin and rosiglitazone combination therapy is known to improve insulin resistance and postpone diabetes mellitus development in subjects with impaired glucose tolerance." | 5.15 | Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: a double-blind, randomized, controlled study. ( Li, D; Li, X; Li, Y; Ming, J; Shi, Y; Xie, Y; Zhang, N, 2011) |
| "In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10)." | 5.15 | Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. ( Adawadkar, SS; Arrowood, JA; Cheang, KI; Essah, PA; Nestler, JE; Stovall, DW, 2011) |
| " The metformin therapy improved insulin sensitivity as evidenced by an increase in ISI by 41." | 5.15 | [Effects of metformin therapy on markers of coagulation disorders in hyperinsulinemic women with polycystic ovary syndrome]. ( Banaszewska, B; Pawelczyk, L; Serdyńska-Szuster, M; Spaczyński, R, 2011) |
| "To evaluate the clinical, endocrine and metabolic effects of metformin and N-acetyl-cysteine (NAC) in patients with polycystic ovary syndrome (PCOS)." | 5.15 | Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. ( Muderris, II; Oner, G, 2011) |
| "This randomized controlled study investigated metformin and fenofibrate, compared with metformin alone, for the treatment of peripheral insulin resistance in patients with simple obesity with hyperinsulinaemia but not diabetes." | 5.15 | Combination therapy with metformin and fenofibrate for insulin resistance in obesity. ( Li, XM; Li, Y; Shi, YQ; Xie, YH; Zhang, NN, 2011) |
| "Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study." | 5.14 | Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. ( Atkin, SL; Cho, LW; Coady, AM; Keevil, BG; Kilpatrick, ES, 2009) |
| "In polycystic ovary syndrome, metformin improves insulin resistance, inflammatory markers, and endothelial function." | 5.14 | Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. ( Hutchison, SK; McGrath, BP; Meyer, C; Moran, LJ; Teede, HJ; Zoungas, S, 2010) |
| " Hirsutism was significantly better controlled in the metformin group (p = 0." | 5.14 | Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome. ( Adibi, N; Asilian, A; Kachuei, A; Rezvanian, H; Shojaee-Moradie, F; Siavash, M, 2009) |
| "Rimonabant has been shown to reduce weight, free androgen index (FAI) and insulin resistance in obese patients with polycystic ovary syndrome (PCOS) compared to metformin." | 5.14 | Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). ( Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T, 2009) |
| "There were no adverse effects of short-term cyclic MPA plus metformin treatment on metabolic parameters or insulin resistance in patients with PCOS over a 3-month treatment period." | 5.14 | Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome. ( Bagis, T; Haydardedeoglu, B; Kilicdag, EB; Simsek, E, 2009) |
| "Circulating levels of interleukin-6 (IL-6) and C-reactive protein (CRP) were determined in 59 women with polycystic ovary syndrome, of whom 37 were retested after receiving metformin for 6 weeks and 6 months, to ascertain the response of these inflammatory markers to weight loss and insulin sensitization." | 5.14 | Determinants of interleukin-6 and C-reactive protein vary in polycystic ovary syndrome, as do effects of short- and long-term metformin therapy. ( Conway, GS; Mohamed-Ali, V; Tsilchorozidou, T, 2009) |
| " Total renin, aldosterone, androgen levels and insulin sensitivity indices were significantly improved after 6 months on metformin treatment." | 5.14 | Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. ( Diamanti-Kandarakis, E; Economou, FN; Livadas, S; Panidis, D; Papavassiliou, AG; Piperi, C; Tantalaki, E, 2009) |
| " Among the treatment groups, EE/CA-metformin may be a more effective therapeutic option than the other protocols and this may be due to the beneficial effect of EE/CA-metformin on insulin resistance." | 5.14 | Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. ( Alacacioglu, A; Kebapcilar, AG; Kebapcilar, L; Sari, I; Taner, CE, 2010) |
| "In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity." | 5.14 | Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. ( Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW, 2009) |
| "This study assessed the efficacy of adding metformin to a structured lifestyle intervention in reducing BMI in obese adolescents with insulin resistance." | 5.14 | Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. ( Baker, JE; Clark, HE; Clarson, CL; Hill, DJ; Mahmud, FH; McKay, WM; Schauteet, VD, 2009) |
| "The aim of this randomized, placebo-controlled study was to explore the effect of metformin in children with a neurogenic or myogenic motor deficit, who are therefore prone to develop overweight, adiposity, and insulin resistance." | 5.14 | Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit. ( Casteels, K; Coudyzer, W; de Zegher, F; Fieuws, S; Goemans, N; Loeckx, D; van Helvoirt, M; Verpoorten, C, 2010) |
| "Clozapine is the most effective agent in treatment-resistant schizophrenia." | 5.14 | Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. ( Baptista, T; Carrizo, E; Connell, L; de Baptista, EA; Fernández, I; Fernández, V; Mogollón, J; Prieto, D; Sandia, I; Valbuena, D, 2009) |
| " To elucidate the dynamics of FSH, LH, prolactin (PRL), TSH and insulin secretion in women with polycystic ovarian syndrome (PCOS) treated with metformin (MET)." | 5.14 | Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. ( Adamopoulos, DA; Antsaklis, A; Billa, E; Kapolla, N; Koukkou, E; Milingos, S; Nicopoulou, SC; Venaki, E, 2009) |
| "To evaluate the effect of a short-course pretreatment with metformin on hyperandrogenism, insulin resistance, cervical scores, and pregnancy rates in women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS)." | 5.14 | Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. ( Ghaffarpasand, F; Kazerooni, M; Kazerooni, T; Kazerooni, Y; Setoodeh, S, 2009) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 5.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| "The Indian Diabetes Prevention Programme-1 (IDPP-1) showed that lifestyle modification (LSM) and metformin were effective for primary prevention of diabetes in subjects with impaired glucose tolerance (IGT)." | 5.14 | Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1). ( Mary, S; Nanditha, A; Ramachandran, A; Sathish Kumar, CK; Selvam, S; Shetty, SB; Snehalatha, C, 2009) |
| "Adding metformin to peginterferon and ribavirin was safe and improved insulin sensitivity." | 5.14 | Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. ( Andrade, RJ; Calleja, JL; De la Mata, M; Diago, M; Durán, S; Fernández-Rodríguez, CM; García-Samaniego, J; Herrerías, JM; Moreno-Otero, R; Nuñez, O; Olveira, A; Planas, R; Romero-Gómez, M; Salmerón, J; Solà, R, 2009) |
| "To compare the hormonal-metabolic profiles and reproductive outcomes in clomiphene-resistant patients with polycystic ovary syndrome and insulin resistance between women receiving metformin and those undergoing laparoscopic ovarian drilling." | 5.14 | Metformin versus laparoscopic ovarian drilling in clomiphene- and insulin-resistant women with polycystic ovary syndrome. ( Ahmed, MA; Ahmed, OG; Hamed, HO; Hasan, AF, 2010) |
| "Sibutramine and metformin are drugs commonly used to obtain weight loss." | 5.14 | Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women. ( Akbas, H; Coban, E; Eray, E; Ozdem, S; Sari, R, 2010) |
| " The aim of this study was to determine leptin concentrations in PCOS patients before and after metformin treatment depending on BMI, insulin resistance calculated on the basis of the Homeostasis Model Assessment (HOMA) index, as well as concentrations of androgens: testosterone and androstendion." | 5.14 | Leptin concentrations in patients with polycystic ovary syndrome before and after met-formin treatment depending on insulin resistance, body mass index and androgen con-centrations--introductory report. ( Brodowska, A; Marciniak, A; Nawrocka-Rutkowska, J; Sienkiewicz, R; Starczewski, A; Szydłowska, I, 2009) |
| " Metformin improves insulin sensitivity and circulating markers of cardiovascular risk in patients with PCOS, but it is unclear whether this translates into improvements in vascular function." | 5.14 | Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. ( Agarwal, N; Bolusani, H; Dunseath, G; Ludgate, M; Luzio, SD; Rees, DA; Rice, SP, 2010) |
| "The aim of this study was to evaluate long-term changes in endocrine and metabolic parameters and body mass index in women with polycystic ovary syndrome (PCOS) who were treated with metformin over 2 years without caloric restriction." | 5.14 | The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome. ( Beckmann, MW; Cupisti, S; Dittrich, R; Jentsch, K; Kronawitter, D; Mueller, A; Oppelt, PG; Reissmann, C, 2010) |
| "The aim of the study was to compare the effects of the addition of sitagliptin or metformin to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients on body weight, glycemic control, beta-cell function, insulin resistance, and inflammatory state parameters." | 5.14 | Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA, 2010) |
| " 'Cases' were women with PCOS who conceived while taking Metformin and it whom it was continued throughout pregnancy." | 5.14 | Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome. ( Nawaz, FH; Rizvi, J, 2010) |
| "This report has demonstrated that the combination of metformin and simvastatin could lead to a better reduction of T and LH levels and thus reversing the LH:FSH ratio, lipid profile, and insulin resistance in patients with PCOS and may be an appropriate management option for patients with PCOS." | 5.14 | Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. ( Asadi, N; Dehbashi, S; Ghaffarpasand, F; Kazerooni, T; Kazerooni, Y; Shojaei-Baghini, A, 2010) |
| "Study the effects of exenatide (EXE) plus rosiglitazone (ROSI) on beta-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type 2 diabetes on metformin." | 5.14 | Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. ( DeFronzo, RA; Glass, LC; Lewis, MS; Maggs, D; Qu, Y; Triplitt, C, 2010) |
| "Metformin has been proffered as a therapy for adolescent obesity, although long-term controlled studies have not been reported." | 5.14 | Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. ( Abrams, SH; Aye, T; Feldman, HA; Lee, PD; Lenders, C; Lustig, RH; Osganian, SV; Wilson, DM, 2010) |
| "The aim of this study was to evaluate the effects of metformin in addition to diet and exercise on endocrine and metabolic disturbances in women with polycystic ovary syndrome (PCOS) in a prospective, double-blind, randomized, placebo (PBO) control trial." | 5.14 | Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. ( Fux Otta, C; Gaido, MI; Iraci, GS; Kaplan, R; Torres, D; Wior, M; Wyse, EP, 2010) |
| " The aim of our study was to evaluate the effects of exenatide compared to glibenclamide on body weight, glycemic control, beta-cell function, insulin resistance, and inflammatory state in patients with diabetes." | 5.14 | Exenatide versus glibenclamide in patients with diabetes. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA, 2010) |
| " Metformin had no effect on adiponectin in spite of significant decreases in weight, fasting glucose, and insulin resistance." | 5.14 | Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study. ( Flyvbjerg, A; Frystyk, J; Lauszus, FF; Trolle, B, 2010) |
| "Pioglitazone was associated with a rapid increase in body weight and an increase in diurnal proximal sodium reabsorption, without any change in renal haemodynamics or in the modulation of the renin-angiotensin aldosterone system to changes in salt intake." | 5.14 | Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. ( Burnier, M; Deleaval, P; Jornayvaz, FR; Maillard, M; Nussberger, J; Pechere-Bertschi, A; Vinciguerra, M; Zanchi, A, 2010) |
| "The role of leptin in atypical antipsychotic-induced metabolic dysfunction was explored by assessing the anthropometric and metabolic profile and the response to metformin (MET) of clozapine- (CLZ) treated schizophrenia patients according to their single nucleotide polymorphisms (SNPs) in the leptin promoter (LEP2548/GA) and leptin receptor (LEPR Q223R) genes." | 5.14 | Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin. ( Baptista, T; Carrizo, E; Connell, L; de Baptista, EA; Fernández, E; Fernández, I; Fernández, V; Mogollón, J; Prieto, D; Sandia, I; Valbuena, D, 2010) |
| "Obese European adolescents' insulin sensitivity improved without weight change during placebo or metformin intervention in addition to lifestyle intervention." | 5.14 | Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. ( Bürmann, M; Grüters, A; Holl, RW; Hübel, H; Krude, H; l'Allemand, D; Martus, P; Wiegand, S, 2010) |
| " We aimed to study if the changes observed in the insulin sensitivity of PCOS patients during treatment with oral contraceptives or metformin associate changes in the serum inflammatory markers interleukin-6 (IL-6) and interleukin-18 (IL-18)." | 5.14 | Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations. ( Escobar-Morreale, HF; Luque-Ramírez, M, 2010) |
| "As compared with the patients receiving insulin monotherapy, the patients taking metformin alone or in combination showed a more effective recovery of carbohydrate and lipid metabolic disturbances, diminished insulin resistance (IR), lowered blood pressure and albuminuria, reduced diastolic dysfunction, and a smaller cardiovascular risk." | 5.14 | [Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus]. ( Elsukova, OS; Onuchin, SG; Onuchina, EL; Solov'ev, OV, 2010) |
| "To determine the effects of metformin treatment on serum androgen levels ahead of and during the IVF cycle in infertile polycystic ovary syndrome (PCOS) women." | 5.14 | Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome. ( Carlsen, SM; Kjøtrød, SB; Sunde, A; von Düring, V, 2009) |
| "Our first specific aim in an observational study of 431 nondiabetic women with polycystic ovary syndrome (PCOS), aged >or=20 years and with >or=11 months follow-up on metformin diet, was to prospectively assess relationships between pretreatment glucose and insulin resistance (IR) and the development of type 2 diabetes mellitus (T2DM) or gestational diabetes (GD)." | 5.13 | An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet. ( Glueck, CJ; Goldenberg, N; Sieve, L; Wang, P, 2008) |
| "To determine whether metformin treatment for 6 months is effective in reducing body weight and hyperinsulinemia and also ameliorating insulin sensitivity indices in obese adolescents with hyperinsulinemia." | 5.13 | Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. ( Atabek, ME; Pirgon, O, 2008) |
| "Although metformin (MET) is an insulin sensitizer currently used as an adjunct to the treatment of some of the complications of childhood obesity besides type 2 diabetes mellitus, few studies have comprehensively examined its metabolic and clinical effects in obese children with normal glucose tolerance (NGT)." | 5.13 | Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. ( Burgert, TS; Caprio, S; Duran, EJ; Dziura, J; Goldberg-Gell, R; Katz, S; Tamborlane, WV; Yeckel, CW, 2008) |
| "Despite improvements in insulin sensitivity and glycemic regulation, either pioglitazone or metformin treatment did not result in any effect on blood visfatin levels in patients with treatment naïve T2DM." | 5.13 | The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. ( Bozoglu, E; Dogru, T; Ercin, CN; Erdem, G; Muhsiroglu, O; Sonmez, A; Tapan, S; Tasci, I, 2008) |
| " pioglitazone on measures of beta-cell function and insulin sensitivity as well as cardiac load." | 5.13 | Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone? ( Dorkhan, M; Frid, A; Groop, L, 2008) |
| "Treatment with pioglitazone was associated with significant improvements of lipid and glycemic parameters that are linked to insulin resistance and cardiovascular risk in patients with T2DM in their routine clinical care." | 5.13 | [Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus]. ( Mesa, J; Polavieja, P; Reviriego, J; Rodríguez, A, 2008) |
| "Our study shows that in severely obese, non-diabetic, hyperinsulinaemic patients undergoing a nutritional programme, rosiglitazone is more effective than metformin in producing favourable changes in fasting-based indexes of glucose metabolism, with a reduction of both insulin resistance and hyperinsulinaemia." | 5.13 | Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients. ( Brunani, A; Castagna, G; Caumo, A; Graci, S; Liuzzi, A; Viberti, G, 2008) |
| "One hundred forty-two nondiabetic women with polycystic ovary syndrome (PCOS) who had at least one live-birth (LB) pregnancy on metformin diet (172 pregnancies, 180 LBs)." | 5.13 | Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. ( Aregawi, D; Glueck, CJ; Pranikoff, J; Wang, P, 2008) |
| "To test the efficacy of lifestyle intervention and metformin alone and in combination for antipsychotic-induced weight gain and abnormalities in insulin sensitivity." | 5.13 | Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. ( Chen, JD; Fang, MS; Guo, XF; He, YQ; Jin, H; Li, LH; Liu, YJ; Shao, P; Wu, RR; Zhao, JP, 2008) |
| "Six hundred and ninety-four consecutive overweight and obese type 2 diabetic patients were evaluated and 56 patients were intolerant to metformin at maximum dosage." | 5.13 | Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Piccinni, MN; Ragonesi, PD; Salvadeo, SA, 2008) |
| "In subjects with impaired glucose tolerance (IGT) who participated in the Indian Diabetes Prevention Programme (IDPP), abnormalities related to body mass index, waist circumference (WC), blood pressure (BP), lipid profile and electrocardiography were analysed (at baseline and third-year follow-up) in control, lifestyle modification (LSM), metformin (MET) and LSM + MET groups." | 5.13 | Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. ( Joshi, VV; Mary, S; Ramachandran, A; Snehalatha, C, 2008) |
| "To compare the effects of insulin sensitization with metformin to weight reduction by rimonabant on biochemical hyperandrogenaemia and insulin resistance in patients with PCOS." | 5.13 | A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. ( Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T, 2008) |
| "To investigate the effects of extended-release metformin (MXR) compared with immediate-release metformin (MIR) on post-prandial glycaemic excursion, chronic glycaemia, lipid profiles, insulin resistance and islet function in type 2 diabetes." | 5.13 | The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study. ( Gao, H; Hong, T; Wang, C; Xiao, W; Yang, J; Yang, W; Yang, Y; Zhang, J, 2008) |
| "In a randomized double-blind placebo controlled trial, 85 adolescents with insulin resistance were randomized to receive metformin (70%) or placebo (30%), along with monthly goal setting for diet and exercise modification." | 5.13 | Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. ( Love-Osborne, K; Sheeder, J; Zeitler, P, 2008) |
| " Metformin, which is widely prescribed for type 2 diabetes mellitus (T2DM) patients, regulates blood sugar by inhibiting hepatic gluconeogenesis and promoting insulin sensitivity to facilitate glucose uptake by cells." | 5.12 | New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Cancer: Nonapoptotic Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway. ( Cheng, KC; Chiu, CC; Hsu, SK; Lin, YH; Mgbeahuruike, MO; Sheu, SJ; Wang, HD; Wu, CY; Yen, CH, 2021) |
| "The main mechanism of gestational diabetes mellitus (GDM) is insulin resistance, therefore using metformin as a medicine reducing insulin resistance appears to be promising." | 5.12 | Metformin administration during pregnancy - current insight. ( Cypryk, K; Krekora, M; Skibinska, M; Zurawska-Klis, M, 2021) |
| "With this systematic review of RCTs, we suggest that metformin has modest but favorable effects on weight and insulin resistance and a tolerable safety profile among children and adolescents with obesity." | 5.12 | Efficacy and Safety of Metformin for Obesity: A Systematic Review. ( Aloe, S; Brunetti, VC; Filion, KB; Henderson, M; Masarwa, R; Platt, RW, 2021) |
| "To improve insulin action, most clinicians prescribe Metformin in patients with insulin resistance (IR)." | 5.12 | Metformin does not improve insulin sensitivity over hypocaloric diets in women with polycystic ovary syndrome: a systematic review of 12 studies. ( Garcia-Hernandez, SC; Gonzalez-Mejia, ME; López-Bayghen, E; Pacheco-Soto, BT; Porchia, LM, 2021) |
| " Clinical trials investigating metformin effects on the evaluation of homeostatic models of insulin resistance (HOMA-IR), Ki-67, body mass index (BMI), fasting blood sugar (FBS), and insulin were selected for further analysis." | 5.12 | Impact of Metformin on Cancer Biomarkers in Non-Diabetic Cancer Patients: A Systematic Review and Meta-Analysis of Clinical Trials. ( Amirabadizadeh, A; Aramjoo, H; Farkhondeh, T; Llorens, S; Roshanravan, B; Saeedi, F; Samarghandian, S; Shakibaei, M; Talebi, M, 2021) |
| " If insufficient in monotherapy, it can preferably be used in combination with metformin, which targets insulin resistance, and also in combination with sodium-glucose cotransporter 2 inhibition, thiazolidinediones and insulin, which target other mechanisms." | 5.12 | Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition. ( Ahrén, B, 2021) |
| "Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone." | 5.12 | Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. ( He, B; Xing, C; Zhang, J; Zhao, H, 2021) |
| "It has been reported that women with polycystic ovary syndrome (PCOS) benefit from metformin therapy." | 5.12 | Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. ( Balen, AH; Barth, JH; Glanville, J; Hayden, CJ; Tang, T; White, D, 2006) |
| " Much better decrease in the level of testosterone and free androgen index was established in group treated with metformin, while the indices of insulin resistance were better influenced in the group treated with rosiglitazone." | 5.12 | Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. ( Mitkov, M; Pehlivanov, B; Terzieva, D, 2006) |
| " For this reason, we investigated circulating bioactive lipopolysaccharide and the effects of changing insulin action-after treatment with an insulin sensitizer (metformin)-on circulating BPI in subjects with glucose intolerance." | 5.12 | Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein. ( Biarnés, J; Fernández-Real, JM; Gubern, C; López-Bermejo, A; Ricart, W; Vendrell, J, 2006) |
| "To assess the use of oral glucose tolerance testing (OGTT) to predict efficacy of insulin sensitization (metformin) or suppression (octreotide) because insulin resistance and insulin hypersecretion may impact pharmacotherapeutic efficacy in obese children." | 5.12 | Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children. ( Bacchetti, P; Christensen, ML; Lazar, AA; Lustig, RH; Mietus-Snyder, ML; Velasquez-Mieyer, PA, 2006) |
| "Metformin significantly lowered total testosterone concentrations, increased the likelihood of menses, and improved high-density lipoprotein cholesterol levels without affecting measures of insulin sensitivity or body weight." | 5.12 | Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. ( Baltzer, F; Bridger, T; MacDonald, S; Rodd, C, 2006) |
| " Fasting plasma glucose, A1C, HOMA-IR for insulin resistance, lipid profile, and plasma beta-endorphin-like immunoreactivity (BER) were measured before treatment and weekly at the end of each dosing period." | 5.12 | Metformin increases insulin sensitivity and plasma beta-endorphin in human subjects. ( Cheng, JT; Ou, HY; Wu, TJ; Yu, EH, 2006) |
| "We assessed the effect of metformin on body composition and insulin sensitivity in pediatric subjects with exogenous obesity." | 5.12 | Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. ( Ambler, GR; Baur, LA; Cowell, CT; Garnett, SP; Srinivasan, S; Tepsa, M; Ward, GM; Yap, F, 2006) |
| "To assess whether metformin prevents body weight gain (BWG) and metabolic dysfunction in patients with schizophrenia who are treated with olanzapine." | 5.12 | Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. ( Arapé, Y; Baptista, T; Beaulieu, S; de Mendoza, S; Hernández, L; Lacruz, A; Martínez, J; Martinez, M; Rangel, N; Serrano, A; Teneud, L, 2006) |
| "To evaluate the effects of metformin on insulin resistance, androgen concentration, ovulation rates and pregnancy rates in infertile women with polycystic ovary syndrome (PCOS)." | 5.12 | Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. ( Kocak, I; Ustün, C, 2006) |
| "To compare the effects of moxonidine and metformin on glycaemic control in patients with impaired glucose tolerance and signs of the metabolic syndrome." | 5.12 | Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. ( Almazov, VA; Chazova, I; Shlyakhto, E, 2006) |
| "The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome." | 5.12 | Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. ( Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A, 2006) |
| "8 kg/m2, we assessed effeicacy of metformin-diet for 1 year for reduction of weight, insulin, HOMA insulin resistance (IR), cholesterol, triglycerides, and resumption of regular menses." | 5.12 | Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Luo, G; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "This study was designed to assess the usefulness of a model-based index of insulin sensitivity during an oral glucose tolerance test (OGTT) in the identification of possible changes in this metabolic parameter produced by pharmacological agents known to be potent insulin sensitizers, that is metformin (M) and thiazolidinedione (T)." | 5.12 | Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. ( Hanusch-Enserer, U; Kautzky-Willer, A; Ludvik, B; Pacini, G; Prager, R; Tura, A; Wagner, OF; Winzer, C, 2006) |
| "In comparison with placebo (n = 17), metformin recipients (n = 16) showed significant reductions in weight and in homeostatic model assessment for insulin resistance (p < 0." | 5.12 | Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. ( Cobbe, SM; Ferrell, W; Greer, IA; Jadhav, S; Petrie, JR; Sattar, N, 2006) |
| "Pioglitazone therapy appears to be better in achieving glycaemic control and increasing plasma adiponectin and insulin sensitivity in newly detected type 2 diabetics." | 5.12 | Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. ( Bhansali, A; Malhotra, S; Pandhi, P; Sharma, PK; Sialy, R, 2006) |
| "Metformin therapy is safe and effective in abrogating weight gain, decreased insulin sensitivity, and abnormal glucose metabolism resulting from treatment of children and adolescents with atypicals." | 5.12 | A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. ( Barton, BA; Cottingham, EM; Klein, DJ; Morrison, JA; Sorter, M, 2006) |
| "to compare the clinical, hormonal and biochemical changes after the application of the two ways of influence upon insulin resistance in women with PCOS - reduction of weight and application of metformin." | 5.12 | [Clinical, hormonal and biochemical changes after treatment with metformin and weight reduction in women with polycystic ovary syndrome]. ( Kavŭrdzhikova, S; Mitkov, M; Pekhlivanov, B, 2006) |
| "Adjuvant metformin can improve QOL, insulin sensitivity and glycaemic control in overweight adults with T1DM." | 5.12 | The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. ( Bascombe, LA; Holt, RI; Moon, RJ, 2007) |
| "In this study, the Authors assessed some insulin counter-regulatory factors, fibrinogen and C-reactive protein after olanzapine administration, and the effect of metformin on these variables, 37 patients with chronic schizophrenia were given olanzapine (10 mg/day for 14 weeks)." | 5.12 | Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. ( Baptista, T; Beaulieu, S; Contreras, Q; de Mendoza, S; Galeazzi, T; Lacruz, A; Rangel, N; Sandia, I; Vargas, D, 2007) |
| "In overweight women with PCOS, metformin and low- and high-dose OCP preparations have similar efficacy but differential effects on insulin resistance and arterial function." | 5.12 | Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. ( McGrath, BP; Meyer, C; Teede, HJ, 2007) |
| "One hundred and two women with insulin-resistant polycystic ovary syndrome were randomized to treatment with a vitamin B preparation, metformin, or both, in conjunction with standard infertility treatment." | 5.12 | Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. ( Friedler, S; Raziel, A; Ron-El, R; Rotem, C; Schachter, M; Strassburger, D, 2007) |
| "In patients with diabetes and hypertension not taking insulin sensitizers, the use of metoprolol tartrate resulted in a worsening of insulin resistance, an effect not seen with carvedilol." | 5.12 | Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. ( Anderson, KM; Bakris, GL; Bell, DS; Fonseca, V; Katholi, RE; Lukas, MA; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Waterhouse, B; Wright, JT, 2007) |
| "Impaired glucose tolerance (IGT) is associated with cardiovascular risk factors, but the effects of pioglitazone and metformin on IGT are not well described." | 5.12 | Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. ( Eguchi, K; Fukuda, T; Hoshide, S; Ishikawa, J; Kario, K; Numao, T; Shimada, K; Tomizawa, H, 2007) |
| "Metformin may safely assist olanzapine-treated patients in body weight and carbohydrate metabolism control." | 5.12 | Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. ( Baptista, T; Beaulieu, S; Carrizo, E; Connell, L; Dávila, A; de Baptista, EA; El Fakih, Y; Fernández, V; Galeazzi, T; Gutiérrez, MA; Rangel, N; Serrano, A; Servigna, M; Uzcátegui, E; Uzcátegui, M, 2007) |
| "The objective of the study was to evaluate the effects of metformin suspension on insulin sensitivity in PCOS patients." | 5.12 | Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. ( De Feo, P; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2007) |
| "To investigate the relative role of the adiponectin and leptin in the insulin resistance (IR) and obesity we studied plasma levels of these adipocytokines in obese and insulin resistant postmenopausal (PM) females with type 2 diabetes (DM2) during 6 months of Metformin therapy." | 5.12 | Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes. ( Adamia, N; Charkviani, N; Khutsishvili, M; Skhirtladze, M; Virsaladze, D, 2007) |
| "Despite the fact that treatment with Diane(35) Diario restored regular menstrual cycles in all the patients, whereas metformin only did so in 50% of them, serum ferritin levels decreased at 12 and 24 weeks of treatment only with metformin, in association with a marked increase in insulin sensitivity." | 5.12 | Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. ( Alvarez-Blasco, F; Botella-Carretero, JI; Escobar-Morreale, HF; Luque-Ramírez, M; San Millán, JL; Sanchón, R, 2007) |
| "To study the effect of simvastatin and metformin on insulin sensitivity and inflammatory markers." | 5.12 | Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. ( Bulcão, C; Ribeiro-Filho, FF; Roberta Ferreira, SG; Sañudo, A, 2007) |
| "We conducted a randomized placebo-controlled trial to examine the effects of metformin on visceral adipose tissue (VAT), appendicular fat, lipid profile and insulin sensitivity in HIV-infected persons with central adiposity and mild insulin resistance." | 5.12 | A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. ( Gorbach, S; Kohli, R; Shevitz, A; Wanke, C, 2007) |
| " Through its effect on RBP4 expression in adipocytes, metformin may improve total insulin sensitivity in obese individuals including those with MS and delay the onset of manifest DM." | 5.12 | [Serum level of retinol-binding protein 4 in obese patients with insulin resistance and in patients with type 2 diabetes treated with metformin]. ( Donicová, V; Ivancová, G; Petrovicová, J; Semanová, Z; Tajtáková, M; Zemberová, E, 2007) |
| "To evaluate and compare effects of 48-week treatment with rosiglitazone and metformin on insulin resistance in patients infected with Human Immunodeficiency Virus (HIV) receiving highly active antiretroviral therapy (HAART), containing a protease inhibitor." | 5.12 | Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial. ( Janez, A; Karner, P; Maticic, M; Sharma, P; Silic, A; Tomazic, J; Vidmar, L, 2007) |
| "Based on the known effect of metformin (MET) in improving insulin sensitivity in type 2 diabetes, with the scope to focus the effects on glycaemic and free fatty acids (FFA) levels, we studied the effects of a short-term treatment with this drug in obese subjects and obese patients with diabetes or family history of diabetes (FHD)." | 5.11 | Effects of short-term metformin treatment on insulin sensitivity of blood glucose and free fatty acids. ( Belfiore, F; Bellomia, D; Camuto, M; Cavaleri, A; Iannello, S; Milazzo, P; Pisano, MG, 2004) |
| "To determine the clinical, hormonal, and biochemical effects of metformin therapy in obese and nonobese patients with polycystic ovary syndrome (PCOS)." | 5.11 | Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. ( Abi Haidar, M; Alves da Motta, EL; Baracat, EC; de Lima, GR; Maciel, GA; Soares Júnior, JM, 2004) |
| "The data suggest that improvement of the insulin sensitivity with metformin may improve the liver disease in patients with non-alcoholic steatohepatitis." | 5.11 | Metformin in the treatment of patients with non-alcoholic steatohepatitis. ( Dagalp, K; Deveci, S; Gulsen, M; Isik, AT; Kadayifci, A; Ozgurtas, T; Tuzun, A; Uygun, A; Yesilova, Z, 2004) |
| "In a prospective observational study of 42 pregnancies in 39 Caucasian women (age 30 +/- 4 years) with polycystic ovary syndrome (PCOS), we examined effects of metformin on maternal insulin, insulin resistance (IR), insulin secretion (IS), weight gain, development of gestational diabetes (GD), testosterone and plasminogen activator inhibitor activity." | 5.11 | Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout preg ( Glueck, CJ; Goldenberg, N; Loftspring, M; Sherman, A; Wang, P, 2004) |
| "To evaluate the effects of metformin on insulin resistance, ovarian androgen production, and clomiphene-induced ovulation and pregnancy rates in infertile women with polycystic ovary syndrome (PCOS)." | 5.11 | The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. ( Aygen, E; Keleştimur, F; Sahin, Y; Yirmibeş, U, 2004) |
| "103 PCOS women (age 18-40) were treated, according to their body weight, with either 1000 mg or 1700 mg metformin per day after assessment of insulin resistance." | 5.11 | [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome]. ( Elsenbruch, S; Finke, R; Gärtner, R; Hahn, S; Janssen, OE; Mann, K; Quadbeck, B, 2004) |
| "To evaluate the effect of PIO monotherapy and in combination therapy with sulfonylurea (SU) or metformin (MET) on insulin sensitivity as assessed by HOMA-S and QUICKI in a large group of patients (approximately 1000)." | 5.11 | Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. ( Gilmore, KJ; Glazer, NB; Johns, D; Tan, MH; Widel, M, 2004) |
| "Combination of orlistat with metformin did not result in an additional effect on weight loss and insulin resistance when compared to orlistat alone in our study." | 5.11 | Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. ( Balci, MK; Coban, E; Sari, R; Yazicioglu, G, 2004) |
| "To assess the effects of 6 months of metformin therapy on clinical and biochemical parameters in polycystic ovary syndrome (PCOS) and to evaluate those parameters in responders and nonresponders to identify the subjects who respond to an insulin sensitizer in PCOS." | 5.11 | Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. ( Agarwal, N; Kriplani, A, 2004) |
| "Both rosiglitazone and metformin increase hepatic insulin sensitivity, but their mechanism of action has not been compared in humans." | 5.11 | Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. ( Häkkinen, AM; Korsheninnikova, E; Mäkimattila, S; Nyman, T; Tiikkainen, M; Yki-Järvinen, H, 2004) |
| "To investigate the effects of metformin and clomiphene on infertility caused by polycystic ovary syndrome (PCOS) with insulin-resistance (IR) and to observe the effects of metformin on PCOS with pseudoacanthosis nigricans (AN) and IR." | 5.11 | [Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome]. ( Cai, Q; Chen, H; Chen, LX; Cui, QH; Ge, J; Liu, ZA; Xue, YM; Yuan, T; Zhang, J, 2004) |
| "The aim of this study was to evaluate the effects of metformin and acarbose on insulin resistance, hormone profiles and ovulation rates in patients with clomiphene citrate-resistant polycystic ovary syndrome (PCOS)." | 5.11 | Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. ( Akgün, A; Koç, S; Ozcan, J; Savan, K; Sönmez, AS; Sut, N; Toklar, A; Yasar, L; Yazicioğu, F, 2005) |
| "Metformin improves insulin sensitivity, which is correlated to phospholipid fatty acid composition in obese type 2 diabetics." | 5.11 | Effect of metformin vs. placebo treatment on serum fatty acids in non-diabetic obese insulin resistant individuals. ( Christophe, AB; Feyen, E; Giri, M; Rodríguez, Y, 2004) |
| "Aim of this study was to compare the effects of metformin and a body weight reduction regimen using sibutramine on insulinemia, insulin sensitivity, and ovarian function in women with anovulatory cycles or infertility." | 5.11 | Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women. ( Dravecka, I; Kraus, V; Lazurova, I; Petrovicova, J, 2004) |
| " metformin on the hormonal and biochemical features of patients with polycystic ovarian syndrome (PCOS)." | 5.11 | Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. ( Atkin, SL; Holding, S; Jayagopal, V; Jennings, PE; Kilpatrick, ES, 2005) |
| "Adding metformin slightly modified the treatment effect of COC, causing a more significant decrease in the free androgen index but having no additional positive impact on lipids, insulin sensitivity, SHBG or testosterone." | 5.11 | The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. ( Cibula, D; Dvorakova, K; Fanta, M; Hill, M; Skrenkova, J; Skrha, J; Stanicka, S; Vrbikova, J; Zivny, J, 2005) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 5.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| " Although long-term treatment with metformin can increase Hcy levels in patients with type II diabetes mellitus or coronary heart disease, it is becoming an increasingly accepted and widespread medication in polycystic ovary syndrome (PCOS)." | 5.11 | Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. ( Aslan, E; Bagis, T; Erkanli, S; Haydardedeoglu, B; Kilicdag, EB; Tarim, E; Zeyneloglu, HB, 2005) |
| " This study was designed to determine whether the insulin sensitizer drugs pioglitazone and metformin would improve glucose intolerance and insulin sensitivity by decreasing IMCL." | 5.11 | Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. ( Di Gregorio, GB; Elbein, SC; Kern, PA; Lu, T; Miles, LM; Rasouli, N; Raue, U, 2005) |
| "To investigate whether the long-term administration of metformin or pioglitazone to women with polycystic ovary syndrome (PCOS) could induce changes in their hypothalamic dopaminergic (DA) tone and to analyze whether these changes correlated with modifications in insulin resistance, we originally studied 57 obese hyperinsulinemic, non-diabetic, insulin resistant women with PCOS, but only 34 completed the study." | 5.11 | Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. ( Arteaga-Troncoso, G; Cardoza, L; Coutiño, B; Hidalgo, R; Ortega-González, C; Parra, A, 2005) |
| " Metformin and pioglitazone had beneficial effects on lipid levels, improved insulin sensitivity and improved insulin secretion also." | 5.11 | Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians. ( Ramachandran, A; Salini, J; Snehalatha, C; Vijay, V, 2004) |
| "Much better and faster decrease in the level of testosterone and free androgen index in group with combined use of metformin and Diane35 was established, without deterioration of the anthropometric and biochemical indices and insulin sensitivity." | 5.11 | Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. ( Mitkov, M; Pehlivanov, B; Terzieva, D, 2005) |
| "Metformin is able to reverse insulin resistance and hyperglycemia in high-risk subjects for type 2 diabetes mellitus independently of the effects on tumor necrosis factor alpha system activity." | 5.11 | Differential regulation of insulin action and tumor necrosis factor alpha system activity by metformin. ( Biarnés, J; del Mar García, M; Fernández-Castañer, M; Fernández-Real, JM; Ricart, W; Soler, J, 2005) |
| "We aimed to investigate whether metformin would reverse the endocrinopathy of polycystic ovary syndrome (PCOS), allowing resumption of cyclic ovulation and regular menses, and whether metformin causes any change in the serum concentration of insulin-like growth factor-I (IGF-I) in patients with PCOS." | 5.11 | Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy. ( Berker, B; Corapcioglu, D; Demirel, C; Emral, R; Kose, K; Unlu, C, 2004) |
| "To measure the effect of metformin on the body composition, insulin resistance and sensitivity in subjects with risk factors for type 2 diabetes mellitus (type 2 DM)." | 5.11 | Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes. ( Gutiérrez-Rosas, MJ; López-Carmona, JM; Robles-López, G; Rodríguez-Moctezuma, JR, 2005) |
| "Open-label treatment with metformin for 24 weeks was notable for improvement in liver chemistry, liver fat, insulin sensitivity and quality of life." | 5.11 | A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. ( Deutsch, R; Lavine, JE; Middleton, MS; Schwimmer, JB, 2005) |
| "181 African American subjects with insulin resistance and normal glucose tolerance test were randomised to receive glipizide 5 mg/day (n = 25), metformin 500 mg/day (n = 59), or placebo (n = 97) for 24 months." | 5.11 | Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study. ( Boudoulas, H; Osei, K; Schuster, DP; Sparks, EA; Stakos, DA; Wooley, CF, 2005) |
| "Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated." | 5.11 | A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. ( Bugianesi, E; David, E; Gentilcore, E; Manini, R; Marchesini, G; Natale, S; Rizzetto, M; Vanni, E; Villanova, N, 2005) |
| "The aim of this study was to investigate the endothelial status in young women with polycystic ovary syndrome (PCOS), using a simple and easily reproducible hemodynamic method combined with a biological marker and to evaluate the effect of metformin treatment on these parameters." | 5.11 | Metformin administration improves endothelial function in women with polycystic ovary syndrome. ( Aessopos, A; Alexandraki, K; Diamanti-Kandarakis, E; Lekakis, J; Mavrikakis, M; Papamichael, C; Piperi, C; Protogerou, A, 2005) |
| "Weight loss is a feature of protracted metformin therapy in obese women with PCOS, with greater weight reduction potentially achievable with higher doses." | 5.11 | Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. ( Fleming, R; Harborne, LR; Norman, JE; Sattar, N, 2005) |
| "Metformin and rosiglitazone both significantly improved insulin sensitivity, but this was not paralleled by improvement in dyslipidaemia." | 5.11 | The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects. ( James, AP; Mamo, JC; Watts, GF, 2005) |
| "Despite their comparable glycaemic effects in patients with Type 2 diabetes mellitus (T2DM), pioglitazone and metformin may have different effects on insulin sensitivity because they have different mechanisms of action." | 5.11 | Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. ( Johns, D; Laakso, M; Mariz, S; Richardson, C; Roden, M; Tan, MH; Urquhart, R; Widel, M, 2005) |
| "Metformin improves both endothelial function and insulin resistance in patients with MS." | 5.11 | Metformin improves endothelial function in patients with metabolic syndrome. ( Cornoldi, A; Fini, M; Mercuro, G; Rosano, GM; Vitale, C; Volterrani, M, 2005) |
| "In order to explore the effects of metformin combined with cyproterone acetate (CPA) on the clinical features, endocrine and metabolism of the patients with polycystic ovarian syndrome (PCOS), 50 cases of non-obese PCOS were randomly subjected to CPA (CPA treatment group, n = 25) and CPA+ metformin (n = 25) treatment for 6 months." | 5.11 | Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. ( Liu, Y; Lv, L; Sun, Y; Tan, K, 2005) |
| " The aim of this study was to assess the effects of rosiglitazone and metformin on cardiovascular disease risk factors such as insulin resistance, oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome (PCOS)." | 5.11 | The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bukan, N; Cakir, N; Karakoç, A; Törüner, F; Yilmaz, M, 2005) |
| " As diabetes and hypertension share common ground in insulin resistance, the aim of this study was to evaluate if Rosiglitazone (RSG) may exert antihypertensive properties." | 5.11 | Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. ( Dazzi, D; Hassan, H; Mangieri, T; Negro, R; Pezzarossa, A, 2005) |
| "Metformin and rosiglitazone treatment improved glycemic control, but only rosiglitazone increased whole-body insulin sensitivity." | 5.11 | Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin. ( Ferrannini, E; Hällsten, K; Iozzo, P; Järvisalo, MJ; Lönnqvist, F; Nuutila, P; Parkkola, R; Rönnemaa, T; Viljanen, AP; Virtanen, KA, 2005) |
| "Adolescents with PCOS treated with metformin or OCP experienced similar beneficial outcomes including reduction in androgen levels, weight loss, and increased insulin sensitivity." | 5.11 | Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. ( Allen, HF; Heptulla, RA; Koenigs, L; Mazzoni, C; Miller, N; Murray, MA; Reiter, EO, 2005) |
| "The primary aim of the present study was to compare the effect of long-term (12-month) combination treatment with glimepiride or rosiglitazone plus metformin on blood pressure in patients with type 2 diabetes mellitus (DM-2) and the metabolic syndrome." | 5.11 | Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. ( Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S, 2005) |
| "To evaluate metformin efficacy and safety in patients with gout and insulin resistance (IR)." | 5.11 | [Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)]. ( Barskova, VG; Eliseev, MS; Iakunina, IA; Il'inykh, EV; Kudaeva, FM; Nasonov, EL; Tsapina, TN; Volkov, AV; Zilov, AV, 2005) |
| "To evaluate whether, in adolescents with type 1 diabetes, the addition of metformin to insulin and standard diabetes management results in 1) higher insulin sensitivity and 2) lower HbA1c, fasting glucose, insulin dosage (units per kilogram per day) and BMI." | 5.10 | Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. ( Cummings, E; Daneman, D; Finegood, D; Hamilton, J; Zdravkovic, V, 2003) |
| "Pioglitazone, a thiazolidinedione, improves glycemic control primarily by increasing peripheral insulin sensitivity in patients with type 2 diabetes, whereas metformin, a biguanide, exerts its effect primarily by decreasing hepatic glucose output." | 5.10 | Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. ( Festa, A; Gyimesi, A; Herz, M; Jermendy, G; Johns, D; Kerenyi, Z; Pavo, I; Schluchter, BJ; Shestakova, M; Shoustov, S; Tan, MH; Varkonyi, TT, 2003) |
| "Metformin effectively restores insulin sensitivity in insulin-resistant women with polycystic ovary syndrome (PCOS)." | 5.10 | The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. ( Abyholm, T; Dale, PO; Fedorcsák, P; Storeng, R; Tanbo, T, 2003) |
| " Further we tried to identify the preventive influence of metformin on development of ovarian hyperstimulation syndrome." | 5.10 | [Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome]. ( Crha, I; Ventruba, P; Visnová, H; Záková, J, 2003) |
| "This study aims to evaluate the impact of metformin on ovarian response when co-administered during recombinant (r)FSH using the low-dose step-up protocol in clomiphene citrate-resistant polycystic ovarian syndrome (PCOS) patients with normal glucose tolerance." | 5.10 | Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. ( Bükülmez, O; Demirol, A; Koray, Z; Yarali, H; Yiğit, N; Yildiz, BO; Zeyneloğlu, HB, 2002) |
| " After treatment, women in the OC + metformin group had significant decreases in BMI and WHR, and a significant increase in insulin sensitivity, in contrast to those in the OC group, who had insignificant changes in these parameters." | 5.10 | Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. ( Durmusoglu, F; Elter, K; Imir, G, 2002) |
| "Nineteen obese patients with impaired glucose tolerance (IGT) were treated with either metformin or placebo in a randomized, double-blind, placebo-controlled, cross-over study." | 5.09 | Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. ( Golay, A; Lehmann, T; Morel, Y; Pasik, C; Perneger, T; Reaven, GM; Vadas, L, 1999) |
| "This study suggests that a relatively low dosage of metformin reduces insulin resistance and related cardiovascular risk parameters in HIV-infected patients with lipodystrophy." | 5.09 | Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. ( Basgoz, N; Corcoran, C; Davis, B; Grinspoon, S; Hadigan, C; Sax, P, 2000) |
| "Metformin, a biguanide antihyperglycemic drug, has been shown to improve ovarian function and glucose metabolism in women with polycystic ovary syndrome (PCOS), but results concerning its effects on insulin sensitivity are controversial." | 5.09 | Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tapanainen, JS; Vauhkonen, I, 2000) |
| " The effects of metformin, an antidiabetic agent that improves insulin sensitivity, on endothelial function have not been reported." | 5.09 | Improved endothelial function with metformin in type 2 diabetes mellitus. ( Anderson, TJ; Mather, KJ; Verma, S, 2001) |
| "To determine the clinical, hormonal and biochemical effect of 4-5 months of insulin-sensitizing therapy (hypocaloric diet+metformin) in obese patients with polycystic ovary syndrome (PCOS)." | 5.09 | Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. ( Kinalska, I; Kinalski, M; Kowalska, I; Straczkowski, M; Wolczyski, S, 2001) |
| "Since metformin improves insulin sensitivity, it has been indicated for patients with diabetes and hypertension, which are insulin-resistant conditions." | 5.09 | Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. ( Ferreira, SR; Kohlmann, NE; Uehara, MH; Zanella, MT, 2001) |
| "The BIGuanides and Prevention of Risks in Obesity (BIGPRO1) results suggest that metformin would be a suitable candidate for long-term intervention for the prevention of diabetes but that its use in a trial of primary prevention of cardiovascular diseases requires either a reevaluation of its properties toward the most potentially atherogenic anomalies of the IRS or a better definition of the target population." | 5.08 | The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. ( André, P; Bard, JM; Charles, MA; Cohen, JM; Eschwège, E; Fontbonne, A; Grandmottet, P; Isnard, F; Juhan-Vague, I; Safar, ME; Vague, P, 1996) |
| "Metformin effects on insulin resistance and insulin/glucose relationships during an oral glucose tolerance test (OGTT) were investigated in 60 non-diabetic male patients previously treated with coronary artery bypass surgery or angioplasty in an open, 12 week prospective study." | 5.08 | Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease. ( Carlsen, SM; Følling, I; Grill, V, 1998) |
| "To evaluate the effect of metformin on insulin sensitivity and to further examine the relationship between insulin resistance, sympathetic nerve activity and blood pressure, 6 obese insulin resistant, normoglycemic hypertensive men were investigated (age 49 +/- 2 years, BMI 27." | 5.07 | The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men. ( Attvall, S; Elam, M; Friberg, P; Gudbjörnsdottir, S; Lönnroth, P; Wallin, BG, 1994) |
| "To investigate the effects of metformin on glycemic control, insulin resistance, and risk factors for cardiovascular disease in NIDDM subjects from two ethnic groups (Caucasian and Asian) with different risks of cardiovascular disease." | 5.07 | Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. ( Nagi, DK; Yudkin, JS, 1993) |
| " Because metformin improves peripheral insulin sensitivity, we examined the acute effect of metformin and placebo on glucose and lipid metabolism in nine insulin-resistant first-degree relatives of NIDDM patients with the euglycemic insulin-clamp technique combined with indirect calorimetry and infusion of [3-3H]glucose." | 5.07 | Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. ( Eriksson, JG; Groop, LC; Widén, EI, 1992) |
| "The effects of metformin on glycaemia, insulin and c-peptide levels, hepatic glucose production and insulin sensitivity (using the euglycaemic, hyperinsulinaemic clamp) were evaluated at fortnightly intervals in 9 Type 2 diabetic patients using a stepwise dosing protocol: Stage 1--no metformin for four weeks; stage 2--metformin 500mg mane; stage 3--metformin 500mg thrice daily; stage 4--metformin 1000mg thrice daily." | 5.07 | Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. ( Bird, DM; Cameron, DP; Ma, A; McIntyre, HD; Paterson, CA; Ravenscroft, PJ, 1991) |
| "The aim of this study was to review TZD and metformin as pharmacological treatments for insulin resistance associated with obesity and cancer." | 5.05 | Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin. ( Biondo, LA; de O S Ferreira, KC; Neto, JCR; Teixeira, AAS, 2020) |
| " Metformin seems to be safe and presents evident positive effects on insulin sensitivity, but long-term and consistent data are still missing to establish its role in the pediatric population and the possible effectiveness of other emergent treatments such as glucagon-like peptide-1 analogues, dipeptidylpeptidase-4 inhibitors, dual inhibitors of SGLT1 and SGLT2 and weight loss drugs." | 5.05 | Metabolic syndrome in children. ( Chiarelli, F; Samvelyan, S; Tagi, VM, 2020) |
| "For overweight women with PCOS, both metformin combined with GLP-1 receptor agonists and metformin combined with TZDs appear superior to monotherapy in improving hyperandrogenemia." | 5.05 | Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS. ( He, B; Li, C; Xing, C, 2020) |
| "Breast cancer patients receiving metformin as treatment for diabetes showed significant reduction in levels of insulin, fasting glucose, CRP, HOMA, leptin, BMI, and Ki-67." | 5.05 | The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials. ( Chhabra, M; Clark, C; Gudi, SK; Manzari, N; Mousavi, SM; Naik, G; Rahmani, J; Thompson, J; Varkaneh, HK; Zhang, Y, 2020) |
| " The aim of this was to measure the effect of metformin (850 mg/twice daily) on insulin sensitivity." | 5.05 | Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. ( Aubertin, J; Brottier, E; Gin, H; Messerchmitt, C, 1985) |
| "Metformin enhances insulin sensitivity, being used to prevent and treat diabetes, although its mechanism of action remains elusive." | 5.01 | Metabolic Effects of Metformin in Humans. ( Adeva-Andany, MM; Fernández-Fernández, C; Pazos-García, C; Rañal-Muíño, E; Vila-Altesor, M, 2019) |
| "Metformin induces reductions in thyroid nodule size and TSH and HOMA-IR levels in patients with thyroid nodules and insulin resistance." | 5.01 | Role of Metformin in the Treatment of Patients with Thyroid Nodules and Insulin Resistance: A Systematic Review and Meta-Analysis. ( He, X; Hu, C; Liu, C; Liu, Y; Tang, W; Wu, D; Xu, B; Xu, T, 2019) |
| "Metformin has shown its effectiveness in reducing body mass index (BMI) in obese children and adolescents, but relevant evidence for improving insulin resistance in overweight or obese children and adolescents is inconclusive." | 5.01 | The effects of metformin on insulin resistance in overweight or obese children and adolescents: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. ( He, H; Sun, J; Wang, Y; Zhang, X, 2019) |
| "" On the 1-year anniversary of his death in 2018, we challenge three myths associated with insulin resistance: metformin improves insulin resistance; measurement of waist circumference predicts insulin resistance better than body mass index; and insulin resistance causes weight gain." | 5.01 | Myths about Insulin Resistance: Tribute to Gerald Reaven. ( Abbasi, F; Kim, SH, 2019) |
| "To perform meta-analyses of studies evaluating the risk of pre-eclampsia in high-risk insulin-resistant women taking metformin prior to, or during pregnancy." | 4.98 | Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. ( Alqudah, A; Graham, U; Lyons, TJ; McClements, L; McKinley, MC; McNally, R; Watson, CJ, 2018) |
| "In September 2018, we searched PubMed, Embase, and the Cochrane Library for studies published in English using the keywords metformin, obesity/overweight, and weight loss." | 4.98 | Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review. ( Knibbe, CAJ; Lentferink, YE; van der Vorst, MMJ, 2018) |
| " The vast majority of published data on insulin sensitizing PCOS treatments are reported in adult women; these have included weight loss, metformin, thiazolidinediones, and the inositols." | 4.95 | Insulin sensitizers in adolescents with polycystic ovary syndrome. ( LE, TN; Nestler, JE; Wickham, EP, 2017) |
| " Metformin is the primary insulin-sensitising drug to be used as an adjuvant therapy to lifestyle modification in patients with insulin resistance and impaired glucose tolerance, as well as in those referred to infertility treatment." | 4.95 | Insulin and the polycystic ovary syndrome. ( Bjekić-Macut, J; Doknić, M; Macut, D; Rahelić, D, 2017) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 4.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| "For several years there is an evidence for a relationship between the polycystic ovary syndrome (PCOS) and of insulin resistance; therefore metformin, an insulin sensitizer, is used for the treatment for more than 10 years." | 4.93 | [Metformin for the treatment of polycystic ovary syndrome]. ( Bekes, I; Gundelach, T; Hancke, K; Janni, W; Rodewald, M, 2016) |
| ", pioglitazone and metformin) used for the treatment of insulin resistance in PCOS, on androgen production." | 4.93 | Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS. ( Indran, IR; Lee, BH; Yong, EL, 2016) |
| "Metformin is a biguanide used in the treatment of type 2 diabetes mellitus and obesity." | 4.93 | Relationships Between Metformin, Paraoxonase-1 and the Chemokine (C-C Motif) Ligand 2. ( Arenas, M; Cabre, N; Camps, J; Garcia-Heredia, A; Hernandez-Aguilera, A; Joven, J; Luciano-Mateo, F, 2016) |
| "We conducted a search on Medline, EMBASE, and the Cochrane Library for relevant studies published before May 2014 based on "metformin" and "diabetes mellitus, type 1." | 4.91 | Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis. ( Li, L; Li, P; Liu, C; Wu, D; Zheng, X, 2015) |
| "Combined statin and metformin therapy can improve lipid and inflammation parameters, but cannot effectively improve insulin sensitivity and reduce hyperandrogenism in women with PCOS." | 4.91 | An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials. ( Cai, R; Huang, R; Sun, H; Sun, J; Wang, P; Wang, S; Xia, W; Yuan, Y; Zhou, Y, 2015) |
| " Treatment with metformin has been shown to improve insulin sensitivity, lowering blood glucose and androgen levels." | 4.90 | Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. ( Spritzer, PM, 2014) |
| " Metformin emerges as a choice candidate as it acts both on reducing gluconeogenesis and improving insulin sensitivity, and has demonstrated tumour suppressor properties in multiple cancer types." | 4.90 | Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment. ( Chevalier, S; Farsijani, S, 2014) |
| "Despite the known glucose-lowering effects of metformin, more recent clinical interest lies in its potential as a weight loss drug." | 4.90 | Effects of metformin on weight loss: potential mechanisms. ( Kashyap, SR; Malin, SK, 2014) |
| "L-Carnitine combined with HDI may have helped with the calcium channel blocker (CCB) poisoning by decreasing insulin resistance, promoting intracellular glucose transport, facilitating the metabolism of free fatty acids, and increasing calcium channel sensitivity." | 4.89 | L-Carnitine for the treatment of a calcium channel blocker and metformin poisoning. ( Ajmo, I; Laliberté, M; Poirier, D; St-Onge, M, 2013) |
| "Metformin is an effective oral anti-hyperglycemic agent that is widely used to manage diabetes mellitus type 2 in the general population and more recently, in pregnancy." | 4.89 | Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. ( Goulis, DG; Lautatzis, ME; Vrontakis, M, 2013) |
| "Short-term metformin treatment appears to moderately affect weight reduction in severely obese children and adolescents, with a concomitant improvement in fasting insulin sensitivity." | 4.89 | Systematic review of metformin use in obese nondiabetic children and adolescents. ( Brufani, C; Cappa, M; Crinò, A; Fintini, D; Manco, M; Patera, PI, 2013) |
| "Sitagliptin is similar to metformin in reducing HbA1c, decreasing body weight, and improving the function of beta cells, but is inferior to metformin in improving insulin sensitivity." | 4.89 | Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis. ( Du, Q; Liang, YY; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2013) |
| " Antidiabetic biguanides such as metformin, which reduce hyperglycemia and hyperinsulinemia by decreasing insulin resistance, extend lifespan, and inhibit carcinogenesis in rodents." | 4.89 | Metformin: do we finally have an anti-aging drug? ( Anisimov, VN, 2013) |
| " The use of pioglitazone has been associated with an increased risk of bladder cancer, edema, heart failure, weight gain, and distal bone fractures in postmenopausal women." | 4.89 | [Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus]. ( de Pablos-Velasco, PL; Valerón, PF, 2013) |
| "Metformin is a widely used and extensively studied insulin sensitising drug for the treatment of women with polycystic ovary syndrome (PCOS), with various actions in tissues responding to insulin that include the liver, skeletal muscle, adipose tissue, the endothelium of blood vessels, and the ovaries." | 4.88 | Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin. ( Hodges, P; Randeva, HS; Tan, BK; Weickert, MO, 2012) |
| "Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)." | 4.88 | A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012) |
| "In agreement with the previous review, metformin was associated with improved clinical pregnancy but there was no evidence that metformin improves live birth rates whether it is used alone or in combination with clomiphene, or when compared with clomiphene." | 4.88 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2012) |
| " Insulin resistance drives islet cell upregulation, manifested by elevated glucagon and c-peptide levels, early in the transition to IGT." | 4.88 | Insulin resistance in type 2 diabetic youth. ( Cree-Green, M; Mizokami-Stout, K; Nadeau, KJ, 2012) |
| "Compared to metformin, TZDs had the same effectiveness in treating insulin sensitivity and lowering androgen in PCOS patients, but the effect on weight loss was not as good as metformin." | 4.88 | Comparative efficacy of thiazolidinediones and metformin for polycystic ovary syndrome. ( Du, Q; Wang, YJ, 2012) |
| "A literature review using PubMed with the keywords: AMPK, androgen deprivation therapy, insulin resistance, metabolic syndrome, metformin and prostate cancer was undertaken." | 4.87 | Metformin in prostate cancer: two for the price of one. ( Ali, SS; Clements, A; Gao, B; Gurney, H; Wong, MKY; Yeap, SHO, 2011) |
| "In agreement with the previous review, metformin is still of benefit in improving clinical pregnancy and ovulation rates." | 4.86 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2010) |
| " However, the antihyperglycaemic agent metformin appears promising in some recent studies and we review the literature that evaluates metformin for limiting or reversing atypical antipsychotic drug-induced weight gain and glucose metabolism dysregulation." | 4.86 | Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. ( Fredrickson, SK; Hasnain, M; Vieweg, WV, 2010) |
| " Agents that decrease intestinal carbohydrate digestion (alpha-glucosidase inhibitors) or decrease insulin resistance (metformin) might be alternative adjunctive therapies in T1DM, though its benefits are marginally supported by clinical data." | 4.86 | Adjunct therapy for type 1 diabetes mellitus. ( Lebovitz, HE, 2010) |
| " While metformin has been shown to attenuate weight gain and insulin resistance, not all studies have shown a benefit in the reduction of antipsychotic-induced weight gain and insulin resistance." | 4.86 | The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. ( Coleman, CI; Ehret, M; Goethe, J; Lanosa, M, 2010) |
| "Metformin has become a mainstay in the modest therapeutic armamentarium for the treatment of the insulin resistance of type 2 diabetes mellitus." | 4.86 | An energetic tale of AMPK-independent effects of metformin. ( Birnbaum, MJ; Miller, RA, 2010) |
| "Metformin is widely used in the treatment of diabetes mellitus type 2 where it reduces insulin resistance and diabetes-related morbidity and mortality." | 4.86 | Metformin: taking away the candy for cancer? ( de Jong, S; de Vries, EG; Gans, RO; Gietema, JA; Jalving, M; Lefrandt, JD; Reyners, AK, 2010) |
| " The only drug that proved to be effective in reducing cardiovascular events is metformin, which increases AMP-activated protein kinase activity and has a potent cardioprotective effect against ischemia-reperfusion injury." | 4.86 | [Hypoglycemic therapy in heart disease patients with type 2 diabetes mellitus]. ( Cosmi, D; Cosmi, F, 2010) |
| " Recent epidemiologic studies have shown that the fracture rate was decreased in patients treated with metformin, one of the anti-hyperglycemic agents by improving insulin resistance." | 4.85 | [Usefulness of metformin in diabetes-related bone disease]. ( Kanazawa, I, 2009) |
| " Metformin is currently the preferred insulin-sensitizing drug for chronic treatment of PCOS and has been shown to improve the metabolic profile, menstrual cyclicity and fertility in women with PCOS, and is associated with weight loss." | 4.85 | Polycystic ovary syndrome and metabolic comorbidities: therapeutic options. ( De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC; Palermo, V; Petraglia, F, 2009) |
| " The biguanide, N, N' dimethyl-biguanide: Metformin is an antidiabetic drug that increases glucose utilization in insulin-sensitive tissues and is useful in the reduction of both insulin resistance and circulating androgens as well as restoring ovulation." | 4.84 | Metformin in the treatment of polycystic ovary syndrome. ( Motta, DA, 2008) |
| " Reduction of hyperinsulinism and improvement of insulin sensitivity with metformin has been reported to ameliorate these abnormalities in many, but not all studies, with few adverse effects." | 4.84 | Metformin and polycystic ovary syndrome. ( Lebinger, TG, 2007) |
| " We included randomized trials of at least 8 weeks duration that compared metformin with placebo or no treatment in persons without diabetes and evaluated body mass index, fasting glucose, fasting insulin, calculated insulin resistance, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and the incidence of new-onset diabetes." | 4.84 | Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. ( Buckley, NS; Kahn, JA; Salpeter, EE; Salpeter, SR, 2008) |
| "Metformin is an insulin sensitizer currently used for treating type-2 diabetes mellitus and recently administered for inducing ovulatory menstrual cycles in oligo-amenorrhoeic patients with polycystic ovary syndrome (PCOS)." | 4.84 | Outlook: metformin use in infertile patients with polycystic ovary syndrome: an evidence-based overview. ( Oppedisano, R; Orio, F; Palomba, S; Tolino, A; Zullo, F, 2008) |
| "The antidiabetic compound pioglitazone, an activator of the intracellular peroxisome proliferator-activated receptor-gamma, and decreases metabolic and vascular insulin resistance." | 4.83 | Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. ( Forst, T; Pfützner, A; Schneider, CA, 2006) |
| " These initiatives, together with developments in beta(3)-adrenoceptor agonists, 11 beta-hydroxysteroid dehydrogenase Type 1 inhibitors and modulators of the glucagon-like peptide 1 axis, all of which also potentially enhance insulin sensitivity, are critically evaluated." | 4.82 | Insulin sensitisation in the treatment of Type 2 diabetes. ( Smith, SA; Tadayyon, M, 2003) |
| "In obese type 2 diabetic patients inadequately controlled on MET alone, addition of rosiglitazone improves glycaemic control, insulin sensitivity and beta-cell function to a clinically important extent." | 4.82 | Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. ( Jones, NP; Jones, TA; Sautter, M; Van Gaal, LF, 2003) |
| " In at least two randomized controlled studies, metformin proved to be clinically effective in increasing insulin sensitivity in hyperinsulinemic, nondiabetic adolescents." | 4.82 | Insulin resistance syndrome in children : pathophysiology and potential management strategies. ( Decsi, T; Molnár, D, 2003) |
| "Both metformin and thiazolidinedione derivatives(TZDs) improve insulin resistance, a major pathogenesis of type 2 diabetes, and decrease blood glucose levels without stimulating insulin secretion." | 4.82 | [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives]. ( Satoh, J, 2003) |
| " Metformin is a biguanide compound which is antihyperglycaemic, reduces insulin resistance and has cardioprotective effects on lipids, thrombosis and blood flow." | 4.82 | Beneficial effects of metformin on haemostasis and vascular function in man. ( Grant, PJ, 2003) |
| " Search terms used were insulin resistance, diabetes, insulin sensitivity, obesity, cardiovascular disease, metformin, thiazolidinediones, pioglitazone, rosiglitazone, and troglitazone." | 4.82 | Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. ( Henry, RR, 2003) |
| "Metformin is a common treatment for women who have insulin resistance manifesting as type 2 diabetes or polycystic ovarian syndrome (PCOS)." | 4.82 | Metformin in obstetric and gynecologic practice: a review. ( Boyle, J; McCarthy, EA; McLachlan, K; Permezel, M; Walker, SP, 2004) |
| "The evidence suggests that the predominant effect of metformin is inhibition of hepatic glucose production, whereas the primary effects of TZDs is reduction of insulin resistance and promotion of peripheral glucose uptake." | 4.82 | A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. ( Bates, PC; Dietrich, K; Lübben, G; Seufert, J, 2004) |
| "The debate on metformin use in polycystic ovary syndrome (PCOS) has mainly focused on its treatment for infertility in ovulation induction and menstrual cyclicity." | 4.81 | Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction. ( Oehninger, S; Stadtmauer, LA; Wong, BC, 2002) |
| " Although no clinical trials over 6 months in duration have assessed the long-term efficacy of metformin use in adolescents, short-term trials have shown promising effects in lowering insulin secretion, improving insulin sensitivity, restoring normal menstrual cycles, and correcting lipid abnormalities." | 4.81 | Polycystic ovary syndrome in adolescents. ( Kent, SC; Legro, RS, 2002) |
| " Metformin and troglitazone, approved for use in the treatment of type 2 diabetes mellitus (DM), improve insulin sensitivity and lower plasma glucose concentrations." | 4.80 | Insulin resistance syndrome: options for treatment. ( Fonseca, VA; Granberry, MC, 1999) |
| "Insulin resistance is a major component of type 2 diabetes; therefore, an insulin sensitizer agent like the thiazolidinedione compound troglitazone is considered a very promising drug." | 4.80 | Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. ( Lefèbvre, PJ; Scheen, AJ, 1999) |
| " Metformin, an antihyperglycemic drug of the biguanide class, may be effective in subjects with IGT by reducing hepatic glucose output, enhancing insulin sensitivity, or through other mechanisms such as weight loss." | 4.79 | [Drug therapy in subjects with impaired glucose tolerance]. ( Kawamori, R; Yoshii, H, 1996) |
| " Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure." | 4.79 | [Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997) |
| " Moreover, compared to diabetic untreated and metformin-treated animals, those treated with PAP1 had the lowest risk of developing the life-threatening arrhythmia Torsade de Pointes under cardiac challenge." | 4.31 | Kv1.3 Channel Blockade Improves Inflammatory Profile, Reduces Cardiac Electrical Remodeling, and Prevents Arrhythmia in Type 2 Diabetic Rats. ( Alquiza, A; Casis, O; Echeazarra, L; Fernández-López, V; Gallego, M; Rodríguez-de-Yurre, A; Zayas-Arrabal, J, 2023) |
| "Low birth weight (LBW) followed by a rapid postnatal catch-up in weight predisposes individuals to a central distribution of body fat, which is reverted by metformin." | 4.31 | Circulating GDF15 concentrations in girls with low birth weight: effects of prolonged metformin treatment. ( Bassols, J; Carreras-Badosa, G; de Zegher, F; Díaz, M; Gavaldà-Navarro, A; Ibáñez, L; López-Bermejo, A; Villarroya, F; Villarroya, J, 2023) |
| "To study the effectiveness of metformin treatment in patients with acne but who do not have PCOS and to understand the mechanisms of action of metformin in acne not related to PCOS." | 4.31 | Effects of metformin on clinical, hormonal and relevant gene expression parameters in patients with acne: an observational study. ( De, D; Dutta, P; Handa, S; Kamboj, P; Kaushik, A; Pal, A; Saikia, UN, 2023) |
| "The obtained results suggest that myo-inositol supplementation potentiates the inhibitory effect of metformin on prolactin levels in women with hyperprolactinemia." | 4.31 | Myo-Inositol Potentiates the Inhibitory Effect of Metformin on Prolactin Levels. ( Basiak, M; Krysiak, R; Okopień, B; Szkróbka, W, 2023) |
| "The keywords of PCOS research focused on PCOS, insulin resistance (IR), obesity and metformin." | 4.31 | Past and present: a bibliometric study on polycystic ovary syndrome. ( Cai, M; Ni, Z; Yao, R; Yu, C; Yu, J; Yuan, Z; Zhang, D; Zhou, L, 2023) |
| " We compared the clinical pregnancy rate (primary outcome) and controlled ovarian stimulation (COS)-related parameters (secondary outcomes) between patients with and without metformin pre-treatment for all PCOS patients not grouped by HOMA-IR, PCOS patients with HOMA-IR < 2." | 4.31 | The homeostasis model assessment of insulin resistance is a judgment criterion for metformin pre-treatment before IVF/ICSI and embryo transfer cycles in patients with polycystic ovarian syndrome. ( Gao, R; Li, Z; Min, W; Qin, L, 2023) |
| " To explore the potential effects of swertiamarin, on abrupted insulin and steroidogenic signaling in human luteinized granulosa cells from PCOS patients with or without insulin resistance." | 4.31 | Investigating the potential role of swertiamarin on insulin resistant and non-insulin resistant granulosa cells of poly cystic ovarian syndrome patients. ( Banker, M; Belani, MA; Gupta, SS; Shah, P, 2023) |
| "The study aims to assess the levels of Neuregulin 1 (NRG1) in patients with Polycystic Ovary Syndrome (PCOS) and to determine the impact of metformin treatment on their serum NRG1 levels." | 4.31 | METFORMIN EFFECTS ON NEUREGULIN-1 IN POLYCYSTIC OVARIAN WOMEN. ( Sarhat, E; Tawfeq, M, 2023) |
| " Metformin treatment resulted in significant elevation of the studied miRNA, significant downregulation of PI3K/AKT target genes, and significant amelioration of the gonadotrophic hormonal imbalance and insulin resistance markers: fasting blood glucose, HBA1C, fasting insulin, and GLUT4 gene expression." | 4.31 | Non-coding RNA genes modulate PI3K/AKT signaling pathway in polycystic ovary syndrome. ( Faruk, EM; Fouad, H; Ibrahim, OA; Omar, HS; Safwat, M; Sayed, MG, 2023) |
| "The high-fat diet-induced mouse model of obesity and insulin resistance of both sexes was developed in a randomized block experiment and bulk RNA-Seq of the ileum tissue was the method of choice for comparative transcriptional profiling after metformin intervention for ten weeks." | 4.31 | Metformin targets intestinal immune system signaling pathways in a high-fat diet-induced mouse model of obesity and insulin resistance. ( Ansone, L; Birzniece, L; Brīvība, M; Elbere, I; Jagare, L; Kalniņa, I; Kloviņš, J; Silamiķele, L; Silamiķelis, I, 2023) |
| " We explored the beneficial effect of combined sodium glucose co transporter-2 inhibitor (SGLT-2i); (empagliflozin) and metformin on hormonal and metabolic parameters in an animal model of PCOS and insulin resistance (IR)." | 4.31 | SGLT-2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model. ( Hussien, RES; Kamar, SS; Kamel, O; Mahmoud, MM; Rashed, LA; Sayed, SM; Soliman, SA, 2023) |
| "Twelve-month metformin treatment reduced fat content, waist circumference, glycated hemoglobin, glucose and triglycerides, as well as improved insulin sensitivity." | 4.12 | Impaired metabolic effects of metformin in men with early-onset androgenic alopecia. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "The current study was to evaluate the effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes." | 4.12 | Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes. ( Hao, Z; Li, G; Liu, Y; Shen, Y; Sun, Y; Wen, Y, 2022) |
| "Co-administration of metformin (250 mg/kg) with berberine (125 mg/kg) could not only further improve insulin sensitivity, but also demonstrate different alterations on gut microbial communities than that of their individual treatment in db/db mice." | 4.12 | Effects of combination treatment with metformin and berberine on hypoglycemic activity and gut microbiota modulation in db/db mice. ( Kong, APS; Li, D; Li, Z; Lyu, Y; Ming, X; Shaw, PC; Yuan, X; Zhang, C; Zhang, J; Zuo, Z, 2022) |
| " Both metformin and myo-inositol were found to improve insulin sensitivity and to reduce thyrotropin levels in individuals with hypothyroidism." | 4.12 | Differences in levothyroxine action on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity between metformin- and myo-inositol-treated women with autoimmune subclinical hypothyroidism. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| " The present study compared the impact of low-grade systemic inflammation and insulin resistance on levothyroxine action in subjects with this disorder." | 4.12 | Thyroid Antibody Titers and Hypothalamic-Pituitary-Thyroid Axis Activity in Levothyroxine-Treated Women With Autoimmune Subclinical Hypothyroidism Receiving Atorvastatin or Metformin. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "Of those prescribed metformin, 83% were overweight or obese and 72% had elevated HOMA2-IR scores." | 4.12 | Metabolic and clinical profiles of young people with mood or psychotic disorders who are prescribed metformin in an inpatient setting. ( Carpenter, J; Hickie, IB; McHugh, C; Park, S; Scott, EM; Wilson, C, 2022) |
| "5 % cholic acid and 60 % cocoa butter for 6 weeks causing a number of metabolic and hepatic alterations including insulin resistance, dyslipidemia, systemic inflammation, increased hepatic oxidative stress and lipid peroxidation, hepatic steatosis, lobular inflammation, as well as increased markers of liver inflammation and hepatocyte apoptosis." | 4.12 | Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms. ( Aly, RG; Alzaim, I; El-Mallah, A; El-Yazbi, AF; Shaaban, HH; Wahid, A, 2022) |
| "We compared the efficacy of n3-polyunsaturated fatty acids (n3-PUFAs) and metformin in halting the progression of non-alcoholic fatty liver disease (NAFLD) developed in the milieu of insulin deficiency." | 4.12 | The hepatoprotective effects of n3-polyunsaturated fatty acids against non-alcoholic fatty liver disease in diabetic rats through the FOXO1/PPARα/GABARAPL1 signalling pathway. ( El-Mesery, A; Elmasry, K; Elsayed, HRH; Eraky, SM; Ramadan, NM, 2022) |
| "Metformin, a drug widely used to treat insulin resistance, and training that combines aerobic and strength exercise modalities (i." | 4.12 | Overweight and Obese Adult Patients Show Larger Benefits from Concurrent Training Compared with Pharmacological Metformin Treatment on Insulin Resistance and Fat Oxidation. ( Afonso, J; Azócar-Gallardo, J; García-García, JM; González-Rojas, L; Granacher, U; Ojeda-Aravena, A; Ramirez-Campillo, R; Sá, M, 2022) |
| "The results showed that CGA decreased body weight and improved glucose tolerance and insulin resistance, and these effects were similar to those of metformin." | 4.12 | Chlorogenic acid improves glucose tolerance, lipid metabolism, inflammation and microbiota composition in diabetic db/db mice. ( Guo, K; Li, Q; Shen, L; Yan, Y; Zhou, X, 2022) |
| "This study, conducted at a university-affiliated medical center, included two groups of postmenopausal women with prediabetes, matched for age, FSH and LH levels, and insulin sensitivity: women taking myo-inositol preparations for at least 6 months (group A, n = 23) and women not receiving inositol preparations (group B, n = 23)." | 4.12 | Myo-Inositol Enhances the Inhibitory Effect of Metformin on Gonadotropin Levels in Postmenopausal Women. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "This study aimed to investigate the effects of metformin on gingival wound healing in insulin-resistant prediabetes." | 4.12 | Metformin accelerates wound healing by Akt phosphorylation of gingival fibroblasts in insulin-resistant prediabetes mice. ( Buranasin, P; Iwata, T; Kido, D; Kominato, H; Mikami, R; Mizutani, K; Nagasawa, T; Nakagawa, K; Saito, N; Takeda, K; Takemura, S, 2022) |
| " After metformin and exenatide supplementation, body weight, chow intake and ovarian morphology were observed." | 4.02 | Metformin and exenatide upregulate hepatocyte nuclear factor-4α, sex hormone binding globulin levels and improve hepatic triglyceride deposition in polycystic ovary syndrome with insulin resistance rats. ( He, B; Li, X; Lv, B; Wang, D; Xing, C; Zhao, H, 2021) |
| "The beneficial effects of metformin, especially its capacity to ameliorate insulin resistance (IR) in polycystic ovary syndrome (PCOS), explains why it is widely prescribed." | 4.02 | Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance. ( Li, S; Xiao, L; Xie, Y, 2021) |
| "PSO and metformin had the beneficial effect on attenuating gut inflammation and metabolic disturbance in obese-insulin resistance." | 4.02 | Perilla Seed Oil Alleviates Gut Dysbiosis, Intestinal Inflammation and Metabolic Disturbance in Obese-Insulin-Resistant Rats. ( Chattipakorn, N; Chattipakorn, SC; Kangwan, N; Kongkaew, A; Pintha, K; Pratchayasakul, W, 2021) |
| "Resveratrol (RSV) and metformin (MET) play a role in the treatment of diabetes; however, the mechanisms through which they mediate insulin resistance by regulating long non‑coding RNAs (lncRNAs) remain unknown." | 4.02 | Comparative analysis of long non‑coding RNA expression profiles induced by resveratrol and metformin treatment for hepatic insulin resistance. ( Hou, X; Ma, H; Shu, L; Song, G; Wang, C, 2021) |
| "Metformin (MET), the most common medicine for type 2 diabetes (T2DM), improves insulin sensitivity by targeting the liver, intestine and other organs." | 4.02 | Restoration of mRNA Expression of Solute Carrier Proteins in Liver of Diet-Induced Obese Mice by Metformin. ( Chen, Y; Fu, Y; Han, Q; Ji, H; Le, J; Li, J; Lin, X; Pi, P; Wang, Q; Wei, X; Ye, J; Zhang, X; Zhang, Y, 2021) |
| " Gas6 levels were found to be in proportion to the expression of adiponectin, which has been regarded as closely relevant to improved insulin sensitivity after metformin treatment." | 4.02 | Growth arrest-specific 6 modulates adiponectin expression and insulin resistance in adipose tissue. ( Chiang, CF; Hsieh, CH; Hung, YJ; Lee, CH; Liu, JS; Lu, GH; Shieh, YS; Su, SC, 2021) |
| "In our study, we treated high fructose diet-induced insulin resistance in rats with any of metformin, cabbage (80%w/w) or combined metformin and cabbage (MetCabb), and observed the activities of glycolysis and gluconeogenesis regulatory enzymes, incretin hormones and other hormones affecting glucose homeostasis." | 4.02 | Potentiation of incretin hormones and modulation of metabolic enzymes as possible mechanisms behind the insulin sensitizing effects of cabbage-metformin treatment. ( Amadi, JA; Amadi, PU; Njoku, UC; Osuoha, JO, 2021) |
| "The present study aimed to investigate the possible effects of metformin on the olanzapine-induced insulin resistance in rats." | 4.02 | Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats. ( Guo, C; Li, H; Liu, J, 2021) |
| " Insulin and C-peptide responses and insulin sensitivity were calculated from 2-h oral glucose tolerance tests." | 4.02 | Association of glycemia with insulin sensitivity and β-cell function in adults with early type 2 diabetes on metformin alone. ( Banerji, MA; Barzilay, J; Cohen, RM; Gonzalez, EV; Ismail-Beigi, F; Kahn, SE; Lachin, JM; Mather, KJ; Raskin, P; Rasouli, N; Utzschneider, KM; Wexler, DJ; Younes, N, 2021) |
| "High uric acid (HUA) is associated with insulin resistance (IR) in cardiomyocytes." | 4.02 | Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo. ( Chen, Y; Jiao, Z; Li, Y; Li, Z; Xie, Y, 2021) |
| " Metformin increases insulin sensitivity, but it is associated with unsatisfied benefits of weight loss." | 4.02 | The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis. ( Deng, Y; Ding, X; Ma, R; Sun, A; Wang, Y, 2021) |
| "Sixty-two obese patients in treatment with metformin-with prediabetes (n = 41) or newly diagnosed T2DM (n = 21), were studied." | 4.02 | Insulin resistance and NAFLD may influence memory performance in obese patients with prediabetes or newly-diagnosed type 2 diabetes. ( Ciotti, S; Cipollone, F; Consoli, A; Desideri, G; Di Castelnuovo, A; Guagnano, MT; Liani, R; Santilli, F; Simeone, PG; Tartaro, A; Tripaldi, R; Vadini, F, 2021) |
| "Metformin with lifestyle interventions significantly reduced weight, BMI, and BMI z score in pediatric patients with obesity and insulin resistance up to 24 months, compared with intensive and routine counseling alone." | 4.02 | Metformin for pediatric obesity and insulin resistance: a retrospective study within an integrated health care system. ( Concepcion, JQ; Huang, K; Tucker, LY, 2021) |
| " We aim to study the profile of duodenal cytokines and chemokines in patients with morbid obesity (MO), its relation with insulin resistance (IR) and the intake of metformin, and with the evolution of MO after sleeve gastrectomy (SG)." | 3.96 | A lower duodenal immune response is associated with an increase of insulin resistance in patients with morbid obesity. ( Alcaín-Martínez, G; Escamilla, A; Garcia-Fuentes, E; Garcia-Muñoz, B; García-Serrano, S; Garrido-Sanchez, L; Gonzalo, M; Ho-Plagaro, A; Montiel-Casado, C; Rodriguez, C; Ruiz-Santana, N; Santiago-Fernandez, C; Vázquez-Pedreño, L, 2020) |
| " In both groups, metformin reduced glucose levels, homeostasis model assessment 1 of insulin resistance index (HOMA1-IR), thyrotropin levels and Jostel's thyrotropin index, as well as increased SPINA-GT." | 3.96 | The impact of oral hormonal contraception on metformin action on hypothalamic-pituitary-thyroid axis activity in women with diabetes and prediabetes: A pilot study. ( Kowalcze, K; Krysiak, R; Okopień, B; Wolnowska, M, 2020) |
| "Initial triple combination therapy with the DPP4 inhibitor, metformin, and thiazolidinedione showed a higher achievement of the target HbA1c goal with a lower risk of hypoglycemia, better restoration of β-cell function, and multiple metabolic benefits, implying durable glycemic control." | 3.96 | Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study. ( Davies, MJ; Kim, KM; Ku, EJ; Lee, JE; Lee, JH; Lee, SY; Lim, S, 2020) |
| "To examine (1) effects of short-term metformin treatment on serum holotranscobalamin (holoTC) and folate and (2) their association with insulin sensitivity in recent-onset type 2 diabetes." | 3.96 | Vitamin B12 and Folate Concentrations in Recent-onset Type 2 Diabetes and the Effect of Metformin Treatment. ( Anadol-Schmitz, E; Bobrov, P; Burkart, V; Kahl, S; Kanti, G; Karusheva, Y; Markgraf, DF; Roden, M; Sarabhai, T; Strassburger, K; Szendroedi, J; Trenkamp, S; Zaharia, OP; Ziegler, D, 2020) |
| "Our data suggest a potential use of treprostinil as an early treatment for mild metabolic syndrome-associated PH-HFpEF and that combined treatment with treprostinil and metformin may improve hyperglycemia and cardiac function in a more severe disease." | 3.96 | Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. ( Avolio, T; Bachman, TN; Bai, Y; Baust, JJ; Bonetto, A; Considine, RV; Cook, T; Fisher, A; Gladwin, MT; Goncharov, DA; Goncharova, EA; Halliday, G; Hu, J; Huot, JR; Lai, YC; Machado, RF; McTiernan, CF; Mora, AL; Satoh, T; Sebastiani, A; Tan, J; Vanderpool, RR; Wang, L, 2020) |
| " Weight loss, lifestyle modification and combined hormonal pill and metformin are considered first-line treatment." | 3.96 | Hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN syndrome): an extreme subphenotype of polycystic ovary syndrome. ( Dahiya, R; Kimble, R; O'Brien, B, 2020) |
| "Metformin is the most commonly prescribed drug in the management of metabolic disorders such as polycystic ovarian syndrome (PCOS) and gestational diabetes in women of reproductive age." | 3.96 | Antidiabetic drug metformin affects the developmental competence of cleavage-stage embryos. ( Adiga, SK; Agarwal, P; Kalthur, G; Kalthur, SG; Kumari, S; Mutalik, S; Nayak, G; Rao, A; Salian, SR; Shreya, AB; Suresh Poojary, P, 2020) |
| "The current results suggest that exenatide is equivalent to metformin in controlling insulin resistance, body weight gain, improving liver function, suppressing inflammation, and attenuating NAFLD progression in male rats." | 3.96 | Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin. ( Ahmed, AAM; Khodeer, DM; Moustafa, YM; Saad, ZA; Zaitone, SA, 2020) |
| "To describe the composition of jejunal microbiota in morbidly obese patients, as well as its link with insulin resistance and metformin treatment." | 3.96 | Mucosa-associated microbiota in the jejunum of patients with morbid obesity: alterations in states of insulin resistance and metformin treatment. ( García-Fuentes, E; Gonzalo, M; Gutiérrez-Repiso, C; Ho-Plágaro, A; Martín-Núñez, GM; Moreno-Indias, I; Rodríguez-Cañete, A; Tinahones, FJ, 2020) |
| "After six months, the fasting insulin, glucose/insulin ratio, and homeostatic model assessment estimates for insulin resistance were significantly improved in metformin group." | 3.96 | Metformin metabolic and vascular effects in normal weight hyperinsulinemic polycystic ovary syndrome patients treated with contraceptive vaginal ring. A pilot study. ( Artini, PG; Battaglia, B; Battaglia, C; Casadio, P; Rizzo, R, 2020) |
| " This study was set out to explore the molecular mechanism of metformin in the treatment of T1D insulin resistance." | 3.96 | Metformin Decreases Insulin Resistance in Type 1 Diabetes Through Regulating p53 and RAP2A in vitro and in vivo. ( Jiao, PF; Ma, XJ; Ren, GF; Xiao, LL; Yan, YS, 2020) |
| "The aim of this study was to investigate the effects of metformin supplementation on metabolic dysfunction, testicular antioxidant capacity, apoptosis, inflammation and spermatogenesis in male mice with high-fat and high-cholesterol diet-induced obesity." | 3.96 | Metformin Ameliorates Testicular Function and Spermatogenesis in Male Mice with High-Fat and High-Cholesterol Diet-Induced Obesity. ( Cha, TL; Chang, TC; Lin, SH; Liu, CY; Tsao, CW; Wu, ST, 2020) |
| " In both study arms, metformin reduced plasma glucose levels and improved insulin sensitivity but this effect was stronger in subjects receiving vitamin D." | 3.96 | The impact of combination therapy with metformin and exogenous vitamin D on hypothalamic-pituitary-thyroid axis activity in women with autoimmune thyroiditis and high-normal thyrotropin levels. ( Kowalcze, K; Krysiak, R; Okopień, B, 2020) |
| "This study aims to demonstrate the effects of metformin on epicardial adipose tissue and electromechanical delay in patients using metformin for insulin resistance." | 3.96 | Effects of metformin on epicardial adipose tissue and atrial electromechanical delay of obese children with insulin resistance. ( Çelik, E; Güneş, H; Özmen, Ş; Temiz, F, 2020) |
| "Metformin is an ideal candidate to treat the liver tumor with insulin resistance because of its good performance in the treatment of type 2 diabetes and the advantage in cancer therapy." | 3.96 | Novel Albumin Nanoparticle Enhanced the Anti-Insulin-Resistant-Hepatoma Activity of Metformin. ( Li, JQ; Lin, YR; Lu, Z; Qi, L; Sun, L; Wang, GC; Yu, JM; Zhang, L, 2020) |
| " Metformin reduced glucose levels and glycated haemoglobin, improved insulin sensitivity and decreased thyrotrophin levels." | 3.96 | Different effects of metformin on hypothalamic-pituitary-thyroid axis activity in levothyroxine-treated and levothyroxine-naïve women with non-autoimmune hypothyroidism. ( Kowalcze, K; Krysiak, R; Okopień, B, 2020) |
| "Metformin reduced insulin resistance in adipocytes by reduction of miR223 expression and improving of IRS/Akt/GLUT4 signaling pathways." | 3.96 | Metformin downregulates miR223 expression in insulin-resistant 3T3L1 cells and human diabetic adipose tissue. ( Didehdar, R; Heiranizadeh, N; Mohiti, A; Mohiti-Ardakani, J; Naghiaee, Y; Pourrajab, F; Rahmanian, M, 2020) |
| "What is the central question of this study? Studies reported the efficacy of metformin as a promising drug for preventing or treating of metabolic diseases." | 3.96 | Early metformin treatment improves pancreatic function and prevents metabolic dysfunction in early overfeeding male rats at adulthood. ( Alves, VS; de Moraes, AMP; de Oliveira, JC; Francisco, FA; Franco, CCDS; Malta, A; Martins, IP; Mathias, PCF; Matiusso, CCI; Miranda, RA; Moreira, VM; Pavanello, A; Prates, KV; Previate, C, 2020) |
| " Metformin is a widely used, well-tolerated drug that improves insulin sensitivity and displays anti-inflammatory properties." | 3.96 | Rationale and Study Design of a Randomized Clinical Trial of Metformin to Prevent Frailty in Older Adults With Prediabetes. ( Bair-Kelps, D; Conde, A; Espinoza, SE; Ganapathy, V; Jergensen, TE; Jiwani, R; Kelly, LC; Li, Y; Michalek, J; Moris, M; Musi, N; Orsak, B; Powers, B; Romo, T; Wang, CP, 2020) |
| "Although the results of our and other studies show that baicalin can enhance glucose uptake and insulin sensitivity in skeletal muscle and adipocytes of mice, the specific metabolic contribution of baicalin on hepatic insulin resistance and gluconeogenic activity is still unclear." | 3.91 | Baicalin ameliorates hepatic insulin resistance and gluconeogenic activity through inhibition of p38 MAPK/PGC-1α pathway. ( Bo, P; Bu, L; Fang, P; Gu, X; Shi, M; Sun, Y; Zhang, Z, 2019) |
| " Improvement of insulin sensitivity by both aerobic exercise and metformin ameliorated HFD-induced abnormalities." | 3.91 | Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain. ( Dasari, S; Kabiraj, P; Klaus, KA; Lucchinetti, CF; McCarthy, CB; Nair, KS; Ruegsegger, GN; Vanderboom, PM, 2019) |
| " Metformin, a first-line antidiabetic drug, functions mainly by improving patients' hyperglycemia and insulin resistance." | 3.91 | Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK. ( An, H; Guo, S; He, L; Hussain, M; Liu, T; Maheshwari, A; O'Rourke, B; Qin, C; Radovick, S; Sesaki, H; Wang, Y; Wondisford, FE, 2019) |
| " We examined the effects of SGLT2 inhibitor-dapagliflozin on insulin resistance, hepatic gluconeogenesis, hepatic injury and pancreatic ER stress in high-fat diet-induced obese rats." | 3.91 | Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. ( Chatsudthipong, V; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Swe, MT; Thongnak, L, 2019) |
| " Metformin is commonly used to treat insulin resistance-glucose intolerance, and flutamide, an androgen receptor (AR) antagonist, is used to target hyperandrogenemia and dyslipidemia." | 3.91 | Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. ( Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R, 2019) |
| " Therefore, we have tested whether the previously proven blood-brain barrier protective agent, probucol, can prevent blood-brain barrier breakdown and cognitive decline in a dietary-induced murine model of diabetic insulin resistance." | 3.91 | Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet. ( Al-Salami, H; Brook, E; Fimognari, N; Lam, V; Mamo, JC; Mooranian, A; Nesbit, M; Takechi, R, 2019) |
| "We examine the effects of metformin on insulin resistance (IR) and mood including in adolescent and adult women with polycystic ovary syndrome (PCOS)." | 3.91 | A pilot trial of metformin for insulin resistance and mood disturbances in adolescent and adult women with polycystic ovary syndrome. ( Aghamohammadzadeh, N; Erensoy, H; Ghafarzadeh, S; Nader, ND; Niafar, M, 2019) |
| "Diabetogenesis triggered by arsenic contributed to the mitochondrial ROS overproduction, impaired complex II activity, glucose homeostasis, glucose tolerance and insulin sensitivity." | 3.91 | SirT3 regulates diabetogenic effects caused by arsenic: An implication for mitochondrial complex II modification. ( Javadipour, M; Keshtzar, E; Khodayar, MJ; Rezaei, M, 2019) |
| "Background Whether metformin might affect the risk of benign nodular goiter in patients with type 2 diabetes mellitus has not been investigated." | 3.91 | Metformin reduces risk of benign nodular goiter in patients with type 2 diabetes mellitus. ( Tseng, CH, 2019) |
| "Insulin and metformin improve the quality of the skin in rats with diabetes and insulin resistance, by restoring the content of hyaluronic acid to the healthy skin level." | 3.91 | Selected elements of extracellular matrix of the skin in diabetes and insulin resistance. ( Car, H; Knaś, M; Niczyporuk, M, 2019) |
| "Metformin with reduction of ECM component as collagen VI, MMP2 and MMP9, integrin/ERK pathway, necrosis markers as RIPK1, RIPK3 and MLKL, and apoptosis markers including DAP, DAPK1, DAPK3 and SIVA effects on fibrosis in insulin resistant and hypertrophied adipocytes in vitro." | 3.91 | Metformin reduces fibrosis factors in insulin resistant and hypertrophied adipocyte via integrin/ERK, collagen VI, apoptosis, and necrosis reduction. ( Malekpour-Dehkordi, Z; Mohiti-Ardakani, J; Naghiaee, Y; Nourbakhsh, M; Sharifi, R; Teimourian, S, 2019) |
| "Serum ApoJ levels are closely correlated with the magnitude of insulin resistance regardless of obesity, and decrease along with improvement of insulin resistance in response only to rosiglitazone in type 2 diabetes." | 3.88 | Circulating ApoJ is closely associated with insulin resistance in human subjects. ( Choe, C; Ciaraldi, TP; Farr, O; Henry, RR; Hwang, WM; Kang, MC; Kim, SS; Kim, YB; Lim, DM; Mantzoros, C; Park, KS; Seo, JA, 2018) |
| "The aim of this study was to evaluate the effect of orlistat or metformin combined with Diane-35 on anthropometric, hormonal and metabolic parameters in overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance (fasting insulin > 10 mIU/L)." | 3.88 | Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| " The aim of the current work was to investigate the effect of metformin versus vitamin D (and also simultaneous administration) therapy in type 2 diabetic (T2D) rats on the state of the muscle and insulin sensitivity." | 3.88 | Synergistic actions of vitamin D and metformin on skeletal muscles and insulin resistance of type 2 diabetic rats. ( Amin, SN; Hassan, SS; Hussein, UK; Rashed, LA; Yassa, HD, 2018) |
| "Objective The study's objective was to evaluate the thyroid parameters in obese insulin-resistant patients with euthyroid diffuse or nodular goiter, following Metformin treatment." | 3.88 | The effect of Metformin treatment in obese insulin-resistant patients with euthyroid goiter. ( Bolboacă, SD; Ghervan, C; Mârza, S; Moga, D; Răcătăianu, N; Sitar-Tăut, AV; Valea, A, 2018) |
| " The aim of present study was to investigate the therapeutic potentials of resveratrol (RSV) alone and/or in combination with vitamin-E (Vit-E) against hyperglycemia-induced modulations using experimentally alloxan-induced diabetic animal model." | 3.88 | Resveratrol regulates hyperglycemia-induced modulations in experimental diabetic animal model. ( Akash, MSH; Munawar, SM; Rehman, K; Saeed, K, 2018) |
| " Accordingly, O304 reduced fasting plasma glucose levels and homeostasis model assessment of insulin resistance (HOMA-IR) in a proof-of-concept phase IIa clinical trial in type 2 diabetes (T2D) patients on Metformin." | 3.88 | PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. ( Backlund, F; Berggren, E; Bergqvist, I; Dahl, U; Edlund, H; Edlund, T; Ericsson, M; Eriksson, B; Kjellkvist, E; Lidh, E; Lindahl, E; Linde, K; Lundberg, I; Steneberg, P; Straseviciene, J; Westman, J, 2018) |
| "The aim of this study was to evaluate the risk of major birth defects and spontaneous abortion after metformin use during the first trimester of pregnancy." | 3.88 | Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study. ( Beck, E; Grupe, K; Schaefer, C; Scherneck, S; Schlinke, N; Weber-Schoendorfer, C, 2018) |
| " Ursolic acid, metformin, gliclazide and their combinations when administered daily for 30 days significantly improved insulin sensitivity apart from behavioral and biochemical alterations in stressed mice." | 3.88 | Synergistic action of ursolic acid and metformin in experimental model of insulin resistance and related behavioral alterations. ( Ahuja, S; Akhtar, A; Kumar, A; Mourya, A; Sah, SP, 2018) |
| "To evaluate the effect of metformin and pioglitazone on leutinizing hormone and follicle stimulating hormone receptor mRNA expression, hyperandrogenism and insulin resistance in high fat diet induced and letrozole induced PCOS in rats." | 3.88 | Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats. ( Patel, R; Shah, G, 2018) |
| "Metformin treatment significantly improved IR but had no effect on peak VO(2), the primary endpoint of our study." | 3.86 | The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. ( AlZadjali, MA; Ang, DS; Choy, A; Lang, CC; Ogston, S; Petrie, JR; Struthers, AD; Symon, R; Wong, AK, 2012) |
| " Compared with vehicle-treated mice, borapetoside E markedly improved hyperglycemia, insulin resistance, hepatic steatosis, hyperlipidemia, and oxygen consumption in obese mice, and the effects were comparable to or better than the drug metformin." | 3.85 | Borapetoside E, a Clerodane Diterpenoid Extracted from Tinospora crispa, Improves Hyperglycemia and Hyperlipidemia in High-Fat-Diet-Induced Type 2 Diabetes Mice. ( Gao, Y; Hu, J; Liu, J; Lu, Y; Niu, Y; Peng, L; Qin, W; Wang, F; Xiong, W; Xu, Y, 2017) |
| "An extensive body of literature indicates a relationship between insulin resistance and the up-regulation of the kynurenine pathway, i." | 3.85 | Successful metformin treatment of insulin resistance is associated with down-regulation of the kynurenine pathway. ( Burghardt, P; Kumar, A; Muzik, O; Seyoum, B; Yi, Z, 2017) |
| "The present investigation was designed to explore the effectiveness of pterostilbene (PT) on insulin resistance, metabolic syndrome and oxidative stress in fructose-fed insulin resistant rats." | 3.85 | Pterostilbene ameliorates insulin sensitivity, glycemic control and oxidative stress in fructose-fed diabetic rats. ( Kosuru, R; Singh, S, 2017) |
| "Metformin treatment increased whole-body insulin sensitivity." | 3.85 | Metformin attenuates the TLR4 inflammatory pathway in skeletal muscle of diabetic rats. ( Barbosa, LN; Caixeta, DC; de Assis de Araújo, F; Deconte, SR; Espindola, FS; Peixoto, LG; Sabino-Silva, R; Teixeira, RR; Vilela, DD, 2017) |
| "Sitagliptin can reduce BMI and the occurrence of hypoglycemia in obese patients with insulin treatment-induced diabetes mellitus, and the effect may be related to decreased HOMA-IR, decreased leptin and visfatin levels, and increased adiponectin levels." | 3.85 | The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus. ( Li, H; Li, S; Wang, R; Zhang, JP, 2017) |
| " In the present study, we investigated the potential therapeutic effects of metformin (Met) and saxagliptin (Saxa), as insulin sensitizing agents, in a rat model of brain aging and AD using D-galactose (D-gal, 150 mg/kg/day, s." | 3.85 | Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. ( Attia, A; El-Shenawy, S; Gomaa, N; Hassan, A; Hegazy, R; Kenawy, S; Zaki, H, 2017) |
| " We hypothesized that co-administration of SB extract and metformin exerts a better effect on obesity-induced insulin resistance and lipid metabolism than treatment with metformin alone." | 3.85 | In vivo therapeutic effect of combination treatment with metformin and Scutellaria baicalensis on maintaining bile acid homeostasis. ( Bose, S; Chin, YW; Choi, HS; Han, K; Kim, H; Kim, YM; Lim, SK; Wang, JH, 2017) |
| "To compare metformin and pioglitazone with standard interferon and ribavirin in achieving sustained virological response in chronic hepatitis C patients." | 3.85 | Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study. ( Butt, NF; Hamid, S; Khan, IM; Malik, BR; Malik, U; Randhawa, FA, 2017) |
| "We aim to assess the effects of metformin treatment on metabolic and endocrine parameters and genes expression related to the insulin-responsive pathway in polycystic ovary syndrome (PCOS)." | 3.85 | IGF-1R and Leptin Expression Profile and the Effects of Metformin Treatment on Metabolic and Endocrine Parameters in PCOS Mice. ( Abi Haidar, M; Berguio Vidotti, D; de Almeida, BC; de Jesus Simões, M; Prado Correia, LE; Silva, I, 2017) |
| "BMI in overweight patients were significantly improved with metformin treatment duration (p < 0." | 3.85 | Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome. ( Chen, PC; Ou, HT; Wu, MH, 2017) |
| "To compare the therapeutic potential of TP-113, a unique molecular entity linking DHA with metformin, for alleviating insulin resistance in obese diabetic mice through the PDX/IL-6 pathway." | 3.85 | Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice. ( Barbier, O; Lachance, D; Marette, A; Mitchell, PL; Nachbar, R; St-Pierre, P; Trottier, J, 2017) |
| "TODAY participants underwent periodic oral glucose tolerance tests to determine insulin sensitivity, C-peptide index, and oral disposition index (oDI), with measurements of total and high-molecular-weight adiponectin (HMWA)." | 3.85 | Adiponectin, Insulin Sensitivity, β-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY. ( Arslanian, S; Bacha, F; Caprio, S; El Ghormli, L; Goland, R; Haymond, MW; Levitsky, L; Nadeau, KJ; White, NH; Willi, SM, 2017) |
| "To evaluate the impact of depression on NASH through the involvement of JNK1 and to assess the effect of sitagliptin and metformin on hepatic JNK1 expression in both NASH and NASH associated with depression." | 3.85 | Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress. ( Abd-Elaziz, LF; Aboul-Fotouh, S; El-Kharashi, OA; Magdy, YM; Nabih, ES; Shaker, SM, 2017) |
| "Metformin increased insulin sensitivity, but did not affect neointimal thickness in either the normal fat or high fat diet-fed rats." | 3.85 | High-dose metformin (420mg/kg daily p.o.) increases insulin sensitivity but does not affect neointimal thickness in the rat carotid balloon injury model of restenosis. ( Breen, DM; Dalvi, P; Dolinsky, VW; Giacca, A; Guo, J; Lam, L; Pereira, TJ; Swain, N; Yeung, LSN, 2017) |
| " Twenty-nine patients without insulin resistance were treated with OC (group 1), and 20 patients with insulin resistance were treated with metformin and OC (group 2)." | 3.83 | Assessment of Anti-Müllerian Hormone Level in Management of Adolescents with Polycystic Ovary Syndrome. ( Dursun, F; Güven, A; Yıldız, M, 2016) |
| " In patients with untreated amiodarone-induced hypothyroidism, but not in the other groups of patients, metformin reduced serum levels of thyrotropin and this effect correlated weakly with its action on insulin sensitivity." | 3.83 | The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and amiodarone-induced hypothyroidism. ( Gilowska, M; Krysiak, R; Okopień, B; Szkróbka, W, 2016) |
| "To compare the efficacy of acarbose and metformin in overweight and/or obese patients with newly diagnosed type 2 diabetes mellitus (T2DM)." | 3.83 | Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity. ( Chen, J; Liao, L; Sun, W; Wang, Y; Zeng, C, 2016) |
| "This substudy of the AWARD-3 trial evaluated the effects of the once-weekly glucagon-like peptide-1 receptor agonist, dulaglutide, versus metformin on glucose control, pancreatic function and insulin sensitivity, after standardized test meals in patients with type 2 diabetes." | 3.83 | Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes. ( de la Peña, A; Del Prato, S; Karanikas, CA; Ludvik, B; Mari, A; Milicevic, Z; Pechtner, V; Shurzinske, L, 2016) |
| "Metformin administration attenuates endotoxemia and enhances insulin signaling in high-fat fed mice, which contributes to its anti-diabetic effects." | 3.83 | Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling. ( Chai, DD; Ren, LW; Yang, HY; Yu, ZW; Zhan, P; Zhou, ZY, 2016) |
| " Here we show that treatment with the antidiabetic drug metformin inhibits excessive ECM deposition in WAT of ob/ob mice and mice with diet-induced obesity, as evidenced by decreased collagen deposition surrounding adipocytes and expression of fibrotic genes including the collagen cross-linking regulator LOX Inhibition of interstitial fibrosis by metformin is likely attributable to the activation of AMPK and the suppression of transforming growth factor-β1 (TGF-β1)/Smad3 signaling, leading to enhanced systemic insulin sensitivity." | 3.83 | AMPK Activation by Metformin Suppresses Abnormal Extracellular Matrix Remodeling in Adipose Tissue and Ameliorates Insulin Resistance in Obesity. ( Fry, J; Han, J; Jiang, B; Li, Q; Luo, T; Nocon, A; Rui, X; Sherban, A; Xu, XJ; Yan, Y; Yang, Q; Zang, M, 2016) |
| " The present study aimed to evaluate the comparative effects of sodium butyrate (NaB) and metformin on the glucose homeostasis, insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat." | 3.83 | Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: A comparative study with metformin. ( Jena, G; Khan, S, 2016) |
| "This study aims to investigate the effects of metformin and resveratrol on muscle insulin resistance with emphasis on the regulation of lipolysis in hypoxic adipose tissue." | 3.83 | Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue. ( Feng, X; Hou, T; Li, A; Liu, B; Liu, K; Zhang, N; Zhao, W, 2016) |
| "We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats." | 3.83 | Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016) |
| " TZDs are commonly prescribed in combination with metformin (MET) and thus we sought to examine the combined effects of RSV and MET in treating insulin resistance." | 3.83 | Beneficial effects of combined resveratrol and metformin therapy in treating diet-induced insulin resistance. ( Frendo-Cumbo, S; MacPherson, RE; Wright, DC, 2016) |
| "Metformin is the first-line oral medication to increase insulin sensitivity in patients with type 2 diabetes (T2D)." | 3.83 | Metformin Effect on Nontargeted Metabolite Profiles in Patients With Type 2 Diabetes and in Multiple Murine Tissues. ( Adam, J; Adamski, J; Ankerst, D; Bi, J; Brandmaier, S; Chi, S; Giani, G; Gieger, C; Heier, M; Herder, C; Hrabĕ de Angelis, M; Illig, T; Kastenmüller, G; Leonhardt, J; Li, Y; Meitinger, T; Mohney, RP; Neschen, S; Peters, A; Rathmann, W; Roden, M; Rotter, M; Scheerer, MF; Strauch, K; Suhre, K; Troll, M; Wang-Sattler, R; Xu, T, 2016) |
| "This study investigated the molecular mechanism of saponarin, a flavone glucoside, in the regulation of insulin sensitivity." | 3.81 | Saponarin activates AMPK in a calcium-dependent manner and suppresses gluconeogenesis and increases glucose uptake via phosphorylation of CRTC2 and HDAC5. ( Jia, Y; Lee, JH; Lee, SJ; Seo, WD; Wu, C, 2015) |
| "To evaluate effects of metformin on endocrine, metabolic parameters and endometrial androgen receptor (AR) expression in polycystic ovary syndrome (PCOS)." | 3.81 | Effects of metformin on endocrine, metabolic milieus and endometrial expression of androgen receptor in patients with polycystic ovary syndrome. ( Fujimori, K; Hashimoto, S; Ito-Yamaguchi, A; Kumagami, A; Suganuma, R; Yoshida-Komiya, H, 2015) |
| " Ten adolescents with hyperinsulinemia and dyslipidemia received therapy with metformin (500-1500 mg/daily) and micronized fenofibrate (160 mg/daily)." | 3.81 | Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. ( Kalina, MA; Kalina-Faska, B; Mandera, M; Małecka Tendera, E; Skała-Zamorowska, E; Wilczek, M, 2015) |
| " We aimed to elucidate the mechanism of JLD treatment, in comparison to metformin treatment, on ameliorating insulin sensitivity in insulin resistant rats and to reveal its anti-oxidant properties." | 3.81 | Jinlida reduces insulin resistance and ameliorates liver oxidative stress in high-fat fed rats. ( Duan, L; Li, L; Li, X; Liu, Y; Song, A; Song, G; Wang, C; Wang, Y; Yu, X; Zang, S; Zhu, Y, 2015) |
| " Metformin has been introduced in the treatment of PCOS to manage insulin resistance and hyperglycemia." | 3.81 | Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model. ( Abramovich, D; Bas, D; Bianchi, MS; Di Pietro, M; Irusta, G; Parborell, F; Pascuali, N; Tesone, M, 2015) |
| "Our findings suggest that the loss-of-function variant OCT2-T201M (rs145450955) contribute to changes in insulin resistance and beta cell activity in patients with T2D treated with metformin." | 3.81 | The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin. ( Alizadeh, A; Bahar, A; Hashemi-Soteh, MB; Kashi, Z; Mahrooz, A; Masoumi, P, 2015) |
| " Leucine (Leu) activates Sirt1 by lowering its Km for NAD(+) and potentiates other sirtuin/AMPK-activators, resulting in improvement of insulin sensitivity." | 3.81 | Leucine amplifies the effects of metformin on insulin sensitivity and glycemic control in diet-induced obese mice. ( Bruckbauer, A; Cao, Q; Cui, X; Fu, L; Li, F; Shi, H; Wu, R; Xue, B; Zemel, MB, 2015) |
| " Metformin, which is widely used in the treatment of diabetes, ameliorates insulin sensitivity." | 3.81 | Metformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-+Leprdb/+Leprdb mice. ( Baba, A; Kochi, T; Kubota, M; Moriwaki, H; Ohno, T; Shimizu, M; Shirakami, Y; Tanaka, T; Tsurumi, H, 2015) |
| " L6 muscle cells were incubated with palmitic acid (PA) to induce insulin resistance and then treated with metformin and/or the AMPK inhibitor, compound C." | 3.81 | Metformin attenuates palmitic acid-induced insulin resistance in L6 cells through the AMP-activated protein kinase/sterol regulatory element-binding protein-1c pathway. ( Bi, Y; Bu, R; Cao, S; Shi, J; Tang, S; Wu, W; Yin, W; Zhu, D, 2015) |
| "To examine, in an animal study, whether EA combined with metformin (EA-metformin) results in a better glucose-lowering effect and greater insulin sensitivity than metformin alone in steroid-induced insulin-resistant rats." | 3.81 | Electroacupuncture plus metformin lowers glucose levels and facilitates insulin sensitivity by activating MAPK in steroid-induced insulin-resistant rats. ( Chang, SL; Lee, YC; Liao, HY; Lin, JG; Sun, MF, 2015) |
| "The skin matrix metalloproteinase 3, tissue inhibitors of matrix metalloproteinase 2 and collagen III content changes in type 1 diabetes and insulin resistance treated with insulin and metformin were studied." | 3.81 | The skin remodeling in type 1 diabetes and insulin resistance animal models. ( Kasacka, I; Knaś, M; Mikucka-Niczyporuk, A; Niczyporuk, M; Wołosik, K; Zalewska, A, 2015) |
| "To evaluate the effects of treatment with metformin on a murine model of obesity-associated erectile dysfunction." | 3.81 | Treatment With Metformin Improves Erectile Dysfunction in a Murine Model of Obesity Associated With Insulin Resistance. ( Alexandre, EC; Antunes, E; Calixto, MC; Calmasini, FB; Silva, FH, 2015) |
| "The aim of this study was to determine the relevance of apelin and insulin resistance (IR) with polycystic ovary syndrome (PCOS) and to assess the possible therapeutic effect of the combined therapy of drospirenone-ethinylestradiol (DRSP-EE) combined with metformin." | 3.81 | Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin. ( Sun, X; Wu, X; Yu, X; Zhang, W; Zhou, Y, 2015) |
| "Sixty six adult patients with schizophrenia or schizoaffective disorder treated, with atypical antipsychotics, and who had increased by more than 10% their pre treatment body weight, were randomly assigned to receive metformin or placebo in a double-blind study." | 3.81 | Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. ( Dayabandara, M; de Silva, VA; Gunewardena, H; Hanwella, R; Henegama, T; Suraweera, C; Wijesundara, H, 2015) |
| " The aim of this study was to assess the effects of metformin on insulin resistance, oxidant-antioxidant status, endothelial dysfunction, lipid metabolism and their contribution to the risks of cardiovascular disease in women with PCOS." | 3.80 | The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. ( Bayram, F; Diri, H; Kocer, D, 2014) |
| "Insulin-sensitizer treatment with metformin is common in polycystic ovary syndrome (PCOS)." | 3.80 | Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism. ( Lerchbaum, E; Obermayer-Pietsch, B; Pieber, T; Schweighofer, N; Schwetz, V; Trummer, O, 2014) |
| "Metformin treatment (850 mg twice daily for 6 months) substantially increased serum adipolin concentrations (P < 0·05) in women with polycystic ovary syndrome (PCOS), a pro-inflammatory state associated with obesity, diabetes, dyslipidaemia and atherosclerosis." | 3.80 | Circulatory changes of the novel adipokine adipolin/CTRP12 in response to metformin treatment and an oral glucose challenge in humans. ( Amar, O; Chen, J; Hu, J; Lehnert, H; Mattu, HS; Patel, V; Ramanjaneya, M; Randeva, HS; Tan, BK, 2014) |
| " To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity." | 3.80 | Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. ( An, X; Botchlett, R; Chen, L; Guo, T; Guo, X; Hu, X; Huo, Y; Li, H; Li, Q; Pei, Y; Qi, T; Woo, SL; Wu, C; Xiao, X; Xu, H; Xu, Y; Zhao, J; Zhao, Y; Zheng, J, 2014) |
| "Metformin and swimming exercise improved lipid profile, and increased insulin sensitivity and body weight reduction were observed." | 3.80 | Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats. ( Gao, Y; Luo, L; Pan, T; Wang, C, 2014) |
| "The combination of dimethylbiguanide and pioglitazone was more effective for the treatment of PCOS complicated with IR than simple pioglitazone; chronic inflammation occurrence was possibly one of reasons for insulin sensitivity reduction of patients with PCOS." | 3.80 | Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer. ( Hu, L; Hu, MH; Shen, H; Tian, L; Wu, QF, 2014) |
| "Although both vildagliptin and metformin improved insulin resistance and attenuate myocardial injury caused by I/R, combined drugs provided better outcomes than single therapy by reducing arrhythmia score and mortality rate." | 3.80 | Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. ( Apaijai, N; Chattipakorn, N; Chattipakorn, S; Chinda, K; Palee, S, 2014) |
| "To study the effect of Mudan Granule (MD) on the glucose metabolism and beta cell function in monosodium glutamate (MSG) induced obese mice with insulin resistance (IR)." | 3.80 | [Effect of Mudan Granule on islets beta cell function in monosodium glutamate induced obese mice with insulin resistance: an experimental study]. ( Hou, SC; Liu, Q; Liu, SN; Shen, ZF; Sun, SJ, 2014) |
| "To investigate the therapeutical effects of visfatin and metformin on insulin resistance and reproductive endocrine disorder in rats with polycystic ovary syndrome (PCOS)." | 3.80 | [Effects of visfatin and metformin on insulin resistance and reproductive endocrine in rats with polycystic ovary syndrome]. ( Gu, J; Li, T; Su, S; Wan, J; Zhang, T; Zou, X, 2014) |
| "Chronic metformin treatment improved the glycemic homeostasis in pre-diabetic MSG-rats, glucose intolerance, tissue insulin resistance, hyperinsulinemia and decreased the fat tissue accretion." | 3.80 | Protective effect of metformin against walker 256 tumor growth is not dependent on metabolism improvement. ( Agostinho, AR; Barella, LF; Beraldi, EJ; de Castro Prado, MA; de Oliveira, JC; de Sant'Anna, JR; de Souza, CO; de Souza, HM; Franco, CC; Gravena, C; Malta, A; Mathias, PC; Miranda, RA; Prates, KV; Tófolo, LP; Torrezan, R; Trombini, AB, 2014) |
| "To analyze the level of serum leptin and its relations with insulin resistance in patients with polycystic ovary syndrome (PCOS) so as to investigate the clinical effect of aciesis in PCOS under treatment of metformin." | 3.80 | [Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome]. ( Cheng, X; Guo, J; Xie, J, 2014) |
| " Peripheral insulin resistance was also enhanced and the GP in charge decided to discontinue the dosing of metformin as a result." | 3.80 | [Improvement of clinical parameters in a patient with metabolic syndrome through intervention in nutrition education and improvement of lifestyle]. ( Alegre, A; Ferri, A; Martinez, MI; Mateos, AM, 2014) |
| " The cytokine serum levels, glycated hemoglobin (HbA1c) as a marker of glucoregulation, homeostasis model assessment index as a measure of insulin resistance (HOMA-IR), and body mass index (BMI) were determined before and after 12 weeks of therapy consisting of standard lifestyle modification and metformin (1000 mg b." | 3.79 | Therapeutic improvement of glucoregulation in newly diagnosed type 2 diabetes patients is associated with a reduction of IL-17 levels. ( Cvijovic, G; Janjetovic, K; Jeremic, D; Micic, D; Pantovic, A; Stamenkovic-Pejkovic, D; Stevanovic, D; Sumarac-Dumanovic, M; Trajkovic, V, 2013) |
| "Women with anovulatory polycystic ovary syndrome (PCOS) are generally insulin-resistant and as a consequence are often treated with the biguanide metformin." | 3.79 | Metformin inhibits follicle-stimulating hormone (FSH) action in human granulosa cells: relevance to polycystic ovary syndrome. ( Elia, A; Jawad, Z; Mason, HD; Pellatt, L; Rice, S, 2013) |
| " Metformin is a first-line drug for treatment of type 2 diabetes that improves peripheral insulin resistance." | 3.79 | TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats. ( Ito, R; Matsuda-Nagasumi, K; Mori, I; Negoro, N; Takeuchi, K; Tsujihata, Y, 2013) |
| "Metformin treatment enhances both adiponectin activity and insulin sensitivity, resulting in a less hyperandrogenic state in patients with PCOS." | 3.79 | Role of adiponectin and its receptor in prediction of reproductive outcome of metformin treatment in patients with polycystic ovarian syndrome. ( Hamed, HO, 2013) |
| "BCAA/AAAs changed acutely during glipizide and metformin administration, and the magnitude and direction of change differed by the insulin resistance status of the individual and the intervention." | 3.79 | Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitus. ( Ackerman, RJ; Altshuler, D; Billings, LK; Chamarthi, B; Clish, CB; Davis, J; Deik, A; Fanelli, RR; Florez, JC; Gerszten, RE; Grant, RW; Hernandez, AM; Huang, C; Hudson, MS; Khan, SQ; Littleton, KR; Lo, J; McCarthy, RM; Rhee, EP; Stolerman, E; Taylor, A; Walford, GA; Wang, TJ; Warner, AS, 2013) |
| " The secondary objective was to evaluate changes in body mass index (BMI), waist-to-hip ratio (WHR), and insulin sensitivity after 3 months of metformin therapy." | 3.79 | Insulin resistance assessment in patients with polycystic ovary syndrome using different diagnostic criteria--impact of metformin treatment. ( Brodowska, A; Ciećwież, S; Kotlega, D; Marciniak, A; Nawrocka-Rutkowska, J; Starczewski, A; Wiśniewska, B, 2013) |
| "Telmisartan acts beneficially against diabetes-induced inflammation and improves insulin resistance in pre-diabetes OLETF rats fed with HFD." | 3.79 | Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action. ( Li, LY; Luo, R; Sun, LT; Tian, FS; Xiong, HL; Zhao, ZQ; Zheng, XL, 2013) |
| " The AMP-activated protein kinase (AMPK) activator metformin reverses obesity-associated insulin resistance (IR) and inhibits different types of inflammatory responses." | 3.79 | Metformin attenuates the exacerbation of the allergic eosinophilic inflammation in high fat-diet-induced obesity in mice. ( André, DM; Anhê, GF; Antunes, E; Bordin, S; Calixto, MC; Ferreira, D; Landgraf, RG; Leiria, LO; Lellis-Santos, C; Lintomen, L, 2013) |
| "Gemfibrozil is a PPAR-α ligand that inhibits the progression of atherosclerosis in insulin resistance type 2 diabetes mellitus (IR type 2 DM)." | 3.79 | Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats. ( Kurmi, MK; Raikwar, SK; Sharma, AK; Srinivasan, BP, 2013) |
| "The efficacy of metformin for the treatment of obesity has been evaluated in few clinical trials with inconclusive results." | 3.79 | Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. ( Schehler, B; Schneider, HJ; Seifarth, C, 2013) |
| " We also followed up a subset of male patients with HIV and hepatitis C virus (HCV) coinfection (n = 47) who were not receiving antiviral treatment and for whom metformin was prescribed for insulin resistance, which tends to have a higher incidence and severity in coinfected patients." | 3.79 | Metformin: a cheap and well-tolerated drug that provides benefits for viral infections. ( Alonso-Villaverde, C; Aragonès, G; Beltrán-Debón, R; Camps, J; Espinel, E; Fernandez-Sender, L; Joven, J; Menéndez, JA; Pedro-Botet, J; Riera-Borrull, M; Rodríguez-Gallego, E; Rull, A, 2013) |
| "We investigated metformin-mediated SHP production improved insulin resistance through the regulation of an IL-6-dependent pathway (involving signal transducer and activator of transcription 3 [STAT3] and suppressor of cytokine signalling 3 [SOCS3]) in both Shp knockdown and Shp null mice." | 3.78 | Metformin ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models. ( Ahn, SW; Chanda, D; Cho, YM; Choi, HS; Kim, DK; Kim, YD; Kim, YH; Lee, CH; Lee, JM; Shong, M, 2012) |
| "Regular exercise training and metformin medication are widely considered to increase insulin sensitivity and protect against type 2 diabetes, however, evaluating the effect of exercise training on the disposition and pharmacokinetics of metformin is unclear." | 3.78 | Swim training reduces metformin levels in fructose-induced insulin resistant rats. ( Chien, KY; Hsu, KF; Hsu, MC; Huang, CC; Kuo, CH, 2012) |
| "After 6 weeks treatment, metformin reduced the body weight gain and enhanced insulin sensitivity of high-fat fed rats." | 3.78 | Downregulation of chemerin and alleviation of endoplasmic reticulum stress by metformin in adipose tissue of rats. ( Ao, N; Du, J; Liu, H; Pei, L; Yang, J; Zhang, Y, 2012) |
| "Serum hsCRP improved with lifestyle modification and metformin therapy for 3 months in overweight subjects from India with PCOS, along with serum total cholesterol, triglycerides, and HDL-C." | 3.78 | Effect of lifestyle modification and metformin therapy on emerging cardiovascular risk factors in overweight Indian women with polycystic ovary syndrome. ( Bitla, A; P V L N Rao, S; Rajagopal, G; Reddy, AP; Sachan, A; Suresh, V; Venkata Harinarayan, C, 2012) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 3.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "Insulin resistance is a risk factor for non-response to interferon/ribavirin therapy in patients with chronic hepatitis C." | 3.78 | Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice. ( García-Ruiz, I; Gómez-Izquierdo, E; Muñoz-Yagüe, MT; Solís-Herruzo, JA; Solís-Muñoz, P; Valverde, AM, 2012) |
| " At the end of the feeding schedule, Dia group had insulin resistance along with increased blood glucose, triglyceride, uric acid and nitric oxide (NO) levels." | 3.78 | Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. ( Bagul, PK; Banerjee, SK; Bastia, T; Chakravarty, S; Madhusudana, K; Matapally, S; Middela, H; Padiya, R; Reddy, BR, 2012) |
| " In contrast, glyburide failed to reverse the glucose intolerance caused by olanzapine despite increasing insulin levels." | 3.78 | Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. ( Barr, AM; Boyda, HN; Hawkes, E; Honer, WG; Jin, CH; Pang, CC; Procyshyn, RM; Tse, L, 2012) |
| " We hypothesised that intervention with metformin would diminish the HF-feeding-evoked cognitive deficit by improving insulin sensitivity." | 3.78 | A high-fat-diet-induced cognitive deficit in rats that is not prevented by improving insulin sensitivity with metformin. ( Balfour, DJ; McNeilly, AD; Stewart, CA; Sutherland, C; Williamson, R, 2012) |
| "Our findings suggest that metformin effectively improves peripheral insulin sensitivity, prevents brain mitochondrial dysfunction, and completely restores learning behavior, which were all impaired by long-term HFD consumption." | 3.78 | Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H; Pratchayasakul, W, 2012) |
| " Metformin treatment improved the insulin sensitivity, and normalized the in vitro bladder hypercontractility and cystometric dysfunction in obese mice." | 3.78 | Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice. ( Anhê, GF; Antunes, E; Calixto, MC; De Nucci, G; Grant, AD; Leiria, LO; Lintomen, L; Mónica, FZ; Sollon, C; Zanesco, A, 2012) |
| "Metformin improved the glucose rate and the homeostasis model assessment-insulin resistance (HOMA-IR) index and caused partial reversion of ovaries and uterine morphology in female rats androgenized with testosterone." | 3.77 | Effects of metformin on the reproductive system of androgenized female rats. ( Baracat, EC; de Jesus Simões, M; Maganhin, CC; Mahamed, RR; Simões, RS; Soares, JM, 2011) |
| " Of the available agents affecting insulin sensitivity, metformin has been the most widely used but despite an enormous literature reporting beneficial effects on reproductive, cutaneous and metabolic manifestations of PCOS, its efficacy is unproven apart from in those subjects with impaired glucose tolerance or frank diabetes." | 3.77 | When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome? ( Franks, S, 2011) |
| "Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women." | 3.77 | Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. ( Aboul Foutouh, I; Ashmawi, HS; Khattab, S; Mohsen, IA; Mohsen, MN; van der Veen, F; van Wely, M; Youssef, MA, 2011) |
| "The administration of a HFD induces insulin resistance in the liver sinusoidal endothelium, which is mediated, at least in part, through iNOS upregulation and can be prevented by the administration of metformin." | 3.77 | Insulin resistance and liver microcirculation in a rat model of early NAFLD. ( Abraldes, JG; Bosch, J; García-Pagán, JC; La Mura, V; Pasarín, M; Rodríguez-Vilarrupla, A, 2011) |
| "A high rate of GD or IGT already was observed in the first weeks of pregnancy in our cohort under metformin treatment." | 3.77 | Early onset and high prevalence of gestational diabetes in PCOS and insulin resistant women before and after assisted reproduction. ( Bals-Pratsch, M; Grosser, B; Ortmann, O; Seifarth, C; Seifert, B, 2011) |
| "To investigate the potential preventive effects of metformin on non-alcoholic fatty liver disease (NAFLD) and roles of phospholipase A2/lysophosphatidylcholine pathway in hepatocyte lipoapoptosis in a rat NAFLD model induced by high-fat diet." | 3.77 | [Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes]. ( Fu, JF; Huang, Y; Liu, LR; Shi, HB, 2011) |
| " During the first year of treatment, exenatide, in combination with metformin and repaglinide, led to a weight loss of 14 kg and fat mass and waist circumference were respectively reduced from 31 to 25." | 3.77 | Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. ( Buysschaert, M; de la Tribonnière, X; Hermans, MP; Oriot, P; Selvais, P, 2011) |
| "Aspirin is a kind of anti-inflammatory drug and may be used to reverse hyperglycemia, hyperinsulinemia, and dyslipidemia by improving insulin resistance." | 3.77 | Effect of aspirin on the expression of hepatocyte NF-κB and serum TNF-α in streptozotocin-induced type 2 diabetic rats. ( Han, F; Han, L; Sun, X; Wang, B; Yi, J, 2011) |
| "In the Canadian Normoglycemia Outcome Evaluation (CANOE) trial, low-dose rosiglitazone/metformin reduced the risk of diabetes in subjects with impaired glucose tolerance by 66% over a median of 3." | 3.77 | Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. ( Hanley, AJ; Harris, SB; Qi, Y; Retnakaran, R; Zinman, B, 2011) |
| " Moreover, in comparingson of changes in HOMA among the groups, the metformin- treated group showed significantly improved metabolic control and insulin sensitivity (HOMA) at the end of the study." | 3.77 | Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. ( Akcam, M; Boyaci, A; Dundar, BN; Kaya, S; Pirgon, O; Uysal, S, 2011) |
| "To evaluate serum visfatin levels and to determine the effects of metformin treatment on visfatin levels in patients with polycystic ovary syndrome (PCOS)." | 3.76 | Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. ( Cakal, E; Engin-Ustun, Y; Ozkaya, M; Ustun, Y, 2010) |
| "Several data have demonstrated the efficacy of metformin in inducing ovulation in patients with polycystic ovary syndrome (PCOS), however, the exact mechanism by which this drug acts remains unknown." | 3.76 | Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2010) |
| " We tested the hypothesis that a gene variant in STK11 contributes to variation in insulin sensitivity and metformin efficacy." | 3.76 | A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Morán, E, 2010) |
| "A whole new area of investigation has emerged recently with regards to the anti-diabetic drug metformin and breast cancer." | 3.76 | Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. ( Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2010) |
| "Metformin reportedly enhances insulin sensitivity of peripheral tissues without stimulating insulin secretion, but bioavailability in horses is low." | 3.76 | Pharmacokinetics of metformin after enteral administration in insulin-resistant ponies. ( Edwards, S; Hackett, LP; Harris, PA; Noble, GK; Sillence, MN; Tinworth, KD, 2010) |
| " Insulin resistance was induced in theca cells without (Con) or with dexamethasone (Dex); cells were further treated by troglitazone (Tro) and metformin (Met) in IR cells or by vehicle only in IR and Con cells." | 3.75 | Insulin resistance directly contributes to androgenic potential within ovarian theca cells. ( Erkkola, R; Gao, L; Hou, L; Qu, J; Wang, Y; Wu, X, 2009) |
| " Pioglitazone was added to her treatment, and follow-up showed improvement of metabolic control 7 months after introducing pioglitazone, and improvement of insulin sensitivity 2 years later." | 3.75 | Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report. ( Beressi, JP; Billon-Bancel, A; Collet-Gaudillat, C, 2009) |
| "To evaluate the effect of metformin addition during ovarian hyperstimulation on cycle parameters and outcome of in vitro fertilization (IVF) treatment in polycystic ovary syndrome (PCOS) patients with a body mass index (BMI) <28 kg/m(2)." | 3.75 | Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization. ( Kahraman, S; Kumbak, B, 2009) |
| "Metformin attenuated oxidative stress-induced cardiomyocyte apoptosis and prevented the progression of heart failure in dogs, along with activation of AMPK." | 3.75 | Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. ( Asakura, M; Asanuma, H; Fujita, M; Ito, S; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Mochizuki, N; Ogai, A; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2009) |
| " The present study was carried out to compare the effects of administration of fenugreek seed polyphenolic extract (FPEt), quercetin and metformin (a positive control) in an acquired model of insulin resistance (IR)." | 3.75 | Insulin sensitizing actions of fenugreek seed polyphenols, quercetin & metformin in a rat model. ( Anuradha, CV; Kannappan, S, 2009) |
| "The aim of this prospective study was to evaluate results of metformin (MF) therapy during 1 year of uric acid (UA) metabolism and the clinical course of gout with insulin resistance (IR)." | 3.75 | [Effect of metformin on the clinical course of gout and insulin resistance]. ( Aleksandrova, EN; Barskova, VG; Eliseev, MS; Kudaeva, FM; Nasonov, EL; Nasonova, VA; Volkov, AV, 2009) |
| "To study insulin sensitivity, as well as the effects of estrogen, metformin and GnRHa treatment on glucose homeostasis, in an aromatase-deficient girl." | 3.75 | Metformin, estrogen replacement therapy and gonadotropin inhibition fail to improve insulin sensitivity in a girl with aromatase deficiency. ( Belgorosky, A; Di Palma, MI; Guercio, G; Mazza, C; Pepe, C; Prieto, M; Rivarola, MA; Saraco, NI; Saure, C, 2009) |
| "This study aimed to assess the perinatal outcome, especially foetal growth, following the continuation of metformin during the first trimester of pregnancy." | 3.75 | Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity. ( Bolton, S; Cleary, B; Dempsey, E; Turner, MJ; Walsh, J, 2009) |
| "The purpose of the study was to investigate the effects of swimming on the pharmacokinetic and insulin sensitivity of metformin in insulin resistant rats." | 3.74 | Effects of swimming on the pharmacokinetics and glucose tolerance of metformin in insulin-resistant rats. ( Chen, FA; Chien, KY; Hsu, KF; Hsu, MC; Kuo, CH; Lo, HI; Pan, RN, 2008) |
| "Most research confirms that metformin therapy has a positive influence on cardiovascular risk factors (CVRF) such as dyslipidemia, insulin resistance and hyperandrogenism in polycystic ovary syndrome (PCOS)." | 3.74 | Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. ( Bednarek-Tupikowska, G; Bohdanowicz-Pawlak, A; Demissie, M; Jakubowska, J; Milewicz, A; Szymczak, J, 2008) |
| "05) were higher on the IL/H study day than on the glycerol study day, indicating persistence of NEFA-induced insulin resistance." | 3.74 | Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes. ( Basu, A; Basu, R; Chandramouli, V; Cohen, O; Dicke, B; Landau, BR; Norby, B; Rizza, RA; Shah, P, 2008) |
| " In impaired glucose tolerance subjects, these procedures were performed before and after treatment with pioglitazone or metformin." | 3.74 | Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. ( Bodles, AM; Fried, SK; Kern, LM; Kern, PA; Lee, MJ; McGehee, RE; Phanavanh, B; Rasouli, N; Spencer, HJ; Starks, T; Varma, V; Yao-Borengasser, A, 2007) |
| "To evaluate the acute effects of metformin therapy on biochemical markers and polycystic ovarian morphology among insulin-resistant (IR) and noninsulin-resistant (NIR) patients with polycystic ovary syndrome (PCOS)." | 3.74 | Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. ( Bayrak, A; Mor, E; Paulson, RJ; Stanczyk, FZ; Terbell, H; Urwitz-Lane, R, 2007) |
| "In the present study, we investigated the effect of an association of micronutrients (zinc (Zn), selenium (Se) and vitamin E (vit E)) on insulin activity and antioxidant status in an animal model of insulin resistance, the high-fructose-fed rat." | 3.74 | Comparison of the effects of zinc alone and zinc associated with selenium and vitamin E on insulin sensitivity and oxidative stress in high-fructose-fed rats. ( Barclay, D; Faure, P; Halimi, S; Joyeux-Faure, M, 2007) |
| " At the beginning of the therapy, among the biochemical measurements, insulin resistance was defined and metformin treatment was begun." | 3.74 | Nutritional approach to metabolic changes arising out of schizophrenia therapy: case report. ( Balci, H; Eker, E; Ozenoglu, A; Ugurlu, S, 2007) |
| "Before and 3 months after low-dose metformin therapy, eight overweight/obese Japanese subjects [body mass index (BMI) >25 kg/m2] were studied with blood sampling, measurement of IHL and IMCL by 1H magnetic resonance spectroscopy and glucose infusion rate (GIR) during euglycaemic-hyperinsulinaemic clamp as an index of peripheral insulin sensitivity." | 3.74 | Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects. ( Hirose, T; Kawamori, R; Kumashiro, N; Sakurai, Y; Sato, F; Tamura, Y; Tanaka, Y; Watada, H, 2008) |
| "To study the effect of metformin on insulin receptor (IRc) protein tyrosine kinase (PTK) activity of HIT-T15 cell exposed to high glucose and free fatty acid (FFA) concentration, and to explore the mechanism of metformin (MF) improving beta cell insulin resistance." | 3.74 | [The effect of metformin on insulin receptor protein tyrosine kinase activity of HIT-T15 cell exposed to high concentration glucose and free fatty acid]. ( Li, J; Li, XJ; Tong, NW; Wang, Y; Wu, YH; Zhang, M; Zhao, TY, 2007) |
| "Here we investigate the effect of rosiglitazone (RSG), metformin (MET) and glyburide (GLIB) on plasma glucose levels, beta-cell mass, function and insulin sensitivity in 10-week-old diabetic male Zucker diabetic fatty (mZDF) rats using quantitative morphometry and a mathematical model beta-cell mass, insulin and glucose kinetics (betaIG)." | 3.74 | Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats. ( Atkinson, LL; Benkoczi, C; Finegood, DT; McDonald-Dyck, C, 2008) |
| " Metformin, a biguanide, improves insulin resistance by reducing gluconeogenesis and enhancing peripheral glucose uptake, promoting reduction of the plasma glucose level." | 3.74 | Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db/db mice. ( Chung, SH; Han, EJ; Sung, JH; Yoon, SH, 2007) |
| "The effect of 6 months of metformin treatment was prospectively assessed in 188 PCOS patients, divided into three groups according to body mass index (BMI; lean: BMI<25 kg/m2, overweight: BMI 25-29 kg/m2, and obese: BMI30 kg/m2)." | 3.74 | Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. ( Benson, S; Dietz, T; Elsenbruch, S; Hahn, S; Janssen, OE; Kimmig, R; Lahner, H; Mann, K; Moeller, LC; Schmidt, M; Tan, S, 2007) |
| "A 2-hour oral glucose tolerance test (OGTT) and a rapid intravenous glucose tolerance test (IVGTT) were performed before treatment was initiated, after treatment with metformin and at the end of 1 year of combination therapy with metformin and rosiglitazone to calculate quantitative insulin sensitivity check index (QUICKI) and acute insulin response (AIR)." | 3.74 | Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome. ( Anhalt, H; Bhangoo, A; Collin, GB; Maclaren, N; Marshall, JD; Naggert, JK; Sinha, SK; Ten, S, 2007) |
| " In this study, therefore, we aimed (1) to determine the circulating ADMA concentrations in 44 women with PCOS and 22 age- and BMI-matched healthy controls, (2) to evaluate its correlations with insulin resistance, gonadotrophins, and androgen secretion, and (3) to compare effects of metformin and ethinyl estradiol-cyproterone acetate (EE/CPA) treatments on circulating ADMA concentrations." | 3.74 | Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). ( Baser, I; Dede, M; Erbil, MK; Kenar, L; Oktenli, C; Ozgurtas, T; Sanisoglu, SY; Tapan, S; Yenen, MC; Yesilova, Z, 2008) |
| "A MEDLINE literature search was conducted (1950-January 2008) using the search terms acanthosis nigricans (AN), metformin, rosiglitazone, octreotide, retinoic acid, acitretin, etretinate, and isotretinoin." | 3.74 | Treatment options in insulin resistance obesity-related acanthosis nigricans. ( Benavides, S; Romo, A, 2008) |
| "We prospectively assessed whether metabolic and menstrual benefits of metformin-diet were equally realized in women with polycystic ovary syndrome (PCOS), categorized by pretreatment top (n = 32) and bottom (n = 35) quintile homeostasis model assessment insulin resistance (IR)." | 3.73 | Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. ( Glueck, CJ; Goldenberg, N; Loftspring, M; Sherman, A; Wang, P, 2005) |
| "Metformin had differential effects on fasting insulin levels, insulin resistance as demonstrated by homeostasis model assessment (HOMA), LH, total testosterone, dehydroepiandrosterone sulphate and free testosterone index on the basis of IRS genotype." | 3.73 | The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome. ( Aktas, A; Dilek, S; Erdal, EM; Ertunc, D; Tok, EC, 2005) |
| "Based on the favourable international experience with metformin in the most common female endocrine disease, the polycystic ovary syndrome, which has insulin resistance in the background, the author's treatment advice has been this in such cases since early 2002: for sexually active women who do not want to become pregnant for the time being, anti-androgenic contraceptive pill; for those who do not want to take contraceptives, contraceptives are contraindicated, or who do want to conceive, metformin." | 3.73 | [Treatment experience with metformin in polycystic ovary syndrome]. ( Petrányi, G, 2005) |
| "Recent data indicate that women affected by the polycystic ovary syndrome (PCOS) are at greater risk for cardiovascular disease and that metformin may improve the metabolic alterations in these patients." | 3.73 | Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. ( Azziz, R; Cascella, T; Colao, A; De Simone, B; Lombardi, G; Manguso, F; Orio, F; Palomba, S; Russo, T; Savastano, S; Tolino, A; Zullo, F, 2005) |
| "To investigate the effects of metformin on fatty livers in insulin-resistant rats." | 3.73 | [Effects of metformin on fatty liver in insulin-resistant rats]. ( Chen, SQ; Deng, JC; Liu, Q; Sun, H; Tang, L, 2005) |
| "Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well." | 3.73 | The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M, 2005) |
| "Plasma androgen levels were decreased significantly by metformin treatment, as were plasma LH and allopregnanolone levels and insulin resistance." | 3.73 | Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. ( Baraldi, E; Casarosa, E; Genazzani, AD; Genazzani, AR; Lanzoni, C; Luisi, M; Mehmeti, H; Ricchieri, F; Strucchi, C, 2006) |
| "Although the role of insulin sensitivity is not negligible, insulin secretion appears to be the major determinant of diabetic control in overt type 2 diabetic patients who are treated with metformin alone or with a two-drug therapy combining metformin and glyburide." | 3.73 | Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes. ( Colette, C; Lapinski, H; Monnier, L; Thuan, JF, 2006) |
| " The aim of this work was: (1) to estimate the role of SI glucose fluxes in glucose homeostasis in insulin resistance states (induced by high-fat (HF) feeding); (2) to assess the effect of metformin, an anti-diabetic molecule, on these fluxes." | 3.73 | Glucose utilization is suppressed in the gut of insulin-resistant high fat-fed rats and is restored by metformin. ( Mithieux, G; Rajas, F; Zitoun, C, 2006) |
| "To investigate the therapeutic effects of insulin-sensitizing drugs, rosiglitazone and metformin, on nonalcoholic fatty liver disease (NAFLD)." | 3.73 | [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats]. ( Chen, WK; Wang, T; Zhang, DM; Zhang, GY; Zhong, HJ, 2006) |
| " Metformin therapy reduces whole-body insulin resistance (IR) in patients with type-2 diabetes mellitus (DM)." | 3.73 | Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance. ( Caliskan, M; Erdogan, D; Gullu, H; Muderrisoglu, H; Ozcimen, EE; Tok, D; Topcu, S; Uckuyu, A; Zeyneloglu, H, 2006) |
| "To determine whether women with polycystic ovary syndrome (PCOS) and abnormal insulin levels treated with metformin had different rates of ovulation and pregnancy from women with PCOS and normal insulin levels." | 3.73 | Use of metformin for ovulation induction in women who have polycystic ovary syndrome with or without evidence of insulin resistance. ( Liu, KE; Sagle, M; Tataryn, IV, 2006) |
| " However, obese mares exhibited a significantly longer duration of the oestrous cycle, significant increases in circulating concentrations of leptin and insulin, and decreased insulin sensitivity and concentrations of thyroxine compared with feed-restricted mares throughout the experiment." | 3.73 | Obesity is associated with altered metabolic and reproductive activity in the mare: effects of metformin on insulin sensitivity and reproductive cyclicity. ( Fitzgerald, BP; Kennedy, EL; Murphy, BA; Reedy, SE; Sessions, DR; Vick, MM, 2006) |
| "In 74 women with polycystic ovary syndrome, treated for 4 years with metformin (MET) and diet, we prospectively assessed whether, and to what degree, weight loss, reduction of insulin resistance, and amelioration of coronary heart disease risk factors could be sustained." | 3.73 | Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Sieve, L; Wang, P; Winiarska, M, 2006) |
| " The aim of this work was: (1) to estimate the role of SI glucose fluxes in glucose homeostasis in insulin resistance states (induced by high-fat (HF) feeding); (2) to assess the effect of metformin, an anti-diabetic molecule, on these fluxes." | 3.73 | Glucose utilization is suppressed in the gut of insulin-resistant high fat-fed rats and is restored by metformin. ( Mithieux, G; Rajas, F; Zitoun, C, 2006) |
| "The purpose of this review is to provide a critical summary of recent studies on the clinical effects of metformin in polycystic ovary syndrome." | 3.72 | The role of metformin in the management of polycystic ovary syndrome. ( Prelevic, GM; Tsilchorozidou, T, 2003) |
| "In the presence of the severe hepatic insulin resistance of the LIRKO mouse, neither metformin nor RSG had any significant effect on glucose or insulin tolerance tests." | 3.72 | Effects of insulin-sensitising agents in mice with hepatic insulin resistance. ( Cohen, SE; Kahn, CR; Michael, MD; Tseng, YH, 2004) |
| "(1) High-fat diet induces insulin resistance in SD rats; this was associated with an increase in visceral fat and a decrease in the level of adiponectin; (2) Metformin treatment improved insulin sensitivity accompanied by a decrease in body weight and TG level; (3) Rosiglitazone treatment ameliorates IR in a greater extent and is accompanied by a reduction of FFA, TG and an increase of adiponectin levels." | 3.72 | [Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats]. ( Bu, S; Chen, XP; Liu, XL; Wang, N; Xiao, JZ; Yang, WY; Zhao, WH, 2004) |
| "Rosiglitazone and metformin prevented fatty-acid-induced insulin resistance (reduced clamp glucose infusion rate)." | 3.72 | Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. ( Cleasby, ME; Cooney, GJ; Dzamko, N; Furler, SM; Hegarty, BD; Kraegen, EW; Ye, JM, 2004) |
| "The objective of the study was to determine whether plasma migration inhibitor factor (MIF) concentration and mononuclear cell (MNC) mRNA are elevated in obesity and whether treatment with metformin reduces plasma MIF concentration." | 3.72 | Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. ( Aljada, A; Chaudhuri, A; Dandona, P; Ghanim, H; Hofmeyer, D; Mohanty, P; Tripathy, C, 2004) |
| "The aim of the present study was to evaluate the effect of metformin on body weight, body fat mass, waist circumference, lipid parameters, insulin secretion and insulin resistance in obese subjects with normal glucose tolerance." | 3.72 | Metformin in the treatment of obesity in subjects with normal glucose tolerance. ( Dakovska, L; Kirilov, G; Koev, D; Tankova, T, 2003) |
| "To investigate the effect of glimepiride and metformin on free fatty acid (FFA) in patients with Type 2 diabetes mellitus and to further study the relationship between free fatty acid and insulin resistance in patients with Type 2 diabetes mellitus." | 3.72 | [Effects of glimepiride and metformin on free fatty acid in patients with Type 2 diabetes mellitus]. ( Feng, Q; Mao, JP; Tang, JZ; Tang, WL; Yang, ZF; Zhou, ZG, 2004) |
| " The aim of the present study was to investigate the effect of metformin on insulin sensitivity, adipose tissue mass and sympathetic nervous system (SNS) activity in fructose fed rats." | 3.71 | Increased intraabdominal adipose tissue mass in fructose fed rats: correction by metformin. ( Baret, G; Dalmaz, Y; Géloën, A; Grassi-Kassisse, D; Peyronnet, J; Wiernsperger, N, 2002) |
| "The aim of the present study was to evaluate the effect of metformin in very obese subjects with acanthosis nigricans." | 3.71 | Therapeutic approach in insulin resistance with acanthosis nigricans. ( Dakovska, L; Kirilov, G; Koev, D; Tankova, T, 2002) |
| "After adding metformin to the insulin regimen of type 2 diabetics after three months a statistically significant drop of body weight and the daily insulin dose occurred." | 3.71 | [Short-term and long-term effect of metformin in type 1 diabetics]. ( Cechurová, D; Jankovec, Z; Kárová, R; Kyselová, P; Lacigová, S; Rusavý, Z, 2001) |
| "The present study represents a new insight into the Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 study population at inclusion." | 3.71 | Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study. ( André, P; Bard, JM; Charles, MA; Eschwege, E; Fruchart, JC; Juhan-Vague, I; Safar, M; Vague, P, 2001) |
| "Long-term metformin treatment reduced various steroid enzymatic activities both in the ovary and the adrenal glands, without apparent changes in basal steroid levels and in insulin sensitivity." | 3.71 | The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. ( Bendlová, B; Cibula, D; Hill, M; Snajderová, M; Stárka, L; Sulcová, J; Vondra, K; Vrbíková, J, 2001) |
| "Both metformin and troglitazone were comparably effective in reducing insulin resistance." | 3.71 | Comparison of the metabolic effects of metformin and troglitazone on fructose-induced insulin resistance in male Sprague-Dawley rats. ( Chang, CT; Chen, CC; Chen, RH; Sheen, LY; Shih, HC; Wang, HJ; Wang, TY, 2001) |
| " Metformin, an oral hypoglycaemic agent that increases insulin sensitivity, has been shown to reduce serum concentrations of insulin and androgens, to reduce hirsutism, and to improve ovulation rates." | 3.71 | Metformin and intervention in polycystic ovary syndrome. Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group. ( Cuneo, RC; Kidson, WJ; Norman, RJ; Zacharin, MR, 2001) |
| "The aim of the present study was to investigate the steroidogenic response pattern to HCG in obese women with polycystic ovary syndrome (PCOS) and the possible effects of metformin treatment on it." | 3.71 | Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tapanainen, JS, 2001) |
| "Long-term therapy with metformin led to the improvement in menstrual cyclicity, without significant change in basal steroid levels or parameters of insulin resistance." | 3.71 | [Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome]. ( Bendlová, B; Cibula, D; Hill, M; Snajderová, M; Stárka, L; Sulcová, J; Vondra, K; Vrbíková, J, 2001) |
| " We hypothesized that correction of insulin resistance with metformin might also restore anabolic effects of GH." | 3.71 | Metformin restores responses to insulin but not to growth hormone in Sprague-Dawley rats. ( Borst, SE; Kim, YW; Ross, H; Scarpace, PJ; Snellen, HG, 2002) |
| "Before metformin therapy, after covariance adjustment for age, the two cohorts did not differ in height, weight, basal metabolic index, insulin, insulin resistance, or insulin secretion." | 3.71 | Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. ( Glueck, CJ; Kobayashi, S; Phillips, H; Sieve-Smith, L; Wang, P, 2002) |
| " In the present study we tested the hypothesis that metformin therapy in obese adolescents with PCOS will attenuate the adrenal steroidogenic response to ACTH, with reduction of insulin resistance/insulinemia." | 3.71 | Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. ( Arslanian, SA; Danadian, K; Lewy, V; Saad, R, 2002) |
| "The objective of the study was to find predictors of a successful therapy with metformin in polycystic ovary syndrome." | 3.71 | Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome. ( Hill, M; Stárka, L; Vondra, K; Vrbíková, J, 2002) |
| "We investigated the role of glucose-6 phosphatase (Glc6Pase), glucokinase (GK), and glucose-6 phosphate (Glc6P) in liver insulin resistance, an early characteristic of type 2 diabetes, and its correction by metformin." | 3.70 | Role of glucose-6 phosphatase, glucokinase, and glucose-6 phosphate in liver insulin resistance and its correction by metformin. ( Minassian, C; Mithieux, G; Tarpin, S, 1998) |
| "This study investigates the effect of the antidiabetic drug metformin on dexamethasone-induced hyperglycaemia and insulin resistance in mice." | 3.70 | Prevention of dexamethasone-induced insulin resistance by metformin. ( Bailey, CJ; Jefferson, WH; Thomas, CR; Turner, SL, 1998) |
| " Metformin therapy resulted in some improvement in insulin sensitivity and reduced the basal and post-glucose load insulin levels." | 3.70 | The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome. ( Bayram, F; Keleştimur, F; Sahin, Y; Unlühizarci, K, 1999) |
| "To determine whether hypoglycemic agents such as sulfonylureas, biguanides and the newly developed insulin sensitizers such as troglitazone, have hypotensive effects in an animal model of non-insulin-dependent diabetes mellitus associated with insulin resistance, male Otsuka Long Evans Tokushima Fatty (OLETF) rats aged 12 weeks were administered following hypoglycemic agents or vehicle by gavage for 26 weeks; glibenclamide (5 mg/kg/day), metformin (100 mg/kg/day) and troglitazone (70 mg/kg/day)." | 3.70 | Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats. ( Awata, T; Chen, S; Katayama, S; Kosegawa, I; Negishi, K, 1999) |
| " Metformin therapy improved menstrual disturbances in 25% of the women with PCOS and also resulted in some improvement in insulin sensitivity and reduced basal and post glucose load insulin levels." | 3.70 | The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. ( Bayram, F; Keleştimur, F; Sahin, Y; Tutuş, A; Unlühizarci, K, 1999) |
| " Metformin, a medication that improves insulin sensitivity and decreases serum insulin levels, restores menstrual cyclicity and ovulatory function and may improve fertility rates in women with PCOS." | 3.70 | Association of metformin and pregnancy in the polycystic ovary syndrome. A report of three cases. ( Neal, GS; Robinson, RD; Seale, FG, 2000) |
| " The aim was to define the insulin-sensitizing effects of S15261, the cleavage products, and troglitazone and metformin in the JCR:LA-cp rat, an animal model of the obesity/insulin resistance syndrome that exhibits an associated vasculopathy and cardiovascular disease." | 3.70 | Beneficial insulin-sensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat. ( Brindley, DN; Davidge, ST; Delrat, P; Jochemsen, R; Kelly, SE; O'Brien, SF; Pégorier, JP; Ravel, D; Russell, JC, 2000) |
| "Metformin treatment prevented the development of fructose-induced insulin resistance, hyperinsulinaemia and hypertension." | 3.70 | Metformin treatment corrects vascular insulin resistance in hypertension. ( Dumont, AS; McNeill, JH; Verma, S; Yao, L, 2000) |
| "The aim of this study was to determine the distribution of plasma total homocysteine (tHcy) concentrations in type 2 diabetic patients and to assess whether high tHcy values were related to chronic complications (particularly macroangiopathy and nephropathy) and/or the degree of insulin resistance." | 3.70 | Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. ( Buysschaert, M; Dramais, AS; Hermans, MP; Wallemacq, PE, 2000) |
| "Using polycystic ovary syndrome (PCOS) as a model of insulin resistance and hyperandrogenism, our specific aim was to assess the effect of Metformin on lipoproteins, sex hormones, gonadotropins, and blood pressure in 26 women with PCOS who were studied at baseline, received Metformin 1." | 3.69 | Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. ( Glueck, CJ; Hamer, T; Mendoza, S; Sosa, F; Velazquez, EM, 1994) |
| "Insulin sensitivity, the mean fasting serum levels of glucose, insulin, total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total T, free T, androstenedione, DHEAS, and LH:FSH ratio, and the areas under the curve for plasma glucose and insulin during OGTT were not changed by either placebo or metformin treatment." | 3.69 | Can metformin reduce insulin resistance in polycystic ovary syndrome? ( Açbay, O; Gündoğdu, S, 1996) |
| "To determine whether improvement of insulin resistance decreases blood pressure as well as obesity, metformin (100 mg/kg/d) or vehicle was administered for 20 weeks to 12-week-old male Otsuka Long-Evans Tokushima Fatty (OLETF) rats (n = 10 each), a newly developed animal model of non-insulin-dependent diabetes mellitus (NIDDM) with mild obesity, hyperinsulinemia, and hypertriglyceridemia." | 3.69 | Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. ( Inukai, K; Ishii, J; Kashiwabara, H; Katayama, S; Kikuchi, C; Kosegawa, I; Negishi, K; Oka, Y, 1996) |
| "To assess the effects of metformin on tissue insulin sensitivity in obese and hyperandrogenic women." | 3.69 | [Effects of metformin on insulin resistance in obese and hyperandrogenic women]. ( Calvillán, M; Castillo, T; López, G; Muñoz, S; Sir, T, 1997) |
| "It is confirmed that berberin could raise insulin sensitivity of high fat diet rats similar to metformin." | 3.69 | [Experimental study on berberin raised insulin sensitivity in insulin resistance rat models]. ( Gao, CR; Huang, QL; Zhang, JQ, 1997) |
| "To examine the cellular mechanism of the antihyperglycemic action of in vivo metformin (M) we used an animal model of severe insulin resistance, the genetically obese (fa/fa) Zucker rat." | 3.68 | In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. ( Benecke, H; Greten, H; Hamann, A; Häring, HU; Klein, HH; Matthaei, S; Reibold, JP, 1993) |
| "The effect of metformin on insulin binding and insulin action in the presence of anti-insulin receptor antibodies was investigated in a case of type B extreme insulin resistance." | 3.68 | Metformin ameliorates extreme insulin resistance in a patient with anti-insulin receptor antibodies: description of insulin receptor and postreceptor effects in vivo and in vitro. ( Di Paolo, S, 1992) |
| "To examine the cellular mechanism of the antihyperglycemic action of metformin we studied the effect of metformin on various functional and molecular parameters involved in the pathogenesis of insulin resistance." | 3.68 | Evidence that metformin ameliorates cellular insulin-resistance by potentiating insulin-induced translocation of glucose transporters to the plasma membrane. ( Greten, H; Matthaei, S, 1991) |
| "We have evaluated the effect of metformin on haemorheology, lipid levels and insulin resistance in insulin-dependent diabetic patients over a 6-week period." | 3.68 | Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). ( De Leeuw, I; Janssen, M; Rillaerts, E, 1991) |
| "In early type 2 diabetes, the strategy of "induction" with short-term intensive insulin therapy followed by "maintenance" with metformin can stabilize pancreatic beta-cell function in some patients but not others." | 3.30 | Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes. ( Emery, A; Gerstein, HC; Harris, SB; Kramer, CK; McInnes, N; Pu, J; Reichert, SM; Retnakaran, R; Zinman, B, 2023) |
| " This study investigates the clinical efficacy of Bushen Huatan Decoction combined with Baduanjin in IR-PCOS, to form a specific TCM-behaviour intervention plan in the treatment of IR-PCOS." | 3.01 | Efficacy of Bushen Huatan Decoction combined with Baduanjin in the treatment of polycystic ovary syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness: study protocol for a randomized controlled trial. ( Cui, L; Qian, H; Tang, M; Wang, J; Wang, L; Wang, R; Wei, M; Xu, W, 2021) |
| "The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that glycemic failure rates were significantly lower in youth randomized to metformin plus rosiglitazone treatment than in youth randomized to metformin alone or metformin plus intensive lifestyle intervention." | 3.01 | Postintervention Effects of Varying Treatment Arms on Glycemic Failure and β-Cell Function in the TODAY Trial. ( , 2021) |
| "Metformin treatment was associated with a significant decrease in HOMA-IR." | 3.01 | Metformin in non-diabetic patients with metabolic syndrome and diastolic dysfunction: the MET-DIME randomized trial. ( Bettencourt, N; Braga, P; Fontes-Carvalho, R; Gama, V; Ladeiras-Lopes, R; Leite, S; Leite-Moreira, A; Sampaio, F; Santos-Ferreira, D; Vilela, E, 2021) |
| "Patients with schizophrenia have exceedingly high rates of metabolic comorbidity including type 2 diabetes and lose 15-20 years of life due to cardiovascular diseases, with early accrual of cardiometabolic disease." | 3.01 | Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial. ( Agarwal, SM; Caravaggio, F; Chintoh, AF; Costa-Dookhan, KA; Graff-Guerrero, A; Hahn, MK; Hashim, E; Kirpalani, A; Kramer, CK; Leung, G; MacKenzie, NE; Matheson, K; Panda, R; Remington, GJ; Treen, QC; Voineskos, AN, 2021) |
| " Data are limited regarding the pharmacodynamic effects of metformin and glyburide during pregnancy." | 2.94 | Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus. ( Ahmed, MS; Brown, LM; Brown, Z; Caritis, S; Clark, S; Easterling, TR; Flood Nichols, SK; Haas, DM; Haneline, LS; Hebert, MF; Ma, X; Manuck, TA; Quinney, SK; Ren, Z; Shen, DD; Shireman, LM; Shuster, DL; Thummel, KE; Tita, AT; Venkataramanan, R, 2020) |
| " Co-supplementation of high dosage VD with spironolactone or pioglitazone are more effective in reducing plasma leptin levels than metformin, and thus might prove to be better therapeutic strategies for women with PCOS." | 2.94 | Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study. ( Bhat, GA; Ganie, MA; Rashid, A; Shah, ZA; Shaheen, F; Shrivastava, M; Wani, IA, 2020) |
| "In treatment options for type 2 diabetes in adolescents and youth (TODAY), 4." | 2.94 | Beta cell function and insulin sensitivity in obese youth with maturity onset diabetes of youth mutations vs type 2 diabetes in TODAY: Longitudinal observations and glycemic failure. ( Arslanian, S; Chan, CL; Chernausek, SD; El Ghormli, L; Gandica, RG; Gubitosi-Klug, R; Haymond, MH; Levitsky, LL; Siska, M; Willi, SM, 2020) |
| "Men and women with type 2 diabetes treated with lifestyle modification ± metformin were included." | 2.94 | Diet-induced weight loss alters hepatic glucocorticoid metabolism in type 2 diabetes mellitus. ( Andrew, R; Olsson, T; Otten, J; Ryberg, M; Stomby, A; Walker, BR, 2020) |
| "Treatment with metformin is associated with a time-dependent decrease in mtDNA-CN in patients with PCOS who are treated over the course of one year." | 2.94 | Changes in peripheral mitochondrial DNA copy number in metformin-treated women with polycystic ovary syndrome: a longitudinal study. ( Chang, CH; Chen, MJ; Chen, SU; Chou, CH; Ho, HN; Yang, PK, 2020) |
| "In the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study, metformin plus rosiglitazone (M + R) maintained glycemic control better than metformin alone (M) or metformin plus lifestyle (M + L) in youth with type 2 diabetes (T2D)." | 2.90 | Changes in Visceral and Subcutaneous Fat in Youth With Type 2 Diabetes in the TODAY Study. ( Copeland, KC; Dhaliwal, R; El Ghormli, L; Geffner, ME; Higgins, J; Levitsky, LL; Nadeau, KJ; Shepherd, JA; Weinstock, RS; White, NH, 2019) |
| "To characterize girls with irregular menses and effects of glycemic treatments on menses and sex steroids in the Treatment Options for Type 2 Diabetes in Youth (TODAY) study." | 2.87 | Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. ( Arslanian, SA; Braffett, BH; Caprio, S; Geffner, ME; Kelsey, MM; Levitsky, LL; McKay, SV; Shah, R; Sprague, JE, 2018) |
| "One hundred two type 2 diabetes participants (M/F = 48/54) were investigated." | 2.87 | Saxagliptin Upregulates Nesfatin-1 Secretion and Ameliorates Insulin Resistance and Metabolic Profiles in Type 2 Diabetes Mellitus. ( Chen, K; Mei, Q; Wang, J; Zhuo, T, 2018) |
| "Improving insulin sensitivity is one of many proven favourable effects of metformin." | 2.84 | Protocol for a pilot randomised controlled trial of metformin in pre-diabetes after kidney transplantation: the Transplantation and Diabetes (Transdiab) study. ( Alnasrallah, B; Manley, P; Pilmore, H, 2017) |
| " We examine potential mechanisms for these effects based on pharmacologically dosed studies and propose that metformin may improve human microvascular insulin resistance by attenuating oxidative stress, inflammation, and endothelial dysfunction." | 2.82 | Metformin's Impact on the Microvascular Response to Insulin. ( Barrett, EJ; Horton, WB; Love, KM, 2022) |
| "Metformin as a first-line drug for type 2 diabetes mellitus(T2DM) treatment is widely studied." | 2.82 | Mechanism of metformin regulation in central nervous system: Progression and future perspectives. ( Cao, G; Du, Y; Ge, T; Gong, T; Liu, J; Wang, Y, 2022) |
| "Whether metformin is related to nonalcoholic fatty liver disease (NAFLD) is controversial." | 2.82 | Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology. ( Huang, Y; Li, C; Liang, E; Liu, T; Mao, J; Wang, X; Yan, C; Zhang, L, 2022) |
| "Acne is a common and complex skin disease, with a very complex pathogenesis." | 2.82 | Low glycaemic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments. ( Colao, A; Del Prete, M; Donnarumma, M; Fabbrocini, G; Faggiano, A; Izzo, R; Marasca, C; Marciello, F; Monfrecola, G; Savastano, R, 2016) |
| "A total of 657 type 2 diabetes patients who were randomly assigned to 48 weeks of therapy with either acarbose or metformin in the MARCH trial were divided into two groups based upon their hemoglobin A1c (HbA1c) levels at the end of follow-up: HbA1c <7% (<53 mmol/mol) and ≥7% (≥53 mmol/mol)." | 2.82 | Factors that influence the efficacy of acarbose and metformin as initial therapy in Chinese patients with newly diagnosed type 2 diabetes: a subanalysis of the MARCH trial. ( Wang, N; Wang, X; Xing, X; Yang, W; Yang, Z; Zhang, J, 2016) |
| "Metformin treatment (median 20 days, range 7-34) was associated with a 17." | 2.82 | Measuring the biological effect of presurgical metformin treatment in endometrial cancer. ( Ali, S; Crosbie, EJ; Gilmour, K; Kitchener, HC; Kitson, S; McVey, R; Pemberton, P; Renehan, AG; Roberts, C; Sivalingam, VN, 2016) |
| " This study aimed to compare the different effects of drospirenone (DRP)-containing COCs with cyproterone acetate (CPA)-containing COCs, combined with metformin and lifestyle modifications in women with PCOS and metabolic disorders." | 2.82 | Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial. ( Feng, GM; Huang, W; Song, Y; Wang, QS; Wang, QY; Xiao, L, 2016) |
| "Eligibility criteria for subjects includes: type 2 diabetes mellitus with more than 10 years duration; having been treated with secretagogues, metformin and insulin in combination with LIRA for at least 6 months; poor glycemic control [glycosylated hemoglobin A1c(HbA1c) 7%-10%]." | 2.82 | [The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus]. ( Chen, C; Chen, P; Guo, W; Huang, LH; Huang, Q; Li, CM; Shao, ZL; Xu, XJ; Yang, XZ, 2016) |
| "Secondary outcomes include changes in liver fibrosis using AST to platelet ratio index, changes in glucose and lipid levels, anthropometric measures, changes in alpha-fetoprotein levels, patient acceptability, and changes in dietary and physical activity parameters." | 2.82 | Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. ( Cooper, C; Doyle, MA; Lee, T; Muir, M; Singer, J, 2016) |
| "Metformin plays an important role in diabetes treatment." | 2.80 | The Efficacy and Safety of Chinese Herbal Medicine Jinlida as Add-On Medication in Type 2 Diabetes Patients Ineffectively Managed by Metformin Monotherapy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial. ( Chen, X; Guo, J; Li, Z; Lian, F; Ma, L; Piao, C; Tian, J; Tong, X; Wang, CZ; Xia, C; Yuan, CS; Zhao, L, 2015) |
| "Metformin treatment is not associated with reductions in hepcidin but hypocaloric diet could be involved." | 2.80 | Circulating hepcidin in type 2 diabetes: A multivariate analysis and double blind evaluation of metformin effects. ( Aguilar-de Plata, C; Arbeláez, A; Esteve, E; Fernández-Real, JM; Moreno, M; Moreno-Navarrete, JM; Mosquera, M; Ricart, W; Suárez-Ortegón, MF; Xifra, G, 2015) |
| "Treatment with metformin is safe in nondiabetic patients, and it yields objective PSA responses and may induce disease stabilization." | 2.79 | Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). ( Bärtschi, D; Cathomas, R; Endt, K; Gillessen, S; Hayoz, S; Lui, L; Pollak, M; Rothermundt, C; Rüschoff, JH; Schiess, R; Strebel, RT; Templeton, AJ; Winterhalder, R, 2014) |
| "Type 2 diabetes mellitus is increasingly diagnosed in obese children and adolescents." | 2.79 | Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study. ( Narasimhan, S; Weinstock, RS, 2014) |
| "Both repaglinide and metformin were effective in glycaemic control in new onset patients with type 2 diabetes in China." | 2.79 | Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China. ( Liao, Y; Liu, LY; Liu, W; Ma, J; Tao, T; Wu, PH, 2014) |
| "The METFORMIN study is a multi-centre prospective study that consists of two 18-month phases: a double-blind randomized placebo-controlled trial (part 1) and an open-label follow-up study (part 2)." | 2.79 | METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents - study protocol of a randomized controlled study. ( Elst, MA; Knibbe, CA; van der Aa, MP; van der Vorst, MM; van Mil, EG, 2014) |
| "When treated with metformin and an exercise program, a structured, reduced energy diet, which is either high-carbohydrate or moderate-carbohydrate with increased-protein, can achieve clinically significant improvements in obese adolescents at risk of type 2 diabetes." | 2.79 | Improved insulin sensitivity and body composition, irrespective of macronutrient intake, after a 12 month intervention in adolescents with pre-diabetes; RESIST a randomised control trial. ( Ambler, GR; Baur, LA; Briody, J; Broderick, CR; Chisholm, K; Cowell, CT; De, S; Garnett, SP; Gow, M; Ho, M; Noakes, M; Srinivasan, S; Steinbeck, K; Woodhead, HJ, 2014) |
| "Pioglitazone-treated patients showed a significant increase in HDL-C compared to placebo group (6." | 2.78 | Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients. ( Bravi, F; Brunetti, P; Chinea, B; Comaschi, M; Cucinotta, D; Di Pietro, C; Egan, CG; Genovese, S; Passaro, A, 2013) |
| "116 patients with type 2 diabetes mellitus were randomly divided into control group and observation group from Aug." | 2.78 | [Clinical efficacy of special effect san xiao decoction on type 2 diabetes mellitus]. ( Chang, HJ; Li, ZQ; Sang, WF, 2013) |
| "Chronic low-grade inflammation is a common feature of insulin resistant states, including obesity and type 2 diabetes." | 2.78 | Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. ( Aroda, V; Ciaraldi, TP; Henry, RR; Mudaliar, SR, 2013) |
| "In newly diagnosed type 2 diabetes, therapy with oral drugs + insulin has had favourable outcomes on recovery and maintenance of β-cell function and protracted glycaemic remission compared with treatment with oral drugs alone." | 2.77 | Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes. ( Chen, YM; Lu, HY; Mu, PW; Shu, J; Wang, MM; Wen, XQ; Xie, RY; Zeng, LY; Zhang, YH, 2012) |
| "Berberine (BBR) is an isoquinoline derivative alkaloid extracted from Chinese medicinal herbs that has been used as an insulin sensitizer." | 2.77 | A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. ( Deng, H; Guan, Y; Liang, K; Ma, Y; Sui, M; Wang, A; Wei, W; Zhang, H; Zhang, Y; Zhao, H, 2012) |
| "Metformin treatment was associated with significant decrease in AI during one year treatment in NAFLD patients." | 2.77 | Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? ( Boaz, M; Gavish, D; Matas, Z; Omelchenko, E; Shargorodsky, M, 2012) |
| "Metformin treatment reduced plasma levels/activity of the assessed haemostatic risk factors, and this effect correlated with the improvement in insulin sensitivity." | 2.77 | Haemostatic effects of metformin in simvastatin-treated volunteers with impaired fasting glucose. ( Krysiak, R; Okopien, B, 2012) |
| "Pioglitazone treatment significantly increased body mass index (P<0." | 2.76 | Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. ( Ahn, CW; Cha, BS; Cho, MH; Kim, KR; Lee, HC; Nam, JS; Park, JS; Yoo, JS, 2011) |
| "Dyslipidemia in patients with type 2 diabetes is characterized by elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol, and a predominance of small dense low-density lipoprotein (LDL) particles." | 2.76 | PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. ( Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D, 2011) |
| "Metformin (M) group has the same results of PO group except in high density lipoprotein cholesterol (HDL(C)), LDL(C), and ALP levels had a different pattern." | 2.76 | Effects of Portulaca oleracea L. seeds in treatment of type-2 diabetes mellitus patients as adjunctive and alternative therapy. ( El-Sayed, MI, 2011) |
| "A total of 2368 patients with type 2 diabetes mellitus and clinically stable, angiographically documented coronary artery disease were randomized to treatment with 1 of the 2 strategies and followed for an average of 5 years." | 2.76 | Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. ( Brooks, MM; Frye, RL; Genuth, S; Hardison, RM; Huber, K; Krishnaswami, A; McBane, RD; Pratley, RE; Schneider, DJ; Sobel, BE; Wolk, R, 2011) |
| "Obesity is epidemic among adolescents in the United States." | 2.75 | Intraperitoneal fat and insulin resistance in obese adolescents. ( , 2010) |
| "Both pioglitazone and metformin treatment were associated with significant reductions in hyperglycemia, HOMA-IR and HbA1c levels." | 2.75 | Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes. ( Adachi, T; Fujinami, A; Fukui, M; Hara, H; Hasegawa, G; Ishihara, K; Kitagawa, Y; Nakamura, N; Nakano, K; Obayashi, H; Ogata, M; Ohta, M; Takashima, T; Yamasaki, M, 2010) |
| "They confirm that treatment of insulin resistance decreases T production in this population and demonstrate that pharmacologic lowering of T does not affect insulin resistance." | 2.75 | Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial. ( Basu, A; Cappola, AR; Fuller, C; Iqbal, N; Kaul, S; Patel, SM; Ratcliffe, SJ; Reilly, MP; Rickels, MR; Scattergood, T, 2010) |
| "Insulin resistance is a major feature of type 2 diabetes mellitus, obesity and nonalcoholic fatty liver disease (NAFLD)." | 2.74 | The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. ( Gedik, O; Nar, A, 2009) |
| "Twenty-eight patients with type 2 diabetes already on metformin, without known cardiovascular disease, were randomized in 2 groups; glimepiride (4 mg od) was added in group A (n=14) and pioglitazone (30 mg od) in group B (n=14) for 6 months." | 2.74 | Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes. ( Kanioglou, C; Katsouras, CS; Kazakos, N; Kolettis, T; Liveris, K; Makriyiannis, D; Michalis, LK; Naka, KK; Papathanassiou, K; Pappas, K; Tsatsoulis, A, 2009) |
| "Five hundred and seventy-six consecutive Caucasian obese type 2 diabetic patients were evaluated during a 12-months period and fifty-two patients were resulted intolerant to metformin at maximum dosage (3,000 mg/day)." | 2.74 | Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Piccinni, MN; Salvadeo, SA, 2009) |
| "Two hundred seventy-one type 2 diabetes mellitus patients with poor glycemic control and who were overweight were enrolled in this study." | 2.74 | Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA, 2009) |
| "Metformin treatment increases serum TSP-1 in these women." | 2.74 | Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. ( Adya, R; Chen, J; Farhatullah, S; Heutling, D; Lehnert, H; Mitchell, D; Randeva, HS; Tan, BK, 2009) |
| "Metformin treatment decreases serum chemerin in these women." | 2.74 | Insulin and metformin regulate circulating and adipose tissue chemerin. ( Adya, R; Chen, J; Farhatullah, S; Heutling, D; Kaur, J; Lehnert, H; Lewandowski, KC; O'Hare, JP; Randeva, HS; Tan, BK, 2009) |
| "placebo in patients with type 2 diabetes uncontrolled by metformin and a sulphonylurea or a glinide." | 2.74 | Earlier triple therapy with pioglitazone in patients with type 2 diabetes. ( Charpentier, G; Halimi, S, 2009) |
| "Twenty-seven patients with type 2 diabetes mellitus were divided into pioglitazone-treated (Pio), metformin-treated (Met), and exercise-treated (Ex) groups." | 2.73 | Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. ( Araki, T; Emoto, M; Inaba, M; Koyama, H; Lee, E; Mori, K; Nishizawa, Y; Shoji, T; Teramura, M; Yokoyama, H, 2008) |
| "Fourteen patients with type 2 diabetes (age 51+/-2 yr, body mass index 33." | 2.73 | Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. ( Hakkarainen, A; Häkkinen, AM; Juurinen, L; Tiikkainen, M; Yki-Järvinen, H, 2007) |
| "One hundred twenty (120) patients with type 2 diabetes mellitus were randomized and treated with glimepiride plus rosiglitazone or glimepiride plus metformin for 12 weeks." | 2.73 | Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. ( Ahn, CW; Cha, BS; Chung, CH; Kang, ES; Kim, DJ; Kim, HJ; Kim, SH; Lee, HC; Lee, KW; Nam, CM; Nam, M, 2007) |
| "The data demonstrate that in type 2 diabetes metformin rapidly affects glucose handling without changing the concentrations of insulin." | 2.73 | Short-term effects of metformin in type 2 diabetes. ( Attvall, S; Bonnier, M; Eriksson, A; Eriksson, JW; Karlsson, FA; Rosander, B, 2007) |
| "Strategies for the addition of RSG in combination with GLIM were evaluated with data from two randomized, double-blind, placebo (PBO)-controlled studies." | 2.73 | Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes. ( Chou, HS; Hamann, A; Matthaei, S; Rosenstock, J; Seidel, DK, 2008) |
| " GH dosage was increased from 0." | 2.72 | Insulin resistant diabetes mellitus in SHORT syndrome: case report and literature review. ( Fujisawa, Y; Fukami, M; Inoue, T; Kagami, M; Masunaga, Y; Muramatsu, M; Ogata, T; Ono, H; Saitsu, H, 2021) |
| "Metformin is a widely used glucose-lowering drug, although its impact on adipose tissue function remains elusive." | 2.72 | Adipokines as a therapeutic target by metformin to improve metabolic function: A systematic review of randomized controlled trials. ( Cirilli, I; Dludla, PV; Louw, J; Marcheggiani, F; Mazibuko-Mbeje, SE; Mokgalaboni, K; Mxinwa, V; Nkambule, BB; Nyambuya, TM; Tiano, L; Ziqubu, K, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) is one of the most common reasons for the increase in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels." | 2.72 | The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis. ( Hu, H; Li, X; Meng, J; Shen, L; Shi, D; Wang, J, 2021) |
| "Metformin treatment had no significant impact on GSK-3 protein expression in either adipocytes or skeletal muscle." | 2.72 | Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. ( Baxi, S; Christiansen, L; Ciaraldi, TP; Henry, RR; Kong, AP; Mudaliar, S; Nikoulina, SE; Oh, DK, 2006) |
| "Obesity is often accompanied by insulin resistance and/or hyperinsulinemia." | 2.72 | Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study. ( Bellot-Rojas, P; Caracas-Portilla, N; Cardoso-Saldaña, G; Jurado-Santacruz, F; Posadas-Romero, C; Posadas-Sanchez, R; Zamora-Gonzalez, J, 2006) |
| "Metabolic syndrome was more frequent and microalbuminuria less frequent in NAC." | 2.72 | A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. ( Freed, MI; Haffner, S; Heise, MA; Herman, WH; Holman, R; Jones, NP; Kahn, SE; Kravitz, B; Lachin, J; O'Neill, MC; Viberti, G; Zinman, B, 2006) |
| "Type 2 diabetes mellitus is characterized by both insulin deficiency and insulin resistance." | 2.71 | Beneficial effects of a glyburide/metformin combination preparation in type 2 diabetes mellitus. ( Bokhari, SU; Duckworth, WC; Gopal, UM, 2003) |
| "Flutamide-metformin treatment (n = 30) was followed within 3 months by marked decreases in hirsutism score and serum androgens, by a more than 50% increase in insulin sensitivity and by a less atherogenic lipid profile (all P < 0." | 2.71 | Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2003) |
| " In conclusion, combination treatment with metformin and sulfonylurea is more effective than these drugs alone in improving glycemic control in type 2 diabetes, while also allowing a reduction of the dosage of each drug." | 2.71 | Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. ( Brun, E; Coppini, A; Gori, M; Moghetti, P; Muggeo, M; Perobelli, L; Spiazzi, G; Tosi, F; Zanolin, E, 2003) |
| "Hirsutism is a common and distressing symptom frequently encountered in women with polycystic ovary syndrome (PCOS), who also show relative insulin resistance." | 2.71 | Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. ( Fleming, R; Harborne, L; Lyall, H; Norman, J; Sattar, N, 2003) |
| "A total of 34 subjects with type 2 diabetes (17 men and 17 women, aged 54+/-2 years and body mass index (BMI) 26." | 2.71 | Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. ( Ishibashi, S; Ishikawa, SE; Kusaka, I; Nagasaka, S; Nakamura, T; Yatagai, T; Yoshitaka, A, 2004) |
| "In metformin-treated girls, all these abnormalities significantly reversed within 6 months, and body composition continued to improve between 6 and 12 months." | 2.71 | Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2004) |
| "Metformin treatment was associated with only a transient improvement in liver chemistries." | 2.71 | Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. ( Diehl, AM; Farr, GH; Nair, S; Perrillo, RP; Wiseman, M, 2004) |
| "Glyburide treatment of diabetes decreased CRP and did so even though body weight increased." | 2.71 | Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. ( Bar, RS; Goldner, WS; Haynes, WG; Putz, DM; Sivitz, WI, 2004) |
| "In conclusion, metformin treatment improved insulin sensitivity and decreased androgen levels, and flutamide decreased androgen levels but failed to improve insulin sensitivity in the non-obese women with PCOS." | 2.71 | Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. ( Aral, Y; Culha, C; Demirbas, B; Karakurt, F; Kosar, F; Sahin, I; Serter, R; Taskapan, C, 2004) |
| "Patients with type 2 diabetes mellitus who showed poor glycemic control with glimepiride (4 mg/d) were randomized to rosiglitazone (4 mg/d) and metformin (500 mg bid) treatment groups." | 2.71 | The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. ( Cho, YM; Jung, HS; Kim, SY; Lee, HK; Park, HJ; Park, KS; Shin, CS; Youn, BS; Yu, KY, 2005) |
| "Troglitazone therapy was compared with other DPP interventions, considering both the short-term "in-trial" results and the longer-term results after troglitazone were discontinued." | 2.71 | Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. ( Barrett-Connor, E; Edelstein, SL; Ehrmann, DA; Fowler, SE; Hamman, RF; Kahn, SE; Knowler, WC; Nathan, DM; Walker, EA, 2005) |
| "Treatment with metformin had no significant effect on total, HDL and LDL cholesterol." | 2.71 | Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART. ( Janez, A; Karner, P; Maticic, M; Sharma, PM; Tomazic, J; Vidmar, L, 2005) |
| "Metformin was well tolerated and no one discontinued treatment due to side effects." | 2.70 | Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. ( Grinspoon, S; Hadigan, C; Rabe, J, 2002) |
| "We hypothesized that dyslipidemia and anovulation in nonobese women with polycystic ovary syndrome are essentially secondary to the concerted effects of hyperandrogenism and insulin resistance." | 2.70 | Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. ( De Zegher, F; Dunger, DB; Ferrer, A; Ibáñez, L; Ong, K; Valls, C, 2002) |
| "Metformin was well tolerated except for one case of flatulence." | 2.69 | Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. ( Bergiele, A; Diamanti-Kandarakis, E; Kouli, C; Tsianateli, T, 1998) |
| "Insulin resistance is becoming an increasingly studied target for therapy, most evidence stemming from the time-honored metformin use." | 2.66 | Current treatment for polycystic ovary syndrome: focus on adolescence. ( Catellani, C; Cirillo, F; Dauriz, M; Lazzeroni, P; Moghetti, P; Sartori, C; Street, ME, 2020) |
| "Polycystic Ovary Syndrome is a very complex syndrome, with typical hormonal and metabolic features." | 2.66 | Polycystic ovary syndrome (PCOS) and adolescence: How can we manage it? ( Capozzi, A; Lello, S; Scambia, G, 2020) |
| "Metformin is a widely used drug that results in clear benefits in relation to glucose metabolism and diabetes-related complications." | 2.66 | The clinical application of metformin in children and adolescents: A short update. ( Alaaraj, N; De Sanctis, V; Hamed, N; Soliman, A, 2020) |
| "Mycophenolic acid was detected in all cats." | 2.61 | ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019) |
| "Insulin resistance is a key feature of Type 2 diabetes and an important therapeutic target to address glycemic control to prevent diabetic complications." | 2.61 | Molecular mechanisms by which aerobic exercise induces insulin sensitivity. ( Atkin, SL; Sahebkar, A; Simental-Mendía, LE; Yaribeygi, H, 2019) |
| "Similar insulin resistance is found in type 2 diabetes and is currently treated with insulin sensitizers (IS)." | 2.61 | A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice. ( Craig, A; Issberner, J; Parvez, F, 2019) |
| "Depression is a common comorbidity in diabetes but conventional antidepressant treatments do not consistently improve outcomes." | 2.58 | Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials. ( Hopkins, CWP; Ismail, K; Moulton, CD; Stahl, D, 2018) |
| "Recently, fatty liver index and NAFLD fatty liver score analyzed in large cohorts of PCOS women have been shown as accurate markers of liver damage in this metabolically vulnerable population." | 2.55 | MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease. ( Bjekić-Macut, J; Božić-Antić, I; Macut, D; Tziomalos, K, 2017) |
| "Metformin is an effective alternative to insulin in glycemic control in pregnant women." | 2.55 | Gestational diabetes - is diet and insulin the only solution? ( Bieniek, E; Brzozowska, M; Lewinski, A; Szosland, K, 2017) |
| "Metformin remains the cure for the treatment of insulin resistance." | 2.55 | [The Role of Reactive Oxygen Species in the Pathogenesis of Adipocyte Dysfunction in Metabolic Syndrome. Prospects of Pharmacological Correction]. ( Bespalova, ID; Ivanov, VV; Maslov, LN; Pismennyi, DS; Prokudina, ES; Voronkov, NS, 2017) |
| "Metformin has been gradually used in the management of gestational diabetes mellitus (GDM)." | 2.55 | Metformin - a potentially effective drug for gestational diabetes mellitus: a systematic review and meta-analysis. ( Feng, Y; Yang, H, 2017) |
| "Type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD) are highly prevalent in the community, and share common pathogenic mechanisms." | 2.55 | Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? ( Caletti, MT; Forlani, G; Marchesini, G; Marchignoli, F; Mazzotti, A, 2017) |
| "Diabetes mellitus is associated with an elevation in gynecologic cancer risk." | 2.53 | Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives. ( Alexandrou, A; Botsis, D; Creatsas, G; Grigoriadis, C; Iavazzo, C; Iliodromiti, Z; Sifakis, S; Siristatidis, C; Vrachnis, N, 2016) |
| "Metformin is a cornerstone in the treatment of diabetes mellitus type 2." | 2.53 | Metformin and pancreatic cancer: Is there a role? ( De Souza, A; Khawaja, KI; Masud, F; Saif, MW, 2016) |
| "Clinical trials in pre-surgical endometrial cancer patients exhibited a significant decrease in Ki67 with metformin monotherapy." | 2.53 | Repurposing metformin for cancer treatment: current clinical studies. ( Altman, JK; Arya, A; Carneiro, B; Chae, YK; Chandra, S; Giles, F; Kalyan, A; Kaplan, J; Malecek, MK; Platanias, L; Shin, DS, 2016) |
| "Hirsutism affects 5-25% women, and the condition is most often caused by polycystic ovary syndrome (PCOS)." | 2.53 | Endocrine and metabolic characteristics in polycystic ovary syndrome. ( Glintborg, D, 2016) |
| "The link between NAFLD/NASH and PCOS is not just a coincidence." | 2.53 | Hepatic manifestations of women with polycystic ovary syndrome. ( Chen, MJ; Ho, HN, 2016) |
| "Iatrogenic and compensatory hyperinsulinemia are metabolic disruptors of β-cells, liver, muscle, kidney, brain, heart and vasculature, inflammation, and lipid homeostasis, among other systems." | 2.53 | Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile. ( Herman, ME; Jellinger, PS; Schwartz, SS, 2016) |
| "A diagnosis of Gestational Diabetes (GDM) confers adverse risk to the health of the mother and fetus both in pregnancy and later life." | 2.53 | Prediction and prevention of Gestational Diabetes: an update of recent literature. ( Kennelly, MA; McAuliffe, FM, 2016) |
| "Insulin resistance is considered to play an important role in the associations between DM and dementia." | 2.53 | Impact of Insulin Sensitizers on the Incidence of Dementia: A Meta-Analysis. ( Luo, YJ; Xiao, J; Ye, F; Yi, G; Yu, NW, 2016) |
| "The overall incidence of gestational diabetes mellitus (GDM) is increasing worldwide." | 2.53 | Gestational diabetes mellitus: does an effective prevention strategy exist? ( Agha-Jaffar, R; Johnston, D; Oliver, N; Robinson, S, 2016) |
| "Maturity onset diabetes of the young (MODY), the most common monogenic form of diabetes, accounts for 1-2% of all diabetes diagnoses." | 2.53 | A review of maturity onset diabetes of the young (MODY) and challenges in the management of glucokinase-MODY. ( Bishay, RH; Greenfield, JR, 2016) |
| "Obesity is now a major international health concern." | 2.52 | Obesity and polycystic ovary syndrome. ( Boyle, J; De Courten, B; Joham, A; Naderpoor, N; Shorakae, S; Teede, HJ, 2015) |
| "Metformin is a widely used drug in the treatment of type 2 diabetes mellitus (T2DM)." | 2.52 | Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease. ( Bettencourt, N; Fontes-Carvalho, R; Gama, V; Ladeiras-Lopes, R; Leite-Moreira, A; Sampaio, F, 2015) |
| "Insulin resistance is prevalent in women with polycystic ovary syndrome (PCOS), and plays a critical pathophysiologic role in both the metabolic and reproductive complications of PCOS." | 2.52 | Polycystic ovary syndrome and insulin: our understanding in the past, present and future. ( Evans, WS; Mayer, SB; Nestler, JE, 2015) |
| "Diabetes and obesity are associated with nonalcoholic fatty liver disease (NAFLD) and an increased incidence of hepatocellular carcinoma (HCC)." | 2.52 | Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. ( Noureddin, M; Rinella, ME, 2015) |
| "Metabolic syndrome is a cluster of conditions that synergistically increase the risk of cardiovascular disease, type 2 diabetes, and premature mortality." | 2.52 | Metabolic Syndrome: Insulin Resistance and Prediabetes. ( Mayans, L, 2015) |
| "The different types of cancer, heterogeneity of populations and presence of comorbidity make it difficult to determine the benefits of metformin in cancer prevention and treatment." | 2.52 | Metformin: risk-benefit profile with a focus on cancer. ( Cazzaniga, M; DeCensi, A; Dunn, BK; Gorlero, F; Lazzeroni, M; Provinciali, N, 2015) |
| "Polycystic ovary syndrome is recognized as the most common hormonal and metabolic disorder likely to affect women." | 2.52 | [Evidence-based therapy of polycystic ovarian syndrome]. ( Csenteri, OK; Gődény, S, 2015) |
| "The key histologic feature of nonalcoholic steatohepatitis (NASH) is hepatocellular ballooning (HB)." | 2.50 | Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). ( Doycheva, I; Loomba, R, 2014) |
| "Metformin was effective in reducing enzyme levels in the short period, but very limited and controversial information are available on liver histology." | 2.50 | Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. ( Abenavoli, L; Milic, N; Rouabhia, S, 2014) |
| " Currently, there is no evidence that cardiovascular morbidity is decreased by long-term use of insulin sensitizers in PCOS women." | 2.50 | Metformin and other insulin sensitizers in polycystic ovary syndrome. ( Bhagavath, B; Hoeger, K; Queenan, J; Vitek, W, 2014) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world comprising a spectrum of liver damage from fatty liver infiltration to end-stage liver disease, in patients without significant alcohol consumption." | 2.50 | Nonalcoholic fatty liver disease and polycystic ovary syndrome. ( Vassilatou, E, 2014) |
| "Metformin is a first-line drug in the treatment of overweight and obese type 2 diabetic patients, offering a selective pathophysiological approach by its effect on insulin resistance." | 2.50 | The therapy of insulin resistance in other diseases besides type 2 diabetes. ( Barbaro, V; Dicembrini, I; Pala, L; Rotella, CM, 2014) |
| "Metformin is an oral insulin-sensitizing anti-diabetic drug." | 2.50 | [Metformin in pregnancy]. ( Bijok, J; Bińkowska, M; Jakiel, G, 2014) |
| "The incidence of type 2 diabetes mellitus (T2DM) has risen to epidemic proportions, and this is associated with enormous cost." | 2.50 | What are the pharmacotherapy options for treating prediabetes? ( Abdul-Ghani, M; Daniele, G; DeFronzo, RA, 2014) |
| "Metabolic alterations, such as hyperinsulinemia, increased levels of insulin growth factor-1, and insulin resistance could be on the basis of development and progression of many tumors, including prostate cancer, and changes in body composition, in turn, can represent some side effects of androgen deprivation therapy and novel drugs, such as mammalian target of rapamycin inhibitors." | 2.49 | Metabolic syndrome as a peculiar target for management of prostate cancer patients. ( Aieta, M; Ardito, R; Bozza, G; Conteduca, V; Di Lorenzo, G, 2013) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide." | 2.49 | Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. ( Belfiore, A; Fruci, B; Giuliano, S; Malaguarnera, R; Mazza, A, 2013) |
| "The metabolic syndrome affects 30% of the US population with increasing prevalence." | 2.48 | The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration. ( Hutcheson, R; Rocic, P, 2012) |
| "Obesity is also a feature of this syndrome and contributes to associated metabolic abnormalities." | 2.48 | Polycystic ovarian syndrome management options. ( Bates, GW; Propst, AM, 2012) |
| "Obesity is known to be the most common cause of simple steatosis in the preadolescent and adolescent population with a consequent serious health risk." | 2.47 | [Fatty liver and its clinical management in obese adolescents]. ( Álvarez Ferre, J; González Jiménez, E; Schmidt Río-Valle, J, 2011) |
| "In obese patients, especially with type 2 diabetes mellitus (DM2), only the PI 3-K, but not the MAP-K, is resistant to insulin stimulation: hence insulin resistance is better defined as metabolic insulin resistance." | 2.47 | Insulin resistance: pathophysiology and rationale for treatment. ( Muntoni, S, 2011) |
| "In the pathophysiology of type 2 diabetes there are several biological processes, which may explain the higher cancer risk in type 2 diabetes." | 2.47 | [Diabetes and cancer risk: oncologic considerations]. ( Rosta, A, 2011) |
| "Hepatic insulin resistance is characteristic of T3cDM and is caused by deficiencies of both insulin and pancreatic polypeptide." | 2.47 | Pancreatogenic diabetes: special considerations for management. ( Andersen, DK; Cui, Y, 2011) |
| "Insulin resistance is linked to polycystic ovary syndrome." | 2.47 | Current perspectives of insulin resistance and polycystic ovary syndrome. ( Legro, RS; Pauli, JM; Raja-Khan, N; Wu, X, 2011) |
| "Obesity and insulin resistance have been associated with breast cancer risk, and breast cancer outcomes." | 2.47 | Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin. ( Goodwin, PJ; Stambolic, V, 2011) |
| "Non-alcoholic fatty liver disease (NAFLD) is closely linked with obesity and the prevalence of NAFLD is about 17% to 33% in the Western world." | 2.47 | Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. ( Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N, 2011) |
| "Metformin's molecular targets in cancer cells (e." | 2.47 | Metformin: multi-faceted protection against cancer. ( Bosch-Barrera, J; Cufí, S; Del Barco, S; Joven, J; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A, 2011) |
| "Metformin has recently gained much attention as it appears to reduce cancer incidence and improve prognosis of patients with diabetes." | 2.47 | Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. ( Gallagher, EJ; LeRoith, D, 2011) |
| "Weight loss is the best treatment option, which can be a challenging task for patients to achieve and maintain." | 2.46 | Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management. ( Brown, A; Desai, M; Taneja, D; Tannock, LR, 2010) |
| "Patients with type 2 diabetes are reported to have a worse response to cancer chemotherapy, have more complications, and have a poorer prognosis than patients with cancer without diabetes." | 2.46 | Insulin, insulin resistance, obesity, and cancer. ( Gallagher, EJ; LeRoith, D, 2010) |
| "Insulin resistance is a new target in the challenging management of chronic hepatitis C." | 2.46 | Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management. ( del Campo, JA; López, RA; Romero-Gómez, M, 2010) |
| "Metformin was the only insulin-sensitizer to demonstrate beneficial effects on all three components of HALS." | 2.46 | The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. ( Larson, RJ; Sheth, SH, 2010) |
| "Active Cushing's syndrome is associated with insulin resistance induced by the high and prolonged circulating level of glucocorticoids." | 2.46 | Management of diabetes mellitus in Cushing's syndrome. ( Munir, A; Newell-Price, J, 2010) |
| "This favors not only formation of type 2 diabetes or cardiovascular diseases, but also increaseas the incidence and prevalence of malignant tumors." | 2.46 | [Antidiabetic therapy--a new possibility in the complex therapy of cancer?]. ( Bánhegyi, RJ; Martyin, T; Nagy, AK; Pikó, B; Rus-Gal, PO; Varga, R; Wágner, R, 2010) |
| "Metformin is an insulin-sensitizing agent that may lower androgen levels." | 2.45 | The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. ( Akl, EA; Barba, M; Guyatt, G; Musicco, F; Muti, P; Schünemann, HJ; Sperati, F, 2009) |
| "Metabolic syndrome is a chronic low-grade inflammatory condition in which adipokines play a major role." | 2.45 | Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. ( Damato, AB; Depalo, R; Garruti, G; Giampetruzzi, F; Giorgino, F; Lorusso, F; Vita, MG, 2009) |
| "Insulin resistance is nearly universal in NASH and is thought to play an important role in its pathogenesis leading to dysregulated lipid metabolism." | 2.45 | Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. ( Dong, MH; Loomba, R; Stein, LL, 2009) |
| "This inflammation is characterized by infiltration with macrophages, alterations of adipokine secretion, development of insulin resistance." | 2.45 | [Adipose tissue inflammation and atherosclerosis]. ( Shwarts, V, 2009) |
| "In many patients with type 2 diabetes, hyperglycemia can be reduced with appropriate changes in diet and exercise, however, some patients with type 2 diabetes and insulin resistance syndromes need pharmacological therapy to improve their metabolic control." | 2.45 | [Could oral antidiabetic agents be useful in the management of different types of diabetes and syndromes of insulin resistance in children and adolescents?]. ( Jarosz-Chobot, P; Nowowiejska, B; Otto-Buczkowska, E; Stańczyk, J, 2009) |
| "Early stages of fatty liver are clinically silent and include elevation of ALT and GGTP, hyperechogenic liver in USG and/or hepatomegaly." | 2.44 | [Non-alcoholic fatty liver disease--new view]. ( Lawniczak, M; Marlicz, W; Miezyńska-Kurtycz, J; Milkiewicz, P; Raszeja-Wyszomirska, J, 2008) |
| "Vildagliptin is a potent and selective inhibitor of dipeptidyl peptidase-IV (DPP-4), orally active, that improves glycemic control in patients with type 2 diabetes (T2DM) primarily by enhancing pancreatic (alpha and beta) islet function." | 2.44 | Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. ( Dejager, S; Foley, J; Halimi, S; Minic, B; Schweizer, A, 2008) |
| "Insulin resistance is an independent risk factor for the development of macro- and microvascular complications of Type 1 diabetes and may also contribute to the development of the disease." | 2.44 | Addressing insulin resistance in Type 1 diabetes. ( Narendran, P; Pang, TT, 2008) |
| "Nonalcoholic steatohepatitis (NASH) is one of the most common liver disorders in North America." | 2.44 | Treatment of fibrosis in nonalcoholic fatty liver disease. ( Anania, FA; Hoteit, MA, 2007) |
| "As insulin resistance is a pathophysiologic cornerstone of diabetes and cardiovascular disease, the use of Avandamet represents an optimal approach to the treatment of diabetes." | 2.44 | Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes. ( Smiley, D; Umpierrez, G, 2007) |
| "Type 2 diabetes is a chronic disease characterized by progressive worsening of glycaemic control as indicated by the United Kingdom Prospective Diabetes Study (UKPDS)." | 2.44 | beta-cell function and anti-diabetic pharmacotherapy. ( Bianchi, C; Del Prato, S; Marchetti, P, 2007) |
| " This article reviews the clinical data behind the use of metformin in combination with TZDs for the management of diabetes, its impact on vascular health, side effects and potential mechanisms of action for combined use." | 2.44 | Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. ( Elasy, T; Stafford, JM, 2007) |
| "Weight loss has been shown to improve sensitivity to insulin as a result of either altered diet or exercise." | 2.44 | Effects of insulin resistance on endothelial function: possible mechanisms and clinical implications. ( Cokkinos, D; Stefanadis, C; Tousoulis, D; Tsarpalis, K, 2008) |
| "The recommended first step for treatment of metabolic syndrome is lifestyle modifications such as weight loss, aerobic exercise, smoking cessation, and improved diet which independently improve insulin resistance and slow progression to type 2 diabetes mellitus." | 2.44 | Metabolic syndrome: are we at risk? ( Paudel, B, 2007) |
| "Type 2 diabetes is a progressive syndrome that evolves toward complete insulin deficiency during the patient's life." | 2.44 | Treatment of type 2 diabetes with combined therapy: what are the pros and cons? ( Massi-Benedetti, M; Orsini-Federici, M, 2008) |
| "Therefore, treatment of IGT and type 2 diabetes should aim at restoring the normal relation between insulin sensitivity and secretion." | 2.43 | Islet adaptation to insulin resistance: mechanisms and implications for intervention. ( Ahrén, B; Pacini, G, 2005) |
| "Obesity is not necessary to observe insulin resistance in humans since severe insulin resistance also characterizes patients lacking subcutaneous fat such as those with HAART (highly-active antiretroviral therapy) - associated lipodystrophy." | 2.43 | The fatty liver and insulin resistance. ( Westerbacka, J; Yki-Järvinen, H, 2005) |
| "The primary aim must be the treatment of the insulin resistance." | 2.43 | [Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus]. ( Schumm-Draeger, PM, 2005) |
| "Metformin has proven to be effective in the management of the metabolic disturbances, anovulation and hirsutism and is now a widely accepted therapy." | 2.43 | [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences]. ( Madsbad, S; Nilas, L; Nørgaard, K; Svendsen, PF, 2005) |
| "Although insulin resistance is not part of the diagnostic criteria for PCOS, its importance in the pathogenesis of PCOS can not be denied." | 2.43 | Insulin resistance in polycystic ovarian disease. ( Bhatia, V, 2005) |
| "The finding that insulin resistance has important implications in the pathogenesis of polycystic ovarian disease has elicit the concept of a therapeutic approach of insulin-sensitizing drugs." | 2.43 | [Insulin sensitizers in the treatment of polycystic ovary]. ( Ayala, AR; Hernández Marín, I; Ortiz Núñez, DA, 2005) |
| "Insulin resistance is an integral part of the underlying pathophysiology in most patients with nonalcoholic fatty liver disease (NAFLD)." | 2.43 | Therapy of NAFLD: insulin sensitizing agents. ( Al-Osaimi, AM; Argo, CK; Caldwell, SH, 2006) |
| "Type 2 diabetes and obesity are common metabolic disorders characterized by resistance to the actions of insulin to stimulate skeletal muscle glucose disposal." | 2.43 | Insulin resistance and improvements in signal transduction. ( Goodyear, LJ; Musi, N, 2006) |
| "Nonalcoholic steatohepatitis (NASH), which is considered the hepatic manifestation of the metabolic syndrome is an increasingly cause of chronic liver disease in Japan." | 2.43 | [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. ( Kawaguchi, K; Korenaga, K; Korenaga, M; Sakaida, I; Uchida, K, 2006) |
| "Insulin resistance has a complex etiology, with multiple manifestations across the organ systems involved in glucose homeostasis." | 2.43 | Metformin and pioglitazone: Effectively treating insulin resistance. ( Staels, B, 2006) |
| "Polycystic ovary syndrome is a multi-system endocrinopathy with long-term metabolic and cardiovascular health consequences." | 2.43 | Contemporary medical therapy for polycystic ovary syndrome. ( Domino, SE; Lanham, MS; Lebovic, DI, 2006) |
| "Insulin resistance is now considered to be major pathogenesis for diabetic macroangiopathy." | 2.43 | [Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin]. ( Daita, H; Mokuno, H; Tamura, H, 2006) |
| "Insulin resistance is an important pathophysiological feature of the polycystic ovary syndrome (PCOS)." | 2.43 | Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? ( Cheang, KI; Nestler, JE; Sharma, ST, 2006) |
| "Metformin is a widely used drug in the therapy of patients affected by diabetes mellitus." | 2.43 | Metformin beyond diabetes: new life for an old drug. ( Mannucci, E; Monami, M; Rotella, CM, 2006) |
| "Metformin has been shown to reduce ovarian production, enhance ovulatory cycles and in some cases increase fertility." | 2.42 | [Insulin resistance and polycystic ovary syndrome]. ( Basille, C; Bernard, L; Chabbert-Buffet, N; Christin-Maître, S, 2003) |
| "Metformin effectiveness has been shown for the reduction of diabetes related complications and mortality, mainly in the cardiovascular field." | 2.42 | [Metabolic syndrome: to observe or to act?]. ( Picard, S; Slama, G, 2003) |
| "Polycystic ovary syndrome is a frequent endocrine disorder often associated with insulin resistance and hyperinsulinaemia which may play a role in hyperandrogenism and anovulation." | 2.42 | [Should infertile women with polycystic ovarian syndrome be treated with metformine?]. ( Basille, C; Bry-Gauillard, H; Cédrin-Durnerin, I; Galey, J; Hugues, JN; Massin, N; Théron-Gérard, L, 2003) |
| "Patients with type 2 diabetes mellitus are associated with insulin resistance and/or impaired insulin secretion." | 2.42 | [Nateglinide and mitiglinide]. ( Odawara, M, 2003) |
| "Metformin is a hypoglycaemic agent widely used in the management of type 2 diabetes." | 2.42 | Antiatherogenic properties of metformin: the experimental evidence. ( Mamputu, JC; Renier, G; Wiernsperger, NF, 2003) |
| "Insulin resistance is a common feature of PCOS and is more marked in obese women, suggesting that PCOS and obesity have a synergistic effect on the magnitude of the insulin disorder." | 2.42 | Insulin-lowering agents in the management of polycystic ovary syndrome. ( De Leo, V; la Marca, A; Petraglia, F, 2003) |
| "Insulin resistance is central to the pathogenesis of type 2 diabetes and may contribute to atherogenesis, either directly or through associated risk factors." | 2.42 | Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. ( Evans, M; Rees, A; Roberts, AW; Thomas, A, 2003) |
| "Treatment with metformin was less effective than lifestyle modifications, resulting in an average reduction of risk for development of type 2 diabetes by 31% compared with placebo." | 2.42 | [Progress in the prevention of type 2 diabetes]. ( Schernthaner, G, 2003) |
| "Metformin has beneficial effects on endothelial function which appear to be mediated through its effects to improve insulin resistance." | 2.42 | Insulin resistance as a therapeutic target for improved endothelial function: metformin. ( Anderson, T; Brame, L; Lteif, A; Mather, K; Verma, S, 2004) |
| "Insulin resistance is a condition in which the glycemic response to insulin is less than normal." | 2.42 | Treatment of insulin resistance in diabetes mellitus. ( Banerji, MA; Lebovitz, HE, 2004) |
| "Insulin resistance is a central feature of polycystic ovary syndrome (PCOS)." | 2.42 | Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? ( Cheang, KI; Nestler, JE, 2004) |
| "While the treatment of hyperandrogenism makes use of different drugs already studied, the debate about the use of insulin sensitizing drugs is still open." | 2.42 | Which treatment options should be used in adolescents with polycystic ovary syndrome? ( Barini, A; Di Sebastiano, F; Fulghesu, AM; Lanzone, A; Rossodivita, A; Sagnella, F; Villa, P, 2004) |
| "Metformin is a first-line drug in the treatment of overweight and obese type 2 diabetic patients, offering a selective pathophysiological approach by its effect on insulin resistance." | 2.42 | Current indications for metformin therapy. ( Tankova, T, 2003) |
| "Insulin resistance is a major endocrinopathy underlying the development of hyperglycaemia and cardiovascular disease in type 2 diabetes." | 2.42 | Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes. ( Bailey, CJ; Day, C, 2004) |
| "Insulin resistance is a prominent feature of polycystic ovarian syndrome (PCOS), and women with the disorder are at increased risk for the development of other diseases that have been linked to insulin resistance-namely, type 2 diabetes and cardiovascular disease." | 2.41 | Should patients with polycystic ovarian syndrome be treated with metformin?: an enthusiastic endorsement. ( Nestler, JE, 2002) |
| "The pathophysiologic knowledge on type 2 diabetes has moved and the disease is nowadays more complex with a loss of the beta cell mass and an insulin resistance state of the liver, muscle and adipocyte tissue associated with a defect in gastro-intestinal hormones in the postprandial state." | 2.41 | Oral anti diabetic polychemotherapy in type 2 diabetes mellitus. ( Gin, H; Rigalleau, V, 2002) |
| "Lactic acidosis is a rare, serious adverse effect of metformin, which can be prevented by carefully observing the contra-indications." | 2.41 | [Metformin efficacious in poorly controlled diabetes mellitus type 2]. ( Hoekstra, JB; Holleman, F; Stades, AM, 2000) |
| "Women with severe insulin resistance are a unique subset of polycystic ovary syndrome." | 2.41 | Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. ( Barbieri, RL, 2000) |
| "The characteristic dyslipidemia of insulin resistance consists of elevated triglyceride and triglyceride-rich lipoprotein levels, low levels of high-density lipoprotein cholesterol, and increased concentrations of small, dense low-density lipoprotein cholesterol." | 2.41 | Pathophysiology and treatment of the dyslipidemia of insulin resistance. ( Capuzzi , DM; Cohn, G; Valdes, G, 2001) |
| "Biguanides have been used in treatment of diabetes mellitus for over 30 years now." | 2.40 | [Value of biguanide in therapy of diabetes mellitus]. ( Haupt, E; Panten, U, 1997) |
| "Insulin resistance is one of the cardinal pathophysiological components of the metabolic syndrome, type 2 diabetes, and frequently co-exists with essential hypertension." | 2.40 | Insulin resistance: site of the primary defect or how the current and the emerging therapies work. ( Caro, JF; Kolaczynski, JW, 1998) |
| "Metformin has been used for over 40 years as an effective glucose-lowering agent in type 2 (noninsulin-dependent) diabetes mellitus." | 2.40 | A risk-benefit assessment of metformin in type 2 diabetes mellitus. ( Bailey, CJ; Howlett, HC, 1999) |
| " Careful selection of most relevant data in terms of dosage prompted this original review, largely devoted to the drug action at the cell level and whose hypotheses/conclusions are tentatively interpreted according to corresponding basic scientific knowledge." | 2.40 | Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. ( Wiernsperger, NF, 1999) |
| "The relief of insulin resistance is one of the two therapeutic targets of the treatment of type 2 diabetes." | 2.40 | [Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs]. ( Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N, 1999) |
| "NIDDM is characterized by a decrease in insulin sensitivity of the liver, the muscles and adipocytes." | 2.40 | [Insulin resistance: therapeutic approaches]. ( Gin, H; Rigalleau, V, 1999) |
| " They also suggest that long term administration of metformin might be helpful in treating insulin resistance, thus reducing risks of type 2 (non-insulin-dependent) diabetes and cardiovascular disease in these patients." | 2.40 | Insulin resistance, polycystic ovary syndrome and metformin. ( Ducluzeau, PH; Pugeat, M, 1999) |
| "In an attempt to treat the possible insulin resistance in hypertension, an antidiabetic agent, metformin, which enhances glucose uptake, was given to non-obese, non-diabetic, untreated hypertensives in a pilot study." | 2.38 | Metformin and blood pressure. ( Landin-Wilhelmsen, K, 1992) |
| "Metformin or exenatide treatment could prevent the degradation of insulin receptor substrate-1 protein by reducing the effect of suppressors of cytokine signaling-1 and suppressors of cytokine signaling-3 proteins, especially in the liver tissue." | 1.91 | Effects of antidiabetics and exercise therapy on suppressors of cytokine signaling-1, suppressors of cytokine signaling-3, and insulin receptor substrate-1 molecules in diabetes and obesity. ( Akarsu, E; Balcı, SO; Bozdag, Z; Demirel, C; Korkmaz, M; Sayiner, ZA; Yılmaz, I, 2023) |
| "Metformin was used as a positive control." | 1.91 | Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α. ( He, B; Lv, B; Wang, D; Wang, X; Xing, C; Zhao, H, 2023) |
| "Metformin is a commonly used drug of PCOS but few studies on whether metformin can improve the follicle development and ovarian function in PCOS." | 1.91 | Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis. ( Chang, Q; Chen, X; He, R; Hei, C; Li, G; Liang, X; Liu, H; Liu, X; Ouyang, J; Peng, Q; Ren, S; Sun, M; Sun, Y; Wang, C; Wang, Q; Wu, X; Xie, H, 2023) |
| "Insulin resistance was assessed using homeostasis model assessment for insulin resistance." | 1.91 | Association of Hepcidin levels in Type 2 Diabetes Mellitus treated with metformin or combined anti-diabetic agents in Pakistani population. ( Aziz, Q; Basit, A; Fawwad, A; Najeeb, T; Nangrejo, R; Siddiqui, IA; Soomro Late, MS; Waris, N, 2023) |
| "Scopoletin-treated groups showed a significant decline in glucose levels, especially in the MD (5." | 1.91 | Scopoletin Improves Glucose Homeostasis in the High-Fructose High-Fat Diet-Induced Diabetes Model in Wistar Rats. ( Anand, A; Batra, GK; Bhansali, S; Patil, AN; Sharma, S, 2023) |
| "Cirsimaritin is a dimethoxy flavon that has different biological activities such as antiproliferative, antimicrobial, and antioxidant activities." | 1.91 | The Emerging Importance of Cirsimaritin in Type 2 Diabetes Treatment. ( AbuDalo, R; Al-Hashimi, N; Alqudah, A; Alqudah, M; Alshaikh, HA; Athamneh, RY; Gammoh, O; Oqal, M; Qnais, E, 2023) |
| "Cardiovascular diseases are characterized by problems affecting the circulatory system, specifically the heart and blood vessels." | 1.91 | Diabetes mellitus: relation between cardiovascular events and pharmacological treatment. ( Brito-Costa, S; Margalho, L; Monteiro, P; Santos, C, 2023) |
| "Obesity was significantly associated with the cAMP signal pathway, and HHIP was a secreted protein related to cAMP signalling, as determined by KEGG analysis." | 1.91 | Hedgehog interacting protein as a circulating biomarker in women with obesity: a cross-sectional study and intervention studies. ( Dai, H; Hu, W; Li, K; Li, L; Liang, Z; Qiu, S; Wang, H; Wang, Y; Yang, G; Yang, M; Zhang, H; Zhang, L, 2023) |
| " However, it is poorly absorbed and has low bioavailability." | 1.91 | A Microstirring Oral Pill for Improving the Glucose-Lowering Effect of Metformin. ( Abbas, A; Askarinam, N; Fang, RH; Holay, M; Kubiatowicz, L; Mundaca-Uribe, R; Sage-Sepulveda, JS; Wang, J; Zhang, L, 2023) |
| "It has been used for the treatment of obesity, gestational diabetes, and polycystic ovary syndrome." | 1.91 | Role of metformin in the management of type 2 diabetes: recent advances. ( Gonzalez-Lopez, C; Wojeck, BS, 2023) |
| "Treatment with metformin also resulted in a decrease in body mass index, blood glucose, insulin, and HOMA-IR." | 1.91 | METFORMIN EFFECTS ON BLOOD LEVELS OF GREMLIN-1 IN POLYCYSTIC OVARIAN WOMEN. ( Allow, S; Sarhat, E, 2023) |
| "Chronic inflammation is a risk factor for diabetes, but it can also be a complication of diabetes, leading to severe diabetes and causing many other clinical manifestations." | 1.91 | Molecular insights of anti-diabetic compounds and its hyaluronic acid conjugates against aldose reductase enzyme through molecular modeling and simulations study-a novel treatment option for inflammatory diabetes. ( Jayabal, D; Jayanthi, S; Shimu, MSS; Thirumalaisamy, R, 2023) |
| "Metformin is a widely used drug for treating type 2 diabetes and is also used for delaying sexual maturation in girls with precocious puberty." | 1.72 | Metformin treatment of juvenile mice alters aging-related developmental and metabolic phenotypes. ( Bartke, A; Fang, Y; Medina, D; Yuan, R; Zhu, Y, 2022) |
| "Hypothalamic insulin resistance is known to precede that in the periphery, thus a critical unanswered question is whether central insulin resistance creates a specific hypothalamic miRNA signature that can be identified and targeted." | 1.72 | Hypothalamic miR-1983 Targets Insulin Receptor β and the Insulin-mediated miR-1983 Increase Is Blocked by Metformin. ( Belsham, DD; Chalmers, JA; Dalvi, PS; Dash, S; Eversley, JA; Loganathan, N; McIlwraith, EK; Mohan, H; Nazarians-Armavil, A; Stahel, P; Wellhauser, L; Wheeler, MB, 2022) |
| "Microvascular insulin resistance is present in metabolic syndrome and may contribute to increased cardiovascular disease risk and the impaired metabolic response to insulin observed." | 1.72 | Metformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome. ( Barrett, EJ; Hartline, L; Jahn, LA; Liu, Z, 2022) |
| "metformin and PA treatment." | 1.72 | Effect of Propionic Acid on Diabetes-Induced Impairment of Unfolded Protein Response Signaling and Astrocyte/Microglia Crosstalk in Rat Ventromedial Nucleus of the Hypothalamus. ( Chaikovsky, YB; Klys, YG; Labudzinskyi, DO; Lisakovska, OO; Natrus, LV; Osadchuk, YS, 2022) |
| "Metformin (MTF) treatment improves insulin signaling in endometrial tissues, but its mechanism is not fully understood." | 1.72 | Metformin Treatment Regulates the Expression of Molecules Involved in Adiponectin and Insulin Signaling Pathways in Endometria from Women with Obesity-Associated Insulin Resistance and PCOS. ( Astorga, I; Carvajal, R; García, V; Oróstica, ML; Plaza-Parrochia, F; Poblete, C; Romero, C; Vega, M, 2022) |
| "Obesity is associated with an increased incidence and aggressiveness of breast cancer and is estimated to increment the development of this tumor by 50 to 86%." | 1.72 | Sera from women with different metabolic and menopause states differentially regulate cell viability and Akt activation in a breast cancer in-vitro model. ( Cabrera-Quintero, AJ; Flores-García, LC; García-García, E; Hernández-Juárez, AJ; Méndez, JP; Meraz-Cruz, N; Naranjo-Meneses, MA; Pedraza-Sánchez, S; Ramírez-Ruíz, A; Romero-Córdoba, SL; Vadillo-Ortega, F; Ventura-Gallegos, JL; Zentella-Dehesa, A, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is a common cause of clinical liver dysfunction and an important prepathological change of liver cirrhosis." | 1.72 | Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice. ( Cui, W; Kong, L; Yang, X; Zhou, ST, 2022) |
| "Metformin treatment may protect men with early-onset androgenic alopecia against the development of gonadotroph hyperplasia and/or focal testicular changes." | 1.72 | Pituitary Effects of Metformin in Men With Early-Onset Androgenic Alopecia. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "Metformin alone reduced hyperinsulinemia and circulating c-reactive protein, but exacerbated nephropathy." | 1.72 | Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice. ( Calcutt, NA; Doty, R; Flurkey, K; Harrison, DE; Koza, RA; Reifsnyder, PC, 2022) |
| "Metformin is a well-known AMPK activator widely used for the treatment of metabolic syndrome, while the mechanism of AMPK activation remains unclear." | 1.72 | Metformin alleviates long-term high-fructose diet-induced skeletal muscle insulin resistance in rats by regulating purine nucleotide cycle. ( Chen, J; Cheng, J; Guan, F; Huang, X; Li, M; Li, Y; Lin, G; Liu, Y; Ma, X; Su, Z; Xie, J; Xu, L; Yu, Q, 2022) |
| "Metformin is an orally effective insulin-sensitizing drug widely prescribed for treating type 2 diabetes mellitus (T2DM)." | 1.72 | Lipids Alterations Associated with Metformin in Healthy Subjects: An Investigation Using Mass Spectrometry Shotgun Approach. ( Abdel Rahman, AM; Alfadda, AA; AlMalki, RH; Arafat, T; Benabdelkamel, H; Dahabiyeh, LA; Mujammami, M, 2022) |
| "Metformin is a first-line antidiabetic drug for the treatment of type 2 diabetes mellitus (DM2); its molecular target is AMP-activated protein kinase (AMPK), which is involved in many metabolic processes." | 1.72 | [Metformin and malignant neoplasms: a possible mechanism of antitumor action and prospects for use in practice]. ( Frolova, YS; Gaimakova, DV; Galimova, AM; Islamgulov, AH; Karimova, AR; Kuznetsov, KO; Nazmieva, KA; Oganesyan, IY; Rizvanova, EV; Sadertdinova, AG; Safina, ER, 2022) |
| "Metformin is a drug that has been widely used around the world for many years." | 1.72 | Use of metformin in patients who require intravascular administration of a contrast agent. ( Rokicka, D; Stołtny, D; Strojek, K; Wróbel, M, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are serious health concerns for which lifestyle interventions are the only effective first-line treatment." | 1.72 | Combining Dietary Intervention with Metformin Treatment Enhances Non-Alcoholic Steatohepatitis Remission in Mice Fed a High-Fat High-Sucrose Diet. ( Amigó, N; Baiges-Gaya, G; Camps, J; Castañé, H; Jiménez-Franco, A; Joven, J; Rodríguez-Tomàs, E, 2022) |
| "Aging is associated with central fat redistribution and insulin resistance." | 1.62 | Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. ( Atlan, M; Auclair, M; Bereziat, V; Capeau, J; Fève, B; Foresti, R; Gorwood, J; Laforge, M; Lagathu, C; Le Pelletier, L; Mantecon, M; Motterlini, R, 2021) |
| "Insulin resistance was induced by HFrHFD feeding for 16 weeks." | 1.62 | Propranolol and low-dose isoproterenol ameliorate insulin resistance, enhance β-arrestin2 signaling, and reduce cardiac remodeling in high-fructose, high-fat diet-fed mice: Comparative study with metformin. ( Ahmed, HMS; Ibrahim, IAAE; Ibrahim, WS; Mahmoud, AAA; Mahmoud, MF, 2021) |
| "Metformin was administered intragastrically, and aerobic exercise was performed using treadmill with 7-12 m/min, 30-40 min/day, 5 days/week." | 1.62 | Morphological and functional characterization of diabetic cardiomyopathy in db/db mice following exercise, metformin alone, or combination treatments. ( Liu, J; Lu, J; Tang, Q; Wang, X; Zhang, L; Zhang, Y, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) has become an important health problem in the world." | 1.62 | Combination of metformin and chlorogenic acid attenuates hepatic steatosis and inflammation in high-fat diet fed mice. ( Aliabadi, M; Emamgholipour, S; Ghasempour, G; Hashemnia, SMR; Meshkani, R; Zamani-Garmsiri, F, 2021) |
| "A rat model of PCOS-IR was established using a high-fat diet (49 d) combined with letrozole (1 mg/kg·d, for 28 d)." | 1.62 | Effects of total flavonoids from Eucommia ulmoides Oliv. leaves on polycystic ovary syndrome with insulin resistance model rats induced by letrozole combined with a high-fat diet. ( Li, CX; Li, M; Miao, MS; Peng, MF; Ren, Z; Song, YG; Tian, S, 2021) |
| "Berberine was used to uncover the mechanisms for the treatment of hyperinsulinemia in IR model." | 1.62 | Berberine ameliorates neuronal AD-like change via activating Pi3k/PGCε pathway. ( Bao, Y; Chen, Q; Han, Y; Liu, C; Liu, W; Liu, X; Wang, J; Wu, N; Ye, Y; Yu, Y, 2021) |
| "Non-alcoholic fatty liver disease (NAFLD) is one of the primary causes of chronic liver disease and is closely linked to insulin resistance, type 2 diabetes mellitus (T2DM), and dyslipidemia." | 1.62 | Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats. ( Gu, X; Li, X; Zhang, C; Zhu, H; Zou, W, 2021) |
| "Treatment with metformin reduced peripheral metabolic impairment and cardiac dysfunction via decreased cardiac mitochondrial dysfunction, mitochondrial dynamic imbalance, and apoptosis." | 1.62 | Necrostatin-1 reduces cardiac and mitochondrial dysfunction in prediabetic rats. ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Jinawong, K; Kerdphoo, S; Singhanat, K, 2021) |
| "Metformin was found to reduce elevated prolactin levels in women but not in men." | 1.56 | Endogenous testosterone determines metformin action on prolactin levels in hyperprolactinaemic men: A pilot study. ( Krysiak, R; Okopień, B; Szkróbka, W, 2020) |
| "Myo-inositol (MYO) is an insulin-sensitizing compound used in PCOS patients; however, its insulin-sensitizing mechanism is unclear." | 1.56 | The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment. ( Cabrera-Cruz, H; Oróstica, L; Plaza-Parrochia, F; Romero, C; Torres-Pinto, I; Vega, M, 2020) |
| "Metformin treatment elevates serum MANF levels and alleviates insulin resistance and hyperandrogenism in PCOS women." | 1.56 | Decreased Circulating MANF in Women with PCOS is Elevated by Metformin Therapy and is Inversely Correlated with Insulin Resistance and Hyperandrogenism. ( Deng, W; Jia, Y; Li, Y; Liu, D; Long, M; Wang, C; Wei, J; Yang, G, 2020) |
| "Excess insulin resistance is considered the predominant pathophysiological mechanism in obese women who develop gestational diabetes (GDM)." | 1.56 | Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study. ( Begum, S; Lawlor, DL; Nelson, SM; Pasupathy, D; Poston, L; Sattar, N; Seed, P; Vieira, MC; Welsh, P; White, SL, 2020) |
| "In this study, mice with type 2 diabetes mellitus (T2DM) induced by high-fat diet were used to investigate the antidiabetic effect and mechanism of action of peanut skin extract (PSE)." | 1.56 | Peanut skin extract ameliorates the symptoms of type 2 diabetes mellitus in mice by alleviating inflammation and maintaining gut microbiota homeostasis. ( Osada, H; Pan, W; Qi, J; Wu, Q; Xiang, L; Yoshida, M, 2020) |
| "Metformin treatment of HFD rats reduced fasting insulin and free fatty acid concentrations and lowered body weight and adiposity." | 1.51 | Metformin improves vascular and metabolic insulin action in insulin-resistant muscle. ( Attrill, E; Betik, AC; Bradley, EA; Hu, D; Keske, MA; Premilovac, D; Rattigan, S; Richards, SM, 2019) |
| "We show that prediabetic serum hyperinsulinemia is reflected in the cerebrospinal fluid and that this chronically elevated insulin renders neurons resistant to insulin." | 1.51 | Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence. ( Chen, G; Cheng, A; Chow, HM; Gao, Y; Herrup, K; Shi, M; So, RWL; Song, X; Zhang, J, 2019) |
| "Metformin was used as positive control." | 1.51 | Eugenol ameliorates insulin resistance, oxidative stress and inflammation in high fat-diet/streptozotocin-induced diabetic rat. ( Al-Trad, B; Al-Zoubi, M; Alkhateeb, H; Alsmadi, W, 2019) |
| " Long-term use of OCPs needs to be considered carefully for PCOS patients who are already burdened with associated risk factors." | 1.51 | Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with Polycystic Ovarian Syndrome: An observational study. ( Amin, S; Bhat, IA; Fatima, Q; Ganie, MA; Jeelani, H; Kawa, IA; Manzoor, S; Rashid, F; Shah, ZA; Yousuf, SD, 2019) |
| "Podocyte insulin sensitivity is critical for glomerular function, and the loss of appropriate insulin signaling leads to alterations and disorders featuring diabetic nephropathy." | 1.48 | Metformin overcomes high glucose-induced insulin resistance of podocytes by pleiotropic effects on SIRT1 and AMPK. ( Angielski, S; Audzeyenka, I; Piwkowska, A; Rachubik, P; Rogacka, D; Rychłowski, M; Szrejder, M, 2018) |
| "Metformin treatment did not increase the serum METRL levels after 12 weeks." | 1.48 | Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes. ( Choung, S; Joung, KH; Kang, YE; Kim, HJ; Kim, JM; Ku, BJ; Lee, JH, 2018) |
| "Insulin sensitivity was determined by euglycemic hyperinsulinemic clamp." | 1.48 | Salvianolate Reduces Glucose Metabolism Disorders in Dimethylnitrosamine-Induced Cirrhotic Rats. ( Liu, CH; Tang, LR; Tao, YY; Wang, HN, 2018) |
| "Metformin was found to reduce elevated serum thyrotropin levels, and this effect was partially determined by endogenous dopaminergic tone." | 1.48 | Effect of Metformin on Hypothalamic-Pituitary-Thyroid Axis Activity in Elderly Antipsychotic-Treated Women With Type 2 Diabetes and Subclinical Hypothyroidism: A Preliminary Study. ( Krysiak, R; Okopień, B; Szkróbka, W, 2018) |
| "Type 2 diabetes is characterized by insulin resistance, hyperinsulinemia and hepatic overproduction of glucose and lipids." | 1.48 | Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance. ( Cleland, C; Farese, RV; Foufelle, F; Lee, MC; Sajan, J; Sajan, MP, 2018) |
| "Dapagliflozin or metformin treatment decreased insulin resistance, hypercholesterolemia, creatinine clearance and renal oxidative stress leading to improved renal function." | 1.48 | Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model. ( Chatsudthipong, V; Chattipakorn, N; Chueakula, N; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Thongnak, L; Wanchai, K, 2018) |
| "Metformin has a well described antifibrotic effect, and increases phosphorylation of ACC by AMPK, thereby increasing FAO." | 1.48 | Phosphorylation of Acetyl-CoA Carboxylase by AMPK Reduces Renal Fibrosis and Is Essential for the Anti-Fibrotic Effect of Metformin. ( Galic, S; Gleich, K; Katerelos, M; Kemp, BE; Lee, M; Mount, PF; Power, DA, 2018) |
| "Metformin has been widely used for the treatment of type 2 diabetes." | 1.46 | Effects of metformin on compensatory pancreatic β-cell hyperplasia in mice fed a high-fat diet. ( Kyohara, M; Okuyama, T; Shirakawa, J; Tajima, K; Terauchi, Y; Togashi, Y; Yamazaki, S, 2017) |
| "Insulin resistance was assessed by 3-h oral glucose tolerance test (OGTT)." | 1.46 | Metabolic and androgen profile in underweight women with polycystic ovary syndrome. ( Anastasiou, OE; Canbay, A; Fuhrer, D; Reger-Tan, S, 2017) |
| "Insulin resistance was by Homeostasis model assessment." | 1.46 | Association of divalent cations and insulin resistance with thyroid hormones in patients with type 2 diabetes mellitus. ( Gopal, N; Jayanthi, R; Ramaswamy, R; Srinivasan, AR, 2017) |
| "Metformin was originally shown to lower testosterone levels in women with PCOS in the 1990s, an effect presumably related to its insulin sensitising actions." | 1.46 | Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. ( Ehrmann, DA; Sam, S, 2017) |
| "Metformin has outstanding utility in reducing insulin resistance and preventing type-2-diabetes mellitus, but has not been studied for statin-associated muscle symptom rescue or prevention." | 1.46 | Pleiotropic effects of metformin to rescue statin-induced muscle injury and insulin resistance: A proposed mechanism and potential clinical implications. ( Carris, NW; Chapalamadugu, KC; Magness, DJ; Magness, RR; Tipparaju, SM, 2017) |
| "Osteoprotegerin has been shown to be increased in cardiovascular disorders and type 2 diabetes mellitus." | 1.46 | Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes. ( Arslan, MS; Biyikli Gencturk, Z; Cakal, E; Delibasi, T; Karakose, M; Ozbek, M; Ozturk, G; Sahin, M; Tutal, E; Ucan, B, 2017) |
| " The mice fed with HFD were dosed with metformin (200 mg/kg) or thymol (20, 40 mg/kg) daily." | 1.46 | Thymol improves high-fat diet-induced cognitive deficits in mice via ameliorating brain insulin resistance and upregulating NRF2/HO-1 pathway. ( Li, H; Li, M; Ma, S; Qin, T, 2017) |
| "Metformin-treated rats exhibited a reduction in body weight, adiposity, and HbA1c ( P < 0." | 1.46 | Transcriptomic effects of metformin in skeletal muscle arteries of obese insulin-resistant rats. ( Akter, S; Davis, JW; Jenkins, NT; Laughlin, MH; Martin, JS; Padilla, J; Rector, RS; Thorne, PK, 2017) |
| "102 women with newly diagnosed breast cancer were divided into 2 main groups, a control group and a metformin group." | 1.43 | Metformin may protect nondiabetic breast cancer women from metastasis. ( El-Bassiouny, NA; El-Haggar, SM; El-Shitany, NA; Mostafa, MF, 2016) |
| "Metformin treatment remarkably improved liver function, alleviated lipid peroxidation and histological damages of the liver, and ameliorated glucose intolerance and insulin resistance." | 1.43 | Metformin improves hepatic IRS2/PI3K/Akt signaling in insulin-resistant rats of NASH and cirrhosis. ( Chen, F; Liu, Y; Ping, J; Ruo, R; Shou, Q; Xu, H; Zhou, Y, 2016) |
| " We report here that a low-carbohydrate diet combined with an SGLT2 inhibitor was effective and safe to treat refractory hyperglycemia in the perioperative period in a type 2 diabetes patient complicated with a high titer of insulin antibodies." | 1.43 | Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies. ( Abiru, N; Ando, T; Horie, I; Kawakami, A; Shigeno, R, 2016) |
| "Melatonin treatment alone improved circadian activity rhythms, attenuated induction of β-cell failure, and enhanced glucose tolerance." | 1.43 | Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats. ( Hoang, J; Matveyenko, AV; Nguyen, A; Rakshit, K; Thomas, AP; Vongbunyong, K, 2016) |
| "A significant decrement of hyperinsulinemia, triglyceridemia, serum IL6 and oxidised LDL were observed at the end of the study." | 1.43 | Metformin preconditioned adipose derived mesenchymal stem cells is a better option for the reversal of diabetes upon transplantation. ( Bhonde, RR; Shree, N, 2016) |
| "Metformin is the mainstay therapy for type 2 diabetes (T2D) and many patients also take salicylate-based drugs [i." | 1.42 | Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. ( Blümer, RM; Bujak, AL; Crane, JD; Day, EA; Ford, RJ; Fullerton, MD; Gerstein, HC; Kemp, BE; Marcinko, K; Oakhill, JS; Pinkosky, SL; Scott, JW; Smith, BK; Steinberg, GR, 2015) |
| "Metformin is a first-line therapeutic option for the treatment of type 2 diabetes, even though its underlying mechanisms of action are relatively unclear." | 1.42 | Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. ( Côté, CD; Duca, FA; Filippi, BM; Lam, TK; Rasmussen, BA; Rutter, GA; Zadeh-Tahmasebi, M, 2015) |
| "Insulin resistance is a prevalent condition commonly associated with unhealthy lifestyles." | 1.42 | [Second Consensus of the Chilean Society of Endocrinology and Diabetes about insulin resistance]. ( Araya, V; Arrese, M; Aylwin, CG; Bezanilla, CG; Carrasco, E; Carrasco, F; Codner, E; Díaz, E; Durruty, P; Galgani, J; García, H; Lahsen, R; Lanas, A; Liberman, C; López, G; Maíz, A; Mujica, V; Pollak, F; Poniachik, J; Sapunar, J; Sir, T; Soto, N; Valderas, J; Villaseca, P; Zavala, C, 2015) |
| "The metformin treatment of Wistar rats with obesity induced by high-fat diet was carried out for 2 months (daily dose of 200 mg/kg)." | 1.42 | [THE EFFECTS OF LONG-TERM METFORMIN TREATMENT ON THE ACTIVITY OF ADENYLYL CYCLASE SYSTEM AND NO-SYNTHASES IN THE BRAIN AND THE MYOCARDIUM OF RATS WITH OBESITY]. ( Bondareva, VM; Derkach, KV; Ignatieva, PA; Kuznetsova, LA; Sharova, TS; Shpakov, AO, 2015) |
| "During hyperinsulinemia, glucose infusion rate (GINF) to maintain euglycemia (reflective of whole-body insulin sensitivity) was higher in Veh/Veh vs other groups." | 1.42 | Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance. ( Ahsan, Z; Chintoh, A; Giacca, A; Guenette, M; Hahn, MK; Remington, GJ; Teo, C; Wilson, V, 2015) |
| "Metformin treatment can improve NAFLD and decrease the level of chemerin." | 1.42 | Therapeutic Effect of Metformin on Chemerin in Non-Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). ( Jiang, D; Li, L; Li, X; Lou, F; Lou, N; Pan, Z; Sun, A; Sun, F; Zhang, L; Zhuang, X, 2015) |
| "Metformin is a safe, effective and inexpensive generic medication favouring weight loss, recommended as initial treatment of type 2 diabetes by the American Diabetes Association." | 1.40 | A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report. ( Greenway, F; Heiman, M; Wang, S, 2014) |
| "Treatment with metformin resulted in progressive improvement of metabolic status, while blood pressure values normalized with atenolol therapy." | 1.40 | LMNA gene mutation as a model of cardiometabolic dysfunction: from genetic analysis to treatment response. ( Amorini, M; Arrigo, T; Briuglia, S; Chirico, V; Ferraù, V; Lacquaniti, A; Loddo, I; Salpietro, C; Salpietro, V, 2014) |
| "Pioglitazone treatment suppressed mRNA and protein expression of fetuin-A in Fao hepatoma cells." | 1.40 | Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. ( Emoto, M; Fukumoto, S; Imanishi, Y; Inaba, M; Ishimura, E; Koyama, H; Mori, K; Morioka, T; Motoyama, K; Nakatani, S; Ochi, A, 2014) |
| "Treatment with metformin attenuated the severity of liver injury, restored AMPK activity and normalized the expression of acetyl-CoA carboxylase and fatty acid synthase." | 1.40 | Involvement of insulin resistance in the protective effect of metformin against alcoholic liver injury. ( Jiang, Z; Nanji, AA; Wang, W; Zhao, C; Zhen, Z; Zhou, D; Zhou, J; Zhu, Z, 2014) |
| "Metformin treatments would have positive effects on growth patterns, adiposity and metabolic features of young females from ethnicities with thrifty genotype or developing leptin resistance, but a negative effect by advancing the attainment of puberty." | 1.40 | Advanced onset of puberty after metformin therapy in swine with thrifty genotype. ( Astiz, I; Astiz, S; Barbero, A; Garcia-Real, I; Gonzalez-Bulnes, A; Perez-Solana, ML, 2014) |
| " These results indicated that chronic administration of Met regulated pancreatic inflammation generation, ion and hormone homeostasis and improved β cell function of diabetic KKAy mice." | 1.40 | [Metformin ameliorates β-cell dysfunction by regulating inflammation production, ion and hormone homeostasis of pancreas in diabetic KKAy mice]. ( Hou, SC; Liu, Q; Liu, SN; Shen, ZF; Sun, SJ; Wang, Y, 2014) |
| "We observe, in patients with type 2 diabetes of recent onset, the activity of the autonomic nervous system and glucose metabolic impairment." | 1.39 | Correlation between glycemic trends assessed by 24 h continuous monitoring and autonomic activity in patients with recent onset type 2 diabetes. ( Borgognoni, L; Di Stefano, A; Fiorentini, A; Fontana, V; Paris, A; Pascucci, M; Picciarella, A; Russo, A; Tubani, L, 2013) |
| "Treatment with metformin significantly attenuates neointimal hyperplasia through inhibition of smooth muscle cell proliferation, migration, and inflammation as well as by improvement of the insulin signaling pathway." | 1.39 | The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats. ( Adeli, K; Ji, J; Jiang, B; Liu, L; Lu, J; Meng, H; Meng, QH; Randell, E; Wang, D, 2013) |
| "Metformin treatment after 6 and 12 months significantly reduced weight, BMI, waist circumference, insulin and HOMA-IR (p=0." | 1.39 | Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment. ( Velija-Ašimi, Z, 2013) |
| "Insulin resistance is a characteristic feature of Type 2 diabetes." | 1.39 | Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. ( Anthony, J; Bhumra, SK; Deka, N; Kelkar, A; Marita, AR; Mutt, S; Mutt, SJ; Ranjith, V; Sharma, S; Sivaramakrishnan, H; Wilankar, C, 2013) |
| "Metformin treatment, lead to a significant decrease in serum insulin (p = 0." | 1.39 | Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. ( Ferriani, RA; Japur de Sá Rosa-e-Silva, AC; Nascimento, AD; Reis, RM; Silva Lara, LA, 2013) |
| "Nonalcoholic fatty liver disease (NAFLD), one of chronic liver diseases, seems to be rising as the obesity epidemic continues." | 1.38 | Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease. ( Chen, J; Chen, L; Huang, L; Lai, H; Liang, X; Liu, J; Ma, L; Pei, H; Peng, A; Ran, Y; Sang, Y; Wei, Y; Xiang, M; Xie, C, 2012) |
| " A γ-conglutin dosage of 28 mg/kg body weight was daily administered to animals for 21 d." | 1.38 | Lupin seed γ-conglutin lowers blood glucose in hyperglycaemic rats and increases glucose consumption of HepG2 cells. ( Castiglioni, S; Duranti, M; Lovati, MR; Magni, C; Manzoni, C; Parolari, A, 2012) |
| "Obesity and insulin resistance are associated with chronic, low grade inflammation." | 1.38 | Energy-sensing factors coactivator peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonist. ( Aatsinki, SM; Buler, M; Georgiadi, A; Hakkola, J; Kerkelä, R; Kersten, S; Komka, Z; Skoumal, R; Tóth, M, 2012) |
| "Metformin treatment improved these alterations." | 1.38 | Improvement of metabolic parameters and vascular function by metformin in obese non-diabetic rats. ( Akamine, EH; Carvalho, MH; Filgueira, FP; Fortes, ZB; Hagihara, GN; Lobato, NS; Pariz, JR; Tostes, RC, 2012) |
| "Type 2 diabetes mellitus is likely the third modifiable risk factor for pancreatic cancer after cigarette smoking and obesity." | 1.38 | Diabetes and pancreatic cancer. ( Li, D, 2012) |
| "Metformin has been shown to be effective therapy and could be used more widely in obese adolescents with hyperandrogenemia, a forerunner of PCOS." | 1.38 | Should all women with PCOS be treated for insulin resistance? ( Dunaif, A; Marshall, JC, 2012) |
| "Insulin resistance is a recently identified mechanism involved in the pathophysiology of chronic heart failure (CHF)." | 1.38 | Metformin prevents the development of chronic heart failure in the SHHF rat model. ( Aimaretti, G; Cittadini, A; Isgaard, J; Longobardi, S; Monti, MG; Napoli, R; Netti, PA; Rea, D; Saccà, L; Samà, M; Walser, M, 2012) |
| "Obesity is a common problem and its health consequences depend on the phenotype of obesity." | 1.38 | Menopausal obesity and metabolic syndrome - PolSenior study. ( Milewicz, A, 2012) |
| "Insulin resistance has been shown to be associated with cardiac sympathovagal imbalance, myocardial dysfunction, and cardiac mitochondrial dysfunction." | 1.38 | Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet. ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H, 2012) |
| "Metformin use lead to lower MBD in 4 of 14 (28." | 1.38 | [The influence of metformin and N-acetylcysteine on mammographic density in postmenopausal women]. ( Bershteĭn, LM; Boiarkina, MP; Kisel'nikov, KS; Kovalenko, IG; Poroshina, TE; Vasil'ev, DA; Zaĭtsev, AN, 2012) |
| "Metformin treatment is useful to improve insulin resistance in DM1." | 1.38 | [Glucose intolerance in myotonic dystrophy type 1]. ( Goto, T; Kon, S; Oyama, Y; Takada, H, 2012) |
| "Insulin resistance was diagnosed in 90." | 1.38 | [Metformin efficiency for the adolescent PCOS treatment]. ( Boyadzhieva, M; Kedikova, S; Sirakov, M, 2012) |
| "Metformin treatment decreases serum ASAA in these women." | 1.37 | The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis. ( Adya, R; Aghilla, M; Keay, SD; Lehnert, H; Randeva, HS; Shan, X; Tan, BK, 2011) |
| "Approximately 40% of patients with type 2 diabetes may progress to nephropathy and a good metabolic control can prevent the development of diabetic renal injury." | 1.37 | Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats. ( da Cunha, FX; Louro, TM; Matafome, PN; Nunes, EC; Seiça, RM, 2011) |
| "non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes are associated with dyslipidaemia, inflammation and oxidative stress." | 1.37 | Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. ( Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R, 2011) |
| "Treatment with metformin sensitized the impaired insulin actions and also prevented appearance of molecular and pathological characteristics observed in AD." | 1.37 | Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. ( Bisht, B; Dey, CS; Gupta, A, 2011) |
| "Metformin is a widely used insulin-sensitizing drug; however, the mechanism by which metformin acts is poorly understood." | 1.37 | Metformin sensitizes insulin signaling through AMPK-mediated PTEN down-regulation in preadipocyte 3T3-L1 cells. ( Jung, JH; Kim, HS; Kim, JH; Kim, SJ; Lee, JO; Lee, SK; Moon, JW; Park, JM; Park, SH; Suh, PG; Uhm, KO; You, GY, 2011) |
| "Insulin sensitivity was assessed 4 h postexercise with a euglycemic hyperinsulinemic (40 mU." | 1.36 | Combining short-term metformin treatment and one bout of exercise does not increase insulin action in insulin-resistant individuals. ( Braun, B; Chipkin, SR; Goodyear, LJ; Hagobian, TA; Hirshman, MF; Malin, SK; Sharoff, CG; Yu, H, 2010) |
| "Treatment with metformin significantly reduced ACF formation." | 1.36 | Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. ( Chihara, T; Endo, H; Fujita, K; Hosono, K; Inamori, M; Nakagama, H; Nakajima, A; Nozaki, Y; Shimpo, K; Sugiyama, M; Suzuki, K; Takahashi, H; Tomatsu, A; Uchiyama, T; Yoneda, K; Yoneda, M, 2010) |
| "Insulin resistance is a characteristic of type 2 diabetes and is a major independent risk factor for progression to the disease." | 1.36 | Generation, validation and humanisation of a novel insulin resistant cell model. ( Brady, JD; Crowther, D; Feuerstein, GZ; Grierson, CE; Hansen, MK; Hundal, HS; Logie, L; Morris, AD; Pearson, E; Ruiz-Alcaraz, AJ; Schofield, CJ; Shepherd, B; Sutherland, C; Tommasi, AM, 2010) |
| "We hypothesized that hyperinsulinemia precedes the development of insulin resistance and increased adiposity in these mice with a defective adipoinsular axis." | 1.36 | Hyperinsulinemia precedes insulin resistance in mice lacking pancreatic beta-cell leptin signaling. ( Covey, SD; Donald, C; Gray, SL; Jetha, A; Kieffer, TJ, 2010) |
| " Long-term use of metformin in complex multifactorial therapy of women with decompensated type 2 diabetes DM, AH and abdominal obesity provides improvement of carbohydrate and lipid metabolism, lowering of arterial pressure, diminishment of albuminuria, diastolic dysfunction, and stiffness of left ventricular myocardium." | 1.36 | [Dynamics of structural-functional parameters of cardiovascular system during use of complex therapy of women with type 2 diabetes mellitus]. ( Elsukova, OS; Onuchin, SG; Onuchina, EL; Solov'ev, OV, 2010) |
| "Metformin has now been established as the drug of choice for the first-line management of type 2 diabetes mellitus." | 1.35 | Metformin: diamonds are forever. ( Maltezos, E; Mikhailidis, DP; Papanas, N, 2009) |
| " Our objectives were to assess the ability of rainbow trout to deal with a glucose load and to improve glucose utilization in fish receiving a chronic administration of insulin plus metformin treatments." | 1.35 | Glucose homeostasis is impaired by a paradoxical interaction between metformin and insulin in carnivorous rainbow trout. ( Panserat, S; Polakof, S; Skiba-Cassy, S, 2009) |
| "Sixty women with gestational and type 2 diabetes were enrolled, 30 each for metformin and insulin." | 1.35 | Metformin--a convenient alternative to insulin for Indian women with diabetes in pregnancy. ( Kamath, A; Meenakshi, D; Rai, L, 2009) |
| "Insulin resistance is a central feature of the PCOS and may increase cardiovascular risk." | 1.35 | Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. ( Best, AM; Cheang, KI; Essah, PA; Huszar, JM; Nestler, JE; Sharma, S, 2009) |
| "Metformin treatment led to improvement of hormonal and metabolic parameters and decreased ADMA levels possibly independent of BMI and metabolic changes." | 1.35 | Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. ( Heutling, D; Kaltwasser, P; Kleinstein, J; Krzyzanowska, K; Lehnert, H; Mittermayer, F; Nickel, I; Randeva, H; Schernthaner, G; Schulz, H; Westphal, S; Wolzt, M, 2008) |
| "Twenty-one patients with type 2 diabetes mellitus were observed for more than 6 months after treatment with pioglitazone, and 31 patients with type 2 diabetes mellitus were observed for more than 6 months after the treatment with metformin." | 1.35 | The ratio of leptin to adiponectin can be used as an index of insulin resistance. ( Fujita, T; Hayakawa, N; Horikawa, Y; Imamura, S; Inagaki, K; Itoh, M; Kakizawa, H; Oda, N; Suzuki, A; Takeda, J; Uchida, Y, 2008) |
| " Further studies are required to define appropriate selection of subjects warranting therapy, dosing schedule and pharmacokinetics." | 1.35 | The effect of metformin on measurements of insulin sensitivity and beta cell response in 18 horses and ponies with insulin resistance. ( Durham, AE; Newton, JE; Rendle, DI, 2008) |
| "Metformin treatment for one year improved HbA1c in both groups (with and without type-1 LADA)." | 1.34 | [Detection of LADA-type diabetes in overweight diabetic patients. Is treatment with metformin suitable?]. ( Arroyo Bros, J; Campos Bonilla, B; Granada Ybern, ML; Lóriz Peralta, O; Sanmartí Sala, A, 2007) |
| "Metformin treatment of the hepatocytes resulted in activation of the AMP-activated kinase, attenuation of the mTOR/S6K1 pathway, reduction of IRS-1 phosphorylation, and a leftward shift in the insulin dose-response curve for PKB activation." | 1.34 | Activation of mammalian target of rapamycin complex 1 and insulin resistance induced by palmitate in hepatocytes. ( Iynedjian, PB; Mordier, S, 2007) |
| "Pioglitazone treatment reduced both hepatic lipid content (12." | 1.34 | Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. ( Fujii, M; Hirota, Y; Kasuga, M; Kawamitsu, H; Kouyama, K; Maeda, K; Ohara, T; Sugimura, K; Teranishi, T; Zenibayashi, M, 2007) |
| "Treatment with metformin or rosiglitazone prevents excess adrenal androgen synthesis." | 1.34 | Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. ( Bahtiyar, G; Sacerdote, AS; Weiss, K, 2007) |
| "It is important to choose the optimal treatment for DM in myotonic dystrophy, because the patients have hyperinsulinemia caused by specific mechanism and could not reduce the insulin resistance." | 1.33 | Low-dose metformin improves hyperglycaemia related to myotonic dystrophy. ( Komiya, I; Kouki, T; Nakachi, A; Takasu, N; Tamanaha, T; Tawata, M, 2005) |
| " In this study, the effects of an oral administration of SD at dosages of 100, 300, and 500 mg kg(-1) once a day, respectively, on the formation of insulin resistance were investigated in vivo in two models of insulin-resistant rats, HFD rats (high-fat diet-induced insulin-resistant rats) and IILI rats (induced by the intraperitoneal injections of long-acting insulin at dosage of 0." | 1.33 | Effect of Sanguis draxonis (a Chinese traditional herb) on the formation of insulin resistance in rats. ( Hou, Z; Wu, H; Zhang, Z, 2005) |
| "A patient with type 2 diabetes and hypothalamic damage due to a suprasellar tumor developed impaired glycemic control and central obesity." | 1.33 | Markedly improved glycemic control and enhanced insulin sensitivity in a patient with type 2 diabetes complicated by a suprasellar tumor treated with pioglitazone and metformin. ( Goto, T; Igaki, N; Tanaka, M, 2005) |
| "Type 2 diabetes mellitus is a heterogeneous condition in which the clinical manifestation of hyperglycemia is a reflection of the impaired balance between insulin sensitivity and insulin secretion." | 1.33 | Type 2 diabetes mellitus in youth: the complete picture to date. ( Arslanian, S; Bacha, F; Gungor, N; Hannon, T; Libman, I, 2005) |
| "When used late in the course of type 2 diabetes, TZDs result in improved and prolonged glycaemic control which persisted for a median time of 6 years." | 1.33 | Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes. ( Bell, DS; Ovalle, F, 2006) |
| "The patients were those with type 2 diabetes mellitus hospitalized with a first MI and the controls were those with diabetes mellitus randomly selected from the same geographic area." | 1.33 | Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. ( Berlin, JA; Cappola, AR; Kimmel, SE; Sauer, WH, 2006) |
| "Metformin is a logical treatment in these circumstances but there has always been concern about its safety for the fetus, particularly as it crosses the placenta and it may increase the risk of teratogenesis." | 1.33 | Metformin use and diabetic pregnancy-has its time come? ( Hawthorne, G, 2006) |
| "Effective long-term treatment of Type 2 Diabetes Mellitus (T2DM) implies modification of the disease processes that cause this progressive disorder." | 1.33 | A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. ( Danhof, M; de Winter, W; DeJongh, J; Eckland, D; Moules, I; Ploeger, B; Post, T; Urquhart, R, 2006) |
| "Metformin vs placebo treatment of diabetic pigs (twice 1." | 1.33 | Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model. ( Ackermans, M; Corbijn, H; Dekker, R; Koopmans, SJ; Mroz, Z; Sauerwein, H, 2006) |
| "Thirty-six patients with type 2 diabetes and HbA1c >or= 6." | 1.33 | Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes. ( Dorkhan, M; Frid, A; Groop, L; Hallengren, B; Lantz, M, 2006) |
| "Metformin treatment significantly improved hyperandrogenism, menstrual cyclicity, body weight, and insulin resistance independent of GNAS1 genotype." | 1.33 | The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome. ( Frey, UH; Hahn, S; Janssen, OE; Mann, K; Siffert, W; Tan, S, 2006) |
| "For the treatment of type 2 diabetes we now have available a wide spectrum of oral antidiabetic agents and insulins that make it possible to offer the patient an individualized, pathophysiologically oriented therapy." | 1.32 | [Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes]. ( Fischer, S; Hanefeld, M, 2003) |
| "Type 2 diabetes can present as diabetic ketoacidosis in obese adolescent subjects." | 1.32 | Type 2 diabetes presenting as diabetic ketoacidosis in adolescence. ( Cox, J; Elkeles, RS; Elwig, C; Poulter, C; Valabhji, J; Watson, M, 2003) |
| "Hirsutism is the manifestation of hyperandrogenemia in PCOS." | 1.32 | The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004) |
| "Their underlying insulin resistance is determined with the help of a checklist and a method called homeostasis model assessment (HOMA)." | 1.32 | [Diabetes update: preventing type 2 diabetes. Individualized stepwise therapy (oral antidiabetic agents). Multifactorial intervention]. ( Müller, B; Trepp, R, 2004) |
| " Data have been lacking on their use in combination with both sulfonylurea and metformin among patients of type 2 diabetes who are on insulin therapy secondary to failure of routine oral hypoglycemic drugs in controlling their diabetes." | 1.32 | Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy. ( Chandalia, HB; Fafadia, A; Joshi, SR; Panikar, V; Santvana, C, 2003) |
| "Metformin or vehicle was administered to rats daily for 1 week." | 1.32 | Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms. ( Cleasby, ME; Cooney, GJ; Dzamko, N; Hegarty, BD; Kraegen, EW; Ye, JM, 2004) |
| "Metformin was then administered." | 1.32 | Metformin use in an obese diabetic patient from weeks 1 to 21 of pregnancy. ( Imamura, M; Mori, M; Nagai, T, 2003) |
| "Insulin sensitivity was significantly reduced by dexamethasone already at week 1, before the increase in blood pressure (day 15) and without significant changes in body weight compared with vehicle." | 1.31 | Low-dose dexamethasone in the rat: a model to study insulin resistance. ( Brizzi, P; Maioli, M; Secchi, G; Severino, C; Solinas, A; Tonolo, G, 2002) |
| "Insulin sensitivity was measured by modified glucose-insulin tolerance test (K value)." | 1.31 | Effects of konjac extract on insulin sensitivity in high fat diet rats. ( Gu, ZL; Mao, CP; Xie, ML, 2002) |
| "Metformin treatment restored PI 3-kinase activity in insulin-resistant myotubes." | 1.31 | Metformin enhances insulin signalling in insulin-dependent and-independent pathways in insulin resistant muscle cells. ( Dey, CS; Kumar, N, 2002) |
| "Insulin sensitivity was assessed by homeostasis model assessment (HOMA) and continuous infusion of glucose with model assessment (CIGMA) in all patients." | 1.31 | Circulating ghrelin levels in patients with polycystic ovary syndrome. ( Brabant, G; Horn, R; Müller, MJ; Schill, T; Schlösser, HW; Schöfl, C, 2002) |
| "The plasma glucose-lowering action induced by tolbutamide was significantly enhanced in obese Zucker rats receiving the repeated administration of die-huang-wan at dosage of 26 mg/kg for 3 d." | 1.31 | Increase of insulin sensitivity in diabetic rats received die-huang-wan, a herbal mixture used in Chinese traditional medicine. ( Cheng, JT; Hsu, JH; Liou, SS; Liu, IM; Su, HC; Wu, YC, 2002) |
| " Specifically, dose-response experiments of acetylcholine (ACh) with or without N-nitro-L-arginine (LNNA) were performed." | 1.31 | Metformin improves vascular function in insulin-resistant rats. ( Hoenig, M; Katakam, PV; Miller, AW; Ujhelyi, MR, 2000) |
| "Vanadyl sulfate (3-4 wk treatment or after 5-6 h in vitro) enhanced the sustained K(+) current." | 1.31 | Insulin resistance and the modulation of rat cardiac K(+) currents. ( Ewart, HS; Severson, D; Shimoni, Y, 2000) |
| "There is no known treatment for fatty liver, a ubiquitous cause of chronic liver disease." | 1.31 | Metformin reverses fatty liver disease in obese, leptin-deficient mice. ( Chuckaree, C; Diehl, AM; Kuhajda, F; Lin, HZ; Ronnet, G; Yang, SQ, 2000) |
| "Polycystic ovary syndrome is considered the most frequent endocrine abnormality during the fertile age." | 1.31 | [Effects of metformin on insulin resistance and on ovarian steroidogenesis in women with polycystic ovary syndrome]. ( De Conciliis, B; Passannanti, G; Romano, L; Santarpia, R, 2001) |
| "Insulin sensitivity was measured using the insulin tolerance test (ITT), both in STZ diabetic and in Zucker diabetic fatty (ZDF) rats (model of type 2 diabetes)." | 1.31 | Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models. ( Bíró, K; Jednákovits, A; Kukorelli, T; Kürthy, M; Mogyorósi, T; Nagy, K; Tálosi, L, 2002) |
| "Polycystic ovary syndrome is a heterogeneous disorder characterized by signs and symptoms of hyperandrogenism and insulin resistance." | 1.30 | Ovarian responses to hCG stimulation: insulin resistance/hyperinsulinaemia vs. insulin deficiency. ( Arslanian, S; Witchel, SF, 1999) |
| "Metformin plays a particularly important role in the treatment of diabetes mellitus type 2 by decreasing insulin resistance." | 1.30 | [Renaissance of metformin]. ( Sieradzki, J, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (0.52) | 18.7374 |
| 1990's | 70 (4.52) | 18.2507 |
| 2000's | 497 (32.06) | 29.6817 |
| 2010's | 709 (45.74) | 24.3611 |
| 2020's | 266 (17.16) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, CH | 1 |
| Chen, MF | 1 |
| Chung, HH | 1 |
| Cheng, JT | 3 |
| Ma, L | 2 |
| Xie, C | 2 |
| Ran, Y | 1 |
| Liang, X | 3 |
| Huang, L | 3 |
| Pei, H | 1 |
| Chen, J | 9 |
| Liu, J | 13 |
| Sang, Y | 1 |
| Lai, H | 1 |
| Peng, A | 1 |
| Xiang, M | 1 |
| Wei, Y | 2 |
| Chen, L | 7 |
| Sashidhara, KV | 1 |
| Singh, SP | 1 |
| Varshney, S | 1 |
| Beg, M | 1 |
| Gaikwad, AN | 1 |
| Seo, WD | 1 |
| Lee, JH | 3 |
| Jia, Y | 2 |
| Wu, C | 4 |
| Lee, SJ | 1 |
| Patel, OP | 1 |
| Mishra, A | 2 |
| Maurya, R | 1 |
| Saini, D | 1 |
| Pandey, J | 1 |
| Taneja, I | 1 |
| Raju, KS | 1 |
| Kanojiya, S | 1 |
| Shukla, SK | 1 |
| Srivastava, MN | 1 |
| Wahajuddin, M | 1 |
| Tamrakar, AK | 1 |
| Srivastava, AK | 2 |
| Yadav, PP | 1 |
| Xu, Y | 9 |
| Niu, Y | 1 |
| Gao, Y | 4 |
| Wang, F | 2 |
| Qin, W | 1 |
| Lu, Y | 1 |
| Hu, J | 3 |
| Peng, L | 3 |
| Xiong, W | 1 |
| Li, X | 12 |
| Xu, Q | 1 |
| Li, C | 5 |
| Luo, J | 2 |
| Wang, L | 10 |
| Jiang, B | 4 |
| Shi, D | 2 |
| Xing, C | 5 |
| Lv, B | 2 |
| Zhao, H | 6 |
| Wang, D | 3 |
| He, B | 5 |
| Xie, Y | 4 |
| Xiao, L | 2 |
| Li, S | 6 |
| Cojic, M | 1 |
| Kocic, R | 1 |
| Klisic, A | 1 |
| Kocic, G | 1 |
| Cai, X | 1 |
| Liu, Z | 7 |
| Dong, X | 1 |
| Wang, Y | 25 |
| Zhu, L | 2 |
| Li, M | 7 |
| Hsu, SK | 1 |
| Cheng, KC | 1 |
| Mgbeahuruike, MO | 1 |
| Lin, YH | 1 |
| Wu, CY | 1 |
| Wang, HD | 1 |
| Yen, CH | 1 |
| Chiu, CC | 2 |
| Sheu, SJ | 1 |
| Le Pelletier, L | 1 |
| Mantecon, M | 1 |
| Gorwood, J | 1 |
| Auclair, M | 1 |
| Foresti, R | 1 |
| Motterlini, R | 1 |
| Laforge, M | 1 |
| Atlan, M | 1 |
| Fève, B | 1 |
| Capeau, J | 2 |
| Lagathu, C | 1 |
| Bereziat, V | 2 |
| Vandanmagsar, B | 1 |
| Yu, Y | 2 |
| Simmler, C | 1 |
| Dang, TN | 1 |
| Kuhn, P | 1 |
| Poulev, A | 1 |
| Ribnicky, DM | 1 |
| Pauli, GF | 1 |
| Floyd, ZE | 1 |
| Kangwan, N | 1 |
| Pratchayasakul, W | 6 |
| Kongkaew, A | 1 |
| Pintha, K | 1 |
| Chattipakorn, N | 12 |
| Chattipakorn, SC | 10 |
| Shu, L | 1 |
| Hou, X | 3 |
| Song, G | 2 |
| Wang, C | 10 |
| Ma, H | 4 |
| Dare, A | 1 |
| Channa, ML | 1 |
| Nadar, A | 1 |
| Zayas-Arrabal, J | 1 |
| Alquiza, A | 1 |
| Rodríguez-de-Yurre, A | 1 |
| Echeazarra, L | 1 |
| Fernández-López, V | 1 |
| Gallego, M | 1 |
| Casis, O | 1 |
| Kim, HW | 1 |
| Le, J | 2 |
| Fu, Y | 1 |
| Han, Q | 1 |
| Wei, X | 1 |
| Ji, H | 1 |
| Chen, Y | 11 |
| Wang, Q | 5 |
| Pi, P | 1 |
| Li, J | 12 |
| Lin, X | 1 |
| Zhang, X | 6 |
| Zhang, Y | 14 |
| Ye, J | 5 |
| Ibrahim, WS | 1 |
| Ahmed, HMS | 1 |
| Mahmoud, AAA | 1 |
| Mahmoud, MF | 2 |
| Ibrahim, IAAE | 1 |
| Soldat-Stanković, V | 1 |
| Popović-Pejičić, S | 1 |
| Stanković, S | 1 |
| Prtina, A | 1 |
| Malešević, G | 1 |
| Bjekić-Macut, J | 4 |
| Livadas, S | 3 |
| Ognjanović, S | 1 |
| Mastorakos, G | 2 |
| Micić, D | 2 |
| Macut, D | 3 |
| Abdulmalek, S | 1 |
| Eldala, A | 1 |
| Awad, D | 1 |
| Balbaa, M | 2 |
| Abdalla, MA | 1 |
| Shah, N | 1 |
| Deshmukh, H | 1 |
| Sahebkar, A | 4 |
| Östlundh, L | 1 |
| Al-Rifai, RH | 1 |
| Atkin, SL | 11 |
| Sathyapalan, T | 7 |
| Cai, M | 3 |
| Shao, X | 3 |
| Xing, F | 1 |
| Gao, X | 3 |
| Zeng, Q | 1 |
| Dilimulati, D | 1 |
| Qu, S | 2 |
| Zhang, M | 5 |
| Qian, H | 1 |
| Xu, W | 1 |
| Cui, L | 2 |
| Wang, R | 2 |
| Wang, J | 14 |
| Tang, M | 1 |
| Wei, M | 1 |
| Lu, J | 3 |
| Zhang, L | 7 |
| Wang, X | 7 |
| Tang, Q | 2 |
| Zhu, Y | 4 |
| Fang, Y | 1 |
| Medina, D | 1 |
| Bartke, A | 1 |
| Yuan, R | 1 |
| Hernández-Jiménez, JL | 1 |
| Barrera, D | 1 |
| Espinoza-Simón, E | 1 |
| González, J | 1 |
| Ortíz-Hernández, R | 1 |
| Escobar, L | 1 |
| Echeverría, O | 1 |
| Torres-Ramírez, N | 1 |
| Oo, TT | 1 |
| Sumneang, N | 1 |
| Ongnok, B | 1 |
| Arunsak, B | 2 |
| Chunchai, T | 2 |
| Kerdphoo, S | 2 |
| Apaijai, N | 7 |
| Liang, G | 1 |
| Zhao, YX | 1 |
| Wang, LJ | 2 |
| Gong, FY | 1 |
| Pan, H | 1 |
| Miao, H | 1 |
| Duan, L | 2 |
| Yang, HB | 1 |
| Zhu, HJ | 1 |
| Kumari, S | 2 |
| Bubak, MT | 1 |
| Schoenberg, HM | 2 |
| Davidyan, A | 1 |
| Elliehausen, CJ | 1 |
| Kuhn, KG | 1 |
| VanWagoner, TM | 1 |
| Karaman, R | 1 |
| Scofield, RH | 1 |
| Miller, BF | 2 |
| Konopka, AR | 2 |
| Krysiak, R | 17 |
| Kowalcze, K | 9 |
| Okopień, B | 17 |
| Wen, Q | 3 |
| Hu, M | 2 |
| Lai, M | 2 |
| Hu, Z | 2 |
| Quan, K | 1 |
| Liu, H | 7 |
| Meng, Y | 2 |
| Wang, S | 4 |
| Wen, X | 1 |
| Yu, C | 3 |
| Huang, S | 1 |
| Zheng, Y | 1 |
| Lin, H | 1 |
| Lu, L | 2 |
| Mai, Z | 1 |
| Zhang, C | 3 |
| Wu, T | 2 |
| Ng, EHY | 1 |
| Stener-Victorin, E | 5 |
| Chalmers, JA | 1 |
| Dalvi, PS | 1 |
| Loganathan, N | 1 |
| McIlwraith, EK | 1 |
| Wellhauser, L | 1 |
| Nazarians-Armavil, A | 1 |
| Eversley, JA | 1 |
| Mohan, H | 1 |
| Stahel, P | 1 |
| Dash, S | 1 |
| Wheeler, MB | 1 |
| Belsham, DD | 1 |
| Jahn, LA | 1 |
| Hartline, L | 1 |
| Barrett, EJ | 3 |
| Garzia, E | 1 |
| Galiano, V | 1 |
| Marfia, G | 1 |
| Navone, S | 1 |
| Grossi, E | 1 |
| Marconi, AM | 1 |
| Aggarwal, H | 1 |
| Pathak, P | 1 |
| Kumar, Y | 1 |
| Jagavelu, K | 1 |
| Dikshit, M | 1 |
| Bakhtyukov, AA | 1 |
| Derkach, KV | 2 |
| Sorokoumov, VN | 1 |
| Stepochkina, AM | 1 |
| Romanova, IV | 1 |
| Morina, IY | 1 |
| Zakharova, IO | 1 |
| Bayunova, LV | 1 |
| Shpakov, AO | 3 |
| Yang, ML | 1 |
| Lu, C | 1 |
| Fan, ZF | 1 |
| Zhao, TR | 1 |
| Cheng, GG | 1 |
| Wang, YD | 1 |
| Cao, JX | 1 |
| Liu, YP | 2 |
| Green, CJ | 1 |
| Marjot, T | 1 |
| Walsby-Tickle, J | 1 |
| Charlton, C | 1 |
| Cornfield, T | 1 |
| Westcott, F | 1 |
| Pinnick, KE | 1 |
| Moolla, A | 1 |
| Hazlehurst, JM | 1 |
| McCullagh, J | 1 |
| Tomlinson, JW | 1 |
| Hodson, L | 1 |
| Tian, JL | 1 |
| Si, X | 1 |
| Shu, C | 1 |
| Wang, YH | 1 |
| Tan, H | 1 |
| Zang, ZH | 1 |
| Zhang, WJ | 1 |
| Xie, X | 1 |
| Li, B | 1 |
| Lule, KO | 1 |
| Akarsu, E | 2 |
| Sayiner, ZA | 2 |
| Lule, NO | 1 |
| Balci, SO | 2 |
| Demirel, C | 3 |
| Bozdag, Z | 2 |
| Korkmaz, M | 2 |
| Yilmaz, I | 2 |
| Czika, A | 1 |
| Yang, Y | 5 |
| Yang, JP | 1 |
| Adu-Gyamfi, EA | 1 |
| Ullah, A | 1 |
| Ruan, LL | 1 |
| Chen, XM | 1 |
| Wang, YX | 1 |
| Wang, MJ | 1 |
| Ding, YB | 1 |
| Natrus, LV | 1 |
| Osadchuk, YS | 1 |
| Lisakovska, OO | 1 |
| Labudzinskyi, DO | 1 |
| Klys, YG | 1 |
| Chaikovsky, YB | 1 |
| Aylor, KW | 1 |
| Chai, W | 1 |
| Moreno-Cabañas, A | 3 |
| Ortega, JF | 4 |
| Morales-Palomo, F | 3 |
| Ramirez-Jimenez, M | 2 |
| Alvarez-Jimenez, L | 2 |
| Mora-Rodriguez, R | 4 |
| Hao, Z | 2 |
| Sun, Y | 9 |
| Li, G | 3 |
| Shen, Y | 2 |
| Wen, Y | 1 |
| Liu, Y | 10 |
| Notaro, ALG | 1 |
| Neto, FTL | 1 |
| Herman, R | 1 |
| Kravos, NA | 1 |
| Jensterle, M | 4 |
| Janež, A | 6 |
| Dolžan, V | 1 |
| Palomba, S | 8 |
| Oróstica, ML | 1 |
| Astorga, I | 1 |
| Plaza-Parrochia, F | 2 |
| Poblete, C | 1 |
| Carvajal, R | 1 |
| García, V | 1 |
| Romero, C | 2 |
| Vega, M | 2 |
| Flores-García, LC | 1 |
| Ventura-Gallegos, JL | 1 |
| Romero-Córdoba, SL | 1 |
| Hernández-Juárez, AJ | 1 |
| Naranjo-Meneses, MA | 1 |
| García-García, E | 1 |
| Méndez, JP | 1 |
| Cabrera-Quintero, AJ | 1 |
| Ramírez-Ruíz, A | 1 |
| Pedraza-Sánchez, S | 1 |
| Meraz-Cruz, N | 1 |
| Vadillo-Ortega, F | 1 |
| Zentella-Dehesa, A | 1 |
| Zhou, ST | 1 |
| Cui, W | 1 |
| Kong, L | 3 |
| Yang, X | 3 |
| García-Sáenz, M | 1 |
| Lobaton-Ginsberg, M | 1 |
| Ferreira-Hermosillo, A | 1 |
| Jethaliya, H | 1 |
| Gajjar, N | 1 |
| Patel, V | 2 |
| Deshpande, S | 1 |
| Patel, R | 2 |
| Lyu, Y | 1 |
| Li, D | 5 |
| Yuan, X | 1 |
| Li, Z | 8 |
| Zhang, J | 15 |
| Ming, X | 1 |
| Shaw, PC | 1 |
| Kong, APS | 1 |
| Zuo, Z | 1 |
| Poonprasartporn, A | 1 |
| Chan, KLA | 1 |
| Cui, YY | 1 |
| Jiajue, JRZ | 1 |
| Chen, MP | 1 |
| Yu, M | 1 |
| Samms, RJ | 1 |
| Cheng, CC | 1 |
| Fourcaudot, M | 1 |
| Heikkinen, S | 1 |
| Khattab, A | 1 |
| Adams, J | 2 |
| Cersosimo, E | 3 |
| Triplitt, C | 4 |
| Puckett, C | 2 |
| Tsintzas, K | 1 |
| Adams, AC | 1 |
| Abdul-Ghani, MA | 2 |
| DeFronzo, RA | 7 |
| Norton, L | 1 |
| Gallagher, EJ | 3 |
| Kase, NG | 1 |
| Bickell, NA | 1 |
| LeRoith, D | 3 |
| Smirnov, VV | 1 |
| Beeraka, NM | 1 |
| Butko, DY | 1 |
| Nikolenko, VN | 1 |
| Bondarev, SA | 1 |
| Achkasov, EE | 1 |
| Sinelnikov, MY | 1 |
| Vikram, PRH | 1 |
| Díaz, M | 4 |
| Carreras-Badosa, G | 1 |
| Villarroya, J | 1 |
| Gavaldà-Navarro, A | 1 |
| Bassols, J | 2 |
| de Zegher, F | 8 |
| López-Bermejo, A | 5 |
| Villarroya, F | 2 |
| Ibáñez, L | 9 |
| Wilson, C | 1 |
| Carpenter, J | 1 |
| Park, S | 1 |
| McHugh, C | 1 |
| Scott, EM | 1 |
| Hickie, IB | 1 |
| Utzschneider, KM | 2 |
| Ehrmann, DA | 6 |
| Arslanian, SA | 4 |
| Barengolts, E | 1 |
| Buchanan, TA | 3 |
| Caprio, S | 7 |
| Edelstein, SL | 4 |
| Hannon, TS | 3 |
| Kahn, SE | 9 |
| Kozedub, A | 1 |
| Mather, KJ | 7 |
| Nadeau, KJ | 10 |
| Sam, S | 2 |
| Tripputi, M | 2 |
| Xiang, AH | 2 |
| El Ghormli, L | 4 |
| Benes, J | 1 |
| Kotrc, M | 1 |
| Kroupova, K | 1 |
| Wohlfahrt, P | 1 |
| Kovar, J | 1 |
| Franekova, J | 1 |
| Hegarova, M | 1 |
| Hoskova, L | 1 |
| Hoskova, E | 1 |
| Pelikanova, T | 1 |
| Jarolim, P | 2 |
| Kautzner, J | 1 |
| Melenovsky, V | 1 |
| Joham, AE | 1 |
| Norman, RJ | 6 |
| Legro, RS | 6 |
| Franks, S | 3 |
| Moran, LJ | 2 |
| Boyle, J | 3 |
| Teede, HJ | 8 |
| Fleifel, AM | 1 |
| Soubh, AA | 1 |
| Abdallah, DM | 1 |
| Ahmed, KA | 1 |
| El-Abhar, HS | 1 |
| Fernández-García, JC | 1 |
| Barrios-Rodríguez, R | 1 |
| Asenjo-Plaza, M | 1 |
| Ramos-Molina, B | 1 |
| Molina-Vega, M | 1 |
| Guzmán-Guzmán, A | 1 |
| Moreno-León, L | 1 |
| Yubero-Serrano, EM | 1 |
| Rius-Díaz, F | 1 |
| Valdés, S | 2 |
| Martínez-González, MÁ | 1 |
| Jiménez-Moleón, JJ | 1 |
| Tinahones, FJ | 3 |
| Reifsnyder, PC | 1 |
| Flurkey, K | 1 |
| Doty, R | 1 |
| Calcutt, NA | 1 |
| Koza, RA | 1 |
| Harrison, DE | 1 |
| Zeng, X | 3 |
| Tan, J | 3 |
| Yi, C | 1 |
| Cheng, J | 3 |
| Xu, L | 2 |
| Yu, Q | 1 |
| Lin, G | 1 |
| Ma, X | 3 |
| Guan, F | 1 |
| Huang, X | 1 |
| Xie, J | 3 |
| Su, Z | 1 |
| Li, Y | 15 |
| Elmaghraby, AM | 1 |
| Ali, N | 1 |
| Mostafa, I | 1 |
| El-Shazly, AM | 1 |
| Abdelfattah, MAO | 1 |
| Sobeh, M | 1 |
| Shaaban, HH | 1 |
| Alzaim, I | 1 |
| El-Mallah, A | 1 |
| Aly, RG | 1 |
| El-Yazbi, AF | 1 |
| Wahid, A | 1 |
| Chen, X | 9 |
| Lan, Y | 2 |
| Yang, L | 3 |
| Li, H | 8 |
| Zhu, X | 2 |
| Zhao, Y | 5 |
| Long, C | 1 |
| Wang, M | 3 |
| Xie, Q | 1 |
| Wu, J | 4 |
| Cheng, X | 2 |
| Dong, H | 2 |
| Ma, R | 2 |
| Zou, Y | 1 |
| Wang, W | 6 |
| Zheng, Q | 2 |
| Feng, Y | 3 |
| Tan, Z | 1 |
| Deng, Y | 5 |
| Gu, B | 1 |
| Sun, A | 3 |
| Love, KM | 1 |
| Horton, WB | 1 |
| Dahabiyeh, LA | 1 |
| Mujammami, M | 1 |
| AlMalki, RH | 1 |
| Arafat, T | 1 |
| Benabdelkamel, H | 1 |
| Alfadda, AA | 1 |
| Abdel Rahman, AM | 1 |
| Cao, G | 2 |
| Gong, T | 1 |
| Du, Y | 2 |
| Ge, T | 1 |
| Eleazu, CO | 1 |
| Obeten, UN | 1 |
| Ozor, G | 1 |
| Njemanze, CC | 1 |
| Eleazu, KC | 1 |
| Egedigwe-Ekeleme, AC | 1 |
| Okorie, UC | 1 |
| Ogunwa, SC | 1 |
| Adeolu, AI | 1 |
| Okoh, PN | 1 |
| Kalu, AO | 1 |
| Onyia, CJ | 1 |
| Onyia, S | 1 |
| Ossai, P | 1 |
| Chikezie, CC | 1 |
| Odii, BC | 1 |
| Obi, V | 1 |
| Igwe, VM | 1 |
| Amobi, CA | 1 |
| Ugada, OJ | 1 |
| Kalu, WO | 1 |
| Kanu, S | 1 |
| Fakhrolmobasheri, M | 1 |
| Abhari, AP | 1 |
| Manshaee, B | 1 |
| Heidarpour, M | 1 |
| Shafie, D | 1 |
| Mohammadbeigi, E | 1 |
| Mozafari, AM | 1 |
| Mazaheri-Tehrani, S | 1 |
| Huang, Y | 3 |
| Yan, C | 1 |
| Liang, E | 1 |
| Liu, T | 2 |
| Mao, J | 2 |
| Ramadan, NM | 1 |
| Elmasry, K | 1 |
| Elsayed, HRH | 1 |
| El-Mesery, A | 1 |
| Eraky, SM | 1 |
| Kuznetsov, KO | 1 |
| Safina, ER | 1 |
| Gaimakova, DV | 1 |
| Frolova, YS | 1 |
| Oganesyan, IY | 1 |
| Sadertdinova, AG | 1 |
| Nazmieva, KA | 1 |
| Islamgulov, AH | 1 |
| Karimova, AR | 1 |
| Galimova, AM | 1 |
| Rizvanova, EV | 1 |
| Azócar-Gallardo, J | 1 |
| Ramirez-Campillo, R | 1 |
| Afonso, J | 1 |
| Sá, M | 1 |
| Granacher, U | 1 |
| González-Rojas, L | 1 |
| Ojeda-Aravena, A | 1 |
| García-García, JM | 1 |
| Gao, L | 5 |
| Cheng, Z | 3 |
| Su, B | 3 |
| Su, X | 3 |
| Song, W | 3 |
| Guo, Y | 4 |
| Liao, L | 5 |
| Tan, X | 3 |
| Xu, F | 3 |
| Pang, S | 4 |
| Wang, K | 3 |
| Sun, J | 5 |
| Ji, L | 3 |
| Al-Kuraishy, HM | 5 |
| Al-Gareeb, AI | 5 |
| Alexiou, A | 3 |
| Papadakis, M | 3 |
| Nadwa, EH | 3 |
| Albogami, SM | 3 |
| Alorabi, M | 3 |
| Saad, HM | 5 |
| Batiha, GE | 5 |
| Wan, Y | 3 |
| Xu, J | 4 |
| Yan, Y | 5 |
| Li, Q | 6 |
| Shen, L | 4 |
| Guo, K | 3 |
| Zhou, X | 8 |
| Motta, BP | 2 |
| Pinheiro, CG | 2 |
| Figueiredo, ID | 2 |
| Cardoso, FN | 2 |
| Oliveira, JO | 2 |
| Machado, RTA | 2 |
| da Silva, PB | 2 |
| Chorilli, M | 2 |
| Brunetti, IL | 2 |
| Baviera, AM | 2 |
| Rokicka, D | 3 |
| Wróbel, M | 2 |
| Stołtny, D | 2 |
| Strojek, K | 3 |
| Baiges-Gaya, G | 1 |
| Rodríguez-Tomàs, E | 1 |
| Castañé, H | 1 |
| Jiménez-Franco, A | 1 |
| Amigó, N | 1 |
| Camps, J | 3 |
| Joven, J | 4 |
| Lee, CH | 3 |
| Chiang, CF | 2 |
| Lin, FH | 1 |
| Kuo, FC | 1 |
| Su, SC | 2 |
| Huang, CL | 1 |
| Li, PF | 1 |
| Liu, JS | 2 |
| Lu, CH | 2 |
| Hsieh, CH | 2 |
| Hung, YJ | 3 |
| Shieh, YS | 2 |
| Khalafani, Z | 1 |
| Zamani-Garmsiri, F | 2 |
| Panahi, G | 1 |
| Meshkani, R | 2 |
| Kamboj, P | 1 |
| Kaushik, A | 1 |
| Handa, S | 1 |
| Dutta, P | 1 |
| Saikia, UN | 1 |
| Pal, A | 1 |
| De, D | 1 |
| Rabah, HM | 1 |
| Mohamed, DA | 1 |
| Mariah, RA | 1 |
| Abd El-Khalik, SR | 1 |
| Khattab, HA | 1 |
| AbuoHashish, NA | 1 |
| Abdelsattar, AM | 1 |
| Raslan, MA | 1 |
| Farghal, EE | 1 |
| Eltokhy, AK | 1 |
| Alqudah, A | 3 |
| Qnais, EY | 1 |
| Wedyan, MA | 1 |
| Altaber, S | 1 |
| Abudalo, R | 2 |
| Gammoh, O | 2 |
| Alkhateeb, H | 2 |
| Bataineh, S | 1 |
| Athamneh, RY | 2 |
| Oqal, M | 2 |
| Abu-Safieh, K | 1 |
| McClements, L | 2 |
| Kakoty, V | 1 |
| Kc, S | 1 |
| Yang, CH | 1 |
| Dubey, SK | 1 |
| Taliyan, R | 1 |
| Wu, Z | 3 |
| Zhang, B | 2 |
| Chen, F | 2 |
| Xia, R | 1 |
| Zhu, D | 5 |
| Chen, B | 1 |
| Lin, A | 1 |
| Zheng, C | 2 |
| Hou, D | 1 |
| Zhang, S | 6 |
| Hou, K | 1 |
| Basiak, M | 1 |
| Szkróbka, W | 6 |
| Peng, Q | 1 |
| Ouyang, J | 1 |
| Ren, S | 1 |
| Xie, H | 2 |
| Wu, X | 6 |
| Hei, C | 1 |
| Sun, M | 1 |
| Chang, Q | 1 |
| Liu, X | 3 |
| He, R | 1 |
| Najeeb, T | 1 |
| Soomro Late, MS | 1 |
| Fawwad, A | 1 |
| Waris, N | 1 |
| Nangrejo, R | 1 |
| Siddiqui, IA | 1 |
| Aziz, Q | 1 |
| Basit, A | 2 |
| Ni, Z | 1 |
| Yuan, Z | 1 |
| Yu, J | 1 |
| Zhang, D | 1 |
| Yao, R | 1 |
| Zhou, L | 2 |
| Gao, R | 1 |
| Qin, L | 1 |
| Min, W | 1 |
| Batra, GK | 1 |
| Anand, A | 1 |
| Sharma, S | 4 |
| Bhansali, S | 1 |
| Patil, AN | 1 |
| Belani, MA | 1 |
| Shah, P | 2 |
| Banker, M | 1 |
| Gupta, SS | 1 |
| Gao, H | 2 |
| Rao, Y | 1 |
| Qian, L | 1 |
| Thongnak, L | 3 |
| Pengrattanachot, N | 1 |
| Promsan, S | 1 |
| Phengpol, N | 1 |
| Sutthasupha, P | 1 |
| Jaikumkao, K | 3 |
| Lungkaphin, A | 3 |
| Qnais, E | 1 |
| Alshaikh, HA | 1 |
| Al-Hashimi, N | 1 |
| Alqudah, M | 1 |
| Subramaniam, S | 1 |
| Ong, KC | 1 |
| Sabaratnam, V | 1 |
| Chua, KH | 1 |
| Kuppusamy, UR | 1 |
| Santos, C | 1 |
| Brito-Costa, S | 1 |
| Margalho, L | 1 |
| Monteiro, P | 2 |
| Hambly, R | 1 |
| Kearney, N | 1 |
| Hughes, R | 1 |
| Fletcher, JM | 1 |
| Kirby, B | 1 |
| Matowane, GR | 1 |
| Mashele, SS | 1 |
| Makhafola, TJ | 1 |
| Chukwuma, CI | 2 |
| Wang, H | 6 |
| Zhang, H | 7 |
| Liang, Z | 1 |
| Hu, W | 2 |
| Qiu, S | 1 |
| Li, K | 2 |
| Dai, H | 1 |
| Yang, M | 5 |
| Yang, G | 6 |
| Li, L | 12 |
| Alsoghachi, H | 1 |
| Althanoon, Z | 1 |
| Mundaca-Uribe, R | 1 |
| Holay, M | 1 |
| Abbas, A | 1 |
| Askarinam, N | 1 |
| Sage-Sepulveda, JS | 1 |
| Kubiatowicz, L | 1 |
| Fang, RH | 1 |
| Zeng, H | 1 |
| Liu, D | 6 |
| Xie, T | 1 |
| Chen, Z | 1 |
| Huang, Q | 3 |
| Lai, X | 1 |
| Nazirudeen, R | 1 |
| Sridhar, S | 1 |
| Priyanka, R | 1 |
| Sumathi, B | 1 |
| Natarajan, V | 1 |
| Subbiah, E | 1 |
| Raghavan, KS | 1 |
| Sangumani, J | 1 |
| Lopez-Candales, A | 1 |
| Monte, S | 1 |
| Sawalha, K | 1 |
| Norgard, NB | 1 |
| Gonzalez-Lopez, C | 1 |
| Wojeck, BS | 1 |
| Fang, S | 1 |
| Liang, Y | 1 |
| Tian, Y | 1 |
| Yuan, J | 1 |
| Chen, Q | 3 |
| Tawfeq, M | 1 |
| Sarhat, E | 2 |
| Allow, S | 1 |
| Tosti, G | 1 |
| Barberio, A | 1 |
| Tartaglione, L | 1 |
| Rizzi, A | 1 |
| Di Leo, M | 1 |
| Viti, L | 1 |
| Sirico, A | 1 |
| De Carolis, S | 1 |
| Pontecorvi, A | 1 |
| Lanzone, A | 2 |
| Pitocco, D | 1 |
| Jayabal, D | 1 |
| Jayanthi, S | 1 |
| Thirumalaisamy, R | 1 |
| Shimu, MSS | 1 |
| Ismail, HM | 1 |
| Barua, S | 1 |
| Sabharwal, A | 1 |
| Libman, I | 3 |
| Bacha, F | 5 |
| Tosur, M | 1 |
| Redondo, MJ | 1 |
| Retnakaran, R | 4 |
| Pu, J | 1 |
| Emery, A | 1 |
| Harris, SB | 3 |
| Reichert, SM | 1 |
| Gerstein, HC | 2 |
| McInnes, N | 1 |
| Kramer, CK | 2 |
| Zinman, B | 6 |
| Guarano, A | 1 |
| Capozzi, A | 2 |
| Cristodoro, M | 1 |
| Di Simone, N | 1 |
| Lello, S | 2 |
| Melin, J | 1 |
| Forslund, M | 1 |
| Alesi, S | 1 |
| Piltonen, T | 1 |
| Romualdi, D | 1 |
| Spritzer, PM | 2 |
| Tay, CT | 1 |
| Pena, A | 1 |
| Witchel, SF | 2 |
| Mousa, A | 1 |
| Teede, H | 1 |
| Mora-Gonzalez, D | 1 |
| Omar, HS | 1 |
| Ibrahim, OA | 1 |
| Sayed, MG | 1 |
| Faruk, EM | 1 |
| Fouad, H | 1 |
| Safwat, M | 1 |
| Gkiourtzis, N | 1 |
| Michou, P | 1 |
| Moutafi, M | 1 |
| Glava, A | 1 |
| Cheirakis, K | 1 |
| Christakopoulos, A | 1 |
| Vouksinou, E | 1 |
| Fotoulaki, M | 1 |
| Wei, L | 1 |
| Zhu, S | 1 |
| Brīvība, M | 1 |
| Silamiķele, L | 1 |
| Kalniņa, I | 1 |
| Silamiķelis, I | 1 |
| Birzniece, L | 1 |
| Ansone, L | 1 |
| Jagare, L | 1 |
| Elbere, I | 1 |
| Kloviņš, J | 1 |
| Erukainure, OL | 1 |
| Oyebode, OA | 1 |
| Chuturgoon, AA | 1 |
| Ghazi, T | 1 |
| Muhammad, A | 1 |
| Aljoundi, A | 1 |
| Elamin, G | 1 |
| Islam, MS | 1 |
| Hjortebjerg, R | 1 |
| Kristiansen, MR | 1 |
| Brandslund, I | 1 |
| Aa Olsen, D | 1 |
| Stidsen, JV | 1 |
| Nielsen, JS | 1 |
| Frystyk, J | 2 |
| Qu, H | 1 |
| Shou, L | 1 |
| Mahmoud, MM | 1 |
| Rashed, LA | 2 |
| Soliman, SA | 1 |
| Sayed, SM | 1 |
| Kamel, O | 1 |
| Kamar, SS | 1 |
| Hussien, RES | 1 |
| Yang, AJT | 2 |
| Mohammad, A | 1 |
| Finch, MS | 1 |
| Tsiani, E | 1 |
| Spencer, G | 1 |
| Necakov, A | 1 |
| MacPherson, REK | 2 |
| Bradley, EA | 1 |
| Premilovac, D | 1 |
| Betik, AC | 1 |
| Hu, D | 2 |
| Attrill, E | 1 |
| Richards, SM | 1 |
| Rattigan, S | 1 |
| Keske, MA | 1 |
| Shang, J | 1 |
| Zhou, W | 1 |
| Bobenko, AI | 1 |
| Heller, S | 1 |
| Schmitt, N | 1 |
| Cherdtrakulkiat, R | 1 |
| Lawung, R | 1 |
| Nabu, S | 1 |
| Tantimavanich, S | 1 |
| Sinthupoom, N | 1 |
| Prachayasittikul, S | 1 |
| Prachayasittikul, V | 1 |
| Zhang, Z | 6 |
| Yan, K | 1 |
| Xiao, Y | 1 |
| He, D | 1 |
| Zhao, F | 1 |
| Su, JF | 1 |
| Lun, SM | 1 |
| Hou, YJ | 1 |
| Duan, LJ | 1 |
| Wang, NC | 1 |
| Shen, FF | 1 |
| Zhang, YW | 2 |
| Gao, ZW | 1 |
| Du, XJ | 1 |
| Zhou, FY | 1 |
| Yin, Z | 1 |
| Zhu, J | 3 |
| Yan, D | 2 |
| Lou, H | 1 |
| Yu, H | 2 |
| Feng, C | 1 |
| Wang, Z | 2 |
| Hu, X | 2 |
| Chen, H | 2 |
| Duan, Y | 1 |
| Zhi, D | 1 |
| Zou, M | 3 |
| Zhao, Z | 1 |
| Popović, KJ | 1 |
| Popović, DJ | 1 |
| Miljković, D | 1 |
| Lalošević, D | 1 |
| Čapo, I | 1 |
| Popović, JK | 1 |
| Liu, M | 2 |
| Song, H | 2 |
| Xing, Z | 1 |
| Lu, G | 1 |
| Chen, D | 1 |
| Valentini, AM | 1 |
| Di Pinto, F | 1 |
| Coletta, S | 1 |
| Guerra, V | 1 |
| Armentano, R | 1 |
| Caruso, ML | 1 |
| Gong, J | 2 |
| Wang, N | 4 |
| Bian, L | 1 |
| Ye, M | 1 |
| Wen, N | 1 |
| Fu, M | 1 |
| Fan, W | 1 |
| Dong, G | 1 |
| Lin, XH | 1 |
| Liu, HH | 1 |
| Gao, DM | 1 |
| Cui, JF | 1 |
| Ren, ZG | 1 |
| Chen, RX | 1 |
| Önal, B | 1 |
| Özen, D | 1 |
| Demir, B | 1 |
| Akkan, AG | 1 |
| Özyazgan, S | 1 |
| Payette, G | 1 |
| Geoffroy, V | 1 |
| Martineau, C | 1 |
| Villemur, R | 1 |
| Jameel, T | 1 |
| Baig, M | 1 |
| Gazzaz, ZJ | 1 |
| Tashkandi, JM | 1 |
| Al Alhareth, NS | 1 |
| Khan, SA | 1 |
| Butt, NS | 1 |
| Geng, Y | 1 |
| Miao, T | 1 |
| Liu, W | 4 |
| Jiang, W | 1 |
| Yu, ZY | 1 |
| Wu, L | 2 |
| Qu, B | 1 |
| Sun, JX | 1 |
| Cai, AL | 1 |
| Xie, LM | 1 |
| Groeneveld, J | 1 |
| Ho, SL | 1 |
| Mackensen, A | 1 |
| Mohtadi, M | 1 |
| Laepple, T | 1 |
| Genovesi, S | 1 |
| Nava, E | 1 |
| Bartolucci, C | 1 |
| Severi, S | 1 |
| Vincenti, A | 1 |
| Contaldo, G | 1 |
| Bigatti, G | 1 |
| Ciurlino, D | 1 |
| Bertoli, SV | 1 |
| Slovak, JE | 1 |
| Hwang, JK | 1 |
| Rivera, SM | 1 |
| Villarino, NF | 1 |
| Ling, M | 1 |
| Ji, J | 2 |
| Zhao, D | 1 |
| Sha, Y | 1 |
| Liang, C | 2 |
| Guo, Q | 1 |
| Zhou, C | 1 |
| Ma, Z | 1 |
| Zhao, W | 2 |
| Xia, X | 1 |
| Jiang, Y | 2 |
| Peng, J | 1 |
| Jia, Z | 1 |
| Li, F | 2 |
| Mo, J | 1 |
| Huang, T | 3 |
| Zhu, Q | 1 |
| Ge, RS | 1 |
| Fortunato, G | 1 |
| Lin, J | 2 |
| Agarwal, PK | 1 |
| Kohen, A | 1 |
| Singh, P | 1 |
| Cheatum, CM | 1 |
| Hayman, A | 1 |
| Kebede, B | 1 |
| Stewart, I | 1 |
| Chen, G | 3 |
| Frew, R | 1 |
| Guo, X | 3 |
| Gong, Q | 1 |
| Borowiec, J | 1 |
| Han, S | 1 |
| Willis, M | 1 |
| Kreouzis, T | 1 |
| Yu, K | 1 |
| Chirvony, VS | 1 |
| Sekerbayev, KS | 1 |
| Pérez-Del-Rey, D | 1 |
| Martínez-Pastor, JP | 1 |
| Palazon, F | 1 |
| Boix, PP | 1 |
| Taurbayev, TI | 1 |
| Sessolo, M | 1 |
| Bolink, HJ | 1 |
| Lu, M | 1 |
| Xiao, J | 3 |
| Song, M | 1 |
| Chen, C | 3 |
| Cao, Y | 1 |
| Ho, CT | 1 |
| Qi, B | 1 |
| Zhang, W | 3 |
| Fang, L | 1 |
| Xie, CL | 1 |
| Chen, R | 1 |
| Yang, S | 3 |
| Xia, JM | 1 |
| Zhang, GY | 2 |
| Chen, CH | 2 |
| Yang, XW | 1 |
| Domenech-Ximenos, B | 1 |
| Garza, MS | 1 |
| Prat-González, S | 1 |
| Sepúlveda-Martínez, Á | 2 |
| Crispi, F | 1 |
| Perea, RJ | 1 |
| Garcia-Alvarez, A | 1 |
| Sitges, M | 1 |
| Kalumpha, M | 1 |
| Guyo, U | 1 |
| Zinyama, NP | 1 |
| Vakira, FM | 1 |
| Nyamunda, BC | 1 |
| Varga, M | 1 |
| Drácz, L | 1 |
| Kolbenheyer, E | 1 |
| Varga, F | 1 |
| Patai, ÁV | 1 |
| Solymosi, N | 1 |
| Patai, Á | 1 |
| Kiss, J | 1 |
| Gaál, V | 1 |
| Nyul, Z | 1 |
| Mosdósi, B | 1 |
| Valdez, M | 1 |
| Moosavi, L | 1 |
| Heidari, A | 1 |
| Novakovic-Agopian, T | 1 |
| Kornblith, E | 1 |
| Abrams, G | 1 |
| McQuaid, JR | 1 |
| Posecion, L | 1 |
| Burciaga, J | 1 |
| D'Esposito, M | 1 |
| Chen, AJW | 1 |
| Samy El Gendy, NM | 1 |
| Wesolowska, P | 1 |
| Georg, D | 1 |
| Lechner, W | 1 |
| Kazantsev, P | 1 |
| Bokulic, T | 1 |
| Tedgren, AC | 1 |
| Adolfsson, E | 1 |
| Campos, AM | 1 |
| Alves, VGL | 1 |
| Suming, L | 1 |
| Hao, W | 1 |
| Ekendahl, D | 1 |
| Koniarova, I | 1 |
| Bulski, W | 1 |
| Chelminski, K | 1 |
| Samper, JLA | 1 |
| Vinatha, SP | 1 |
| Rakshit, S | 1 |
| Siri, S | 1 |
| Tomsejm, M | 1 |
| Tenhunen, M | 1 |
| Povall, J | 1 |
| Kry, SF | 1 |
| Followill, DS | 1 |
| Thwaites, DI | 1 |
| Izewska, J | 1 |
| Kang, JH | 1 |
| Yoon, Y | 1 |
| Song, J | 4 |
| Van de Winckel, A | 1 |
| Gauthier, L | 1 |
| Chao, CT | 1 |
| Lee, YH | 1 |
| Li, CM | 2 |
| Han, DS | 1 |
| Huang, JW | 1 |
| Huang, KC | 1 |
| Ni, L | 1 |
| Güttinger, R | 1 |
| Triana, CA | 1 |
| Spingler, B | 1 |
| Baldridge, KK | 1 |
| Patzke, GR | 1 |
| Shen, X | 2 |
| Wang, B | 2 |
| Xie, S | 2 |
| Deng, W | 2 |
| Wu, D | 3 |
| Zhang, Q | 2 |
| Voskamp, BJ | 1 |
| Peelen, MJCS | 1 |
| Ravelli, ACJ | 1 |
| van der Lee, R | 1 |
| Mol, BWJ | 1 |
| Pajkrt, E | 1 |
| Ganzevoort, W | 1 |
| Kazemier, BM | 1 |
| Tibrewala, R | 1 |
| Bahroos, E | 1 |
| Mehrabian, H | 1 |
| Foreman, SC | 1 |
| Link, TM | 1 |
| Pedoia, V | 1 |
| Majumdar, S | 1 |
| Jablonski, CL | 1 |
| Leonard, C | 1 |
| Salo, P | 1 |
| Krawetz, RJ | 1 |
| Yoon, N | 1 |
| Hong, SN | 1 |
| Cho, JG | 1 |
| Jeong, HK | 1 |
| Lee, KH | 1 |
| Park, HW | 1 |
| Barman, S | 1 |
| Konai, MM | 1 |
| Samaddar, S | 1 |
| Haldar, J | 1 |
| Mohamed, HSH | 1 |
| Li, CF | 1 |
| Hu, ZY | 1 |
| Deng, Z | 1 |
| Chen, LH | 1 |
| Su, BL | 1 |
| Chu, K | 1 |
| Li, YB | 1 |
| Xu, C | 3 |
| Zou, Z | 1 |
| Xia, Y | 1 |
| Zhao, P | 1 |
| Wang, HT | 1 |
| de Biase, S | 1 |
| Pellitteri, G | 1 |
| Gigli, GL | 1 |
| Valente, M | 1 |
| Abdulmalek, SA | 1 |
| Frendo-Cumbo, S | 2 |
| Fang, P | 1 |
| Gu, X | 2 |
| Shi, M | 2 |
| Bo, P | 1 |
| Bu, L | 1 |
| Tao, X | 1 |
| Cai, L | 1 |
| Ge, S | 1 |
| Deng, X | 1 |
| Ruegsegger, GN | 1 |
| Vanderboom, PM | 1 |
| Dasari, S | 1 |
| Klaus, KA | 1 |
| Kabiraj, P | 1 |
| McCarthy, CB | 1 |
| Lucchinetti, CF | 1 |
| Nair, KS | 3 |
| Ho-Plagaro, A | 2 |
| Santiago-Fernandez, C | 1 |
| García-Serrano, S | 1 |
| Rodriguez, C | 1 |
| Garrido-Sanchez, L | 1 |
| Escamilla, A | 1 |
| Gonzalo, M | 2 |
| Montiel-Casado, C | 1 |
| Alcaín-Martínez, G | 1 |
| Garcia-Muñoz, B | 1 |
| Ruiz-Santana, N | 1 |
| Vázquez-Pedreño, L | 1 |
| Garcia-Fuentes, E | 2 |
| De Gaetano, A | 1 |
| Hardy, TA | 1 |
| Chow, HM | 1 |
| Cheng, A | 1 |
| Song, X | 1 |
| So, RWL | 1 |
| Herrup, K | 1 |
| An, H | 1 |
| Qin, C | 1 |
| Sesaki, H | 1 |
| Guo, S | 2 |
| Radovick, S | 2 |
| Hussain, M | 1 |
| Maheshwari, A | 1 |
| Wondisford, FE | 2 |
| O'Rourke, B | 1 |
| He, L | 2 |
| Ganie, MA | 6 |
| Rashid, A | 2 |
| Sood, M | 1 |
| Sofi, NY | 1 |
| Wani, IA | 4 |
| Nisar, S | 2 |
| Butt, TP | 1 |
| Gupta, N | 3 |
| Bhat, D | 1 |
| Choh, N | 1 |
| Masoodi, SR | 1 |
| Adeyemi, WJ | 1 |
| Olayaki, LA | 1 |
| Abdussalam, TA | 1 |
| Fabiyi, TO | 1 |
| Raji, TL | 1 |
| Adetunji, AA | 1 |
| Duan, C | 1 |
| Hu, Y | 3 |
| Huang, W | 2 |
| Xie, YJ | 1 |
| Liu, YT | 1 |
| Long, SL | 1 |
| Mo, ZC | 1 |
| Shuster, DL | 2 |
| Shireman, LM | 2 |
| Shen, DD | 2 |
| Flood Nichols, SK | 2 |
| Ahmed, MS | 2 |
| Clark, S | 2 |
| Caritis, S | 2 |
| Venkataramanan, R | 2 |
| Haas, DM | 2 |
| Quinney, SK | 2 |
| Haneline, LS | 2 |
| Tita, AT | 2 |
| Manuck, TA | 2 |
| Thummel, KE | 2 |
| Morris Brown, L | 1 |
| Ren, Z | 3 |
| Brown, Z | 2 |
| Easterling, TR | 2 |
| Hebert, MF | 2 |
| Serfaty, L | 1 |
| Swe, MT | 1 |
| Pongchaidecha, A | 2 |
| Chatsudthipong, V | 2 |
| Zhou, N | 1 |
| Gai, S | 1 |
| Brown, LM | 1 |
| Cabrera-Cruz, H | 1 |
| Oróstica, L | 1 |
| Torres-Pinto, I | 1 |
| Vatopoulou, A | 1 |
| Tziomalos, K | 2 |
| Wolnowska, M | 1 |
| Lim, S | 2 |
| Ku, EJ | 1 |
| Lee, SY | 2 |
| Lee, JE | 2 |
| Kim, KM | 1 |
| Davies, MJ | 1 |
| Biondo, LA | 1 |
| Teixeira, AAS | 1 |
| de O S Ferreira, KC | 1 |
| Neto, JCR | 1 |
| Mohamad, HE | 1 |
| Asker, ME | 1 |
| Keshawy, MM | 1 |
| Abdel Aal, SM | 1 |
| Mahmoud, YK | 1 |
| Bhat, GA | 1 |
| Shaheen, F | 1 |
| Shrivastava, M | 1 |
| Shah, ZA | 4 |
| Arslanian, S | 5 |
| Haymond, MH | 1 |
| Chan, CL | 1 |
| Chernausek, SD | 1 |
| Gandica, RG | 1 |
| Gubitosi-Klug, R | 1 |
| Levitsky, LL | 3 |
| Siska, M | 1 |
| Willi, SM | 2 |
| Wei, J | 2 |
| Long, M | 1 |
| Stomby, A | 1 |
| Otten, J | 1 |
| Ryberg, M | 1 |
| Andrew, R | 1 |
| Walker, BR | 3 |
| Olsson, T | 1 |
| García-Beltran, C | 1 |
| Cereijo, R | 1 |
| Quesada-López, T | 1 |
| Malpique, R | 1 |
| Kanti, G | 1 |
| Anadol-Schmitz, E | 1 |
| Bobrov, P | 1 |
| Strassburger, K | 1 |
| Kahl, S | 1 |
| Zaharia, OP | 1 |
| Sarabhai, T | 1 |
| Karusheva, Y | 1 |
| Burkart, V | 1 |
| Markgraf, DF | 1 |
| Trenkamp, S | 1 |
| Ziegler, D | 1 |
| Szendroedi, J | 1 |
| Roden, M | 3 |
| White, SL | 2 |
| Begum, S | 1 |
| Vieira, MC | 1 |
| Seed, P | 1 |
| Lawlor, DL | 1 |
| Sattar, N | 8 |
| Nelson, SM | 1 |
| Welsh, P | 3 |
| Pasupathy, D | 1 |
| Poston, L | 1 |
| Feng, R | 1 |
| Yue, J | 1 |
| Qian, C | 1 |
| Rayner, CK | 1 |
| Ma, J | 3 |
| Halliday, G | 1 |
| Huot, JR | 1 |
| Satoh, T | 1 |
| Baust, JJ | 1 |
| Fisher, A | 1 |
| Cook, T | 1 |
| Avolio, T | 1 |
| Goncharov, DA | 1 |
| Bai, Y | 2 |
| Vanderpool, RR | 1 |
| Considine, RV | 1 |
| Bonetto, A | 1 |
| Bachman, TN | 1 |
| Sebastiani, A | 1 |
| McTiernan, CF | 1 |
| Mora, AL | 1 |
| Machado, RF | 1 |
| Goncharova, EA | 1 |
| Gladwin, MT | 1 |
| Lai, YC | 1 |
| Tagi, VM | 1 |
| Samvelyan, S | 1 |
| Chiarelli, F | 1 |
| O'Brien, B | 1 |
| Dahiya, R | 1 |
| Kimble, R | 1 |
| Nayak, G | 1 |
| Salian, SR | 1 |
| Agarwal, P | 1 |
| Suresh Poojary, P | 1 |
| Rao, A | 1 |
| Kalthur, SG | 1 |
| Shreya, AB | 1 |
| Mutalik, S | 1 |
| Adiga, SK | 1 |
| Kalthur, G | 1 |
| Jinawong, K | 3 |
| Wongsuchai, S | 1 |
| Saad, ZA | 1 |
| Khodeer, DM | 1 |
| Zaitone, SA | 1 |
| Ahmed, AAM | 1 |
| Moustafa, YM | 1 |
| Naghiaee, Y | 3 |
| Didehdar, R | 2 |
| Malekpour-Dehkordi, Z | 2 |
| Pourrajab, F | 2 |
| Mohiti-Ardakani, J | 3 |
| Shah, M | 2 |
| Adel, MM | 1 |
| Tahsin, B | 1 |
| Guerra, Y | 1 |
| Fogelfeld, L | 2 |
| Rai, RC | 1 |
| Bagul, PK | 3 |
| Banerjee, SK | 3 |
| Street, ME | 1 |
| Cirillo, F | 1 |
| Catellani, C | 1 |
| Dauriz, M | 1 |
| Lazzeroni, P | 1 |
| Sartori, C | 1 |
| Moghetti, P | 4 |
| Gutiérrez-Repiso, C | 1 |
| Moreno-Indias, I | 1 |
| Martín-Núñez, GM | 1 |
| Rodríguez-Cañete, A | 1 |
| Tu, H | 1 |
| Yao, J | 1 |
| Jiang, Z | 2 |
| Zhang, R | 2 |
| Huo, P | 1 |
| Lei, X | 1 |
| Scambia, G | 1 |
| Battaglia, C | 2 |
| Battaglia, B | 1 |
| Casadio, P | 1 |
| Rizzo, R | 1 |
| Artini, PG | 2 |
| Su, M | 1 |
| Sun, L | 2 |
| Li, W | 2 |
| Yuan, Y | 2 |
| Zheng, L | 1 |
| Yin, S | 1 |
| Dai, C | 1 |
| Zhao, C | 2 |
| Pan, Z | 2 |
| Chee, YJ | 1 |
| Tan, SK | 1 |
| Yeoh, E | 1 |
| Warrilow, A | 1 |
| Somerset, S | 1 |
| Pumpa, K | 1 |
| Fleet, R | 1 |
| Ren, GF | 1 |
| Xiao, LL | 1 |
| Ma, XJ | 1 |
| Yan, YS | 1 |
| Jiao, PF | 1 |
| Liu, CY | 1 |
| Chang, TC | 1 |
| Lin, SH | 1 |
| Wu, ST | 1 |
| Cha, TL | 1 |
| Tsao, CW | 1 |
| Palacios, T | 1 |
| Vitetta, L | 1 |
| Coulson, S | 1 |
| Madigan, CD | 1 |
| Lam, YY | 1 |
| Manuel, R | 1 |
| Briskey, D | 1 |
| Hendy, C | 1 |
| Kim, JN | 1 |
| Ishoey, T | 1 |
| Soto-Giron, MJ | 1 |
| Schott, EM | 1 |
| Toledo, G | 1 |
| Caterson, ID | 1 |
| Yang, PK | 1 |
| Chou, CH | 1 |
| Chang, CH | 1 |
| Chen, SU | 1 |
| Ho, HN | 2 |
| Chen, MJ | 2 |
| Xu, XH | 1 |
| Hu, Q | 1 |
| Zhou, LS | 1 |
| Xu, LJ | 2 |
| Zou, X | 3 |
| Lu, FE | 2 |
| Yi, P | 2 |
| Xiang, L | 1 |
| Wu, Q | 1 |
| Osada, H | 1 |
| Yoshida, M | 1 |
| Pan, W | 1 |
| Qi, J | 2 |
| Güneş, H | 2 |
| Özmen, Ş | 1 |
| Çelik, E | 1 |
| Temiz, F | 1 |
| Morgante, G | 8 |
| Massaro, MG | 3 |
| Scolaro, V | 1 |
| Cappelli, V | 3 |
| Luddi, A | 1 |
| Troìa, L | 1 |
| De Leo, V | 10 |
| De Diego, MV | 1 |
| Gómez-Pardo, O | 1 |
| Groar, JK | 1 |
| López-Escobar, A | 1 |
| Martín-Estal, I | 1 |
| Castilla-Cortázar, I | 1 |
| Rodríguez-Zambrano, MÁ | 1 |
| Larsen, AH | 1 |
| Wiggers, H | 1 |
| Dollerup, OL | 1 |
| Jespersen, NR | 1 |
| Hansson, NH | 1 |
| Frøkiær, J | 1 |
| Brøsen, K | 1 |
| Nørrelund, H | 1 |
| Bøtker, HE | 1 |
| Møller, N | 1 |
| Jessen, N | 1 |
| Kim, HS | 2 |
| Ren, G | 2 |
| Kim, T | 1 |
| Bhatnagar, S | 1 |
| Yang, Q | 3 |
| Bahk, YY | 1 |
| Kim, JA | 1 |
| Lu, Z | 2 |
| Qi, L | 1 |
| Lin, YR | 1 |
| Wang, GC | 1 |
| Li, JQ | 1 |
| Yu, JM | 1 |
| Kyo, S | 1 |
| Nakayama, K | 1 |
| Cao, D | 1 |
| Yan, M | 1 |
| Malin, SK | 5 |
| Stewart, NR | 1 |
| Suresh, J | 1 |
| Khor, IW | 1 |
| Kaur, P | 1 |
| Heng, HL | 1 |
| Torta, F | 1 |
| Dawe, GS | 1 |
| Tai, ES | 1 |
| Tolwinski, NS | 1 |
| de Oliveira, AM | 1 |
| de Freitas, AFS | 1 |
| Costa, MDS | 1 |
| Torres, MKDS | 1 |
| Castro, YAA | 1 |
| Almeida, AMR | 1 |
| Paiva, PMG | 1 |
| Carvalho, BM | 1 |
| Napoleão, TH | 1 |
| Masunaga, Y | 1 |
| Fujisawa, Y | 1 |
| Muramatsu, M | 1 |
| Ono, H | 1 |
| Inoue, T | 1 |
| Fukami, M | 1 |
| Kagami, M | 1 |
| Saitsu, H | 1 |
| Ogata, T | 1 |
| Mahey, R | 1 |
| Gupta, M | 1 |
| Bansiwal, R | 1 |
| Sethi, A | 1 |
| Komosinska-Vassev, K | 1 |
| Gala, O | 1 |
| Olczyk, K | 1 |
| Jura-Półtorak, A | 1 |
| Olczyk, P | 1 |
| Soliman, A | 1 |
| De Sanctis, V | 1 |
| Alaaraj, N | 1 |
| Hamed, N | 1 |
| Lu, GH | 1 |
| Rahmanian, M | 1 |
| Heiranizadeh, N | 1 |
| Mohiti, A | 1 |
| Woo, YS | 1 |
| Lim, HK | 1 |
| Wang, SM | 1 |
| Bahk, WM | 1 |
| Zeitler, PS | 2 |
| Aludwan, M | 1 |
| Kobyliak, N | 1 |
| Abenavoli, L | 2 |
| Kyriienko, D | 1 |
| Fagoonee, S | 1 |
| Pellicano, R | 1 |
| Komisarenko, I | 1 |
| Frenkel, JDH | 1 |
| Ackart, DF | 1 |
| Todd, AK | 1 |
| DiLisio, JE | 1 |
| Hoffman, S | 1 |
| Tanner, S | 1 |
| Kiran, D | 1 |
| Murray, M | 1 |
| Chicco, A | 1 |
| Obregón-Henao, A | 1 |
| Podell, BK | 1 |
| Basaraba, RJ | 1 |
| Dludla, PV | 1 |
| Nkambule, BB | 1 |
| Mazibuko-Mbeje, SE | 1 |
| Nyambuya, TM | 1 |
| Mxinwa, V | 1 |
| Mokgalaboni, K | 1 |
| Ziqubu, K | 1 |
| Cirilli, I | 1 |
| Marcheggiani, F | 1 |
| Louw, J | 1 |
| Tiano, L | 1 |
| Previate, C | 1 |
| Malta, A | 2 |
| Miranda, RA | 2 |
| Martins, IP | 1 |
| Pavanello, A | 1 |
| de Oliveira, JC | 2 |
| Prates, KV | 2 |
| Alves, VS | 1 |
| Francisco, FA | 1 |
| Moreira, VM | 1 |
| Matiusso, CCI | 1 |
| de Moraes, AMP | 1 |
| Mathias, PCF | 1 |
| Franco, CCDS | 1 |
| Amadi, JA | 1 |
| Amadi, PU | 1 |
| Njoku, UC | 1 |
| Osuoha, JO | 1 |
| Pongkan, W | 2 |
| Jaiwongkam, T | 2 |
| Tokuda, M | 1 |
| Guo, C | 1 |
| Piltonen, TT | 1 |
| Giudice, LC | 1 |
| Ghasempour, G | 1 |
| Aliabadi, M | 1 |
| Hashemnia, SMR | 1 |
| Emamgholipour, S | 1 |
| Majore, S | 1 |
| Agolini, E | 1 |
| Micale, L | 1 |
| Pascolini, G | 1 |
| Zuppi, P | 1 |
| Cocciadiferro, D | 1 |
| Morlino, S | 1 |
| Mattiuzzo, M | 1 |
| Valiante, M | 1 |
| Castori, M | 1 |
| Novelli, A | 1 |
| Grammatico, P | 1 |
| Ferrer, MJ | 2 |
| Silva, AF | 2 |
| Abruzzese, GA | 2 |
| Velázquez, ME | 1 |
| Motta, AB | 2 |
| Dalsgaard, NB | 1 |
| Gasbjerg, LS | 1 |
| Hansen, LS | 1 |
| Hansen, NL | 1 |
| Stensen, S | 1 |
| Hartmann, B | 1 |
| Rehfeld, JF | 1 |
| Holst, JJ | 2 |
| Vilsbøll, T | 1 |
| Knop, FK | 1 |
| Vukašin, T | 1 |
| Velija-Ašimi, Z | 4 |
| Bureković, A | 1 |
| Zdravković, M | 1 |
| Andrić, Z | 1 |
| Branković, M | 1 |
| Crevar-Marinović, S | 1 |
| Madić, T | 1 |
| Stanojlović, O | 1 |
| Milutinović, DV | 1 |
| Jurczak, MJ | 1 |
| Lear, TB | 1 |
| Lin, B | 1 |
| Larsen, MB | 1 |
| Kennerdell, JR | 1 |
| Huckestein, BR | 1 |
| Nguyen, MK | 1 |
| Tuncer, F | 1 |
| Monga, SP | 1 |
| O'Donnell, CP | 1 |
| Finkel, T | 1 |
| Chen, BB | 1 |
| Mallampalli, RK | 1 |
| Skibinska, M | 1 |
| Zurawska-Klis, M | 1 |
| Krekora, M | 1 |
| Cypryk, K | 1 |
| Deehan, EC | 1 |
| Colin-Ramirez, E | 1 |
| Triador, L | 1 |
| Madsen, KL | 1 |
| Prado, CM | 1 |
| Field, CJ | 1 |
| Ball, GDC | 1 |
| Tan, Q | 1 |
| Orsso, C | 1 |
| Dinu, I | 1 |
| Pakseresht, M | 1 |
| Rubin, D | 1 |
| Sharma, AM | 1 |
| Tun, H | 1 |
| Walter, J | 1 |
| Newgard, CB | 1 |
| Freemark, M | 1 |
| Wine, E | 1 |
| Haqq, AM | 1 |
| Masarwa, R | 1 |
| Brunetti, VC | 1 |
| Aloe, S | 1 |
| Henderson, M | 1 |
| Platt, RW | 1 |
| Filion, KB | 1 |
| Peng, MF | 1 |
| Tian, S | 1 |
| Song, YG | 1 |
| Li, CX | 1 |
| Miao, MS | 1 |
| Chang, YC | 1 |
| Hee, SW | 1 |
| Chuang, LM | 1 |
| Hu, H | 1 |
| Meng, J | 1 |
| Kelsey, MM | 2 |
| Hilkin, A | 1 |
| Pyle, L | 3 |
| Severn, C | 1 |
| Utzschneider, K | 1 |
| Van Pelt, RE | 1 |
| Wu, N | 1 |
| Han, Y | 2 |
| Ye, Y | 2 |
| Bao, Y | 1 |
| Liu, C | 3 |
| Younes, N | 1 |
| Rasouli, N | 8 |
| Barzilay, J | 1 |
| Banerji, MA | 2 |
| Cohen, RM | 1 |
| Gonzalez, EV | 1 |
| Ismail-Beigi, F | 2 |
| Raskin, P | 2 |
| Wexler, DJ | 1 |
| Lachin, JM | 2 |
| Snaith, JR | 1 |
| Samocha-Bonet, D | 1 |
| Evans, J | 1 |
| Kowalski, G | 1 |
| Bruce, C | 1 |
| Holmes-Walker, DJ | 1 |
| Greenfield, JR | 2 |
| Ladeiras-Lopes, R | 2 |
| Sampaio, F | 2 |
| Leite, S | 1 |
| Santos-Ferreira, D | 1 |
| Vilela, E | 1 |
| Leite-Moreira, A | 2 |
| Bettencourt, N | 2 |
| Gama, V | 2 |
| Braga, P | 1 |
| Fontes-Carvalho, R | 2 |
| Agarwal, SM | 1 |
| Panda, R | 1 |
| Costa-Dookhan, KA | 1 |
| MacKenzie, NE | 1 |
| Treen, QC | 1 |
| Caravaggio, F | 1 |
| Hashim, E | 1 |
| Leung, G | 1 |
| Kirpalani, A | 1 |
| Matheson, K | 1 |
| Chintoh, AF | 1 |
| Voineskos, AN | 1 |
| Graff-Guerrero, A | 1 |
| Remington, GJ | 2 |
| Hahn, MK | 2 |
| Sohrevardi, SM | 1 |
| Heydari, B | 1 |
| Azarpazhooh, MR | 1 |
| Teymourzadeh, M | 1 |
| Simental-Mendía, LE | 2 |
| Karimi-Zarchi, M | 1 |
| Garcia-Hernandez, SC | 1 |
| Porchia, LM | 1 |
| Pacheco-Soto, BT | 1 |
| López-Bayghen, E | 1 |
| Gonzalez-Mejia, ME | 1 |
| Farkhondeh, T | 1 |
| Amirabadizadeh, A | 1 |
| Aramjoo, H | 1 |
| Llorens, S | 1 |
| Roshanravan, B | 1 |
| Saeedi, F | 1 |
| Talebi, M | 1 |
| Shakibaei, M | 1 |
| Samarghandian, S | 1 |
| Ahrén, B | 2 |
| Li, P | 2 |
| Lu, B | 1 |
| Tian, X | 1 |
| Han, B | 1 |
| Xie, Z | 1 |
| Liao, Q | 1 |
| Siamashvili, M | 1 |
| Davis, SN | 1 |
| Hurrell, A | 1 |
| Webster, LM | 1 |
| Gokulakrishnan, K | 1 |
| Pandey, GK | 1 |
| Sathishkumar, C | 1 |
| Sundararajan, S | 1 |
| Durairaj, P | 1 |
| Manickam, N | 1 |
| Mohan, V | 1 |
| Balasubramanyam, M | 1 |
| Tauqir, S | 1 |
| Israr, M | 1 |
| Rauf, B | 1 |
| Malik, MO | 1 |
| Habib, SH | 1 |
| Shah, FA | 1 |
| Usman, M | 1 |
| Raza, MA | 1 |
| Shah, I | 1 |
| Badshah, H | 1 |
| Ehtesham, E | 1 |
| Jiao, Z | 1 |
| Hashemi, P | 1 |
| Pezeshki, S | 1 |
| Ding, X | 1 |
| Zhang, JH | 1 |
| Zhang, JF | 1 |
| Deng, L | 1 |
| Feng, CP | 1 |
| Xu, XY | 1 |
| Guo, HX | 1 |
| Gu, Y | 1 |
| Jin, C | 1 |
| Zheng, JF | 1 |
| Zhen, Z | 2 |
| Su, H | 1 |
| Zou, W | 1 |
| Zhu, H | 1 |
| Sardana, O | 1 |
| Goyal, R | 1 |
| Bedi, O | 1 |
| Yang, W | 4 |
| Liao, W | 1 |
| Shen, JZ | 1 |
| Ai, W | 1 |
| Pan, Q | 2 |
| Zhang, K | 2 |
| Qiu, Y | 1 |
| Dai, Q | 1 |
| Zheng, H | 2 |
| Vadini, F | 1 |
| Simeone, PG | 1 |
| Desideri, G | 1 |
| Liani, R | 1 |
| Tripaldi, R | 1 |
| Ciotti, S | 1 |
| Tartaro, A | 1 |
| Guagnano, MT | 1 |
| Di Castelnuovo, A | 1 |
| Cipollone, F | 1 |
| Consoli, A | 1 |
| Santilli, F | 1 |
| Alimoradi, N | 1 |
| Firouzabadi, N | 1 |
| Fatehi, R | 1 |
| Singhanat, K | 1 |
| Mika, K | 1 |
| Szafarz, M | 1 |
| Bednarski, M | 1 |
| Kuder, K | 1 |
| Szczepańska, K | 1 |
| Pociecha, K | 1 |
| Pomierny, B | 1 |
| Kieć-Kononowicz, K | 1 |
| Sapa, J | 1 |
| Kotańska, M | 1 |
| Concepcion, JQ | 1 |
| Tucker, LY | 1 |
| Huang, K | 1 |
| Tseng, CH | 2 |
| Kominato, H | 1 |
| Takeda, K | 1 |
| Mizutani, K | 1 |
| Mikami, R | 1 |
| Kido, D | 1 |
| Buranasin, P | 1 |
| Saito, N | 2 |
| Takemura, S | 1 |
| Nakagawa, K | 1 |
| Nagasawa, T | 1 |
| Iwata, T | 1 |
| Goricar, K | 1 |
| Chamarthi, B | 2 |
| Cincotta, AH | 1 |
| Sharma, Y | 1 |
| Bashir, S | 1 |
| Faraz Khan, M | 1 |
| Ahmad, A | 1 |
| Khan, F | 2 |
| Muzik, O | 1 |
| Burghardt, P | 1 |
| Yi, Z | 1 |
| Kumar, A | 3 |
| Seyoum, B | 1 |
| LE, TN | 1 |
| Wickham, EP | 1 |
| Nestler, JE | 14 |
| Tajima, K | 1 |
| Shirakawa, J | 1 |
| Okuyama, T | 1 |
| Kyohara, M | 1 |
| Yamazaki, S | 1 |
| Togashi, Y | 1 |
| Terauchi, Y | 1 |
| Zabielski, P | 3 |
| Chacinska, M | 3 |
| Charkiewicz, K | 1 |
| Baranowski, M | 1 |
| Gorski, J | 2 |
| Blachnio-Zabielska, AU | 3 |
| Stagi, S | 1 |
| Ricci, F | 1 |
| Bianconi, M | 1 |
| Sammarco, MA | 1 |
| Municchi, G | 1 |
| Toni, S | 1 |
| Lenzi, L | 1 |
| Verrotti, A | 1 |
| de Martino, M | 1 |
| Xu, D | 1 |
| Zhang, T | 5 |
| Anastasiou, OE | 1 |
| Canbay, A | 1 |
| Fuhrer, D | 1 |
| Reger-Tan, S | 1 |
| Mesmar, B | 1 |
| Poola-Kella, S | 1 |
| Malek, R | 1 |
| Kosuru, R | 1 |
| Singh, S | 1 |
| Rahelić, D | 1 |
| Doknić, M | 1 |
| Abbas, SY | 2 |
| Basyouni, WM | 2 |
| El-Bayouk, KAM | 1 |
| Tohamy, WM | 1 |
| Aly, HF | 1 |
| Arafa, A | 1 |
| Soliman, MS | 1 |
| Maniar, K | 1 |
| Moideen, A | 1 |
| Bhattacharyya, R | 1 |
| Banerjee, D | 1 |
| Božić-Antić, I | 1 |
| Jayanthi, R | 1 |
| Srinivasan, AR | 1 |
| Gopal, N | 1 |
| Ramaswamy, R | 1 |
| Dawson, AJ | 1 |
| Kilpatrick, ES | 8 |
| Coady, AM | 7 |
| Elshewehy, AMM | 1 |
| Dakroury, Y | 2 |
| Ahmed, L | 2 |
| Lu, P | 1 |
| Shao, S | 1 |
| Hu, S | 1 |
| He, W | 1 |
| Zhao, J | 3 |
| Yu, X | 4 |
| Nas, K | 1 |
| Tűű, L | 1 |
| Wu, MC | 1 |
| Ye, WR | 1 |
| Zheng, YJ | 1 |
| Zhang, SS | 1 |
| Mutlur Krishnamoorthy, R | 1 |
| Carani Venkatraman, A | 1 |
| Giri, D | 1 |
| Alsaffar, H | 1 |
| Ramakrishnan, R | 1 |
| Kaplowitz, P | 1 |
| Peixoto, LG | 1 |
| Teixeira, RR | 1 |
| Vilela, DD | 1 |
| Barbosa, LN | 1 |
| Caixeta, DC | 1 |
| Deconte, SR | 1 |
| de Assis de Araújo, F | 1 |
| Sabino-Silva, R | 1 |
| Espindola, FS | 1 |
| Wróbel, MP | 1 |
| Marek, B | 1 |
| Kajdaniuk, D | 1 |
| Szymborska-Kajanek, A | 1 |
| Zhang, JP | 1 |
| Kenawy, S | 1 |
| Hegazy, R | 1 |
| Hassan, A | 1 |
| El-Shenawy, S | 1 |
| Gomaa, N | 1 |
| Zaki, H | 1 |
| Attia, A | 1 |
| Pedersen, AJT | 1 |
| Stage, TB | 1 |
| Glintborg, D | 3 |
| Andersen, M | 2 |
| Christensen, MMH | 1 |
| Alnasrallah, B | 1 |
| Pilmore, H | 1 |
| Manley, P | 1 |
| Di Sabatino, A | 3 |
| Gutiérrez-Lara, EJ | 1 |
| Navarrete-Vázquez, G | 1 |
| Sánchez-López, A | 1 |
| Centurión, D | 1 |
| Han, K | 1 |
| Bose, S | 1 |
| Wang, JH | 1 |
| Lim, SK | 1 |
| Chin, YW | 1 |
| Kim, YM | 1 |
| Choi, HS | 2 |
| Kim, H | 1 |
| Scinta, W | 1 |
| Bayes, H | 1 |
| Smith, N | 2 |
| Carris, NW | 1 |
| Tipparaju, SM | 1 |
| Magness, DJ | 1 |
| Chapalamadugu, KC | 1 |
| Magness, RR | 1 |
| Seo, JA | 1 |
| Kang, MC | 1 |
| Ciaraldi, TP | 3 |
| Kim, SS | 1 |
| Park, KS | 5 |
| Choe, C | 1 |
| Hwang, WM | 1 |
| Lim, DM | 2 |
| Farr, O | 1 |
| Mantzoros, C | 1 |
| Henry, RR | 6 |
| Kim, YB | 1 |
| Zhou, D | 2 |
| Chu, S | 1 |
| Campbell, JM | 1 |
| Adanichkin, N | 1 |
| Kurmis, R | 1 |
| Munn, Z | 1 |
| Rogacka, D | 2 |
| Audzeyenka, I | 2 |
| Rychłowski, M | 1 |
| Rachubik, P | 1 |
| Szrejder, M | 1 |
| Angielski, S | 2 |
| Piwkowska, A | 2 |
| McKinley, MC | 1 |
| McNally, R | 1 |
| Graham, U | 1 |
| Watson, CJ | 1 |
| Lyons, TJ | 1 |
| Cao, H | 1 |
| Liao, S | 1 |
| Zhong, W | 1 |
| Xiao, X | 2 |
| Dornelles Severo, M | 1 |
| Stürmer Andrade, T | 1 |
| Correa Junior, V | 1 |
| Antonio Naujorks, A | 1 |
| Gus, M | 1 |
| Schaan, BD | 1 |
| Levesque, C | 1 |
| Bao, S | 1 |
| Sheng, S | 1 |
| Tu, W | 1 |
| Valdés, E | 1 |
| Candia, P | 1 |
| Abusada, N | 1 |
| Orellana, R | 1 |
| Manukian, B | 1 |
| Cuellar, E | 1 |
| Lundgren, JA | 1 |
| Kim, SH | 4 |
| Burt Solorzano, CM | 1 |
| McCartney, CR | 1 |
| Marshall, JC | 2 |
| Kang, YE | 1 |
| Kim, JM | 1 |
| Choung, S | 1 |
| Joung, KH | 1 |
| Kim, HJ | 2 |
| Ku, BJ | 2 |
| Brzozowska, M | 1 |
| Bieniek, E | 1 |
| Szosland, K | 1 |
| Lewinski, A | 1 |
| Ige, AO | 1 |
| Iwaloye, OI | 1 |
| Adewoye, EO | 1 |
| Ruan, X | 2 |
| Gu, M | 2 |
| Mueck, AO | 2 |
| Morley, LC | 1 |
| Tang, T | 4 |
| Yasmin, E | 4 |
| Balen, AH | 5 |
| Amin, SN | 1 |
| Hussein, UK | 1 |
| Yassa, HD | 1 |
| Hassan, SS | 1 |
| Tang, LR | 1 |
| Tao, YY | 1 |
| Liu, CH | 1 |
| Wang, HN | 1 |
| Khan, IM | 1 |
| Malik, BR | 1 |
| Randhawa, FA | 1 |
| Butt, NF | 1 |
| Malik, U | 1 |
| Hamid, S | 1 |
| Sajan, MP | 1 |
| Lee, MC | 1 |
| Foufelle, F | 1 |
| Sajan, J | 1 |
| Cleland, C | 1 |
| Farese, RV | 1 |
| Chon, S | 1 |
| Rhee, SY | 1 |
| Ahn, KJ | 1 |
| Baik, SH | 3 |
| Park, Y | 1 |
| Nam, MS | 1 |
| Lee, KW | 3 |
| Yoo, SJ | 1 |
| Koh, G | 1 |
| Lee, DH | 1 |
| Kim, YS | 1 |
| Woo, JT | 1 |
| Dos Santos, IK | 1 |
| de Lima Nunes, R | 1 |
| Soares, GM | 1 |
| de Oliveira Maranhão, TM | 1 |
| Dantas, PMS | 1 |
| de Fatima Silva, F | 1 |
| Ortiz-Silva, M | 1 |
| Galia, WBS | 1 |
| Cassolla, P | 1 |
| da Silva, FG | 1 |
| Graciano, MFR | 1 |
| Carpinelli, AR | 1 |
| de Souza, HM | 2 |
| Prokudina, ES | 1 |
| Maslov, LN | 1 |
| Ivanov, VV | 1 |
| Bespalova, ID | 1 |
| Pismennyi, DS | 1 |
| Voronkov, NS | 1 |
| Gu, F | 1 |
| Guan, JL | 1 |
| Allin, KH | 1 |
| Tremaroli, V | 1 |
| Caesar, R | 1 |
| Jensen, BAH | 1 |
| Damgaard, MTF | 1 |
| Bahl, MI | 1 |
| Licht, TR | 1 |
| Hansen, TH | 1 |
| Nielsen, T | 1 |
| Dantoft, TM | 1 |
| Linneberg, A | 1 |
| Jørgensen, T | 1 |
| Vestergaard, H | 2 |
| Kristiansen, K | 1 |
| Franks, PW | 3 |
| Hansen, T | 1 |
| Bäckhed, F | 1 |
| Pedersen, O | 1 |
| McKillop, AM | 1 |
| Stevenson, CL | 1 |
| Moran, BM | 1 |
| Abdel-Wahab, YHA | 1 |
| Flatt, PR | 1 |
| Prado Correia, LE | 1 |
| de Almeida, BC | 1 |
| de Jesus Simões, M | 2 |
| Abi Haidar, M | 2 |
| Berguio Vidotti, D | 1 |
| Silva, I | 1 |
| Răcătăianu, N | 1 |
| Bolboacă, SD | 1 |
| Sitar-Tăut, AV | 1 |
| Mârza, S | 1 |
| Moga, D | 1 |
| Valea, A | 1 |
| Ghervan, C | 1 |
| Shen, Z | 1 |
| Zhou, H | 1 |
| Nyström, T | 1 |
| Nathanson, D | 1 |
| Du, X | 1 |
| Lu, W | 1 |
| Hu, C | 2 |
| Shi, B | 2 |
| Rehman, K | 1 |
| Saeed, K | 1 |
| Munawar, SM | 1 |
| Akash, MSH | 1 |
| El-Aal, AA | 1 |
| El-Ghffar, EAA | 1 |
| Ghali, AA | 1 |
| Zughbur, MR | 1 |
| Sirdah, MM | 1 |
| Chueakula, N | 1 |
| Wanchai, K | 1 |
| Safai, N | 1 |
| Suvitaival, T | 1 |
| Ali, A | 1 |
| Spégel, P | 1 |
| Al-Majdoub, M | 1 |
| Carstensen, B | 1 |
| Ridderstråle, M | 1 |
| Gregg, BE | 1 |
| Botezatu, N | 1 |
| Brill, JD | 1 |
| Hafner, H | 1 |
| Vadrevu, S | 1 |
| Satin, LS | 1 |
| Alejandro, EU | 1 |
| Bernal-Mizrachi, E | 1 |
| Underdal, MO | 2 |
| Stridsklev, S | 1 |
| Oppen, IH | 1 |
| Høgetveit, K | 1 |
| Andersen, MS | 2 |
| Vanky, E | 2 |
| Braffett, BH | 1 |
| Geffner, ME | 2 |
| McKay, SV | 2 |
| Shah, R | 1 |
| Sprague, JE | 1 |
| Lv, Y | 1 |
| Tian, N | 1 |
| Soobryan, N | 1 |
| Murugesan, S | 1 |
| Pandiyan, A | 1 |
| Moodley, J | 1 |
| Mackraj, I | 1 |
| Hady, HR | 1 |
| Roszczyc, K | 1 |
| Moulton, CD | 1 |
| Hopkins, CWP | 1 |
| Ismail, K | 1 |
| Stahl, D | 1 |
| Bodur, S | 1 |
| Dundar, O | 1 |
| Kanat-Pektas, M | 1 |
| Kinci, MF | 1 |
| Tutuncu, L | 1 |
| Puscheck, EE | 1 |
| Bolnick, A | 1 |
| Awonuga, A | 1 |
| Abdulhasan, M | 1 |
| Secor, E | 1 |
| Louden, E | 1 |
| Hüttemann, M | 1 |
| Rappolee, DA | 1 |
| Chen, K | 2 |
| Zhuo, T | 1 |
| Mei, Q | 1 |
| Steneberg, P | 1 |
| Lindahl, E | 1 |
| Dahl, U | 1 |
| Lidh, E | 1 |
| Straseviciene, J | 1 |
| Backlund, F | 1 |
| Kjellkvist, E | 1 |
| Berggren, E | 1 |
| Lundberg, I | 1 |
| Bergqvist, I | 1 |
| Ericsson, M | 1 |
| Eriksson, B | 1 |
| Linde, K | 1 |
| Westman, J | 1 |
| Edlund, T | 1 |
| Edlund, H | 1 |
| Lee, M | 1 |
| Katerelos, M | 1 |
| Gleich, K | 1 |
| Galic, S | 2 |
| Kemp, BE | 3 |
| Mount, PF | 1 |
| Power, DA | 1 |
| Scherneck, S | 1 |
| Schlinke, N | 1 |
| Beck, E | 1 |
| Grupe, K | 1 |
| Weber-Schoendorfer, C | 1 |
| Schaefer, C | 1 |
| Abbas, NAT | 1 |
| El Salem, A | 1 |
| Mourya, A | 1 |
| Akhtar, A | 2 |
| Ahuja, S | 2 |
| Sah, SP | 2 |
| Kumar, R | 1 |
| Pilania, RK | 1 |
| Bhatia, A | 1 |
| Dayal, D | 1 |
| Otto-Buczkowska, E | 2 |
| Grzyb, K | 1 |
| Jainta, N | 1 |
| Shah, G | 1 |
| Davis, SR | 2 |
| Robinson, PJ | 2 |
| Jane, F | 2 |
| White, S | 1 |
| Brown, KA | 1 |
| Piessens, S | 1 |
| Edwards, A | 1 |
| McNeilage, J | 1 |
| Woinarski, J | 1 |
| Chipman, M | 1 |
| Bell, RJ | 2 |
| Singh, MK | 1 |
| Das, BK | 1 |
| Choudhary, S | 1 |
| Gupta, D | 1 |
| Patil, UK | 1 |
| Kupreeva, M | 1 |
| Diane, A | 1 |
| Lehner, R | 1 |
| Watts, R | 1 |
| Ghosh, M | 1 |
| Proctor, S | 1 |
| Vine, D | 1 |
| Mamo, JC | 2 |
| Lam, V | 1 |
| Brook, E | 1 |
| Mooranian, A | 1 |
| Al-Salami, H | 1 |
| Fimognari, N | 1 |
| Nesbit, M | 1 |
| Takechi, R | 1 |
| Erensoy, H | 1 |
| Niafar, M | 1 |
| Ghafarzadeh, S | 1 |
| Aghamohammadzadeh, N | 1 |
| Nader, ND | 1 |
| Lentferink, YE | 2 |
| van der Aa, MP | 3 |
| van Mill, EGAH | 1 |
| Knibbe, CAJ | 2 |
| van der Vorst, MMJ | 2 |
| Zayed, EA | 1 |
| AinShoka, AA | 1 |
| El Shazly, KA | 1 |
| Abd El Latif, HA | 1 |
| Trigo, E | 1 |
| Martinez, M | 2 |
| Katkhouda, N | 1 |
| Beale, E | 1 |
| Chow, T | 1 |
| Montgomery, C | 1 |
| Nayak, KS | 1 |
| Hendee, F | 1 |
| Karateke, A | 1 |
| Dokuyucu, R | 1 |
| Dogan, H | 1 |
| Ozgur, T | 1 |
| Tas, ZA | 1 |
| Tutuk, O | 1 |
| Agturk, G | 1 |
| Tumer, C | 1 |
| Adeva-Andany, MM | 1 |
| Rañal-Muíño, E | 1 |
| Fernández-Fernández, C | 1 |
| Pazos-García, C | 1 |
| Vila-Altesor, M | 1 |
| Sahu, A | 1 |
| Tripathy, P | 1 |
| Mohanty, J | 1 |
| Nagy, A | 1 |
| Rezaei, M | 1 |
| Keshtzar, E | 1 |
| Khodayar, MJ | 1 |
| Javadipour, M | 1 |
| Al-Trad, B | 1 |
| Alsmadi, W | 1 |
| Al-Zoubi, M | 1 |
| Gu, T | 1 |
| Shao, J | 1 |
| Sun, Z | 1 |
| Zhong, S | 1 |
| Bi, Y | 3 |
| Laurin, JL | 1 |
| Reid, JJ | 1 |
| Castor, WM | 1 |
| Wolff, CA | 1 |
| Musci, RV | 1 |
| Safairad, OD | 1 |
| Linden, MA | 1 |
| Biela, LM | 1 |
| Bailey, SM | 1 |
| Hamilton, KL | 1 |
| He, X | 1 |
| Xu, T | 2 |
| Xu, B | 1 |
| Tang, W | 1 |
| Yaribeygi, H | 1 |
| Li, R | 2 |
| Friden, C | 1 |
| Chang, C | 1 |
| Huo, Z | 1 |
| Ji, X | 1 |
| Linden-Hirschberg, A | 1 |
| Qiao, J | 1 |
| Nommsen-Rivers, L | 1 |
| Thompson, A | 1 |
| Riddle, S | 1 |
| Ward, L | 1 |
| Wagner, E | 1 |
| King, E | 1 |
| El-Naggar, AR | 1 |
| Zaafar, D | 1 |
| Elyamany, M | 1 |
| Hassanin, S | 1 |
| Bassyouni, A | 1 |
| Abdel-Latif, H | 1 |
| He, H | 1 |
| Kujawska-Luczak, M | 1 |
| Szulinska, M | 1 |
| Skrypnik, D | 1 |
| Musialik, K | 1 |
| Swora-Cwynar, E | 1 |
| Kregielska-Narozna, M | 1 |
| Markuszewski, L | 1 |
| Grzymislawska, M | 1 |
| Bogdanski, P | 1 |
| Tang, L | 2 |
| Shi, Y | 3 |
| Waise, TMZ | 1 |
| Rasti, M | 1 |
| Duca, FA | 2 |
| Zhang, SY | 1 |
| Bauer, PV | 1 |
| Rhodes, CJ | 1 |
| Lam, TKT | 1 |
| El Sharkwy, I | 1 |
| Sharaf El-Din, M | 1 |
| Xourgia, E | 1 |
| Papazafiropoulou, A | 1 |
| Papanas, N | 2 |
| Melidonis, A | 1 |
| Michalakis, K | 1 |
| Heber, MF | 1 |
| Ferreira, SR | 2 |
| Espinoza, SE | 1 |
| Musi, N | 3 |
| Wang, CP | 1 |
| Michalek, J | 1 |
| Orsak, B | 1 |
| Romo, T | 1 |
| Powers, B | 1 |
| Conde, A | 1 |
| Moris, M | 1 |
| Bair-Kelps, D | 1 |
| Ganapathy, V | 1 |
| Jergensen, TE | 1 |
| Kelly, LC | 1 |
| Jiwani, R | 1 |
| Tong, C | 1 |
| Qi, H | 1 |
| Abbasi, F | 1 |
| Cree-Green, M | 2 |
| Bergman, BC | 1 |
| Cengiz, E | 1 |
| Fox, LA | 1 |
| Miller, K | 1 |
| Nathan, B | 1 |
| Kahn, D | 1 |
| Tansey, M | 1 |
| Tichy, E | 1 |
| Tsalikian, E | 1 |
| Fu, J | 1 |
| Yang, N | 1 |
| Wang, G | 2 |
| Zhu, Z | 2 |
| Xia, H | 1 |
| Kato, K | 1 |
| Yamanaka, K | 1 |
| An, Y | 1 |
| Yousuf, SD | 2 |
| Jeelani, S | 1 |
| Mudassar, S | 1 |
| Zargar, MA | 2 |
| Amin, S | 2 |
| Rashid, F | 2 |
| Salvesen, Ø | 1 |
| Schmedes, A | 1 |
| Mohan, M | 2 |
| Al-Talabany, S | 1 |
| McKinnie, A | 1 |
| Mordi, IR | 1 |
| Singh, JSS | 1 |
| Gandy, SJ | 1 |
| Baig, F | 2 |
| Hussain, MS | 1 |
| Bhalraam, U | 1 |
| Choy, AM | 3 |
| Matthew, S | 1 |
| Houston, JG | 1 |
| Struthers, AD | 3 |
| George, J | 1 |
| Lang, CC | 5 |
| Rahmani, J | 1 |
| Manzari, N | 1 |
| Thompson, J | 1 |
| Gudi, SK | 1 |
| Chhabra, M | 1 |
| Naik, G | 1 |
| Mousavi, SM | 1 |
| Varkaneh, HK | 1 |
| Clark, C | 1 |
| Dujic, T | 1 |
| Bego, T | 1 |
| Malenica, M | 1 |
| Ahlqvist, E | 1 |
| Groop, L | 3 |
| Pearson, ER | 2 |
| Causevic, A | 1 |
| Semiz, S | 1 |
| Morotti, E | 1 |
| Giovanni Artini, P | 1 |
| Persico, N | 1 |
| Masaeli, A | 1 |
| Nayeri, H | 1 |
| Mirzaee, M | 1 |
| Palui, R | 1 |
| Sahoo, J | 1 |
| Kamalanathan, S | 1 |
| Kar, SS | 1 |
| Sridharan, K | 1 |
| Durgia, H | 1 |
| Raj, H | 1 |
| Patil, M | 1 |
| Niczyporuk, M | 2 |
| Knaś, M | 2 |
| Car, H | 1 |
| Zemdegs, J | 1 |
| Martin, H | 1 |
| Pintana, H | 3 |
| Bullich, S | 1 |
| Manta, S | 1 |
| Marqués, MA | 1 |
| Moro, C | 1 |
| Layé, S | 1 |
| Ducrocq, F | 1 |
| Rampon, C | 1 |
| Pénicaud, L | 2 |
| Fioramonti, X | 1 |
| Guiard, BP | 1 |
| Dhaliwal, R | 1 |
| Shepherd, JA | 1 |
| Copeland, KC | 1 |
| Higgins, J | 1 |
| Weinstock, RS | 3 |
| White, NH | 4 |
| Uniyal, A | 1 |
| Hunt, NJ | 1 |
| Lockwood, GP | 1 |
| Kang, SWS | 1 |
| Pulpitel, T | 1 |
| Clark, X | 1 |
| Mao, H | 1 |
| McCourt, PAG | 1 |
| Cooney, GJ | 3 |
| Wali, JA | 1 |
| Le Couteur, FH | 1 |
| Le Couteur, DG | 1 |
| Cogger, VC | 1 |
| Craig, A | 1 |
| Parvez, F | 1 |
| Issberner, J | 1 |
| Lin, L | 1 |
| Burke, J | 1 |
| Venkatesh, S | 1 |
| Sadana, P | 1 |
| Long, J | 1 |
| Cheng, W | 1 |
| Chen, M | 2 |
| Manzoor, S | 1 |
| Bhat, IA | 1 |
| Jeelani, H | 1 |
| Kawa, IA | 1 |
| Fatima, Q | 1 |
| Yu, HM | 1 |
| Kim, SJ | 2 |
| Chun, SW | 1 |
| Park, KY | 1 |
| Lee, JM | 2 |
| Hong, JH | 1 |
| Boccardi, V | 1 |
| Murasecco, I | 1 |
| Mecocci, P | 1 |
| Teimourian, S | 1 |
| Nourbakhsh, M | 1 |
| Sharifi, R | 1 |
| Derosa, G | 19 |
| Cicero, AF | 14 |
| Franzetti, IG | 7 |
| Querci, F | 9 |
| Carbone, A | 9 |
| Piccinni, MN | 8 |
| D'Angelo, A | 14 |
| Fogari, E | 14 |
| Maffioli, P | 18 |
| Juárez-López, C | 1 |
| Klünder-Klünder, M | 1 |
| Madrigal-Azcárate, A | 1 |
| Flores-Huerta, S | 1 |
| Muneyyirci-Delale, O | 1 |
| Kaplan, J | 2 |
| Joulak, I | 1 |
| Von Gizycki, H | 1 |
| Nacharaju, VL | 1 |
| Borgognoni, L | 1 |
| Picciarella, A | 1 |
| Di Stefano, A | 1 |
| Fontana, V | 1 |
| Russo, A | 1 |
| Pascucci, M | 1 |
| Paris, A | 1 |
| Tubani, L | 1 |
| Fiorentini, A | 1 |
| Genovese, S | 1 |
| Passaro, A | 1 |
| Brunetti, P | 1 |
| Comaschi, M | 1 |
| Cucinotta, D | 1 |
| Egan, CG | 1 |
| Chinea, B | 1 |
| Bravi, F | 1 |
| Di Pietro, C | 1 |
| Garnett, SP | 6 |
| Gow, M | 4 |
| Ho, M | 4 |
| Baur, LA | 5 |
| Noakes, M | 2 |
| Woodhead, HJ | 2 |
| Broderick, CR | 2 |
| Burrell, S | 1 |
| Chisholm, K | 2 |
| Halim, J | 2 |
| De, S | 2 |
| Steinbeck, K | 2 |
| Srinivasan, S | 3 |
| Ambler, GR | 3 |
| Kohn, MR | 1 |
| Cowell, CT | 7 |
| Meng, H | 1 |
| Liu, L | 1 |
| Randell, E | 1 |
| Adeli, K | 1 |
| Meng, QH | 1 |
| Gdula-Dymek, A | 1 |
| Zhou, DF | 1 |
| Zhou, JY | 1 |
| Dong, RQ | 1 |
| Xing, WL | 1 |
| Tauchert, S | 2 |
| Ludwig, AK | 1 |
| Diedrich, K | 2 |
| Weiss, JM | 2 |
| Nixon, A | 1 |
| Sumarac-Dumanovic, M | 1 |
| Jeremic, D | 1 |
| Pantovic, A | 1 |
| Janjetovic, K | 1 |
| Stamenkovic-Pejkovic, D | 1 |
| Cvijovic, G | 1 |
| Stevanovic, D | 1 |
| Trajkovic, V | 1 |
| Ragonesi, PD | 6 |
| St-Onge, M | 1 |
| Ajmo, I | 1 |
| Poirier, D | 1 |
| Laliberté, M | 1 |
| Zheng, YH | 1 |
| Wang, XH | 2 |
| Lai, MH | 1 |
| Yao, H | 1 |
| Ma, HX | 1 |
| Greenway, F | 1 |
| Heiman, M | 1 |
| Conteduca, V | 1 |
| Di Lorenzo, G | 1 |
| Bozza, G | 1 |
| Ardito, R | 1 |
| Aieta, M | 1 |
| Auble, B | 1 |
| Elder, D | 1 |
| Gross, A | 1 |
| Hillman, JB | 1 |
| Ciccarelli, L | 7 |
| Li, ZQ | 1 |
| Chang, HJ | 1 |
| Sang, WF | 1 |
| Salman, ZK | 1 |
| Refaat, R | 1 |
| Selima, E | 1 |
| El Sarha, A | 1 |
| Ismail, MA | 1 |
| Mazza, A | 3 |
| Fruci, B | 3 |
| Guzzi, P | 1 |
| D'Orrico, B | 1 |
| Malaguarnera, R | 3 |
| Veltri, P | 1 |
| Fava, A | 1 |
| Belfiore, A | 3 |
| Rice, S | 1 |
| Elia, A | 1 |
| Jawad, Z | 1 |
| Pellatt, L | 1 |
| Mason, HD | 1 |
| Khurana, ML | 1 |
| Shah, PA | 1 |
| Kulshrestha, B | 1 |
| Wani, TA | 1 |
| Mudasir, S | 1 |
| Mir, FA | 1 |
| Taing, S | 1 |
| Ito, R | 1 |
| Tsujihata, Y | 1 |
| Matsuda-Nagasumi, K | 1 |
| Mori, I | 1 |
| Negoro, N | 1 |
| Takeuchi, K | 1 |
| Anderson, J | 1 |
| Peña, AS | 1 |
| Sullivan, T | 1 |
| Gent, R | 1 |
| D'Arcy, B | 1 |
| Olds, T | 1 |
| Coppin, B | 1 |
| Couper, J | 1 |
| Hamed, HO | 2 |
| Eldor, R | 1 |
| Abdul-Ghani, M | 2 |
| Lautatzis, ME | 1 |
| Goulis, DG | 1 |
| Vrontakis, M | 1 |
| Brufani, C | 2 |
| Crinò, A | 1 |
| Fintini, D | 2 |
| Patera, PI | 2 |
| Cappa, M | 2 |
| Manco, M | 2 |
| Du, Q | 3 |
| Wu, B | 2 |
| Wang, YJ | 4 |
| Zhao, YY | 2 |
| Liang, YY | 1 |
| Walford, GA | 2 |
| Davis, J | 2 |
| Warner, AS | 1 |
| Ackerman, RJ | 1 |
| Billings, LK | 2 |
| Fanelli, RR | 1 |
| Hernandez, AM | 1 |
| Huang, C | 2 |
| Khan, SQ | 1 |
| Littleton, KR | 1 |
| Lo, J | 1 |
| McCarthy, RM | 1 |
| Rhee, EP | 1 |
| Deik, A | 1 |
| Stolerman, E | 1 |
| Taylor, A | 1 |
| Hudson, MS | 1 |
| Wang, TJ | 2 |
| Altshuler, D | 1 |
| Grant, RW | 2 |
| Clish, CB | 1 |
| Gerszten, RE | 1 |
| Florez, JC | 4 |
| Musacchio, MC | 5 |
| Orvieto, R | 2 |
| Aroda, V | 1 |
| Mudaliar, SR | 1 |
| Ortega, FJ | 3 |
| Moreno-Navarrete, JM | 5 |
| Mayas, D | 1 |
| Serino, M | 2 |
| Rodriguez-Hermosa, JI | 1 |
| Ricart, W | 7 |
| Luche, E | 2 |
| Burcelin, R | 2 |
| Frühbeck, G | 2 |
| Mingrone, G | 2 |
| Fernández-Real, JM | 8 |
| Bajuk Studen, K | 1 |
| Jensterle Sever, M | 1 |
| Pfeifer, M | 3 |
| Pasquali, R | 5 |
| Gambineri, A | 5 |
| Jung, TW | 1 |
| Hong, HC | 1 |
| Choi, HY | 1 |
| Yoo, HJ | 1 |
| Choi, KM | 1 |
| Kim, D | 1 |
| Jung, YJ | 1 |
| Lee, AS | 1 |
| Lee, S | 1 |
| Park, SK | 1 |
| Park, BH | 1 |
| Kim, W | 1 |
| Kang, KP | 1 |
| Nawrocka-Rutkowska, J | 2 |
| Ciećwież, S | 1 |
| Marciniak, A | 2 |
| Brodowska, A | 2 |
| Wiśniewska, B | 1 |
| Kotlega, D | 1 |
| Starczewski, A | 3 |
| Zhao, ZQ | 1 |
| Luo, R | 1 |
| Li, LY | 1 |
| Tian, FS | 1 |
| Zheng, XL | 1 |
| Xiong, HL | 1 |
| Sun, LT | 1 |
| Yuan, H | 2 |
| Weng, C | 1 |
| Xing, X | 2 |
| Fullerton, MD | 2 |
| Marcinko, K | 2 |
| Sikkema, S | 1 |
| Pulinilkunnil, T | 1 |
| Chen, ZP | 1 |
| O'Neill, HM | 1 |
| Ford, RJ | 2 |
| Palanivel, R | 1 |
| O'Brien, M | 1 |
| Hardie, DG | 1 |
| Macaulay, SL | 1 |
| Schertzer, JD | 1 |
| Dyck, JR | 1 |
| van Denderen, BJ | 1 |
| Steinberg, GR | 2 |
| Anisimov, VN | 1 |
| Tong, G | 1 |
| Hua, X | 1 |
| Zhong, Y | 1 |
| Gu, G | 1 |
| Feng, W | 1 |
| Huang, H | 1 |
| Anthony, J | 1 |
| Kelkar, A | 1 |
| Wilankar, C | 1 |
| Ranjith, V | 1 |
| Bhumra, SK | 1 |
| Mutt, SJ | 1 |
| Mutt, S | 1 |
| Deka, N | 1 |
| Sivaramakrishnan, H | 1 |
| Marita, AR | 1 |
| Calixto, MC | 3 |
| Lintomen, L | 2 |
| André, DM | 1 |
| Leiria, LO | 2 |
| Ferreira, D | 1 |
| Lellis-Santos, C | 1 |
| Anhê, GF | 2 |
| Bordin, S | 1 |
| Landgraf, RG | 1 |
| Antunes, E | 3 |
| Rizvi, AA | 1 |
| Nikolic, D | 1 |
| Sallam, HS | 1 |
| Montalto, G | 1 |
| Rizzo, M | 1 |
| Abate, N | 1 |
| Ibrahim, MI | 1 |
| Hamdy, A | 1 |
| Shafik, A | 1 |
| Taha, S | 1 |
| Anwar, M | 1 |
| Faris, M | 1 |
| Mudaliar, S | 2 |
| Boden, G | 2 |
| Smith, S | 1 |
| Chalamandaris, AG | 1 |
| Duchesne, D | 1 |
| Iqbal, N | 3 |
| List, J | 1 |
| Giuliano, S | 2 |
| Baldi, JC | 1 |
| Manning, PJ | 1 |
| Hofman, PL | 1 |
| Walker, RJ | 1 |
| Mazzella, N | 1 |
| Ricciardi, LM | 1 |
| Mazzotti, A | 2 |
| Marchesini, G | 5 |
| Shaw, RJ | 2 |
| Gonçalves, LH | 1 |
| Silva, MV | 1 |
| Duarte, RC | 1 |
| Dusse, LM | 1 |
| Fernandes, AP | 1 |
| Bosco, AA | 1 |
| Gomes, KB | 1 |
| Carvalho, Md | 1 |
| Christophi, CA | 3 |
| Jablonski, KA | 2 |
| Delahanty, LM | 1 |
| Horton, ES | 2 |
| Knowler, WC | 5 |
| Wu, W | 2 |
| Shi, J | 3 |
| Liang, H | 1 |
| Yin, W | 2 |
| Tang, S | 2 |
| Cao, S | 2 |
| Shen, S | 2 |
| Gao, Q | 1 |
| Weng, J | 1 |
| Doycheva, I | 1 |
| Loomba, R | 2 |
| Barthelmess, EK | 1 |
| Naz, RK | 1 |
| Rothermundt, C | 1 |
| Hayoz, S | 1 |
| Templeton, AJ | 1 |
| Winterhalder, R | 1 |
| Strebel, RT | 1 |
| Bärtschi, D | 1 |
| Pollak, M | 3 |
| Lui, L | 1 |
| Endt, K | 1 |
| Schiess, R | 1 |
| Rüschoff, JH | 1 |
| Cathomas, R | 1 |
| Gillessen, S | 1 |
| Harmel, E | 1 |
| Grenier, E | 1 |
| Bendjoudi Ouadda, A | 1 |
| El Chebly, M | 1 |
| Ziv, E | 1 |
| Beaulieu, JF | 1 |
| Sané, A | 1 |
| Spahis, S | 1 |
| Laville, M | 2 |
| Levy, E | 1 |
| Valerón, PF | 1 |
| de Pablos-Velasco, PL | 1 |
| Mercader, JM | 2 |
| Rovira, O | 1 |
| Guerra, E | 1 |
| Esteve, E | 2 |
| Xifra, G | 3 |
| Martínez, C | 1 |
| Rieusset, J | 1 |
| Rome, S | 1 |
| Karczewska-Kupczewska, M | 1 |
| Straczkowski, M | 2 |
| Chirico, V | 1 |
| Ferraù, V | 1 |
| Loddo, I | 1 |
| Briuglia, S | 1 |
| Amorini, M | 1 |
| Salpietro, V | 1 |
| Lacquaniti, A | 1 |
| Salpietro, C | 1 |
| Arrigo, T | 2 |
| Konda, VR | 1 |
| Desai, A | 1 |
| Darland, G | 1 |
| Grayson, N | 1 |
| Bland, JS | 1 |
| Mumoli, L | 1 |
| Gambardella, A | 1 |
| Labate, A | 1 |
| Succurro, E | 1 |
| De Sarro, G | 1 |
| Arturi, F | 1 |
| Gallelli, L | 1 |
| Kocer, D | 1 |
| Bayram, F | 4 |
| Diri, H | 2 |
| Schweighofer, N | 1 |
| Lerchbaum, E | 1 |
| Trummer, O | 1 |
| Schwetz, V | 1 |
| Pieber, T | 1 |
| Obermayer-Pietsch, B | 1 |
| Joslowski, G | 1 |
| Goletzke, J | 1 |
| Louie, JC | 1 |
| Buyken, AE | 1 |
| Kruszyńska, A | 1 |
| Słowińska-Srzednicka, J | 1 |
| Jeske, W | 1 |
| Zgliczyński, W | 1 |
| Ochi, A | 1 |
| Mori, K | 2 |
| Emoto, M | 2 |
| Nakatani, S | 1 |
| Morioka, T | 1 |
| Motoyama, K | 1 |
| Fukumoto, S | 1 |
| Imanishi, Y | 1 |
| Koyama, H | 2 |
| Ishimura, E | 1 |
| Inaba, M | 2 |
| Ma, Y | 3 |
| Goldberg, RB | 2 |
| Horton, E | 1 |
| Barrett-Connor, E | 3 |
| Rouabhia, S | 1 |
| Milic, N | 1 |
| Watson, JD | 1 |
| Izetbegovic, S | 1 |
| Karamehic, J | 1 |
| Coric, J | 1 |
| Panjeta, M | 1 |
| Macic-Dzankovic, A | 1 |
| Djelilovic-Vranic, J | 1 |
| Dizdarevic-Bostandzic, A | 1 |
| Pau, CT | 1 |
| Keefe, C | 1 |
| Duran, J | 1 |
| Welt, CK | 1 |
| Hong, ES | 1 |
| Kim, EK | 1 |
| Kang, SM | 1 |
| Khang, AR | 1 |
| Choi, SH | 1 |
| Jang, HC | 1 |
| Tan, BK | 7 |
| Amar, O | 1 |
| Mattu, HS | 1 |
| Ramanjaneya, M | 1 |
| Lehnert, H | 6 |
| Randeva, HS | 7 |
| Preiss, D | 3 |
| Lloyd, SM | 1 |
| Ford, I | 1 |
| McMurray, JJ | 1 |
| Holman, RR | 3 |
| Fisher, M | 1 |
| Packard, CJ | 1 |
| Woo, SL | 1 |
| Xu, H | 2 |
| Guo, T | 1 |
| Botchlett, R | 1 |
| Qi, T | 1 |
| Pei, Y | 1 |
| Zheng, J | 1 |
| An, X | 1 |
| Huo, Y | 1 |
| Dabelea, D | 1 |
| Marcovina, S | 1 |
| Saudek, CD | 1 |
| Arakaki, R | 2 |
| Orchard, TJ | 2 |
| Goldberg, R | 1 |
| Palmer, J | 1 |
| Hamman, RF | 2 |
| Hamouti, N | 1 |
| Fernández-Elías, VE | 1 |
| de Prada, MV | 1 |
| Martínez-Vizcaíno, V | 1 |
| Chow, K | 1 |
| Alam, S | 1 |
| Lindquist, K | 1 |
| Campbell, S | 1 |
| McFann, K | 1 |
| Klingensmith, G | 1 |
| Walravens, P | 1 |
| Narasimhan, S | 1 |
| Pan, T | 1 |
| Luo, L | 1 |
| Aw, DK | 1 |
| Sinha, RA | 1 |
| Xie, SY | 1 |
| Yen, PM | 1 |
| Jankowski, M | 1 |
| Song, Y | 3 |
| Wu, Y | 3 |
| Han, C | 1 |
| Zou, J | 2 |
| Liu, LY | 1 |
| Wu, PH | 1 |
| Liao, Y | 1 |
| Tao, T | 1 |
| Zhou, J | 1 |
| Nanji, AA | 1 |
| Temprosa, MG | 1 |
| Kitabchi, AE | 2 |
| Watson, KE | 1 |
| Bonaventura, A | 5 |
| Bianchi, L | 5 |
| Romano, D | 5 |
| Chevalier, S | 1 |
| Farsijani, S | 1 |
| Cadeddu, C | 3 |
| Nocco, S | 3 |
| Cugusi, L | 1 |
| Deidda, M | 3 |
| Bina, A | 3 |
| Fabio, O | 1 |
| Bandinu, S | 1 |
| Cossu, E | 3 |
| Baroni, MG | 1 |
| Mercuro, G | 4 |
| Elst, MA | 2 |
| van Mil, EG | 2 |
| Knibbe, CA | 2 |
| van der Vorst, MM | 2 |
| Qin, ZY | 2 |
| Dai, YM | 1 |
| Wang, YM | 2 |
| Zhu, GZ | 2 |
| Zhao, YP | 1 |
| Ji, CB | 2 |
| Qiu, J | 2 |
| Cao, XG | 2 |
| Guo, XR | 2 |
| Bhagavath, B | 1 |
| Vitek, W | 1 |
| Queenan, J | 1 |
| Hoeger, K | 1 |
| Sjöstrand, M | 1 |
| Hirshberg, B | 1 |
| Benitez-Aguirre, PZ | 1 |
| Tam, CS | 1 |
| Donaghue, KC | 2 |
| Craig, ME | 1 |
| Hsu, CS | 1 |
| Hsu, SJ | 1 |
| Lin, HH | 1 |
| Tseng, TC | 1 |
| Wang, CC | 1 |
| Chen, DS | 1 |
| Kao, JH | 1 |
| Yoon, JW | 1 |
| Jung, HS | 2 |
| Jang, JY | 1 |
| Kim, MJ | 1 |
| Kim, JH | 3 |
| Ohn, JH | 1 |
| Lee, HM | 1 |
| Kim, HC | 1 |
| Lee, KB | 1 |
| Choi, SA | 1 |
| Kim, SW | 1 |
| Hu, L | 1 |
| Shen, H | 1 |
| Wu, QF | 1 |
| Tian, L | 1 |
| Hu, MH | 1 |
| Garabadu, D | 3 |
| Krishnamurthy, S | 2 |
| Moser, C | 1 |
| Vickers, SP | 1 |
| Brammer, R | 1 |
| Cheetham, SC | 1 |
| Drewe, J | 1 |
| Vassilatou, E | 1 |
| Chinda, K | 1 |
| Palee, S | 1 |
| Chattipakorn, S | 1 |
| Pala, L | 1 |
| Barbaro, V | 1 |
| Dicembrini, I | 1 |
| Rotella, CM | 2 |
| Astiz, S | 1 |
| Gonzalez-Bulnes, A | 1 |
| Astiz, I | 1 |
| Barbero, A | 1 |
| Perez-Solana, ML | 1 |
| Garcia-Real, I | 1 |
| Xu, X | 1 |
| Du, C | 1 |
| Kashyap, SR | 1 |
| Bijok, J | 1 |
| Bińkowska, M | 1 |
| Jakiel, G | 1 |
| Konrad, K | 1 |
| Datz, N | 1 |
| Engelsberger, I | 1 |
| Grulich-Henn, J | 1 |
| Hoertenhuber, T | 1 |
| Knauth, B | 1 |
| Meissner, T | 1 |
| Wiegand, S | 2 |
| Woelfle, J | 1 |
| Holl, RW | 2 |
| Liu, SN | 2 |
| Sun, SJ | 2 |
| Liu, Q | 3 |
| Hou, SC | 2 |
| Shen, ZF | 2 |
| Daniele, G | 1 |
| Zhao, X | 1 |
| Dai, Y | 1 |
| Ito-Yamaguchi, A | 1 |
| Suganuma, R | 1 |
| Kumagami, A | 1 |
| Hashimoto, S | 1 |
| Yoshida-Komiya, H | 1 |
| Fujimori, K | 1 |
| DeCensi, A | 3 |
| Puntoni, M | 2 |
| Gandini, S | 1 |
| Guerrieri-Gonzaga, A | 2 |
| Johansson, HA | 1 |
| Cazzaniga, M | 3 |
| Pruneri, G | 2 |
| Serrano, D | 2 |
| Schwab, M | 1 |
| Hofmann, U | 1 |
| Mora, S | 1 |
| Aristarco, V | 2 |
| Macis, D | 1 |
| Bassi, F | 2 |
| Luini, A | 2 |
| Lazzeroni, M | 3 |
| Bonanni, B | 2 |
| Pollak, MN | 1 |
| Su, S | 1 |
| Li, T | 1 |
| Wan, J | 1 |
| Gu, J | 1 |
| Zeng, JB | 1 |
| Sun, Q | 1 |
| Li, YX | 1 |
| Agrawal, A | 1 |
| Wang, JQ | 2 |
| Huang, LP | 1 |
| Kurzthaler, D | 1 |
| Hadziomerovic-Pekic, D | 1 |
| Wildt, L | 1 |
| Seeber, BE | 1 |
| Mkrtumian, AM | 1 |
| Markova, TN | 1 |
| Kichigin, VA | 1 |
| Podachina, SV | 1 |
| Zhuchkova, SM | 1 |
| Worsley, R | 1 |
| Zheng, X | 2 |
| Basios, G | 1 |
| Trakakis, E | 1 |
| Chrelias, Ch | 1 |
| Panagopoulos, P | 1 |
| Vaggopoulos, V | 1 |
| Skarpas, P | 1 |
| Kassanos, D | 1 |
| Dimitriadis, G | 1 |
| Hatziagelaki, E | 1 |
| Kabil Kucur, S | 1 |
| Gozukara, I | 1 |
| Aksoy, A | 1 |
| Uludag, EU | 1 |
| Keskin, H | 1 |
| Kamalak, Z | 1 |
| Carlioglu, A | 1 |
| Naderpoor, N | 1 |
| Shorakae, S | 1 |
| Joham, A | 1 |
| De Courten, B | 1 |
| Briody, J | 1 |
| Maggs, D | 2 |
| Andrews, M | 1 |
| Soto, N | 2 |
| Arredondo-Olguín, M | 1 |
| Louden, ED | 1 |
| Luzzo, KM | 1 |
| Jimenez, PT | 1 |
| Chi, T | 1 |
| Chi, M | 1 |
| Moley, KH | 1 |
| Enkhtuvshin, B | 1 |
| Nagashima, S | 1 |
| Wakabayashi, T | 1 |
| Ando, A | 1 |
| Takahashi, M | 1 |
| Sakai, K | 1 |
| Yamamuro, D | 1 |
| Nagasaka, S | 3 |
| Tamemoto, H | 1 |
| Ishibashi, S | 2 |
| Blagosklonny, MV | 1 |
| Messinis, IE | 1 |
| Messini, CI | 1 |
| Anifandis, G | 1 |
| Dafopoulos, K | 1 |
| Franco, CC | 1 |
| Barella, LF | 1 |
| Agostinho, AR | 1 |
| Trombini, AB | 1 |
| Torrezan, R | 1 |
| Gravena, C | 1 |
| Tófolo, LP | 1 |
| de Sant'Anna, JR | 1 |
| de Castro Prado, MA | 1 |
| de Souza, CO | 1 |
| Beraldi, EJ | 1 |
| Mathias, PC | 1 |
| Kalina, MA | 1 |
| Wilczek, M | 1 |
| Kalina-Faska, B | 1 |
| Skała-Zamorowska, E | 1 |
| Mandera, M | 1 |
| Małecka Tendera, E | 1 |
| McSwiggan, S | 1 |
| Rutherford, L | 1 |
| Song, A | 1 |
| Zang, S | 1 |
| Jin, SM | 1 |
| Park, CY | 1 |
| Cho, YM | 3 |
| Ahn, CW | 3 |
| Cha, BS | 3 |
| Min, KW | 1 |
| Sung, YA | 1 |
| Yoon, KH | 1 |
| Lee, MK | 1 |
| Park, SW | 1 |
| Macauley, M | 1 |
| Smith, FE | 1 |
| Thelwall, PE | 1 |
| Hollingsworth, KG | 1 |
| Taylor, R | 1 |
| Chiswick, CA | 1 |
| Reynolds, RM | 1 |
| Denison, FC | 1 |
| Whyte, SA | 1 |
| Drake, AJ | 1 |
| Newby, DE | 1 |
| Forbes, S | 1 |
| Murray, GD | 1 |
| Quenby, S | 1 |
| Wray, S | 1 |
| Norman, JE | 2 |
| Di Pietro, M | 1 |
| Parborell, F | 1 |
| Irusta, G | 1 |
| Pascuali, N | 1 |
| Bas, D | 1 |
| Bianchi, MS | 1 |
| Tesone, M | 1 |
| Abramovich, D | 1 |
| Guo, J | 3 |
| Christianson, MS | 1 |
| Wu, H | 4 |
| Yemini, M | 1 |
| Leong, M | 1 |
| Shoham, Z | 1 |
| Ortega, F | 1 |
| Moreno, M | 2 |
| Kashi, Z | 1 |
| Masoumi, P | 1 |
| Mahrooz, A | 1 |
| Hashemi-Soteh, MB | 1 |
| Bahar, A | 1 |
| Alizadeh, A | 1 |
| Fang, X | 1 |
| Zhu, W | 1 |
| Martinez, MI | 1 |
| Ferri, A | 1 |
| Mateos, AM | 1 |
| Alegre, A | 1 |
| Buse, JB | 1 |
| Durrwell, L | 1 |
| Mingrino, R | 1 |
| Jaekel, K | 1 |
| El Azzouzi, B | 1 |
| Andjelkovic, M | 1 |
| Herz, M | 2 |
| Irving, BA | 2 |
| Carter, RE | 2 |
| Soop, M | 2 |
| Weymiller, A | 1 |
| Syed, H | 1 |
| Karakelides, H | 1 |
| Bhagra, S | 1 |
| Short, KR | 1 |
| Tatpati, L | 2 |
| Barazzoni, R | 1 |
| Pinkosky, SL | 1 |
| Day, EA | 1 |
| Scott, JW | 1 |
| Oakhill, JS | 1 |
| Bujak, AL | 1 |
| Smith, BK | 1 |
| Crane, JD | 1 |
| Blümer, RM | 1 |
| Mayer, SB | 1 |
| Evans, WS | 1 |
| Al-Zubeidi, H | 1 |
| Klein, KO | 1 |
| Cai, R | 1 |
| Sun, H | 2 |
| Zhou, Y | 3 |
| Wang, P | 10 |
| Huang, R | 1 |
| Xia, W | 1 |
| Jung, HW | 1 |
| Park, YK | 1 |
| Côté, CD | 1 |
| Rasmussen, BA | 1 |
| Zadeh-Tahmasebi, M | 1 |
| Rutter, GA | 1 |
| Filippi, BM | 1 |
| Lam, TK | 1 |
| Fu, L | 1 |
| Bruckbauer, A | 1 |
| Cao, Q | 1 |
| Cui, X | 1 |
| Wu, R | 2 |
| Shi, H | 1 |
| Zemel, MB | 1 |
| Xue, B | 1 |
| Ohno, T | 1 |
| Shimizu, M | 1 |
| Shirakami, Y | 1 |
| Baba, A | 1 |
| Kochi, T | 1 |
| Kubota, M | 1 |
| Tsurumi, H | 1 |
| Tanaka, T | 1 |
| Moriwaki, H | 1 |
| Bu, R | 1 |
| Noureddin, M | 1 |
| Rinella, ME | 1 |
| de Kreutzenberg, SV | 1 |
| Ceolotto, G | 2 |
| Cattelan, A | 1 |
| Pagnin, E | 1 |
| Mazzucato, M | 1 |
| Garagnani, P | 1 |
| Borelli, V | 1 |
| Bacalini, MG | 1 |
| Franceschi, C | 1 |
| Fadini, GP | 1 |
| Avogaro, A | 1 |
| Wang, DF | 1 |
| Yang, HJ | 1 |
| Gu, JQ | 1 |
| Cao, YL | 1 |
| Meng, X | 1 |
| Wang, XL | 1 |
| Lin, YC | 1 |
| Gao, M | 1 |
| Randriamboavonjy, V | 1 |
| Mann, WA | 1 |
| Elgheznawy, A | 1 |
| Popp, R | 1 |
| Rogowski, P | 1 |
| Dornauf, I | 1 |
| Dröse, S | 1 |
| Fleming, I | 1 |
| Matsumoto, Y | 1 |
| Ishii, M | 1 |
| Hayashi, Y | 1 |
| Miyazaki, S | 1 |
| Sugita, T | 1 |
| Sumiya, E | 1 |
| Sekimizu, K | 1 |
| Liao, HY | 1 |
| Sun, MF | 1 |
| Lin, JG | 1 |
| Chang, SL | 1 |
| Lee, YC | 1 |
| Wołosik, K | 1 |
| Zalewska, A | 1 |
| Mikucka-Niczyporuk, A | 1 |
| Kasacka, I | 1 |
| Fabbrocini, G | 1 |
| Izzo, R | 1 |
| Faggiano, A | 1 |
| Del Prete, M | 1 |
| Donnarumma, M | 1 |
| Marasca, C | 1 |
| Marciello, F | 1 |
| Savastano, R | 1 |
| Monfrecola, G | 1 |
| Colao, A | 3 |
| Lian, F | 1 |
| Tian, J | 1 |
| Piao, C | 1 |
| Zhao, L | 2 |
| Xia, C | 1 |
| Wang, CZ | 1 |
| Yuan, CS | 1 |
| Tong, X | 1 |
| Zonszein, J | 1 |
| Lombardero, M | 1 |
| Palumbo, P | 1 |
| Foucher, S | 1 |
| Groenewoud, Y | 1 |
| Cushing, G | 1 |
| Wajchenberg, B | 1 |
| Genuth, S | 2 |
| Lin, XF | 1 |
| Wu, RR | 4 |
| Du, J | 2 |
| Liao, YC | 1 |
| Zhang, XB | 1 |
| Chen, A | 1 |
| Jiang, SJ | 1 |
| Li, JB | 1 |
| Wang, KF | 1 |
| Ding, L | 1 |
| Qu, Z | 1 |
| Chi, J | 1 |
| Shi, R | 1 |
| Hou, L | 2 |
| Silva, FH | 1 |
| Alexandre, EC | 1 |
| Calmasini, FB | 1 |
| Pollak, F | 1 |
| Araya, V | 1 |
| Lanas, A | 1 |
| Sapunar, J | 1 |
| Arrese, M | 1 |
| Aylwin, CG | 1 |
| Bezanilla, CG | 1 |
| Carrasco, E | 1 |
| Carrasco, F | 1 |
| Codner, E | 1 |
| Díaz, E | 1 |
| Durruty, P | 1 |
| Galgani, J | 1 |
| García, H | 1 |
| Lahsen, R | 1 |
| Liberman, C | 1 |
| López, G | 2 |
| Maíz, A | 1 |
| Mujica, V | 1 |
| Poniachik, J | 1 |
| Sir, T | 2 |
| Valderas, J | 1 |
| Villaseca, P | 1 |
| Zavala, C | 1 |
| Ghadge, A | 1 |
| Harke, S | 1 |
| Khadke, S | 1 |
| Diwan, A | 1 |
| Pankaj, M | 1 |
| Kulkarni, O | 1 |
| Ranjekar, P | 1 |
| Harsulkar, A | 1 |
| Kuvalekar, AA | 1 |
| Mayans, L | 1 |
| Kuznetsova, LA | 1 |
| Sharova, TS | 1 |
| Ignatieva, PA | 1 |
| Bondareva, VM | 1 |
| Sun, X | 4 |
| Fan, Y | 1 |
| Zhang, N | 3 |
| Shen, C | 1 |
| Fan, X | 1 |
| Ren, F | 1 |
| Shen, J | 1 |
| Yang, J | 3 |
| Victor, VM | 1 |
| Rovira-Llopis, S | 1 |
| Bañuls, C | 1 |
| Diaz-Morales, N | 1 |
| Castelló, R | 2 |
| Falcón, R | 1 |
| Gómez, M | 1 |
| Rocha, M | 1 |
| Hernández-Mijares, A | 1 |
| Hurliman, A | 1 |
| Keller Brown, J | 1 |
| Maille, N | 1 |
| Mandala, M | 1 |
| Casson, P | 1 |
| Osol, G | 1 |
| Teo, C | 1 |
| Wilson, V | 1 |
| Chintoh, A | 1 |
| Guenette, M | 1 |
| Ahsan, Z | 1 |
| Giacca, A | 2 |
| Vrachnis, N | 1 |
| Iavazzo, C | 1 |
| Iliodromiti, Z | 1 |
| Sifakis, S | 1 |
| Alexandrou, A | 1 |
| Siristatidis, C | 1 |
| Grigoriadis, C | 1 |
| Botsis, D | 1 |
| Creatsas, G | 1 |
| Kwon, B | 1 |
| Querfurth, HW | 1 |
| Provinciali, N | 1 |
| Gorlero, F | 1 |
| Dunn, BK | 1 |
| Tanaka, K | 1 |
| Saisho, Y | 1 |
| Manesso, E | 1 |
| Tanaka, M | 2 |
| Meguro, S | 1 |
| Irie, J | 1 |
| Sugiura, H | 1 |
| Kawai, T | 1 |
| Jinzaki, M | 1 |
| Cobelli, C | 1 |
| Itoh, H | 1 |
| Karaburgu, S | 1 |
| Acmaz, B | 1 |
| Unluhizarci, K | 4 |
| Tanriverdi, F | 1 |
| Karaca, Z | 1 |
| Kelestimur, F | 5 |
| Sokhal, D | 1 |
| Kraus, C | 1 |
| Cheng, F | 1 |
| Jia, F | 1 |
| Suárez-Ortegón, MF | 1 |
| Arbeláez, A | 1 |
| Mosquera, M | 1 |
| Aguilar-de Plata, C | 1 |
| Peplow, PV | 1 |
| Lee, PD | 2 |
| Lustig, RH | 3 |
| Lenders, C | 2 |
| Baillargeon, J | 1 |
| Wilson, DM | 2 |
| Heeba, GH | 1 |
| Morsy, MA | 1 |
| de Silva, VA | 1 |
| Dayabandara, M | 1 |
| Wijesundara, H | 1 |
| Henegama, T | 1 |
| Gunewardena, H | 1 |
| Suraweera, C | 1 |
| Hanwella, R | 1 |
| Hivert, MF | 1 |
| Pollin, TI | 1 |
| Perreault, L | 1 |
| Gődény, S | 1 |
| Csenteri, OK | 1 |
| Mitsuhashi, A | 1 |
| Sato, Y | 1 |
| Kiyokawa, T | 1 |
| Koshizaka, M | 1 |
| Hanaoka, H | 1 |
| Shozu, M | 1 |
| Braun, B | 3 |
| Klinepeter Bartz, S | 1 |
| Connelly, PJ | 1 |
| Chadwick, R | 1 |
| Exley, AR | 1 |
| Shneerson, JM | 1 |
| Anil, C | 1 |
| Kut, A | 1 |
| Atesagaoglu, B | 1 |
| Nar, A | 2 |
| Bascil Tutuncu, N | 1 |
| Gursoy, A | 1 |
| Zhuang, X | 1 |
| Sun, F | 1 |
| Jiang, D | 1 |
| Lou, N | 1 |
| Lou, F | 1 |
| Patterson, RE | 1 |
| Marinac, CR | 1 |
| Natarajan, L | 1 |
| Hartman, SJ | 1 |
| Cadmus-Bertram, L | 1 |
| Flatt, SW | 1 |
| Parker, B | 1 |
| Oratowski-Coleman, J | 1 |
| Villaseñor, A | 1 |
| Godbole, S | 1 |
| Kerr, J | 1 |
| Yang, Z | 1 |
| De Souza, A | 1 |
| Khawaja, KI | 1 |
| Masud, F | 1 |
| Saif, MW | 1 |
| Dursun, F | 1 |
| Güven, A | 1 |
| Yıldız, M | 1 |
| Kutbay, NO | 1 |
| Yurekli, BS | 1 |
| Onay, H | 1 |
| Altay, CT | 1 |
| Atik, T | 1 |
| Hekimsoy, Z | 1 |
| Saygili, F | 1 |
| Akinci, B | 1 |
| Mogul, H | 1 |
| Freeman, R | 1 |
| Nguyen, K | 1 |
| Sivalingam, VN | 1 |
| Kitson, S | 1 |
| McVey, R | 1 |
| Roberts, C | 1 |
| Pemberton, P | 1 |
| Gilmour, K | 1 |
| Ali, S | 1 |
| Renehan, AG | 1 |
| Kitchener, HC | 1 |
| Crosbie, EJ | 1 |
| Zhang, FY | 1 |
| Gao, KM | 1 |
| Ou, JJ | 2 |
| Shao, P | 3 |
| Jin, H | 3 |
| Guo, WB | 1 |
| Chan, PK | 2 |
| Zhao, JP | 3 |
| Rankin, N | 1 |
| Kangas, AJ | 1 |
| Soininen, P | 1 |
| Würtz, P | 1 |
| Ala-Korpela, M | 1 |
| El-Haggar, SM | 1 |
| El-Shitany, NA | 1 |
| Mostafa, MF | 1 |
| El-Bassiouny, NA | 1 |
| Gilowska, M | 1 |
| Ping, J | 1 |
| Shou, Q | 1 |
| Ruo, R | 1 |
| Fan, H | 1 |
| Zhang, P | 1 |
| Elkrief, L | 1 |
| Rautou, PE | 1 |
| Sarin, S | 1 |
| Valla, D | 1 |
| Paradis, V | 1 |
| Moreau, R | 1 |
| Gundelach, T | 1 |
| Rodewald, M | 1 |
| Bekes, I | 1 |
| Janni, W | 1 |
| Hancke, K | 1 |
| Chae, YK | 1 |
| Arya, A | 1 |
| Malecek, MK | 1 |
| Shin, DS | 1 |
| Carneiro, B | 1 |
| Chandra, S | 1 |
| Kalyan, A | 1 |
| Altman, JK | 1 |
| Platanias, L | 1 |
| Giles, F | 1 |
| Haberzettl, P | 1 |
| McCracken, JP | 1 |
| Bhatnagar, A | 1 |
| Conklin, DJ | 1 |
| Fruzzetti, F | 2 |
| Ghiadoni, L | 1 |
| Virdis, A | 1 |
| De Negri, F | 1 |
| Perini, D | 2 |
| Bucci, F | 2 |
| Giannarelli, C | 1 |
| Gadducci, A | 2 |
| Taddei, S | 1 |
| Inthachai, T | 1 |
| Lekawanvijit, S | 1 |
| Sun, W | 1 |
| Zeng, C | 1 |
| Mari, A | 1 |
| Del Prato, S | 5 |
| Ludvik, B | 2 |
| Milicevic, Z | 1 |
| de la Peña, A | 1 |
| Shurzinske, L | 1 |
| Karanikas, CA | 1 |
| Pechtner, V | 1 |
| Ganesh, S | 1 |
| Rustgi, VK | 1 |
| Wang, QY | 1 |
| Wang, QS | 1 |
| Feng, GM | 1 |
| Siegmund, T | 1 |
| Indran, IR | 1 |
| Lee, BH | 1 |
| Yong, EL | 1 |
| Seow, KM | 1 |
| Lee, WL | 1 |
| Wang, PH | 1 |
| Ou, HT | 1 |
| Chen, PC | 1 |
| Wu, MH | 1 |
| Firouzjaei, A | 1 |
| Li, GC | 1 |
| Liu, WX | 1 |
| Zhu, BM | 1 |
| Chen, P | 1 |
| Xu, XJ | 2 |
| Shao, ZL | 1 |
| Huang, LH | 1 |
| Yang, XZ | 1 |
| Guo, W | 1 |
| Amblee, A | 1 |
| Lious, D | 1 |
| Zhou, ZY | 1 |
| Ren, LW | 1 |
| Zhan, P | 1 |
| Yang, HY | 1 |
| Chai, DD | 1 |
| Yu, ZW | 1 |
| El-Bayouki, KA | 1 |
| Abdel-Rahman, RF | 1 |
| Luo, T | 1 |
| Nocon, A | 1 |
| Fry, J | 1 |
| Sherban, A | 1 |
| Rui, X | 1 |
| Han, J | 1 |
| Zang, M | 3 |
| Schwartz, SS | 1 |
| Jellinger, PS | 1 |
| Herman, ME | 1 |
| Steurer, J | 1 |
| Zawiejska, A | 1 |
| Wender-Ozegowska, E | 1 |
| Grewling-Szmit, K | 1 |
| Brazert, M | 1 |
| Brazert, J | 1 |
| Kennelly, MA | 1 |
| McAuliffe, FM | 1 |
| Ye, F | 1 |
| Luo, YJ | 1 |
| Yu, NW | 1 |
| Yi, G | 1 |
| Elshewehy, AM | 1 |
| Magnussen, LV | 1 |
| Hermann, P | 1 |
| Hougaard, DM | 1 |
| Højlund, K | 1 |
| Kaneuchi, M | 1 |
| Khan, S | 1 |
| Jena, G | 1 |
| Shigeno, R | 1 |
| Horie, I | 1 |
| Ando, T | 1 |
| Abiru, N | 1 |
| Kawakami, A | 1 |
| Sivasinprasasn, S | 1 |
| Sa-Nguanmoo, P | 1 |
| Agha-Jaffar, R | 1 |
| Oliver, N | 1 |
| Johnston, D | 1 |
| Robinson, S | 1 |
| Li, A | 1 |
| Feng, X | 1 |
| Hou, T | 1 |
| Liu, K | 1 |
| Liu, B | 1 |
| Katz, LL | 1 |
| Anderson, BJ | 1 |
| Izquierdo, R | 1 |
| Casey, TL | 1 |
| Higgins, LA | 1 |
| Wauters, A | 1 |
| Hirst, K | 1 |
| Jeschke, MG | 2 |
| Abdullahi, A | 1 |
| Burnett, M | 1 |
| Rehou, S | 1 |
| Stanojcic, M | 1 |
| Hsieh, PS | 1 |
| Sam, WJ | 1 |
| Roza, O | 1 |
| Hon, YY | 1 |
| Alfaro, RM | 1 |
| Calis, KA | 3 |
| Reynolds, JC | 2 |
| Yanovski, JA | 2 |
| Dravecká, I | 3 |
| Figurová, J | 2 |
| Javorský, M | 2 |
| Petríková, J | 2 |
| Vaľková, M | 1 |
| Lazúrová, I | 3 |
| Doyle, MA | 1 |
| Singer, J | 1 |
| Lee, T | 1 |
| Muir, M | 1 |
| Cooper, C | 1 |
| Tjokroprawiro, A | 1 |
| Murtiwi, S | 1 |
| Tjandrawinata, RR | 1 |
| MacPherson, RE | 1 |
| Wright, DC | 1 |
| Yang, H | 1 |
| Tikoo, K | 1 |
| Sharma, E | 1 |
| Amara, VR | 1 |
| Pamulapati, H | 1 |
| Dhawale, VS | 1 |
| van de Garde, EM | 1 |
| Vellanki, P | 1 |
| Smiley, DD | 1 |
| Stefanovski, D | 1 |
| Anzola, I | 1 |
| Duan, W | 1 |
| Hudson, M | 1 |
| Pasquel, FJ | 1 |
| Umpierrez, GE | 1 |
| Reddy, BR | 2 |
| Maitra, S | 1 |
| Jhelum, P | 1 |
| Kumar, KP | 1 |
| Kaur, G | 1 |
| Chakravarty, S | 2 |
| Pandey, S | 1 |
| Kulkarni, SS | 1 |
| Joffraud, M | 1 |
| Boutant, M | 1 |
| Ratajczak, J | 1 |
| Gao, AW | 1 |
| Maclachlan, C | 1 |
| Hernandez-Alvarez, MI | 1 |
| Raymond, F | 1 |
| Metairon, S | 1 |
| Descombes, P | 1 |
| Houtkooper, RH | 1 |
| Zorzano, A | 2 |
| Cantó, C | 1 |
| Adam, J | 1 |
| Brandmaier, S | 1 |
| Leonhardt, J | 1 |
| Scheerer, MF | 1 |
| Mohney, RP | 1 |
| Bi, J | 1 |
| Rotter, M | 1 |
| Troll, M | 1 |
| Chi, S | 1 |
| Heier, M | 1 |
| Herder, C | 1 |
| Rathmann, W | 1 |
| Giani, G | 1 |
| Adamski, J | 1 |
| Illig, T | 1 |
| Strauch, K | 1 |
| Gieger, C | 1 |
| Peters, A | 2 |
| Suhre, K | 1 |
| Ankerst, D | 1 |
| Meitinger, T | 1 |
| Hrabĕ de Angelis, M | 1 |
| Neschen, S | 1 |
| Kastenmüller, G | 1 |
| Wang-Sattler, R | 1 |
| Hernandez-Aguilera, A | 1 |
| Garcia-Heredia, A | 1 |
| Cabre, N | 1 |
| Luciano-Mateo, F | 1 |
| Arenas, M | 1 |
| Thomas, AP | 1 |
| Hoang, J | 1 |
| Vongbunyong, K | 1 |
| Nguyen, A | 1 |
| Rakshit, K | 1 |
| Matveyenko, AV | 1 |
| Antu, KA | 1 |
| Riya, MP | 1 |
| Nair, A | 1 |
| Raghu, KG | 1 |
| Arslan, MS | 1 |
| Tutal, E | 1 |
| Sahin, M | 1 |
| Karakose, M | 1 |
| Ucan, B | 1 |
| Ozturk, G | 1 |
| Cakal, E | 2 |
| Biyikli Gencturk, Z | 1 |
| Ozbek, M | 1 |
| Delibasi, T | 1 |
| Kępczyńska-Nyk, A | 1 |
| Muszel, M | 1 |
| Radziszewski, M | 1 |
| Wocial, K | 1 |
| Qin, T | 1 |
| Ma, S | 1 |
| Garibay-Nieto, N | 1 |
| Queipo-García, G | 1 |
| Alvarez, F | 1 |
| Bustos, M | 1 |
| Villanueva, E | 1 |
| Ramírez, F | 1 |
| León, M | 1 |
| Laresgoiti-Servitje, E | 1 |
| Duggirala, R | 1 |
| Macías, T | 1 |
| Cuevas, S | 1 |
| Jalife, A | 1 |
| Fonseca-Sánchez, M | 1 |
| Serratos, F | 1 |
| López-Alvarenga, JC | 2 |
| Mitchell, PL | 1 |
| Nachbar, R | 1 |
| Lachance, D | 1 |
| St-Pierre, P | 1 |
| Trottier, J | 1 |
| Barbier, O | 1 |
| Marette, A | 1 |
| Cintosun, U | 1 |
| Naharci, MI | 1 |
| Doruk, H | 1 |
| Goland, R | 2 |
| Haymond, MW | 1 |
| Levitsky, L | 2 |
| Russo, M | 1 |
| Shree, N | 1 |
| Bhonde, RR | 1 |
| Bishay, RH | 1 |
| Timmers, S | 1 |
| de Ligt, M | 1 |
| Phielix, E | 1 |
| van de Weijer, T | 1 |
| Hansen, J | 1 |
| Moonen-Kornips, E | 1 |
| Schaart, G | 1 |
| Kunz, I | 1 |
| Hesselink, MK | 1 |
| Schrauwen-Hinderling, VB | 1 |
| Schrauwen, P | 1 |
| Porksen, N | 1 |
| Linnebjerg, H | 1 |
| Garhyan, P | 1 |
| Lam, EC | 1 |
| Knadler, MP | 1 |
| Jacober, SJ | 1 |
| Hoevelmann, U | 1 |
| Plum-Moerschel, L | 1 |
| Watkins, E | 1 |
| Gastaldelli, A | 1 |
| Heise, T | 1 |
| Magdy, YM | 1 |
| El-Kharashi, OA | 1 |
| Nabih, ES | 1 |
| Shaker, SM | 1 |
| Abd-Elaziz, LF | 1 |
| Aboul-Fotouh, S | 1 |
| Vendelbo, MH | 1 |
| Lu, ML | 2 |
| Huang, MC | 1 |
| Chen, PY | 1 |
| Lin, YK | 1 |
| Lin, SK | 1 |
| Pedersen, C | 1 |
| Gallagher, E | 1 |
| Horton, F | 1 |
| Ellis, RJ | 1 |
| Ijaz, UZ | 1 |
| Jaiyeola, E | 1 |
| Diribe, O | 1 |
| Duparc, T | 1 |
| Cani, PD | 1 |
| Gibson, GR | 1 |
| Hinton, P | 1 |
| Wright, J | 1 |
| La Ragione, R | 1 |
| Robertson, MD | 1 |
| Maurizi, AR | 1 |
| Menduni, M | 1 |
| Del Toro, R | 1 |
| Kyanvash, S | 1 |
| Maggi, D | 1 |
| Guglielmi, C | 1 |
| Pantano, AL | 1 |
| Defeudis, G | 1 |
| Fioriti, E | 1 |
| Manfrini, S | 1 |
| Pozzilli, P | 1 |
| Luo, C | 1 |
| Wen, T | 1 |
| Zhuang, W | 1 |
| Hong, L | 1 |
| Hisatome, I | 1 |
| Yamamoto, T | 2 |
| Arman, Y | 1 |
| Kirna, K | 1 |
| Ugurlukisi, B | 1 |
| Kutlu, O | 1 |
| Dikker, O | 1 |
| Cil, EO | 1 |
| Akarsu, M | 1 |
| Ozcan, M | 1 |
| Yuruyen, G | 1 |
| Demir, P | 1 |
| Altun, O | 1 |
| Ozsenel, EB | 1 |
| Erdem, MG | 1 |
| Sandikci, R | 1 |
| Tukek, T | 1 |
| Sheriba, NA | 1 |
| Ahmed, IZ | 1 |
| Abdelsalam, MM | 1 |
| Eid, YM | 1 |
| Mahdy, MM | 1 |
| Mansour, HK | 1 |
| Caletti, MT | 1 |
| Marchignoli, F | 1 |
| Forlani, G | 1 |
| Padilla, J | 1 |
| Thorne, PK | 1 |
| Martin, JS | 1 |
| Rector, RS | 1 |
| Akter, S | 1 |
| Davis, JW | 1 |
| Laughlin, MH | 1 |
| Jenkins, NT | 1 |
| Al Khalifah, RA | 1 |
| Alnhdi, A | 1 |
| Alghar, H | 1 |
| Alanazi, M | 1 |
| Florez, ID | 1 |
| Freis, A | 1 |
| Renke, T | 1 |
| Kämmerer, U | 1 |
| Jauckus, J | 1 |
| Strowitzki, T | 1 |
| Germeyer, A | 1 |
| Nistala, R | 1 |
| Raja, A | 1 |
| Pulakat, L | 1 |
| Pereira, TJ | 1 |
| Dalvi, P | 1 |
| Yeung, LSN | 1 |
| Swain, N | 1 |
| Breen, DM | 1 |
| Lam, L | 1 |
| Dolinsky, VW | 1 |
| Gouaref, I | 1 |
| Detaille, D | 1 |
| Wiernsperger, N | 3 |
| Khan, NA | 1 |
| Leverve, X | 1 |
| Koceir, EA | 1 |
| Haas, J | 1 |
| Bentov, Y | 1 |
| Ng, EH | 1 |
| Su, N | 1 |
| Cho, LW | 3 |
| Keevil, BG | 1 |
| Hanley, AJ | 3 |
| Vuksan, V | 1 |
| Hamilton, JK | 1 |
| Chien, KY | 2 |
| Hsu, KF | 2 |
| Lo, HI | 1 |
| Pan, RN | 1 |
| Kuo, CH | 2 |
| Chen, FA | 1 |
| Hsu, MC | 2 |
| Ma, F | 1 |
| Qiao, L | 1 |
| Yue, H | 1 |
| Jiang, M | 1 |
| Xu, K | 1 |
| Glueck, CJ | 10 |
| Goldenberg, N | 4 |
| Sieve, L | 4 |
| Atabek, ME | 2 |
| Pirgon, O | 3 |
| Cocksedge, KA | 1 |
| Li, TC | 1 |
| Saravelos, SH | 1 |
| Metwally, M | 1 |
| Nobili, V | 2 |
| Ciampalini, P | 1 |
| Alisi, A | 1 |
| Devito, R | 1 |
| Bugianesi, E | 2 |
| Marcellini, M | 1 |
| Jakubowska, J | 1 |
| Bohdanowicz-Pawlak, A | 1 |
| Milewicz, A | 2 |
| Szymczak, J | 1 |
| Bednarek-Tupikowska, G | 1 |
| Demissie, M | 1 |
| Sebestjen, M | 1 |
| Prezelj, J | 2 |
| Kocjan, T | 1 |
| Keber, I | 1 |
| Qu, J | 1 |
| Erkkola, R | 1 |
| Motta, DA | 1 |
| Raszeja-Wyszomirska, J | 1 |
| Lawniczak, M | 1 |
| Marlicz, W | 1 |
| Miezyńska-Kurtycz, J | 1 |
| Milkiewicz, P | 1 |
| Araki, T | 1 |
| Yokoyama, H | 1 |
| Lee, E | 1 |
| Teramura, M | 1 |
| Shoji, T | 1 |
| Nishizawa, Y | 1 |
| Burgert, TS | 1 |
| Duran, EJ | 1 |
| Goldberg-Gell, R | 1 |
| Dziura, J | 1 |
| Yeckel, CW | 1 |
| Katz, S | 1 |
| Tamborlane, WV | 1 |
| Basu, R | 1 |
| Basu, A | 2 |
| Chandramouli, V | 1 |
| Norby, B | 1 |
| Dicke, B | 1 |
| Cohen, O | 1 |
| Landau, BR | 1 |
| Rizza, RA | 1 |
| Erdem, G | 1 |
| Dogru, T | 1 |
| Tasci, I | 1 |
| Bozoglu, E | 1 |
| Muhsiroglu, O | 1 |
| Tapan, S | 2 |
| Ercin, CN | 1 |
| Sonmez, A | 1 |
| Wong, AK | 3 |
| AlZadjali, MA | 2 |
| Halimi, S | 3 |
| Schweizer, A | 1 |
| Minic, B | 1 |
| Foley, J | 1 |
| Dejager, S | 1 |
| Gedik, O | 1 |
| Drown, DJ | 1 |
| Dorkhan, M | 2 |
| Frid, A | 2 |
| Kashi, MR | 1 |
| Torres, DM | 1 |
| Harrison, SA | 1 |
| Meyer, C | 4 |
| Hutchison, SK | 4 |
| Zoungas, S | 3 |
| McGrath, BP | 2 |
| Ecker, JL | 1 |
| Mathur, R | 1 |
| Alexander, CJ | 1 |
| Yano, J | 1 |
| Trivax, B | 1 |
| Azziz, R | 2 |
| Rodríguez, A | 1 |
| Reviriego, J | 1 |
| Polavieja, P | 1 |
| Mesa, J | 1 |
| Rezvanian, H | 1 |
| Adibi, N | 1 |
| Siavash, M | 1 |
| Kachuei, A | 1 |
| Shojaee-Moradie, F | 1 |
| Asilian, A | 1 |
| Ozkaya, M | 1 |
| Ustun, Y | 1 |
| Engin-Ustun, Y | 1 |
| Papathanassiou, K | 1 |
| Naka, KK | 2 |
| Kazakos, N | 2 |
| Kanioglou, C | 1 |
| Makriyiannis, D | 1 |
| Pappas, K | 1 |
| Katsouras, CS | 2 |
| Liveris, K | 1 |
| Kolettis, T | 1 |
| Tsatsoulis, A | 2 |
| Michalis, LK | 2 |
| Haydardedeoglu, B | 2 |
| Simsek, E | 1 |
| Kilicdag, EB | 2 |
| Bagis, T | 2 |
| Barba, M | 1 |
| Schünemann, HJ | 1 |
| Sperati, F | 1 |
| Akl, EA | 1 |
| Musicco, F | 1 |
| Guyatt, G | 1 |
| Muti, P | 1 |
| Pang, TT | 1 |
| Narendran, P | 1 |
| Mascitelli, L | 3 |
| Pezzetta, F | 3 |
| Goldstein, MR | 3 |
| Tsilchorozidou, T | 2 |
| Mohamed-Ali, V | 1 |
| Conway, GS | 1 |
| Valizadeh, N | 1 |
| Tehrani, MR | 1 |
| Amoli, MM | 1 |
| Bandarian, F | 1 |
| Diamanti-Kandarakis, E | 9 |
| Economou, FN | 2 |
| Tantalaki, E | 1 |
| Piperi, C | 3 |
| Papavassiliou, AG | 1 |
| Panidis, D | 3 |
| Collet-Gaudillat, C | 1 |
| Billon-Bancel, A | 1 |
| Beressi, JP | 1 |
| Mereu, R | 2 |
| Salvadeo, SA | 5 |
| Ferrari, I | 6 |
| Gravina, A | 3 |
| Tahrani, AA | 1 |
| Piya, MK | 1 |
| Barnett, AH | 1 |
| Kumbak, B | 1 |
| Kahraman, S | 1 |
| Kebapcilar, L | 2 |
| Taner, CE | 2 |
| Kebapcilar, AG | 2 |
| Alacacioglu, A | 1 |
| Sari, I | 2 |
| van der Meer, RW | 1 |
| Rijzewijk, LJ | 1 |
| de Jong, HW | 1 |
| Lamb, HJ | 1 |
| Lubberink, M | 1 |
| Romijn, JA | 1 |
| Bax, JJ | 1 |
| de Roos, A | 1 |
| Kamp, O | 1 |
| Paulus, WJ | 1 |
| Heine, RJ | 1 |
| Lammertsma, AA | 1 |
| Smit, JW | 1 |
| Diamant, M | 1 |
| Svendsen, PF | 2 |
| Nilas, L | 2 |
| Madsbad, S | 2 |
| Gropler, RJ | 1 |
| Clarson, CL | 1 |
| Mahmud, FH | 1 |
| Baker, JE | 1 |
| Clark, HE | 1 |
| McKay, WM | 1 |
| Schauteet, VD | 1 |
| Hill, DJ | 1 |
| Palumbo, I | 1 |
| Adya, R | 5 |
| Farhatullah, S | 3 |
| Heutling, D | 4 |
| Mitchell, D | 1 |
| Sasaki, H | 1 |
| Asanuma, H | 1 |
| Fujita, M | 1 |
| Takahama, H | 1 |
| Wakeno, M | 1 |
| Ito, S | 2 |
| Ogai, A | 1 |
| Asakura, M | 1 |
| Kim, J | 1 |
| Minamino, T | 1 |
| Takashima, S | 1 |
| Sanada, S | 1 |
| Sugimachi, M | 1 |
| Komamura, K | 1 |
| Mochizuki, N | 1 |
| Kitakaze, M | 1 |
| Hemmingsen, B | 1 |
| Lund, SS | 1 |
| Vaag, A | 1 |
| Sabet, A | 1 |
| Djedjos, S | 1 |
| Miller, R | 1 |
| Hussain, MA | 1 |
| Kaku, K | 1 |
| Wasniewska, M | 1 |
| Crisafulli, G | 1 |
| Lombardo, F | 1 |
| Messina, MF | 1 |
| Salzano, G | 1 |
| Valenzise, M | 1 |
| De Luca, F | 1 |
| Casteels, K | 1 |
| Fieuws, S | 1 |
| van Helvoirt, M | 1 |
| Verpoorten, C | 1 |
| Goemans, N | 1 |
| Coudyzer, W | 1 |
| Loeckx, D | 1 |
| Kaur, J | 1 |
| Lewandowski, KC | 1 |
| O'Hare, JP | 1 |
| Dhar, GC | 1 |
| Carrizo, E | 3 |
| Fernández, V | 3 |
| Connell, L | 3 |
| Sandia, I | 3 |
| Prieto, D | 2 |
| Mogollón, J | 2 |
| Valbuena, D | 2 |
| Fernández, I | 2 |
| de Baptista, EA | 3 |
| Baptista, T | 6 |
| Zong, H | 1 |
| Billa, E | 1 |
| Kapolla, N | 1 |
| Nicopoulou, SC | 1 |
| Koukkou, E | 1 |
| Venaki, E | 1 |
| Milingos, S | 1 |
| Antsaklis, A | 1 |
| Adamopoulos, DA | 1 |
| Kannappan, S | 1 |
| Anuradha, CV | 2 |
| Kazerooni, T | 2 |
| Ghaffarpasand, F | 2 |
| Kazerooni, Y | 2 |
| Kazerooni, M | 1 |
| Setoodeh, S | 1 |
| Zhang, JL | 1 |
| Zou, DJ | 1 |
| Qiu, JL | 1 |
| Zhao, XX | 1 |
| Qin, YW | 1 |
| Snehalatha, C | 4 |
| Mary, S | 2 |
| Selvam, S | 1 |
| Sathish Kumar, CK | 1 |
| Shetty, SB | 1 |
| Nanditha, A | 1 |
| Ramachandran, A | 4 |
| Brill, DS | 1 |
| Moenter, SM | 1 |
| Charpentier, G | 1 |
| Katsiki, N | 1 |
| Georgiadou, E | 1 |
| Hatzitolios, AI | 1 |
| Xing, XH | 1 |
| Zhang, ZM | 1 |
| Hu, XZ | 1 |
| Wu, RQ | 1 |
| Yao-Borengasser, A | 5 |
| Varma, V | 5 |
| Spencer, HJ | 3 |
| McGehee, RE | 4 |
| Peterson, CA | 2 |
| Mehta, JL | 1 |
| Kern, PA | 6 |
| Omer, Z | 1 |
| Cetinkalp, S | 1 |
| Akyildiz, M | 1 |
| Yilmaz, F | 1 |
| Batur, Y | 1 |
| Yilmaz, C | 1 |
| Akarca, U | 1 |
| Maltezos, E | 1 |
| Mikhailidis, DP | 1 |
| Barskova, VG | 2 |
| Eliseev, MS | 2 |
| Kudaeva, FM | 2 |
| Aleksandrova, EN | 1 |
| Volkov, AV | 2 |
| Nasonova, VA | 1 |
| Nasonov, EL | 2 |
| Wagner, J | 1 |
| Allen, NA | 1 |
| Swalley, LM | 1 |
| Melkus, GD | 1 |
| Whittemore, R | 1 |
| Kanazawa, I | 1 |
| Sharma, AK | 2 |
| Srinivasan, BP | 3 |
| Polakof, S | 1 |
| Skiba-Cassy, S | 1 |
| Panserat, S | 1 |
| Donadon, V | 1 |
| Balbi, M | 1 |
| Zanette, G | 1 |
| Klein, F | 1 |
| Christakou, CD | 1 |
| Kandaraki, E | 1 |
| Guercio, G | 1 |
| Di Palma, MI | 1 |
| Pepe, C | 1 |
| Saraco, NI | 1 |
| Prieto, M | 1 |
| Saure, C | 1 |
| Mazza, C | 1 |
| Rivarola, MA | 1 |
| Belgorosky, A | 2 |
| Romero-Gómez, M | 3 |
| Diago, M | 1 |
| Andrade, RJ | 1 |
| Calleja, JL | 1 |
| Salmerón, J | 1 |
| Fernández-Rodríguez, CM | 1 |
| Solà, R | 1 |
| García-Samaniego, J | 1 |
| Herrerías, JM | 1 |
| De la Mata, M | 1 |
| Moreno-Otero, R | 1 |
| Nuñez, O | 1 |
| Olveira, A | 1 |
| Durán, S | 1 |
| Planas, R | 1 |
| Bao, WF | 1 |
| Forcheron, F | 1 |
| Basset, A | 1 |
| Del Carmine, P | 1 |
| Beylot, M | 1 |
| Hasan, AF | 1 |
| Ahmed, OG | 1 |
| Ahmed, MA | 1 |
| Garruti, G | 1 |
| Depalo, R | 1 |
| Vita, MG | 1 |
| Lorusso, F | 1 |
| Giampetruzzi, F | 1 |
| Damato, AB | 1 |
| Giorgino, F | 1 |
| Geroldi, D | 1 |
| Emanuele, E | 1 |
| Stein, LL | 1 |
| Dong, MH | 1 |
| Sari, R | 2 |
| Eray, E | 1 |
| Ozdem, S | 1 |
| Akbas, H | 1 |
| Coban, E | 2 |
| Yilmaz, Y | 1 |
| Yonal, O | 1 |
| Imeryuz, N | 1 |
| Sienkiewicz, R | 1 |
| Szydłowska, I | 1 |
| Agarwal, N | 2 |
| Rice, SP | 1 |
| Bolusani, H | 1 |
| Luzio, SD | 1 |
| Dunseath, G | 1 |
| Ludgate, M | 1 |
| Rees, DA | 2 |
| Oppelt, PG | 1 |
| Mueller, A | 1 |
| Jentsch, K | 1 |
| Kronawitter, D | 1 |
| Reissmann, C | 1 |
| Dittrich, R | 1 |
| Beckmann, MW | 1 |
| Cupisti, S | 1 |
| Quinn, SM | 1 |
| Gadaleta, G | 2 |
| Nawaz, FH | 1 |
| Rizvi, J | 1 |
| Kim, DS | 2 |
| Jeong, SK | 1 |
| Kim, HR | 1 |
| Chae, SW | 1 |
| Chae, HJ | 1 |
| Shwarts, V | 1 |
| Nowowiejska, B | 1 |
| Jarosz-Chobot, P | 1 |
| Stańczyk, J | 1 |
| Palermo, V | 1 |
| Petraglia, F | 3 |
| Sharoff, CG | 1 |
| Hagobian, TA | 1 |
| Chipkin, SR | 2 |
| Hirshman, MF | 1 |
| Goodyear, LJ | 2 |
| Ballian, N | 1 |
| Rabiee, A | 1 |
| Andersen, DK | 2 |
| Elahi, D | 1 |
| Gibson, BR | 1 |
| Rai, L | 1 |
| Meenakshi, D | 1 |
| Kamath, A | 1 |
| Shojaei-Baghini, A | 1 |
| Dehbashi, S | 2 |
| Asadi, N | 1 |
| Lord, JM | 2 |
| Falbo, A | 4 |
| Russo, T | 4 |
| Orio, F | 6 |
| Tolino, A | 6 |
| Zullo, F | 5 |
| Qu, Y | 1 |
| Lewis, MS | 1 |
| Glass, LC | 1 |
| Brown, A | 1 |
| Desai, M | 1 |
| Taneja, D | 1 |
| Tannock, LR | 1 |
| Abrams, SH | 1 |
| Aye, T | 1 |
| Osganian, SV | 1 |
| Feldman, HA | 1 |
| Fux Otta, C | 1 |
| Wior, M | 1 |
| Iraci, GS | 1 |
| Kaplan, R | 1 |
| Torres, D | 1 |
| Gaido, MI | 1 |
| Wyse, EP | 1 |
| Hasnain, M | 1 |
| Vieweg, WV | 1 |
| Fredrickson, SK | 1 |
| Nakano, K | 1 |
| Hasegawa, G | 1 |
| Fukui, M | 1 |
| Yamasaki, M | 1 |
| Ishihara, K | 1 |
| Takashima, T | 1 |
| Kitagawa, Y | 1 |
| Fujinami, A | 1 |
| Ohta, M | 1 |
| Hara, H | 1 |
| Adachi, T | 1 |
| Ogata, M | 1 |
| Obayashi, H | 1 |
| Nakamura, N | 1 |
| Di Berardino, OM | 1 |
| Simi, G | 1 |
| Papini, F | 1 |
| Ruggiero, M | 1 |
| Monteleone, P | 1 |
| Cela, V | 1 |
| Trolle, B | 1 |
| Lauszus, FF | 1 |
| Flyvbjerg, A | 1 |
| Patel, SM | 1 |
| Kaul, S | 1 |
| Ratcliffe, SJ | 1 |
| Rickels, MR | 1 |
| Reilly, MP | 1 |
| Scattergood, T | 1 |
| Fuller, C | 1 |
| Cappola, AR | 2 |
| Morán, E | 1 |
| Cheang, KI | 4 |
| Huszar, JM | 1 |
| Best, AM | 1 |
| Essah, PA | 2 |
| Lebovitz, HE | 2 |
| Zanchi, A | 1 |
| Maillard, M | 1 |
| Jornayvaz, FR | 1 |
| Vinciguerra, M | 1 |
| Deleaval, P | 1 |
| Nussberger, J | 1 |
| Burnier, M | 1 |
| Pechere-Bertschi, A | 1 |
| Souza-Mello, V | 1 |
| Gregório, BM | 1 |
| Cardoso-de-Lemos, FS | 1 |
| de Carvalho, L | 1 |
| Aguila, MB | 1 |
| Mandarim-de-Lacerda, CA | 1 |
| Ehret, M | 1 |
| Goethe, J | 1 |
| Lanosa, M | 1 |
| Coleman, CI | 1 |
| del Campo, JA | 2 |
| López, RA | 1 |
| Bilgir, O | 1 |
| Bozkaya, G | 1 |
| Yildiz, Y | 1 |
| Hosono, K | 2 |
| Endo, H | 2 |
| Takahashi, H | 2 |
| Sugiyama, M | 2 |
| Uchiyama, T | 2 |
| Suzuki, K | 2 |
| Nozaki, Y | 1 |
| Yoneda, K | 2 |
| Fujita, K | 1 |
| Yoneda, M | 1 |
| Inamori, M | 2 |
| Tomatsu, A | 1 |
| Chihara, T | 1 |
| Shimpo, K | 1 |
| Nakagama, H | 2 |
| Nakajima, A | 2 |
| Sheth, SH | 1 |
| Larson, RJ | 1 |
| Hou, M | 1 |
| Venier, N | 1 |
| Sugar, L | 1 |
| Musquera, M | 1 |
| Kiss, A | 1 |
| Fleshner, N | 1 |
| Klotz, L | 1 |
| Venkateswaran, V | 1 |
| Miller, RA | 1 |
| Birnbaum, MJ | 1 |
| Fernández, E | 1 |
| Genazzani, AD | 2 |
| Ricchieri, F | 2 |
| Lanzoni, C | 2 |
| Logie, L | 1 |
| Ruiz-Alcaraz, AJ | 1 |
| Schofield, CJ | 1 |
| Hundal, HS | 1 |
| Feuerstein, GZ | 1 |
| Brady, JD | 1 |
| Crowther, D | 1 |
| Tommasi, AM | 1 |
| Grierson, CE | 1 |
| Shepherd, B | 1 |
| Morris, AD | 2 |
| Hansen, MK | 1 |
| Pearson, E | 1 |
| Sutherland, C | 2 |
| Gray, SL | 1 |
| Donald, C | 1 |
| Jetha, A | 1 |
| Covey, SD | 1 |
| Kieffer, TJ | 1 |
| l'Allemand, D | 1 |
| Hübel, H | 1 |
| Krude, H | 1 |
| Bürmann, M | 1 |
| Martus, P | 1 |
| Grüters, A | 1 |
| Jalving, M | 1 |
| Gietema, JA | 1 |
| Lefrandt, JD | 1 |
| de Jong, S | 1 |
| Reyners, AK | 1 |
| Gans, RO | 1 |
| de Vries, EG | 1 |
| Kalantaridou, SN | 1 |
| Kravariti, M | 1 |
| Bechlioulis, A | 1 |
| Makrigiannakis, A | 1 |
| Chrousos, GP | 1 |
| Vazquez-Martin, A | 2 |
| Oliveras-Ferraros, C | 2 |
| Cufí, S | 2 |
| Martin-Castillo, B | 2 |
| Menendez, JA | 3 |
| Luque-Ramírez, M | 5 |
| Escobar-Morreale, HF | 5 |
| Brouwers, MC | 1 |
| de Graaf, J | 1 |
| van Greevenbroek, MM | 1 |
| Schaper, N | 1 |
| Stehouwer, CD | 1 |
| Stalenhoef, AF | 1 |
| Kirana, H | 1 |
| Mamas, MA | 1 |
| Deaton, C | 1 |
| Rutter, MK | 1 |
| Yuille, M | 1 |
| Williams, SG | 1 |
| Ray, SG | 1 |
| New, J | 1 |
| Gibson, JM | 1 |
| Neyses, L | 1 |
| Sakai, E | 1 |
| Iida, H | 1 |
| Sakamoto, Y | 1 |
| Koide, T | 1 |
| Tokoro, C | 1 |
| Abe, Y | 1 |
| Campbell, RK | 3 |
| Cobble, ME | 3 |
| Reid, TS | 3 |
| Shomali, ME | 3 |
| Mahamed, RR | 1 |
| Maganhin, CC | 1 |
| Simões, RS | 1 |
| Baracat, EC | 2 |
| Soares, JM | 1 |
| Munir, A | 1 |
| Newell-Price, J | 1 |
| Onuchin, SG | 2 |
| Elsukova, OS | 2 |
| Solov'ev, OV | 2 |
| Onuchina, EL | 2 |
| Georgopoulos, NA | 1 |
| Piouka, A | 1 |
| Katsikis, I | 2 |
| Saltamavros, AD | 1 |
| Decavalas, G | 1 |
| Jadeja, RN | 1 |
| Thounaojam, MC | 1 |
| Patel, VB | 1 |
| Devkar, RV | 1 |
| Ramachandran, AV | 1 |
| Shan, X | 1 |
| Aghilla, M | 1 |
| Keay, SD | 2 |
| Tinworth, KD | 2 |
| Edwards, S | 1 |
| Noble, GK | 2 |
| Harris, PA | 2 |
| Sillence, MN | 2 |
| Hackett, LP | 1 |
| Cosmi, F | 1 |
| Cosmi, D | 1 |
| van Wijk, JP | 1 |
| Hoepelman, AI | 1 |
| de Koning, EJ | 1 |
| Dallinga-Thie, G | 1 |
| Rabelink, TJ | 1 |
| Cabezas, MC | 1 |
| Park, JS | 1 |
| Cho, MH | 1 |
| Nam, JS | 1 |
| Yoo, JS | 1 |
| Kim, KR | 1 |
| Lee, HC | 2 |
| Kadoglou, NP | 1 |
| Kapelouzou, A | 1 |
| Tsanikidis, H | 1 |
| Vitta, I | 1 |
| Liapis, CD | 1 |
| Sailer, N | 1 |
| Ratziu, V | 1 |
| Caldwell, S | 1 |
| Neuschwander-Tetri, BA | 1 |
| Kilic, S | 1 |
| Yilmaz, N | 1 |
| Zulfikaroglu, E | 1 |
| Erdogan, G | 1 |
| Aydin, M | 1 |
| Batioglu, S | 1 |
| Rezzónico, J | 1 |
| Rezzónico, M | 1 |
| Pusiol, E | 1 |
| Pitoia, F | 1 |
| Niepomniszcze, H | 1 |
| Coker, RH | 1 |
| Ranganathan, G | 2 |
| Phanavanh, B | 3 |
| Chu, H | 1 |
| Duan, H | 1 |
| Bánhegyi, RJ | 1 |
| Rus-Gal, PO | 1 |
| Nagy, AK | 1 |
| Martyin, T | 1 |
| Wágner, R | 1 |
| Varga, R | 1 |
| Pikó, B | 1 |
| Louro, TM | 1 |
| Matafome, PN | 1 |
| Nunes, EC | 1 |
| da Cunha, FX | 1 |
| Seiça, RM | 1 |
| Gebel, E | 1 |
| Tosti, C | 1 |
| Piomboni, P | 2 |
| Álvarez-Blasco, F | 3 |
| Alpañés, M | 1 |
| González Jiménez, E | 1 |
| Schmidt Río-Valle, J | 1 |
| Álvarez Ferre, J | 1 |
| Matafome, P | 1 |
| Louro, T | 1 |
| Rodrigues, L | 1 |
| Crisóstomo, J | 1 |
| Nunes, E | 1 |
| Amaral, C | 1 |
| Cipriano, A | 1 |
| Seiça, R | 1 |
| Krakoff, J | 1 |
| Salaita, CG | 1 |
| McDuffie, JR | 1 |
| Kozlosky, M | 1 |
| Sebring, NG | 1 |
| Brady, SM | 1 |
| Khattab, S | 1 |
| Mohsen, IA | 1 |
| Aboul Foutouh, I | 1 |
| Ashmawi, HS | 1 |
| Mohsen, MN | 1 |
| van Wely, M | 1 |
| van der Veen, F | 1 |
| Youssef, MA | 1 |
| Glanville, J | 2 |
| Barth, J | 1 |
| Gupta, A | 1 |
| Bisht, B | 1 |
| Dey, CS | 3 |
| Muntoni, S | 2 |
| Joya-Galeana, J | 1 |
| Fernandez, M | 1 |
| Cervera, A | 1 |
| Reyna, S | 1 |
| Ghosh, S | 1 |
| Boston, RC | 1 |
| Raidal, SL | 1 |
| Pasarín, M | 1 |
| Abraldes, JG | 1 |
| Rodríguez-Vilarrupla, A | 1 |
| La Mura, V | 1 |
| García-Pagán, JC | 1 |
| Bosch, J | 1 |
| Brufani, M | 1 |
| Bals-Pratsch, M | 1 |
| Grosser, B | 1 |
| Seifert, B | 1 |
| Ortmann, O | 2 |
| Seifarth, C | 2 |
| Haffner, SM | 3 |
| Aftring, RP | 1 |
| Paul, G | 2 |
| Kravitz, BG | 1 |
| Herman, WH | 2 |
| Viberti, G | 3 |
| Clements, A | 1 |
| Gao, B | 2 |
| Yeap, SHO | 1 |
| Wong, MKY | 1 |
| Ali, SS | 1 |
| Gurney, H | 1 |
| Fu, JF | 1 |
| Shi, HB | 1 |
| Liu, LR | 1 |
| Karakas, S | 1 |
| Mortada, R | 1 |
| Fellow, C | 1 |
| Pfützner, A | 3 |
| Schöndorf, T | 1 |
| Tschöpe, D | 1 |
| Lobmann, R | 1 |
| Merke, J | 1 |
| Müller, J | 1 |
| Lehmann, U | 1 |
| Fuchs, W | 1 |
| Forst, T | 3 |
| Xu, S | 1 |
| Mihaylova, MM | 1 |
| Zheng, B | 1 |
| Park, O | 1 |
| Luo, Z | 1 |
| Lefai, E | 1 |
| Shyy, JY | 1 |
| Wierzbicki, M | 1 |
| Verbeuren, TJ | 1 |
| Cohen, RA | 3 |
| Lee, SK | 1 |
| Lee, JO | 1 |
| You, GY | 1 |
| Moon, JW | 1 |
| Jung, JH | 1 |
| Park, SH | 1 |
| Uhm, KO | 1 |
| Park, JM | 1 |
| Suh, PG | 1 |
| Schwanstecher, C | 1 |
| Schwanstecher, M | 1 |
| Berent-Spillson, A | 1 |
| Love, T | 1 |
| Pop-Busui, R | 1 |
| Sowers, M | 1 |
| Persad, CC | 1 |
| Pennington, KP | 1 |
| Eyvazaddeh, AD | 1 |
| Padmanabhan, V | 1 |
| Zubieta, JK | 1 |
| Smith, YR | 1 |
| Weerakiet, S | 1 |
| Sophonsritsuk, A | 1 |
| Lertvikool, S | 1 |
| Satirapot, C | 1 |
| Leelaphiwat, S | 1 |
| Jultanmas, R | 1 |
| Tian, YJ | 1 |
| Zhao, JJ | 1 |
| Xin, Y | 1 |
| Xing, HY | 1 |
| Dong, JJ | 1 |
| Sharif, A | 1 |
| Lázaro, I | 1 |
| Cabré, A | 1 |
| Masana, L | 1 |
| Adeneye, AA | 1 |
| Agbaje, EO | 1 |
| Olagunju, JA | 1 |
| Williams, FN | 1 |
| Branski, LK | 1 |
| Herndon, DN | 1 |
| Putignano, P | 1 |
| Bossi, AC | 1 |
| Guazzini, B | 1 |
| Testori, G | 1 |
| Oriot, P | 1 |
| Hermans, MP | 2 |
| Selvais, P | 1 |
| Buysschaert, M | 2 |
| de la Tribonnière, X | 1 |
| Han, F | 1 |
| Yi, J | 1 |
| Han, L | 1 |
| Ming, J | 1 |
| Qi, Y | 1 |
| Rosta, A | 1 |
| El-Sayed, MI | 1 |
| Lovati, MR | 1 |
| Manzoni, C | 1 |
| Castiglioni, S | 1 |
| Parolari, A | 1 |
| Magni, C | 1 |
| Duranti, M | 1 |
| Arrowood, JA | 1 |
| Adawadkar, SS | 1 |
| Stovall, DW | 1 |
| Serdyńska-Szuster, M | 1 |
| Banaszewska, B | 1 |
| Spaczyński, R | 1 |
| Pawelczyk, L | 1 |
| Cui, Y | 2 |
| Sobel, BE | 2 |
| Hardison, RM | 1 |
| Brooks, MM | 1 |
| McBane, RD | 1 |
| Schneider, DJ | 1 |
| Pratley, RE | 1 |
| Huber, K | 1 |
| Wolk, R | 1 |
| Krishnaswami, A | 1 |
| Frye, RL | 1 |
| Boguszewski, MC | 1 |
| Mericq, V | 1 |
| Bergada, I | 1 |
| Damiani, D | 1 |
| Gunczler, P | 1 |
| Ortiz, T | 1 |
| Llano, M | 1 |
| Domené, HM | 1 |
| Calzada-León, R | 1 |
| Blanco, A | 1 |
| Barrientos, M | 1 |
| Procel, P | 1 |
| Lanes, R | 1 |
| Jaramillo, O | 1 |
| Ye, C | 1 |
| Aguilar, D | 1 |
| Oner, G | 1 |
| Muderris, II | 1 |
| Durham, AE | 2 |
| Mu, PW | 1 |
| Chen, YM | 1 |
| Lu, HY | 1 |
| Wen, XQ | 1 |
| Zhang, YH | 1 |
| Xie, RY | 1 |
| Shu, J | 1 |
| Wang, MM | 1 |
| Zeng, LY | 1 |
| Nobes, JP | 1 |
| Langley, SE | 1 |
| Klopper, T | 1 |
| Russell-Jones, D | 1 |
| Laing, RW | 1 |
| Dool, CJ | 1 |
| Mashhedi, H | 1 |
| Zakikhani, M | 1 |
| David, S | 1 |
| Birman, E | 1 |
| Carboni, JM | 1 |
| Gottardis, M | 1 |
| Blouin, MJ | 1 |
| Pauli, JM | 1 |
| Raja-Khan, N | 1 |
| Afanas'ev, VV | 1 |
| Striuk, RI | 1 |
| Arutiunian, SE | 1 |
| Eliseeva, LV | 1 |
| Bychkov, RA | 1 |
| Goodwin, PJ | 1 |
| Stambolic, V | 1 |
| Wei, W | 1 |
| Wang, A | 1 |
| Sui, M | 1 |
| Liang, K | 1 |
| Deng, H | 1 |
| Guan, Y | 1 |
| Gerber, R | 1 |
| Shyangdan, D | 1 |
| Clar, C | 1 |
| Ghouri, N | 1 |
| Henderson, R | 1 |
| Gurung, T | 1 |
| Fraser, A | 1 |
| Waugh, N | 1 |
| Buler, M | 1 |
| Aatsinki, SM | 1 |
| Skoumal, R | 1 |
| Komka, Z | 1 |
| Tóth, M | 1 |
| Kerkelä, R | 1 |
| Georgiadi, A | 1 |
| Kersten, S | 1 |
| Hakkola, J | 1 |
| Li, XM | 1 |
| Zhang, NN | 1 |
| Xie, YH | 1 |
| Shi, YQ | 1 |
| Lobato, NS | 1 |
| Filgueira, FP | 1 |
| Hagihara, GN | 1 |
| Akamine, EH | 1 |
| Pariz, JR | 1 |
| Tostes, RC | 1 |
| Carvalho, MH | 1 |
| Fortes, ZB | 1 |
| Dunaif, A | 2 |
| Garinis, GA | 1 |
| Del Barco, S | 1 |
| Bosch-Barrera, J | 1 |
| Akın, S | 1 |
| Aksoy, DY | 1 |
| Cınar, N | 1 |
| Aydın, K | 1 |
| Karaağaoğlu, E | 1 |
| Arıyürek, M | 1 |
| Gülçelik, NE | 1 |
| Usman, A | 1 |
| Gürlek, A | 1 |
| Nadeau, K | 1 |
| Cuttler, L | 1 |
| Haymond, M | 1 |
| Lynch, J | 1 |
| Cittadini, A | 1 |
| Napoli, R | 1 |
| Monti, MG | 1 |
| Rea, D | 1 |
| Longobardi, S | 1 |
| Netti, PA | 1 |
| Walser, M | 1 |
| Samà, M | 1 |
| Aimaretti, G | 1 |
| Isgaard, J | 1 |
| Saccà, L | 1 |
| Kim, YD | 1 |
| Kim, YH | 1 |
| Kim, DK | 1 |
| Ahn, SW | 1 |
| Chanda, D | 1 |
| Shong, M | 1 |
| Huang, CC | 1 |
| Weickert, MO | 1 |
| Hodges, P | 1 |
| Guarino, E | 1 |
| Nigi, L | 1 |
| Patti, A | 1 |
| Fondelli, C | 1 |
| Dotta, F | 1 |
| Tong, JH | 1 |
| Zhu, G | 1 |
| Liang, GM | 1 |
| Yan, HF | 1 |
| Wang, XZ | 1 |
| Kuller, LH | 1 |
| Pei, L | 1 |
| Ao, N | 1 |
| Ziaee, A | 1 |
| Oveisi, S | 1 |
| Abedini, A | 1 |
| Hashemipour, S | 1 |
| Karimzadeh, T | 1 |
| Ghorbani, A | 1 |
| Han, P | 1 |
| Rajagopal, G | 1 |
| Reddy, AP | 1 |
| Venkata Harinarayan, C | 1 |
| Suresh, V | 1 |
| Bitla, A | 1 |
| P V L N Rao, S | 1 |
| Sachan, A | 1 |
| Kulshreshtha, B | 1 |
| Ammini, AC | 1 |
| Yu, JW | 1 |
| Sun, LJ | 1 |
| Zhao, YH | 1 |
| Kang, P | 1 |
| Yan, BZ | 1 |
| Motta, EL | 1 |
| Domingues, TS | 1 |
| Soares Júnior, JM | 2 |
| García-Ruiz, I | 1 |
| Solís-Muñoz, P | 1 |
| Gómez-Izquierdo, E | 1 |
| Muñoz-Yagüe, MT | 1 |
| Valverde, AM | 1 |
| Solís-Herruzo, JA | 1 |
| Spruss, A | 1 |
| Kanuri, G | 1 |
| Stahl, C | 1 |
| Bischoff, SC | 1 |
| Bergheim, I | 1 |
| Gennari, A | 1 |
| Trabacca, MS | 1 |
| Galimberti, V | 1 |
| Veronesi, P | 1 |
| Johansson, H | 1 |
| Varricchio, C | 1 |
| Viale, G | 1 |
| Bruzzi, P | 1 |
| Evia-Viscarra, ML | 1 |
| Rodea-Montero, ER | 1 |
| Apolinar-Jiménez, E | 1 |
| Muñoz-Noriega, N | 1 |
| García-Morales, LM | 1 |
| Leaños-Pérez, C | 1 |
| Figueroa-Barrón, M | 1 |
| Sánchez-Fierros, D | 1 |
| Reyes-García, JG | 1 |
| Konstantopoulos, N | 1 |
| Molero, JC | 1 |
| McGee, SL | 1 |
| Spolding, B | 1 |
| Connor, T | 1 |
| de Vries, M | 1 |
| Wanyonyi, S | 1 |
| Fahey, R | 1 |
| Morrison, S | 1 |
| Swinton, C | 1 |
| Jones, S | 1 |
| Cooper, A | 1 |
| Garcia-Guerra, L | 1 |
| Foletta, VC | 1 |
| Krippner, G | 1 |
| Andrikopoulos, S | 1 |
| Walder, KR | 1 |
| Campagnoli, C | 1 |
| Pasanisi, P | 1 |
| Abbà, C | 1 |
| Ambroggio, S | 1 |
| Biglia, N | 1 |
| Brucato, T | 1 |
| Colombero, R | 1 |
| Danese, S | 1 |
| Donadio, M | 1 |
| Venturelli, E | 1 |
| Zito, G | 1 |
| Berrino, F | 1 |
| Cadeddu, F | 2 |
| Demuru, P | 2 |
| Baroni, M | 2 |
| Middela, H | 1 |
| Matapally, S | 1 |
| Padiya, R | 1 |
| Bastia, T | 1 |
| Madhusudana, K | 1 |
| Bershteĭn, LM | 1 |
| Vasil'ev, DA | 1 |
| Kovalenko, IG | 1 |
| Poroshina, TE | 1 |
| Kisel'nikov, KS | 1 |
| Boiarkina, MP | 1 |
| Zaĭtsev, AN | 1 |
| Boyda, HN | 1 |
| Procyshyn, RM | 1 |
| Tse, L | 1 |
| Hawkes, E | 1 |
| Jin, CH | 1 |
| Pang, CC | 1 |
| Honer, WG | 1 |
| Barr, AM | 1 |
| Akcam, M | 1 |
| Boyaci, A | 1 |
| Kaya, S | 1 |
| Uysal, S | 1 |
| Dundar, BN | 1 |
| Shargorodsky, M | 1 |
| Omelchenko, E | 1 |
| Matas, Z | 1 |
| Boaz, M | 1 |
| Gavish, D | 1 |
| McCoy, RG | 1 |
| Srinivasan, M | 1 |
| Chow, L | 1 |
| Weymiller, AJ | 1 |
| Franzetti, I | 1 |
| Gao, K | 1 |
| Twamley, EW | 1 |
| Guo, XF | 2 |
| Davis, JM | 1 |
| Mizokami-Stout, K | 1 |
| Symon, R | 1 |
| Ang, DS | 1 |
| Ogston, S | 1 |
| Choy, A | 1 |
| Petrie, JR | 2 |
| Ulas, T | 1 |
| Tursun, I | 1 |
| Dal, MS | 1 |
| Demir, ME | 1 |
| Buyukhatipoglu, H | 1 |
| Zuckerwise, LC | 1 |
| Werner, EF | 1 |
| Pettker, CM | 1 |
| McMahon-Brown, EK | 1 |
| Thung, SF | 1 |
| Han, CS | 1 |
| Hutcheson, R | 1 |
| Rocic, P | 1 |
| Veilleux-Lemieux, M | 1 |
| DiVasta, AD | 1 |
| Shepherd, J | 1 |
| Lansdown, A | 1 |
| Chen, SG | 1 |
| He, JW | 1 |
| Sheng, CJ | 1 |
| Cheng, XY | 1 |
| Wang, KS | 1 |
| Yu, YC | 1 |
| McNeilly, AD | 1 |
| Williamson, R | 1 |
| Balfour, DJ | 1 |
| Stewart, CA | 1 |
| Yuan, GH | 1 |
| Song, WL | 1 |
| Huang, YY | 1 |
| Guo, XH | 1 |
| Jakubowicz, D | 1 |
| Wainstein, J | 1 |
| Homburg, R | 3 |
| Shi, CM | 1 |
| Yue, HN | 1 |
| González-Ortiz, M | 1 |
| Martínez-Abundis, E | 1 |
| Robles-Cervantes, JA | 1 |
| Ramos-Zavala, MG | 1 |
| Barrera-Durán, C | 1 |
| González-Canudas, J | 1 |
| Kashani, L | 1 |
| Omidvar, T | 1 |
| Farazmand, B | 1 |
| Modabbernia, A | 1 |
| Ramzanzadeh, F | 1 |
| Tehraninejad, ES | 1 |
| Ashrafi, M | 1 |
| Tabrizi, M | 1 |
| Akhondzadeh, S | 1 |
| Lexis, CP | 1 |
| van der Horst, IC | 1 |
| Lipsic, E | 1 |
| Raikwar, SK | 1 |
| Kurmi, MK | 1 |
| García-Valdecasas, M | 1 |
| Rojas, L | 1 |
| Rojas, Á | 1 |
| Sollon, C | 1 |
| Mónica, FZ | 1 |
| De Nucci, G | 1 |
| Zanesco, A | 1 |
| Grant, AD | 1 |
| Schehler, B | 1 |
| Schneider, HJ | 1 |
| Fernandez-Sender, L | 1 |
| Espinel, E | 1 |
| Rull, A | 1 |
| Beltrán-Debón, R | 1 |
| Rodríguez-Gallego, E | 1 |
| Riera-Borrull, M | 1 |
| Pedro-Botet, J | 1 |
| Alonso-Villaverde, C | 1 |
| Aragonès, G | 1 |
| Bates, GW | 1 |
| Propst, AM | 1 |
| Nascimento, AD | 1 |
| Silva Lara, LA | 1 |
| Japur de Sá Rosa-e-Silva, AC | 1 |
| Ferriani, RA | 1 |
| Reis, RM | 1 |
| Takada, H | 1 |
| Oyama, Y | 1 |
| Kon, S | 1 |
| Goto, T | 2 |
| Sabater, M | 1 |
| Pueyo, N | 1 |
| Ruiz, B | 1 |
| Naon, D | 1 |
| Botas, P | 1 |
| Delgado, E | 1 |
| Bosch, F | 1 |
| Motshakeri, M | 1 |
| Ebrahimi, M | 1 |
| Goh, YM | 1 |
| Matanjun, P | 1 |
| Mohamed, S | 1 |
| Carmina, E | 1 |
| Panahi, Y | 1 |
| Ghamarchehreh, ME | 1 |
| Beiraghdar, F | 1 |
| Zare, R | 1 |
| Jalalian, HR | 1 |
| Lawrence, JM | 1 |
| Andrade, SE | 1 |
| Avalos, LA | 1 |
| Beaton, SJ | 1 |
| Chiu, VY | 1 |
| Davis, RL | 1 |
| Dublin, S | 1 |
| Pawloski, PA | 1 |
| Raebel, MA | 1 |
| Smith, DH | 1 |
| Toh, S | 1 |
| Kaplan, S | 1 |
| Amini, T | 1 |
| Hampp, C | 1 |
| Hammad, TA | 1 |
| Scott, PE | 1 |
| Cheetham, TC | 1 |
| Esfahanian, F | 1 |
| Zamani, MM | 1 |
| Heshmat, R | 1 |
| Moini nia, F | 1 |
| Beydoun, H | 1 |
| Kancherla, V | 1 |
| Stadtmauer, L | 1 |
| Beydoun, M | 1 |
| Kedikova, S | 1 |
| Sirakov, M | 1 |
| Boyadzhieva, M | 1 |
| Brännmark, C | 1 |
| Nyman, E | 1 |
| Fagerholm, S | 1 |
| Bergenholm, L | 1 |
| Ekstrand, EM | 1 |
| Cedersund, G | 1 |
| Strålfors, P | 1 |
| Severino, C | 1 |
| Brizzi, P | 1 |
| Solinas, A | 1 |
| Secchi, G | 1 |
| Maioli, M | 1 |
| Tonolo, G | 1 |
| Ghazourian, N | 1 |
| Awartani, KA | 1 |
| Cheung, AP | 1 |
| Mao, CP | 1 |
| Xie, ML | 1 |
| Gu, ZL | 1 |
| Kumar, N | 2 |
| Schöfl, C | 1 |
| Horn, R | 1 |
| Schill, T | 1 |
| Schlösser, HW | 1 |
| Müller, MJ | 1 |
| Brabant, G | 1 |
| Hadigan, C | 3 |
| Rabe, J | 2 |
| Grinspoon, S | 2 |
| Baret, G | 1 |
| Peyronnet, J | 1 |
| Grassi-Kassisse, D | 1 |
| Dalmaz, Y | 1 |
| Géloën, A | 1 |
| Serrano Rios, M | 1 |
| Ascaso Gimilio, JF | 1 |
| Blázquez Fernández, E | 1 |
| Cabezas Cerraro, J | 1 |
| Carmena Rodríguez, R | 1 |
| Escobar Jiménez, F | 1 |
| Gabriel Sánchez, R | 1 |
| Gomis de Barberá, R | 1 |
| Grande Aragón, C | 1 |
| Herrera Pomba, JL | 1 |
| Pallardo Sánchez, LF | 1 |
| Potau Vilalta, N | 1 |
| Ricart Engel, W | 1 |
| Rovira Loscos, A | 1 |
| Zorzano Olarte, A | 1 |
| Yamasaki, Y | 1 |
| Kuroda, A | 1 |
| Robinson, K | 1 |
| Tankova, T | 3 |
| Koev, D | 2 |
| Dakovska, L | 2 |
| Kirilov, G | 2 |
| Stadtmauer, LA | 1 |
| Wong, BC | 1 |
| Oehninger, S | 1 |
| Gin, H | 3 |
| Rigalleau, V | 2 |
| Wu, YC | 1 |
| Hsu, JH | 1 |
| Liu, IM | 1 |
| Liou, SS | 1 |
| Su, HC | 1 |
| Pagotto, U | 2 |
| Vicennati, V | 1 |
| Heiman, ML | 1 |
| Tschöp, M | 1 |
| Hamilton, J | 1 |
| Cummings, E | 1 |
| Zdravkovic, V | 1 |
| Finegood, D | 1 |
| Daneman, D | 1 |
| Yuan, L | 1 |
| Ziegler, R | 1 |
| Hamann, A | 4 |
| Cleasby, ME | 3 |
| Livingstone, DE | 1 |
| Nyirenda, MJ | 1 |
| Seckl, JR | 1 |
| Ruderman, NB | 2 |
| Cacicedo, JM | 1 |
| Itani, S | 1 |
| Yagihashi, N | 1 |
| Saha, AK | 1 |
| Ye, JM | 3 |
| Carling, D | 1 |
| Keaney, J | 1 |
| Kraegen, EW | 3 |
| Ido, Y | 1 |
| Bokhari, SU | 1 |
| Gopal, UM | 1 |
| Duckworth, WC | 1 |
| Tadayyon, M | 1 |
| Smith, SA | 1 |
| Hanefeld, M | 2 |
| Fischer, S | 1 |
| Pavo, I | 1 |
| Jermendy, G | 1 |
| Varkonyi, TT | 1 |
| Kerenyi, Z | 1 |
| Gyimesi, A | 1 |
| Shoustov, S | 1 |
| Shestakova, M | 1 |
| Johns, D | 4 |
| Schluchter, BJ | 1 |
| Festa, A | 1 |
| Tan, MH | 4 |
| Jones, TA | 1 |
| Sautter, M | 1 |
| Van Gaal, LF | 1 |
| Jones, NP | 2 |
| Decsi, T | 1 |
| Molnár, D | 1 |
| Bernard, L | 1 |
| Christin-Maître, S | 1 |
| Basille, C | 2 |
| Chabbert-Buffet, N | 1 |
| Slama, G | 1 |
| Picard, S | 1 |
| Valabhji, J | 1 |
| Watson, M | 1 |
| Cox, J | 1 |
| Poulter, C | 1 |
| Elwig, C | 1 |
| Elkeles, RS | 1 |
| Massin, N | 1 |
| Galey, J | 1 |
| Théron-Gérard, L | 1 |
| Bry-Gauillard, H | 1 |
| Cédrin-Durnerin, I | 1 |
| Hugues, JN | 1 |
| Pugeat, M | 2 |
| Ong, K | 3 |
| Ferrer, A | 3 |
| Amin, R | 2 |
| Dunger, D | 2 |
| Baillargeon, JP | 2 |
| Iuorno, MJ | 4 |
| Fedorcsák, P | 1 |
| Dale, PO | 1 |
| Storeng, R | 1 |
| Abyholm, T | 1 |
| Tanbo, T | 1 |
| Streicher, P | 1 |
| Vigouroux, C | 1 |
| Tosi, F | 2 |
| Muggeo, M | 2 |
| Brun, E | 1 |
| Spiazzi, G | 1 |
| Perobelli, L | 1 |
| Zanolin, E | 2 |
| Gori, M | 1 |
| Coppini, A | 1 |
| Satoh, J | 2 |
| Odawara, M | 1 |
| Visnová, H | 1 |
| Ventruba, P | 1 |
| Crha, I | 1 |
| Záková, J | 1 |
| Goodarzi, MO | 1 |
| Korenman, SG | 1 |
| Scheen, AJ | 3 |
| Fonseca, VA | 2 |
| Harborne, L | 1 |
| Fleming, R | 2 |
| Lyall, H | 1 |
| Norman, J | 1 |
| Vague, P | 3 |
| Giannarelli, R | 1 |
| Aragona, M | 1 |
| Coppelli, A | 1 |
| Grant, PJ | 2 |
| Mamputu, JC | 1 |
| Wiernsperger, NF | 3 |
| Renier, G | 1 |
| Bouskela, E | 1 |
| la Marca, A | 3 |
| Roberts, AW | 1 |
| Thomas, A | 1 |
| Rees, A | 1 |
| Evans, M | 1 |
| Prelevic, GM | 1 |
| Iannello, S | 1 |
| Camuto, M | 1 |
| Cavaleri, A | 1 |
| Milazzo, P | 1 |
| Pisano, MG | 1 |
| Bellomia, D | 1 |
| Belfiore, F | 1 |
| Yatagai, T | 1 |
| Nakamura, T | 1 |
| Kusaka, I | 2 |
| Ishikawa, SE | 1 |
| Yoshitaka, A | 1 |
| Cohen, SE | 1 |
| Tseng, YH | 1 |
| Michael, MD | 1 |
| Kahn, CR | 1 |
| Schröder, AK | 1 |
| Schernthaner, G | 3 |
| McCarthy, EA | 1 |
| Walker, SP | 1 |
| McLachlan, K | 1 |
| Permezel, M | 1 |
| Kaul, CL | 1 |
| Ishrath, A | 1 |
| Maciel, GA | 1 |
| Alves da Motta, EL | 1 |
| de Lima, GR | 1 |
| Srividhya, S | 1 |
| Ravichandran, MK | 1 |
| Ajossa, S | 1 |
| Guerriero, S | 1 |
| Paoletti, AM | 1 |
| Orrù, M | 1 |
| Melis, GB | 1 |
| Petersen, KU | 1 |
| Herrmann, BL | 2 |
| Berg, C | 2 |
| Vogel, E | 1 |
| Nowak, T | 1 |
| Renzing-Koehler, K | 1 |
| Mann, K | 5 |
| Saller, B | 2 |
| Uygun, A | 1 |
| Kadayifci, A | 2 |
| Isik, AT | 1 |
| Ozgurtas, T | 2 |
| Deveci, S | 1 |
| Tuzun, A | 1 |
| Yesilova, Z | 2 |
| Gulsen, M | 1 |
| Dagalp, K | 1 |
| Loftspring, M | 2 |
| Sherman, A | 2 |
| Brame, L | 1 |
| Verma, S | 3 |
| Anderson, T | 1 |
| Lteif, A | 1 |
| Mather, K | 1 |
| Kazuga, M | 1 |
| Cariou, B | 1 |
| Capitaine, N | 1 |
| Le Marcis, V | 1 |
| Vega, N | 1 |
| Kergoat, M | 1 |
| Girard, J | 2 |
| Vidal, H | 1 |
| Burnol, AF | 1 |
| Sahin, Y | 3 |
| Yirmibeş, U | 1 |
| Aygen, E | 1 |
| Chen, XP | 1 |
| Yang, WY | 1 |
| Bu, S | 1 |
| Xiao, JZ | 1 |
| Liu, XL | 1 |
| Zhao, WH | 1 |
| Hahn, S | 3 |
| Quadbeck, B | 1 |
| Elsenbruch, S | 2 |
| Gärtner, R | 1 |
| Finke, R | 1 |
| Janssen, OE | 4 |
| Glazer, NB | 1 |
| Widel, M | 3 |
| Gilmore, KJ | 2 |
| Müller, B | 1 |
| Trepp, R | 1 |
| Dandona, P | 2 |
| Aljada, A | 2 |
| Chaudhuri, A | 2 |
| Mohanty, P | 2 |
| Balci, MK | 1 |
| Yazicioglu, G | 1 |
| Kriplani, A | 1 |
| Nair, S | 1 |
| Diehl, AM | 2 |
| Wiseman, M | 1 |
| Farr, GH | 1 |
| Perrillo, RP | 1 |
| Dzamko, N | 2 |
| Hegarty, BD | 2 |
| Furler, SM | 1 |
| Villa, P | 1 |
| Di Sebastiano, F | 1 |
| Rossodivita, A | 1 |
| Sagnella, F | 1 |
| Barini, A | 1 |
| Fulghesu, AM | 1 |
| Enriquez, YR | 1 |
| Giri, M | 2 |
| Rottiers, R | 2 |
| Christophe, A | 1 |
| Negro, R | 2 |
| Dazzi, D | 2 |
| Hassan, H | 2 |
| Pezzarossa, A | 2 |
| Panikar, V | 1 |
| Chandalia, HB | 1 |
| Joshi, SR | 1 |
| Fafadia, A | 1 |
| Santvana, C | 1 |
| Ben-Haroush, A | 1 |
| Yogev, Y | 1 |
| Fisch, B | 1 |
| Seufert, J | 1 |
| Lübben, G | 2 |
| Dietrich, K | 1 |
| Bates, PC | 1 |
| Tiikkainen, M | 2 |
| Häkkinen, AM | 2 |
| Korsheninnikova, E | 1 |
| Nyman, T | 1 |
| Mäkimattila, S | 1 |
| Yki-Järvinen, H | 3 |
| Lavine, JE | 2 |
| Schwimmer, JB | 2 |
| Zuccollo, A | 1 |
| Nagata, D | 1 |
| Walsh, K | 1 |
| Herscovitz, H | 1 |
| Brecher, P | 1 |
| Ghanim, H | 1 |
| Tripathy, C | 1 |
| Hofmeyer, D | 1 |
| Jakubowicz, DJ | 2 |
| Jakubowicz, S | 1 |
| Liu, ZA | 1 |
| Xue, YM | 1 |
| Chen, LX | 1 |
| Cai, Q | 1 |
| Cui, QH | 1 |
| Ge, J | 1 |
| Yuan, T | 1 |
| Sönmez, AS | 1 |
| Yasar, L | 1 |
| Savan, K | 1 |
| Koç, S | 1 |
| Ozcan, J | 1 |
| Toklar, A | 1 |
| Yazicioğu, F | 1 |
| Akgün, A | 1 |
| Sut, N | 1 |
| Rodríguez, Y | 1 |
| Feyen, E | 1 |
| Christophe, AB | 1 |
| Bailey, CJ | 4 |
| Day, C | 1 |
| Kraus, V | 1 |
| Petrovicova, J | 2 |
| Jayagopal, V | 1 |
| Holding, S | 1 |
| Jennings, PE | 1 |
| Putz, DM | 1 |
| Goldner, WS | 1 |
| Bar, RS | 1 |
| Haynes, WG | 1 |
| Sivitz, WI | 1 |
| Sahhar, NN | 1 |
| Ahmad, AT | 1 |
| Ammari, FL | 1 |
| Ajlouni, KM | 1 |
| Cibula, D | 3 |
| Fanta, M | 1 |
| Vrbikova, J | 5 |
| Stanicka, S | 1 |
| Dvorakova, K | 1 |
| Hill, M | 5 |
| Skrha, J | 1 |
| Zivny, J | 1 |
| Skrenkova, J | 1 |
| Khan, M | 1 |
| Edwards, G | 1 |
| Urquhart, R | 3 |
| Mariz, S | 2 |
| Ortega-González, C | 2 |
| Luna, S | 1 |
| Hernández, L | 3 |
| Crespo, G | 1 |
| Aguayo, P | 1 |
| Arteaga-Troncoso, G | 2 |
| Parra, A | 2 |
| Zeyneloglu, HB | 2 |
| Tarim, E | 1 |
| Aslan, E | 1 |
| Erkanli, S | 1 |
| Lam, PM | 1 |
| Cheung, LP | 1 |
| Haines, C | 1 |
| Raue, U | 1 |
| Miles, LM | 2 |
| Lu, T | 2 |
| Di Gregorio, GB | 2 |
| Elbein, SC | 1 |
| Lacigová, S | 1 |
| Rusavý, Z | 1 |
| Kyselová, P | 1 |
| Jankovec, Z | 1 |
| Kárová, R | 1 |
| Cechurová, D | 1 |
| Pacini, G | 2 |
| Cardoza, L | 1 |
| Coutiño, B | 1 |
| Hidalgo, R | 1 |
| Salini, J | 1 |
| Vijay, V | 2 |
| Mitkov, M | 4 |
| Pehlivanov, B | 2 |
| Terzieva, D | 2 |
| Ertunc, D | 1 |
| Tok, EC | 1 |
| Aktas, A | 1 |
| Erdal, EM | 1 |
| Dilek, S | 1 |
| Ceriello, A | 1 |
| Eckland, DJ | 1 |
| Andy, C | 1 |
| Flake, D | 1 |
| French, L | 1 |
| Biarnés, J | 2 |
| Fernández-Castañer, M | 1 |
| del Mar García, M | 1 |
| Soler, J | 1 |
| Siddiqui, NI | 1 |
| Sahin, I | 1 |
| Serter, R | 1 |
| Karakurt, F | 1 |
| Demirbas, B | 1 |
| Culha, C | 1 |
| Taskapan, C | 1 |
| Kosar, F | 1 |
| Aral, Y | 1 |
| Berker, B | 1 |
| Emral, R | 2 |
| Corapcioglu, D | 2 |
| Unlu, C | 1 |
| Kose, K | 1 |
| Stratmann, M | 1 |
| Rodríguez-Moctezuma, JR | 1 |
| Robles-López, G | 1 |
| López-Carmona, JM | 1 |
| Gutiérrez-Rosas, MJ | 1 |
| Kouki, T | 1 |
| Takasu, N | 1 |
| Nakachi, A | 1 |
| Tamanaha, T | 1 |
| Komiya, I | 1 |
| Tawata, M | 1 |
| Youn, BS | 1 |
| Yu, KY | 1 |
| Park, HJ | 1 |
| Shin, CS | 1 |
| Kim, SY | 1 |
| Lee, HK | 1 |
| Ishida, W | 1 |
| Kawamori, R | 3 |
| Kume, A | 1 |
| Miyazaki, T | 1 |
| Daida, H | 1 |
| Walker, EA | 1 |
| Fowler, SE | 2 |
| Nathan, DM | 1 |
| Middleton, MS | 1 |
| Deutsch, R | 1 |
| Hou, Z | 1 |
| McCarty, MF | 1 |
| Stakos, DA | 1 |
| Schuster, DP | 1 |
| Sparks, EA | 1 |
| Wooley, CF | 1 |
| Osei, K | 1 |
| Boudoulas, H | 1 |
| Gentilcore, E | 1 |
| Manini, R | 2 |
| Natale, S | 2 |
| Vanni, E | 1 |
| Villanova, N | 1 |
| David, E | 1 |
| Rizzetto, M | 1 |
| Alexandraki, K | 2 |
| Protogerou, A | 1 |
| Papamichael, C | 1 |
| Aessopos, A | 2 |
| Lekakis, J | 1 |
| Mavrikakis, M | 1 |
| Harborne, LR | 1 |
| Westerbacka, J | 1 |
| Schumm-Draeger, PM | 1 |
| James, AP | 1 |
| Watts, GF | 1 |
| Zhu, WF | 1 |
| Wang, XK | 1 |
| Manguso, F | 4 |
| Annamaria, C | 1 |
| Dale, B | 1 |
| Moreno Sánchez, D | 1 |
| Petrányi, G | 1 |
| Laakso, M | 1 |
| Richardson, C | 1 |
| Pekhlivanov, B | 2 |
| Minoura, H | 1 |
| Takeshita, S | 1 |
| Mabuchi, M | 1 |
| Hirosumi, J | 1 |
| Takakura, S | 1 |
| Kawamura, I | 1 |
| Seki, J | 1 |
| Manda, T | 1 |
| Ita, M | 1 |
| Mutoh, S | 1 |
| Temprosa, M | 1 |
| Andres, R | 1 |
| Saudek, C | 1 |
| Murphy, MB | 1 |
| Shamoon, H | 1 |
| Tang, JZ | 1 |
| Mao, JP | 1 |
| Yang, ZF | 1 |
| Zhou, ZG | 1 |
| Tang, WL | 1 |
| Feng, Q | 1 |
| Vitale, C | 1 |
| Cornoldi, A | 1 |
| Fini, M | 1 |
| Volterrani, M | 1 |
| Rosano, GM | 1 |
| Lv, L | 1 |
| Tan, K | 1 |
| Nørgaard, K | 1 |
| Cascella, T | 1 |
| De Simone, B | 1 |
| Savastano, S | 1 |
| Lombardi, G | 2 |
| Yilmaz, M | 2 |
| Bukan, N | 1 |
| Ayvaz, G | 2 |
| Karakoç, A | 2 |
| Törüner, F | 2 |
| Cakir, N | 2 |
| Arslan, M | 2 |
| Mangieri, T | 1 |
| Fujita, H | 1 |
| Fujishima, H | 1 |
| Koshimura, J | 1 |
| Hosoba, M | 1 |
| Yoshioka, N | 1 |
| Shimotomai, T | 1 |
| Morii, T | 1 |
| Narita, T | 1 |
| Kakei, M | 1 |
| van Santbrink, EJ | 1 |
| Eijkemans, MJ | 1 |
| Laven, JS | 1 |
| Fauser, BC | 1 |
| Fernández Fernández, I | 1 |
| Igaki, N | 1 |
| Viljanen, AP | 1 |
| Virtanen, KA | 1 |
| Järvisalo, MJ | 1 |
| Hällsten, K | 1 |
| Parkkola, R | 1 |
| Rönnemaa, T | 1 |
| Lönnqvist, F | 1 |
| Iozzo, P | 1 |
| Ferrannini, E | 1 |
| Nuutila, P | 1 |
| Hayden, CJ | 1 |
| White, D | 1 |
| Barth, JH | 1 |
| Tomazic, J | 2 |
| Karner, P | 2 |
| Vidmar, L | 2 |
| Maticic, M | 2 |
| Sharma, PM | 1 |
| Allen, HF | 1 |
| Mazzoni, C | 1 |
| Heptulla, RA | 1 |
| Murray, MA | 1 |
| Miller, N | 1 |
| Koenigs, L | 1 |
| Reiter, EO | 1 |
| Bhatia, V | 1 |
| Agostini, F | 1 |
| Gaddi, AV | 1 |
| Salvadeo, S | 1 |
| Pricolo, F | 1 |
| Ghelfi, M | 1 |
| Fogari, R | 1 |
| Gungor, N | 1 |
| Hannon, T | 1 |
| Ortiz Núñez, DA | 1 |
| Hernández Marín, I | 1 |
| Ayala, AR | 1 |
| Bell, DS | 2 |
| Ovalle, F | 1 |
| Gubern, C | 1 |
| Vendrell, J | 1 |
| Chen, SQ | 1 |
| Deng, JC | 1 |
| Mietus-Snyder, ML | 1 |
| Bacchetti, P | 1 |
| Lazar, AA | 1 |
| Velasquez-Mieyer, PA | 1 |
| Christensen, ML | 1 |
| Biri, A | 1 |
| Bingöl, B | 1 |
| Tiras, B | 1 |
| Zhu, B | 1 |
| Meigs, JB | 2 |
| Sauer, WH | 1 |
| Berlin, JA | 1 |
| Kimmel, SE | 1 |
| Hawthorne, G | 1 |
| Paterakis, T | 1 |
| Katsilambros, N | 1 |
| Kreatsas, G | 1 |
| Tsapina, TN | 1 |
| Zilov, AV | 1 |
| Iakunina, IA | 1 |
| Il'inykh, EV | 1 |
| Bridger, T | 1 |
| MacDonald, S | 1 |
| Baltzer, F | 1 |
| Rodd, C | 1 |
| Strucchi, C | 1 |
| Luisi, M | 1 |
| Casarosa, E | 1 |
| Baraldi, E | 1 |
| Mehmeti, H | 1 |
| Genazzani, AR | 1 |
| Ou, HY | 1 |
| Yu, EH | 1 |
| Wu, TJ | 1 |
| Caldwell, SH | 1 |
| Argo, CK | 1 |
| Al-Osaimi, AM | 1 |
| de Winter, W | 1 |
| DeJongh, J | 1 |
| Post, T | 1 |
| Ploeger, B | 1 |
| Moules, I | 1 |
| Eckland, D | 1 |
| Danhof, M | 1 |
| Maji, D | 1 |
| Roy, RU | 1 |
| Das, S | 1 |
| Tepsa, M | 1 |
| Yap, F | 1 |
| Ward, GM | 1 |
| Foretz, M | 1 |
| Guigas, B | 1 |
| Viollet, B | 1 |
| Martínez, J | 1 |
| Lacruz, A | 2 |
| Rangel, N | 3 |
| Beaulieu, S | 3 |
| Serrano, A | 2 |
| Arapé, Y | 1 |
| de Mendoza, S | 3 |
| Teneud, L | 1 |
| Monnier, L | 1 |
| Colette, C | 1 |
| Thuan, JF | 1 |
| Lapinski, H | 1 |
| Mithieux, G | 3 |
| Rajas, F | 2 |
| Zitoun, C | 2 |
| Oh, DK | 1 |
| Christiansen, L | 1 |
| Nikoulina, SE | 1 |
| Kong, AP | 1 |
| Baxi, S | 1 |
| Hoek, JB | 1 |
| Kocak, I | 1 |
| Ustün, C | 1 |
| Korenaga, M | 1 |
| Kawaguchi, K | 1 |
| Korenaga, K | 1 |
| Uchida, K | 1 |
| Sakaida, I | 1 |
| Merriman, RB | 1 |
| Sharma, ST | 2 |
| Chazova, I | 1 |
| Almazov, VA | 1 |
| Shlyakhto, E | 1 |
| Koopmans, SJ | 1 |
| Mroz, Z | 1 |
| Dekker, R | 1 |
| Corbijn, H | 1 |
| Ackermans, M | 1 |
| Sauerwein, H | 1 |
| Ulloa-Aguirre, A | 1 |
| Portocarrero, L | 1 |
| Zariñán, T | 1 |
| Olivares, A | 1 |
| Carranza-Lira, S | 1 |
| Veldhuis, JD | 1 |
| Zhang, DM | 1 |
| Wang, T | 1 |
| Zhong, HJ | 1 |
| Chen, WK | 1 |
| Lantz, M | 1 |
| Hallengren, B | 1 |
| Topcu, S | 1 |
| Tok, D | 1 |
| Caliskan, M | 1 |
| Ozcimen, EE | 1 |
| Gullu, H | 1 |
| Uckuyu, A | 1 |
| Erdogan, D | 1 |
| Zeyneloglu, H | 1 |
| Muderrisoglu, H | 1 |
| Shi, XB | 1 |
| Zhou, LY | 1 |
| Fu, SX | 1 |
| Chen, JL | 1 |
| Patton, L | 1 |
| Vaccina, A | 1 |
| Cacciari, M | 1 |
| Morselli-Labate, AM | 1 |
| Cavazza, C | 1 |
| Aregawi, D | 3 |
| Winiarska, M | 2 |
| Agloria, M | 2 |
| Luo, G | 1 |
| Staels, B | 1 |
| Liu, KE | 1 |
| Tataryn, IV | 1 |
| Sagle, M | 1 |
| Schneider, CA | 1 |
| Kautzky-Willer, A | 1 |
| Tura, A | 1 |
| Winzer, C | 1 |
| Wagner, OF | 1 |
| Hanusch-Enserer, U | 1 |
| Prager, R | 1 |
| Vick, MM | 1 |
| Sessions, DR | 1 |
| Murphy, BA | 1 |
| Kennedy, EL | 1 |
| Reedy, SE | 1 |
| Fitzgerald, BP | 1 |
| Jadhav, S | 1 |
| Ferrell, W | 1 |
| Greer, IA | 2 |
| Cobbe, SM | 1 |
| Goldstein, BJ | 1 |
| Weissman, PN | 1 |
| Wooddell, MJ | 1 |
| Waterhouse, BR | 1 |
| Cobitz, AR | 1 |
| Satyavani, K | 1 |
| Sivasankari, S | 1 |
| Lanham, MS | 1 |
| Lebovic, DI | 1 |
| Domino, SE | 1 |
| Rosenstock, J | 3 |
| Rood, J | 2 |
| Cobitz, A | 2 |
| Garber, A | 2 |
| Biswas, N | 1 |
| Chou, H | 1 |
| Bellot-Rojas, P | 1 |
| Posadas-Sanchez, R | 1 |
| Caracas-Portilla, N | 1 |
| Zamora-Gonzalez, J | 1 |
| Cardoso-Saldaña, G | 1 |
| Jurado-Santacruz, F | 1 |
| Posadas-Romero, C | 1 |
| Frey, UH | 1 |
| Siffert, W | 1 |
| Tan, S | 2 |
| Tamura, H | 1 |
| Mokuno, H | 1 |
| Daita, H | 1 |
| Bodles, AM | 2 |
| Lee, MJ | 2 |
| Starks, T | 2 |
| Kern, LM | 2 |
| Fried, SK | 2 |
| Juurinen, L | 1 |
| Hakkarainen, A | 1 |
| Lachin, J | 1 |
| Holman, R | 1 |
| Haffner, S | 1 |
| Kravitz, B | 1 |
| Heise, MA | 1 |
| O'Neill, MC | 1 |
| Freed, MI | 1 |
| Sharma, PK | 1 |
| Bhansali, A | 1 |
| Sialy, R | 1 |
| Malhotra, S | 1 |
| Pandhi, P | 1 |
| Klein, DJ | 1 |
| Cottingham, EM | 1 |
| Sorter, M | 1 |
| Barton, BA | 1 |
| Morrison, JA | 1 |
| Kavŭrdzhikova, S | 1 |
| Moon, RJ | 1 |
| Bascombe, LA | 1 |
| Holt, RI | 1 |
| Chavez-Tapia, NC | 1 |
| Barrientos-Gutierrez, T | 1 |
| Tellez-Avila, FI | 1 |
| Sanchez-Avila, F | 1 |
| Montano-Reyes, MA | 1 |
| Uribe, M | 1 |
| Kang, ES | 1 |
| Kim, DJ | 1 |
| Nam, M | 1 |
| Chung, CH | 1 |
| Nam, CM | 1 |
| Bayrak, A | 1 |
| Terbell, H | 1 |
| Urwitz-Lane, R | 1 |
| Mor, E | 1 |
| Stanczyk, FZ | 1 |
| Paulson, RJ | 1 |
| Inagaki, K | 2 |
| Suzuki, A | 2 |
| Nagata, M | 1 |
| Sekiguchi, S | 1 |
| Itoi, T | 1 |
| Asano, S | 1 |
| Hiroaki, K | 1 |
| Hayakawa, N | 2 |
| Oda, N | 2 |
| Itoh, M | 2 |
| Angelico, F | 1 |
| Burattin, M | 1 |
| Alessandri, C | 1 |
| Del Ben, M | 1 |
| Lirussi, F | 1 |
| Contreras, Q | 1 |
| Galeazzi, T | 2 |
| Vargas, D | 1 |
| Hoteit, MA | 1 |
| Anania, FA | 1 |
| Schachter, M | 1 |
| Raziel, A | 1 |
| Strassburger, D | 1 |
| Rotem, C | 1 |
| Ron-El, R | 1 |
| Friedler, S | 1 |
| Lóriz Peralta, O | 1 |
| Campos Bonilla, B | 1 |
| Granada Ybern, ML | 1 |
| Sanmartí Sala, A | 1 |
| Arroyo Bros, J | 1 |
| Eriksson, A | 1 |
| Attvall, S | 2 |
| Bonnier, M | 1 |
| Eriksson, JW | 1 |
| Rosander, B | 1 |
| Karlsson, FA | 1 |
| Brunani, A | 1 |
| Caumo, A | 1 |
| Graci, S | 1 |
| Castagna, G | 1 |
| Liuzzi, A | 1 |
| Botella-Carretero, JI | 2 |
| Martínez-Bermejo, E | 2 |
| Lasunción, MA | 1 |
| Bruno, RV | 1 |
| de Avila, MA | 1 |
| Neves, FB | 1 |
| Nardi, AE | 1 |
| Crespo, CM | 1 |
| Sobrinho, AT | 1 |
| Fonseca, V | 1 |
| Bakris, GL | 1 |
| McGill, JB | 1 |
| Messerli, FH | 1 |
| Phillips, RA | 1 |
| Katholi, RE | 1 |
| Wright, JT | 1 |
| Waterhouse, B | 1 |
| Lukas, MA | 1 |
| Anderson, KM | 1 |
| Eguchi, K | 1 |
| Tomizawa, H | 1 |
| Ishikawa, J | 1 |
| Hoshide, S | 1 |
| Numao, T | 1 |
| Fukuda, T | 1 |
| Shimada, K | 1 |
| Kario, K | 1 |
| El Fakih, Y | 1 |
| Uzcátegui, E | 1 |
| Gutiérrez, MA | 1 |
| Servigna, M | 1 |
| Dávila, A | 1 |
| Uzcátegui, M | 1 |
| Faure, P | 1 |
| Barclay, D | 1 |
| Joyeux-Faure, M | 1 |
| Nawrocka, J | 1 |
| De Feo, P | 1 |
| Adamia, N | 1 |
| Virsaladze, D | 1 |
| Charkviani, N | 1 |
| Skhirtladze, M | 1 |
| Khutsishvili, M | 1 |
| Sanchón, R | 1 |
| San Millán, JL | 1 |
| Smiley, D | 1 |
| Umpierrez, G | 1 |
| Rashidi, AA | 1 |
| Di Biase, S | 1 |
| Giallauria, F | 1 |
| Labella, D | 1 |
| Bulcão, C | 1 |
| Ribeiro-Filho, FF | 1 |
| Sañudo, A | 1 |
| Roberta Ferreira, SG | 1 |
| Thaler, CJ | 1 |
| Ozenoglu, A | 1 |
| Ugurlu, S | 1 |
| Balci, H | 1 |
| Eker, E | 1 |
| Pranikoff, J | 1 |
| Nagai, T | 1 |
| Imamura, M | 1 |
| Mori, M | 1 |
| Mordier, S | 1 |
| Iynedjian, PB | 1 |
| Chodorowski, Z | 1 |
| Sein Anand, J | 1 |
| Cylkowska, B | 1 |
| Hajduk, A | 1 |
| Kujawska-Danecka, H | 1 |
| Kohli, R | 1 |
| Shevitz, A | 1 |
| Gorbach, S | 1 |
| Wanke, C | 1 |
| Bradbury, RA | 1 |
| Samaras, K | 1 |
| Bianchi, C | 1 |
| Marchetti, P | 1 |
| Teranishi, T | 1 |
| Ohara, T | 1 |
| Maeda, K | 1 |
| Zenibayashi, M | 1 |
| Kouyama, K | 1 |
| Hirota, Y | 1 |
| Kawamitsu, H | 1 |
| Fujii, M | 1 |
| Sugimura, K | 1 |
| Kasuga, M | 1 |
| Lebinger, TG | 1 |
| Tamura, Y | 1 |
| Watada, H | 1 |
| Sato, F | 1 |
| Kumashiro, N | 1 |
| Sakurai, Y | 1 |
| Hirose, T | 1 |
| Tanaka, Y | 1 |
| Li, XJ | 1 |
| Wu, YH | 1 |
| Tong, NW | 1 |
| Zhao, TY | 1 |
| Bahtiyar, G | 1 |
| Weiss, K | 1 |
| Sacerdote, AS | 1 |
| Stafford, JM | 1 |
| Elasy, T | 1 |
| Atkinson, LL | 1 |
| McDonald-Dyck, C | 1 |
| Benkoczi, C | 1 |
| Finegood, DT | 1 |
| Yoon, SH | 1 |
| Han, EJ | 1 |
| Sung, JH | 1 |
| Chung, SH | 1 |
| Khashab, M | 1 |
| Chalasani, N | 1 |
| Benson, S | 1 |
| Dietz, T | 1 |
| Lahner, H | 1 |
| Moeller, LC | 1 |
| Schmidt, M | 1 |
| Kimmig, R | 1 |
| Schulz, H | 1 |
| Nickel, I | 1 |
| Kleinstein, J | 1 |
| Kaltwasser, P | 1 |
| Westphal, S | 1 |
| Mittermayer, F | 1 |
| Wolzt, M | 1 |
| Krzyzanowska, K | 1 |
| Randeva, H | 1 |
| Sucharda, P | 1 |
| Tajtáková, M | 1 |
| Semanová, Z | 1 |
| Ivancová, G | 1 |
| Donicová, V | 1 |
| Zemberová, E | 1 |
| Tousoulis, D | 1 |
| Tsarpalis, K | 1 |
| Cokkinos, D | 1 |
| Stefanadis, C | 1 |
| Sinha, SK | 1 |
| Bhangoo, A | 1 |
| Anhalt, H | 1 |
| Maclaren, N | 1 |
| Marshall, JD | 1 |
| Collin, GB | 1 |
| Naggert, JK | 1 |
| Ten, S | 1 |
| Silic, A | 1 |
| Sharma, P | 1 |
| Cubeddu, LX | 1 |
| Alfieri, AB | 1 |
| Hoffmann, IS | 1 |
| Paudel, B | 1 |
| Garcia-Puig, J | 1 |
| Donaldson, J | 1 |
| Stewart, M | 1 |
| Fang, MS | 1 |
| He, YQ | 1 |
| Liu, YJ | 1 |
| Chen, JD | 1 |
| Li, LH | 1 |
| Imamura, S | 1 |
| Fujita, T | 1 |
| Uchida, Y | 1 |
| Kakizawa, H | 1 |
| Takeda, J | 1 |
| Horikawa, Y | 1 |
| Molavi, B | 1 |
| Rassouli, N | 1 |
| Bagwe, S | 1 |
| Chou, HS | 1 |
| Matthaei, S | 3 |
| Seidel, DK | 1 |
| Monami, M | 1 |
| Mannucci, E | 1 |
| Massi-Benedetti, M | 1 |
| Orsini-Federici, M | 1 |
| Standl, E | 1 |
| Schnell, O | 1 |
| Salpeter, SR | 1 |
| Buckley, NS | 1 |
| Kahn, JA | 1 |
| Salpeter, EE | 1 |
| Pollack, MN | 1 |
| Nader, S | 1 |
| Oktenli, C | 1 |
| Dede, M | 1 |
| Kenar, L | 1 |
| Sanisoglu, SY | 1 |
| Yenen, MC | 1 |
| Erbil, MK | 1 |
| Baser, I | 1 |
| Kjøtrød, SB | 1 |
| Sunde, A | 1 |
| von Düring, V | 1 |
| Carlsen, SM | 2 |
| Mlinar, B | 1 |
| Marc, J | 1 |
| Oppedisano, R | 1 |
| Kennedy, CR | 1 |
| Harrison, C | 1 |
| Stepto, N | 1 |
| Joshi, VV | 1 |
| Inzucchi, SE | 1 |
| Xiao, W | 1 |
| Hong, T | 1 |
| Venkatasubramanian, G | 1 |
| Fisken, RA | 1 |
| Targher, G | 1 |
| Lippi, G | 1 |
| Idilman, R | 1 |
| Mizrak, D | 1 |
| Bektas, M | 1 |
| Doganay, B | 1 |
| Sayki, M | 1 |
| Coban, S | 1 |
| Erden, E | 1 |
| Soykan, I | 1 |
| Uysal, AR | 1 |
| Ozden, A | 1 |
| Sheng, CH | 1 |
| Di, J | 1 |
| Jin, Y | 1 |
| Zhang, YC | 1 |
| Wu, M | 1 |
| Zhang, GZ | 1 |
| Bolton, S | 1 |
| Cleary, B | 1 |
| Walsh, J | 1 |
| Dempsey, E | 1 |
| Turner, MJ | 1 |
| Rendle, DI | 1 |
| Newton, JE | 1 |
| Love-Osborne, K | 1 |
| Sheeder, J | 1 |
| Zeitler, P | 1 |
| Romo, A | 1 |
| Benavides, S | 1 |
| Pernet, A | 1 |
| Gudbjörnsdottir, S | 1 |
| Friberg, P | 1 |
| Elam, M | 1 |
| Lönnroth, P | 1 |
| Wallin, BG | 1 |
| Donnelly, R | 1 |
| Verge, CF | 1 |
| Williams, PF | 1 |
| Silink, M | 1 |
| Semplicini, A | 2 |
| Giusto, M | 2 |
| Campagnolo, M | 2 |
| Palatini, P | 2 |
| Rossi, GP | 1 |
| Valle, R | 1 |
| Dorella, M | 2 |
| Albertin, G | 1 |
| Pessina, AC | 1 |
| Velazquez, EM | 1 |
| Mendoza, S | 1 |
| Hamer, T | 1 |
| Sosa, F | 1 |
| Meglasson, MD | 1 |
| Wilson, JM | 1 |
| Yu, JH | 1 |
| Robinson, DD | 1 |
| Wyse, BM | 1 |
| de Souza, CJ | 1 |
| Reibold, JP | 1 |
| Benecke, H | 1 |
| Häring, HU | 1 |
| Greten, H | 2 |
| Klein, HH | 1 |
| Huupponen, R | 1 |
| Pyykkö, K | 1 |
| Koulu, M | 1 |
| Rouru, J | 1 |
| Nagi, DK | 1 |
| Yudkin, JS | 2 |
| Letiexhe, MR | 1 |
| Lefèbvre, PJ | 2 |
| Açbay, O | 1 |
| Gündoğdu, S | 1 |
| Worm, D | 1 |
| Handberg, A | 1 |
| Hoppe, E | 1 |
| Vinten, J | 1 |
| Beck-Nielsen, H | 2 |
| Da Tos, V | 1 |
| Rossi, G | 1 |
| Felice, M | 1 |
| Kosegawa, I | 2 |
| Katayama, S | 3 |
| Kikuchi, C | 1 |
| Kashiwabara, H | 1 |
| Negishi, K | 2 |
| Ishii, J | 1 |
| Inukai, K | 1 |
| Oka, Y | 1 |
| Fontbonne, A | 2 |
| Charles, MA | 2 |
| Juhan-Vague, I | 2 |
| Bard, JM | 2 |
| André, P | 6 |
| Isnard, F | 5 |
| Cohen, JM | 1 |
| Grandmottet, P | 1 |
| Safar, ME | 1 |
| Eschwège, E | 3 |
| Yoshii, H | 1 |
| Solomon, SS | 1 |
| Mishra, SK | 1 |
| Cwik, C | 1 |
| Rajanna, B | 1 |
| Postlethwaite, AE | 1 |
| Haupt, E | 1 |
| Panten, U | 1 |
| Kouli, C | 3 |
| Tsianateli, T | 2 |
| Bergiele, A | 2 |
| Grill, V | 1 |
| Følling, I | 1 |
| Castillo, T | 1 |
| Muñoz, S | 1 |
| Calvillán, M | 1 |
| Quan, J | 1 |
| Tsai, J | 1 |
| Hobensack, CK | 1 |
| Sullivan, C | 1 |
| Hector, R | 1 |
| Reaven, GM | 2 |
| Hopkinson, ZE | 1 |
| Minassian, C | 1 |
| Tarpin, S | 1 |
| Thomas, CR | 1 |
| Turner, SL | 1 |
| Jefferson, WH | 1 |
| Gao, CR | 1 |
| Zhang, JQ | 1 |
| Huang, QL | 1 |
| Granberry, MC | 1 |
| Kolaczynski, JW | 1 |
| Caro, JF | 1 |
| Chen, S | 1 |
| Awata, T | 1 |
| Saint-Marc, T | 1 |
| Touraine, JL | 1 |
| Blonde, L | 1 |
| Sandberg, MI | 1 |
| Guthrie, RD | 1 |
| Howlett, HC | 1 |
| Tutuş, A | 1 |
| Morel, Y | 1 |
| Golay, A | 1 |
| Perneger, T | 1 |
| Lehmann, T | 1 |
| Vadas, L | 1 |
| Pasik, C | 1 |
| Brogard, JM | 1 |
| Neyrolles, N | 1 |
| Andres, E | 1 |
| Blicklé, JF | 1 |
| Ginsberg, H | 1 |
| Plutzky, J | 1 |
| Sieradzki, J | 1 |
| Zimmet, P | 1 |
| Collier, G | 1 |
| Ducluzeau, PH | 1 |
| Tack, CJ | 1 |
| Smits, P | 1 |
| Gandar, R | 1 |
| Spizzo, M | 1 |
| Collin, D | 1 |
| Egbe, TO | 1 |
| Paglia, T | 1 |
| Cianci, A | 1 |
| Ciani, A | 1 |
| Negri, C | 1 |
| Perrone, F | 1 |
| Caputo, M | 1 |
| Katakam, PV | 1 |
| Ujhelyi, MR | 1 |
| Hoenig, M | 1 |
| Miller, AW | 1 |
| Hermann, LS | 1 |
| Melander, A | 1 |
| Rique, S | 1 |
| Marcos, MV | 1 |
| Carrascosa, A | 1 |
| Potau, N | 1 |
| Zapanti, E | 1 |
| Göke, B | 1 |
| Seale, FG | 1 |
| Robinson, RD | 1 |
| Neal, GS | 1 |
| Corcoran, C | 1 |
| Basgoz, N | 1 |
| Davis, B | 1 |
| Sax, P | 1 |
| Shimoni, Y | 1 |
| Severson, D | 1 |
| Ewart, HS | 1 |
| Taylor, AE | 1 |
| Lin, HZ | 1 |
| Yang, SQ | 1 |
| Chuckaree, C | 1 |
| Kuhajda, F | 1 |
| Ronnet, G | 1 |
| Morin-Papunen, LC | 2 |
| Vauhkonen, I | 1 |
| Koivunen, RM | 2 |
| Ruokonen, A | 2 |
| Martikainen, HK | 2 |
| Tapanainen, JS | 2 |
| Blüher, M | 1 |
| Windgassen, M | 1 |
| Paschke, R | 1 |
| Stades, AM | 1 |
| Holleman, F | 1 |
| Hoekstra, JB | 1 |
| Russell, JC | 1 |
| Ravel, D | 1 |
| Pégorier, JP | 1 |
| Delrat, P | 1 |
| Jochemsen, R | 1 |
| O'Brien, SF | 1 |
| Kelly, SE | 1 |
| Davidge, ST | 1 |
| Brindley, DN | 1 |
| Yao, L | 1 |
| Dumont, AS | 1 |
| McNeill, JH | 1 |
| Barbieri, RL | 1 |
| Dramais, AS | 1 |
| Wallemacq, PE | 1 |
| D'Agostino, RB | 1 |
| Wilson, PW | 1 |
| Lipinska, I | 1 |
| Tofler, GH | 1 |
| Grinspoon, SS | 1 |
| Safar, M | 1 |
| Fruchart, JC | 1 |
| Schneider, MB | 1 |
| Matsuzaki, H | 1 |
| Haorah, J | 1 |
| Ulrich, A | 1 |
| Standop, J | 1 |
| Ding, XZ | 1 |
| Adrian, TE | 1 |
| Pour, PM | 1 |
| Anderson, TJ | 1 |
| Malacara, JM | 1 |
| Fajardo, ME | 1 |
| Nava, LE | 1 |
| Kowalska, I | 1 |
| Kinalski, M | 1 |
| Wolczyski, S | 1 |
| Kinalska, I | 1 |
| Stárka, L | 4 |
| Bendlová, B | 3 |
| Vondra, K | 4 |
| Sulcová, J | 2 |
| Snajderová, M | 2 |
| Chen, CC | 1 |
| Wang, HJ | 1 |
| Shih, HC | 1 |
| Sheen, LY | 1 |
| Chang, CT | 1 |
| Chen, RH | 1 |
| Wang, TY | 1 |
| De Conciliis, B | 1 |
| Passannanti, G | 1 |
| Romano, L | 1 |
| Santarpia, R | 1 |
| Kidson, WJ | 1 |
| Cuneo, RC | 1 |
| Zacharin, MR | 1 |
| Mehnert, H | 1 |
| Cohn, G | 1 |
| Valdes, G | 1 |
| Capuzzi , DM | 1 |
| Borst, SE | 2 |
| Snellen, HG | 2 |
| Prieto, LA | 1 |
| Boyero, EC | 1 |
| Parsanezhad, ME | 1 |
| Alborzi, S | 1 |
| Zarei, A | 1 |
| Omrani, G | 1 |
| Spina, G | 1 |
| Migdalis, I | 1 |
| Uehara, MH | 1 |
| Kohlmann, NE | 1 |
| Zanella, MT | 1 |
| Kotler, DP | 1 |
| Roth, GS | 1 |
| Ingram, DK | 1 |
| Lane, MA | 1 |
| Stovall, D | 1 |
| Akhter, N | 1 |
| Yarali, H | 1 |
| Yildiz, BO | 1 |
| Demirol, A | 1 |
| Yiğit, N | 1 |
| Bükülmez, O | 1 |
| Koray, Z | 1 |
| Kent, SC | 1 |
| Lee, F | 1 |
| Patel, HR | 1 |
| Copland, P | 1 |
| Kahn, L | 1 |
| Ross, H | 1 |
| Scarpace, PJ | 1 |
| Kim, YW | 1 |
| Combs, TP | 1 |
| Wagner, JA | 1 |
| Berger, J | 1 |
| Doebber, T | 1 |
| Wang, WJ | 1 |
| Zhang, BB | 1 |
| Tanen, M | 1 |
| Berg, AH | 1 |
| O'Rahilly, S | 1 |
| Savage, DB | 1 |
| Chatterjee, K | 1 |
| Weiss, S | 1 |
| Larson, PJ | 1 |
| Gottesdiener, KM | 1 |
| Gertz, BJ | 1 |
| Charron, MJ | 1 |
| Scherer, PE | 1 |
| Moller, DE | 1 |
| Kobayashi, S | 1 |
| Phillips, H | 1 |
| Sieve-Smith, L | 1 |
| Fruehwald-Schultes, B | 1 |
| Oltmanns, KM | 1 |
| Toschek, B | 1 |
| Sopke, S | 1 |
| Kern, W | 1 |
| Born, J | 1 |
| Fehm, HL | 1 |
| Lewy, V | 1 |
| Danadian, K | 1 |
| Saad, R | 1 |
| Laboureau-Soares Barbosa, S | 1 |
| Rodien, P | 1 |
| Rohmer, V | 1 |
| Nĕmcová, D | 1 |
| Bílek, R | 1 |
| Hampl, R | 1 |
| Hoza, J | 1 |
| Kot'átková, A | 1 |
| Zamrazil, V | 1 |
| Valls, C | 1 |
| Dunger, DB | 1 |
| Brousseau, VJ | 1 |
| Kürthy, M | 1 |
| Mogyorósi, T | 1 |
| Nagy, K | 1 |
| Kukorelli, T | 1 |
| Jednákovits, A | 1 |
| Tálosi, L | 1 |
| Bíró, K | 1 |
| Elter, K | 1 |
| Imir, G | 1 |
| Durmusoglu, F | 1 |
| Frayn, KN | 1 |
| Boyd, K | 1 |
| Rogers, C | 1 |
| Boreham, C | 1 |
| Andrews, WJ | 1 |
| Hadden, DR | 1 |
| Di Paolo, S | 1 |
| Widén, EI | 1 |
| Eriksson, JG | 1 |
| Groop, LC | 1 |
| Landin-Wilhelmsen, K | 1 |
| McIntyre, HD | 1 |
| Ma, A | 1 |
| Bird, DM | 1 |
| Paterson, CA | 1 |
| Ravenscroft, PJ | 1 |
| Cameron, DP | 1 |
| Janssen, M | 1 |
| Rillaerts, E | 1 |
| De Leeuw, I | 1 |
| Landin, K | 1 |
| Tengborn, L | 1 |
| Smith, U | 1 |
| Galuska, D | 1 |
| Zierath, J | 1 |
| Thörne, A | 1 |
| Sonnenfeld, T | 1 |
| Wallberg-Henriksson, H | 1 |
| Melin, B | 1 |
| Cherqui, G | 1 |
| Blivet, MJ | 1 |
| Caron, M | 1 |
| Lascols, O | 1 |
| Picard, J | 1 |
| Triadou, N | 1 |
| Lavieuville, M | 1 |
| Noël, M | 1 |
| Hitier, Y | 1 |
| Ferré, P | 1 |
| Ibagnez, A | 1 |
| Labeille, B | 1 |
| Lalau, JD | 1 |
| Chouquais, L | 1 |
| Debussche, X | 1 |
| Terminassian, L | 1 |
| Quichaud, J | 1 |
| Denoeux, JP | 1 |
| Sauer, H | 1 |
| Messerchmitt, C | 1 |
| Brottier, E | 1 |
| Aubertin, J | 1 |
| Vermeulen, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial[NCT02491333] | Phase 3 | 342 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Effects of Exercise Training as a Non-pharmacological Treatment for Metabolic Syndrome and Its Interactions With Subjects Habitual Medications.[NCT03019796] | Early Phase 1 | 40 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Beta Cell Restoration Through Fat Mitigation[NCT01763346] | 88 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| Restoring Insulin Secretion Adult Medication Study[NCT01779362] | Phase 3 | 267 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Canagliflozin Administration in Non-diabetic Women With Polycystic Ovarian Syndrome[NCT04973891] | Phase 1/Phase 2 | 52 participants (Actual) | Interventional | 2021-04-07 | Completed | ||
| Anti-Inflammatory, Insulin-Sensitizing Agent for Treatment of Cognitive Decline Due to Degenerative Dementias[NCT05227820] | Phase 2 | 23 participants (Actual) | Interventional | 2022-01-19 | Completed | ||
| Effects of Metformin on Metabolic and Reproductive Outcomes in Chinese PCOS Patients[NCT05463627] | 1,440 participants (Anticipated) | Observational | 2016-01-01 | Recruiting | |||
| Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility[NCT05952882] | Phase 3 | 188 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Prospective Study on Diabetes Mellitus and Its Complications in Newly Diagnosed Adult Patients[NCT01055093] | 2,000 participants (Anticipated) | Observational | 2005-09-30 | Recruiting | |||
| Glucocorticoid Effects in Patients With DM Type 2[NCT03661684] | Early Phase 1 | 10 participants (Actual) | Interventional | 2016-06-03 | Completed | ||
| [NCT00172523] | 0 participants | Observational | 2004-10-31 | Recruiting | |||
| Effects of Metformin Treatment on Myocardial Efficiency in Patients With Heart Failure: A Randomized, Double-blind, Placebo-controlled Study[NCT02810132] | Phase 2 | 36 participants (Actual) | Interventional | 2017-01-20 | Completed | ||
| Restoring Insulin Secretion Pediatric Medication Study[NCT01779375] | Phase 3 | 91 participants (Actual) | Interventional | 2013-06-16 | Completed | ||
| TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study of the TODAY Clinical Trial Cohort[NCT01364350] | 550 participants (Actual) | Observational | 2011-03-31 | Completed | |||
| Fiber Supplementation and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance: Interactions With the Gut Microbiome.[NCT04578652] | Phase 3 | 90 participants (Anticipated) | Interventional | 2021-10-22 | Recruiting | ||
| Combined Influence of Puberty and Obesity on Insulin Resistance in Adolescents[NCT01775813] | Phase 4 | 104 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study[NCT01794143] | Phase 3 | 5,047 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction[NCT05847244] | Phase 2 | 80 participants (Anticipated) | Interventional | 2023-10-01 | Recruiting | ||
| Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness[NCT02167620] | Phase 4 | 35 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress Response in Patients With PCOS: A Double Blind Randomized Clinical Trial[NCT04113889] | Phase 2 | 147 participants (Actual) | Interventional | 2019-10-15 | Completed | ||
| The Effects of Acetyl L--Carnitine and Myo/Chiro-Inositol on Improving Ovulation, Pregnancy Rate, Ovarian Function and Perceived Stress Response in Patients With PCOS[NCT05767515] | 120 participants (Anticipated) | Interventional | 2023-04-15 | Not yet recruiting | |||
| A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability During Treatment of Type 2 Diabetes (T2DM) With Usual Diabetes Therapy (UDT) and Either Cycloset or Placebo[NCT00377676] | Phase 3 | 3,095 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity[NCT01960205] | Phase 4 | 80 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients[NCT03151005] | Phase 4 | 70 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| The Change in Microbiome Following Treatment of Women With Polycystic Ovaries[NCT04836910] | 40 participants (Anticipated) | Observational | 2024-09-01 | Recruiting | |||
| Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection[NCT04267809] | Phase 2 | 44 participants (Anticipated) | Interventional | 2021-10-22 | Recruiting | ||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls (JCM025)[NCT01427595] | 25 participants (Actual) | Interventional | 2009-02-18 | Completed | |||
| Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS:A Double Blind Randomized Placebo Controlled Trial[NCT05653895] | 250 participants (Anticipated) | Interventional | 2022-12-07 | Recruiting | |||
| Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451] | Phase 1/Phase 2 | 120 participants (Actual) | Interventional | 2020-07-27 | Completed | ||
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome (PCOS)[NCT00159536] | Phase 3 | 257 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study[NCT03259919] | Phase 2 | 40 participants (Actual) | Interventional | 2000-10-31 | Completed | ||
| Cyclophosphamide in the Treatment of Panniculitis Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes[NCT03936829] | 10 participants (Anticipated) | Interventional | 2019-04-28 | Recruiting | |||
| Efficacy and Safety of Saxagliptin and Glimepiride in Chinese Patients With Type 2 Diabetes Controlled Inadequately With Metformin Monotherapy (SPECIFY Study) : a 48-week, Multi-center, Randomized, Open-label Trial[NCT02280486] | Phase 4 | 388 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Acupuncture or Metformin for Insulin Resistance in Women With Polycystic Ovary Syndrome: A Randomized Controlled Trial[NCT02647827] | Phase 2 | 303 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Metformin to Augment Low Milk Supply in Pre-diabetic Mothers, a Phase I/II Randomized Clinical Trial[NCT02179788] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (T1D)--Insulin Clamp Ancillary Study for Assessment of Insulin Resistance[NCT02045290] | Phase 3 | 37 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Efficacy of Metformin as add-on Therapy in Non-Diabetic Heart Failure Patients[NCT05177588] | Phase 4 | 70 participants (Actual) | Interventional | 2021-07-21 | Completed | ||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases: A Randomized Placebo-controlled Clinical Trial[NCT04475276] | Phase 4 | 120 participants (Anticipated) | Interventional | 2021-02-23 | Recruiting | ||
| Dietary Oxysterols and β-Cell Function Among African Americans[NCT05072587] | 24 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | |||
| Non-Pharmacologic Alternatives for the Treatment of Childhood Obesity in Mexico[NCT03670875] | 300 participants (Actual) | Interventional | 2021-07-31 | Completed | |||
| Effect of Two Omega 3 Polyunsaturated Fatty Acid Schemes on Insulin Resistance and the Inflammatory and Lipid Profile in Obese Children[NCT05488223] | 133 participants (Actual) | Interventional | 2014-02-17 | Completed | |||
| Effect of Acupuncture on Insulin Sensitivity in Women With Polycystic Ovary Syndrome and Insulin Resistance: Study Protocol of a Prospective Observational Study[NCT02026323] | 112 participants (Anticipated) | Interventional | 2014-01-31 | Enrolling by invitation | |||
| Effect of Acupuncture Pre-treatment Combined With Letrozole on Live Birth in Infertile Women With Polycystic Ovary Syndrome[NCT02491320] | Phase 3 | 384 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study[NCT01526616] | 56 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.[NCT05136287] | 140 participants (Actual) | Observational | 2022-02-01 | Active, not recruiting | |||
| Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial[NCT02523898] | Phase 2 | 388 participants (Anticipated) | Interventional | 2015-11-30 | Enrolling by invitation | ||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Metformin in Castration Resistant Prostate Cancer. A Multicenter Phase II Trial.[NCT01243385] | Phase 2 | 44 participants (Actual) | Interventional | 2010-12-23 | Completed | ||
| A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821] | Phase 3 | 168 participants (Actual) | Interventional | 2018-07-12 | Terminated (stopped due to Manufacturer discontinued the production of study drugs.) | ||
| Mansmed Trial : Repurposing Metformin as Anticancer Drug, RCT in Advanced Prostate Cancer[NCT03137186] | Phase 2 | 120 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | ||
| Inter-relationships Among Iron Stores, the Gut Metagenome, Glucose Levels, and Different Cognitive Domains: the Role of Circulating MicroRNAs (IRONmiRNA Study).[NCT05345106] | 120 participants (Anticipated) | Observational | 2022-03-28 | Recruiting | |||
| Metabolic Responses of Metformin and Genetic Polymorphisms (rs628031 and rs2282143) of Solute Carrier Family 22 Member 1 Gene in Polycystic Ovary Syndrome[NCT05680805] | Phase 4 | 100 participants (Anticipated) | Interventional | 2023-05-27 | Recruiting | ||
| Effects of Metformin on Mitochondrial Function in Polycystic Ovary Syndrome[NCT02198417] | 20 participants (Anticipated) | Interventional | 2014-07-31 | Active, not recruiting | |||
| Polycystic Ovary Syndrome Genetics and Treatment Response[NCT01389778] | 200 participants (Anticipated) | Interventional | 2011-06-30 | Active, not recruiting | |||
| A Randomised Placebo-controlled Trial of Metformin on Progression of Carotid Atherosclerosis in Non-diabetic Patients With Cardiovascular Disease Treated With Conventional Risk Reducing Agents[NCT00723307] | Phase 4 | 173 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| Optimizing Exercise Training Effects on Metabolic Syndrome Factors by Altering the Timing of Medication and Meal Ingestion[NCT04477590] | 160 participants (Anticipated) | Interventional | 2022-06-07 | Recruiting | |||
| An Efficacy, Safety and Pharmacokinetic Study on the Short-term and Long-term Use of Metformin in Obese Children and Adolescents[NCT01487993] | Phase 3 | 62 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy[NCT02613897] | 56 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug in Partially Pancreatectomized Patients Due to Benign Pancreatic Neoplasm.[NCT01922492] | 28 participants (Actual) | Interventional | 2008-05-31 | Active, not recruiting | |||
| Pilot Randomized Controlled Trial of Spironolactone in Young Women With Nonalcoholic Steatohepatitis (NASH)[NCT03576755] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2019-01-09 | Completed | ||
| Effects of Metformin and Combination of Metformin and Pioglitazone on Plasma Interleukin-6 and Interleukin-8 Levels in Polycystic Ovarian Syndrome[NCT03117517] | Early Phase 1 | 106 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Effect of Metformin and Combination of Olive Oil Plus Nutritional Supplements on Inflammatory Markers IL-6 and IL-8 in PCOS.[NCT05952349] | Phase 2 | 88 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632] | Phase 3 | 104 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | ||
| Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction[NCT03658031] | Phase 3 | 576 participants (Anticipated) | Interventional | 2019-03-01 | Not yet recruiting | ||
| MetfoRmin and Its Effects on Myocardial Dimension and Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease[NCT02226510] | Phase 4 | 68 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| A Single-center,Double-blind,Randomised,Placebo-controlled,Parallel-group Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin on Insulin Sensitivity and Its Underlying Mechanism in Patients With T2DM Treated With Metformin[NCT01356381] | Phase 4 | 43 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar Monotherapy Compared With Placebo in Patients With Type 2 Diabetes Mellitus (T2D) Who Are Drug-Naïve to Anti-Hyperg[NCT01691755] | Phase 3 | 196 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,PHASE III STUDY TO ASSESS THE EFFICACY,SAFETY AND TOLERABILITY OF ALEGLITAZAR ADDED TO A SU OR ADDED TO A SU IN COMBINATION WITH MET IN PATIENTS WITH T2D INADEQUATELY CONTROLLED WITH SU MONOTHERA[NCT01691989] | Phase 3 | 197 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance[NCT00443755] | Phase 2 | 28 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial[NCT01765946] | Phase 4 | 38 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Pilot Study: Metformin as an Inflammatory Modulating Therapy in Older Adults Without Diabetes[NCT03772964] | Phase 1/Phase 2 | 32 participants (Actual) | Interventional | 2019-01-22 | Completed | ||
| Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome[NCT03355469] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2017-08-07 | Recruiting | ||
| Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone[NCT02733679] | Phase 4 | 27 participants (Actual) | Interventional | 2016-09-29 | Completed | ||
| Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
| EMPOWIR: Enhance the Metabolic Profile of Women With Insulin Resistance: Carbohydrate Modified Diet Alone and in Combination With Metformin or Metformin Plus Avandia in Non-diabetic Women With Midlife Weight Gain and Documented Insulin Elevations (Syndrom[NCT00618072] | Phase 2 | 46 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
| Umbilical Cord Mesenchymal Stem Cell Infusion With Liraglutide in Type 2 Diabetes Mellitus[NCT01954147] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2013-10-31 | Active, not recruiting | ||
| Lower Vitamin D Levels During Second Trimester Are Associated With Developing Gestational Diabetes Mellitus: an Observational Cross-sectional Study[NCT03665974] | 80 participants (Actual) | Observational | 2013-01-05 | Completed | |||
| A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744] | Phase 2 | 112 participants (Anticipated) | Interventional | 2021-08-03 | Recruiting | ||
| Improving Treatment and Liver Fibrosis Outcomes With Metformin in HCV-HIV Co-infected and HCV Mono-infected Patients With Insulin Resistance.[NCT02306070] | Phase 2 | 0 participants (Actual) | Interventional | 2016-01-31 | Withdrawn (stopped due to insufficient funding) | ||
| Ketosis-Prone Diabetes in African Americans: Predictive Markers, Underlying Mechanisms, and Treatment Outcomes: The Effects of Metformin vs. Sitagliptin on Beta-Cell Preservation in Obese Subjects With Ketosis-Prone Type 2 Diabetes Mellitus[NCT01099618] | Phase 4 | 48 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes: Pilot Study[NCT03848533] | Phase 2 | 42 participants (Anticipated) | Interventional | 2019-08-22 | Recruiting | ||
| Effect of an Intervention Program With Healthy Habits Plus Metformin or Conjugated Linoleic Acid Over Clinical Parameters and Molecular Pathways of Insulin Resistance in Obese Pediatric Patients[NCT02063802] | Phase 2 | 120 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| Effects of Inositols on Insulin Resistance in Children With Obesity (ONIRICO Trial)[NCT05701813] | 56 participants (Anticipated) | Interventional | 2023-02-01 | Not yet recruiting | |||
| Open-label, Flexible-dose Adjunctive Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance[NCT03575000] | Phase 4 | 20 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Treatment of Metabolic Abnormalities in Patients With Schizophrenia: Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities[NCT02751307] | Phase 4 | 55 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| A Pilot Study of D-Chiro-Inositol Plus Folic Acid in Overweight Patients With Type 1 Diabetes[NCT02730949] | Phase 3 | 26 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling[NCT02437084] | Phase 4 | 115 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance[NCT00667498] | Phase 4 | 28 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Improving Insulin Resistance to Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study[NCT02457286] | Phase 1 | 0 participants (Actual) | Interventional | 2015-06-30 | Withdrawn (stopped due to patients do not want to participate) | ||
| Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome[NCT02633488] | 19 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828] | Phase 3 | 164 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP): A Randomised Clinical Trial[NCT02347501] | Phase 2 | 118 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197] | Phase 2 | 20 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| An Evaluation of the Metabolic Effects of Exenatide, Rosiglitazone, and Exenatide Plus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin[NCT00135330] | Phase 3 | 137 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Effects of Metformin on Energy Intake, Energy Expenditure, and Body Weight in Overweight Children With Insulin Resistance[NCT00005669] | Phase 2 | 100 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| A Multi-Center, Randomized, Placebo Controlled, Double Blind Trial of Metformin in Obese Adolescents.[NCT00209482] | Phase 2/Phase 3 | 76 participants | Interventional | 2003-10-31 | Active, not recruiting | ||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes[NCT02694575] | 241 participants (Actual) | Observational | 2015-03-01 | Completed | |||
| Randomized, Cross-over Trial With Metformin in Women With Polycystic Ovary Syndrome[NCT02280057] | Phase 4 | 56 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| Liraglutide in the Treatment of Type 1 Diabetes Mellitus[NCT01722266] | Phase 3 | 72 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| Effects of the PPAR-gamma Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Diabetic and Hypertensive Subjects[NCT01090752] | Phase 4 | 16 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives[NCT00428311] | Phase 4 | 50 participants | Interventional | 2004-04-30 | Completed | ||
| Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia[NCT00770653] | Phase 3 | 305 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Influence of Insulin Resistance on Cognitive, Emotional and Opioid System Functioning in Women With Polycystic Ovary Syndrome[NCT00670800] | 14 participants (Actual) | Interventional | 2008-01-31 | Completed | |||
| Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)[NCT00682890] | Phase 4 | 28 participants (Actual) | Interventional | 2005-11-30 | Terminated (stopped due to Lack of recruitment) | ||
| Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes[NCT00006305] | Phase 3 | 2,368 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes[NCT02526810] | Phase 4 | 70 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Multicenter, Randomized, Controlled Clinical Trial Research Evaluating the Use of Combination Therapy of Glucocorticoids and Metformin to Decrease Glucocorticoids Side Effects in Patients With Autoimmune Uveitis[NCT03525028] | 138 participants (Anticipated) | Interventional | 2018-11-01 | Recruiting | |||
| Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch Followed by Ledipasvir-Sofosbuvir HCV Therapy in HIV-HCV Co-Infection: A CIHR Canadian HIV Trials Network-Gilead Pilot Trial Proposal[NCT02660905] | Phase 3 | 25 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| Pilot Study of Metformin (MF) IN HNSCC (Head and Neck Squamous Cell Carcinoma) as Window Trial Design in Operable HNSCC, to Investigate the Effects of MF, Tumor Genotype and MF Genotype Interactions, on Tumor Metabolism and Anoikis[NCT02402348] | Early Phase 1 | 3 participants (Actual) | Interventional | 2014-12-31 | Terminated (stopped due to Funding not available, PI left institution) | ||
| Inflammatory Mediators in Obese Adolescents With Insulin Resistance Following Metformin Treatment: Controlled Randomized Clinical Trial[NCT01410604] | Phase 4 | 31 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| [NCT01084486] | Phase 1/Phase 2 | 0 participants | Interventional | Completed | |||
| Metformin in Insulin Resistant LV Dysfunction, a Double-blind, Placebo-controlled Trial (TAYSIDE Trial)[NCT00473876] | Phase 4 | 62 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Clinical and Biochemical Study of the Effects of Rosuvastatin, Vitamin E, and N-Acetyl Cysteine on Patients With Non-alcoholic Steatohepatitis: a Randomized Controlled Trial[NCT06105060] | Early Phase 1 | 160 participants (Anticipated) | Interventional | 2023-12-17 | Not yet recruiting | ||
| Markers of Oxidative Stress and Inflammation in Patients With Intestinal Metaplasia and Metabolic Syndrome[NCT02695186] | 180 participants (Anticipated) | Observational | 2016-02-29 | Recruiting | |||
| Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb[NCT04625985] | Phase 2 | 20 participants (Actual) | Interventional | 2020-07-14 | Completed | ||
| Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.[NCT04626089] | Phase 2 | 0 participants (Actual) | Interventional | 2021-02-28 | Withdrawn (stopped due to Administrative decision of the company) | ||
| Effect of DMMET-01 on Insulin Sensitivity in Naive Type 2 Diabetes Patients by Glucose CLAMP Technique[NCT00940797] | Phase 2 | 20 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Study of Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Subjects With Hyperinsulinemia and Elevated Waist/Hip Ratio[NCT00015691] | 105 participants | Interventional | Completed | ||||
| Effect of Myoinositol on Serum Asprosin Levels in PCOS Patients[NCT05951309] | 30 participants (Actual) | Interventional | 2021-09-01 | Completed | |||
| DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488] | Phase 4 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| Does Metformin Improve Pregnancy Outcomes (Incidence of LGA (≥90% Birth Weight Centile) Babies, Onset of Maternal GDM, Hypertension, PET, Macrosomia, Shoulder Dystocia, Admission to SCBU) in Obese Non-diabetic Women?[NCT01273584] | Phase 2/Phase 3 | 450 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Randomized Clinical Trial, Effect of Metformin and Rosiglitazone Over Glucose Homeoastasis in no Diabetic With Metabolic Syndrome Patients.[NCT04148183] | Phase 2/Phase 3 | 30 participants (Actual) | Interventional | 2004-01-01 | Completed | ||
| Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer[NCT01589367] | Phase 2 | 208 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).[NCT01588873] | Phase 4 | 42 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance[NCT00108615] | Phase 4 | 48 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Effects of Pioglitazone on Reverse Cholesterol Transport and HDL Function in Persons With Diabetes[NCT01156597] | Phase 3 | 30 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome[NCT00784615] | 80 participants (Anticipated) | Observational | 2007-12-31 | Recruiting | |||
| Anxiety and Sexual Malfunction in Infertile Polycystic Ovarian Syndrome Patients[NCT05056272] | 128 participants (Anticipated) | Observational | 2022-01-01 | Recruiting | |||
| The Impact of Continuous Aerobic Exercise and High-Intensity Interval Training on Reproductive Outcomes in Polycystic Ovary Syndrome: A Pilot Randomized Controlled Trial.[NCT03362918] | 60 participants (Actual) | Interventional | 2018-01-01 | Completed | |||
| Adipose Tissue Angiogenesis in Polycystic Ovary Syndrome (PCOS)[NCT01745471] | 36 participants (Anticipated) | Observational | 2012-12-06 | Active, not recruiting | |||
| Lifestyle Intervention and Antioxidants in Children With Nonalcoholic Fatty Liver Disease: A Randomized, Controlled Trial[NCT00655018] | Phase 2/Phase 3 | 90 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| What is the Following Step to Improve Fertility in Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin? A Randomized Controlled Clinical Study.[NCT00502229] | Phase 4 | 0 participants (Actual) | Interventional | 2010-01-31 | Withdrawn | ||
| Metformin Addition to Gonadotropins Ovarian Stimulation in High Responder Patients With PCOS Undergoing In-vitro Fertilization[NCT01233206] | Phase 4 | 120 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Metformin in Children With Motor Deficit[NCT00720161] | 42 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| Pilot Trial of Bicalutamide Versus Placebo in Reproductive-Aged Women With Nonalcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovary Syndrome (PCOS)[NCT05979389] | Phase 1 | 50 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Metabolic Syndrome in PCOS: Precursors and Interventions[NCT00442689] | 97 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity[NCT02438020] | Phase 4 | 30 participants (Anticipated) | Interventional | 2015-06-30 | Not yet recruiting | ||
| Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes[NCT02303730] | Phase 4 | 76 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed [NCT00279045] | Phase 3 | 4,426 participants (Actual) | Interventional | 2000-01-03 | Completed | ||
| Bioequivalence Study of 2 mg Cyproterone Acetate and 0.035 mg Ethinyl Estradiol in Indonesian Healthy Females[NCT04964193] | 24 participants (Actual) | Interventional | 2019-03-12 | Completed | |||
| Vigorous Exercise Versus Moderate Exercise to Improve Glucose Metabolism and Metabolic Parameters in Women With Polycystic Ovary Syndrome and Insulin Resistance: A Prospective Randomized Pilot Study[NCT02303470] | 47 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | |||
| [NCT00483392] | 0 participants | Interventional | Completed | ||||
| Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain: a Randomized Double-Blind Placebo- Controlled Comparison[NCT00451399] | Phase 4 | 128 participants | Interventional | 2004-10-31 | Completed | ||
| Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea:a 24-week, Randomized, Placebo-controlled, Double-blind, Fixed-dose Study[NCT01423487] | 0 participants (Actual) | Interventional | 2011-08-31 | Withdrawn (stopped due to Difficult to obtain informed consent) | |||
| Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly[NCT04841668] | 136 participants (Anticipated) | Observational | 2021-04-10 | Recruiting | |||
| Time to Complications Occurs in Diabetes. Risk Factors Determine When Diabetes Complications Occur[NCT00969956] | 17 participants (Actual) | Observational | 2012-04-30 | Terminated (stopped due to Local regulations) | |||
| The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes[NCT01741467] | 110 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| Evaluation of Longevity Diet and Fasting Mimicking Diet Programs on Body Composition, Disease Risk Factors, and Aging Markers: a Randomized Clinical Trial[NCT05698654] | 501 participants (Anticipated) | Interventional | 2023-01-30 | Recruiting | |||
| Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis: A Prospective Randomized Double Blind Controlled Study[NCT02644954] | Phase 3 | 40 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| The Effect of Semaglutide Compared to Metformin in Obese Women With Polycystic Ovary Syndrome (PCOS): a Randomised Controlled Study (Semaglutide-PCOS Trial).[NCT05646199] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients[NCT00941382] | Phase 3 | 60 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| "Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"[NCT04826692] | Phase 3 | 60 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| [NCT01626443] | Phase 4 | 46 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| A Comparison of a Pulse-Based Diet and the Therapeutic Lifestyle Changes Diet on Reproductive and Metabolic Parameters in Women With Polycystic Ovary Syndrome[NCT05428566] | 110 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| The Effects of Metformin on Vascular Structure and Function in Subjects With the Metabolic Syndrome (MET Trial)[NCT00105066] | Phase 2 | 77 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Different Variables Predicting Ovulatory Response Among Clomiphene Citrate Resistance and Clomiphene Citrate Sensitive Patients With Polycystic Ovarian Syndrome.[NCT04887402] | 100 participants (Anticipated) | Observational [Patient Registry] | 2021-01-01 | Recruiting | |||
| Effects of Metformin on Fertility and Pregnancy in Women With Polycystic Ovary Syndrome: a Randomized, Prospective, Placebo-controlled Multicenter Study[NCT00994812] | Phase 3 | 326 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)[NCT00244244] | Phase 2 | 80 participants | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Nude body weight. Value is the difference between the placebo and antihypertensive medication. (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | kg (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 92.1 | 90.0 |
| PLACEBO | 92.5 | 90.8 |
Determined using a ECG-gated automated sphygmomanometer. Value is the difference between the placebo and antihypertensive medication. (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | mmHg (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 75 | 72 |
| PLACEBO | 79 | 77 |
"Index of cardiorespiratory fitness assessed during an incremental cycle-ergometer test using an indirect calorimetry system.~Value is the difference between the placebo and antihypertensive medication." (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | Liters of O2/kg weight/min (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 2.26 | 2.49 |
| PLACEBO | 2.26 | 2.49 |
"Calculated in grams per min during the incremental cycloergometer test wih the use of indirect calorimetry system.~Value is the difference between the placebo and antihypertensive medication." (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | grams/min (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 0.24 | 0.28 |
| PLACEBO | 0.24 | 0.28 |
Determined using a ECG-gated automated sphygmomanometer. Value is the difference between the placebo and antihypertensive medication. (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | mmHg (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 92 | 89 |
| PLACEBO | 97 | 96 |
Determined using a ECG-gated automated sphygmomanometer. Value is the difference between the placebo and antihypertensive medication. (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | mmHg (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 126 | 124 |
| PLACEBO | 134 | 133 |
HbA1C (NCT01763346)
Timeframe: 24 months
| Intervention | percent of hemoglobin (Mean) |
|---|---|
| Metformin | 5.84 |
| Gastric Banding | 5.73 |
mean plasma C-peptide concentration during clamp steady state, adjusted for mean clamp insulin sensitivity (NCT01763346)
Timeframe: 24 months
| Intervention | (nmol/L) adjusted for M/I (Geometric Mean) |
|---|---|
| Metformin | 3.01 |
| Gastric Banding | 3.19 |
fasting and 2-hour OGTT glucose levels (NCT01763346)
Timeframe: 24 months
| Intervention | mmol/l (Mean) | |
|---|---|---|
| fasting glucose | 2-hour glucose | |
| Gastric Banding | 5.85 | 9.92 |
| Metformin | 5.95 | 10.87 |
First phase response from the hyperglycemic clamp (NCT01779362)
Timeframe: 3-months after a medication washout
| Intervention | nmol/L (Geometric Mean) |
|---|---|
| Metformin Alone | 1.68 |
| Glargine Followed by Metformin | 1.68 |
| Placebo | 1.68 |
| Liraglutide + Metformin | 1.68 |
Clamp measure of insulin sensitivity (NCT01779362)
Timeframe: 3-months after a medication washout
| Intervention | x 10-5 mmol/kg/min per pmol/L (Geometric Mean) |
|---|---|
| Metformin Alone | 3.53 |
| Glargine Followed by Metformin | 3.38 |
| Placebo | 3.63 |
| Liraglutide + Metformin | 3.49 |
Participants had 12-months of active therapy. Secondary results at the end of active intervention. (NCT01779362)
Timeframe: Secondary analysis was on all participants with a Month 12 visit.
| Intervention | nmol/L (Geometric Mean) | ||
|---|---|---|---|
| ACRPg | Steady State C-peptide | ACRPmax | |
| Glargine Followed by Metformin | 1.88 | 11.6 | 14.1 |
| Liraglutide + Metformin | 2.68 | 21.2 | 10.1 |
| Metformin Alone | 1.93 | 11.7 | 13.4 |
| Placebo | 1.69 | 10.8 | 13.6 |
Clamp measures of ß-cell response, co-primary outcomes (NCT01779362)
Timeframe: 3-months after medication washout (Month 15)
| Intervention | nmol/L (Geometric Mean) | |
|---|---|---|
| Steady State C-peptide | ACPRmax | |
| Glargine Followed by Metformin | 3.58 | 4.32 |
| Liraglutide + Metformin | 3.73 | 4.58 |
| Metformin Alone | 3.65 | 4.61 |
| Placebo | 3.60 | 4.45 |
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
First phase response (NCT01779375)
Timeframe: 3-months after a medication washout
| Intervention | nmol/L (Mean) |
|---|---|
| Metformin Alone | 1.11 |
| Glargine Followed by Metformin | 1.12 |
Participants had 12-months of active therapy. Secondary results at the end of active intervention. (NCT01779375)
Timeframe: End of active intervention (Month 12)
| Intervention | x 10-5 mmol/kg/min per pmol/L (Mean) |
|---|---|
| Metformin Alone | 1.52 |
| Glargine Followed by Metformin | 1.93 |
Clamp measure of insulin sensitivity (NCT01779375)
Timeframe: 3-months after a medication washout
| Intervention | x 10-5 mmol/kg/min per pmol/L (Mean) |
|---|---|
| Metformin Alone | 1.48 |
| Glargine Followed by Metformin | 1.70 |
Participants had 12-months of active therapy. Secondary results at the end of active intervention. (NCT01779375)
Timeframe: End of active intervention (Month 12).
| Intervention | nmol/L (Mean) | ||
|---|---|---|---|
| Steady State C-peptide | ACPRmax | ACPRg | |
| Glargine Followed by Metformin | 4.37 | 5.79 | 1.03 |
| Metformin Alone | 4.78 | 6.95 | 1.06 |
Clamp measures of ß-cell response, co-primary outcomes (NCT01779375)
Timeframe: 3-months after medication washout (Month 15)
| Intervention | nmol/L (Mean) | |
|---|---|---|
| Steady State C-peptide | ACPRmax | |
| Glargine Followed by Metformin | 4.18 | 5.95 |
| Metformin Alone | 4.82 | 6.92 |
ALT measured in serum at each time point (NCT01775813)
Timeframe: Baseline (Tanner 2-3), Tanner 4, Tanner 5
| Intervention | international units per liter (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 25.022 | 27.059 | 26.121 | NA |
| Obese - Metformin | 52.400 | 42.545 | 39.636 | 45.000 |
| Obese - NT/Placebo | 35.194 | 44.571 | 38.650 | NA |
| Obese - Placebo | 41.125 | 51.182 | 47.500 | 50.231 |
AST measured in serum at each time point (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | international units per liter (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 42.174 | 35.706 | 33.364 | NA |
| Obese - Metformin | 54.150 | 40.273 | 34.091 | 36.273 |
| Obese - NT/Placebo | 41.250 | 44.429 | 36.650 | NA |
| Obese - Placebo | 43.542 | 43.636 | 42.333 | 39.077 |
estradiol metabolite (E1c) measured in an overnight urine sample at each time point (NCT01775813)
Timeframe: Baseline, every 6 months during the trial, Final visit-average 3 yrs after baseline
| Intervention | ng/mgCr (Mean) | |||
|---|---|---|---|---|
| Tanner 2/3 | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 7.711 | 22.919 | 41.036 | NA |
| Obese - Metformin | 28.451 | 37.722 | 71.546 | 30.883 |
| Obese - NT/Placebo | 17.353 | 8.584 | 7.825 | 26.402 |
| Obese - Placebo | 17.353 | 8.584 | 7.825 | 26.402 |
FSH measured in overnight urine sample at time points below (NCT01775813)
Timeframe: Baseline, every 6 months during the trial, Final visit-average 3 yrs after baseline
| Intervention | international units per milliliter (IU/m (Mean) | |||
|---|---|---|---|---|
| Tanner 2/3 | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 3.911 | 2.555 | 6.540 | NA |
| Obese - Metformin | 3.615 | 3.162 | 3.213 | 3.911 |
| Obese - NT/Placebo | 3.837 | 4.874 | 4.093 | 5.993 |
| Obese - Placebo | 3.837 | 4.874 | 4.093 | 5.993 |
LH measured in an overnight urine sample at time points below (NCT01775813)
Timeframe: Baseline, every 6 months during the trial, Final visit (average 3 yrs after baseline)
| Intervention | international units per liter (Mean) | |||
|---|---|---|---|---|
| Tanner 2/3 | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 3.849 | 4.518 | 4.494 | NA |
| Obese - Metformin | 3.809 | 3.729 | 8.993 | 30.861 |
| Obese - NT/Placebo | 2.257 | 3.310 | 2.014 | 5.373 |
| Obese - Placebo | 2.257 | 3.310 | 2.014 | 5.373 |
DHEA-S measured in serum at each time point (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | mcg/dl (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 90.146 | 101.889 | 130.206 | NA |
| Obese - Metformin | 107.600 | 129.545 | 145.818 | 176.818 |
| Obese - NT/Placebo | 96.750 | 101.533 | 137.250 | NA |
| Obese - Placebo | 91.167 | 116.182 | 137.083 | 132.154 |
Please see primary outcome for more detail about timing of measurement. Disposition index is measured via (IVGTT) as calculated by Bergman's minimal model. Higher numbers indicate a better outcome. It reflects the product of outcome measures 1 and 2 (Si x AIRg). (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline, 6 mos post-treatment-average 3 yrs from baseline
| Intervention | x10-4/min-1 (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 3750.463 | 3706.940 | 3234.061 | NA |
| Obese - Metformin | 4438.821 | 5046.218 | 3537.273 | 2539.933 |
| Obese - NT/Placebo | 4195.921 | 3269.039 | 2897.244 | NA |
| Obese - Placebo | 4286.209 | 2897.689 | 3194.773 | 3627.762 |
Estradiol measured in serum at each time point (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 22.375 | 50.583 | 57.382 | NA |
| Obese - Metformin | 14.750 | 23.364 | 48.000 | 69.636 |
| Obese - NT/Placebo | 15.722 | 35.867 | 42.800 | NA |
| Obese - Placebo | 15.833 | 44.545 | 48.833 | 70.923 |
HbA1c measured by HPLC at time points below (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | mmol/mol (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 5.139 | 5.200 | 5.233 | NA |
| Obese - Metformin | 5.400 | 5.570 | 5.473 | 5.691 |
| Obese - NT/Placebo | 5.336 | 5.627 | 5.476 | NA |
| Obese - Placebo | 5.336 | 5.627 | 5.500 | 5.515 |
Please see primary outcome for more detail about timing of measurement. (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline, 6 mos post-treatment-average 3 yrs from baseline
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 51.442 | 51.667 | 46.909 | NA |
| Obese - Metformin | 41.368 | 42.273 | 43.000 | 41.818 |
| Obese - NT/Placebo | 39.306 | 39.455 | 38.944 | NA |
| Obese - Placebo | 38.917 | 39.455 | 39.333 | 40.923 |
hsCRP measured in serum at each time point (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 1.001 | 0.305 | 1.015 | NA |
| Obese - Metformin | 3.962 | 1.841 | 0.961 | 2.667 |
| Obese - NT/Placebo | 2.523 | 4.530 | 3.331 | NA |
| Obese - Placebo | 3.117 | 4.357 | 3.985 | 3.958 |
As measured by IVGTT as calculated by Bergman's minimal model. Higher numbers indicate a better outcome. Please see primary outcome for more detail about timing of measurement. (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline, 6 mos post-treatment-average 3 yrs from baseline
| Intervention | µIU/mL (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 583.535 | 783.191 | 680.858 | NA |
| Obese - Metformin | 2368.931 | 2157.349 | 1804.026 | 1667.713 |
| Obese - NT/Placebo | 1877.895 | 1951.323 | 2103.309 | NA |
| Obese - Placebo | 1858.16 | 1996.867 | 2013.628 | 1943.542 |
As measured by in intravenous glucose tolerance test (IVGTT) as calculated by Bergman's minimal model. Higher numbers indicate a better outcome. Patients are randomized to receive metformin or placebo at Tanner stage 2-3 of puberty. They are reassessed at Tanner 4 and again at Tanner 5. At that point, the treatment is stopped and they are reassessed 6 months after stopping treatment to see if effects of treatment persist. (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline, 6 mos post-treatment-average 3 yrs from baseline
| Intervention | x10-4/min-1/mIU/mL (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 8.559 | 6.661 | 6.438 | NA |
| Obese - Metformin | 2.985 | 2.873 | 2.990 | 2.182 |
| Obese - NT | 3.425 | 1.995 | 2.082 | NA |
| Obese - Placebo | 3.756 | 1.868 | 2.383 | 3.017 |
IGF-1 measured in serum at each time point (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | ng/ml (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 313.500 | 405.389 | 398.000 | NA |
| Obese - Metformin | 281.700 | 410.300 | 404.800 | 395.818 |
| Obese - NT/Placebo | 262.278 | 370.800 | 389.800 | NA |
| Obese - Placebo | 243.042 | 380.273 | 351.833 | 319.692 |
Leptin measured in serum at time points below (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 5.956 | 5.964 | 8.338 | NA |
| Obese - Metformin | 32.215 | 29.791 | 31.182 | 48.445 |
| Obese - NT/Placebo | 32.097 | 36.867 | 38.155 | NA |
| Obese - Placebo | 33.917 | 44.036 | 47.642 | 53.200 |
Liver fat percent. Measured in a subset (10 per group) by fast MRI technique (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | percentage of liver mass (Mean) | |
|---|---|---|
| Baseline | Tanner 5 | |
| Normal Weight | 1.376 | 2.208 |
| Obese - Metformin | 13.765 | 10.327 |
| Obese - Placebo | 8.290 | 8.291 |
| Obese NT/Placebo | 8.290 | 8.219 |
Please see primary outcome for more detail about timing of measurement. (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline, 6 mos post-treatment-average 3 yrs from baseline
| Intervention | mg/dl (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 79.488 | 75.367 | 78.485 | NA |
| Obese - Metformin | 83.779 | 81.818 | 75.000 | 86.545 |
| Obese - NT/Placebo | 86.533 | 96.636 | 96.222 | NA |
| Obese - Placebo | 88.583 | 96.636 | 97.667 | 103.154 |
% body fat measured by DXA at time points below (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | percentage of body fat (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 24.883 | 25.054 | 25.500 | NA |
| Obese - Metformin | 43.826 | 40.610 | 39.964 | 41.418 |
| Obese - NT/Placebo | 42.126 | 43.380 | 42.889 | NA |
| Obese - Placebo | 44.700 | 44.264 | 44.555 | 43.962 |
SHBG measured in serum at each time point (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | nmol/l (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 61.958 | 50.417 | 43.500 | NA |
| Obese - Metformin | 17.550 | 19.545 | 16.455 | 17.273 |
| Obese - NT/Placebo | 20.417 | 17.200 | 16.250 | NA |
| Obese - Placebo | 18.958 | 16.364 | 15.750 | 15.538 |
Testosterone measured in serum at each time point (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 4-average 1.5 years from baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | ng/dl (Mean) | |||
|---|---|---|---|---|
| Baseline | Tanner 4 | Tanner 5 | Post-Puberty | |
| Normal Weight | 108.625 | 145.972 | 235.559 | NA |
| Obese - Metformin | 41.050 | 121.727 | 117.909 | 150.727 |
| Obese - NT/Placebo | 35.278 | 87.933 | 158.300 | NA |
| Obese - Placebo | 30.125 | 89.364 | 165.750 | 152.692 |
Percent Visceral Fat, Measured in a subset (10 per group) by single slice MRI (NCT01775813)
Timeframe: Baseline, Tanner (puberty) stage 5-average 2.5 yrs from baseline
| Intervention | Percent (Mean) | |
|---|---|---|
| Baseline | Tanner 5 | |
| Normal Weight | 7.647 | 6.322 |
| Obese - Metformin | 12.076 | 10.079 |
| Obese - NT/Placebo | 12.007 | 12.236 |
| Obese - Placebo | 12.007 | 12.236 |
The difference between Cycloset and placebo in the change in HbA1c from baseline to Week 24 was analyzed for subjects with a baseline HbA1c of ≥ 7.5% who were taking at least one oral hypoglycemia agent (OHA) at baseline. The primary analysis was based on subjects from the evaluable per protocol efficacy (EPPE) analysis set with a secondary analysis using subjects from the intent to treat efficacy (ITTE) analysis set for subjects completing 24 weeks of treatment. Change is reported as the absolute difference in % HbA1c. (NCT00377676)
Timeframe: Baseline to week 24
| Intervention | percent (Least Squares Mean) |
|---|---|
| Cycloset | -0.41 |
| Placebo | 0.041 |
"Change in HbA1c from baseline to week 24 in subjects failing treatment with metformin plus a sulfonylurea with failure defined as having a baseline HbA1c value of ≥ 7.5%. Change was measured at week 24 after randomization in subjects having no major protocol violations.~Change is reported as the absolute difference in % HbA1c." (NCT00377676)
Timeframe: Baseline to week 24
| Intervention | percent (Least Squares Mean) |
|---|---|
| Cycloset | -0.49 |
| Placebo | -0.04 |
The secondary safety endpoint is number subjects with occurrences of first cardiovascular SAE (myocardial infarction, stroke, in-patient hospitalization for heart failure, angina or revascularization surgery). (NCT00377676)
Timeframe: Baseline to week 52.
| Intervention | Subjects (Number) |
|---|---|
| Cycloset | 31 |
| Placebo | 30 |
Number of subjects reporting all-cause Serious Adverse Events (SAEs) for usual drug therapy plus Cycloset vs. that for usual drug therapy (UDT) plus placebo from baseline to week 52. (NCT00377676)
Timeframe: From baseline to week 52.
| Intervention | participants (Number) |
|---|---|
| Cycloset | 176 |
| Placebo | 98 |
Systolic blood pressure was measured in mmHg. (NCT03151005)
Timeframe: 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 122.83 |
| Metformin-Oral Contraceptive(OC) | 122.40 |
Alanine transaminase was measured in IU/L. (NCT03151005)
Timeframe: 12 weeks
| Intervention | IU/L (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 39.09 |
| Metformin-Oral Contraceptive(OC) | 36.73 |
Changes in testosterone levels were measured (NCT03151005)
Timeframe: 12 weeks
| Intervention | nmol/L (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 1.82 |
| Metformin-Oral Contraceptive(OC) | 2.14 |
Concentration of LH was measured in mIU/ml. (NCT03151005)
Timeframe: 12 weeks
| Intervention | mIU/ml (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 5.52 |
| Metformin-Oral Contraceptive(OC) | 5.33 |
Weight and height will be combined to report BMI in kg/m^2. (NCT03151005)
Timeframe: 12 weeks
| Intervention | kg/m^2 (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 26.26 |
| Metformin-Oral Contraceptive(OC) | 27.12 |
The progesterone (P4) sensitivity index is defined as the percent change in 11-hour LH pulse frequency before and after P4 and estradiol administration for 7 days, divided by the day 7 mean serum P4 concentration. We compared the P4 sensitivity index after metformin administration to the baseline P4 sensitivity index, using Wilcoxon signed-rank test. (NCT01427595)
Timeframe: 12 weeks following start of metformin treatment
| Intervention | % change in LH pulses/day 7 P4 level (Mean) | |
|---|---|---|
| Before Metformin | After Metformin | |
| Metformin, Progesterone , Estrace | -4.12 | -4.29 |
Maximal change in maternal breast milk production (g/24 hours) between baseline and 4 weeks post-intervention in a model adjusted for baseline milk volume, maternal day postpartum of randomization, and baseline fasting plasma glucose. (NCT02179788)
Timeframe: baseline and 4 weeks post-intervention
| Intervention | milliliters (Median) |
|---|---|
| Standard Care Plus Metformin | 8 |
| Standard Care Plus Placebo | -58 |
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
Change in BMI (body mass index) from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | Kg/m^2 (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.8 |
| DAPA (Dapagliflozin Plus Placebo) | -0.66 |
| PCB (Placebo Plus Placebo) | 0.16 |
Change in body weight from baseline to 16 weeks (NCT02613897)
Timeframe: Baseline to 16 weeks
| Intervention | Kg (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -2.28 |
| DAPA (Dapagliflozin Plus Placebo) | -1.76 |
| PCB (Placebo Plus Placebo) | 0.26 |
A measure of the change in fasting plasma glucagon from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -28.52 |
| DAPA (Dapagliflozin Plus Placebo) | 26.89 |
| PCB (Placebo Plus Placebo) | 6.88 |
Measure of change in Free Fatty Acids from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mEq/L (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.06 |
| DAPA (Dapagliflozin Plus Placebo) | -0.01 |
| PCB (Placebo Plus Placebo) | 0.00 |
Change in percentage of glucose oxidation from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -22.07 |
| DAPA (Dapagliflozin Plus Placebo) | -46.54 |
| PCB (Placebo Plus Placebo) | 4.65 |
Change in lipid oxidation percentage from baseline to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -11.87 |
| DAPA (Dapagliflozin Plus Placebo) | 22.02 |
| PCB (Placebo Plus Placebo) | -6.69 |
Change in blood glucose level measured over a 3 month period from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage change in blood glucose level (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -1.67 |
| DAPA (Dapagliflozin Plus Placebo) | -1.46 |
| PCB (Placebo Plus Placebo) | 0.44 |
Measure of change in OGTT from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -49.62 |
| DAPA (Dapagliflozin Plus Placebo) | -44.24 |
| PCB (Placebo Plus Placebo) | 20.26 |
All subjects received a Double-Tracer Oral Glucose Tolerance Test (OGTT) with 75g of glucose containing 14C-glucose together with intravenous primed-continuous infusion of 3(3H)-glucose for 240 minutes, at baseline (prior to) and after 16 weeks of therapy. Blood and urine samples were obtained during the OGTT to determine EGP. (NCT02613897)
Timeframe: Baseline and 16 weeks
| Intervention | mg/kg*min (Mean) | |
|---|---|---|
| Baseline Measurement | 16 weeks | |
| DAPA (Dapagliflozin Plus Placebo) | 2.56 | 2.8 |
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | 2.45 | 2.4 |
| PCB (Placebo Plus Placebo) | 1.95 | 2.15 |
IL-6 and IL-8 levels by ELISA method using commercially available kits. (NCT03117517)
Timeframe: Baseline and after 3 Months
| Intervention | pg/ml (Geometric Mean) | |||
|---|---|---|---|---|
| IL-6 levels at baseline | IL-6 levels after 3 months of treatment | IL-8 Llevels at baseline | IL-8 Llevels after treatment | |
| Metformin | 14.60 | 12.65 | 61.92 | 32.70 |
| Metformin, Pioglitazone | 14.12 | 11.12 | 41.86 | 22.00 |
Serum level of LH was measure at baseline and after 3 months of treatment (NCT03117517)
Timeframe: Baseine and after 3 Months
| Intervention | mIU/ml (Geometric Mean) | |
|---|---|---|
| LH level at baseline | LH level after treatment | |
| Metformin | 5.79 | 4.92 |
| Metformin, Pioglitazone | 6.625 | 5.16 |
Insulin resistance was measure by calculating HOMA-IR from the data of insulin and sugar levels. (NCT03117517)
Timeframe: Baseline and after 3 months
| Intervention | unitless (Mean) | |
|---|---|---|
| HOMA-IR at baseline | HOMA-IR after treatment | |
| Metformin | 7.19 | 3.97 |
| Metformin, Pioglitazone | 6.22 | 3.84 |
Body fat is reported as a percentage of body weight. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | percentage of body weight (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 1.73 |
| Placebo | -0.01 |
Body Mass Index (BMI) is a health index for comparing weight to height. BMI is a person's weight in kilograms (kg) divided by his or her height in meters squared. The body mass index is an indication if a person is at a suitable weight for his height on an approximation of body fat. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | kg/m^2 (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 0.37 |
| Placebo | -0.21 |
Glucose (sugar) was measured in the blood and reported in milligrams per deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -19.96 |
| Placebo | 8.39 |
FFM was measured using dual energy x-ray absorptiometry (DEXA) scans and is reported in kilograms (kg). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | kilograms (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -1.13 |
| Placebo | -0.34 |
HbA1c is a measure of average blood sugar levels over the preceding 3 month period. HbA1c was measured by ion-exchange chromatography and reported as a percentage. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | percentage (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.35 |
| Placebo | 0.19 |
TNF-α is an inflammatory cytokine and is reported in picograms/milliliter (pg/mL). (NCT00443755)
Timeframe: Baseline, 3 month
| Intervention | pg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.13 |
| Placebo | 0.18 |
Insulin levels in the blood were measured by immunoenzymatic assay and reported in micro International Units per milliliter (mcIU/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | microIU/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -8.13 |
| Placebo | 1.38 |
Insulin sensitivity was measured the morning after an overnight fast during an in-patient stay in the Clinical Research Unit & was determined by the mean GIR necessary to maintain euglycemia during a hyperinsulinemic (1.5 mcIU/kg of FFM per minute)-euglycemic (85-95 mg/dL) clamp. The clamp is an 8 hour process where a hand vein is catheterized to collect blood samples and intravenous lines are used to infuse glucose, saline, insulin, phenylalanine and amino acid solutions at at pre-specified times/rates. The mean GIR was calculated as the rate per kilograms of fat-free mass (FFM) during 4 hours of steady-state (hours 4-8 of the 8 hour clamp) reported as micromols/kilogram of FFM per minute. The FFM was measured by dual-energy x-ray absorptiometry (DEXA) scan. Insulin was infused with 5% essential amino acid solution (3mL/kg of FFM/hour) to prevent the insulin-dependent decrease of amino acids during insulin infusion. (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | micromols/kg of FFM/minute (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 17.95 |
| Placebo | 1.68 |
Adiponectin is an anti-inflammatory cytokine and is reported in milligrams per milliliter (mg/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 9.10 |
| Placebo | 0.46 |
CRP is an inflammatory cytokine and is reported in milligrams per deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.19 |
| Placebo | -0.15 |
IL-6 is an inflammatory cytokine and reported in picograms per deciliter (pg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | pg/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -0.99 |
| Placebo | -1.42 |
Fibrinogen was measured by thrombin clotting rate assay (Beckman Coulter, Inc. Brea, California) and reported in milligrams/deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | 14.00 |
| Placebo | -18.62 |
PAI-1 was measured by enzyme-linked immunosorbent assay (Diagnostica Stago Inc., Parsippany, New Jersey) and reported in nanograms per milliliter (ng/mL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | ng/mL (Mean) |
|---|---|
| Insulin Sensitizer Therapy | -34.17 |
| Placebo | 8.15 |
Change in lipids were measured by the change from baseline to 3 months of triglycerides, high-density lipoprotein cholesterol (HDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). All were reported in milligrams/deciliter (mg/dL). (NCT00443755)
Timeframe: Baseline, 3 months
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Triglycerides | HDL-C-Cholesterol | Non-HDL-Cholesterol | |
| Insulin Sensitizer Therapy | -15.58 | 4.33 | -7.50 |
| Placebo | 17.77 | -0.31 | 4.62 |
Grip strength over time. (NCT03772964)
Timeframe: Day 0 (baseline), 90, and 120 (30 days post metformin exposure)
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| 0 days | 90 days, compared to 0 days | 120 days, compared to 0 days | |
| 1000mg Exposure | 28.9 | -0.4 | 1.1 |
| 1500mg Exposure | 25.7 | -.2 | .3 |
| 500mg Exposure | 28.2 | -5.3 | .1 |
| Placebo | 25.7 | -.3 | -.6 |
The SPPB is a group of measures that combines the results of the gait speed, chair stand and balance tests. The minimum is zero (worse performance) and the maximum is 12 (best performance). (NCT03772964)
Timeframe: Day 0 (baseline), 90, and 120 (30 days post metformin exposure)
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| 0d | 90d, change from 0d | 120d, change from 0d | |
| 1000mg Exposure | 10.8 | 0.4 | 0.2 |
| 1500mg Exposure | 11.1 | 0.4 | 0.3 |
| 500mg Exposure | 11.2 | -0.3 | 0 |
| Placebo | 10.6 | 1.0 | 0.5 |
Aggregometry area under the curve with the Y-axis being % aggregometry and the X-axis time in minutes. (NCT03772964)
Timeframe: Day 0 (baseline), 30, 60, 90, and 120 (30 days post metformin exposure)
| Intervention | arbitrary units*mins (Mean) | ||||
|---|---|---|---|---|---|
| 0 days | 30 day change from day 0 | 60 days change from day 0 | 90 days change from day 0 | 120 days change from day 0 | |
| 1000mg Exposure | 67 | 8.9 | -23.5 | 2.4 | 1.0 |
| 1500mg Exposure | 196 | -166.7 | -139.8 | -222.5 | -196.7 |
| 500mg Exposure | 56.3 | -34.7 | -28.3 | 1.6 | -49.2 |
| Placebo | 83.3 | -29.6 | -49.4 | -66.6 | -47.6 |
"Bacterial communities using 16S rRNA sequencing in relationship to metformin dosing over time. Species richness or diversity in the sample is measured by Choa1 metric. Chao1 is an estimate of how many species are present in an ecosystem. In general, having more species is considered to be healthier and these values typically range from 100-200 for fecal samples. The Chao1 index over numerous samples across time are explored to understand treatment effects." (NCT03772964)
Timeframe: Day 0 (baseline), 30, 60, 90, and 120 (30 days post metformin exposure)
| Intervention | Index (Mean) | ||||
|---|---|---|---|---|---|
| Day 0 | Day 30 | Day 60 | Day 90 | Day 120 | |
| 1000mg Exposure | 107.6 | 130.7 | 137.9 | 135 | 142.2 |
| 1500mg Exposure | 128.1 | 128.1 | 128.6 | 138.2 | 144.2 |
| 500mg Exposure | 136.5 | 139.9 | 121.4 | 137.8 | 134 |
| Placebo | 141.5 | 144.75 | 134.3 | 152 | 159.2 |
Total adiponectin was measured with a commercial ELISA kit (Millipore/Linco Research, St. Charles, MO) in the laboratory of Dr. Philipp Scherer. (NCT00618072)
Timeframe: 6 months
| Intervention | ug/mL (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 10.6 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 10.9 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 18.5 |
Body weight measurement was performed three times and averaged by a single study coordinator. (NCT00618072)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 80.0 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 80.4 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 77.5 |
Blood pressure was assessed using NCEP guidelines. (NCT00618072)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 71.7 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 72.7 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 74.3 |
Insulin was determined with a Siemens Immulite assay with respective intra-and inter-CV's 5.7 and 5.9%, and no cross reactivity to pro-insulin. (NCT00618072)
Timeframe: 6 months
| Intervention | uIU/mL (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 8.1 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 8.0 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 6.3 |
HDL was measured using two reagents homogeneous systems with selective detergents to homogenize the lipoprotein of interest. (NCT00618072)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 56.5 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 70.1 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 68.3 |
HOMA-IR was calculated by the formula: fasting insulin (uU/mL) times fasting glucose (mg/L) divided by 22.5. (NCT00618072)
Timeframe: 6 months
| Intervention | HOMA-IR score (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 1.5 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 1.6 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 1.3 |
Blood pressure was assessed using NCEP guidelines. (NCT00618072)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 113.8 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 107.2 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 114.2 |
Triglycerides were measured by enzymatic immunoassay on an AU400 chemistry auto-analyzer with commercially available enzymatic reagents. (NCT00618072)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 95.2 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 103.1 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 109.2 |
(NCT00618072)
Timeframe: 6 months
| Intervention | cm (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 93.1 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 90.4 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 87.5 |
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 70 |
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 450 |
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 749 |
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 514 |
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 1290 |
For those patients that are able to discontinue insulin therapy at or <12 weeks, how long were they able to well controlled with an A1c <7% on the agent that they were randomized to. (NCT01099618)
Timeframe: 3 years
| Intervention | days (Median) |
|---|---|
| Metformin | 472 |
| Sitagliptin | 589 |
| Placebo | 111 |
Baseline and end-of-treatment fasting plasma glucose (mg/dL) values represent average of up to 3 measurements for each value (obtained at baseline weeks -2, -1, and 0 and at the end of study at weeks 8, 9, and 10). (NCT02437084)
Timeframe: 10 weeks
| Intervention | mg/dL (Median) | |
|---|---|---|
| Baseline | End of Study | |
| Individuals Without Diabetes Eligible to Receive Statin Therapy | 99 | 100 |
Baseline and end-of-treatment fasting plasma insulin (mU/L) values represent average of up to 3 measurements for each value (obtained at baseline weeks -2, -1, and 0 and at the end of study at weeks 8, 9, and 10). (NCT02437084)
Timeframe: 10 weeks
| Intervention | mU/L (Median) | |
|---|---|---|
| Baseline | End of Study | |
| Individuals Without Diabetes Eligible to Receive Statin Therapy | 10.1 | 10.6 |
Insulin secretion measured by ISR-AUC (pmol/min x 4 h) during the graded glucose infusion test. (NCT02437084)
Timeframe: baseline, week 9 or 10
| Intervention | pmol/min x 4 h (Median) | |
|---|---|---|
| Baseline | End of Study | |
| Individuals Without Diabetes Eligible to Receive Statin Therapy | 1824 | 1942 |
Glucose area under the curve (AUC) (mg/dL x 2 h) measured during a 75-gram oral glucose tolerance test (OGTT). (NCT02437084)
Timeframe: baseline, week 8
| Intervention | mg/dL x 2 h (Median) | |
|---|---|---|
| Baseline | End of Study | |
| Individuals Without Diabetes Eligible to Receive Statin Therapy | 295 | 299 |
Insulin area under the curve (AUC) (mU/L x 2h) measured during a 75-gram oral glucose tolerance test (OGTT). (NCT02437084)
Timeframe: baseline, week 8
| Intervention | mU/L x 2 h (Median) | |
|---|---|---|
| Baseline | End of Study | |
| Individuals Without Diabetes Eligible to Receive Statin Therapy | 127 | 133 |
Insulin sensitivity measured by SSPG concentration (mg/dL) during the insulin suppression test. (NCT02437084)
Timeframe: baseline, week 9 or 10
| Intervention | mg/dL (Median) | |
|---|---|---|
| Baseline | End of Study | |
| Individuals Without Diabetes Eligible to Receive Statin Therapy | 130 | 139 |
brachial artery ultrasonography % flow-mediated dilatation (FMD) for assessing endothelial function before and after an insulin clamp to assess insulin's effect on the vasculature (NCT02633488)
Timeframe: before and after 12 weeks on placebo or metformin
| Intervention | percentage of artery dilation (Mean) |
|---|---|
| Pre and Post Placebo 12 Weeks | 6.1 |
| Pre and Post Metformin 12 Weeks | 6.2 |
Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of change (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentile (Mean) |
|---|---|
| Metformin | -1 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | insulin per kg (Mean) |
|---|---|
| Metformin | -0.1 |
| Oral Placebo | -0.0 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | centimeters (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change in Systolic | Change in Diastolic | |
| Metformin | 0 | 0 |
| Oral Placebo | -0 | 0 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| HbA1c | Change from Baseline to 26 Weeks | |
| Metformin | 9.0 | 0.2 |
| Oral Placebo | 8.9 | 0.2 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| HbA1c Decrease ≥0.5% | HbA1c Increase ≥0.5% | HbA1c <7.5% | |
| Metformin | 19 | 44 | 3 |
| Oral Placebo | 18 | 35 | 4 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Change in LDL | Change in VLDL | Change in HDL | Change in Triglycerides | Change in Total Cholesterol | |
| Metformin | -6 | -0 | -0 | 4 | -5 |
| Oral Placebo | 2 | 1 | -1 | 6 | 3 |
High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | µg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 8.4 |
The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmol/L (Median) |
|---|---|
| Sitagliptin | -0.2 |
| Gliclazide | -0.1 |
The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmHg (Median) |
|---|---|
| Sitagliptin | 4 |
| Gliclazide | -9 |
The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
| Intervention | mmol/L (Median) |
|---|---|
| Sitagliptin | 0.1 |
| Gliclazide | -0.1 |
Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Sitagliptin | 3 |
| Gliclazide | 1.8 |
Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Sitagliptin | 9.5 |
| Gliclazide | 9.4 |
The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
| Intervention | kg (Median) |
|---|---|
| Sitagliptin | -0.5 |
| Gliclazide | -0.6 |
Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | dCt (Median) |
|---|---|
| Gliclazide | -1.12 |
| Sitagliptin | 0 |
Interleukin 17 levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
| Intervention | dCt (Median) |
|---|---|
| Sitagliptin | 3.41 |
| Gliclazide | 2.09 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | -0.07 |
| Gliclazide | 0.43 |
"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
| Intervention | pg/ml (Median) |
|---|---|
| Sitagliptin | 0 |
| Gliclazide | 0 |
"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Sitagliptin | 6 |
| Gliclazide | 10 |
"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks
| Intervention | score on a scale (Median) | ||||
|---|---|---|---|---|---|
| DLQI | HAQ-8 | HADS Anxiety | HADS Depression | EQ-5D | |
| Gliclazide | -1.0 | 0.0 | 0 | 0 | -0.2 |
| Sitagliptin | 0.0 | 0.0 | -1 | 0 | 0 |
"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| PASI 50 | PASI 75 | PASI 90 | |
| Gliclazide | 1 | 0 | 0 |
| Sitagliptin | 1 | 0 | 0 |
Average number of episodes of hypoglycemia per 30 days per patient (NCT00135330)
Timeframe: 20 weeks
| Intervention | hypoglycemia events / 30 days / patient (Mean) |
|---|---|
| Exenatide | 0.391 |
| Exenatide Plus Rosiglitazone | 0.594 |
| Rosiglitazone | 0.853 |
Number of subjects experiencing hypoglycemia at any point during the study (NCT00135330)
Timeframe: 20 weeks
| Intervention | participants (Number) |
|---|---|
| Exenatide | 8 |
| Exenatide Plus Rosiglitazone | 9 |
| Rosiglitazone | 6 |
Change in insulin incremental area under the concentration-time curve (ASIiAUC) from baseline to week 20. ASIiAUC is a measure of beta-cell function. (NCT00135330)
Timeframe: 20 weeks
| Intervention | uIU-min/ml (Least Squares Mean) | |
|---|---|---|
| Baseline ASIiAUC | Change in ASIiAUC at week 20 | |
| Exenatide | 643.40 | 747.26 |
| Exenatide Plus Rosiglitazone | 686.41 | 194.68 |
| Rosiglitazone | 786.12 | -99.85 |
Ratio (value at endpoint divided by value at baseline) of AUC(15-180 min) for C-peptide (nmol-min/L) during a MCT from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | nmol-min/L (Geometric Mean) | |
|---|---|---|
| Baseline C-peptide during a MCT | Ratio(endpoint/baseline) of C-peptide during a MCT | |
| Exenatide | 319.77 | 0.908 |
| Exenatide Plus Rosiglitazone | 310.51 | 0.804 |
| Rosiglitazone | 325.65 | 0.854 |
Change in AUC(15-180 min) for glucose during a MCT baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol-min/L (Least Squares Mean) | |
|---|---|---|
| Baseline glucose AUC during MCT | Change in glucose AUC during MCT at week 20 | |
| Exenatide | 1782.86 | -560.12 |
| Exenatide Plus Rosiglitazone | 1799.68 | -635.24 |
| Rosiglitazone | 1741.87 | -425.59 |
Change in body fat mass form baseline to week 20, as assessed during an MCT (NCT00135330)
Timeframe: 20 weeks
| Intervention | kg (Least Squares Mean) | |
|---|---|---|
| Baseline body fat mass | Change in body fat mass at week 20 | |
| Exenatide | 32.05 | -2.76 |
| Exenatide Plus Rosiglitazone | 32.55 | -1.06 |
| Rosiglitazone | 30.54 | -1.99 |
Change in body weight from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | kg (Least Squares Mean) | |
|---|---|---|
| Baseline body weight | Change in body weight at week 20 | |
| Exenatide | 93.05 | -2.82 |
| Exenatide Plus Rosiglitazone | 93.76 | -1.21 |
| Rosiglitazone | 91.78 | 1.48 |
Change in fasting high-density lipoprotein (HDL) cholesterol from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Least Squares Mean) | |
|---|---|---|
| Baseline HDL | Change from baseline HDL at week 20 | |
| Exenatide | 1.13 | 0.022 |
| Exenatide Plus Rosiglitazone | 1.17 | 0.046 |
| Rosiglitazone | 1.17 | 0.055 |
Change in fasting insulin from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | uIU/ml (Geometric Mean) | |
|---|---|---|
| Baseline fasting insulin | Ratio (wk20/baseline)of fasting insulin | |
| Exenatide | 12.84 | 0.980 |
| Exenatide Plus Rosiglitazone | 10.96 | 0.599 |
| Rosiglitazone | 12.77 | 0.755 |
Change in fasting low-density lipoprotein (LDL) cholesterol from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Least Squares Mean) | |
|---|---|---|
| Baseline LDL | Change from baseline LDL at week 20 | |
| Exenatide | 2.59 | -0.049 |
| Exenatide Plus Rosiglitazone | 2.57 | 0.096 |
| Rosiglitazone | 2.71 | 0.334 |
Ratio (endpoint value divided by baseline value) for fasting proinsulin, comparing endpoint (week 20) to baseline (NCT00135330)
Timeframe: Week 20
| Intervention | pmol/L (Geometric Mean) | |
|---|---|---|
| Baseline fasting proinsulin | Ratio(wk20/baseline)of fasting proinsulin | |
| Exenatide | 4.32 | 0.663 |
| Exenatide Plus Rosiglitazone | 3.80 | 0.538 |
| Rosiglitazone | 3.56 | 0.623 |
Change in fasting serum glucose concentration from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Least Squares Mean) | |
|---|---|---|
| Baseline fasting serum glucose | Change fr baseline fasting serum glucose at wk 20 | |
| Exenatide | 8.42 | -1.46 |
| Exenatide Plus Rosiglitazone | 8.43 | -1.60 |
| Rosiglitazone | 8.48 | -1.80 |
Change in fasting total cholestrol from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Least Squares Mean) | |
|---|---|---|
| Baseline total cholesterol | Change fr baseline total cholesterol at week 20 | |
| Exenatide | 4.42 | -0.128 |
| Exenatide Plus Rosiglitazone | 4.41 | 0.258 |
| Rosiglitazone | 4.62 | 0.438 |
Ratio (endpint value divided by baseline value) of fasting triglycerides from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Geometric Mean) | |
|---|---|---|
| Baseline triglyceride | Ratio (endpoint/baseline) for triglycerides | |
| Exenatide | 1.56 | 0.861 |
| Exenatide Plus Rosiglitazone | 1.67 | 0.977 |
| Rosiglitazone | 1.76 | 0.992 |
Change in HbA1c from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | Percentage (Least Squares Mean) | |
|---|---|---|
| Baseline HbA1c | Change from baseline HbA1c at week 20 | |
| Exenatide | 7.79 | -0.908 |
| Exenatide Plus Rosiglitazone | 7.84 | -1.31 |
| Rosiglitazone | 7.92 | -0.968 |
Change in hip circumference form baseline to week 20 (NCT00135330)
Timeframe: 20 weeks
| Intervention | cm (Least Squares Mean) | |
|---|---|---|
| Baseline hip circumference | Change in hip circumference at week 20 | |
| Exenatide | 113.29 | -1.28 |
| Exenatide Plus Rosiglitazone | 112.12 | 0.147 |
| Rosiglitazone | 111.90 | 1.51 |
Change in incremental for postprandial C-peptide (mmol/L) during MCT from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Least Squares Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline C-peptide at 15 min | Change fr baseline C-peptide at 15 min at week 20 | Baseline C-peptide at 30 min | Change fr baseline C-peptide at 30 min at week 20 | Baseline C-peptide at 60 min | Change fr baseline C-peptide at 60 min at week 20 | Baseline C-peptide at 90 min | Change fr baseline C-peptide at 90 min at week 20 | Baseline C-peptide at 120 min | Change fr baseline C-peptide at 120 min at week 20 | Baseline C-peptide at 150 min | Change fr baseline C-peptide at 150 min at week 20 | Baseline C-peptide at 180 min | Change fr baseline C-peptide at 180 min at week 20 | |
| Exenatide | 0.238 | -0.006 | 0.521 | -0.071 | 0.818 | -0.148 | 0.895 | -0.185 | 0.817 | -0.259 | 0.843 | -0.251 | 0.610 | -0.075 |
| Exenatide Plus Rosiglitazone | 0.259 | 0.016 | 0.517 | -0.036 | 0.871 | -0.025 | 0.953 | -0.117 | 0.828 | -0.134 | 0.651 | -0.254 | 0.482 | -0.238 |
| Rosiglitazone | 0.206 | 0.087 | 0.560 | 0.099 | 0.881 | 0.054 | 1.03 | -0.052 | 0.972 | -0.016 | 0.813 | -0.093 | 0.619 | -0.092 |
Change in incremental for postprandial glucose (mmol/L) during a MCT from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Least Squares Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline glucose at 15 min | Change fr baseline glucose at 15 min at wk 20 | Baseline glucose at 30 min | Change fr baseline glucose at 30 min at wk 20 | Baseline glucose at 60 minutes | Change fr baseline glucose at 60 min at wk 20 | Baseline glucose at 90 minutes | Change fr baseline glucose at 90 min at wk 20 | Baseline glucose at 120 minutes | Change fr baseline glucose at 120 min at wk 20 | Baseline glucose at 150 minutes | Change fr baseline glucose at 150 min at wk 20 | Baseline glucose at 180 minutes | Change fr baseline glucose at 180 min at wk 20 | |
| Exenatide | 0.950 | -0.651 | 2.39 | -1.46 | 3.59 | -2.56 | 3.24 | -2.87 | 2.49 | -2.24 | 1.62 | -1.42 | 0.461 | -0.583 |
| Exenatide Plus Rosiglitazone | 1.12 | -0.286 | 2.54 | -1.06 | 3.88 | -2.46 | 3.36 | -2.91 | 2.24 | -2.52 | 1.14 | -1.95 | 0.036 | -0.995 |
| Rosiglitazone | 0.828 | 0.150 | 2.23 | -0.066 | 3.48 | -0.720 | 3.48 | -0.952 | 2.31 | -0.912 | 1.25 | -0.830 | 0.279 | -0.481 |
Change in incremental for postprandial insulin (mmol/L) during meal challenge test (MCT) from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mmol/L (Least Squares Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline insulin at 15 min | Change fr baseline insulin at 15 min at wk 20 | Baseline insulin at 30 min | Change fr baseline insulin at 30 min at wk 20 | Baseline insulin at 60 min | Change fr baseline insulin at 60 min at wk 20 | Baseline insulin at 90 min | Change fr baseline insulin at 90 min at wk 20 | Baseline insulin at 120 min | Change fr baseline insulin at 120 min at wk 20 | Baseline insulin at 150 min | Change fr baseline insulin at 150 min at wk 20 | Baseline insulin at 180 min | Change fr baseline insulin at 180 min at wk 20 | |
| Exenatide | 9.97 | -1.71 | 19.81 | -3.00 | 27.92 | -11.04 | 26.06 | -9.42 | 19.56 | -11.26 | 15.67 | -7.48 | 10.58 | 0.031 |
| Exenatide Plus Rosiglitazone | 8.09 | -1.84 | 14.79 | -2.63 | 27.67 | -7.47 | 21.85 | -9.27 | 17.52 | -8.69 | 12.74 | -8.13 | 8.18 | -5.26 |
| Rosiglitazone | 7.53 | -0.455 | 18.83 | -1.04 | 32.09 | -7.42 | 32.25 | -6.19 | 25.47 | -6.43 | 18.11 | -5.57 | 10.74 | -4.04 |
"Change in insulin AUC in the first stage(uIU-min/ml) from baseline to week 20. First stage represents the first 10 minutes after reaching a steady state during a hyperglycemic clamp test." (NCT00135330)
Timeframe: Week 20
| Intervention | uIU-min/ml (Least Squares Mean) | |
|---|---|---|
| Baseline insulin AUC | Change from baseline insulin AUC at week 20 | |
| Exenatide | 200.50 | 134.88 |
| Exenatide Plus Rosiglitazone | 136.84 | 32.12 |
| Rosiglitazone | 157.49 | -50.81 |
"Change in insulin iAUC in the first stage(uIU-min/ml) from baseline to week 20. First stage represents the first 10 minutes after reaching a steady state during a hyperglycemic clamp test." (NCT00135330)
Timeframe: Week 20
| Intervention | uIU-min/ml (Least Squares Mean) | |
|---|---|---|
| Baseline insulin iAUC | Change from baseline insulin iAUC at week 20 | |
| Exenatide | 5.98 | 99.08 |
| Exenatide Plus Rosiglitazone | -9.92 | 53.71 |
| Rosiglitazone | 23.09 | 11.51 |
Change of M-Value (mg/kg-min) during hyperinsulinemic euglycemic clamp test from baseline to week 20. (NCT00135330)
Timeframe: Week 20
| Intervention | mg/kg-min (Least Squares Mean) | |
|---|---|---|
| M-Value at baseline | Change in M-Value from baseline at week 20 | |
| Exenatide | 3.89 | 0.477 |
| Exenatide Plus Rosiglitazone | 2.49 | 2.07 |
| Rosiglitazone | 4.02 | 1.42 |
Change in lean body mass from baseline to week 20, as assessed during an MCT (NCT00135330)
Timeframe: 20 weeks
| Intervention | kg (Least Squares Mean) | |
|---|---|---|
| Baseline lean body mass | Change in lean body mass at week 20 | |
| Exenatide | 64.62 | -2.99 |
| Exenatide Plus Rosiglitazone | 60.94 | 0.532 |
| Rosiglitazone | 61.09 | 1.23 |
Change in percent body fat from baseline to week 20, as assessed during an MCT (NCT00135330)
Timeframe: 20 weeks
| Intervention | percentage (Least Squares Mean) | |
|---|---|---|
| Baseline percent body fat | Change in percent body fat at week 20 | |
| Exenatide | 33.42 | -1.40 |
| Exenatide Plus Rosiglitazone | 34.07 | -0.347 |
| Rosiglitazone | 32.50 | -1.18 |
Change in waist circumference from baseline to week 20 (NCT00135330)
Timeframe: 20 weeks
| Intervention | cm (Least Squares Mean) | |
|---|---|---|
| Baseline waist circumference | Change in waist circumference at Week 20 | |
| Exenatide | 105.98 | -2.95 |
| Exenatide Plus Rosiglitazone | 106.85 | -2.38 |
| Rosiglitazone | 105.34 | -0.225 |
Change in waist-to-hip ratio (waist circumference divided by hip circumference) from baseline to week 20 (NCT00135330)
Timeframe: 20 weeks
| Intervention | ratio (cm/cm) (Least Squares Mean) | |
|---|---|---|
| Baseline waist-to-hip ratio | Change in waist-to-hip ratio at week 20 | |
| Exenatide | 0.939 | -0.016 |
| Exenatide Plus Rosiglitazone | 0.957 | -0.022 |
| Rosiglitazone | 0.943 | -0.016 |
"Pedal edema scores experienced by each patient throughout the study (1+ indicates a patient experienced a pedal edema score of 1 , 2, or 3; 2+ indicates a patient experienced a pedal edema score of 2 or 3, etc.)~Scale:~Slight pitting, no visible distortion, disappears rapidly~A somewhat deeper pit than in 1+, but again no readily detectable distortion, and it disappears in 10 - 15 seconds~The pit is noticeably deep and may last more than a minute; the dependent extremity looks fuller and swollen~The pit is very deep, lasts as long as 2 - 5 minutes, and the dependent extremity is grossly distorted" (NCT00135330)
Timeframe: 20 weeks
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| No edema | Edema score: 1+ | Edema score: 2+ | Edema score: 3+ | |
| Exenatide | 37 | 7 | 1 | 0 |
| Exenatide Plus Rosiglitazone | 34 | 11 | 3 | 0 |
| Rosiglitazone | 30 | 14 | 6 | 1 |
Ratio (value at endpoint divided by value at baseline) of AUC (15-180 min) for insulin (uIU-min/ml) during MCT. (NCT00135330)
Timeframe: Week 20
| Intervention | uIU-min/ml (Geometric Mean) | |
|---|---|---|
| Baseline AUC for insulin during MCT | Ratio(endpoint/baseline) of insulin AUC during MCT | |
| Exenatide | 5171.40 | 0.806 |
| Exenatide Plus Rosiglitazone | 4324.13 | 0.664 |
| Rosiglitazone | 5816.83 | 0.722 |
Change in body fat mass measured by air displacement plethysmography (kg) (NCT00005669)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | -1.51 |
| Placebo Plus Weight Reduction Counseling | 1.81 |
Change in body fat mass by Dual Energy X-Ray Absorptiometry (kg) (NCT00005669)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | 0.48 |
| Placebo Plus Weight Reduction Counseling | 1.88 |
Change in body weight (kg) (NCT00005669)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | 1.47 |
| Placebo Plus Weight Reduction Counseling | 4.85 |
Change in body weight as determined by body mass index (kg/m2) (NCT00005669)
Timeframe: 6 months
| Intervention | kg/m2 (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | -0.78 |
| Placebo Plus Weight Reduction Counseling | 0.32 |
Change in Body Mass Index standard deviation score (BMI-SDS) determined using tables created by the CDC in 2000. BMI-SDS is a unitless transformation of the body mass index (measured in kg divided by the squared height in meters) using the L M S method. Possible values range from -3 to +3. See http://www.cdc.gov/growthcharts/percentile_data_files.htm for details. (NCT00005669)
Timeframe: 6 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | -0.11 |
| Placebo Plus Weight Reduction Counseling | -0.07 |
(NCT01722266)
Timeframe: 12 weeks
| Intervention | grams (Mean) |
|---|---|
| Placebo | -13.4 |
| Liraglutide 1.8mg | -46.4 |
| Liraglutide 1.2mg | -47.6 |
| Liraglutide 0.6 mg | -23.7 |
(NCT01722266)
Timeframe: Baseline and 12 weeks
| Intervention | Kg (Mean) |
|---|---|
| Placebo | -0.3 |
| Liraglutide 1.8mg | -4.8 |
| Liraglutide 1.2mg | -5.0 |
| Liraglutide 0.6 mg | -2.7 |
(NCT01722266)
Timeframe: Baseline and 12 Weeks
| Intervention | Percent (Mean) |
|---|---|
| Placebo | -0.30 |
| Liraglutide 1.8mg | -0.42 |
| Liraglutide 1.2mg | -0.78 |
| Liraglutide 0.6 mg | -0.26 |
The primary endpoint of the study is to detect a difference from baseline in mean weekly blood glucose concentrations before and after 12 weeks of treatment in each of the Liraglutide groups. (NCT01722266)
Timeframe: 12 Weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | 1 |
| Liraglutide 1.8mg | -10 |
| Liraglutide 1.2mg | -10 |
| Liraglutide 0.6 mg | -0.3 |
Total insulin dose = Basal insulin dose plus bolus insulin dose. (NCT01722266)
Timeframe: Baseline and 12 weeks
| Intervention | Units (Mean) |
|---|---|
| Placebo | -3.4 |
| Liraglutide 1.8mg | -10 |
| Liraglutide 1.2mg | -12.1 |
| Liraglutide 0.6 mg | -2.8 |
24 hour blood pressure measurements were performed after each treatment/diet phase (NCT01090752)
Timeframe: march 2009
| Intervention | mmHg (Mean) |
|---|---|
| Pioglitazone Low Salt/High Salt | 128 |
| Placebo Low Salt/High Salt | 129 |
At the end of each treatment diet phase, renal clearances were performed for the determination of GFR and RBF (NCT01090752)
Timeframe: 2008
| Intervention | ml/min/1.73m2 (Mean) |
|---|---|
| Pioglitazone Low Salt/High Salt | 68.0 |
| Placebo Low Salt/High Salt | 62.4 |
At the end of each treatment and diet phase, 24 urine collections were collected for the determination of sodium and lithium clearances (NCT01090752)
Timeframe: 2007
| Intervention | ml/min (Mean) |
|---|---|
| Pioglitazone Low Salt/High Salt | 1.05 |
| Placebo Low Salt/High Salt | 1.18 |
The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | μg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 6.79 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.72 |
The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -1.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.1 |
The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -3.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.5 |
The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 1.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.4 |
The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.5 |
The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.1 |
The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -.15 |
The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.1 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.4 |
The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.3 |
The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -21.6 |
| Glimepiride 2 mg and Metformin 850 mg BID | -21.1 |
The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -5.18 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.11 |
The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.83 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.95 |
The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/L (Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.87 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.00 |
The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -0.21 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.04 |
The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.4 |
The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 0.1 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.3 |
The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 9.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 11.2 |
The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 6.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | 6.1 |
The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 31.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | 51.6 |
The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | nmol/L (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -2.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 32.5 |
The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | sec (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -30.3 |
| Glimepiride 2 mg and Metformin 850 mg BID | -1.0 |
The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -40.7 |
| Glimepiride 2 mg and Metformin 850 mg BID | 102.4 |
The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -13.0 |
| Glimepiride 2 mg and Metformin 850 mg BID | -3.2 |
The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 11.6 |
| Glimepiride 2 mg and Metformin 850 mg BID | 3.3 |
The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -2.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | 0.5 |
The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | pg/mL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -216.4 |
| Glimepiride 2 mg and Metformin 850 mg BID | 527.8 |
The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -40.9 |
| Glimepiride 2 mg and Metformin 850 mg BID | -16.7 |
The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | percent (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | -19.5 |
| Glimepiride 2 mg and Metformin 850 mg BID | 1.4 |
The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | participants (Number) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 136 |
| Glimepiride 2 mg and Metformin 850 mg BID | 137 |
The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline. (NCT00770653)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone 15 mg and Metformin 850 mg BID | 3.2 |
| Glimepiride 2 mg and Metformin 850 mg BID | -0.3 |
"Mu-opioid binding potential in left amygdala measured before and after 4 months of Metformin treatment.~Mu-opioid binding potential is measured in vivo with C11-carfentanil positron emission tomography in women with PCOS before and after 4 months of metformin treatment.~Binding Potential is measured by the ratio of Mu-opioid receptor concentration (Bmax)/Receptor radiotracer (C11-carfentanil) affinity (Kd.)" (NCT00670800)
Timeframe: Baseline and after 4 months
| Intervention | ratio (Mean) |
|---|---|
| PCOS Affected Women Pre-Metformin (Baseline) | 2.28 |
| PCOS Affected Women Post-Metformin (After 4 Months) | 2.08 |
| Normal Controls | 2.03 |
"Mu-opioid binding potential in left nucleus accumbens is measured before and after 4 months of Metformin treatment.~Mu-opioid binding potential is measured in vivo with C11-carfentanil positron emission tomography in women with PCOS before and after 4 months of metformin treatment.~Binding Potential is measured by the ratio of Mu-opioid receptor concentration (Bmax)/Receptor radiotracer (C11-carfentanil) affinity (Kd.)~Control group was measured at baseline only." (NCT00670800)
Timeframe: Baseline and after 4 months
| Intervention | ratio (Mean) |
|---|---|
| PCOS Affected Women Pre-Metformin (Baseline) | 1.95 |
| PCOS Affected Women Post-Metformin (After 4 Months) | 1.65 |
| Normal Controls | 1.53 |
"Mu-opioid binding potential in right amygdala measured before and after 4 months of Metformin treatment.~Mu-opioid binding potential is measured in vivo with C11-carfentanil positron emission tomography in women with PCOS before and after 4 months of metformin treatment.~Binding Potential is measured by the ratio of Mu-opioid receptor concentration (Bmax)/Receptor radiotracer (C11-carfentanil) affinity (Kd.)~Control group was measured at baseline only." (NCT00670800)
Timeframe: Baseline and 4 months
| Intervention | ratio (Mean) |
|---|---|
| PCOS Affected Women Pre-Metformin (Baseline) | 2.28 |
| PCOS Affected Women Post-Metformin (After 4 Months) | 2.11 |
| Normal Controls | 2.06 |
"Mu-opioid binding potential in right nucleus accumbens measured before and after 4 months of Metformin treatment.~Mu-opioid binding potential is measured in vivo with C11-carfentanil positron emission tomography in women with PCOS before and after 4 months of metformin treatment.~Binding Potential is measured by the ratio of Mu-opioid receptor concentration (Bmax)/Receptor radiotracer (C11-carfentanil) affinity (Kd.)~Control group was measured at baseline only." (NCT00670800)
Timeframe: Baseline and after 4 months
| Intervention | ratio (Mean) |
|---|---|
| PCOS Affected Women Pre-Metformin (Baseline) | 2.40 |
| PCOS Affected Women Post-Metformin (After 4 Months) | 2.11 |
| Normal Control Women | 2.05 |
Insulin sensitivity as measured by a combination of insulin sensitivity index (ISI) which should go up after 3 month treatment period to show improvement, and insulin sensitivity (SI) which should go down after 3 month treatment period to show improvement. Note that the ISI as developed by Matsuda and DeFronzo from a calculation based on results from a standard oral glucose tolerance test (OGTT) (doi: 10.2337/diacare.22.9.1462 Diabetes Care September 1999 vol. 22 no. 9 1462-1470) is recorded as units on an arbitrary scale. SI data is based on a calculation derived from analysis of results of frequently sampled intravenous glucose tolerance test (FSIVGTT) by Bergman et al (doi:10.1172/JCI112886/J Clin Invest. 1987;79(3):790-800) and is reported with units min-1/(µlU/L). (NCT00682890)
Timeframe: baseline and 3 months
| Intervention | min-1/(µlU/L) (Mean) | ||
|---|---|---|---|
| SI at baseline | SI at 3 months | SI change vs baseline | |
| Metformin | 3.83 | 2.11 | -1.72 |
| Placebo | 2.26 | 2.8 | 0.544 |
Insulin sensitivity as measured by a combination of insulin sensitivity index (ISI) which should go up after 3 month treatment period to show improvement, and insulin sensitivity (SI) which should go down after 3 month treatment period to show improvement. Note that the ISI as developed by Matsuda and DeFronzo from a calculation based on results from a standard oral glucose tolerance test (OGTT) (doi: 10.2337/diacare.22.9.1462 Diabetes Care September 1999 vol. 22 no. 9 1462-1470) is recorded as units on an arbitrary scale. SI data is based on a calculation derived from analysis of results of frequently sampled intravenous glucose tolerance test (FSIVGTT) by Bergman et al (doi:10.1172/JCI112886/J Clin Invest. 1987;79(3):790-800) and is reported with units min-1/(µlU/L). (NCT00682890)
Timeframe: baseline and 3 months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| ISI at baseline | ISI at month 3 | ISI change vs baseline | |
| Metformin | 7.3 | 5.9 | -1.4 |
| Placebo | 4.7 | 4.4 | -0.3 |
(NCT00006305)
Timeframe: five years
| Intervention | participants (Number) |
|---|---|
| Revascularization and Insulin Providing (IP) | 80 |
| Revascularization and Insulin Sensitizing (IS) | 75 |
| Medical Therapy and Insulin Providing (IP) | 80 |
| Medical Therapy and Insulin Sensitizing (IS) | 81 |
(NCT00006305)
Timeframe: five years
| Intervention | participants (Number) |
|---|---|
| Revascularization and Insulin Providing (IP) | 145 |
| Revascularization and Insulin Sensitizing (IS) | 121 |
| Medical Therapy and Insulin Providing (IP) | 143 |
| Medical Therapy and Insulin Sensitizing (IS) | 140 |
Change from baseline in Adiponectin after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | µg/mL (Mean) |
|---|---|
| Metformin | -0.71 |
| Placebo | -7.52 |
Change from baseline in Body Mass Index after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | kg/m^2 (Mean) |
|---|---|
| Metformin | -0.74 |
| Placebo | -0.71 |
Change from baseline in Fasting insulin after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | µU/mL (Mean) |
|---|---|
| Metformin | -3.97 |
| Placebo | 11.03 |
Change from baseline in Fasting plasma glucose after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin | -1.08 |
| Placebo | 1.71 |
Change from baseline in High-sensitivity C-reactive protein after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin | -1.26 |
| Placebo | -1.35 |
Change from baseline in Interleukin 6 after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | pg/mL (Mean) |
|---|---|
| Metformin | -34.09 |
| Placebo | 16.42 |
Change from baseline in Tumour necrosis factor alpha after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | pg/mL (Mean) |
|---|---|
| Metformin | -34.08 |
| Placebo | -4.01 |
Change from baseline in Waist circumference after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | cm (Mean) |
|---|---|
| Metformin | -0.57 |
| Placebo | -3.29 |
Peak VO2 after 4 months of intervention with either metformin or placebo. The Mean difference between baseline and after 4 months was analyzed using t-test comparing metformin and placebo. (NCT00473876)
Timeframe: 4 months
| Intervention | ml/kg/min (Mean) |
|---|---|
| Metformin Arm | -0.38 |
| Placebo | 3.6 |
VE/VCO2 Slope, measurement of the abnormal ventilatory response to exercise identified by an increased slope of ventilation (L/min) vs. CO2 production (VE/VCO2) (L/min) to incremental workload (NCT00473876)
Timeframe: 4 months
| Intervention | Unitless (Mean) |
|---|---|
| Metformin Arm | -4.45 |
| Placebo | -0.23 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
The ability of serum HDL to remove cholesterol from cultured cells will be assessed as an in vitro method to evaluate a functional changes in HDL mediated by changes due to pioglitazone treatment. Cells were incubated with 2% serum from each study subject diluted in culture medium and incubations were performed for a total of 4 hours. Cholesterol efflux was calculated as the percent of cholesterol removed from the cells and appearing in the culture medium normalized to a reference serum pool as described in detail by de la Llera-Moya et al (de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801. doi: 10.1161/ATVBAHA.109.199158. PMID: 20075420). (NCT01156597)
Timeframe: 24 weeks
| Intervention | Ratio (Mean) |
|---|---|
| Pioglitazone Group | 1.02 |
| Comparator Group | 1.05 |
Lipoproteins will be isolated and analyzed using the gradient ultracentrifugation-high pressure liquid chromatography technique to isolate very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), LDL, and high density lipoprotein (HDL) subfractions. Protein and lipid compositions of HDL is determined (NCT01156597)
Timeframe: 24 weeks
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| HDL-apoAI at end point | HDL-apoAII at end point | HDL-apoCI at end point | HDL-apoCII at end point | HDL-apoCIII at end point | HDL-apoM at end point | |
| Comparator Group | 65.7 | 22.6 | 8.4 | 2.8 | 12.5 | 0.43 |
| Pioglitazone Group | 65.0 | 26.6 | 10.9 | 3.5 | 11.8 | 0.62 |
"The primary endpoint will be increased high density lipoprotein cholesterol and decreased triglycerides measured as the difference after 12 or 24 weeks of treatment from baseline levels. The data are expressed as the percent change from the baseline value and calculated using he equation:~Change=[100%*(Endpoint value - Baseline Value)/Baseline Value]" (NCT01156597)
Timeframe: 24 weeks
| Intervention | % Change (Mean) | |||
|---|---|---|---|---|
| % Change in HDL cholesterol at 12 weeks | % Change in HDL cholesterol at 24 weeks | % Change in triglycerides at 12 weeks | % Change in triglycerides at 24 weeks | |
| Comparator Group | 2.7 | -1.5 | 7.4 | 19.7 |
| Pioglitazone Group | 7.9 | 15.7 | -10.9 | -15.4 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
Change in disposition index (DI, insulin secretion corrected for insulin secretion) as measured by frequently-sampled IV glucose tolerance test (DI at study endpoint - baseline DI) (NCT00442689)
Timeframe: 6 months
| Intervention | min^-1 (Mean) |
|---|---|
| Oral Contraceptive - 1 | 1653 |
| Flutamide - 2 | 194 |
| Placebo - 3 | -184 |
Change in fat percentage as measured by DEXA scan over the study period (Fat percentage at study endpoint - baseline fat percentage) (NCT00442689)
Timeframe: 6 months
| Intervention | percentage of body mass (Mean) |
|---|---|
| Oral Contraceptive - 1 | 0.4 |
| Flutamide - 2 | -1.9 |
| Placebo - 3 | -1.9 |
Change in high-density lipoprotein (HDL) levels during study period (HDL level at study endpoint - baseline HDL) (NCT00442689)
Timeframe: 6 months
| Intervention | mg/dL (Mean) |
|---|---|
| Oral Contraceptive - 1 | 6 |
| Flutamide - 2 | -5 |
| Placebo - 3 | -2 |
Change in low-density lipoprotein (LDL) levels over the study period (LDL level at study endpoint - baseline LDL level) (NCT00442689)
Timeframe: 6 months
| Intervention | mg/dL (Mean) |
|---|---|
| Oral Contraceptive - 1 | -6 |
| Flutamide - 2 | -9 |
| Placebo - 3 | -7 |
Change in maximal aerobic exercise capacity (VO2 max) over the study period (VO2 max at study endpoint - baseline VO2 max) (NCT00442689)
Timeframe: 6 months
| Intervention | L/min (Mean) |
|---|---|
| Oral Contraceptive - 1 | -0.5 |
| Flutamide - 2 | -1.6 |
| Placebo - 3 | 1.1 |
Change in resting energy expenditure (REE) over the study period (REE at study endpoint - baseline REE) (NCT00442689)
Timeframe: 6 months
| Intervention | Kcal/day (Mean) |
|---|---|
| Oral Contraceptive - 1 | 7 |
| Flutamide - 2 | -79 |
| Placebo - 3 | -88 |
Change in visceral adipose tissue (VAT) volume as measured by MRI (VAT at study endpoint - baseline VAT) (NCT00442689)
Timeframe: 6 months
| Intervention | L (Mean) |
|---|---|
| Oral Contraceptive - 1 | -0.1 |
| Flutamide - 2 | -0.1 |
| Placebo - 3 | 0.1 |
Area Under Curve from 0 to 72 hours (AUCt) (NCT04964193)
Timeframe: before dosing (0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 15, 24, 36, 48 and 72 hours after dosing
| Intervention | pg*hr/mL (Mean) | |
|---|---|---|
| AUC0-t of Cyproterone Acetate | AUC0-t of Ethinyl Estradiol | |
| Diane-35 Sugar-coated Tablet | 127.54 | 842.56 |
| Elzsa Film-coated Tablet | 132.56 | 870.45 |
Maximum plasma concentration (Cmax) (NCT04964193)
Timeframe: before dosing (0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 15, 24, 36, 48 and 72 hours after dosing
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Cmax of Cyproterone Acetate | Cmax of Ethinyl Estradiol | |
| Diane-35 Sugar-coated Tablet | 16.20 | 93.61 |
| Elzsa Film-coated Tablet | 17.39 | 103.69 |
(NCT00105066)
Timeframe: Baseline and 4.5 months
| Intervention | meters / second (Mean) |
|---|---|
| Placebo | -7.2 |
| Metformin | -7.3 |
to evaluate improvement in endothelial function (NCT00105066)
Timeframe: Baseline and 4.5 months
| Intervention | percentage change in diameter (Mean) |
|---|---|
| Placebo | 8.8 |
| Metformin | 10.5 |
Homeostatic Model Assessment of insulin sensitivity (NCT00105066)
Timeframe: 4.5 months
| Intervention | HOMA Score (Mean) |
|---|---|
| Placebo | 57.4 |
| Metformin | 64.5 |
350 reviews available for metformin and Insulin Sensitivity
| Article | Year |
|---|---|
New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Cancer: Nonapoptotic Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway.
Topics: Aging; AMP-Activated Protein Kinases; Blood Glucose; Cell Death; Diabetes Mellitus, Type 2; Diabetic | 2021 |
Metabolomic Approaches to Investigate the Effect of Metformin: An Overview.
Topics: Animals; Biomarkers; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Met | 2021 |
Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acarbose; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Insulin; Insulin Resistance; Metform | 2022 |
Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance.
Topics: Androgens; Electron Transport; Feedback, Physiological; Female; Humans; Hyperandrogenism; Hyperinsul | 2022 |
The use of metformin in women with polycystic ovary syndrome: an updated review.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertility, Female; Insu | 2022 |
Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport.
Topics: Animals; Female; Gene Expression; Glucose; Glucose Transport Proteins, Facilitative; Glucose Transpo | 2022 |
Metformin in Differentiated Thyroid Cancer: Molecular Pathways and Its Clinical Implications.
Topics: Adenocarcinoma; Cell Cycle; Cell Proliferation; Diabetes Mellitus, Type 2; Humans; Insulin Resistanc | 2022 |
Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial.
Topics: Female; Folic Acid; Humans; Inositol; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndr | 2022 |
Updates on Molecular Targets and Epigenetic-Based Therapies for PCOS.
Topics: Female; Humans; Hyperandrogenism; Infertility; Insulin Resistance; Metformin; Polycystic Ovary Syndr | 2023 |
Polycystic ovary syndrome.
Topics: Female; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome | 2022 |
Diabetes mellitus and endometrial carcinoma: Risk factors and etiological links.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Humans; Hypoglycemic Ag | 2022 |
Acupuncture combined with metformin versus metformin alone to improve pregnancy rate in polycystic ovary syndrome: A systematic review and meta-analysis.
Topics: Acupuncture Therapy; Female; Humans; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Pregn | 2022 |
Metformin's Impact on the Microvascular Response to Insulin.
Topics: Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Oxidative Stress | 2022 |
Mechanism of metformin regulation in central nervous system: Progression and future perspectives.
Topics: AMP-Activated Protein Kinases; Central Nervous System; Diabetes Mellitus, Type 2; Humans; Hypoglycem | 2022 |
Effect of sodium-glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Sodi | 2023 |
Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology.
Topics: Class I Phosphatidylinositol 3-Kinases; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Metfo | 2022 |
Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure.
Topics: Diabetes Mellitus, Type 2; Growth Differentiation Factor 15; Humans; Insulin Resistance; Metformin; | 2022 |
Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure.
Topics: Diabetes Mellitus, Type 2; Growth Differentiation Factor 15; Humans; Insulin Resistance; Metformin; | 2022 |
Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure.
Topics: Diabetes Mellitus, Type 2; Growth Differentiation Factor 15; Humans; Insulin Resistance; Metformin; | 2022 |
Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure.
Topics: Diabetes Mellitus, Type 2; Growth Differentiation Factor 15; Humans; Insulin Resistance; Metformin; | 2022 |
Long-term use of metformin and Alzheimer's disease: beneficial or detrimental effects.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Diabetes Mellitus, Type 2; Disease Models, | 2023 |
The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM).
Topics: Diabetes Mellitus, Type 2; Fibroblast Growth Factors; Glucose; Humans; Insulin Resistance; Metformin | 2023 |
Lights and shadows on the use of metformin in pregnancy: from the preconception phase to breastfeeding and beyond.
Topics: Abortion, Spontaneous; Breast Feeding; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Hum | 2023 |
Alpha Lipoic Acid Efficacy in PCOS Treatment: What Is the Truth?
Topics: Antioxidants; Diabetes Mellitus, Type 2; Female; Humans; Inositol; Insulin; Insulin Resistance; Metf | 2023 |
The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Metformin; Polycystic Ov | 2023 |
The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
Topics: Alanine Transaminase; Child; Humans; Insulin; Insulin Resistance; Metformin; Non-alcoholic Fatty Liv | 2023 |
Current status and frontier tracking of clinical trials on Metformin for cancer treatment.
Topics: Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Neoplasms | 2023 |
Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review.
Topics: Female; Humans; Insulin Resistance; Metformin; Periodicity; Polycystic Ovary Syndrome; Pregnancy; Pr | 2023 |
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P | 2019 |
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Topics: Androgens; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obe | 2020 |
[Pharmacological treatment of NASH].
Topics: Antioxidants; Chalcones; Chenodeoxycholic Acid; Cytoprotection; Glucagon-Like Peptide 1; Humans; Imi | 2019 |
Management of obesity in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Female; Humans; Hyperandrogenism; Insulin Resistance; Life Style; Metformin; Pediatric O | 2020 |
Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin.
Topics: Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Neoplasms; Obesi | 2020 |
Metabolic syndrome in children.
Topics: Adolescent; Anti-Obesity Agents; Bariatric Surgery; Cardiovascular Diseases; Child; Dipeptidyl-Pepti | 2020 |
Current treatment for polycystic ovary syndrome: focus on adolescence.
Topics: Adolescent; Contraceptives, Oral, Hormonal; Female; Gene-Environment Interaction; Humans; Hypoglycem | 2020 |
Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS.
Topics: Adult; Androstenedione; Blood Glucose; Female; Glucagon-Like Peptide-1 Receptor; Hormones; Humans; H | 2020 |
Polycystic ovary syndrome (PCOS) and adolescence: How can we manage it?
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Poly | 2020 |
Dissecting the interaction between COVID-19 and diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID- | 2020 |
Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies.
Topics: Diabetes Complications; Drug Resistance, Neoplasm; Endometrial Neoplasms; Estrogens; Female; Glucose | 2020 |
The feasibility of Chinese massage as an auxiliary way of replacing or reducing drugs in the clinical treatment of adult type 2 diabetes: A systematic review and meta-analysis.
Topics: Adult; Aged; Blood Glucose; Case-Control Studies; China; Combined Modality Therapy; Diabetes Mellitu | 2020 |
Metformin May Contribute to Inter-individual Variability for Glycemic Responses to Exercise.
Topics: Animals; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise; Glycemic Con | 2020 |
Shared signaling pathways in Alzheimer's and metabolic disease may point to new treatment approaches.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cerebral Cortex; Diabetes Mellitus, Type 2; Dipeptidyl-Pep | 2021 |
Insulin resistant diabetes mellitus in SHORT syndrome: case report and literature review.
Topics: Brazil; Canagliflozin; Child; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; | 2021 |
The clinical application of metformin in children and adolescents: A short update.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistanc | 2020 |
Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression-A Literature Review.
Topics: Antidepressive Agents; Depression; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Huma | 2020 |
Adipokines as a therapeutic target by metformin to improve metabolic function: A systematic review of randomized controlled trials.
Topics: Adipokines; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Sy | 2021 |
Endometrial function in women with polycystic ovary syndrome: a comprehensive review.
Topics: Endometrium; Female; Humans; Infertility, Female; Insulin Resistance; Metformin; Polycystic Ovary Sy | 2021 |
Lipid Metabolism and Relevant Disorders to Female Reproductive Health.
Topics: Diet, Reducing; Female; Humans; Insulin Resistance; Lipid Metabolism; Metformin; Obesity; Polycystic | 2021 |
Polycystic Ovary Syndrome: A Contemporary Clinical Approach.
Topics: Female; Humans; Hyperandrogenism; Insulin Resistance; Metabolic Syndrome; Metformin; Polycystic Ovar | 2021 |
Metformin administration during pregnancy - current insight.
Topics: Child; Diabetes Mellitus; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Insul | 2021 |
Efficacy and Safety of Metformin for Obesity: A Systematic Review.
Topics: Adolescent; Anti-Obesity Agents; Body Mass Index; Child; Child, Preschool; Humans; Hypoglycemic Agen | 2021 |
T helper 17 cells: A new actor on the stage of type 2 diabetes and aging?
Topics: Aging; Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformi | 2021 |
The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis.
Topics: Alanine Transaminase; Body Mass Index; Humans; Insulin Resistance; Metformin; Non-alcoholic Fatty Li | 2021 |
Metformin does not improve insulin sensitivity over hypocaloric diets in women with polycystic ovary syndrome: a systematic review of 12 studies.
Topics: Blood Glucose; Caloric Restriction; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance | 2021 |
Impact of Metformin on Cancer Biomarkers in Non-Diabetic Cancer Patients: A Systematic Review and Meta-Analysis of Clinical Trials.
Topics: Biomarkers, Tumor; Clinical Trials as Topic; Humans; Insulin; Insulin Resistance; Metformin; Neoplas | 2021 |
Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition.
Topics: Asia, Eastern; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipep | 2021 |
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome.
Topics: Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Heart Disease Risk Factors; Humans; Hypoglycemi | 2021 |
Prescribing for pregnancy: managing diabetes.
Topics: Blood Glucose Self-Monitoring; Female; Gestational Age; Humans; Hypoglycemic Agents; Insulin; Insuli | 2021 |
Repurposing metformin for covid-19 complications in patients with type 2 diabetes and insulin resistance.
Topics: COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Drug Repositioning; Humans; Insulin Resistance; | 2021 |
Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD.
Topics: Adiponectin; alpha-2-HS-Glycoprotein; Animals; Anti-Inflammatory Agents; Caloric Restriction; Humans | 2021 |
Metformin and insulin-resistant related diseases: Emphasis on the role of microRNAs.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metfor | 2021 |
The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Gastrectomy; Humans; Hyperglycemia; Hy | 2021 |
Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
Topics: Berberine; Clinical Decision-Making; Female; Humans; Hypoglycemic Agents; Inositol; Insulin; Insulin | 2021 |
Insulin sensitizers in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Age Factors; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agents; | 2017 |
THE PHYSIOLOGY BEHIND DIABETES MELLITUS IN PATIENTS WITH PHEOCHROMOCYTOMA: A REVIEW OF THE LITERATURE.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Blood Glucose; Catecholamines; Diabetes Mellitus; Diabetes Mel | 2017 |
Insulin and the polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndro | 2017 |
Insulin and the polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndro | 2017 |
Insulin and the polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndro | 2017 |
Insulin and the polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndro | 2017 |
MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Liraglutide; Metformin; Non-alcoholic Fatty | 2017 |
[Pharmacological approaches for correction of thyroid dysfunctions in diabetes mellitus].
Topics: Antioxidants; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gene Expression; Humans; Hypothy | 2017 |
Metformin - a new old drug.
Topics: Diabetes Mellitus, Type 2; Female; Glucose; Humans; Insulin Resistance; Liver; Metformin; Polycystic | 2017 |
Therapeutic approach for metabolic disorders and infertility in women with PCOS.
Topics: Androgen Antagonists; Anovulation; Clomiphene; Contraceptives, Oral, Hormonal; Female; Gonadotropins | 2018 |
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.
Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hypergl | 2018 |
Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis.
Topics: Adult; Cohort Studies; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemi | 2018 |
Management of Diabetes in Children and Adolescents.
Topics: Adolescent; Child; Child Welfare; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy | 2017 |
Gestational diabetes - is diet and insulin the only solution?
Topics: Blood Glucose; Diabetes, Gestational; Diet, Carbohydrate-Restricted; Female; Glucose Tolerance Test; | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
[The Role of Reactive Oxygen Species in the Pathogenesis of Adipocyte Dysfunction in Metabolic Syndrome. Prospects of Pharmacological Correction].
Topics: Adipocytes; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Oxidativ | 2017 |
Angiogenic Dysregulation in Pregnancy-Related Hypertension-A Role for Metformin.
Topics: Angiogenesis Inducing Agents; Animals; Endothelial Cells; Female; Humans; Hypertension, Pregnancy-In | 2018 |
Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials.
Topics: Adult; Antidepressive Agents; Blood Glucose; Clinical Trials as Topic; Depression; Diabetes Mellitus | 2018 |
Why AMPK agonists not known to be stressors may surprisingly contribute to miscarriage or hinder IVF/ART.
Topics: Abortion, Spontaneous; Adenosine Triphosphate; AMP-Activated Protein Kinase Kinases; Blastocyst; Die | 2018 |
Polycystic ovary syndrome (PCOS) and the accompanying disorders of glucose homeostasis among girls at the time of puberty.
Topics: Adolescent; Diabetes Mellitus, Type 1; Female; Homeostasis; Humans; Hyperinsulinism; Hypoglycemic Ag | 2018 |
Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management.
Topics: Animals; Carcinoma, Hepatocellular; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin Resistan | 2018 |
Metabolic Effects of Metformin in Humans.
Topics: Diabetes Mellitus, Type 2; Gluconeogenesis; Glucose; Glycogen; Humans; Hypoglycemic Agents; Insulin | 2019 |
Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review.
Topics: Adult; Body Mass Index; Body Weight; Child; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2018 |
Role of Metformin in the Treatment of Patients with Thyroid Nodules and Insulin Resistance: A Systematic Review and Meta-Analysis.
Topics: Blood Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Obesity; Overwei | 2019 |
Molecular mechanisms by which aerobic exercise induces insulin sensitivity.
Topics: Adipokines; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Glucose; Humans; Hypoglycemic Agents | 2019 |
The effects of metformin on insulin resistance in overweight or obese children and adolescents: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials.
Topics: Adolescent; Blood Glucose; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Female; Huma | 2019 |
Anti-diabetic treatment leads to changes in gut microbiome.
Topics: alpha-Glucosidases; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase | 2019 |
Myths about Insulin Resistance: Tribute to Gerald Reaven.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; History, 20th Century; History, 21st Century; Humans; Hy | 2019 |
The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials.
Topics: Biomarkers; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; | 2020 |
A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cognition; | 2019 |
Diabetes drugs in the fight against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition; Diabetes Mellitus, Type 2; Humans; Hyp | 2019 |
L-Carnitine for the treatment of a calcium channel blocker and metformin poisoning.
Topics: Aged; Antidotes; Antihypertensive Agents; Calcium Channel Blockers; Carnitine; Combined Modality The | 2013 |
Metabolic syndrome as a peculiar target for management of prostate cancer patients.
Topics: Body Composition; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Gro | 2013 |
Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review.
Topics: Adult; Clinical Trials as Topic; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin | 2013 |
Systematic review of metformin use in obese nondiabetic children and adolescents.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Life Style; Metformin; Ped | 2013 |
Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis.
Topics: Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic A | 2013 |
Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome.
Topics: Adolescent; Adult; Androstenes; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thick | 2013 |
Insulin sensitizers in polycystic ovary syndrome.
Topics: Animals; Clomiphene; Diabetes Mellitus, Type 2; Female; Humans; Hyperandrogenism; Hyperinsulinism; I | 2013 |
Metformin: do we finally have an anti-aging drug?
Topics: Aging; Animals; Carcinogenesis; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin | 2013 |
Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents.
Topics: Adipokines; Adipose Tissue; Animals; Anti-Obesity Agents; Azetidines; Ezetimibe; Fibric Acids; Gluco | 2014 |
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Re | 2013 |
The role of medications for the management of patients with NAFLD.
Topics: Antioxidants; Fatty Liver; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Me | 2014 |
Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD).
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Hepatocytes; Humans; Hypoglycemic Agents; Insu | 2014 |
Polycystic ovary syndrome: current status and future perspective.
Topics: Androgens; Disease Management; Female; Humans; Hyperandrogenism; Infertility, Female; Insulin Resist | 2014 |
[Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
Topics: Contraindications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Comb | 2013 |
Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism.
Topics: Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Non-alcoholic Fatty | 2014 |
Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances.
Topics: Adolescent; Female; Humans; Insulin Resistance; Life Style; Menopause; Metabolic Syndrome; Metformin | 2014 |
Cancer cachexia and diabetes: similarities in metabolic alterations and possible treatment.
Topics: Adipose Tissue; Animals; Cachexia; Diabetes Mellitus, Type 2; Energy Metabolism; Glucose; Humans; Hy | 2014 |
Metformin and other insulin sensitizers in polycystic ovary syndrome.
Topics: Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycyst | 2014 |
Nonalcoholic fatty liver disease and polycystic ovary syndrome.
Topics: Adiposity; Animals; Caloric Restriction; Comorbidity; Exercise; Female; Humans; Hypoglycemic Agents; | 2014 |
The therapy of insulin resistance in other diseases besides type 2 diabetes.
Topics: Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Polycystic | 2014 |
Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review.
Topics: Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Metformin; Pol | 2014 |
Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review.
Topics: Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Metformin; Pol | 2014 |
Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review.
Topics: Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Metformin; Pol | 2014 |
Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review.
Topics: Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Metformin; Pol | 2014 |
Effects of metformin on weight loss: potential mechanisms.
Topics: Appetite Depressants; Diabetes Mellitus, Type 2; Eating; Humans; Hypoglycemic Agents; Hypothalamus; | 2014 |
[Metformin in pregnancy].
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycysti | 2014 |
What are the pharmacotherapy options for treating prediabetes?
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance | 2014 |
Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin | 2015 |
Obesity and polycystic ovary syndrome.
Topics: Adipokines; Bariatric Surgery; Combined Modality Therapy; Comorbidity; Diet, Reducing; Exercise Ther | 2015 |
Koschei the immortal and anti-aging drugs.
Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Caloric Restriction; Exercise; Folklore; G | 2014 |
Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Re | 2015 |
Polycystic ovary syndrome and insulin: our understanding in the past, present and future.
Topics: Androgens; Anovulation; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyc | 2015 |
An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials.
Topics: C-Reactive Protein; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutar | 2015 |
Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoprevention; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; | 2015 |
Metabolic Syndrome: Insulin Resistance and Prediabetes.
Topics: Bariatric Surgery; Diabetes Mellitus, Type 2; Exercise; Feeding Behavior; Humans; Hypoglycemic Agent | 2015 |
Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives.
Topics: Diabetes Complications; Diabetes Mellitus; Energy Metabolism; Female; Genital Neoplasms, Female; Hum | 2016 |
Metformin: risk-benefit profile with a focus on cancer.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Incidence; Insulin Resistance; Metformin; Neoplasms; | 2015 |
[Evidence-based therapy of polycystic ovarian syndrome].
Topics: Amenorrhea; Androgen Antagonists; Anovulation; Anti-Obesity Agents; Chorionic Gonadotropin; Contrace | 2015 |
Impact of Metformin on Exercise-Induced Metabolic Adaptations to Lower Type 2 Diabetes Risk.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Exercise T | 2016 |
Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; I | 2016 |
Metformin and pancreatic cancer: Is there a role?
Topics: Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metform | 2016 |
Diabetes mellitus in patients with cirrhosis: clinical implications and management.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Hypoglycemic Agents; I | 2016 |
[Metformin for the treatment of polycystic ovary syndrome].
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2016 |
Repurposing metformin for cancer treatment: current clinical studies.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Clinical Trials as Topic; Coho | 2016 |
Endocrine and metabolic characteristics in polycystic ovary syndrome.
Topics: Biomarkers; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic S | 2016 |
Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
Topics: Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Anti | 2016 |
[Modern antihyperglycaemic agents--what is the patient benefit?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; | 2016 |
Hepatic manifestations of women with polycystic ovary syndrome.
Topics: Alanine Transaminase; Androgen Antagonists; Aspartate Aminotransferases; Contraceptives, Oral, Hormo | 2016 |
Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS.
Topics: Androgens; Animals; Death Domain Receptor Signaling Adaptor Proteins; Decanoic Acids; Disease Models | 2016 |
Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes | 2016 |
Prediction and prevention of Gestational Diabetes: an update of recent literature.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Pr | 2016 |
Impact of Insulin Sensitizers on the Incidence of Dementia: A Meta-Analysis.
Topics: Aged; Dementia; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Risk Factors; Thiazolidi | 2016 |
Gestational diabetes mellitus: does an effective prevention strategy exist?
Topics: Diabetes, Gestational; Dietary Supplements; Exercise; Female; Fetal Development; Humans; Insulin Res | 2016 |
Metformin - a potentially effective drug for gestational diabetes mellitus: a systematic review and meta-analysis.
Topics: Birth Weight; Diabetes, Gestational; Female; Gestational Age; Glycated Hemoglobin; Humans; Hypoglyce | 2017 |
Relationships Between Metformin, Paraoxonase-1 and the Chemokine (C-C Motif) Ligand 2.
Topics: Animals; Aryldialkylphosphatase; Chemokine CCL2; Diabetes Mellitus, Type 2; Gene Expression Regulati | 2016 |
A review of maturity onset diabetes of the young (MODY) and challenges in the management of glucokinase-MODY.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Genetic Testing; Humans; Hyperglycemia; Hypoglycem | 2016 |
Ovulation induction in polycystic ovary syndrome: Current options.
Topics: Anovulation; Anti-Obesity Agents; Aromatase Inhibitors; Bariatric Surgery; Clomiphene; Diet Therapy; | 2016 |
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Metformin; Non-al | 2017 |
The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: A systematic review and meta-analysis.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Drug Monitoring; Drug Therapy, Combination; Evi | 2017 |
Metformin in the treatment of polycystic ovary syndrome.
Topics: Clinical Trials as Topic; Female; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Metformi | 2008 |
[Non-alcoholic fatty liver disease--new view].
Topics: Biopsy; Causality; Comorbidity; Disease Progression; Fatty Liver; Humans; Hyperglycemia; Insulin Res | 2008 |
Insulin resistance: a potential new target for therapy in patients with heart failure.
Topics: Chronic Disease; Heart Failure; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Thiazoli | 2008 |
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Prog | 2008 |
Current and emerging therapies in nonalcoholic fatty liver disease.
Topics: Animals; Antioxidants; Bariatric Surgery; Body Mass Index; Cannabinoids; Cholagogues and Choleretics | 2008 |
Use of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.
Topics: Drug Resistance; Female; Glucose Tolerance Test; Health Planning Guidelines; Humans; Hyperinsulinism | 2008 |
Use of metformin in polycystic ovary syndrome.
Topics: Adolescent; Adult; Clomiphene; Dose-Response Relationship, Drug; Drug Administration Schedule; Femal | 2008 |
The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis.
Topics: Androgens; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; | 2009 |
Addressing insulin resistance in Type 1 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin | 2008 |
Drug evaluation: vildagliptin-metformin single-tablet combination.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combina | 2009 |
[Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Co | 2009 |
[Progress in therapy for diabetes mellitus--insulin-resistance ameliorating agents].
Topics: Animals; Arteriosclerosis; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mellitus, Typ | 2009 |
The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndro | 2009 |
[Usefulness of metformin in diabetes-related bone disease].
Topics: Bone Density; Bone Diseases, Metabolic; Cell Differentiation; Diabetes Mellitus, Type 2; Fractures, | 2009 |
Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Polycystic | 2010 |
Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment.
Topics: Adipokines; Adipose Tissue; Animals; Female; Humans; Insulin Resistance; Metabolic Syndrome; Metform | 2009 |
Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
Topics: Fatty Liver; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Metf | 2009 |
Treatment of clinical insulin resistance in children: a systematic review.
Topics: Adolescent; Body Mass Index; Child; Child Nutritional Physiological Phenomena; Exercise; Female; Hum | 2010 |
[Adipose tissue inflammation and atherosclerosis].
Topics: Adipokines; Adipose Tissue; Atherosclerosis; Chemotaxis; Cytokines; Endothelium, Vascular; Humans; H | 2009 |
[Could oral antidiabetic agents be useful in the management of different types of diabetes and syndromes of insulin resistance in children and adolescents?].
Topics: Administration, Oral; Adolescent; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Femal | 2009 |
Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Insuli | 2009 |
Glucose metabolism in burn patients: the role of insulin and other endocrine hormones.
Topics: Blood Glucose; Burns; Gluconeogenesis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin | 2010 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Live Bir | 2010 |
Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.
Topics: Amyloid; Bariatric Surgery; Diabetes Mellitus; Diet, Reducing; Dipeptidyl-Peptidase IV Inhibitors; E | 2010 |
Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions.
Topics: Antipsychotic Agents; Cardiovascular Diseases; Glucose Metabolism Disorders; Guidelines as Topic; Hu | 2010 |
Best methods for identification and treatment of PCOS.
Topics: Androgens; Aromatase Inhibitors; Clomiphene; Contraceptives, Oral, Hormonal; Diagnosis, Differential | 2010 |
Adjunct therapy for type 1 diabetes mellitus.
Topics: Amyloid; Carbohydrate Metabolism; Diabetes Mellitus, Type 1; Digestion; Drug Therapy, Combination; E | 2010 |
Insulin, insulin resistance, obesity, and cancer.
Topics: Diabetes Mellitus, Type 2; Humans; Insulin; Insulin Resistance; Metformin; Neoplasms; Obesity | 2010 |
The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis.
Topics: Anthropometry; Antipsychotic Agents; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Humans | 2010 |
Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management.
Topics: Animals; Antiviral Agents; Diabetes Mellitus, Type 2; Fatty Liver; Glucose Clamp Technique; Hepatiti | 2010 |
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.
Topics: Adult; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistanc | 2010 |
An energetic tale of AMPK-independent effects of metformin.
Topics: AMP-Activated Protein Kinases; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Gene Expression; | 2010 |
Use of metformin in the treatment of polycystic ovary syndrome.
Topics: Adaptation, Psychological; Body Mass Index; Endocrine System; Female; Humans; Hyperandrogenism; Hypo | 2010 |
Metformin: taking away the candy for cancer?
Topics: Adipokines; Antineoplastic Agents; Apoptosis; Cell Cycle; Clinical Trials as Topic; Diabetes Mellitu | 2010 |
Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.
Topics: Adipose Tissue; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Discovery; Fatty Liver; Genetic Pr | 2010 |
Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?
Topics: Blood Glucose; Fatty Acids; Glucose Intolerance; Heart Failure; Humans; Hypoglycemic Agents; Increti | 2010 |
Management of diabetes mellitus in Cushing's syndrome.
Topics: Cushing Syndrome; Diabetes Mellitus; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Insulin Resista | 2010 |
[Hypoglycemic therapy in heart disease patients with type 2 diabetes mellitus].
Topics: Administration, Oral; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Human | 2010 |
Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
Topics: Clinical Trials as Topic; Fatty Liver; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Met | 2010 |
[Antidiabetic therapy--a new possibility in the complex therapy of cancer?].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Diabetes Mellitus, Type 2; Feeding Behavior; Humans; | 2010 |
[Fatty liver and its clinical management in obese adolescents].
Topics: Adiponectin; Adolescent; Apoptosis; Biomarkers; Chemokines; Disease Progression; Fatty Liver; Fibros | 2011 |
Insulin resistance: pathophysiology and rationale for treatment.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Humans; Hyperinsulin | 2011 |
Use of metformin in pediatric age.
Topics: Adolescent; Antipsychotic Agents; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty | 2011 |
Metformin in prostate cancer: two for the price of one.
Topics: Animals; Antineoplastic Agents; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syn | 2011 |
Targeting type 2 diabetes.
Topics: Adipose Tissue; Caloric Restriction; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; | 2011 |
What, how, and how much should patients with burns be fed?
Topics: Animals; Blood Glucose; Burns; Catecholamines; Enteral Nutrition; Humans; Hypoglycemic Agents; Insul | 2011 |
[Diabetes and cancer risk: oncologic considerations].
Topics: Adipokines; Age Factors; Animals; Cytokines; Diabetes Complications; Diabetes Mellitus, Type 2; Feed | 2011 |
Pancreatogenic diabetes: special considerations for management.
Topics: Administration, Oral; Animals; Diabetes Mellitus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV In | 2011 |
Current perspectives of insulin resistance and polycystic ovary syndrome.
Topics: Adipose Tissue; Cardiovascular Diseases; Female; Fertility; Humans; Hypoglycemic Agents; Insulin Res | 2011 |
Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.
Topics: Animals; Breast Neoplasms; Chemoprevention; Cohort Studies; Comorbidity; Disease Models, Animal; Fem | 2011 |
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents; | 2011 |
The role of metformin in the management of NAFLD.
Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin | 2012 |
Metformin: multi-faceted protection against cancer.
Topics: Cell Transformation, Neoplastic; Cellular Senescence; Diabetes Mellitus; DNA Damage; Epithelial-Mese | 2011 |
Diabetes, cancer, and metformin: connections of metabolism and cell proliferation.
Topics: Androgens; Animals; Caloric Restriction; Cell Proliferation; Diabetes Complications; Diabetes Mellit | 2011 |
Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin.
Topics: Adipokines; Androgens; Endocrine System; Fatty Acids, Nonesterified; Fatty Liver; Female; Hormones; | 2012 |
Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Topics: Adamantane; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV | 2012 |
Metformin use among individuals at risk for type 2 diabetes.
Topics: Atherosclerosis; Blood Glucose; Diabetes Mellitus, Type 2; Early Diagnosis; Fasting; Female; Humans; | 2012 |
A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome.
Topics: Blood Glucose; Body Mass Index; Female; Hirsutism; Humans; Hyperinsulinism; Insulin Resistance; Metf | 2012 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Female; Inositol; Insulin | 2012 |
Insulin resistance in type 2 diabetic youth.
Topics: Adolescent; Body Mass Index; C-Peptide; Child; Diabetes Mellitus, Type 2; Exercise Tolerance; Female | 2012 |
The effect of metformin on insulin resistance and exercise parameters in patients with heart failure.
Topics: Aged; Diabetes Mellitus; Double-Blind Method; Exercise; Exercise Test; Exercise Tolerance; Female; H | 2012 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxid | 2012 |
The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target?
Topics: Animals; Continuous Positive Airway Pressure; Electroacupuncture; Female; Heart Rate; Humans; Insuli | 2012 |
Comparative efficacy of thiazolidinediones and metformin for polycystic ovary syndrome.
Topics: Body Mass Index; China; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycyst | 2012 |
Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Heart; Heart Failur | 2012 |
Polycystic ovarian syndrome management options.
Topics: Clomiphene; Contraceptives, Oral, Hormonal; Estrogen Antagonists; Exercise; Female; Humans; Infertil | 2012 |
PCOS: metabolic impact and long-term management.
Topics: Adolescent; Adult; Antihypertensive Agents; Cardiovascular Diseases; Child; Comorbidity; Diabetes Me | 2012 |
Should patients with polycystic ovarian syndrome be treated with metformin?: an enthusiastic endorsement.
Topics: Contraceptives, Oral; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypoglycemic A | 2002 |
Metformin and polycystic ovary syndrome: a literature review.
Topics: Androgens; Body Mass Index; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Lipi | 2002 |
[Adverse effect of biguanides].
Topics: Acidosis, Lactic; Biguanides; Diabetes Mellitus, Type 2; Gastrointestinal Diseases; Humans; Hypoglyc | 2002 |
Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction.
Topics: Androgens; Cardiovascular Diseases; Female; Fertilization in Vitro; Gonadotropins; Humans; Hypoglyce | 2002 |
Oral anti diabetic polychemotherapy in type 2 diabetes mellitus.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; H | 2002 |
Detection of insulin resistance and its treatment in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Blood Glucose; Diabetes Mellitus; Female; Glucose Tolerance Test; Humans; Insulin Resist | 2002 |
Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus; Endothelium, Vascular; Enzyme Activation; | 2003 |
Insulin sensitisation in the treatment of Type 2 diabetes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenergic beta-3 Receptor Agonists; Cardiovascular Dis | 2003 |
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double- | 2003 |
Insulin resistance syndrome in children : pathophysiology and potential management strategies.
Topics: Child; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic Syndrome; Metformin; Obes | 2003 |
[Insulin resistance and polycystic ovary syndrome].
Topics: Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metf | 2003 |
[Metabolic syndrome: to observe or to act?].
Topics: Body Constitution; Humans; Hypertension; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistan | 2003 |
[Should infertile women with polycystic ovarian syndrome be treated with metformine?].
Topics: Clomiphene; Drug Synergism; Estrogen Antagonists; Female; Fertility Agents, Female; Humans; Hyperand | 2003 |
[Treatment of PCOS without IVF: weight loss, insulin-sensitizing agents].
Topics: Acarbose; Chromans; Enzyme Inhibitors; Female; Glucose Intolerance; Glucosidases; Humans; Hypoglycem | 2003 |
Insulin sensitizers for polycystic ovary syndrome.
Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndr | 2003 |
Metformin and gestational diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose; Humans; | 2003 |
[Lipodystrophies: what treatment?].
Topics: Antiviral Agents; Diabetes Complications; Diabetes Mellitus; Diet; Exercise; HIV-Associated Lipodyst | 2003 |
[Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
Topics: Adipocytes; Adiponectin; Cyclic AMP-Dependent Protein Kinases; Diabetes Complications; Diabetes Mell | 2003 |
[Nateglinide and mitiglinide].
Topics: Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; | 2003 |
The importance of insulin resistance in polycystic ovary syndrome.
Topics: Arteriosclerosis; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metfor | 2003 |
[Medication of the month. Glucovance in type 2 diabetes, a fixed combination of metformin-glibenclamide for the treatment of a bipolar metabolic disease].
Topics: Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; In | 2003 |
Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hyperlipidemias; Hyperten | 2003 |
Is metformin more than an oral hypoglycaemic agent?
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; H | 2003 |
Reducing insulin resistance with metformin: the evidence today.
Topics: Adipose Tissue; Cell Membrane; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Li | 2003 |
Beneficial effects of metformin on haemostasis and vascular function in man.
Topics: Arteriosclerosis; Blood Coagulation; Blood Platelets; Blood Vessels; Cardiovascular Diseases; Diabet | 2003 |
Antiatherogenic properties of metformin: the experimental evidence.
Topics: Animals; Aortic Diseases; Arteries; Arteriosclerosis; Diabetes Mellitus, Type 2; Disease Models, Ani | 2003 |
Microcirculation in insulin resistance and diabetes: more than just a complication.
Topics: Arterioles; Blood Glucose; Capillaries; Capillary Permeability; Cell Adhesion; Diabetes Mellitus; Di | 2003 |
Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resi | 2003 |
Insulin-lowering agents in the management of polycystic ovary syndrome.
Topics: Female; Humans; Insulin; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome; Pregnanc | 2003 |
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Resten | 2003 |
[Insulin resistance in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as | 2003 |
[Progress in the prevention of type 2 diabetes].
Topics: Acarbose; Adult; Alcohol Drinking; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Chromans | 2003 |
Metformin in obstetric and gynecologic practice: a review.
Topics: Abortion, Spontaneous; Anovulation; Diabetes Mellitus, Type 2; Female; Gastrointestinal Tract; Human | 2004 |
Insulin resistance as a therapeutic target for improved endothelial function: metformin.
Topics: Animals; Drug Delivery Systems; Endothelium, Vascular; Humans; Insulin Resistance; Metformin | 2004 |
[Etiology of and therapy for type-2 diabetes mellitus].
Topics: Diabetes Mellitus, Type 2; Diet; Environment; Exercise; Humans; Hypoglycemic Agents; Insulin; Insuli | 2004 |
Treatment of insulin resistance in diabetes mellitus.
Topics: Anti-Inflammatory Agents; Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Hyp | 2004 |
Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome?
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Drug Therapy, Combination; Female; Humans; Hypoglyce | 2004 |
Endothelial dysfunction, inflammation and diabetes.
Topics: Acarbose; Animals; Cardiovascular Agents; Diabetes Mellitus; Diabetic Angiopathies; Endothelium, Vas | 2004 |
Which treatment options should be used in adolescents with polycystic ovary syndrome?
Topics: Adolescent; Adolescent Health Services; Adult; Androgen Antagonists; Estrogens; Female; Flutamide; H | 2004 |
Insulin resistance and metformin in polycystic ovary syndrome.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; In | 2004 |
A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; In Vitro Techniques; | 2004 |
Nonalcoholic fatty liver disease in the pediatric population.
Topics: Adolescent; Alanine Transaminase; Child; Fatty Liver; Female; Histocytochemistry; Humans; Hypoglycem | 2004 |
Current indications for metformin therapy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin R | 2003 |
Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes.
Topics: Contraindications; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Insuli | 2004 |
Revisit of metformin treatment in polycystic ovarian syndrome.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2004 |
Islet adaptation to insulin resistance: mechanisms and implications for intervention.
Topics: Adaptation, Physiological; Animals; Blood Glucose; Cholinergic Agonists; Diabetes Mellitus, Type 2; | 2005 |
Clinical inquiries. Do insulin-sensitizing drugs increase ovulation rates for women with PCOS?
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Ovulation; Polycystic Ovary Synd | 2005 |
[Characteristic of metformin for treatment of impaired glucose tolerance].
Topics: Arteriosclerosis; Biguanides; Diabetes Mellitus, Type 2; Glucose; Glucose Intolerance; Humans; Hypog | 2005 |
[Diabetes prevention program (metformin)].
Topics: Diabetes Mellitus, Type 2; Follow-Up Studies; Glucose Intolerance; Humans; Hypoglycemic Agents; Insu | 2005 |
[Therapies for newly-onset diabetic patients].
Topics: Acarbose; Cyclohexanes; Diabetes Mellitus, Type 2; Diet Therapy; Enzyme Inhibitors; Exercise Therapy | 2005 |
[Treatment for coronary artery disease patients with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Coronary Artery Bypass; Coronary Artery Disease; Glucose Intolerance; Glycosid | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
The fatty liver and insulin resistance.
Topics: Adiponectin; Adipose Tissue; Alanine Transaminase; Animals; Antiretroviral Therapy, Highly Active; C | 2005 |
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gli | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fa | 2005 |
[Metformin for the treatment of polycystic ovary syndrome].
Topics: Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metfo | 2005 |
[Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
Topics: Contraceptives, Oral; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Humans; | 2005 |
Patient-tailored conventional ovulation induction algorithms in anovulatory infertility.
Topics: Algorithms; Anovulation; Clomiphene; Electrocoagulation; Female; Fertilization in Vitro; Follicle St | 2005 |
Insulin resistance in polycystic ovarian disease.
Topics: Cardiovascular Diseases; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Inflamma | 2005 |
Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.
Topics: Body Weight; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Therapy, Combination; Humans; Hypergly | 2005 |
Review article: the treatment of fatty liver disease associated with the metabolic syndrome.
Topics: Adult; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Metabolic Syndrome; | 2005 |
Insulin-sensitisers in the treatment of polycystic ovary syndrome.
Topics: Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Drug Approval; Exercise; Fema | 2005 |
[Insulin sensitizers in the treatment of polycystic ovary].
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Thiaz | 2005 |
Management of the metabolic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Di | 2005 |
Therapy of NAFLD: insulin sensitizing agents.
Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Thiazolidinediones | 2006 |
Insulin resistance and improvements in signal transduction.
Topics: Adiponectin; AMP-Activated Protein Kinases; Appetite Regulation; Diabetes Mellitus, Type 2; Enzyme A | 2006 |
Insulin-sensitizing agents in polycystic ovary syndrome.
Topics: Androgen Antagonists; Contraceptives, Oral; Drug Therapy, Combination; Female; Humans; Hypoglycemic | 2006 |
[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglit | 2006 |
Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Res | 2006 |
Metformin and pioglitazone: Effectively treating insulin resistance.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; | 2006 |
Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.
Topics: Body Weight; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus; Diabetic Angiopathie | 2006 |
Contemporary medical therapy for polycystic ovary syndrome.
Topics: Acne Vulgaris; Adult; Clomiphene; Estrogen Antagonists; Female; Hirsutism; Humans; Hypoglycemic Agen | 2006 |
Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Thiaz | 2006 |
[Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].
Topics: Adiponectin; Arteriosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabeti | 2006 |
Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome?
Topics: Anovulation; Clinical Trials as Topic; Female; Fertility Agents, Female; Humans; Infertility, Female | 2006 |
Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.
Topics: Controlled Clinical Trials as Topic; Diet, Carbohydrate-Restricted; Fatty Liver; Humans; Hypoglycemi | 2006 |
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Humans; Hypoglycemic Agents; Insulin | 2007 |
Treatment of fibrosis in nonalcoholic fatty liver disease.
Topics: Adiponectin; Adipose Tissue; Animals; Antioxidants; Cytokines; Fatty Liver; Humans; Hypoglycemic Age | 2007 |
Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Glucose; Humans; Hypoglycemic Agents; Insulin Resistan | 2007 |
The management of insulin resistance in polycystic ovary syndrome.
Topics: Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Models, Biologi | 2007 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fem | 2008 |
Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost?
Topics: Antiretroviral Therapy, Highly Active; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, | 2008 |
beta-cell function and anti-diabetic pharmacotherapy.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreti | 2007 |
Obesity and the polycystic ovary syndrome.
Topics: Adrenal Glands; Adult; Androgens; Cardiovascular Diseases; Contraceptives, Oral, Hormonal; Diet; Fem | 2007 |
Unmet needs in controlling metabolic disease.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Exercise; Humans; Hyp | 2007 |
Metformin and polycystic ovary syndrome.
Topics: Female; Humans; Hyperinsulinism; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2007 |
Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes.
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hy | 2007 |
Use of insulin sensitizers in NASH.
Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metform | 2007 |
Effects of insulin resistance on endothelial function: possible mechanisms and clinical implications.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Endothelium, Vascular; Exercise | 2008 |
Metabolic syndrome: are we at risk?
Topics: Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2007 |
Metformin for the treatment of the polycystic ovary syndrome.
Topics: Adult; Cholesterol, LDL; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity | 2008 |
A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications.
Topics: Cardiomyopathies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; I | 2007 |
Metformin beyond diabetes: new life for an old drug.
Topics: Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Hypoglyc | 2006 |
Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; H | 2008 |
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin Resis | 2008 |
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin Resis | 2008 |
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin Resis | 2008 |
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin Resis | 2008 |
Insulin, insulin-like growth factors, insulin resistance, and neoplasia.
Topics: Diabetes Complications; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Life Style; Metfor | 2007 |
Ovulation induction in polycystic ovary syndrome.
Topics: Adult; Anovulation; Aromatase Inhibitors; Body Mass Index; Clomiphene; Diathermy; Female; Fertility | 2008 |
Outlook: metformin use in infertile patients with polycystic ovary syndrome: an evidence-based overview.
Topics: Female; Gonadotropins; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Meta-An | 2008 |
Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Infertility; Insulin Resista | 2008 |
Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Infertility; Insulin Resista | 2008 |
Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Infertility; Insulin Resista | 2008 |
Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Infertility; Insulin Resista | 2008 |
Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Topics: alpha-Glucosidases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycoside Hydrola | 2007 |
[Therapeutic approach to a multi-metabolic syndrome].
Topics: Acarbose; Combined Modality Therapy; Diet Therapy; Enzyme Inhibitors; Exercise; Glucose Intolerance; | 1995 |
[The value of metformin in therapy of type 2 diabetes: effect on insulin resistance, diabetic control and cardiovascular risk factors].
Topics: Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 1994 |
Drugs and insulin resistance: clinical methods of evaluation and new pharmacological approaches to metabolism.
Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Benzothiadiazines; Diabetes Mell | 1994 |
The effects of metformin on cardiovascular risk factors.
Topics: Animals; Diabetes Mellitus, Type 2; Fibrinolysis; Glucose; Humans; Hyperlipidemias; Hypertension; Hy | 1995 |
Effects of metformin in obese patients with impaired glucose tolerance.
Topics: Glucose Intolerance; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Ob | 1995 |
[Drug therapy in subjects with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glycoside Hydrolase | 1996 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma | 1997 |
[Value of biguanide in therapy of diabetes mellitus].
Topics: Biguanides; Blood Glucose; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents | 1997 |
Insulin resistance syndrome: options for treatment.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipid | 1999 |
Insulin resistance: site of the primary defect or how the current and the emerging therapies work.
Topics: Adipose Tissue; Appetite Depressants; Diabetes Mellitus, Type 2; Female; Fenfluramine; Humans; Hypog | 1998 |
A risk-benefit assessment of metformin in type 2 diabetes mellitus.
Topics: Acidosis, Lactic; Body Weight; Contraindications; Diabetes Mellitus, Type 2; Female; Glucose; Humans | 1999 |
Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes.
Topics: Animals; Blood Glucose; Cell Membrane; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; | 1999 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine | 1999 |
Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resi | 1999 |
[Insulin resistance: therapeutic approaches].
Topics: Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise Therapy; Humans; Hypoglycemic Agents; | 1999 |
A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering.
Topics: Antioxidants; Blood Coagulation; Cardiovascular Diseases; Cardiovascular System; Cholesterol, LDL; C | 1999 |
Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angio | 1999 |
Insulin resistance, polycystic ovary syndrome and metformin.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Res | 1999 |
New drugs for diabetes.
Topics: Carbamates; Chromans; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin | 1999 |
[Diagnosis and treatment of polycystic ovary syndrome].
Topics: Anovulation; Clomiphene; Diagnosis, Differential; Female; Humans; Hyperinsulinism; Insulin Resistanc | 1999 |
[Combination treatment with insulin and metformin in type 2 diabetes. Improves glycemic control and prevents weight gain].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; In | 1999 |
Insulin-lowering medications in polycystic ovary syndrome.
Topics: Diazoxide; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistanc | 2000 |
[Metformin efficacious in poorly controlled diabetes mellitus type 2].
Topics: Abdominal Pain; Acidosis, Lactic; Aged; Blood Glucose; Contraindications; Diabetes Mellitus; Diabete | 2000 |
Induction of ovulation in infertile women with hyperandrogenism and insulin resistance.
Topics: Acanthosis Nigricans; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Infertility, Female; In | 2000 |
The polycystic ovary syndrome: treatment with insulin sensitizing agents.
Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Obesity; Ovar | 1999 |
Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance.
Topics: Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Preventive Me | 2001 |
Pathophysiology and treatment of the dyslipidemia of insulin resistance.
Topics: Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2001 |
Caloric restriction in primates and relevance to humans.
Topics: Aging; Animals; Biomarkers; Blood Glucose; Body Temperature; Cardiovascular Diseases; Deoxyglucose; | 2001 |
Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome.
Topics: Algorithms; Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertility, | 2002 |
Polycystic ovary syndrome in adolescents.
Topics: Adolescent; Anovulation; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Glucose Intoler | 2002 |
Should patients with polycystic ovarian syndrome be treated with metformin? A note of cautious optimism.
Topics: Anovulation; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Gastrointestin | 2002 |
[Polycystic ovary syndrome: treatment with insulin-sensitizing agents].
Topics: Androgens; Chromans; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing | 2002 |
Polycystic ovary syndrome. Long term sequelae and management.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Contraceptives, Oral; Diabetes Mellitus, Type 2; Diag | 2002 |
[Lipid anomalies in NIDDM and insulin resistance. Role of metformin].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Insulin Resist | 1992 |
Metformin and blood pressure.
Topics: Fibrinolysis; Humans; Hypertension; Insulin Resistance; Lipids; Metformin | 1992 |
[Identification and prevention of vascular risk. Significance of metformin].
Topics: Anthropometry; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; I | 1990 |
[Action of metformin in insulin resistance].
Topics: Animals; Diabetes Mellitus, Type 2; Glucose; Humans; Insulin; Insulin Resistance; Insulin Secretion; | 1985 |
[Action of metformin on vascular risk factors in diabetes].
Topics: Animals; Diabetic Angiopathies; Humans; Insulin; Insulin Resistance; Lipids; Metformin; Microcircula | 1988 |
471 trials available for metformin and Insulin Sensitivity
| Article | Year |
|---|---|
The Effects of Vitamin D Supplementation on Metabolic and Oxidative Stress Markers in Patients With Type 2 Diabetes: A 6-Month Follow Up Randomized Controlled Study.
Topics: Antioxidants; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Supplements; Drug Therap | 2021 |
The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.
Topics: Adiponectin; Adult; Blood Glucose; Body Composition; Body Mass Index; Female; Gonadal Steroid Hormon | 2022 |
Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial.
Topics: Adolescent; Adult; Canagliflozin; China; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resis | 2022 |
Efficacy of Bushen Huatan Decoction combined with Baduanjin in the treatment of polycystic ovary syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness: study protocol for a randomized controlled trial.
Topics: Female; Humans; Insulin; Insulin Resistance; Kidney; Metabolic Syndrome; Metformin; Polycystic Ovary | 2021 |
[Effects of orlistat and metformin on metabolism and gonadal function in overweight or obese patients with polycystic ovary syndrome].
Topics: Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Orlist | 2021 |
Antecedent Metabolic Health and Metformin (ANTHEM) Aging Study: Rationale and Study Design for a Randomized Controlled Trial.
Topics: Aged; Aging; Double-Blind Method; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformi | 2022 |
Effect of acupuncture and metformin on insulin sensitivity in women with polycystic ovary syndrome and insulin resistance: a three-armed randomized controlled trial.
Topics: Acupuncture Therapy; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Insulin Resistance; Male; M | 2022 |
Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients.
Topics: Adult; Biomarkers, Pharmacological; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Ag | 2022 |
Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis.
Topics: Adult; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; | 2022 |
One Bout of Resistance Training Does Not Enhance Metformin Actions in Prediabetic and Diabetic Individuals.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic | 2022 |
FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Fibroblast Growth Factors; Glipizide; Glycated | 2022 |
Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gastroplasty; Glucose Intolerance; Humans; Hypoglyc | 2022 |
Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gastroplasty; Glucose Intolerance; Humans; Hypoglyc | 2022 |
Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gastroplasty; Glucose Intolerance; Humans; Hypoglyc | 2022 |
Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gastroplasty; Glucose Intolerance; Humans; Hypoglyc | 2022 |
Metformin, testosterone, or both in men with obesity and low testosterone: A double-blind, parallel-group, randomized controlled trial.
Topics: Double-Blind Method; Erectile Dysfunction; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; | 2022 |
Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
Topics: Adolescent; Adult; Blood Glucose; Canagliflozin; Female; Humans; Insulin; Insulin Resistance; Metabo | 2022 |
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therap | 2023 |
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therap | 2023 |
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therap | 2023 |
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therap | 2023 |
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therap | 2023 |
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therap | 2023 |
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therap | 2023 |
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therap | 2023 |
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therap | 2023 |
Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: A randomized, controlled, prospective study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fecal Microbiota Transplantation; Feces; Humans; Insulin R | 2022 |
A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Inositol; Insulin; Insulin Resistance; Metformin; Polycystic Ov | 2023 |
Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial.
Topics: Female; Humans; Insulin Resistance; Metformin; Obesity; Pilot Projects; Polycystic Ovary Syndrome; W | 2023 |
Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; I | 2023 |
Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS.
Topics: Adolescent; Adult; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hyperandrogenism; Indi | 2020 |
Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial.
Topics: Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Re | 2020 |
Pharmacodynamics of Metformin in Pregnant Women With Gestational Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes Mellitus.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Healthy | 2020 |
Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus.
Topics: Adolescent; Adult; Blood Glucose; Diabetes, Gestational; Drug Therapy, Combination; Female; Glyburid | 2020 |
Exercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Combined Modality Therapy; Diabetes Mellitus, Type 2; | 2020 |
Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study.
Topics: Adult; Blood Glucose; Female; Humans; Insulin; Insulin Resistance; Leptin; Metformin; Pioglitazone; | 2020 |
Beta cell function and insulin sensitivity in obese youth with maturity onset diabetes of youth mutations vs type 2 diabetes in TODAY: Longitudinal observations and glycemic failure.
Topics: Adolescent; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2020 |
Diet-induced weight loss alters hepatic glucocorticoid metabolism in type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diet, Paleolithic; Diet, Reducing; Exercise; Exercise Therap | 2020 |
Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adolescent; Arrhythmias, Cardiac; Biomarkers; Chemo | 2020 |
Effect of short-term prednisone on beta-cell function in subjects with type 2 diabetes mellitus and healthy subjects.
Topics: Adult; Blood Glucose; C-Peptide; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; In | 2020 |
Metformin use in prediabetes: is earlier intervention better?
Topics: Adult; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Insulin; I | 2020 |
Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study.
Topics: Aged; Bacteroidetes; Blood Glucose; Butyrates; Diabetes Mellitus, Type 2; Fatty Acids, Volatile; Fem | 2020 |
Changes in peripheral mitochondrial DNA copy number in metformin-treated women with polycystic ovary syndrome: a longitudinal study.
Topics: Adolescent; Adult; Body Mass Index; DNA Copy Number Variations; DNA, Mitochondrial; Female; Humans; | 2020 |
Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Aged; Body Composition; Body Weight; Calorimetry, Indirect; Double-Blind Method; Female; Glucagon; G | 2021 |
Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 2; Fasting; Female; Follow-Up Studies; Glu | 2020 |
Postintervention Effects of Varying Treatment Arms on Glycemic Failure and β-Cell Function in the TODAY Trial.
Topics: Adolescent; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agen | 2021 |
The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes.
Topics: Acarbose; Aged; Aged, 80 and over; Blood Glucose; Cross-Over Studies; Denmark; Diabetes Mellitus, Ty | 2021 |
Efficacy of metformin and fermentable fiber combination therapy in adolescents with severe obesity and insulin resistance: study protocol for a double-blind randomized controlled trial.
Topics: Adolescent; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Insulin Res | 2021 |
Two-Year Treatment With Metformin During Puberty Does Not Preserve β-Cell Function in Youth With Obesity.
Topics: Adipose Tissue; Adolescent; Body Composition; Body Mass Index; Child; Diabetes Mellitus, Type 2; Dou | 2021 |
Insulin resistance in type 1 diabetes managed with metformin (INTIMET): Study protocol of a double-blind placebo-controlled, randomised trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Fasting; Female; Glucose Clamp | 2021 |
Metformin in non-diabetic patients with metabolic syndrome and diastolic dysfunction: the MET-DIME randomized trial.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Metformin; | 2021 |
Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose; Humans; Hypoglycemic | 2021 |
Therapeutic Effect of Curcumin in Women with Polycystic Ovary Syndrome Receiving Metformin: A Randomized Controlled Trial.
Topics: Blood Glucose; Curcumin; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin | 2021 |
Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.
Topics: Acetylcarnitine; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycy | 2021 |
Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.
Topics: Acetylcarnitine; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycy | 2021 |
Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.
Topics: Acetylcarnitine; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycy | 2021 |
Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.
Topics: Acetylcarnitine; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycy | 2021 |
Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
Topics: Adult; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor | 2017 |
Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
Topics: Adult; Aged; Aged, 80 and over; Bromocriptine; Diabetes Mellitus, Type 2; Dopamine Agonists; Double- | 2017 |
Retrospective Evaluation of Metformin and/or Metformin Plus a New Polysaccharide Complex in Treating Severe Hyperinsulinism and Insulin Resistance in Obese Children and Adolescents with Metabolic Syndrome.
Topics: Adolescent; Child; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Male; M | 2017 |
Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes.
Topics: Adamantane; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dipeptides; Dipeptidyl-Peptidase | 2017 |
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-C | 2017 |
The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial.
Topics: Adult; Ataxia Telangiectasia Mutated Proteins; Biomarkers; Blood Glucose; Contraceptives, Oral, Horm | 2018 |
Protocol for a pilot randomised controlled trial of metformin in pre-diabetes after kidney transplantation: the Transplantation and Diabetes (Transdiab) study.
Topics: Blood Glucose; Glucose Intolerance; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemi | 2017 |
Metformin effect on TSH in subclinical hypothyroidism: randomized, double-blind, placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Asymptomatic Diseases; Blood Pressure; Cholesterol, HDL; Double-Blind Metho | 2018 |
Metformin as a prophylactic treatment of gestational diabetes in pregnant patients with pregestational insulin resistance: A randomized study.
Topics: Adult; Diabetes, Gestational; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resi | 2018 |
Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Foll | 2018 |
Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance.
Topics: Adiposity; Adult; Aged; Blood Glucose; Body Fat Distribution; Diabetes Mellitus, Type 2; Drug Therap | 2018 |
The effect of vitamin C and/or E supplementations on type 2 diabetic adult males under metformin treatment: A single-blinded randomized controlled clinical trial.
Topics: Adult; Antioxidants; Ascorbic Acid; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellit | 2018 |
Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
Topics: Adipose Tissue; Adult; Androgen Antagonists; Androgens; Cyproterone Acetate; Drug Combinations; Ethi | 2018 |
Effect of metformin on plasma metabolite profile in the Copenhagen Insulin and Metformin Therapy (CIMT) trial.
Topics: Aged; Carnitine; Chromatography, Liquid; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glyca | 2018 |
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycem | 2018 |
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycem | 2018 |
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycem | 2018 |
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycem | 2018 |
Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study.
Topics: Adolescent; Androgens; Aspartate Aminotransferases; Body Mass Index; Diabetes Mellitus, Type 2; Drug | 2018 |
The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study.
Topics: Adult; Androstenes; Apolipoproteins B; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; D | 2018 |
Saxagliptin Upregulates Nesfatin-1 Secretion and Ameliorates Insulin Resistance and Metabolic Profiles in Type 2 Diabetes Mellitus.
Topics: Acarbose; Adamantane; Aged; Blood Glucose; Calcium-Binding Proteins; Diabetes Mellitus, Type 2; Dipe | 2018 |
Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adolescent; Age Factors; Blood Glucose; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2018 |
The benefits of adding metformin to tamoxifen to protect the endometrium-A randomized placebo-controlled trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Double-Blind Method; Endometrium; Fasting; Female; Huma | 2018 |
Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastroplasty; Glucose Intolerance; Gl | 2018 |
Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial.
Topics: Adult; Androgen Antagonists; Androgens; Body Mass Index; Contraceptives, Oral, Combined; Cyproterone | 2019 |
Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Female; | 2019 |
Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults.
Topics: Adaptation, Physiological; Aged; Blood Glucose; Cardiorespiratory Fitness; Cell Respiration; Exercis | 2019 |
Acupuncture or metformin to improve insulin resistance in women with polycystic ovary syndrome: study protocol of a combined multinational cross sectional case-control study and a randomised controlled trial.
Topics: Acupuncture Therapy; Blood Glucose; Case-Control Studies; China; Combined Modality Therapy; Cross-Se | 2019 |
Feasibility and Acceptability of Metformin to Augment Low Milk Supply: A Pilot Randomized Controlled Trial.
Topics: Adult; Breast Feeding; Feasibility Studies; Female; Humans; Hypoglycemic Agents; Infant, Newborn; In | 2019 |
The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients.
Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Di | 2019 |
The influence of orlistat, metformin and diet on serum levels of insulin-like growth factor-1 in obeses women with and without insulin resistance.
Topics: Adult; Anti-Obesity Agents; Caloric Restriction; Diet; Female; Humans; Hypoglycemic Agents; Insulin | 2018 |
l-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial.
Topics: Adult; Blood Glucose; Carnitine; Clomiphene; Drug Resistance; Female; Fertility Agents, Female; Horm | 2019 |
Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes.
Topics: Adipose Tissue; Adolescent; Adult; Blood Glucose; Child; Diabetes Mellitus, Type 1; Double-Blind Met | 2019 |
Comparison of therapeutic effects of acarbose and metformin under different β-cell function status in Chinese patients with type 2 diabetes.
Topics: Acarbose; Adult; Blood Glucose; Body Mass Index; China; Diabetes Mellitus, Type 2; Female; Glycated | 2019 |
A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial.
Topics: Aged; Body Weight; Coronary Artery Disease; Female; Heart Ventricles; Humans; Hypertrophy, Left Vent | 2019 |
Effect of metformin on thyroid function tests in patients with subclinical hypothyroidism: an open-label randomised controlled trial.
Topics: Adiponectin; Adult; Blood Glucose; Cholesterol; Female; Humans; Hypothyroidism; Insulin Resistance; | 2019 |
Changes in Visceral and Subcutaneous Fat in Youth With Type 2 Diabetes in the TODAY Study.
Topics: Adiposity; Adolescent; Blood Glucose; Body Fat Distribution; Child; Combined Modality Therapy; Diabe | 2019 |
Screening for a Simple and Effective Indicator of Insulin Resistance in Chinese Reproductive-Aged Women, with the Insulin Clamp Technique as a Reference.
Topics: Adolescent; Adult; Age Factors; Biomarkers; Body Mass Index; China; Cross-Sectional Studies; Diagnos | 2019 |
A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hu | 2019 |
A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; F | 2013 |
A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; F | 2013 |
Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, | 2013 |
Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, | 2013 |
Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, | 2013 |
Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, | 2013 |
Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone.
Topics: Adolescent; Adult; Aldosterone; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Human | 2013 |
Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients.
Topics: Adult; Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Fe | 2013 |
Optimal macronutrient content of the diet for adolescents with prediabetes; RESIST a randomised control trial.
Topics: Adolescent; Adolescent Behavior; Body Mass Index; Child; Child Behavior; Combined Modality Therapy; | 2013 |
Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance.
Topics: Dose-Response Relationship, Drug; Drug Synergism; Female; Fenofibrate; Fibrinogen; Glucose Intoleran | 2013 |
RETRACTED: Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.
Topics: Adamantane; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fe | 2013 |
Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.
Topics: Abdomen; Acupuncture Therapy; Adult; Blood Glucose; Fasting; Female; Hormones; Humans; Hypoglycemic | 2013 |
Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.
Topics: Abdomen; Acupuncture Therapy; Adult; Blood Glucose; Fasting; Female; Hormones; Humans; Hypoglycemic | 2013 |
Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.
Topics: Abdomen; Acupuncture Therapy; Adult; Blood Glucose; Fasting; Female; Hormones; Humans; Hypoglycemic | 2013 |
Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.
Topics: Abdomen; Acupuncture Therapy; Adult; Blood Glucose; Fasting; Female; Hormones; Humans; Hypoglycemic | 2013 |
Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents | 2013 |
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Topics: Aged; Arginine; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; C-Peptide; Chimerin Protein | 2013 |
[Clinical efficacy of special effect san xiao decoction on type 2 diabetes mellitus].
Topics: Adult; Aged; Blood Glucose; C-Reactive Protein; Case-Control Studies; Diabetes Mellitus, Type 2; Dru | 2013 |
In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Female; Hirsutism; | 2014 |
Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Body Composition; Body Mass Index; Drug Therapy, C | 2013 |
Does metformin improve vascular health in children with type 1 diabetes? Protocol for a one year, double blind, randomised, placebo controlled trial.
Topics: Adolescent; Cardiovascular Diseases; Carotid Intima-Media Thickness; Child; Diabetes Mellitus, Type | 2013 |
Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Topics: Adult; Biomarkers; Chemokines; Cytokines; Drug Therapy, Combination; Female; Glucose Clamp Technique | 2013 |
Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
Topics: Adipokines; Analysis of Variance; Biomarkers; Blood Glucose; Body Mass Index; Chi-Square Distributio | 2013 |
[Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
Topics: Adult; Antioxidants; Blood Glucose; Body Mass Index; Drug Therapy, Combination; Electron Transport; | 2013 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Intensive insulin therapy increases sex hormone-binding globulin in newly diagnosed type 2 diabetic patients.
Topics: Adult; Aged; Alanine Transaminase; Body Mass Index; Diabetes Mellitus, Type 2; Female; gamma-Glutamy | 2014 |
The role of adding metformin in insulin-resistant diabetic pregnant women: a randomized controlled trial.
Topics: Administration, Oral; Adult; Birth Weight; Blood Glucose; Diabetes, Gestational; Egypt; Fasting; Fem | 2014 |
Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; | 2014 |
Acetylsalicylic acid therapy: influence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels.
Topics: Aspirin; Biological Transport; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Hypoglycemic Agen | 2014 |
Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention Program.
Topics: Adult; Blood Glucose; Body Composition; Body Mass Index; Carrier Proteins; Diabetes Mellitus, Type 2 | 2014 |
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple | 2014 |
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple | 2014 |
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple | 2014 |
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple | 2014 |
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple | 2014 |
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple | 2014 |
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple | 2014 |
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple | 2014 |
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Biomarkers, Tumor; Blood Glucose; Carrier Proteins; Comple | 2014 |
Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization.
Topics: Adolescent; Adult; Aged; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Double-Blin | 2014 |
Dietary glycemic load, insulin load, and weight loss in obese, insulin resistant adolescents: RESIST study.
Topics: Adolescent; Body Composition; Body Mass Index; Child; Diet; Energy Intake; Glucose Tolerance Test; G | 2015 |
Proinsulin, adiponectin and hsCRP in reproductive age women with polycystic ovary syndrome (PCOS)--the effect of metformin treatment.
Topics: Adiponectin; Adolescent; Adult; C-Reactive Protein; Female; Humans; Insulin Resistance; Metformin; O | 2014 |
Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program.
Topics: Adipose Tissue; Adiposity; Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellit | 2014 |
The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Cholesterol, LDL; Diabetes | 2013 |
Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.
Topics: Adult; Blood Glucose; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Hypoglyc | 2014 |
Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.
Topics: Adult; Blood Glucose; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Hypoglyc | 2014 |
Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.
Topics: Adult; Blood Glucose; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Hypoglyc | 2014 |
Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.
Topics: Adult; Blood Glucose; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Hypoglyc | 2014 |
Effect of carnitine-orotate complex on glucose metabolism and fatty liver: a double-blind, placebo-controlled study.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Glucose; Carnitine; DNA | 2014 |
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.
Topics: Aged; Blood Glucose; Carotid Intima-Media Thickness; Coronary Disease; Double-Blind Method; Female; | 2014 |
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.
Topics: Aged; Blood Glucose; Carotid Intima-Media Thickness; Coronary Disease; Double-Blind Method; Female; | 2014 |
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.
Topics: Aged; Blood Glucose; Carotid Intima-Media Thickness; Coronary Disease; Double-Blind Method; Female; | 2014 |
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.
Topics: Aged; Blood Glucose; Carotid Intima-Media Thickness; Coronary Disease; Double-Blind Method; Female; | 2014 |
Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program.
Topics: Autoantibodies; Autoimmunity; Blood Glucose; Diabetes Mellitus; Disease Progression; Female; Follow- | 2014 |
Metformin does not attenuate the acute insulin-sensitizing effect of a single bout of exercise in individuals with insulin resistance.
Topics: Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Human | 2014 |
Metformin does not attenuate the acute insulin-sensitizing effect of a single bout of exercise in individuals with insulin resistance.
Topics: Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Human | 2014 |
Metformin does not attenuate the acute insulin-sensitizing effect of a single bout of exercise in individuals with insulin resistance.
Topics: Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Human | 2014 |
Metformin does not attenuate the acute insulin-sensitizing effect of a single bout of exercise in individuals with insulin resistance.
Topics: Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Human | 2014 |
Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study.
Topics: Adolescent; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Ins | 2015 |
Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study.
Topics: Adolescent; Blood Glucose; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy | 2014 |
Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Topics: Body Mass Index; Carbamates; China; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diab | 2014 |
Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes.
Topics: Adult; Aged; Aged, 80 and over; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; | 2014 |
Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
Topics: Adamantane; Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Chol | 2014 |
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method | 2014 |
METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents - study protocol of a randomized controlled study.
Topics: Adolescent; Body Composition; Child; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypogly | 2014 |
Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Topics: Adamantane; Asian People; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidy | 2014 |
Effect of fat loss on arterial elasticity in obese adolescents with clinical insulin resistance: RESIST study.
Topics: Absorptiometry, Photon; Adipose Tissue; Adolescent; Body Composition; Child; Diabetes Mellitus, Type | 2014 |
A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.
Topics: Acarbose; Adult; Aged; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination | 2014 |
Improved Insulin Secretion by Autologous Islet Transplantation, Compared to Oral Antidiabetic Agents, After Distal Pancreatectomy.
Topics: Adamantane; Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gly | 2015 |
Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance.
Topics: Aberrant Crypt Foci; Adult; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; | 2015 |
Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.
Topics: Adult; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Double-Blind Method; Female; Humans; | 2014 |
Therapeutic effects of metformin and laparoscopic ovarian drilling in treatment of clomiphene and insulin-resistant polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Laparoscopy; Me | 2015 |
Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects.
Topics: Adrenal Cortex; Adult; Body Mass Index; Double-Blind Method; Female; Follow-Up Studies; Humans; Hype | 2014 |
[Efficacy of metformin in abdominal obesity].
Topics: Adult; Blood Pressure; Body Mass Index; Body Weight; Female; Humans; Hypoglycemic Agents; Insulin Re | 2014 |
Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; | 2015 |
Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo-controlled pilot study in prepubertal children.
Topics: Abdominal Fat; Adiposity; Anti-Obesity Agents; Biomarkers; Body Mass Index; Child; Cohort Studies; D | 2015 |
Metformin for overweight women at midlife: a double-blind, randomized, controlled trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Double-Blind Method; Fasting; Female; Humans; Hypoglyce | 2015 |
The impact of metformin treatment on adiponectin and resistin levels in women with polycystic ovary syndrome: a prospective clinical study.
Topics: Adiponectin; Adult; Body Mass Index; Female; Humans; Insulin; Insulin Resistance; Metformin; Polycys | 2015 |
Improved insulin sensitivity and body composition, irrespective of macronutrient intake, after a 12 month intervention in adolescents with pre-diabetes; RESIST a randomised control trial.
Topics: Adolescent; Blood Pressure; Body Composition; Body Mass Index; Child; Combined Modality Therapy; Die | 2014 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study.
Topics: Adolescent; Adult; Biomarkers; Cardiac Output; Coronary Artery Disease; Delayed-Action Preparations; | 2015 |
Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fast | 2015 |
Diurnal variation in skeletal muscle and liver glycogen in humans with normal health and Type 2 diabetes.
Topics: Carbon Isotopes; Circadian Rhythm; Diabetes Mellitus, Type 2; Female; Glycogen; Humans; Insulin Resi | 2015 |
Efficacy of metformin in pregnant obese women: a randomised controlled trial.
Topics: Adolescent; Adult; Birth Weight; Blood Glucose; Clinical Protocols; Diabetes, Gestational; Double-Bl | 2015 |
Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
Topics: Adult; Cross-Sectional Studies; Female; Fibronectins; Glucose Tolerance Test; Humans; Hypoglycemic A | 2015 |
Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemog | 2015 |
Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemog | 2015 |
Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemog | 2015 |
Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemog | 2015 |
Effect of insulin sensitizer therapy on amino acids and their metabolites.
Topics: Adult; Amino Acids; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose C | 2015 |
Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome.
Topics: Adolescent; Androgens; Body Mass Index; Child; Chromatography, Liquid; Contraceptives, Oral, Combine | 2015 |
Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial.
Topics: Aging; AMP-Activated Protein Kinases; Biomarkers; Blood Glucose; Cell Death; Female; Humans; Hypogly | 2015 |
Low glycaemic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments.
Topics: Acne Vulgaris; Adolescent; Adult; Combined Modality Therapy; Diet, Reducing; Glucose; Glycemic Index | 2016 |
The Efficacy and Safety of Chinese Herbal Medicine Jinlida as Add-On Medication in Type 2 Diabetes Patients Ineffectively Managed by Metformin Monotherapy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial.
Topics: Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Drugs, Chine | 2015 |
Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D.
Topics: Aged; Biomarkers; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus | 2015 |
Effects of commonly used antidiabetic drugs on antioxidant enzymes and liver function test markers in type 2 diabetes mellitus subjects - pilot study.
Topics: Adult; Alanine Transaminase; Antioxidants; Bilirubin; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2015 |
Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
Topics: Amylases; Blood Glucose; Body Fat Distribution; Body Weight; Diabetes Mellitus, Type 2; Drug Adminis | 2015 |
Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Drug Therapy, Com | 2016 |
Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment.
Topics: Adult; Body Mass Index; Cross-Sectional Studies; Female; Gonadal Steroid Hormones; Humans; Hypoglyce | 2016 |
Circulating hepcidin in type 2 diabetes: A multivariate analysis and double blind evaluation of metformin effects.
Topics: Adult; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Ferritins; H | 2015 |
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1 PREDICTS INSULIN SENSITIVITY AND INSULIN AREA-UNDER-THE-CURVE IN OBESE, NONDIABETIC ADOLESCENTS.
Topics: Adolescent; Area Under Curve; Biomarkers; Blood Glucose; Female; Glucose Tolerance Test; Humans; Ins | 2016 |
Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Genetic Variation; Huma | 2016 |
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Endometrial | 2016 |
Metformin Decreases Thyroid Volume and Nodule Size in Subjects with Insulin Resistance: A Preliminary Study.
Topics: Adult; Aged; Body Mass Index; Body Weights and Measures; Diet; Exercise; Humans; Hypoglycemic Agents | 2016 |
[Effect of Qingre Yangyin Recipe on Endocrine and Metabolism of Polycystic Ovary Syndrome Patients].
Topics: Adiponectin; Blood Glucose; Body Mass Index; Drugs, Chinese Herbal; Estradiol; Female; Follicle Stim | 2015 |
Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors.
Topics: Aged; Aged, 80 and over; Blood Glucose; Breast Neoplasms; C-Reactive Protein; Estradiol; Exercise; F | 2016 |
Factors that influence the efficacy of acarbose and metformin as initial therapy in Chinese patients with newly diagnosed type 2 diabetes: a subanalysis of the MARCH trial.
Topics: Acarbose; Adult; Area Under Curve; Asian People; Blood Glucose; Body Mass Index; China; Clinical Tri | 2016 |
METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN.
Topics: Adipose Tissue; Adult; Aging; Body Fat Distribution; Climacteric; Double-Blind Method; Drug Combinat | 2016 |
Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
Topics: Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Carcinoma, Endometrioid; Endometrial Hyperplasia; | 2016 |
Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Double-Blind Method; Dyslipidemias; Female; | 2016 |
Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study.
Topics: Adult; Amino Acids; Amino Acids, Branched-Chain; Coronary Disease; Diabetes Mellitus, Type 2; Diabet | 2016 |
The Effect of Metformin on Hypothalamic-Pituitary-Thyroid Axis Activity in Women with Interferon-Induced Hypothyroidism: A Pilot Study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Hashimoto Disease; Humans; H | 2016 |
Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial.
Topics: Adolescent; Adult; Androstenes; Carbohydrate Metabolism; Contraceptives, Oral; Cyproterone Acetate; | 2016 |
Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients.
Topics: Acupuncture Therapy; Adiponectin; Adult; Biomarkers; Body Mass Index; Body Weight; Cholesterol, HDL; | 2016 |
[The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypog | 2016 |
Combination of Saxagliptin and Metformin Is Effective as Initial Therapy in New-Onset Type 2 Diabetes Mellitus With Severe Hyperglycemia.
Topics: Adamantane; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; | 2016 |
[Metformin has no effect on median birth weight score in pregnant non-diabetic women with BMI >35].
Topics: Adult; Birth Weight; Body Mass Index; Diabetes, Gestational; Double-Blind Method; Female; Humans; In | 2016 |
Short-term antidiabetic treatment with insulin or metformin has a similar impact on the components of metabolic syndrome in women with gestational diabetes mellitus requiring antidiabetic agents: results of a prospective, randomised study.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglyce | 2016 |
Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome.
Topics: Body Mass Index; Cannabinoid Receptor Antagonists; Cytokines; Female; Hepatocyte Growth Factor; Huma | 2016 |
Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy.
Topics: Adult; Aged; Aging; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Double-Blind Method; | 2016 |
Correlates of Medication Adherence in the TODAY Cohort of Youth With Type 2 Diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Cohort Studies; Depression; Diabetes Mellitus, Ty | 2016 |
Glucose Control in Severely Burned Patients Using Metformin: An Interim Safety and Efficacy Analysis of a Phase II Randomized Controlled Trial.
Topics: Blood Glucose; Burns; Fats; Female; Glucose Tolerance Test; Humans; Hypoglycemia; Insulin; Insulin R | 2016 |
Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance.
Topics: Adiposity; Body Weight; Child; Double-Blind Method; Female; Genotype; Glomerular Filtration Rate; Hu | 2017 |
The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study.
Topics: Adult; Female; Humans; Hydroxycholecalciferols; Hyperandrogenism; Hypoglycemic Agents; Insulin Resis | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr | 2016 |
Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial.
Topics: Adolescent; Body Composition; Child; Double-Blind Method; Exercise; Female; Humans; Hypoglycemic Age | 2016 |
Randomized Controlled Study of Metformin and Sitagliptin on Long-term Normoglycemia Remission in African American Patients With Hyperglycemic Crises.
Topics: Adolescent; Adult; Black or African American; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic K | 2016 |
Effects of Conjugated Linoleic Acid and Metformin on Insulin Sensitivity in Obese Children: Randomized Clinical Trial.
Topics: Adolescent; Biomarkers; Blood Glucose; Body Composition; Cardiovascular Diseases; Child; Double-Blin | 2017 |
Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Metformin; Out | 2017 |
Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug | 2016 |
Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
Topics: Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fema | 2017 |
Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Body Weight; Clozapine; Double-Blind Method; Female; H | 2016 |
Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Body Weight; Clozapine; Double-Blind Method; Female; H | 2016 |
Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Body Weight; Clozapine; Double-Blind Method; Female; H | 2016 |
Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Body Weight; Clozapine; Double-Blind Method; Female; H | 2016 |
Host-microbiome interactions in human type 2 diabetes following prebiotic fibre (galacto-oligosaccharide) intake.
Topics: Adult; Aged; Biomarkers; Cohort Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Dysbiosis; | 2016 |
A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Female; Folic Acid; Humans; Inositol; I | 2017 |
Effect of Metformin Therapy on Serum Fetuin Levels in Insulin Resistant Type 1 Diabetics.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Fetuins; Hum | 2018 |
The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome.
Topics: Adult; Biomarkers; Blood Glucose; Body Mass Index; Bone Density Conservation Agents; Female; Follow- | 2017 |
Acupuncture treatment for insulin sensitivity of women with polycystic ovary syndrome and insulin resistance: a study protocol for a randomized controlled trial.
Topics: Acupuncture Therapy; Adolescent; Adult; Biomarkers; Blood Glucose; China; Clinical Protocols; Combin | 2017 |
Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2009 |
Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test.
Topics: Adult; Area Under Curve; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Toler | 2008 |
An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet.
Topics: Adult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabete | 2008 |
Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial.
Topics: Adolescent; Body Weight; Child; Double-Blind Method; Female; Humans; Hyperinsulinism; Hypoglycemic A | 2008 |
Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Biopsy; Body Mass Index; Child; Fatty | 2008 |
Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome.
Topics: Androgens; Brachial Artery; C-Reactive Protein; Cardiovascular Diseases; Endothelium, Vascular; Fema | 2008 |
Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus.
Topics: Aged; alpha-2-HS-Glycoprotein; Blood Proteins; Diabetes Mellitus, Type 2; Exercise; Exercise Therapy | 2008 |
Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance.
Topics: Adolescent; Body Mass Index; Carbohydrate Metabolism; Cardiovascular Diseases; Exercise Test; Female | 2008 |
The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglyc | 2008 |
The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.
Topics: Adult; Body Mass Index; Diabetes Mellitus, Type 2; Exercise; Fatty Liver; Female; Glycated Hemoglobi | 2009 |
Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone?
Topics: Adiponectin; Adult; Aged; Benzamides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated | 2008 |
Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Topics: Adult; Arginine; Biomarkers; Blood Glucose; C-Reactive Protein; Contraceptives, Oral, Combined; Cont | 2010 |
[Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fem | 2008 |
Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome.
Topics: Adult; Female; Hair Removal; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; | 2009 |
Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS).
Topics: Adult; Androgens; Female; Humans; Insulin Resistance; Metformin; Piperidines; Polycystic Ovary Syndr | 2009 |
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypoglycemic | 2009 |
Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Cholesterol; Contraceptive Agents, Female; Drug Therapy, Combina | 2009 |
Determinants of interleukin-6 and C-reactive protein vary in polycystic ovary syndrome, as do effects of short- and long-term metformin therapy.
Topics: Adiposity; Adult; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Diabetes Mellit | 2009 |
Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy.
Topics: Adult; Aldosterone; Androgens; Area Under Curve; Blood Glucose; Case-Control Studies; Female; Humans | 2009 |
Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Double | 2009 |
Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
Topics: Adult; Blood Coagulation; Cyproterone Acetate; Estrogens; Ethinyl Estradiol; Female; Fibrin Fibrinog | 2010 |
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
Topics: Adenosine Triphosphate; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2009 |
Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance.
Topics: Adipokines; Adolescent; Body Mass Index; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2 | 2009 |
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Mass Index; Caloric Restriction; Diabetes Mel | 2009 |
Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1.
Topics: Adult; Case-Control Studies; Cell Movement; Cells, Cultured; Culture Media, Conditioned; Down-Regula | 2009 |
Metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Female; Humans; Hypoglycemic Agents; Insulin; Ins | 2010 |
Insulin and metformin regulate circulating and adipose tissue chemerin.
Topics: Adipose Tissue; Adolescent; Adult; Androstenedione; Dehydroepiandrosterone Sulfate; Dose-Response Re | 2009 |
Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.
Topics: Adult; Anthropometry; Antipsychotic Agents; Blood Glucose; Blood Pressure; Body Mass Index; Body Wei | 2009 |
Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Pressure; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fasting; Female; Fi | 2009 |
Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome.
Topics: Adolescent; Adult; Androgens; Anovulation; Female; Glucose Tolerance Test; Hormones; Humans; Hypogly | 2009 |
Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Clomiphene; Double-Blind Method; Drug Resistance; | 2009 |
Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Body Mass Index | 2009 |
Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1).
Topics: Adult; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; | 2009 |
Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combin | 2009 |
Association of scavenger receptors in adipose tissue with insulin resistance in nondiabetic humans.
Topics: Adipocytes; Adiponectin; Adult; Aged; CD36 Antigens; Cell Line; Coculture Techniques; Down-Regulatio | 2009 |
Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
Topics: Adult; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Fem | 2010 |
Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS).
Topics: Adult; Atorvastatin; C-Reactive Protein; Drug Synergism; Female; Heptanoic Acids; Humans; Hydroxymet | 2010 |
Intraperitoneal fat and insulin resistance in obese adolescents.
Topics: Abdominal Fat; Absorptiometry, Photon; Adiposity; Adolescent; Anthropometry; Biomarkers; Black or Af | 2010 |
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepatitis | 2009 |
[Advantages of Chinese medicine for treatment of blood sugar and lipid metabolic disorders in patients with polycystic ovarian syndrome].
Topics: Adolescent; Adult; Blood Glucose; Cholesterol, HDL; Cyproterone; Drugs, Chinese Herbal; Female; Huma | 2009 |
Metformin versus laparoscopic ovarian drilling in clomiphene- and insulin-resistant women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Hormones; Humans; Hypoglycemic Agents; Insulin | 2010 |
Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women.
Topics: Adult; Appetite Depressants; C-Reactive Protein; Cyclobutanes; Drug Therapy, Combination; Female; Hu | 2010 |
Leptin concentrations in patients with polycystic ovary syndrome before and after met-formin treatment depending on insulin resistance, body mass index and androgen con-centrations--introductory report.
Topics: Androgens; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Leptin; Metform | 2009 |
Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial.
Topics: Adenylate Kinase; Adult; Aorta; Cross-Over Studies; Endothelium, Vascular; Female; Humans; Hypoglyce | 2010 |
Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial.
Topics: Adenylate Kinase; Adult; Aorta; Cross-Over Studies; Endothelium, Vascular; Female; Humans; Hypoglyce | 2010 |
Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial.
Topics: Adenylate Kinase; Adult; Aorta; Cross-Over Studies; Endothelium, Vascular; Female; Humans; Hypoglyce | 2010 |
Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial.
Topics: Adenylate Kinase; Adult; Aorta; Cross-Over Studies; Endothelium, Vascular; Female; Humans; Hypoglyce | 2010 |
The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome.
Topics: Blood Glucose; Caloric Restriction; Drug Administration Schedule; Endocrine System; Female; Follow-U | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Topics: Adiponectin; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Diet; Double | 2010 |
Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome.
Topics: Abortion, Habitual; Adult; Body Mass Index; Case-Control Studies; Diabetes, Gestational; Female; Fet | 2010 |
Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Anticholesteremic Agents; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Co | 2010 |
Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucose Clamp Techniq | 2010 |
Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up.
Topics: Adolescent; Anthropometry; Body Composition; Body Mass Index; Calcium; Delayed-Action Preparations; | 2010 |
Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up.
Topics: Adolescent; Anthropometry; Body Composition; Body Mass Index; Calcium; Delayed-Action Preparations; | 2010 |
Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up.
Topics: Adolescent; Anthropometry; Body Composition; Body Mass Index; Calcium; Delayed-Action Preparations; | 2010 |
Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up.
Topics: Adolescent; Anthropometry; Body Composition; Body Mass Index; Calcium; Delayed-Action Preparations; | 2010 |
Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial.
Topics: Adult; Blood Pressure; Body Mass Index; Cholesterol; Double-Blind Method; Female; Follicle Stimulati | 2010 |
Exenatide versus glibenclamide in patients with diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Body Weight; C-Reactive | 2010 |
Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes.
Topics: Age of Onset; Body Fat Distribution; Chromatography, Gel; Chromatography, High Pressure Liquid; Diab | 2010 |
Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study.
Topics: Adiponectin; Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypoglycemi | 2010 |
Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial.
Topics: Aged; Double-Blind Method; Female; Fertility Agents, Female; Follicle Stimulating Hormone; Humans; H | 2010 |
Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals.
Topics: Analysis of Variance; Blood Pressure; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Do | 2010 |
Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients.
Topics: Adult; Androgen Antagonists; Body Mass Index; CD40 Antigens; Contraceptives, Oral; Cyproterone Aceta | 2011 |
Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Clozapine; Double-Blind Method; Female; | 2010 |
Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study.
Topics: Adolescent; Body Mass Index; Body Weight; Child; Female; Humans; Hypoglycemic Agents; Insulin; Insul | 2010 |
Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study.
Topics: Adolescent; Adult; Brachial Artery; Cardiovascular Diseases; Endothelium, Vascular; Female; Humans; | 2011 |
Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Interleukin-18; Interleukin-6; Metfo | 2010 |
Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
Topics: Aberrant Crypt Foci; Adenoma; Aged; Antineoplastic Agents; Cell Proliferation; Clinical Trials as To | 2010 |
The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Topics: Adolescent; Adult; Androgen Antagonists; Androstenes; Anti-Mullerian Hormone; Blood Glucose; Body Ma | 2011 |
[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].
Topics: Blood Glucose; Carbohydrate Metabolism; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug The | 2010 |
Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy.
Topics: Area Under Curve; Biomarkers; Cholesterol; Fatty Acids, Nonesterified; HIV-Associated Lipodystrophy | 2011 |
Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; | 2011 |
Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
Topics: Adiponectin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug | 2011 |
Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment.
Topics: Adult; Arginine; Body Mass Index; Cardiovascular Diseases; Contraceptives, Oral; Female; Homocystein | 2011 |
Metformin treatment for small benign thyroid nodules in patients with insulin resistance.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combinati | 2011 |
Metformin improves semen characteristics of oligo-terato-asthenozoospermic men with metabolic syndrome.
Topics: Adult; Androgens; Asthenozoospermia; Humans; Hypoglycemic Agents; Infertility, Male; Insulin Resista | 2011 |
Role of decreased circulating hepcidin concentrations in the iron excess of women with the polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Anthropometry; Antimicrobial Cationic Peptides; Case-Control Studies; F | 2011 |
Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial.
Topics: Body Composition; Body Weight; Child; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insu | 2011 |
Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome.
Topics: Adult; Algorithms; Androgens; Body Mass Index; Cohort Studies; Dose-Response Relationship, Drug; Fem | 2011 |
Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
Topics: Adult; Body Mass Index; Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabet | 2011 |
The effect of oral metformin on insulin sensitivity in insulin-resistant ponies.
Topics: Administration, Oral; Animals; Blood Glucose; Cross-Over Studies; Female; Horse Diseases; Horses; Hy | 2012 |
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin Resistance; | 2011 |
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Topics: Adiponectin; Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; | 2011 |
Randomized controlled trial of different doses of metformin for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Dose-Response Relationship, Drug; Female; Fertility Agents, Female; Humans; Hyper | 2011 |
Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Met | 2011 |
Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess.
Topics: Adolescent; Androgen Antagonists; Biomarkers; Body Mass Index; Child; Contraceptives, Oral, Combined | 2011 |
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients.
Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Femal | 2011 |
Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: a double-blind, randomized, controlled study.
Topics: Administration, Oral; Adult; Anthropometry; Asian People; Body Composition; China; Diabetes Mellitus | 2011 |
Effects of Portulaca oleracea L. seeds in treatment of type-2 diabetes mellitus patients as adjunctive and alternative therapy.
Topics: Adult; Bilirubin; Biomarkers; Blood Glucose; Complementary Therapies; Diabetes Mellitus, Type 2; Dou | 2011 |
Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Contraceptives, Oral, Combined; Contraceptives, Ora | 2011 |
[Effects of metformin therapy on markers of coagulation disorders in hyperinsulinemic women with polycystic ovary syndrome].
Topics: Adult; Blood Coagulation Factors; Body Mass Index; Female; Humans; Hyperinsulinism; Hypoglycemic Age | 2011 |
Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Topics: Adult; Biomarkers; C-Reactive Protein; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Co | 2011 |
Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
Topics: Alanine Transaminase; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Fema | 2012 |
Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome.
Topics: Acetylcysteine; Adolescent; Adult; Anticholesteremic Agents; Antioxidants; Body Mass Index; Female; | 2011 |
Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes.
Topics: Administration, Oral; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans; | 2012 |
A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Behavior Therapy; Blood Glucose; Disease-Free Surviva | 2012 |
A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome.
Topics: Berberine; Cholesterol; Cholesterol, LDL; Female; Humans; Insulin Resistance; Metformin; Polycystic | 2012 |
Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes.
Topics: Adult; AMP-Activated Protein Kinases; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2012 |
Combination therapy with metformin and fenofibrate for insulin resistance in obesity.
Topics: Adult; Body Mass Index; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Humans; | 2011 |
Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; In | 2012 |
Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Double-Blind Method; Femal | 2012 |
Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome.
Topics: Adult; Biomarkers; Blood Glucose; Body Mass Index; Cholesterol; Drug Administration Schedule; Female | 2012 |
The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Enzyme-Lin | 2012 |
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Comb | 2012 |
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Blood Glucose; Breast Neoplasms; Cell Prolife | 2012 |
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Blood Glucose; Breast Neoplasms; Cell Prolife | 2012 |
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Blood Glucose; Breast Neoplasms; Cell Prolife | 2012 |
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Blood Glucose; Breast Neoplasms; Cell Prolife | 2012 |
The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial.
Topics: Adiponectin; Adolescent; Body Mass Index; C-Reactive Protein; Double-Blind Method; Female; Humans; H | 2012 |
Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study.
Topics: Adult; Aged; Algorithms; Breast Neoplasms; Carcinoma; Diabetes Mellitus; Dose-Response Relationship, | 2012 |
Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?
Topics: Adiponectin; Adult; Aged; Biomarkers; Blood Glucose; Down-Regulation; Fatty Liver; Female; Hemodynam | 2012 |
Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistance.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus; Drug Therapy, Combination; Gluc | 2012 |
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
Topics: Blood Glucose; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Drug T | 2012 |
Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study.
Topics: Adolescent; Adult; Amenorrhea; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Do | 2012 |
Haemostatic effects of metformin in simvastatin-treated volunteers with impaired fasting glucose.
Topics: Antigens; Blood Coagulation; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relati | 2012 |
The effect of metformin on insulin resistance and exercise parameters in patients with heart failure.
Topics: Aged; Diabetes Mellitus; Double-Blind Method; Exercise; Exercise Test; Exercise Tolerance; Female; H | 2012 |
Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome.
Topics: Adult; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA | 2012 |
Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
Topics: Adult; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypo | 2012 |
Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus.
Topics: Adult; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Cl | 2012 |
Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus.
Topics: Adult; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Cl | 2012 |
Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus.
Topics: Adult; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Cl | 2012 |
Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus.
Topics: Adult; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Cl | 2012 |
Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus.
Topics: Adult; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Cl | 2012 |
Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus.
Topics: Adult; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Cl | 2012 |
Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus.
Topics: Adult; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Cl | 2012 |
Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus.
Topics: Adult; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Cl | 2012 |
Effect of metformin glycinate on glycated hemoglobin A1C concentration and insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus.
Topics: Adult; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Cl | 2012 |
Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression.
Topics: Adolescent; Adult; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Double-Blind Metho | 2013 |
A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyp | 2012 |
Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.
Topics: Adamantane; Adult; Chemokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double | 2012 |
Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Antioxidants; Aspartate Aminotransferases; | 2012 |
Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
Topics: Adult; Body Mass Index; C-Reactive Protein; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Ins | 2013 |
Encouraging Metformin data reported by researchers.
Topics: CD4 Lymphocyte Count; HIV Infections; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Vi | 2000 |
Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance.
Topics: Adipose Tissue; Adult; Biomarkers; Blood Glucose; Body Composition; Body Mass Index; Cardiovascular | 2002 |
Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels.
Topics: Adult; Androgens; Androstenedione; Diet, Reducing; Female; Ghrelin; Homeostasis; Humans; Hypoglycemi | 2002 |
Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial.
Topics: Adolescent; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glucose Tolerance Test; Gl | 2003 |
Beneficial effects of a glyburide/metformin combination preparation in type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Glyburide; Hemoglobin A; Humans; Hypogl | 2003 |
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
Topics: Adult; Apolipoproteins B; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type | 2003 |
Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.
Topics: Adipose Tissue; Androgen Antagonists; Child; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2003 |
The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial.
Topics: Adult; Buserelin; Cross-Over Studies; Female; Fertilization in Vitro; Follicle Stimulating Hormone; | 2003 |
Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study.
Topics: Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Bli | 2003 |
[Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome].
Topics: Adult; Female; Humans; Infertility, Female; Insulin Resistance; Metformin; Ovarian Hyperstimulation | 2003 |
Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Anthropometry; Blood Glucose; Blood Pressure; Body Mass Index; | 2003 |
Effects of short-term metformin treatment on insulin sensitivity of blood glucose and free fatty acids.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Fema | 2004 |
Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects.
Topics: Blood Glucose; C-Reactive Protein; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic | 2004 |
Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome.
Topics: Adolescent; Body Composition; Body Constitution; Body Mass Index; Child; Disease Progression; Female | 2004 |
Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.
Topics: Administration, Oral; Adult; Body Mass Index; Body Weight; Double-Blind Method; Female; Hormones; Hu | 2004 |
Complementary mode of action of rosiglitazone and metformin in a single tablet for the treatment of diabetes mellitus type 2.
Topics: Adult; Aged; Area Under Curve; Biological Availability; Diabetes Mellitus, Type 2; Dose-Response Rel | 2004 |
Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.
Topics: Aged; Arginine; Blood Glucose; Blood Pressure; Body Composition; Body Constitution; Body Weight; Dia | 2004 |
Metformin in the treatment of patients with non-alcoholic steatohepatitis.
Topics: Adult; Blood Glucose; C-Peptide; Female; Hepatitis; Humans; Hypoglycemic Agents; Insulin Resistance; | 2004 |
Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout preg
Topics: Adult; Body Weight; Cohort Studies; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insu | 2004 |
The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Endometrium; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Inferti | 2004 |
[Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Data Interpretation, Statistical; Female; Follow-Up Studies; Glu | 2004 |
Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes.
Topics: Analysis of Variance; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fem | 2004 |
Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women.
Topics: Adult; Dietary Fats; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypogl | 2004 |
Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Infertility, Female; Insulin; Insulin Resist | 2004 |
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Drug Evaluation; Female; Hepatitis; Humans; Hypog | 2004 |
Pioglitazone reduces blood pressure in non-dipping diabetic patients.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circa | 2004 |
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
Topics: Adipose Tissue; Cholesterol; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Humans; | 2004 |
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Dehydroepiandrosterone Sulfate; Double-Blind Method; Drug Therapy, | 2004 |
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Dehydroepiandrosterone Sulfate; Double-Blind Method; Drug Therapy, | 2004 |
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Dehydroepiandrosterone Sulfate; Double-Blind Method; Drug Therapy, | 2004 |
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Dehydroepiandrosterone Sulfate; Double-Blind Method; Drug Therapy, | 2004 |
[Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome].
Topics: Adult; Body Mass Index; Clomiphene; Drug Therapy, Combination; Female; Humans; Insulin Resistance; M | 2004 |
Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome.
Topics: Acarbose; Adult; Blood Glucose; Clomiphene; Drug Resistance; Female; Follicle Stimulating Hormone; H | 2005 |
Effect of metformin vs. placebo treatment on serum fatty acids in non-diabetic obese insulin resistant individuals.
Topics: Adult; Anthropometry; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; | 2004 |
Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women.
Topics: Adult; Anovulation; Appetite Depressants; Body Mass Index; Chronic Disease; Cyclobutanes; Diet, Redu | 2004 |
Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome.
Topics: Adult; Blood Pressure; Body Mass Index; Body Weight; Cholesterol; Enzyme Inhibitors; Female; Humans; | 2005 |
Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy.
Topics: Adiponectin; Blood Glucose; Body Composition; C-Reactive Protein; Cross-Over Studies; Diabetes Melli | 2004 |
The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.
Topics: Adult; Androgens; Contraceptives, Oral, Combined; Female; Humans; Hypoglycemic Agents; Insulin Resis | 2005 |
The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.
Topics: Adult; Androgens; Contraceptives, Oral, Combined; Female; Humans; Hypoglycemic Agents; Insulin Resis | 2005 |
The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.
Topics: Adult; Androgens; Contraceptives, Oral, Combined; Female; Humans; Hypoglycemic Agents; Insulin Resis | 2005 |
The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.
Topics: Adult; Androgens; Contraceptives, Oral, Combined; Female; Humans; Hypoglycemic Agents; Insulin Resis | 2005 |
Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; | 2004 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
Topics: Adult; Anovulation; Blood Glucose; Body Weight; Female; Folic Acid; Homocysteine; Humans; Hypoglycem | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue.
Topics: Adipose Tissue; Adult; Aged; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; L | 2005 |
Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resist | 2005 |
Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; India; Insulin; Insulin Resis | 2004 |
Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Body Mass Index; Cyproterone Acetate; Dehydroepiandrosterone Sulfate; D | 2005 |
Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Femal | 2005 |
Differential regulation of insulin action and tumor necrosis factor alpha system activity by metformin.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Glucose Intolerance; Gluco | 2005 |
Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Female; Flutamide | 2004 |
Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Body Mass Index; Dehydroepiandrosterone Sulfate; Estradiol; Fem | 2004 |
Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome.
Topics: Adiponectin; Body Composition; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combina | 2005 |
Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes.
Topics: Adult; Blood Glucose; Body Composition; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; | 2005 |
The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Hom | 2005 |
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Humans; Hypoglycemic Agen | 2005 |
A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.
Topics: Adolescent; Blood Glucose; Child; Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistan | 2005 |
Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study.
Topics: Administration, Oral; Adult; Aorta; Blood Flow Velocity; Blood Glucose; Blood Pressure; Double-Blind | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
Metformin administration improves endothelial function in women with polycystic ovary syndrome.
Topics: Adult; Brachial Artery; Endothelin-1; Endothelium, Vascular; Female; Glucose Intolerance; Humans; Hy | 2005 |
Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses.
Topics: Administration, Oral; Androstenedione; Blood Glucose; Dehydroepiandrosterone Sulfate; Female; Humans | 2005 |
The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.
Topics: Adult; Apolipoproteins B; Biomarkers; Blood Glucose; Fatty Acids, Nonesterified; Humans; Hypoglycemi | 2005 |
[Study on the effect of qinggan jiangtang tablet in improving the insulin resistance in patients with multiple metabolic syndrome].
Topics: Adult; Aged; Double-Blind Method; Drugs, Chinese Herbal; Female; Humans; Hypoglycemic Agents; Insuli | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hy | 2005 |
Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone.
Topics: Adipose Tissue; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Count; Chemokin | 2005 |
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Tolerance Tes | 2005 |
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Tolerance Tes | 2005 |
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Tolerance Tes | 2005 |
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Tolerance Tes | 2005 |
Metformin improves endothelial function in patients with metabolic syndrome.
Topics: Brachial Artery; Endothelium, Vascular; Female; Homeostasis; Humans; Hypoglycemic Agents; Image Proc | 2005 |
Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome.
Topics: Adolescent; Adult; Androgen Antagonists; Androstenedione; Body Mass Index; Cyproterone Acetate; Drug | 2005 |
The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Topics: Adult; Androgens; Antioxidants; Blood Glucose; Body Mass Index; Body Weight; Female; Homeostasis; Ho | 2005 |
Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients.
Topics: Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Female; | 2005 |
Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.
Topics: Adipose Tissue; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorodeoxyglucose F18 | 2005 |
Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
Topics: Adult; Anthropometry; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2006 |
Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol, HDL; Cholesterol, LDL; HIV Infections; Hu | 2005 |
Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Child; Contraceptives, Oral; Female; Humans; Hyperinsulinism; Hypoglyc | 2005 |
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Topics: Analysis of Variance; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Dou | 2005 |
Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Dehydroepiandrosterone Sulfate; Female; Humans; Hyperandrogenism; Hypoglycem | 2006 |
Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein.
Topics: Adult; Antimicrobial Cationic Peptides; Blood Proteins; Diabetes Mellitus, Type 2; Gene Expression R | 2006 |
Insulin dynamics predict body mass index and z-score response to insulin suppression or sensitization pharmacotherapy in obese children.
Topics: Adolescent; Black People; Blood Glucose; Body Mass Index; Central Nervous System Diseases; Child; Ch | 2006 |
Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
Topics: Adult; C-Reactive Protein; Case-Control Studies; Cell Adhesion Molecules; E-Selectin; Female; Humans | 2006 |
[Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)].
Topics: Adult; Aged; Blood Glucose; Female; Follow-Up Studies; Gout; Humans; Hypoglycemic Agents; Insulin Re | 2005 |
Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome.
Topics: Adolescent; Cholesterol, HDL; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Hypoglyce | 2006 |
Metformin increases insulin sensitivity and plasma beta-endorphin in human subjects.
Topics: Adult; beta-Endorphin; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Dose-Response Relationsh | 2006 |
Prevention of type 2 diabetes in the prediabetic population.
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Exercise; Female; Glucose I | 2005 |
Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin.
Topics: Adolescent; Body Composition; Body Mass Index; Child; Cross-Over Studies; Double-Blind Method; Fasti | 2006 |
Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin.
Topics: Adolescent; Body Composition; Body Mass Index; Child; Cross-Over Studies; Double-Blind Method; Fasti | 2006 |
Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin.
Topics: Adolescent; Body Composition; Body Mass Index; Child; Cross-Over Studies; Double-Blind Method; Fasti | 2006 |
Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin.
Topics: Adolescent; Body Composition; Body Mass Index; Child; Cross-Over Studies; Double-Blind Method; Fasti | 2006 |
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Diabetes Mellitus, Typ | 2006 |
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue.
Topics: Adult; Aged; Biopsy; Blood Glucose; Caloric Restriction; Chromans; Diabetes Mellitus, Type 2; Female | 2006 |
Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling.
Topics: Adult; Androgens; Blood Glucose; Combined Modality Therapy; Electrocoagulation; Female; Humans; Hypo | 2006 |
Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; G | 2006 |
Metformin treatment is effective in obese teenage girls with PCOS.
Topics: Adolescent; Estradiol; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Insulin Re | 2006 |
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hypo | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Cholesterol; Coronary Disease; Diet; Female; Humans; Insulin; Insulin Resistance; | 2006 |
Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione.
Topics: Blood Glucose; Body Weight; C-Peptide; Cell Adhesion Molecules; Chromans; Diabetes Mellitus, Type 2; | 2006 |
Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Angina Pectoris; Double-Blind Method; Electrocardiography; Exercise Tolerance; Female; Humans | 2006 |
Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Dia | 2006 |
Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians--Result of Indian diabetes prevention programme.
Topics: Adult; Diabetes Mellitus; Female; Glucose Intolerance; Humans; India; Insulin Resistance; Life Style | 2007 |
Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Dru | 2006 |
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combina | 2006 |
Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study.
Topics: Acanthosis Nigricans; Administration, Oral; Adult; Female; Humans; Hypoglycemic Agents; Insulin; Ins | 2006 |
Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes.
Topics: Alanine Transaminase; Basal Metabolism; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Acids, N | 2007 |
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.
Topics: Adult; Age Distribution; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Europe; Female; Glyburide; | 2006 |
Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administrati | 2006 |
A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Blood Glucose; Body Mass Index; Child; Diabetes Melli | 2006 |
[Clinical, hormonal and biochemical changes after treatment with metformin and weight reduction in women with polycystic ovary syndrome].
Topics: Adolescent; Adult; Caloric Restriction; Exercise; Female; Hormones; Humans; Hypoglycemic Agents; Ins | 2006 |
The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being.
Topics: Adolescent; Adult; Body Composition; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; H | 2007 |
Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Topics: Adiponectin; Analysis of Variance; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, | 2007 |
Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; C-Reactive Protein; Double-Blind Method | 2007 |
Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Body Mass Index; Cardiovascular Physiological Phenomena; Contraceptives, Or | 2007 |
Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome.
Topics: Adult; Female; Homocysteine; Humans; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Prosp | 2007 |
Short-term effects of metformin in type 2 diabetes.
Topics: Aged; Area Under Curve; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Drug Administration S | 2007 |
Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
Topics: Adipose Tissue; Adolescent; Adult; Aged; B-Lymphocytes; Blood Glucose; Body Composition; Female; Hum | 2008 |
Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Topics: Administration, Oral; Adult; Androgen Antagonists; Androgens; Blood Glucose; Cardiovascular Diseases | 2007 |
Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference.
Topics: Adult; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2007 |
Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Glucose; Carbazoles; Carvedilol; Diabete | 2007 |
Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Topics: Adiponectin; Aged; Aldosterone; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus; Fa | 2007 |
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass Index; Body | 2007 |
Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance.
Topics: Adult; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycyst | 2007 |
Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Body Mass Index; Body Weight; Female; Glucose Clamp Technique; Hormones; Hu | 2007 |
Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Int | 2007 |
Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
Topics: Adolescent; Adult; Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; | 2007 |
Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study.
Topics: Adolescent; Adult; C-Reactive Protein; Drug Administration Schedule; Female; Humans; Hypoglycemic Ag | 2007 |
Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Biomarkers; Blood Glucose; Body Mass Index; C-Reactive P | 2007 |
Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Weight; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insul | 2008 |
A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy.
Topics: Adipose Tissue; Adiposity; Adult; Area Under Curve; Female; HIV Infections; HIV-Associated Lipodystr | 2007 |
[Serum level of retinol-binding protein 4 in obese patients with insulin resistance and in patients with type 2 diabetes treated with metformin].
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; M | 2007 |
Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Blood Glucose; Drug Administration Schedul | 2007 |
Lowering the threshold for defining microalbuminuria: effects of a lifestyle-metformin intervention in obese "normoalbuminuric" non-diabetic subjects.
Topics: Adult; Albuminuria; Blood Pressure; Caloric Restriction; Cardiovascular Diseases; Creatinine; Exerci | 2008 |
Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; G | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Res | 2008 |
Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome.
Topics: Adrenal Glands; Adult; Androgens; Body Mass Index; Chorionic Gonadotropin; Dehydroepiandrosterone Su | 2009 |
Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Analysis of Variance; Androgens; Female; Gene Expression; Glucose Transporter Typ | 2008 |
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resist | 2008 |
Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Contraceptives, Oral; Cyproterone; Ethinyl Estradiol; Female; Glucose Tolera | 2008 |
Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypo | 2008 |
A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study.
Topics: Adult; Female; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Piperidines; Polycystic Ovar | 2008 |
The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study.
Topics: Adult; Aged; Blood Glucose; Body Weight; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Fem | 2008 |
Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Diet Therapy; Exercise Therapy; Fatty Live | 2008 |
Addition of metformin to a lifestyle modification program in adolescents with insulin resistance.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2008 |
Addition of metformin to a lifestyle modification program in adolescents with insulin resistance.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2008 |
Addition of metformin to a lifestyle modification program in adolescents with insulin resistance.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2008 |
Addition of metformin to a lifestyle modification program in adolescents with insulin resistance.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2008 |
The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Cross-Over Studies; Double-Blind Method; Hum | 1994 |
Short-term effects of metformin on insulin sensitivity and sodium homeostasis in essential hypertensives.
Topics: Adult; Blood Pressure; Double-Blind Method; Female; Homeostasis; Humans; Hypertension; Insulin Resis | 1993 |
Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.
Topics: Albuminuria; Asia; Biomarkers; Blood Glucose; C-Peptide; Cardiovascular Diseases; Cholesterol; Diabe | 1993 |
Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance.
Topics: Adult; Aged; Alanine; Aldosterone; Blood Glucose; Blood Pressure; Body Weight; Cross-Over Studies; D | 1996 |
The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.
Topics: Adipose Tissue; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cholesterol; Diabetes Mellit | 1996 |
Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome.
Topics: Adult; Androstenedione; Blood Glucose; Female; Glucose Clamp Technique; Humans; Hyperandrogenism; Hy | 1998 |
Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease.
Topics: Adult; Blood Glucose; Coronary Disease; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin | 1998 |
The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus; Diabetes Mellitus, | 1999 |
Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; Body Composition; Female; HIV Infections; HIV Protease Inhib | 1999 |
Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance.
Topics: Blood Glucose; C-Peptide; Double-Blind Method; Female; Fructosamine; Glucose Intolerance; Glycated H | 1999 |
Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Chorionic Gonadotropin; Female; Humans; Hyperinsulinism; Hypogl | 2000 |
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Buserelin; Cholesterol; Double-Blind | 2000 |
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Buserelin; Cholesterol; Double-Blind | 2000 |
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Buserelin; Cholesterol; Double-Blind | 2000 |
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Buserelin; Cholesterol; Double-Blind | 2000 |
[Combination treatment with insulin and metformin in type 2 diabetes. Improves glycemic control and prevents weight gain].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; In | 1999 |
Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial.
Topics: Adult; Area Under Curve; Blood Glucose; Double-Blind Method; Female; HIV Infections; Humans; Hyperin | 2000 |
Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Topics: Adult; Androgen Antagonists; Area Under Curve; Blood Glucose; Calorimetry; Cyproterone Acetate; Estr | 2000 |
Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.
Topics: Adipose Tissue; Adult; Cross-Sectional Studies; Female; HIV Infections; Humans; Hypoglycemic Agents; | 2001 |
Improved endothelial function with metformin in type 2 diabetes mellitus.
Topics: Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female | 2001 |
Improved endothelial function with metformin in type 2 diabetes mellitus.
Topics: Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female | 2001 |
Improved endothelial function with metformin in type 2 diabetes mellitus.
Topics: Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female | 2001 |
Improved endothelial function with metformin in type 2 diabetes mellitus.
Topics: Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female | 2001 |
Gonadotropins at menopause: the influence of obesity, insulin resistance, and estrogens.
Topics: Chromans; Clomiphene; Estrogens; Feedback, Physiological; Female; Follicle Stimulating Hormone; Gona | 2001 |
Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistan | 2001 |
Metformin in obesity associated with antipsychotic drug administration: a pilot study.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Area Under Curve; Blood Glucose; Body Mass Index; Brie | 2001 |
Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Clomiphene; Female; Fertility Agents, F | 2001 |
Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Clomiphene; Female; Fertility Agents, F | 2001 |
Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Clomiphene; Female; Fertility Agents, F | 2001 |
Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Clomiphene; Female; Fertility Agents, F | 2001 |
Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hemodynamics; Hu | 2001 |
Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial.
Topics: Adult; Clomiphene; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Fem | 2002 |
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Blood Proteins; Cross-Over Studies; Diabetes Mellitus, | 2002 |
Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men.
Topics: Adipose Tissue; Adult; Blood Pressure; Body Weight; C-Peptide; Diabetes Mellitus; Glucagon; Humans; | 2002 |
Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation.
Topics: Adult; Androgen Antagonists; Anovulation; Drug Combinations; Female; Flutamide; Humans; Hyperandroge | 2002 |
Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.
Topics: Adolescent; Adult; Androstenedione; Body Constitution; Body Mass Index; Cyproterone Acetate; Drug Th | 2002 |
Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Glucose Clamp Technique; Glybu | 1992 |
Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM.
Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; | 1992 |
Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Insulin; | 1991 |
BIGPRO (biguanides and the prevention of the risk of obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance.
Topics: Adult; Aged; Arteriosclerosis; Data Collection; Data Interpretation, Statistical; Diabetes Mellitus; | 1991 |
Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 1; Female; Humans; Insulin Infusion Systems; Insulin Resi | 1985 |
731 other studies available for metformin and Insulin Sensitivity
| Article | Year |
|---|---|
Antihyperglycemic effect of syringaldehyde in streptozotocin-induced diabetic rats.
Topics: Animals; Benzaldehydes; Blood Glucose; Diabetes Mellitus, Experimental; Dose-Response Relationship, | 2012 |
Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Alanine Transaminase; Animals; Barbiturates; Body Weight; Cho | 2012 |
Poliothrysoside and its derivatives as novel insulin sensitizers potentially driving AMPK activation and inhibiting adipogenesis.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; AMP-Activated Protein Kinases; Animals; Benzoates; Dose-Resp | 2014 |
Saponarin activates AMPK in a calcium-dependent manner and suppresses gluconeogenesis and increases glucose uptake via phosphorylation of CRTC2 and HDAC5.
Topics: AMP-Activated Protein Kinases; Apigenin; Benzimidazoles; Biphenyl Compounds; Calcium; Calcium-Calmod | 2015 |
Naturally Occurring Carbazole Alkaloids from Murraya koenigii as Potential Antidiabetic Agents.
Topics: Alkaloids; Animals; Blood Glucose; Carbazoles; Diabetes Mellitus, Experimental; Glucose; Glucose Tra | 2016 |
Borapetoside E, a Clerodane Diterpenoid Extracted from Tinospora crispa, Improves Hyperglycemia and Hyperlipidemia in High-Fat-Diet-Induced Type 2 Diabetes Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Diterpenes, Clerodane; Hyperglycemia; Hyperlipid | 2017 |
Toward a treatment of diabesity: In vitro and in vivo evaluation of uncharged bromophenol derivatives as a new series of PTP1B inhibitors.
Topics: Animals; Body Weight; Cell Line; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Enzyme Inh | 2019 |
Metformin and exenatide upregulate hepatocyte nuclear factor-4α, sex hormone binding globulin levels and improve hepatic triglyceride deposition in polycystic ovary syndrome with insulin resistance rats.
Topics: Animals; Body Weight; Estrous Cycle; Exenatide; Female; Glucose Tolerance Test; Hepatocyte Nuclear F | 2021 |
Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Female; Hyperinsulinism; Hypoglycemic Agents; Insu | 2021 |
Hypoglycemic and lipid lowering effects of theaflavins in high-fat diet-induced obese mice.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Biflavonoids; Blood Glucose; Catechin; Cholesterol, H | 2021 |
Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction.
Topics: Adipocytes; Aging; AMP-Activated Protein Kinases; Cells, Cultured; Cellular Senescence; Female; Huma | 2021 |
Bioactive compounds from Artemisia dracunculus L. activate AMPK signaling in skeletal muscle.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Artemisia; Cell Line; Diet, High | 2021 |
Perilla Seed Oil Alleviates Gut Dysbiosis, Intestinal Inflammation and Metabolic Disturbance in Obese-Insulin-Resistant Rats.
Topics: alpha-Linolenic Acid; Animals; Blotting, Western; Diet, High-Fat; Dysbiosis; Gastrointestinal Microb | 2021 |
Comparative analysis of long non‑coding RNA expression profiles induced by resveratrol and metformin treatment for hepatic insulin resistance.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulati | 2021 |
L-ergothioneine and metformin alleviates liver injury in experimental type-2 diabetic rats via reduction of oxidative stress, inflammation, and hypertriglyceridemia.
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Therapy, Combina | 2021 |
Kv1.3 Channel Blockade Improves Inflammatory Profile, Reduces Cardiac Electrical Remodeling, and Prevents Arrhythmia in Type 2 Diabetic Rats.
Topics: Animals; Arrhythmias, Cardiac; Atrial Remodeling; Cytokines; Diabetes Mellitus, Experimental; Diabet | 2023 |
Restoration of mRNA Expression of Solute Carrier Proteins in Liver of Diet-Induced Obese Mice by Metformin.
Topics: Animals; Diet, High-Fat; Gene Expression Regulation; Glucose; Glucose Tolerance Test; Hepatocytes; I | 2021 |
Propranolol and low-dose isoproterenol ameliorate insulin resistance, enhance β-arrestin2 signaling, and reduce cardiac remodeling in high-fructose, high-fat diet-fed mice: Comparative study with metformin.
Topics: Animals; beta-Arrestin 2; Blood Glucose; Diet, High-Fat; Fructose; Glucose; Heart; Insulin; Insulin | 2021 |
Ameliorative effect of curcumin and zinc oxide nanoparticles on multiple mechanisms in obese rats with induced type 2 diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Curcumin; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2021 |
Morphological and functional characterization of diabetic cardiomyopathy in db/db mice following exercise, metformin alone, or combination treatments.
Topics: Animals; Blood Pressure; Body Weight; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic | 2021 |
Metformin treatment of juvenile mice alters aging-related developmental and metabolic phenotypes.
Topics: Adiponectin; Age Factors; Aging; Animals; Body Weight; Feeding Behavior; Glucose Tolerance Test; Gro | 2022 |
L6H21 protects against cognitive impairment and brain pathologies via toll-like receptor 4-myeloid differentiation factor 2 signalling in prediabetic rats.
Topics: Animals; Brain; Cognitive Dysfunction; Diet, High-Fat; Insulin Resistance; Male; Metformin; Prediabe | 2022 |
Impaired metabolic effects of metformin in men with early-onset androgenic alopecia.
Topics: Alopecia; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Drug Monitoring; Humans | 2022 |
Hypothalamic miR-1983 Targets Insulin Receptor β and the Insulin-mediated miR-1983 Increase Is Blocked by Metformin.
Topics: Adult; Animals; Cell Line; Cells, Cultured; Female; Gene Expression Profiling; Gene Expression Regul | 2022 |
Metformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome.
Topics: Arteries; Blood Flow Velocity; Blood Glucose; Body Mass Index; Endothelium, Vascular; Female; Glucos | 2022 |
Modulation of Insulin Resistance, Dyslipidemia and Serum Metabolome in iNOS Knockout Mice following Treatment with Nitrite, Metformin, Pioglitazone, and a Combination of Ampicillin and Neomycin.
Topics: Ampicillin; Animals; Drug Therapy, Combination; Dyslipidemias; Glucose; Homeostasis; Hypoglycemic Ag | 2021 |
The Effects of Separate and Combined Treatment of Male Rats with Type 2 Diabetes with Metformin and Orthosteric and Allosteric Agonists of Luteinizing Hormone Receptor on Steroidogenesis and Spermatogenesis.
Topics: Adenylate Kinase; Allosteric Regulation; Animals; Area Under Curve; Blood Glucose; Body Weight; Diab | 2021 |
Hypoglycemic and hypolipidemic effects of Epigynum auritum in high fat diet and streptozotocin-induced diabetic rats.
Topics: Animals; Apocynaceae; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Die | 2022 |
Synergistic Effects of Combined Anthocyanin and Metformin Treatment for Hyperglycemia
Topics: Animals; Anthocyanins; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Metformin; Mice; Phos | 2022 |
The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Insulin Receptor Sub | 2022 |
A decrease in cluster of differentiation 2 expression on natural killer cells is associated with polycystic ovary syndrome but not influenced by metformin in a mouse model†.
Topics: Animals; Disease Models, Animal; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Killer Cel | 2022 |
Effect of Propionic Acid on Diabetes-Induced Impairment of Unfolded Protein Response Signaling and Astrocyte/Microglia Crosstalk in Rat Ventromedial Nucleus of the Hypothalamus.
Topics: Animals; Astrocytes; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Chaperone BiP; Glucose; Glycat | 2022 |
Metformin prevents endothelial oxidative stress and microvascular insulin resistance during obesity development in male rats.
Topics: Animals; Glucose; Inflammation; Insulin; Insulin Resistance; Male; Metformin; Muscle, Skeletal; Obes | 2022 |
Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes.
Topics: Biomarkers; Canagliflozin; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin R | 2022 |
Large randomized controlled trials in reproductive medicine: another battle won by biases and confounders?
Topics: Acupuncture Therapy; Bias; Female; Humans; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; | 2022 |
Acupuncture for insulin sensitivity in women with polycystic ovary syndrome.
Topics: Acupuncture Therapy; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Metformin; Polycyst | 2022 |
Metformin Treatment Regulates the Expression of Molecules Involved in Adiponectin and Insulin Signaling Pathways in Endometria from Women with Obesity-Associated Insulin Resistance and PCOS.
Topics: Adiponectin; Endometrium; Female; Humans; Insulin; Insulin Resistance; Metformin; Obesity; Polycysti | 2022 |
Sera from women with different metabolic and menopause states differentially regulate cell viability and Akt activation in a breast cancer in-vitro model.
Topics: Breast Neoplasms; Cell Proliferation; Cell Survival; Female; Humans; In Vitro Techniques; Insulin Re | 2022 |
Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; | 2022 |
Effects of combination treatment with metformin and berberine on hypoglycemic activity and gut microbiota modulation in db/db mice.
Topics: Animals; Berberine; Chromatography, Liquid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2022 |
Pituitary Effects of Metformin in Men With Early-Onset Androgenic Alopecia.
Topics: Adrenocorticotropic Hormone; Alopecia; Androgens; Dehydroepiandrosterone Sulfate; Follicle Stimulati | 2022 |
Label-free study of intracellular glycogen level in metformin and resveratrol-treated insulin-resistant HepG2 by live-cell FTIR spectroscopy.
Topics: Biosensing Techniques; Glycogen; Humans; Insulin; Insulin Resistance; Metformin; Resveratrol; Spectr | 2022 |
[The 495th case: young female-hyperandrogenemia-severe insulin resistance].
Topics: Acanthosis Nigricans; Adult; Diabetes Mellitus; Female; Hirsutism; Humans; Insulin; Insulin Resistan | 2022 |
Metformin and Cancer: Is This the End?
Topics: Breast Neoplasms; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Neopl | 2022 |
Differences in levothyroxine action on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity between metformin- and myo-inositol-treated women with autoimmune subclinical hypothyroidism.
Topics: Autoimmunity; C-Reactive Protein; Female; Glucose; Hashimoto Disease; Humans; Hypothyroidism; Inosit | 2022 |
Circulating GDF15 concentrations in girls with low birth weight: effects of prolonged metformin treatment.
Topics: Androgens; Birth Weight; Female; Growth Differentiation Factor 15; Humans; Hypoglycemic Agents; Infa | 2023 |
Thyroid Antibody Titers and Hypothalamic-Pituitary-Thyroid Axis Activity in Levothyroxine-Treated Women With Autoimmune Subclinical Hypothyroidism Receiving Atorvastatin or Metformin.
Topics: Atorvastatin; C-Reactive Protein; Female; Hashimoto Disease; Humans; Hydroxymethylglutaryl-CoA Reduc | 2022 |
Metabolic and clinical profiles of young people with mood or psychotic disorders who are prescribed metformin in an inpatient setting.
Topics: Adolescent; Body Mass Index; Cardiovascular Diseases; Humans; Inpatients; Insulin Resistance; Metfor | 2022 |
Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF).
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Insulin Resistance; Metformin; Quality of Life; St | 2022 |
Preferential effect of Montelukast on Dapagliflozin: Modulation of IRS-1/AKT/GLUT4 and ER stress response elements improves insulin sensitivity in soleus muscle of a type-2 diabetic rat model.
Topics: Acetates; Animals; Antioxidants; Benzhydryl Compounds; Blood Glucose; Cyclopropanes; Diabetes Mellit | 2022 |
Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty Liver; Hyperglycemia; Hyp | 2022 |
Metformin alleviates long-term high-fructose diet-induced skeletal muscle insulin resistance in rats by regulating purine nucleotide cycle.
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Adenylosuccinate Synthase; AMP-Activated Protein Ki | 2022 |
Black pepper oil (Piper nigrum L.) mitigates dexamethasone induced pancreatic damage via modulation of oxidative and nitrosative stress.
Topics: Animals; Blood Glucose; COVID-19 Drug Treatment; Dexamethasone; Dyslipidemias; Fibrosis; Insulin Res | 2022 |
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Biomarkers; Cholesterol; Chol | 2022 |
The Disparity in the Management of Polycystic Ovary Syndrome between Obstetrician-Gynecologists in Different-Level Hospitals under the Hierarchical Medical System.
Topics: Androgens; Blood Glucose; Female; Hospitals; Humans; Insulin Resistance; Letrozole; Lipids; Metformi | 2022 |
Lipids Alterations Associated with Metformin in Healthy Subjects: An Investigation Using Mass Spectrometry Shotgun Approach.
Topics: Arachidonic Acid; Diabetes Mellitus, Type 2; Female; Glycerophospholipids; Healthy Volunteers; Human | 2022 |
Tert-butylhydroquinone abrogates fructose-induced insulin resistance in rats via mitigation of oxidant stress, NFkB-mediated inflammation in the liver but not the skeletal muscle of high fructose drinking rats.
Topics: Animals; Fructose; Inflammation; Insulin Resistance; Liver; Male; Metabolic Syndrome; Metformin; Mus | 2022 |
The hepatoprotective effects of n3-polyunsaturated fatty acids against non-alcoholic fatty liver disease in diabetic rats through the FOXO1/PPARα/GABARAPL1 signalling pathway.
Topics: Animals; Diabetes Mellitus, Experimental; Diet, High-Fat; Fatty Acids; Fatty Acids, Omega-3; Insulin | 2022 |
[Metformin and malignant neoplasms: a possible mechanism of antitumor action and prospects for use in practice].
Topics: AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resis | 2022 |
Overweight and Obese Adult Patients Show Larger Benefits from Concurrent Training Compared with Pharmacological Metformin Treatment on Insulin Resistance and Fat Oxidation.
Topics: Adult; Body Mass Index; Female; Humans; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; O | 2022 |
Diabetes duration and types of diabetes treatment in data-driven clusters of patients with diabetes.
Topics: Diabetes Mellitus, Type 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Ins | 2022 |
Diabetes duration and types of diabetes treatment in data-driven clusters of patients with diabetes.
Topics: Diabetes Mellitus, Type 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Ins | 2022 |
Diabetes duration and types of diabetes treatment in data-driven clusters of patients with diabetes.
Topics: Diabetes Mellitus, Type 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Ins | 2022 |
Diabetes duration and types of diabetes treatment in data-driven clusters of patients with diabetes.
Topics: Diabetes Mellitus, Type 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Ins | 2022 |
Chlorogenic acid improves glucose tolerance, lipid metabolism, inflammation and microbiota composition in diabetic db/db mice.
Topics: Animals; Chlorogenic Acid; Diabetes Mellitus; Glucose; Inflammation; Insulin Resistance; Lipid Metab | 2022 |
Chlorogenic acid improves glucose tolerance, lipid metabolism, inflammation and microbiota composition in diabetic db/db mice.
Topics: Animals; Chlorogenic Acid; Diabetes Mellitus; Glucose; Inflammation; Insulin Resistance; Lipid Metab | 2022 |
Chlorogenic acid improves glucose tolerance, lipid metabolism, inflammation and microbiota composition in diabetic db/db mice.
Topics: Animals; Chlorogenic Acid; Diabetes Mellitus; Glucose; Inflammation; Insulin Resistance; Lipid Metab | 2022 |
Chlorogenic acid improves glucose tolerance, lipid metabolism, inflammation and microbiota composition in diabetic db/db mice.
Topics: Animals; Chlorogenic Acid; Diabetes Mellitus; Glucose; Inflammation; Insulin Resistance; Lipid Metab | 2022 |
Combined Effects of Lycopene and Metformin on Decreasing Oxidative Stress by Triggering Endogenous Antioxidant Defenses in Diet-Induced Obese Mice.
Topics: Animals; Antioxidants; Diet, High-Fat; Glucose; Insulin Resistance; Lycopene; Metformin; Mice; Mice, | 2022 |
Combined Effects of Lycopene and Metformin on Decreasing Oxidative Stress by Triggering Endogenous Antioxidant Defenses in Diet-Induced Obese Mice.
Topics: Animals; Antioxidants; Diet, High-Fat; Glucose; Insulin Resistance; Lycopene; Metformin; Mice; Mice, | 2022 |
Combined Effects of Lycopene and Metformin on Decreasing Oxidative Stress by Triggering Endogenous Antioxidant Defenses in Diet-Induced Obese Mice.
Topics: Animals; Antioxidants; Diet, High-Fat; Glucose; Insulin Resistance; Lycopene; Metformin; Mice; Mice, | 2022 |
Combined Effects of Lycopene and Metformin on Decreasing Oxidative Stress by Triggering Endogenous Antioxidant Defenses in Diet-Induced Obese Mice.
Topics: Animals; Antioxidants; Diet, High-Fat; Glucose; Insulin Resistance; Lycopene; Metformin; Mice; Mice, | 2022 |
Myo-Inositol Enhances the Inhibitory Effect of Metformin on Gonadotropin Levels in Postmenopausal Women.
Topics: Female; Follicle Stimulating Hormone; Glycated Hemoglobin; Gonadotropins; Humans; Inositol; Insulin; | 2022 |
Myo-Inositol Enhances the Inhibitory Effect of Metformin on Gonadotropin Levels in Postmenopausal Women.
Topics: Female; Follicle Stimulating Hormone; Glycated Hemoglobin; Gonadotropins; Humans; Inositol; Insulin; | 2022 |
Myo-Inositol Enhances the Inhibitory Effect of Metformin on Gonadotropin Levels in Postmenopausal Women.
Topics: Female; Follicle Stimulating Hormone; Glycated Hemoglobin; Gonadotropins; Humans; Inositol; Insulin; | 2022 |
Myo-Inositol Enhances the Inhibitory Effect of Metformin on Gonadotropin Levels in Postmenopausal Women.
Topics: Female; Follicle Stimulating Hormone; Glycated Hemoglobin; Gonadotropins; Humans; Inositol; Insulin; | 2022 |
Use of metformin in patients who require intravascular administration of a contrast agent.
Topics: Contrast Media; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2022 |
Use of metformin in patients who require intravascular administration of a contrast agent.
Topics: Contrast Media; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2022 |
Use of metformin in patients who require intravascular administration of a contrast agent.
Topics: Contrast Media; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2022 |
Use of metformin in patients who require intravascular administration of a contrast agent.
Topics: Contrast Media; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2022 |
Combining Dietary Intervention with Metformin Treatment Enhances Non-Alcoholic Steatohepatitis Remission in Mice Fed a High-Fat High-Sucrose Diet.
Topics: Animals; Body Weight; Diet, High-Fat; Insulin Resistance; Liver; Male; Metformin; Mice; Mice, Inbred | 2022 |
PDIA4, a new endoplasmic reticulum stress protein, modulates insulin resistance and inflammation in skeletal muscle.
Topics: Animals; Cytokines; Endoplasmic Reticulum Stress; Humans; Inflammation; Insulin Resistance; Metformi | 2022 |
Metformin-chlorogenic acid combination reduces skeletal muscle inflammation in c57BL/6 mice on high-fat diets.
Topics: Adipose Tissue; Animals; Chlorogenic Acid; Diet, High-Fat; Inflammation; Insulin Resistance; Metform | 2023 |
Effects of antidiabetics and exercise therapy on suppressors of cytokine signaling-1, suppressors of cytokine signaling-3, and insulin receptor substrate-1 molecules in diabetes and obesity.
Topics: Animals; Cytokines; Diabetes Mellitus, Experimental; Exenatide; Exercise Therapy; Humans; Hypoglycem | 2023 |
Effects of metformin on clinical, hormonal and relevant gene expression parameters in patients with acne: an observational study.
Topics: Acne Vulgaris; Female; Gene Expression; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; In | 2023 |
Novel insights into the synergistic effects of selenium nanoparticles and metformin treatment of letrozole - induced polycystic ovarian syndrome: targeting PI3K/Akt signalling pathway, redox status and mitochondrial dysfunction in ovarian tissue.
Topics: Animals; Female; Humans; Insulin Resistance; Letrozole; Lipids; Metformin; Mitochondria; Nanoparticl | 2023 |
New Treatment for Type 2 Diabetes Mellitus Using a Novel Bipyrazole Compound.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; | 2023 |
Exploring the Epigenetic Regulated Modulation of Fibroblast Growth Factor 21 Involvement in High-Fat Diet Associated Parkinson's Disease in Rats.
Topics: Animals; Diet, High-Fat; Epigenesis, Genetic; Insulin Resistance; Metformin; Parkinson Disease; Rats | 2023 |
Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α.
Topics: Animals; Female; Hepatocyte Nuclear Factors; Humans; Insulin; Insulin Resistance; Lipid Metabolism; | 2023 |
Myo-Inositol Potentiates the Inhibitory Effect of Metformin on Prolactin Levels.
Topics: Adrenocorticotropic Hormone; Blood Glucose; Female; Glycated Hemoglobin; Humans; Hyperprolactinemia; | 2023 |
Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis.
Topics: AMP-Activated Protein Kinases; Animals; Body Weight; Female; Ferroptosis; Humans; Insulin Resistance | 2023 |
Association of Hepcidin levels in Type 2 Diabetes Mellitus treated with metformin or combined anti-diabetic agents in Pakistani population.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Hepcidins; Humans; Hyp | 2023 |
Past and present: a bibliometric study on polycystic ovary syndrome.
Topics: Bibliometrics; Female; Humans; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome | 2023 |
The homeostasis model assessment of insulin resistance is a judgment criterion for metformin pre-treatment before IVF/ICSI and embryo transfer cycles in patients with polycystic ovarian syndrome.
Topics: Embryo Transfer; Female; Fertilization in Vitro; Homeostasis; Humans; Insulin Resistance; Judgment; | 2023 |
Scopoletin Improves Glucose Homeostasis in the High-Fructose High-Fat Diet-Induced Diabetes Model in Wistar Rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diet, High-Fat; Fructose; Glucose; Homeostasis; Hypoglyce | 2023 |
Investigating the potential role of swertiamarin on insulin resistant and non-insulin resistant granulosa cells of poly cystic ovarian syndrome patients.
Topics: Female; Granulosa Cells; Humans; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2023 |
The Gengnianchun recipe attenuates insulin resistance-induced diminished ovarian reserve through inhibiting the senescence of granulosa cells.
Topics: Animals; Female; Gonadal Steroid Hormones; Granulosa Cells; Humans; Insulin; Insulin Resistance; Met | 2023 |
Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPARα pathway.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Gemfibrozil; Insulin; Insulin Resistance; Ki | 2023 |
The Emerging Importance of Cirsimaritin in Type 2 Diabetes Treatment.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; | 2023 |
The Medicinal Mushroom Ganoderma neo-japonicum (Agaricomycetes) Polysaccharide Extract Prevents Obesity-Induced Diabetes in C57BL/6J Mice.
Topics: Agaricales; Animals; Basidiomycota; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Insuli | 2023 |
Diabetes mellitus: relation between cardiovascular events and pharmacological treatment.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans | 2023 |
Metformin Treatment of Hidradenitis Suppurativa: Effect on Metabolic Parameters, Inflammation, Cardiovascular Risk Biomarkers, and Immune Mediators.
Topics: Adipokines; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Heart Dis | 2023 |
The ameliorative effect of zinc acetate with caffeic acid in the animal model of type 2 diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hy | 2023 |
Hedgehog interacting protein as a circulating biomarker in women with obesity: a cross-sectional study and intervention studies.
Topics: Biomarkers; Blood Glucose; Cohort Studies; Cross-Sectional Studies; Female; Hedgehog Proteins; Human | 2023 |
THE THERAPEUTIC EFFECT OF ORAL INSULIN SENSITIZER METFORMIN ON LIPID PROFILE IN WOMEN WITH POLYCYSTIC OVARY SYNDROME.
Topics: Case-Control Studies; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; P | 2023 |
A Microstirring Oral Pill for Improving the Glucose-Lowering Effect of Metformin.
Topics: Animals; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Age | 2023 |
Interaction between OCT1 and LPIN1 polymorphisms and response to pioglitazone-metformin tablets in patients with polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Phosphatidate Phosphatase; Piogl | 2023 |
Time to revisit the true role of metformin in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin | 2023 |
Role of metformin in the management of type 2 diabetes: recent advances.
Topics: Diabetes Mellitus, Type 2; Female; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Metform | 2023 |
METFORMIN EFFECTS ON NEUREGULIN-1 IN POLYCYSTIC OVARIAN WOMEN.
Topics: Blood Glucose; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insu | 2023 |
METFORMIN EFFECTS ON BLOOD LEVELS OF GREMLIN-1 IN POLYCYSTIC OVARIAN WOMEN.
Topics: Blood Glucose; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; In | 2023 |
Molecular insights of anti-diabetic compounds and its hyaluronic acid conjugates against aldose reductase enzyme through molecular modeling and simulations study-a novel treatment option for inflammatory diabetes.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 2; Humans; Hyaluronic Acid; Inflammation; Insulin Resist | 2023 |
Baseline leptin predicts response to metformin in adolescents with type 1 diabetes and increased body mass index.
Topics: Adolescent; Body Mass Index; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; Insuli | 2023 |
Metformin and exercise effects on postprandial insulin sensitivity and glucose kinetics in pre-diabetic and diabetic adults.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Humans; Insulin; Insulin Resistance; Kinet | 2023 |
Non-coding RNA genes modulate PI3K/AKT signaling pathway in polycystic ovary syndrome.
Topics: Female; Glucose; Humans; Insulin; Insulin Resistance; Metformin; MicroRNAs; Phosphatidylinositol 3-K | 2023 |
Metformin targets intestinal immune system signaling pathways in a high-fat diet-induced mouse model of obesity and insulin resistance.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Female; Immune System; Immunoglobulins; Insulin; In | 2023 |
Potential molecular mechanisms underlying the ameliorative effect of Cola nitida (Vent.) Schott & Endl. on insulin resistance in rat skeletal muscles.
Topics: Animals; Cola; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose Transporter Type | 2024 |
Associations between insulin-like growth factor binding protein-2 and insulin sensitivity, metformin, and mortality in persons with T2D.
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Insulin; Insulin Resistance; Insulin-Like Growth Factor | 2023 |
SGLT-2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model.
Topics: Animals; Female; Gonadal Steroid Hormones; Humans; Insulin; Insulin Resistance; Metformin; Polycysti | 2023 |
Influence of metabolic stress and metformin on synaptic protein profile in SH-SY5Y-derived neurons.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Humans; Insulin; Insulin Resistance; Metformin; Ne | 2023 |
Metformin improves vascular and metabolic insulin action in insulin-resistant muscle.
Topics: Animals; Blood Flow Velocity; Blood Glucose; Body Weight; Diet, High-Fat; Femoral Artery; Glucose; G | 2019 |
Metformin and sitagliptin combination therapy ameliorates polycystic ovary syndrome with insulin resistance through upregulation of lncRNA H19.
Topics: Animals; Apoptosis; Cells, Cultured; DNA (Cytosine-5-)-Methyltransferase 1; Drug Therapy, Combinatio | 2019 |
Endogenous testosterone determines metformin action on prolactin levels in hyperprolactinaemic men: A pilot study.
Topics: Adult; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hyperprolactinemia; H | 2020 |
Synergistic effect of nano-selenium and metformin on type 2 diabetic rat model: Diabetic complications alleviation through insulin sensitivity, oxidative mediators and inflammatory markers.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Synergism; H | 2019 |
Resveratrol and Metformin Recover Prefrontal Cortex AMPK Activation in Diet-Induced Obese Mice but Reduce BDNF and Synaptophysin Protein Content.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Autophagy; Blood Glucose; Brain-Derived Neurot | 2019 |
Baicalin ameliorates hepatic insulin resistance and gluconeogenic activity through inhibition of p38 MAPK/PGC-1α pathway.
Topics: Adipocytes; Animals; Diet, High-Fat; Flavonoids; Gene Expression Regulation; Gluconeogenesis; Glucos | 2019 |
Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats.
Topics: AMP-Activated Protein Kinases; Androgens; Animals; Blood Glucose; Disease Models, Animal; Exenatide; | 2019 |
Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain.
Topics: Administration, Intranasal; Administration, Oral; Animals; Astrocytes; Cells, Cultured; Cerebral Cor | 2019 |
A lower duodenal immune response is associated with an increase of insulin resistance in patients with morbid obesity.
Topics: Adult; Cytokines; Diabetes Mellitus, Type 2; Duodenum; Female; Humans; Hypoglycemic Agents; Insulin | 2020 |
A novel fast-slow model of diabetes progression: Insights into mechanisms of response to the interventions in the Diabetes Prevention Program.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Progression; Glucose Tolerance | 2019 |
Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence.
Topics: Aging; Animals; beta Catenin; Cell Cycle; Cell Death; Cellular Senescence; Cyclin-Dependent Kinase 5 | 2019 |
Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK.
Topics: Adenine Nucleotides; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; B | 2019 |
Co-administration of omega-3 fatty acids and metformin showed more desirable effects than the single therapy on indices of bone mineralisation but not gluco-regulatory and antioxidant markers in diabetic rats.
Topics: Animals; Antioxidants; Biomarkers; Bone and Bones; Calcification, Physiologic; Calcium; Diabetes Mel | 2020 |
Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diet, High-Fat; Endoplasmic Reticulum Stress; Gluconeo | 2019 |
Beneficial effects of combination therapy of phloretin and metformin in streptozotocin-induced diabetic rats and improved insulin sensitivity in vitro.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Experimental; Glucose Transporter Type 4; Insulin Recept | 2020 |
The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment.
Topics: Adult; AMP-Activated Protein Kinases; Cells, Cultured; Endometrium; Enzyme Activation; Female; Gluco | 2020 |
The impact of oral hormonal contraception on metformin action on hypothalamic-pituitary-thyroid axis activity in women with diabetes and prediabetes: A pilot study.
Topics: Adult; Case-Control Studies; Contraceptives, Oral, Hormonal; Diabetes Mellitus, Type 2; Drug Interac | 2020 |
Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study.
Topics: Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combinatio | 2020 |
Infliximab ameliorates tumor necrosis factor-alpha exacerbated renal insulin resistance induced in rats by regulating insulin signaling pathway.
Topics: Animals; Blood Glucose; Disease Models, Animal; Glucose Tolerance Test; Humans; Hyperglycemia; Infli | 2020 |
Decreased Circulating MANF in Women with PCOS is Elevated by Metformin Therapy and is Inversely Correlated with Insulin Resistance and Hyperandrogenism.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Tolerance Test; Humans; Hyperandrogen | 2020 |
Vitamin B12 and Folate Concentrations in Recent-onset Type 2 Diabetes and the Effect of Metformin Treatment.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type | 2020 |
Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients.
Topics: Benzhydryl Compounds; Blood Glucose; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Gluco | 2020 |
Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study.
Topics: Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Diet; Female; Humans; Hypoglycemic Agents; | 2020 |
Effects of Metformin and Sitagliptin Monotherapy on Expression of Intestinal and Renal Sweet Taste Receptors and Glucose Transporters in a Rat Model of Type 2 Diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose Tran | 2020 |
Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.
Topics: AMP-Activated Protein Kinases; Animals; Antihypertensive Agents; Diet, High-Fat; Epoprostenol; Heart | 2020 |
Hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN syndrome): an extreme subphenotype of polycystic ovary syndrome.
Topics: Acanthosis Nigricans; Child; Contraceptives, Oral, Hormonal; Female; Humans; Hyperandrogenism; Insul | 2020 |
Antidiabetic drug metformin affects the developmental competence of cleavage-stage embryos.
Topics: Adult; Animals; Blastocyst; Blood Glucose; Diabetes, Gestational; Disease Models, Animal; Embryonic | 2020 |
Necrostatin-1 Mitigates Cognitive Dysfunction in Prediabetic Rats With No Alteration in Insulin Sensitivity.
Topics: Animals; Cognitive Dysfunction; Diet, High-Fat; Hippocampus; Imidazoles; Indoles; Insulin Resistance | 2020 |
Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Progression; Dose-Response Relationship, Drug; Exenati | 2020 |
Descending Expression of miR320 in Insulin-Resistant Adipocytes Treated with Ascending Concentrations of Metformin.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Glucose; Hypogly | 2020 |
NLRP3 inflammasome drives inflammation in high fructose fed diabetic rat liver: Effect of resveratrol and metformin.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fructose; Hypoglycemic Agents; | 2020 |
Mucosa-associated microbiota in the jejunum of patients with morbid obesity: alterations in states of insulin resistance and metformin treatment.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Insulin; Insulin Resistance; Jejunum; Metformin; M | 2020 |
Combined use of Diane-35 and metformin improves the ovulation in the PCOS rat model possibly via regulating glycolysis pathway.
Topics: Androgen Antagonists; Animals; Apoptosis; Body Weight; Cyproterone Acetate; Disease Models, Animal; | 2020 |
Metformin metabolic and vascular effects in normal weight hyperinsulinemic polycystic ovary syndrome patients treated with contraceptive vaginal ring. A pilot study.
Topics: Adult; Blood Glucose; Brachial Artery; Contraceptive Agents, Hormonal; Contraceptive Devices, Female | 2020 |
Metformin alleviates hyperuricaemia-induced serum FFA elevation and insulin resistance by inhibiting adipocyte hypertrophy and reversing suppressed white adipose tissue beiging.
Topics: 3T3-L1 Cells; Adenylate Kinase; Adipocytes; Adipose Tissue, Beige; Adipose Tissue, White; Adult; Ani | 2020 |
Metformin Decreases Insulin Resistance in Type 1 Diabetes Through Regulating p53 and RAP2A in vitro and in vivo.
Topics: 3T3-L1 Cells; Animals; Diabetes Mellitus, Type 1; Female; Humans; Hypoglycemic Agents; Insulin Resis | 2020 |
Metformin Ameliorates Testicular Function and Spermatogenesis in Male Mice with High-Fat and High-Cholesterol Diet-Induced Obesity.
Topics: Animals; Antioxidants; Blood Glucose; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Dietary Sup | 2020 |
Berberine Inhibits Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway.
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Berberine; Diabetes Mellitus, Experimental; | 2020 |
Peanut skin extract ameliorates the symptoms of type 2 diabetes mellitus in mice by alleviating inflammation and maintaining gut microbiota homeostasis.
Topics: Animals; Anti-Inflammatory Agents; Arachis; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; E | 2020 |
The impact of combination therapy with metformin and exogenous vitamin D on hypothalamic-pituitary-thyroid axis activity in women with autoimmune thyroiditis and high-normal thyrotropin levels.
Topics: Adult; Blood Glucose; Case-Control Studies; Drug Synergism; Drug Therapy, Combination; Female; Hashi | 2020 |
Effects of metformin on epicardial adipose tissue and atrial electromechanical delay of obese children with insulin resistance.
Topics: Adipose Tissue; Child; Humans; Insulin Resistance; Metformin; Obesity; Pericardium | 2020 |
Metformin doses and body mass index: clinical outcomes in insulin resistant polycystic ovary syndrome women.
Topics: Adult; Body Mass Index; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Hypoglycem | 2020 |
Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study.
Topics: Adolescent; Adult; Blood Glucose; Contraceptives, Oral, Combined; Female; Glycated Hemoglobin; Human | 2020 |
Metformin reduces saturated fatty acid-induced lipid accumulation and inflammatory response by restoration of autophagic flux in endothelial cells.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Carnitine O-Palmitoyltransferase; Endothelium, Va | 2020 |
Novel Albumin Nanoparticle Enhanced the Anti-Insulin-Resistant-Hepatoma Activity of Metformin.
Topics: Animals; Carcinoma, Hepatocellular; Circular Dichroism; Diabetes Mellitus, Type 2; Drug Delivery Sys | 2020 |
Different effects of metformin on hypothalamic-pituitary-thyroid axis activity in levothyroxine-treated and levothyroxine-naïve women with non-autoimmune hypothyroidism.
Topics: Aged; Blood Glucose; Case-Control Studies; Female; Humans; Hypoglycemic Agents; Hypothalamo-Hypophys | 2020 |
Pilosocereus gounellei (Cactaceae) stem extract decreases insulin resistance, inflammation, oxidative stress, and cardio-metabolic risk in diet-induced obese mice.
Topics: Animals; Cactaceae; Cardiovascular Diseases; Cytokines; Diet, High-Fat; Hyperglycemia; Inflammation; | 2021 |
Successful IVF outcome after repeat laparoscopic ovarian drilling in a case of resistant PCOS.
Topics: Abortion, Habitual; Adult; Female; Fertilization in Vitro; Glucose Metabolism Disorders; Humans; Hyp | 2020 |
The Usefulness of Diagnostic Panels Based on Circulating Adipocytokines/Regulatory Peptides, Renal Function Tests, Insulin Resistance Indicators and Lipid-Carbohydrate Metabolism Parameters in Diagnosis and Prognosis of Type 2 Diabetes Mellitus with Obesi
Topics: Adipokines; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Fibr | 2020 |
Growth arrest-specific 6 modulates adiponectin expression and insulin resistance in adipose tissue.
Topics: Adipocytes; Adipogenesis; Adiponectin; Adipose Tissue; Animals; Humans; Hypoglycemic Agents; Insulin | 2021 |
Metformin downregulates miR223 expression in insulin-resistant 3T3L1 cells and human diabetic adipose tissue.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Glucose Transporter Ty | 2020 |
Vitamin D3 deficiency is associated with more severe insulin resistance and metformin use in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Body Mass Index; C-Peptide; Cholecalciferol; Cross-Sectional Studies; Diabe | 2020 |
Metformin enhances protection in guinea pigs chronically infected with Mycobacterium tuberculosis.
Topics: Animals; Cytokines; Energy Metabolism; Glucose; Glucose Intolerance; Guinea Pigs; Hypoglycemic Agent | 2020 |
Early metformin treatment improves pancreatic function and prevents metabolic dysfunction in early overfeeding male rats at adulthood.
Topics: Adipose Tissue, White; Animals; Animals, Newborn; Blood Glucose; Body Composition; Body Weight; Fema | 2020 |
Potentiation of incretin hormones and modulation of metabolic enzymes as possible mechanisms behind the insulin sensitizing effects of cabbage-metformin treatment.
Topics: Animal Feed; Animals; Brassica; Diet; Dietary Carbohydrates; Fructose; Hypoglycemic Agents; Incretin | 2021 |
Not only metformin, but also D-allulose, alleviates metabolic disturbance and cognitive decline in prediabetic rats.
Topics: Animals; Cognitive Dysfunction; Diet, High-Fat; Drinking Water; Fructose; Insulin Resistance; Insuli | 2022 |
Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents; Blood Glucose; Cytokines; Disease Models, Animal; | 2021 |
Combination of metformin and chlorogenic acid attenuates hepatic steatosis and inflammation in high-fat diet fed mice.
Topics: Animals; Anti-Inflammatory Agents; Chlorogenic Acid; Diet, High-Fat; Glucose Intolerance; Hypoglycem | 2021 |
Clinical presentation and molecular characterization of a novel patient with variant POC1A-related syndrome.
Topics: Acanthosis Nigricans; Adult; Age of Onset; Cell Cycle Proteins; Computer Simulation; Congenital Hype | 2021 |
A Fbxo48 inhibitor prevents pAMPKα degradation and ameliorates insulin resistance.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Cell Line, Transformed; Diet, Hi | 2021 |
Effects of total flavonoids from Eucommia ulmoides Oliv. leaves on polycystic ovary syndrome with insulin resistance model rats induced by letrozole combined with a high-fat diet.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Eucommiaceae; Female; Flavonoids; Gona | 2021 |
Berberine ameliorates neuronal AD-like change via activating Pi3k/PGCε pathway.
Topics: Amyloid beta-Peptides; Animals; Berberine; Cell Line, Tumor; Cognitive Dysfunction; Diabetes Mellitu | 2021 |
Association of glycemia with insulin sensitivity and β-cell function in adults with early type 2 diabetes on metformin alone.
Topics: Blood Glucose; C-Peptide; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Glycated Hemoglobin; H | 2021 |
Chickpea Extract Ameliorates Metabolic Syndrome Symptoms via Restoring Intestinal Ecology and Metabolic Profile in Type 2 Diabetic Rats.
Topics: Animals; Cicer; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dysbiosi | 2021 |
Augmentation of RBP4/STRA6 signaling leads to insulin resistance and inflammation and the plausible therapeutic role of vildagliptin and metformin.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Diet, High-Fat; Glucose; Hypoglycemic Agents; Inf | 2021 |
Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Cells, Cultured; Glucose; Glucose Transporter Type 4; | 2021 |
The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis.
Topics: Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Resistance; Meta-Anal | 2021 |
Effects of Berberine on Diabetes and Cognitive Impairment in an Animal Model: The Mechanisms of Action.
Topics: Animals; Apoptosis; Berberine; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Diet, High-Fa | 2021 |
Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats.
Topics: Animals; Anthocyanins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progressi | 2021 |
Metformin Targets Foxo1 to Control Glucose Homeostasis.
Topics: Animals; Aspirin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; | 2021 |
Insulin resistance and NAFLD may influence memory performance in obese patients with prediabetes or newly-diagnosed type 2 diabetes.
Topics: Age Factors; Blood Glucose; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Female; Hum | 2021 |
Necrostatin-1 reduces cardiac and mitochondrial dysfunction in prediabetic rats.
Topics: Animals; Diet, High-Fat; Imidazoles; Indoles; Insulin Resistance; Male; Metformin; Mitochondria, Hea | 2021 |
Metabolic benefits of novel histamine H
Topics: Adipose Tissue; Animals; Body Weight; C-Peptide; Carrier Proteins; Cholesterol; Energy Intake; Feedi | 2021 |
Metformin for pediatric obesity and insulin resistance: a retrospective study within an integrated health care system.
Topics: Adolescent; Body Mass Index; Child; Delivery of Health Care, Integrated; Humans; Hypoglycemic Agents | 2021 |
Metformin accelerates wound healing by Akt phosphorylation of gingival fibroblasts in insulin-resistant prediabetes mice.
Topics: Animals; Diet, High-Fat; Fibroblasts; Gingiva; Glucose; Insulin; Insulin Resistance; Metformin; Mice | 2022 |
Inhibition of Src homology 2 domain containing protein tyrosine phosphatase as the possible mechanism of metformin-assisted amelioration of obesity induced insulin resistance in high fat diet fed C57BL/6J mice.
Topics: Adipose Tissue; Animals; Diet, High-Fat; Dose-Response Relationship, Drug; Hypoglycemic Agents; Infl | 2017 |
Successful metformin treatment of insulin resistance is associated with down-regulation of the kynurenine pathway.
Topics: Adult; Down-Regulation; Humans; Insulin Resistance; Kynurenine; Metformin | 2017 |
Effects of metformin on compensatory pancreatic β-cell hyperplasia in mice fed a high-fat diet.
Topics: Alanine Transaminase; Animals; Blood Glucose; Blotting, Western; Cell Line; Cell Proliferation; Chol | 2017 |
Effect of metformin on bioactive lipid metabolism in insulin-resistant muscle.
Topics: Animals; Coenzyme A Ligases; Diet, High-Fat; Fatty Acid Transport Proteins; Fatty Acids, Nonesterifi | 2017 |
Metabolic and androgen profile in underweight women with polycystic ovary syndrome.
Topics: Adult; Androgens; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Hypoglycemic Ag | 2017 |
Pterostilbene ameliorates insulin sensitivity, glycemic control and oxidative stress in fructose-fed diabetic rats.
Topics: Animals; beta-Cyclodextrins; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2017 |
New Biguanides as Anti-Diabetic Agents Part I: Synthesis and Evaluation of 1-Substituted Biguanide Derivatives as Anti-Diabetic Agents of Type II Diabetes Insulin Resistant.
Topics: Animals; Biguanides; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hypoglycemic Agents | 2017 |
Metformin exerts anti-obesity effect via gut microbiome modulation in prediabetics: A hypothesis.
Topics: Animals; Anti-Obesity Agents; Butyrates; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Hor | 2017 |
Association of divalent cations and insulin resistance with thyroid hormones in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Magnesium; Male; Metform | 2017 |
Insulin upregulates betatrophin expression via PI3K/Akt pathway.
Topics: Angiopoietin-Like Protein 8; Angiopoietin-like Proteins; Animals; Diabetes Mellitus, Type 2; Female; | 2017 |
A comparative study between myo-inositol and metformin in the treatment of insulin-resistant women.
Topics: Adult; Body Mass Index; Fasting; Female; Folic Acid; Humans; Inositol; Insulin; Insulin Resistance; | 2017 |
Oxamate Enhances the Anti-Inflammatory and Insulin-Sensitizing Effects of Metformin in Diabetic Mice.
Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabet | 2017 |
Polyphenols activate energy sensing network in insulin resistant models.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Cell Differentiation; Cell Line; Cell Surviva | 2017 |
Acanthosis Nigricans and Its Response to Metformin.
Topics: Acanthosis Nigricans; Adolescent; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; | 2017 |
Is There a Role for Metformin in the Treatment of Childhood Obesity?
Topics: Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Pediatric Obesity | 2017 |
Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.
Topics: Body Composition; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ova | 2017 |
Metformin attenuates the TLR4 inflammatory pathway in skeletal muscle of diabetic rats.
Topics: Animals; Chemokine CXCL1; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Insulin Resi | 2017 |
The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female | 2017 |
Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin.
Topics: Adamantane; Aging; Animals; Biomarkers; Body Weight; Brain; Dementia; Dipeptides; Galactose; Glycate | 2017 |
Metformin Therapy for the Management of Infertility in Women with Polycystic Ovary Syndrome: Scientific Impact Paper No. 13.
Topics: Androgen Antagonists; Female; Humans; Infertility, Female; Insulin Resistance; Metformin; Polycystic | 2017 |
Pharmacological evaluation of metformin and N-benzylbiguanide, a novel analogue of metformin, on the vasopressor responses to adrenergic system stimulation in pithed rats with fructose-induced insulin resistance.
Topics: Adrenergic Agonists; Animals; Biguanides; Blood Glucose; Blood Pressure; Fructose; Heart Rate; Hemod | 2017 |
In vivo therapeutic effect of combination treatment with metformin and Scutellaria baicalensis on maintaining bile acid homeostasis.
Topics: Algorithms; Animals; Bile Acids and Salts; Blood Glucose; Blotting, Western; Body Weight; Cholestero | 2017 |
Insulin Resistance and Hunger in Childhood Obesity: A Patient and Physician's Perspective.
Topics: Adolescent; Adult; Attitude to Health; Child; Child, Preschool; Female; Humans; Hunger; Hypoglycemic | 2017 |
Pleiotropic effects of metformin to rescue statin-induced muscle injury and insulin resistance: A proposed mechanism and potential clinical implications.
Topics: Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agen | 2017 |
Circulating ApoJ is closely associated with insulin resistance in human subjects.
Topics: Blood Glucose; Clusterin; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Clamp Technique; Homeo | 2018 |
Beneficial effects of Heqi san on rat model of polycystic ovary syndrome through the PI3K/AKT pathway.
Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; DNA-Binding Proteins; Drugs, Chinese Herbal | 2017 |
Metformin overcomes high glucose-induced insulin resistance of podocytes by pleiotropic effects on SIRT1 and AMPK.
Topics: AMP-Activated Protein Kinases; Animals; Cells, Cultured; Cytoprotection; Female; Glucose; Insulin Re | 2018 |
Synthesis, Characterization, and Biological Evaluations of 1,3,5-Triazine Derivatives of Metformin Cyclization with Berberine and Magnolol in the Presence of Sodium Methylate.
Topics: Anti-Inflammatory Agents; Berberine; Biphenyl Compounds; Cyclization; Humans; Inflammation; Insulin | 2017 |
Insulin resistance in patients with recurrent pregnancy loss is associated with lymphocyte population aberration.
Topics: Abortion, Habitual; Adult; Body Mass Index; CD3 Complex; CD4 Lymphocyte Count; CD56 Antigen; Fasting | 2017 |
Progesterone Suppression of Luteinizing Hormone Pulse Frequency in Adolescent Girls With Hyperandrogenism: Effects of Metformin.
Topics: Adolescent; Feedback, Physiological; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hype | 2018 |
Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Insulin; Insulin Resistance; Intercellular Signaling Pept | 2018 |
Metformin Effects are Augmented by Chronic Intermittent Cold Stress in High Fat Diet Fed Male Wistar Rats.
Topics: Animals; Blood Glucose; Cold Temperature; Diet, High-Fat; Hypoglycemic Agents; Insulin; Insulin Resi | 2017 |
Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
Topics: Adult; Anti-Obesity Agents; Cyproterone Acetate; Drug Combinations; Drug Therapy, Combination; Ethin | 2018 |
Synergistic actions of vitamin D and metformin on skeletal muscles and insulin resistance of type 2 diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Synergism; | 2018 |
Salvianolate Reduces Glucose Metabolism Disorders in Dimethylnitrosamine-Induced Cirrhotic Rats.
Topics: Animals; Dimethylnitrosamine; Glucose; Glucose Tolerance Test; Insulin Resistance; Liver; Liver Cirr | 2018 |
Effect of Metformin on Hypothalamic-Pituitary-Thyroid Axis Activity in Elderly Antipsychotic-Treated Women With Type 2 Diabetes and Subclinical Hypothyroidism: A Preliminary Study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Diabetes Mellitus, Type 2; Dopamine; Female; Humans; | 2018 |
Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study.
Topics: Adult; Antiviral Agents; Blood Glucose; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; I | 2017 |
Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance.
Topics: Adult; Aged; Animals; Cyclopentanes; Diabetes Mellitus, Type 2; Diet, High-Fat; Female; Forkhead Box | 2018 |
Exercise and reproductive function in polycystic ovary syndrome: protocol of a systematic review.
Topics: Diet; Exercise; Female; Fertility; Humans; Hyperandrogenism; Insulin Resistance; Menstrual Cycle; Me | 2017 |
Effects of metformin on insulin resistance and metabolic disorders in tumor-bearing rats with advanced cachexia.
Topics: Animals; Cachexia; Insulin; Insulin Resistance; Male; Metformin; Neoplasms; Proto-Oncogene Proteins | 2018 |
Metformin Might Inhibit Virus through Increasing Insulin Sensitivity.
Topics: Blood Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Viruses | 2018 |
Aberrant intestinal microbiota in individuals with prediabetes.
Topics: Aged; Animals; Anthropometry; Biomarkers; Blood Glucose; Case-Control Studies; Denmark; Diabetes Mel | 2018 |
Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl Peptidase 4; Dipeptidy | 2018 |
IGF-1R and Leptin Expression Profile and the Effects of Metformin Treatment on Metabolic and Endocrine Parameters in PCOS Mice.
Topics: Animals; Blood Glucose; Body Weight; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents | 2017 |
The effect of Metformin treatment in obese insulin-resistant patients with euthyroid goiter.
Topics: Adolescent; Adult; Aged; Female; Goiter, Nodular; Humans; Hypoglycemic Agents; Insulin Resistance; M | 2018 |
Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; Insulin-Li | 2018 |
Topics: Algorithms; Anticholesteremic Agents; Blood Glucose; Diabetes Mellitus, Type 2; Glycoside Hydrolase | 2018 |
Resveratrol regulates hyperglycemia-induced modulations in experimental diabetic animal model.
Topics: Animals; Antioxidants; Blood Glucose; Calcium; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2018 |
Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model.
Topics: Animals; Benzhydryl Compounds; Diet, High-Fat; Disease Models, Animal; Glucosides; Humans; Insulin; | 2018 |
Gestational exposure to metformin programs improved glucose tolerance and insulin secretion in adult male mouse offspring.
Topics: Age Factors; Animals; Disease Models, Animal; Female; Glucose; Glucose Tolerance Test; Insulin; Insu | 2018 |
Metabolic switching in the hypoglycemic and antitumor effects of metformin on high glucose induced HepG2 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Diabetes Mellitus, Type 2; Energy Metabolism; | 2018 |
The effect of high fat diet and metformin treatment on liver lipids accumulation and their impact on insulin action.
Topics: Animals; Blood Glucose; Ceramides; Diet, High-Fat; Diglycerides; Fatty Liver; Humans; Insulin Resist | 2018 |
PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Blood Pressure; Cardiomegaly; Cardiovascular | 2018 |
Phosphorylation of Acetyl-CoA Carboxylase by AMPK Reduces Renal Fibrosis and Is Essential for the Anti-Fibrotic Effect of Metformin.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Analysis of Variance; Animals; Biopsy, Needle | 2018 |
Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Diabetes Mellitus, Type 2; Fe | 2018 |
Metformin, sitagliptin, and liraglutide modulate serum retinol-binding protein-4 level and adipocytokine production in type 2 diabetes mellitus rat model.
Topics: Adipokines; Animals; Blood Glucose; Body Mass Index; Diabetes Mellitus, Experimental; Diabetes Melli | 2018 |
Synergistic action of ursolic acid and metformin in experimental model of insulin resistance and related behavioral alterations.
Topics: Acetylcholinesterase; Adiponectin; Animals; Behavior, Animal; Blood Pressure; Body Weight; Brain; Co | 2018 |
Acquired generalised lipodystrophy and type 1 diabetes mellitus in a child: a rare and implacable association.
Topics: Anticholesteremic Agents; Child; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; In | 2018 |
Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats.
Topics: Animals; Body Weight; Carboxymethylcellulose Sodium; Diet, High-Fat; Female; Glucose Tolerance Test; | 2018 |
Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.
Topics: Androgen Antagonists; Animals; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Blood G | 2019 |
Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Blood-Brain Barrier; Cerebral Cortex; Cognition | 2019 |
A pilot trial of metformin for insulin resistance and mood disturbances in adolescent and adult women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Anxiety; Blood Glucose; Body Mass Index; Depression; Female; Humans; Hypoglycemic | 2019 |
Long-term metformin treatment in adolescents with obesity and insulin resistance, results of an open label extension study.
Topics: Adolescent; Body Mass Index; Child; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; M | 2018 |
Improvement of insulin resistance via increase of GLUT4 and PPARγ in metabolic syndrome-induced rats treated with omega-3 fatty acid or l-carnitine.
Topics: Adiposity; Animals; Carnitine; Diet, Carbohydrate Loading; Diet, High-Fat; Dietary Supplements; Fatt | 2018 |
Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model.
Topics: Analysis of Variance; Animals; Blood Glucose; Cholesterol; Disease Models, Animal; Estrone; Expector | 2018 |
SirT3 regulates diabetogenic effects caused by arsenic: An implication for mitochondrial complex II modification.
Topics: Animals; Arsenic; Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Electron Transport Complex II | 2019 |
Eugenol ameliorates insulin resistance, oxidative stress and inflammation in high fat-diet/streptozotocin-induced diabetic rat.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; | 2019 |
Association between CD16
Topics: Adult; Biomarkers; Case-Control Studies; China; Cross-Sectional Studies; Cyproterone Acetate; Drug C | 2019 |
Inhibition of upper small intestinal mTOR lowers plasma glucose levels by inhibiting glucose production.
Topics: Adenoviridae; Animals; Blood Glucose; Diet, High-Fat; Glucose; Homeostasis; Insulin Resistance; Inte | 2019 |
Adiponectin: the "unusual suspect" between insulin resistance and cancer?
Topics: Adiponectin; Humans; Insulin Resistance; Male; Metformin; Prostatic Neoplasms | 2019 |
Effects of in utero androgen excess and metformin treatment on hepatic functions.
Topics: Animals; Female; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Liver Dis | 2019 |
Rationale and Study Design of a Randomized Clinical Trial of Metformin to Prevent Frailty in Older Adults With Prediabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Frai | 2020 |
Renal dysfunction in a mouse model of GDM is prevented by metformin through MAPKs.
Topics: Animals; Blood Glucose; Diabetes, Gestational; Diet, High-Fat; Disease Models, Animal; Female; Gluco | 2019 |
The protective effect of silk fibroin on high glucose induced insulin resistance in HepG2 cells.
Topics: Catalase; Drug Synergism; Fibroins; Glucose; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin Resi | 2019 |
Effect of six-month use of oral contraceptive pills on plasminogen activator inhibitor-1 & factor VIII among women with polycystic ovary syndrome: An observational pilot study.
Topics: Adult; Blood Glucose; Contraceptives, Oral; Contraceptives, Oral, Combined; Factor VIII; Female; Hum | 2018 |
Metformin reduces risk of benign nodular goiter in patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Goiter, Nodular; Humans; Hypoglycemic Ag | 2019 |
Prolactin and breast increase during pregnancy in PCOS: linked to long-term metabolic health?
Topics: Adolescent; Adult; Blood Pressure; Body Mass Index; Breast; Female; Follow-Up Studies; Gestational A | 2019 |
Effects of TCF7L2 rs7903146 variant on metformin response in patients with type 2 diabetes.
Topics: Adult; Aged; Alleles; Anthropometry; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genotype; Hum | 2019 |
Metformin metabolic and vascular effects in overweight/moderately obese hyperinsulinemic PCOS patients treated with contraceptive vaginal ring: a pilot study.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Contraceptive Devices, Female; Female; Glucose To | 2019 |
Effect of Metformin Treatment on Insulin Resistance Markers, and Circulating Irisin in Women with Polycystic Ovarian Syndrome (PCOS).
Topics: Adult; Biomarkers; Female; Fibronectins; Humans; Insulin; Insulin Resistance; Lipoproteins, LDL; Met | 2019 |
Selected elements of extracellular matrix of the skin in diabetes and insulin resistance.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Extracellular Matrix; Insulin; Insulin Resis | 2019 |
Metformin Promotes Anxiolytic and Antidepressant-Like Responses in Insulin-Resistant Mice by Decreasing Circulating Branched-Chain Amino Acids.
Topics: Amino Acids, Branched-Chain; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Depressio | 2019 |
Alpha lipoic acid and metformin alleviates experimentally induced insulin resistance and cognitive deficit by modulation of TLR2 signalling.
Topics: Animals; Anti-Inflammatory Agents; Cognition Disorders; Disease Models, Animal; Insulin; Insulin Res | 2019 |
Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose Tolerance | 2019 |
Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose Tolerance | 2019 |
Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose Tolerance | 2019 |
Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose Tolerance | 2019 |
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adult; Arginine; B-Lymphocytes; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fa | 2019 |
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adult; Arginine; B-Lymphocytes; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fa | 2019 |
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adult; Arginine; B-Lymphocytes; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fa | 2019 |
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adult; Arginine; B-Lymphocytes; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fa | 2019 |
The Effects of Metformin on Age-Related Changes in the Liver Sinusoidal Endothelial Cell.
Topics: Age Factors; AMP-Activated Protein Kinases; Animals; Cells, Cultured; Endothelial Cells; Insulin Res | 2020 |
AMPK-SIRT1-independent inhibition of ANGPTL3 gene expression is a potential lipid-lowering mechanism of metformin.
Topics: AMP-Activated Protein Kinases; Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Diabetes Mel | 2019 |
Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with Polycystic Ovarian Syndrome: An observational study.
Topics: Adult; Body Mass Index; Coagulation Protein Disorders; Contraceptives, Oral; Ethinyl Estradiol; Fema | 2019 |
Metformin reduces fibrosis factors in insulin resistant and hypertrophied adipocyte via integrin/ERK, collagen VI, apoptosis, and necrosis reduction.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Apoptosis; Cell Differentiation; Collagen Type IV; Extracellular | 2019 |
Correlation between glycemic trends assessed by 24 h continuous monitoring and autonomic activity in patients with recent onset type 2 diabetes.
Topics: Adult; Autonomic Nervous System; Blood Glucose; Blood Glucose Self-Monitoring; Cross-Sectional Studi | 2013 |
The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats.
Topics: Animals; Blood Glucose; Carotid Arteries; Carotid Artery Injuries; Carotid Stenosis; Cells, Cultured | 2013 |
[Protective effect and mechanism of metformin in rats with alcoholic liver disease].
Topics: Animals; Insulin Resistance; Liver Diseases, Alcoholic; Male; Metformin; Rats; Rats, Wistar | 2012 |
Treatment strategies in PCOS patients.
Topics: Clomiphene; Diabetes Mellitus; Diet; Exercise; Female; Fertility Agents, Female; Humans; Hypoglycemi | 2005 |
Switching a hyperinsulinemic patient from insulin to oral hypoglycemics.
Topics: Developmental Disabilities; Diabetes Mellitus; Diet; Humans; Hyperinsulinism; Hypoglycemic Agents; I | 2012 |
Therapeutic improvement of glucoregulation in newly diagnosed type 2 diabetes patients is associated with a reduction of IL-17 levels.
Topics: Adult; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucose; Glycated Hemoglobin; Humans; Hyp | 2013 |
A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report.
Topics: Adult; Antioxidants; beta-Glucans; Blood Glucose; Blueberry Plants; Diabetes Mellitus, Type 2; Dieta | 2014 |
Differences in the management of adolescents with polycystic ovary syndrome across pediatric specialties.
Topics: Adolescent; Adolescent Medicine; Androgen Antagonists; Contraceptives, Oral, Hormonal; Diabetes Mell | 2013 |
The combined effect of metformin and L-cysteine on inflammation, oxidative stress and insulin resistance in streptozotocin-induced type 2 diabetes in rats.
Topics: Animals; Body Weight; C-Reactive Protein; Caspase 3; Chemokine CCL2; Cysteine; Cytochromes c; Diabet | 2013 |
Metformin inhibits follicle-stimulating hormone (FSH) action in human granulosa cells: relevance to polycystic ovary syndrome.
Topics: Aromatase; Cell Line, Tumor; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Female; Fo | 2013 |
TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.
Topics: Animals; Benzofurans; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; | 2013 |
Role of adiponectin and its receptor in prediction of reproductive outcome of metformin treatment in patients with polycystic ovarian syndrome.
Topics: Adiponectin; Adult; Case-Control Studies; Cohort Studies; Female; Humans; Hypoglycemic Agents; Insul | 2013 |
Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.
Topics: Algorithms; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; H | 2013 |
Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitus.
Topics: Aged; Amino Acids, Aromatic; Amino Acids, Branched-Chain; Biomarkers; Blood Glucose; Diabetes Mellit | 2013 |
Alterations in thyroid function among the different polycystic ovary syndrome phenotypes.
Topics: Adult; Body Mass Index; Drug Therapy, Combination; Female; Hospitals, University; Humans; Hypoglycem | 2013 |
Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment.
Topics: Adult; Anovulation; Anthropometry; Body Mass Index; Endocrine System; Estradiol; Female; Follicle St | 2013 |
Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Analysis of Variance; Animals; Bariatric Surgery; Diet, Hi | 2014 |
AMPK activator-mediated inhibition of endoplasmic reticulum stress ameliorates carrageenan-induced insulin resistance through the suppression of selenoprotein P in HepG2 hepatocytes.
Topics: Adolescent; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Carrageenan; Endoplasmic Reti | 2014 |
Metformin decreases high-fat diet-induced renal injury by regulating the expression of adipokines and the renal AMP-activated protein kinase/acetyl-CoA carboxylase pathway in mice.
Topics: Acetyl-CoA Carboxylase; Adipokines; AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Glucose | 2013 |
Insulin resistance assessment in patients with polycystic ovary syndrome using different diagnostic criteria--impact of metformin treatment.
Topics: Adult; Blood Glucose; Body Mass Index; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin | 2013 |
Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pr | 2013 |
Resistin, an adipokine, may affect the improvement of insulin sensitivity in the metabolic syndrome patient treated with metformin.
Topics: Humans; Insulin Resistance; Metabolic Syndrome; Metformin; Models, Biological; Resistin; Rosiglitazo | 2013 |
Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin.
Topics: Acetyl-CoA Carboxylase; Acetyltransferases; AMP-Activated Protein Kinases; Animals; Cells, Cultured; | 2013 |
Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models.
Topics: Adipocytes; Aminopyridines; Animals; Diabetes Mellitus, Type 2; Drug Discovery; Glucose; Hyperinsuli | 2013 |
Metformin attenuates the exacerbation of the allergic eosinophilic inflammation in high fat-diet-induced obesity in mice.
Topics: AMP-Activated Protein Kinases; Animals; Asthma; Blotting, Western; Bronchoalveolar Lavage Fluid; Die | 2013 |
Comment on: TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care 2013;36:1749-1757.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secretin | 2013 |
Metformin trims fats to restore insulin sensitivity.
Topics: Acetyl-CoA Carboxylase; Acetyltransferases; AMP-Activated Protein Kinases; Animals; Insulin; Insulin | 2013 |
Role for sterol regulatory element binding protein-1c activation in mediating skeletal muscle insulin resistance via repression of rat insulin receptor substrate-1 transcription.
Topics: Adenoviridae; Animals; Blotting, Western; Cells, Cultured; Diet, High-Fat; Hypoglycemic Agents; Insu | 2014 |
AMPK in the small intestine in normal and pathophysiological conditions.
Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Caco-2 Cells; Carnitine O-Palmitoyltransferase | 2014 |
LMNA gene mutation as a model of cardiometabolic dysfunction: from genetic analysis to treatment response.
Topics: Adolescent; Amenorrhea; Body Fat Distribution; Cardiovascular Diseases; DNA Mutational Analysis; Fem | 2014 |
KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cells, Cultured; Diabetes Mellitus, Experimental; D | 2014 |
Rosacea-like facial rash related to metformin administration in a young woman.
Topics: Adult; Drug Eruptions; Exanthema; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin | 2014 |
The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Aryldialkylphosphatase; Case-Control Studies; Choleste | 2014 |
Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism.
Topics: Adult; Ataxia Telangiectasia Mutated Proteins; C-Peptide; Drug Resistance; Female; Genetic Associati | 2014 |
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression.
Topics: alpha-2-HS-Glycoprotein; Anilides; Animals; Cell Line, Tumor; Diabetes Mellitus, Type 2; Gene Expres | 2014 |
Type 2 diabetes as a redox disease.
Topics: AMP-Activated Protein Kinases; Antioxidants; Diabetes Mellitus, Type 2; Exercise; Exercise Therapy; | 2014 |
Circulatory changes of the novel adipokine adipolin/CTRP12 in response to metformin treatment and an oral glucose challenge in humans.
Topics: Adipokines; Adult; Blood Glucose; Carotid Intima-Media Thickness; Case-Control Studies; Cross-Sectio | 2014 |
Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity.
Topics: Adipose Tissue; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Glucose; Glucose Intol | 2014 |
Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats.
Topics: Adipose Tissue; Animals; Cholesterol; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Hypog | 2014 |
Differential AMPK phosphorylation by glucagon and metformin regulates insulin signaling in human hepatic cells.
Topics: AMP-Activated Protein Kinases; Cell Line; Cyclic AMP-Dependent Protein Kinases; Gene Knockdown Techn | 2014 |
Involvement of the AMPK-PTEN pathway in insulin resistance induced by high glucose in cultured rat podocytes.
Topics: AMP-Activated Protein Kinases; Animals; Diabetic Nephropathies; Female; Glucose; Insulin Resistance; | 2014 |
Metformin ameliorates insulin resistance in L6 rat skeletal muscle cells through upregulation of SIRT3.
Topics: Animals; Cell Line; Insulin Resistance; Metformin; Muscle Fibers, Skeletal; Oxidative Stress; Rats; | 2014 |
Involvement of insulin resistance in the protective effect of metformin against alcoholic liver injury.
Topics: Adiponectin; Animals; Dose-Response Relationship, Drug; Ethanol; Hypoglycemic Agents; Insulin Resist | 2014 |
Effects of metformin and exercise training, alone or in association, on cardio-pulmonary performance and quality of life in insulin resistance patients.
Topics: Adult; Combined Modality Therapy; Exercise; Exercise Test; Exercise Tolerance; Female; Humans; Hypog | 2014 |
Metformin prevents LYRM1-induced insulin resistance in 3T3-L1 adipocytes via a mitochondrial-dependent mechanism.
Topics: Adipocytes; Animals; Antioxidants; Apoptosis Regulatory Proteins; Cell Line; Hypoglycemic Agents; In | 2014 |
Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, HDL; Cholesterol | 2014 |
Diazepam potentiates the antidiabetic, antistress and anxiolytic activities of metformin in type-2 diabetes mellitus with cooccurring stress in experimental animals.
Topics: Animals; Anti-Anxiety Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diazepam; | 2014 |
Antidiabetic effects of the Cimicifuga racemosa extract Ze 450 in vitro and in vivo in ob/ob mice.
Topics: AMP-Activated Protein Kinases; Animals; Benzophenanthridines; Berberine Alkaloids; Blood Glucose; Bo | 2014 |
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats.
Topics: Adamantane; Animals; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Dipeptidyl-Peptidase IV Inhi | 2014 |
Advanced onset of puberty after metformin therapy in swine with thrifty genotype.
Topics: Adiposity; Age Factors; Animals; Biomarkers; Blood Glucose; Diet, High-Fat; Disease Models, Animal; | 2014 |
Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria.
Topics: Adolescent; Austria; Body Mass Index; Child; Cohort Studies; Diabetes Mellitus, Type 1; Diabetic Ang | 2015 |
[Effect of Mudan Granule on islets beta cell function in monosodium glutamate induced obese mice with insulin resistance: an experimental study].
Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Female; Insulin Resistance; Insulin-Secretin | 2014 |
Effects of metformin on endocrine, metabolic milieus and endometrial expression of androgen receptor in patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; Endometrium; Female; Follicle Stimulating Hormone; Humans; Hy | 2015 |
[Effects of visfatin and metformin on insulin resistance and reproductive endocrine in rats with polycystic ovary syndrome].
Topics: Animals; Female; Humans; Insulin Resistance; Metformin; Nicotinamide Phosphoribosyltransferase; Poly | 2014 |
Phosphatase and tension homolog overexpression in insulin resistant diabetic adipose tissue.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Insulin Resistance; M | 2014 |
Urban, obese, allergic, and breathless: the shape of things to come?
Topics: Adult; Animals; Anti-Inflammatory Agents; Asthma; Child; Dyspnea; Feeding Behavior; Humans; Insulin | 2014 |
How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
Topics: Adolescent; Adult; Androgen Antagonists; Biomarkers; Blood Platelets; Body Mass Index; C-Reactive Pr | 2015 |
Association between ferritin and hepcidin levels and inflammatory status in patients with type 2 diabetes mellitus and obesity.
Topics: Adult; Aged; Body Mass Index; C-Reactive Protein; Case-Control Studies; Diabetes Mellitus, Type 2; F | 2015 |
TallyHO obese female mice experience poor reproductive outcomes and abnormal blastocyst metabolism that is reversed by metformin.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; AMP-Activated Protein Kinases; Animals; Apoptosis; Blastocyst; Blo | 2014 |
Successful pregnancy outcomes in a patient with type A insulin resistance syndrome.
Topics: Adult; Antigens, CD; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Metform | 2015 |
Polycystic ovaries and obesity.
Topics: Adipokines; Adiponectin; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Inf | 2015 |
Protective effect of metformin against walker 256 tumor growth is not dependent on metabolism improvement.
Topics: Animals; Blood Glucose; Carcinoma 256, Walker; Cell Proliferation; Diabetes Mellitus, Experimental; | 2014 |
Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience.
Topics: Adolescent; Carbohydrates; Child; Child, Preschool; Craniopharyngioma; Dyslipidemias; Female; Fenofi | 2015 |
Jinlida reduces insulin resistance and ameliorates liver oxidative stress in high-fat fed rats.
Topics: Animals; Chemical and Drug Induced Liver Injury; Dietary Fats; Drugs, Chinese Herbal; Hypoglycemic A | 2015 |
Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model.
Topics: Angiogenesis Modulating Agents; Angiopoietin-1; Angiopoietin-2; Animals; Dehydroepiandrosterone; Fem | 2015 |
[Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome].
Topics: Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Metformin | 2014 |
Metformin use in patients undergoing in vitro fertilization treatment: results of a worldwide web-based survey.
Topics: Abortion, Spontaneous; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Insulin Resistan | 2015 |
The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and subclinical hyperthyroidism.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hyperthyroidism; Hypogl | 2015 |
PRDM16 sustains white fat gene expression profile in human adipocytes in direct relation with insulin action.
Topics: Adipocytes, White; Adipogenesis; Adipose Tissue, White; Adult; Case-Control Studies; Cells, Cultured | 2015 |
The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.
Topics: C-Peptide; Diabetes Mellitus, Type 2; DNA; Female; Genetic Variation; Genotype; Humans; Hypoglycemic | 2015 |
[Improvement of clinical parameters in a patient with metabolic syndrome through intervention in nutrition education and improvement of lifestyle].
Topics: Aged, 80 and over; Anthropometry; Blood Glucose; Diet Records; Diet, Diabetic; Diet, Fat-Restricted; | 2014 |
Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity.
Topics: AMP-Activated Protein Kinases; Animals; Aspirin; Cardiotonic Agents; Cells, Cultured; Diabetes Melli | 2015 |
[Metformin ameliorates β-cell dysfunction by regulating inflammation production, ion and hormone homeostasis of pancreas in diabetic KKAy mice].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Down-Regulation; Female; Glucose Tolerance | 2014 |
Effects of Icariin on insulin resistance via the activation of AMPK pathway in C2C12 mouse muscle cells.
Topics: Acetyl-CoA Carboxylase; Adiponectin; AMP-Activated Protein Kinases; Animals; Cell Survival; Cells, C | 2015 |
Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Duodenum; Gene Exp | 2015 |
Leucine amplifies the effects of metformin on insulin sensitivity and glycemic control in diet-induced obese mice.
Topics: Adipocytes; AMP-Activated Protein Kinases; Animals; Blood Glucose; Diet, High-Fat; Fasting; Glucose; | 2015 |
Metformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-+Leprdb/+Leprdb mice.
Topics: Adipokines; Animals; Animals, Newborn; Carcinogenesis; Diabetes Mellitus, Experimental; Diethylnitro | 2015 |
Metformin attenuates palmitic acid-induced insulin resistance in L6 cells through the AMP-activated protein kinase/sterol regulatory element-binding protein-1c pathway.
Topics: AMP-Activated Protein Kinases; Animals; Enzyme Activation; Insulin; Insulin Receptor Substrate Prote | 2015 |
Suppression of phosphatase and tensin homolog protects insulin-resistant cells from apoptosis.
Topics: Animals; Apoptosis; Cells, Cultured; Enzyme Activation; Enzyme Inhibitors; Glucosamine; Glucose Tran | 2015 |
Metformin reduces hyper-reactivity of platelets from patients with polycystic ovary syndrome by improving mitochondrial integrity.
Topics: Adult; AMP-Activated Protein Kinases; Blood Platelets; Case-Control Studies; Cell Line; Dose-Respons | 2015 |
Diabetic silkworms for evaluation of therapeutically effective drugs against type II diabetes.
Topics: Animals; Bombyx; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Drug Evaluation, | 2015 |
Electroacupuncture plus metformin lowers glucose levels and facilitates insulin sensitivity by activating MAPK in steroid-induced insulin-resistant rats.
Topics: Animals; Blood Glucose; Combined Modality Therapy; Dexamethasone; Diabetes Mellitus, Type 2; Disease | 2015 |
The skin remodeling in type 1 diabetes and insulin resistance animal models.
Topics: Animals; Collagen Type III; Connective Tissue; Diabetes Mellitus, Type 1; Insulin; Insulin Resistanc | 2015 |
Can Animal Models of PCOS Help Point the Way Towards Early and Effective Therapeutic Intervention in Women With the Syndrome?
Topics: Androgen Antagonists; Animals; Contraceptives, Oral, Hormonal; Disease Models, Animal; Disease Progr | 2015 |
Exploring the significance of sex hormone-binding globulin examination in the treament of women with polycystic ovarian syndrome (PCOS).
Topics: Abortion, Spontaneous; Adult; Androgen Antagonists; Blood Glucose; Body Mass Index; Clomiphene; Cypr | 2015 |
Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.
Topics: Active Transport, Cell Nucleus; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; AM | 2015 |
Effects of preventative application of metformin on bile acid metabolism in high fat-fed/streptozotocin-diabetic rats.
Topics: Animals; Bile Acids and Salts; Blood Glucose; Diabetes Mellitus, Experimental; Diet, High-Fat; Hypog | 2015 |
Treatment With Metformin Improves Erectile Dysfunction in a Murine Model of Obesity Associated With Insulin Resistance.
Topics: Animals; Disease Models, Animal; Erectile Dysfunction; Hypoglycemic Agents; Insulin Resistance; Male | 2015 |
[Second Consensus of the Chilean Society of Endocrinology and Diabetes about insulin resistance].
Topics: Chile; Delphi Technique; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Metfor | 2015 |
[THE EFFECTS OF LONG-TERM METFORMIN TREATMENT ON THE ACTIVITY OF ADENYLYL CYCLASE SYSTEM AND NO-SYNTHASES IN THE BRAIN AND THE MYOCARDIUM OF RATS WITH OBESITY].
Topics: Adenylyl Cyclases; Adipose Tissue; Adrenergic Agonists; Animals; Body Weight; Brain; Cardiotonic Age | 2015 |
Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin.
Topics: Adult; Androstenes; Apelin; Blood Glucose; Body Mass Index; Case-Control Studies; Drug Therapy, Comb | 2015 |
Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus.
Topics: Adamantane; Adult; Apelin; Biomarkers; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type | 2015 |
Effects of metformin on mitochondrial function of leukocytes from polycystic ovary syndrome patients with insulin resistance.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Metformin; Mitochondr | 2015 |
Hyperandrogenism and Insulin Resistance, Not Changes in Body Weight, Mediate the Development of Endothelial Dysfunction in a Female Rat Model of Polycystic Ovary Syndrome (PCOS).
Topics: Androgen Antagonists; Androgens; Animals; Arteries; Blood Pressure; Body Weight; Dihydrotestosterone | 2015 |
Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Glucose Clamp Technique; Hyperinsulin | 2015 |
Palmitate activates mTOR/p70S6K through AMPK inhibition and hypophosphorylation of raptor in skeletal muscle cells: Reversal by oleate is similar to metformin.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Blotting, Western; Cel | 2015 |
Insulin Sensitizers for Treatment of Menstrual Irregularities Associated with PCOS.
Topics: Comparative Effectiveness Research; Contraceptives, Oral; Evidence-Based Practice; Female; Humans; H | 2015 |
Electroacupuncture treatment of insulin resistance in diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Electroacupunctu | 2015 |
Fucoidan ameliorates steatohepatitis and insulin resistance by suppressing oxidative stress and inflammatory cytokines in experimental non-alcoholic fatty liver disease.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cytokines; Diet, High-Fat; Disease Models, Animal; | 2015 |
Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Double-Blind Method; Femal | 2015 |
Recessive mutations in the cancer gene Ataxia Telangiectasia Mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance.
Topics: Adult; Ataxia Telangiectasia Mutated Proteins; Biomarkers, Pharmacological; Blood Glucose; Case-Cont | 2016 |
Therapeutic Effect of Metformin on Chemerin in Non-Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD).
Topics: Administration, Oral; Adult; Biomarkers; Blood Pressure; Chimerin 1; Drug Synergism; Female; Humans; | 2015 |
Assessment of Anti-Müllerian Hormone Level in Management of Adolescents with Polycystic Ovary Syndrome.
Topics: Adolescent; Androgens; Anti-Mullerian Hormone; Biomarkers; Contraceptives, Oral, Combined; Disease M | 2016 |
A case of familial partial lipodystrophy caused by a novel lamin A/C (LMNA) mutation in exon 1 (D47N).
Topics: Adult; Diabetes Mellitus; Exons; Fatty Liver; Female; Heterozygote; Humans; Insulin; Insulin Resista | 2016 |
Metformin may protect nondiabetic breast cancer women from metastasis.
Topics: Adult; Aged; Blood Glucose; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans | 2016 |
The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and amiodarone-induced hypothyroidism.
Topics: Aged; Amiodarone; Diabetes Mellitus, Type 2; Female; Humans; Hypothalamo-Hypophyseal System; Hypothy | 2016 |
Metformin improves hepatic IRS2/PI3K/Akt signaling in insulin-resistant rats of NASH and cirrhosis.
Topics: Animals; Glucose Intolerance; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resi | 2016 |
Effect of Metformin on Fibroblast Growth Factor-21 Levels in Patients with Newly Diagnosed Type 2 Diabetes.
Topics: Adult; Aged; C-Reactive Protein; Case-Control Studies; China; Cross-Sectional Studies; Diabetes Mell | 2016 |
Insulin sensitizers prevent fine particulate matter-induced vascular insulin resistance and changes in endothelial progenitor cell homeostasis.
Topics: Animals; Aorta; Ataxin-1; Caspase 1; Cells, Cultured; Diet, High-Fat; Endothelial Progenitor Cells; | 2016 |
Adolescents with Classical Polycystic Ovary Syndrome Have Alterations in the Surrogate Markers of Cardiovascular Disease but Not in the Endothelial Function. The Possible Benefits of Metformin.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Carotid I | 2016 |
Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction.
Topics: Adamantane; Animals; Cardiotonic Agents; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; | 2016 |
Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity.
Topics: Acarbose; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Hum | 2016 |
Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; | 2016 |
A challenge in the management of women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anti-Mullerian Hormone; Female; Ferritins; Humans; Hypoglycemic Agents; Insul | 2016 |
Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; Female; Glucose Tolerance Test; Humans; Insulin Antagonists; | 2017 |
Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling.
Topics: Animals; Anti-Bacterial Agents; Blood Glucose; Cells, Cultured; Diet, High-Fat; Endotoxemia; Humans; | 2016 |
Synthesis and Evaluation of 1-Substituted-Biguanide Derivatives as Anti-Diabetic Agents for Type II Diabetes Insulin Resistant.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Biguanides; Blood Glucose; Cholesterol; | 2016 |
AMPK Activation by Metformin Suppresses Abnormal Extracellular Matrix Remodeling in Adipose Tissue and Ameliorates Insulin Resistance in Obesity.
Topics: Adipose Tissue; Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Cells, Cultured; Coll | 2016 |
[Diabetes mellitus and endometrial cancer].
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Endometrial Neoplasms; Female; Humans; Hypoglyce | 2016 |
Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: A comparative study with metformin.
Topics: Acetylation; Adipose Tissue; Animals; Blood Glucose; Butyric Acid; Diabetes Mellitus, Experimental; | 2016 |
Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, C | 2016 |
Estrogen and DPP4 inhibitor, but not metformin, exert cardioprotection via attenuating cardiac mitochondrial dysfunction in obese insulin-resistant and estrogen-deprived female rats.
Topics: Adamantane; Animals; Cardiotonic Agents; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Estroge | 2016 |
Metformin and resveratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue.
Topics: 3T3-L1 Cells; Adipose Tissue; Administration, Oral; Animals; Cyclic AMP; Cyclic AMP-Dependent Protei | 2016 |
Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver.
Topics: Adipocytes; Adipokines; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Blood Pressure; Body | 2016 |
DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa, in type-2 diabetes mellitus patients inadequately controlled by metformin and other oral antidiabetic agents.
Topics: Adiponectin; Blood Glucose; Cinnamomum; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female | 2016 |
Beneficial effects of combined resveratrol and metformin therapy in treating diet-induced insulin resistance.
Topics: Adiposity; Animals; Blood Glucose; Diet, High-Fat; Drug Therapy, Combination; Inflammation Mediators | 2016 |
Metformin Improves Metabolic Memory in High Fat Diet (HFD)-induced Renal Dysfunction.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Apoptosis; Blood Glucose; Cardiovascular Sys | 2016 |
Sirtuin 1 and 7 mediate resveratrol-induced recovery from hyper-anxiety in high-fructose-fed prediabetic rats.
Topics: Animals; Antioxidants; Anxiety Disorders; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes M | 2016 |
Piracetam Facilitates the Anti-Amnesic but not Anti-Diabetic Activity of Metformin in Experimentally Induced Type-2 Diabetic Encephalopathic Rats.
Topics: Amnesia; Animals; Blood Glucose; Brain Diseases; Brain-Derived Neurotrophic Factor; Choline; Diabete | 2017 |
Mfn1 Deficiency in the Liver Protects Against Diet-Induced Insulin Resistance and Enhances the Hypoglycemic Effect of Metformin.
Topics: Animals; Diet, High-Fat; GTP Phosphohydrolases; Homeostasis; Hypoglycemic Agents; Insulin Resistance | 2016 |
Metformin Effect on Nontargeted Metabolite Profiles in Patients With Type 2 Diabetes and in Multiple Murine Tissues.
Topics: Adipose Tissue; Animals; Citrulline; Diabetes Mellitus, Type 2; Fasting; Humans; Hypoglycemic Agents | 2016 |
Administration of Melatonin and Metformin Prevents Deleterious Effects of Circadian Disruption and Obesity in Male Rats.
Topics: Adiposity; Animals; Central Nervous System Depressants; Circadian Rhythm; Glucose Intolerance; Hypog | 2016 |
Symplocos cochinchinensis enhances insulin sensitivity via the down regulation of lipogenesis and insulin resistance in high energy diet rat model.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diet, High-Fat; Dose-Response R | 2016 |
Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Fasting; Female; Humans; Hypoglycemic Agents; Insulin; Insuli | 2017 |
[Woman 19-old with hirsutism, obesity and acanthosis nigricans].
Topics: Acanthosis Nigricans; Female; Hirsutism; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Ob | 2016 |
Thymol improves high-fat diet-induced cognitive deficits in mice via ameliorating brain insulin resistance and upregulating NRF2/HO-1 pathway.
Topics: Animals; Antioxidants; Cognition Disorders; Cytokines; Diet, High-Fat; Heme Oxygenase-1; Hypoglycemi | 2017 |
Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Docosahexaenoic Acids; Dr | 2017 |
Comment on "Metformin Decreases Thyroid Volume and Nodule Size in Subjects with Insulin Resistance: A Preliminary Study".
Topics: Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Thyroid Gland; Thyroid Nodule; | 2017 |
Adiponectin, Insulin Sensitivity, β-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY.
Topics: Adiponectin; Adolescent; Black People; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; D | 2017 |
Metformin preconditioned adipose derived mesenchymal stem cells is a better option for the reversal of diabetes upon transplantation.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Diet, Hig | 2016 |
Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress.
Topics: Animals; Behavior, Animal; Biomarkers; Chronic Disease; Depression; Diet, High-Fat; Disease Models, | 2017 |
The Crucial Role of C18-Cer in Fat-Induced Skeletal Muscle Insulin Resistance.
Topics: Acyl Coenzyme A; Animals; Ceramides; Coenzyme A Ligases; Diet, High-Fat; Fatty Acids; Fatty Acids, M | 2016 |
Metformin ameliorates high uric acid-induced insulin resistance in skeletal muscle cells.
Topics: 4-Chloro-7-nitrobenzofurazan; Acetylcysteine; Adenylate Kinase; Animals; Antioxidants; Cell Line; De | 2017 |
The Effects of Blood Glucose Regulation in Omentin-1 Levels among Diabetic Patients.
Topics: Administration, Oral; Adult; Blood Glucose; Case-Control Studies; Cytokines; Diabetes Mellitus, Type | 2017 |
Transcriptomic effects of metformin in skeletal muscle arteries of obese insulin-resistant rats.
Topics: Animals; Arteries; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Muscle | 2017 |
Metformin attenuates hepatic insulin resistance in type-2 diabetic rats through PI3K/Akt/GLUT-4 signalling independent to bicuculline-sensitive GABA
Topics: Androstadienes; Animals; Bicuculline; Calcium; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2017 |
Effects of a hyperandrogenaemic state on the proliferation and decidualization potential in human endometrial stromal cells.
Topics: Adult; Cell Proliferation; Decidua; Dexamethasone; Embryo Implantation; Endometrium; Epithelial Cell | 2017 |
mTORC1 inhibitors rapamycin and metformin affect cardiovascular markers differentially in ZDF rats.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dis | 2017 |
High-dose metformin (420mg/kg daily p.o.) increases insulin sensitivity but does not affect neointimal thickness in the rat carotid balloon injury model of restenosis.
Topics: AMP-Activated Protein Kinases; Animals; Blood Pressure; Carotid Artery Injuries; Carotid Intima-Medi | 2017 |
The desert gerbil Psammomys obesus as a model for metformin-sensitive nutritional type 2 diabetes to protect hepatocellular metabolic damage: Impact of mitochondrial redox state.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gerbillinae; Hypoglycemic Agents; Insuli | 2017 |
Should metformin be included in fertility treatment of PCOS patients?
Topics: Adenosine Triphosphate; Diabetes Mellitus, Type 2; Diabetes, Gestational; Electron Transport; Female | 2017 |
Predictors of menstruation restoration during metformin administration for treatment of antipsychotic drug-induced amenorrhea: A post hoc analysis.
Topics: Amenorrhea; Antipsychotic Agents; Body Weight; Female; Follicle Stimulating Hormone; Humans; Hypogly | 2017 |
Effects of swimming on the pharmacokinetics and glucose tolerance of metformin in insulin-resistant rats.
Topics: Animals; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Physical | 2008 |
Homeostasis model assessment-insulin resistance (HOMA-IR), a key role for assessing the ovulation function in polycystic ovary syndrome (PCOS) patients with insulin resistance.
Topics: Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Homeostasis; Humans; Hypoglycemic | 2008 |
A reappraisal of the role of polycystic ovary syndrome in recurrent miscarriage.
Topics: Abortion, Habitual; Androgens; Anovulation; Female; Gonadotropins; Humans; Infertility, Female; Insu | 2008 |
Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment.
Topics: Adiponectin; Adult; Body Mass Index; C-Reactive Protein; Cytokines; Fasting; Female; Humans; Insulin | 2008 |
Insulin resistance directly contributes to androgenic potential within ovarian theca cells.
Topics: Androgens; Animals; Cell Culture Techniques; Chromans; Female; Glucose Transporter Type 4; Insulin R | 2009 |
Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fa | 2008 |
Metformin: effective in the prevention of new-onset type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Early Diagnosis; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2008 |
Gestational diabetes: an opportunity for improvement.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Disease Progression; Female; Glucose Intolerance; Human | 2008 |
Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; Cross-Sectional Studies; Cytokines; Diabetes Mellitus, Type 2 | 2010 |
Mechanism of action of metformin in nonalcoholic steatohepatitis.
Topics: Alanine Transaminase; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin | 2009 |
Severe acanthosis nigricans in a 17 year-old female with partial lipodystrophic syndrome.
Topics: Acanthosis Nigricans; Adolescent; Diet Therapy; Diet, Carbohydrate-Restricted; Diet, Fat-Restricted; | 2008 |
Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report.
Topics: Adipose Tissue; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; | 2009 |
Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization.
Topics: Adult; Blood Glucose; Body Mass Index; Case-Control Studies; Chorionic Gonadotropin; Dinoprostone; E | 2009 |
Hyperinsulinaemia and iron perturbation in patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exercise; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Iron; | 2009 |
Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Gastric Inhibitory Polypeptide; Glucagon-Like | 2009 |
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty A | 2009 |
Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apoptosis; Cardiotonic Agents; C | 2009 |
Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein.
Topics: Amino Acid Sequence; Animals; Conserved Sequence; CREB-Binding Protein; Cyclic AMP-Dependent Protein | 2009 |
Recovery of acanthosis nigricans under prolonged metformin treatment in an adolescent with normal weight.
Topics: Acanthosis Nigricans; Adolescent; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance | 2009 |
Metformin is a unique drug.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Practice Guid | 2009 |
Insulin sensitizing actions of fenugreek seed polyphenols, quercetin & metformin in a rat model.
Topics: Animals; Blood Glucose; Fatty Acids, Nonesterified; Flavonoids; Fructose; Glucose Tolerance Test; In | 2009 |
Androgen receptor antagonism and an insulin sensitizer block the advancement of vaginal opening by high-fat diet in mice.
Topics: Analysis of Variance; Androgen Antagonists; Animals; Body Weight; Diet, Fat-Restricted; Dietary Fats | 2009 |
Antidiabetic effects of Artemisia sphaerocephala Krasch. gum, a novel food additive in China, on streptozotocin-induced type 2 diabetic rats.
Topics: Animals; Artemisia; Blood Glucose; China; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Experime | 2009 |
Metformin: diamonds are forever.
Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; | 2009 |
[Effect of metformin on the clinical course of gout and insulin resistance].
Topics: Adult; Female; Gout; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; | 2009 |
Depression, depression treatment, and insulin sensitivity in adults at risk for type 2 diabetes.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Connecticut; Depression; Diabetes Mellitus, Type | 2009 |
Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats.
Topics: Animals; Biomarkers; Cardiomyopathies; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Ther | 2009 |
Glucose homeostasis is impaired by a paradoxical interaction between metformin and insulin in carnivorous rainbow trout.
Topics: Animal Nutritional Physiological Phenomena; Animals; Blood Glucose; Feeding Behavior; Gene Expressio | 2009 |
Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and Type 2 diabetes mellitus.
Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Hepatitis C, Chronic; Humans; Hyperins | 2009 |
[Polycystic ovary syndrome. Diet helps control hormone chaos].
Topics: Acne Vulgaris; Adolescent; Adult; Androgens; Child; Combined Modality Therapy; Female; Hirsutism; Hu | 2009 |
Metformin, estrogen replacement therapy and gonadotropin inhibition fail to improve insulin sensitivity in a girl with aromatase deficiency.
Topics: Androgen Antagonists; Androgens; Aromatase; Child; Diabetes Mellitus, Type 2; Estrogen Replacement T | 2009 |
Lipase maturation factor 1: its expression in Zucker diabetic rats, and effects of metformin and fenofibrate.
Topics: Adipose Tissue; Analysis of Variance; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Enzyme | 2009 |
Metformin in chronic hepatitis C virus hepatitis: caution needed with sex-based subgroup analysis.
Topics: Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Sex | 2010 |
Metformin, hepatitis C, and insulin resistance: sufficient evidence?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Hypoglycemic Agents; Insulin Resistance; Int | 2009 |
Metformin regulates palmitate-induced apoptosis and ER stress response in HepG2 liver cells.
Topics: Apoptosis; Blotting, Western; Caspase 3; Cell Culture Techniques; Cell Survival; Endoplasmic Reticul | 2010 |
Combining short-term metformin treatment and one bout of exercise does not increase insulin action in insulin-resistant individuals.
Topics: Adult; AMP-Activated Protein Kinases; Blotting, Western; Exercise; Female; Glucose Clamp Technique; | 2010 |
Metformin--a convenient alternative to insulin for Indian women with diabetes in pregnancy.
Topics: Analysis of Variance; Blood Glucose; Body Mass Index; Confidence Intervals; Diabetes Mellitus, Type | 2009 |
Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response.
Topics: Adult; Androgens; Case-Control Studies; Female; Follicular Fluid; Humans; Hypoglycemic Agents; Insul | 2010 |
A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess.
Topics: AMP-Activated Protein Kinase Kinases; Child; Drug Resistance; Female; Genotype; Humans; Hyperandroge | 2010 |
Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome.
Topics: Adult; Blood Pressure; Body Mass Index; Cholesterol, HDL; Female; Humans; Hypoglycemic Agents; Insul | 2009 |
Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fat | 2010 |
Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Animals; Anticarcinogenic Agents; Apoptosis; Azoxymethane; Cell Proli | 2010 |
Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet.
Topics: Animals; Diet; Dietary Carbohydrates; Dietary Fats; Gluconeogenesis; Hypoglycemic Agents; Insulin; I | 2010 |
Generation, validation and humanisation of a novel insulin resistant cell model.
Topics: Adipose Tissue; Animals; Case-Control Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; | 2010 |
Hyperinsulinemia precedes insulin resistance in mice lacking pancreatic beta-cell leptin signaling.
Topics: Adiposity; Animals; Blood Glucose; Body Weight; Diazoxide; Eating; Female; Hyperinsulinism; Hypoglyc | 2010 |
Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Blood Glucose; Breast Neoplasms; Diabetes Mell | 2010 |
Effect of Cyclea peltata Lam. roots aqueous extract on glucose levels, lipid profile, insulin, TNF-alpha and skeletal muscle glycogen in type 2 diabetic rats.
Topics: Animals; Blood Glucose; Cyclea; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Eva | 2010 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhi | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhi | 2010 |
Distinguishing among incretin-based therapies. Introduction.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors | 2010 |
Effects of metformin on the reproductive system of androgenized female rats.
Topics: Animals; Female; Insulin Resistance; Male; Metformin; Rats; Rats, Wistar; Reproduction; Virilism | 2011 |
[Dynamics of structural-functional parameters of cardiovascular system during use of complex therapy of women with type 2 diabetes mellitus].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Chi-Square Distribution; Data Interpretation, Statis | 2010 |
Protective effect of Clerodendron glandulosum extract against experimentally induced metabolic syndrome in rats.
Topics: Animals; Blood Pressure; Clerodendrum; Disease Models, Animal; Dyslipidemias; Insulin Resistance; Li | 2010 |
The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis.
Topics: Adipokines; Adipose Tissue; Adult; Animals; Atherosclerosis; Case-Control Studies; Female; Humans; I | 2011 |
Pharmacokinetics of metformin after enteral administration in insulin-resistant ponies.
Topics: Administration, Oral; Animals; Area Under Curve; Drug Administration Schedule; Half-Life; Horse Dise | 2010 |
When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?
Topics: Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndro | 2011 |
Adipose triglyceride lipase expression in human adipose tissue and muscle. Role in insulin resistance and response to training and pioglitazone.
Topics: 1-Acylglycerol-3-Phosphate O-Acyltransferase; Adipose Tissue; Bicycling; Body Mass Index; Female; Hu | 2011 |
Synthesis and biological activity of trans-tiliroside derivatives as potent anti-diabetic agents.
Topics: Flavonoids; Glucose; Hep G2 Cells; Humans; Hypoglycemic Agents; Insulin Resistance; Magnetic Resonan | 2010 |
Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dia | 2011 |
A new shine on an old med. The story of metformin's past, present, and possible future.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polyc | 2010 |
Phosphoprotein enriched in diabetes gene product (Ped/pea-15) is increased in omental adipose tissue of women with the polycystic ovary syndrome: ex vivo regulation of ped/pea-15 by glucose, insulin and metformin.
Topics: Adipose Tissue; Adult; Apoptosis Regulatory Proteins; Biomarkers; Female; Glucose; Humans; Insulin; | 2011 |
Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; C-Reactive Protein; Diabetes Complicat | 2011 |
Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study.
Topics: Abdominal Pain; Adult; Cohort Studies; Diabetes, Gestational; Egypt; Female; Fertilization in Vitro; | 2011 |
Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line; Cholinesterases; Diabetes Mellitus, Ex | 2011 |
Insulin resistance and liver microcirculation in a rat model of early NAFLD.
Topics: Acetylcholine; Amidines; Animals; Benzylamines; Diet, High-Fat; Disease Models, Animal; Endothelium; | 2011 |
Early onset and high prevalence of gestational diabetes in PCOS and insulin resistant women before and after assisted reproduction.
Topics: Adult; Age of Onset; Cohort Studies; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inf | 2011 |
[Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes].
Topics: Animals; Apoptosis; Disease Models, Animal; Down-Regulation; Fatty Liver; Insulin Resistance; Lipid | 2011 |
In search of the "LINK": Acute Phase Serum Amyloid A.
Topics: Animals; Female; Humans; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2011 |
AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice.
Topics: AMP-Activated Protein Kinases; Animals; Atherosclerosis; Benzopyrans; Dietary Fats; Disease Models, | 2011 |
Metformin sensitizes insulin signaling through AMPK-mediated PTEN down-regulation in preadipocyte 3T3-L1 cells.
Topics: 3T3-L1 Cells; Adipocytes; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Down-Re | 2011 |
Insulin resistance influences central opioid activity in polycystic ovary syndrome.
Topics: Adult; beta-Endorphin; Binding Sites; Brain; Carbon Radioisotopes; Case-Control Studies; Female; Fen | 2011 |
Should metformin be our antiglycemic agent of choice post-transplantation?
Topics: Anti-Inflammatory Agents; Anticarcinogenic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type | 2011 |
Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Disease Models, Animal; Dyslipidemias; Glyburide; Huma | 2011 |
Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.
Topics: Adipose Tissue; Antiretroviral Therapy, Highly Active; Carbamates; Diabetes Mellitus, Type 2; Drug T | 2011 |
Effect of aspirin on the expression of hepatocyte NF-κB and serum TNF-α in streptozotocin-induced type 2 diabetic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Glucose; Diabetes Mellitus, Experim | 2011 |
Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucose Intolerance; Humans; Hy | 2011 |
Lupin seed γ-conglutin lowers blood glucose in hyperglycaemic rats and increases glucose consumption of HepG2 cells.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Proteins; Dietary Supplements; Glucose; H | 2012 |
Latin American consensus: children born small for gestational age.
Topics: Child, Preschool; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female | 2011 |
Glycated hemoglobin as a prognostic risk marker in nondiabetic patients after acute myocardial infarction: what now?
Topics: Angioplasty, Balloon, Coronary; Diabetes Mellitus, Type 2; Follow-Up Studies; Forecasting; Glycated | 2011 |
Metformin in equine metabolic syndrome: an enigma or a dead duck?
Topics: Animals; Female; Horse Diseases; Hypoglycemic Agents; Insulin Resistance; Metformin | 2012 |
IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.
Topics: Alloxan; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell | 2011 |
Metabolic syndrome and mental illness. Weight gain and other unhealthy attributes increase risk of diabetes and heart disease.
Topics: Antipsychotic Agents; Blood Glucose; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, | 2011 |
[Reactive-dystrophic processes in salivary glands (sialoadenoses) running on the background of metabolic syndrome].
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Diabetes Mellitus, Type 2; Female; Glucose Toler | 2011 |
Energy-sensing factors coactivator peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonist.
Topics: AMP-Activated Protein Kinases; Animals; C-Reactive Protein; Caloric Restriction; Cells, Cultured; En | 2012 |
Improvement of metabolic parameters and vascular function by metformin in obese non-diabetic rats.
Topics: Acetylcholine; Animals; Blood Pressure; Body Weight; Disease Models, Animal; Dyslipidemias; Epoprost | 2012 |
Diabetes and pancreatic cancer.
Topics: Adipokines; Diabetes Mellitus, Type 2; Early Detection of Cancer; Humans; Hypoglycemic Agents; Insul | 2012 |
Should all women with PCOS be treated for insulin resistance?
Topics: Female; Glucose Intolerance; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metab | 2012 |
Pigment epithelium-derived factor increases in type 2 diabetes after treatment with metformin.
Topics: Adult; Body Fat Distribution; Cohort Studies; Diabetes Mellitus, Type 2; Eye Proteins; Female; Glyca | 2012 |
Metformin prevents the development of chronic heart failure in the SHHF rat model.
Topics: Animals; Blood Glucose; Blood Pressure; Chronic Disease; Gene Expression Regulation; Heart Failure; | 2012 |
Metformin ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models.
Topics: AMP-Activated Protein Kinases; Animals; Hypoglycemic Agents; Insulin; Insulin Resistance; Interleuki | 2012 |
Swim training reduces metformin levels in fructose-induced insulin resistant rats.
Topics: Animals; Fructose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; | 2012 |
Menopausal obesity and metabolic syndrome - PolSenior study.
Topics: Age of Onset; Aged; Aged, 80 and over; Anthropometry; Cardiovascular Diseases; Cohort Studies; Diabe | 2012 |
Downregulation of chemerin and alleviation of endoplasmic reticulum stress by metformin in adipose tissue of rats.
Topics: Adipokines; Adipose Tissue; Animals; Blood Glucose; Body Weight; Chemokines; Diet, High-Fat; Down-Re | 2012 |
Effect of lifestyle modification and metformin therapy on emerging cardiovascular risk factors in overweight Indian women with polycystic ovary syndrome.
Topics: Adolescent; Adult; C-Reactive Protein; Cardiovascular Diseases; Female; Homeostasis; Homocysteine; H | 2012 |
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
Topics: Adolescent; Adult; Androgen Antagonists; Female; Glucose Intolerance; Hirsutism; Humans; Hyperglycem | 2012 |
[Use of insulin sensitizers in the treatment of infertility in patients with polycystic ovary syndrome (POS)].
Topics: Female; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Polycystic | 2012 |
Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice.
Topics: Animals; Antiviral Agents; Enzyme Inhibitors; Gene Knockdown Techniques; Gene Silencing; Hep G2 Cell | 2012 |
Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function.
Topics: Animals; Disease Models, Animal; Endotoxins; Fatty Liver; Fructose; Gene Expression; Hypoglycemic Ag | 2012 |
Methazolamide is a new hepatic insulin sensitizer that lowers blood glucose in vivo.
Topics: Animals; Blood Glucose; Carbonic Anhydrase Inhibitors; Diabetes Mellitus, Experimental; Glucose Clam | 2012 |
Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; | 2012 |
Cardiopulmonary and endothelial effects of metformin treatment in an insulin resistant population.
Topics: Adult; Blood Pressure; Endothelium, Vascular; Female; Heart Rate; Homeostasis; Humans; Hypoglycemic | 2012 |
Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats.
Topics: Animals; Ascorbic Acid; Blood Glucose; Body Weight; Catalase; Eating; Fructose; Glucose Tolerance Te | 2012 |
[The influence of metformin and N-acetylcysteine on mammographic density in postmenopausal women].
Topics: Acetylcysteine; Aged; Apoptosis; Breast; Breast Neoplasms; Cell Proliferation; DNA Repair; Female; H | 2012 |
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Female; Glucose Intolerance; Glyburide; Hypoglycemic | 2012 |
Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver.
Topics: Adiponectin; Adolescent; Cholesterol, LDL; Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin | 2011 |
In which HOMA-IR value acceptable for sampling the patients with insulin resistance?
Topics: Blood Pressure; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male | 2013 |
Pregestational diabetes with extreme insulin resistance: use of U-500 insulin in pregnancy.
Topics: Blood Glucose; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; | 2012 |
Severe hyperandrogenemia and insulin resistance in a 12-year-old girl.
Topics: Child; Estrogens; Ethinyl Estradiol; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic | 2012 |
The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice.
Topics: Animals; Blood Glucose; Bone Density; Bone Morphogenetic Protein 2; Core Binding Factor Alpha 1 Subu | 2012 |
A high-fat-diet-induced cognitive deficit in rats that is not prevented by improving insulin sensitivity with metformin.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Body Weight; Brain; Cognition Disorders; Conditioning, | 2012 |
Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats.
Topics: Animals; Blood Glucose; Brain; Dietary Fats; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; | 2012 |
The link between polycystic ovarian syndrome and type 2 diabetes: preventive and therapeutic approach in Israel.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insuli | 2012 |
NYGGF4 (PID1) effects on insulin resistance are reversed by metformin in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Carrier Proteins; Cell Membrane; DNA-Binding Proteins; Glucose Tr | 2012 |
Effects of metformin on insulin resistance in heart failure. Which came first: the chicken or the egg?
Topics: Exercise; Exercise Tolerance; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metform | 2012 |
Relationship between high values of HOMA-IR and cardiovascular response to metformin.
Topics: Blood Pressure; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male | 2013 |
Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats.
Topics: Adiponectin; Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug | 2013 |
The hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistance.
Topics: Cell Line; Comorbidity; Gene Expression Profiling; Gene Expression Regulation; Gene Expression Regul | 2012 |
Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice.
Topics: Adiposity; Amlodipine; Animals; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Cal | 2012 |
Effectiveness of metformin on weight loss in non-diabetic individuals with obesity.
Topics: Adult; Age Factors; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; | 2013 |
Metformin: a cheap and well-tolerated drug that provides benefits for viral infections.
Topics: Adult; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Coinfection; Cytomegalovirus; Cy | 2013 |
Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Anti-Mullerian Hormone; Female; Follicular Phase; H | 2013 |
[Glucose intolerance in myotonic dystrophy type 1].
Topics: Glucose Intolerance; Humans; Insulin Resistance; Metformin; Myotonic Dystrophy | 2012 |
Targeting the association of calgranulin B (S100A9) with insulin resistance and type 2 diabetes.
Topics: Adipose Tissue; Adult; Aged; Alleles; Animals; Calgranulin B; Diabetes Mellitus, Type 2; Diet; Disea | 2013 |
Sargassum polycystum reduces hyperglycaemia, dyslipidaemia and oxidative stress via increasing insulin sensitivity in a rat model of type 2 diabetes.
Topics: Animals; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Di | 2013 |
Prevalence, trends, and patterns of use of antidiabetic medications among pregnant women, 2001-2007.
Topics: Adolescent; Adult; Child; Diabetes, Gestational; Female; Humans; Hyperglycemia; Hypoglycemic Agents; | 2013 |
Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cross-Sectional Studies; Diabetes Melli | 2013 |
[Metformin efficiency for the adolescent PCOS treatment].
Topics: Adolescent; Body Mass Index; Bulgaria; Female; Humans; Hypoglycemic Agents; Incidence; Insulin Resis | 2012 |
Insulin signaling in type 2 diabetes: experimental and modeling analyses reveal mechanisms of insulin resistance in human adipocytes.
Topics: Adipocytes; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Transporter Type 4; Humans; Insulin; | 2013 |
Low-dose dexamethasone in the rat: a model to study insulin resistance.
Topics: Animals; Arginine; Blood Pressure; Dexamethasone; Dose-Response Relationship, Drug; Drug Combination | 2002 |
[Simple corrections in therapy of type 2 diabetes. Lowering HbA1c below 7%].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agen | 2002 |
[Dangerous postprandial glucose peaks. Risk for heart and blood vessels].
Topics: Cyclohexanes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Humans; H | 2002 |
[Islands cells are not activated quickly enough. Risk of obstruction of blood vessels].
Topics: Arteriosclerosis; Blood Glucose; Cyclohexanes; Diabetic Angiopathies; Drug Therapy, Combination; Hum | 2002 |
Effects of konjac extract on insulin sensitivity in high fat diet rats.
Topics: Amorphophallus; Animals; Dietary Fats; Drugs, Chinese Herbal; Hypoglycemic Agents; Insulin Resistanc | 2002 |
Metformin enhances insulin signalling in insulin-dependent and-independent pathways in insulin resistant muscle cells.
Topics: Animals; Cells, Cultured; Deoxyglucose; Hypoglycemic Agents; Imidazoles; Insulin; Insulin Receptor S | 2002 |
Circulating ghrelin levels in patients with polycystic ovary syndrome.
Topics: Adult; Female; Follicle Stimulating Hormone; Gastrectomy; Ghrelin; Gonadal Steroid Hormones; Homeost | 2002 |
Increased intraabdominal adipose tissue mass in fructose fed rats: correction by metformin.
Topics: Adipose Tissue; Animals; Diet; Fructose; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; R | 2002 |
[Insulin resistance and its involvement in multiple risk factors associated with type 2 diabetes mellitus].
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Europe; Female; Humans; Hypercholesterolemia; Hyperli | 2002 |
'Off-label' use of metformin warranted.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2001 |
Therapeutic approach in insulin resistance with acanthosis nigricans.
Topics: Acanthosis Nigricans; Adolescent; Adult; Body Mass Index; Body Weight; Diabetes Complications; Diabe | 2002 |
Increase of insulin sensitivity in diabetic rats received die-huang-wan, a herbal mixture used in Chinese traditional medicine.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drug Interactions; Drugs, Chinese Herbal; H | 2002 |
Metformin modulates insulin post-receptor signaling transduction in chronically insulin-treated Hep G2 cells.
Topics: Carcinoma, Hepatocellular; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Neoplasms; Metform | 2003 |
Is programming of glucocorticoid receptor expression by prenatal dexamethasone in the rat secondary to metabolic derangement in adulthood?
Topics: Animals; Appetite; Body Weight; Corticosterone; Dexamethasone; Female; Gene Expression; Glucocortico | 2003 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug T | 2003 |
[When HbA1c cannot be pushed down under 7. Don't hesitate to use a 2d antidiabetic agent].
Topics: Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insu | 2003 |
Type 2 diabetes presenting as diabetic ketoacidosis in adolescence.
Topics: Acanthosis Nigricans; Adolescent; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; | 2003 |
The role of metformin in the management of polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Repro | 2003 |
Effects of insulin-sensitising agents in mice with hepatic insulin resistance.
Topics: Animals; Blood Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Lipids; Liv | 2004 |
Combination of metformin and thiazolidindiones restore insulin signalling in insulin-resistant cultured myotubes.
Topics: Animals; Blotting, Western; Cells, Cultured; Creatine Kinase; Deoxyglucose; Drug Synergism; Insulin | 2004 |
Metformin attenuates blood lipid peroxidation and potentiates antioxidant defense in high fructose-fed rats.
Topics: Administration, Oral; Animals; Antioxidants; Blood Glucose; Dietary Sucrose; Fructose; Insulin; Insu | 2002 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; | 2004 |
Increased adipose tissue expression of Grb14 in several models of insulin resistance.
Topics: 3T3 Cells; Adaptor Proteins, Signal Transducing; Adipocytes; Adipose Tissue; Animals; Carrier Protei | 2004 |
[Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats].
Topics: Animals; Blood Glucose; Dietary Fats; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metfor | 2004 |
By the way, doctor. I'm a 63-year-old woman with impaired fasting glucose, and I'd like to take Glucophage or Avandia to prevent or delay the onset of diabetes. My weight was well controlled until my 50s, when it started to rise. I think impaired fasting
Topics: Blood Glucose; Fasting; Female; Glucose Metabolism Disorders; Humans; Hypoglycemic Agents; Insulin R | 2004 |
[Diabetes update: preventing type 2 diabetes. Individualized stepwise therapy (oral antidiabetic agents). Multifactorial intervention].
Topics: Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug | 2004 |
Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin.
Topics: Animals; Blood Proteins; Fatty Acids; Fatty Acids, Nonesterified; Glycerol; Heparin; Hypoglycemic Ag | 2004 |
Fatty acid composition of erythrocyte phospholipids is related to insulin levels, secretion and resistance in obese type 2 diabetics on Metformin.
Topics: Adult; Age Factors; Aged; Biomarkers; Diabetes Mellitus, Type 2; Dietary Fats; Erythrocytes; Fatty A | 2004 |
Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans | 2003 |
AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Cell Line, Tumor; Enzyme Activation; Glucose; | 2004 |
Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin.
Topics: Adult; Blood Glucose; Fasting; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Insu | 2004 |
[Current concept of polycystic ovary syndrome].
Topics: Body Mass Index; Female; Humans; Insulin Resistance; Leptin; Metformin; Obesity; Polycystic Ovary Sy | 2004 |
Metformin in the treatment of obesity in subjects with normal glucose tolerance.
Topics: Adult; Body Weights and Measures; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insul | 2003 |
[2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug | 2004 |
Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms.
Topics: Animals; Gene Expression Regulation; Gluconeogenesis; Glucose; Glucose Clamp Technique; Hyperinsulin | 2004 |
Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance.
Topics: Blood Pressure; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Menstruation; Metf | 2005 |
Dysregulation of growth hormone in acquired generalized lipodystrophy.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administrati | 2004 |
[Short-term and long-term effect of metformin in type 1 diabetics].
Topics: Adult; Body Weight; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Follow-Up Studies; Humans; | 2001 |
The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome.
Topics: Adult; Androgens; Arginine; Female; Glycine; Humans; Hypoglycemic Agents; Insulin Receptor Substrate | 2005 |
Insulin sensitizers: past, present and future.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Thiazolidined | 2005 |
Low-dose metformin improves hyperglycaemia related to myotonic dystrophy.
Topics: Blood Glucose; C-Peptide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin | 2005 |
Effect of Sanguis draxonis (a Chinese traditional herb) on the formation of insulin resistance in rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Drugs, Chinese Herbal; Hypoglycemic Agents; | 2005 |
AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome.
Topics: Adipocytes; Adiponectin; AMP-Activated Protein Kinases; Cardiovascular Diseases; Citrates; Diabetes | 2005 |
[Treatment experience with metformin in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistan | 2005 |
Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
Topics: Administration, Oral; Animals; Benzimidazoles; Blood Glucose; Dose-Response Relationship, Drug; Gluc | 2005 |
[Effects of glimepiride and metformin on free fatty acid in patients with Type 2 diabetes mellitus].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Humans; Insulin Resistan | 2004 |
Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study.
Topics: Area Under Curve; Cardiovascular Diseases; Endothelin-1; Endothelium, Vascular; Female; Humans; Hypo | 2005 |
Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice.
Topics: Adiponectin; Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hypoglyc | 2005 |
[The rehabilitation of metformin].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyp | 2005 |
Markedly improved glycemic control and enhanced insulin sensitivity in a patient with type 2 diabetes complicated by a suprasellar tumor treated with pioglitazone and metformin.
Topics: Blood Glucose; Central Nervous System Cysts; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic | 2005 |
Type 2 diabetes mellitus in youth: the complete picture to date.
Topics: Adolescent; Autoantibodies; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Diet; Dyslipid | 2005 |
Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination | 2006 |
[Effects of metformin on fatty liver in insulin-resistant rats].
Topics: Animals; Fatty Liver; Insulin Resistance; Male; Metformin; Random Allocation; Rats; Rats, Wistar | 2005 |
The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
Topics: Adult; Androgens; Blood Glucose; Body Mass Index; Fasting; Female; Follicle Stimulating Hormone; Glu | 2005 |
Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Body Mass Index; Case-Control Studies; Female; Genotype; Humans; Insulin Resi | 2006 |
Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus.
Topics: Adult; Aged; Case-Control Studies; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Dr | 2006 |
Metformin use and diabetic pregnancy-has its time come?
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Fetus; Humans; Hypoglycemic Agents; Insuli | 2006 |
Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgens; Female; Glucose Tolerance Test; Gonadotropins, Pituitary; Hu | 2006 |
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Algorithms; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type | 2006 |
[From cancer to diabetes treatment : the tumor suppressor LKB1 as a new pharmacological target].
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Cyclic AMP Response El | 2006 |
Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemogl | 2006 |
Glucose utilization is suppressed in the gut of insulin-resistant high fat-fed rats and is restored by metformin.
Topics: Animals; Dietary Fats; Glucose; Hypoglycemic Agents; Insulin Resistance; Intestinal Mucosa; Intestin | 2006 |
Metformin and the fate of fat.
Topics: Animals; Disease Models, Animal; Fats; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabo | 2006 |
Metformin, vitamin E, and diet for patients with nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2006 |
Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Eating; Glucose; Glycosuria; Hy | 2006 |
Effects of metformin on inappropriate LH release in women with polycystic ovarian syndrome and insulin resistance.
Topics: Adolescent; Adult; Blood Glucose; Cluster Analysis; Female; Gonadal Steroid Hormones; Gonadotropin-R | 2006 |
[Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cholesterol; Dietary Fats; Disease Model | 2006 |
Insulin-sensitizing agents in women with polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2006 |
Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes.
Topics: Adiponectin; Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combinatio | 2006 |
Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance.
Topics: Adult; Blood Flow Velocity; Case-Control Studies; Coronary Circulation; Diastole; Echocardiography, | 2006 |
[Clinical analysis of 4 treatments for woman polycystic ovarian syndrome with infertility].
Topics: Adult; Chorionic Gonadotropin; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Fema | 2006 |
Use of metformin for ovulation induction in women who have polycystic ovary syndrome with or without evidence of insulin resistance.
Topics: Adult; Blood Glucose; Cohort Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insuli | 2006 |
Obesity is associated with altered metabolic and reproductive activity in the mare: effects of metformin on insulin sensitivity and reproductive cyclicity.
Topics: Animals; Breeding; Dose-Response Relationship, Drug; Estrous Cycle; Female; Food Deprivation; Horse | 2006 |
The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome.
Topics: Androgens; Body Weight; Chromogranins; Female; Genotype; GTP-Binding Protein alpha Subunits, Gs; Hum | 2006 |
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
Topics: Abdominal Fat; Biomarkers; Biopsy; Body Mass Index; Cytokines; Gene Expression; Glucose Intolerance; | 2007 |
Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Energy Intake; Female; Humans; | 2006 |
Some effect of metformin on insulin resistance in an infant with leprechaunism.
Topics: Abnormalities, Multiple; Fatal Outcome; Humans; Hyperglycemia; Hypoglycemic Agents; Infant, Newborn; | 2006 |
Glucose utilization is suppressed in the gut of insulin-resistant high fat-fed rats and is restored by metformin.
Topics: Animals; Dietary Fats; Glucose; Hypoglycemic Agents; Insulin Resistance; Intestinal Mucosa; Intestin | 2006 |
Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology.
Topics: Adult; Anti-Mullerian Hormone; Female; Follicle Stimulating Hormone; Glycoproteins; Humans; Hypoglyc | 2007 |
[Metformine hydrochloride reduces both acanthosis nigricans and insulin resistance in Japanese young female].
Topics: Acanthosis Nigricans; Adult; Asian People; Diet, Diabetic; Female; Humans; Hypoglycemic Agents; Insu | 2006 |
[Detection of LADA-type diabetes in overweight diabetic patients. Is treatment with metformin suitable?].
Topics: Adult; Aged; Autoantibodies; Autoimmune Diseases; Body Mass Index; Confidence Intervals; Diabetes Me | 2007 |
Insulin levels, insulin resistance and the use of metformin in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndro | 2007 |
Comparison of the effects of zinc alone and zinc associated with selenium and vitamin E on insulin sensitivity and oxidative stress in high-fructose-fed rats.
Topics: Animals; Antioxidants; Diet; Dietary Carbohydrates; Fructose; Glucose Clamp Technique; Hypoglycemic | 2007 |
Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone.
Topics: Adipose Tissue; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biomarkers; Body Mas | 2007 |
[Polycystic ovary syndrome (PCOS)].
Topics: Drug Therapy, Combination; Family Practice; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; In | 2007 |
Nutritional approach to metabolic changes arising out of schizophrenia therapy: case report.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Clozapine; Female; Humans; Insulin Resistance; Metfor | 2007 |
Metformin use in an obese diabetic patient from weeks 1 to 21 of pregnancy.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Fetal Macrosomia; Humans; Hypoglycemic Agents; Insulin Res | 2003 |
Activation of mammalian target of rapamycin complex 1 and insulin resistance induced by palmitate in hepatocytes.
Topics: Animals; Fatty Acids; Hepatocytes; Insulin Resistance; Liver; Male; Metformin; Obesity; Phosphorylat | 2007 |
[Insulin resistance in type 2 diabetes patients].
Topics: Aged; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, | 2007 |
Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
Topics: Abdominal Fat; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Fe | 2007 |
Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Clamp Technique; Humans; Hypoglycemic | 2008 |
Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Clamp Technique; Humans; Hypoglycemic | 2008 |
Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Clamp Technique; Humans; Hypoglycemic | 2008 |
Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Clamp Technique; Humans; Hypoglycemic | 2008 |
[The effect of metformin on insulin receptor protein tyrosine kinase activity of HIT-T15 cell exposed to high concentration glucose and free fatty acid].
Topics: Animals; Cell Line; Cricetinae; Fatty Acids, Nonesterified; Glucose; Hypoglycemic Agents; Insulin Re | 2007 |
Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenal Glands; Adult; Aged; Antipsychotic Agents; Cortodo | 2007 |
Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats.
Topics: Animals; Apoptosis; Blood Glucose; Glyburide; Hypoglycemic Agents; Insulin; Insulin Resistance; Insu | 2008 |
Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db/db mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Synergism; | 2007 |
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.
Topics: Body Weight; Female; Humans; Insulin Resistance; Metformin; Obesity; Overweight; Polycystic Ovary Sy | 2007 |
Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment.
Topics: Adult; Androgens; Arginine; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, LDL; Cr | 2008 |
[Fat cells becoming ever more prolific--editorial].
Topics: Adipocytes; Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Met | 2007 |
Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome.
Topics: Abnormalities, Multiple; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; H | 2007 |
The ratio of leptin to adiponectin can be used as an index of insulin resistance.
Topics: Adiponectin; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucose Clamp Techni | 2008 |
Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glyburide; Humans; Hypogl | 2008 |
Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS).
Topics: Adult; Androgens; Arginine; Body Mass Index; Case-Control Studies; Contraceptives, Oral; Cyproterone | 2008 |
Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.
Topics: Adipose Tissue; Adult; Androgens; Biopsy; Blood Glucose; Cytokines; Estradiol; Female; GPI-Linked Pr | 2008 |
Treatment of impaired glucose tolerance in childhood.
Topics: Child; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Insulin Resistance; Metformin; Obesit | 2008 |
Antipsychotic-induced weight gain in patients with schizophrenia.
Topics: Antipsychotic Agents; Exercise; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Growth | 2008 |
Metformin in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2008 |
Metformin in polycystic ovary syndrome.
Topics: Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Sy | 2008 |
Metformin in polycystic ovary syndrome.
Topics: Female; Ferritins; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Synd | 2008 |
Resistin is expressed in human hepatocytes and induces insulin resistance.
Topics: Blotting, Western; Cells, Cultured; Glucose; Hepatocytes; Humans; Hypoglycemic Agents; Immunohistoch | 2008 |
Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity.
Topics: Adult; Birth Weight; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Insulin Resistance; Metfo | 2009 |
The effect of metformin on measurements of insulin sensitivity and beta cell response in 18 horses and ponies with insulin resistance.
Topics: Animals; Area Under Curve; Blood Glucose; Dose-Response Relationship, Drug; Drug Administration Sche | 2008 |
Treatment options in insulin resistance obesity-related acanthosis nigricans.
Topics: Acanthosis Nigricans; Adolescent; Adult; Calcitriol; Humans; Hyperinsulinism; Hypoglycemic Agents; I | 2008 |
Insulin-resistant diabetes during growth hormone therapy in a child with SHORT syndrome.
Topics: Abnormalities, Multiple; Anodontia; Blood Glucose; Child; Diabetes Mellitus, Lipoatrophic; Eye Abnor | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Antihyperglycemic action of guanidinoalkanoic acids: 3-guanidinopropionic acid ameliorates hyperglycemia in diabetic KKAy and C57BL6Job/ob mice and increases glucose disappearance in rhesus monkeys.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, | 1993 |
In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes.
Topics: 3-O-Methylglucose; Adipose Tissue; Animals; Biological Transport; Drug Synergism; Enzyme Activation; | 1993 |
Metformin and liver glycogen synthase activity in obese Zucker rats.
Topics: Animals; Blood Glucose; Glycogen Synthase; Hyperinsulinism; Insulin Resistance; Liver; Liver Glycoge | 1993 |
Can metformin reduce insulin resistance in polycystic ovary syndrome?
Topics: Adult; Androstenedione; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fasting; Fem | 1996 |
Decreased skeletal muscle phosphotyrosine phosphatase (PTPase) activity towards insulin receptors in insulin-resistant Zucker rats measured by delayed Europium fluorescence.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Europium; Fluorescent Ant | 1996 |
Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance.
Topics: Aging; Animals; Blood Glucose; Blood Pressure; Blotting, Northern; Body Weight; Diabetes Mellitus, T | 1996 |
[Insulin resistance, hypertension and diabetes--value of Metformin and ACE-inhibitors].
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Huma | 1994 |
Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; | 1997 |
[40 years of Metformin in the treatment of diabetes mellitus].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; In | 1997 |
[Effects of metformin on insulin resistance in obese and hyperandrogenic women].
Topics: Adult; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity | 1997 |
Nongenetic mouse models of non-insulin-dependent diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Di | 1998 |
Insulin-sensitising agents in polycystic-ovary syndrome.
Topics: Chromans; Controlled Clinical Trials as Topic; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; | 1998 |
Role of glucose-6 phosphatase, glucokinase, and glucose-6 phosphate in liver insulin resistance and its correction by metformin.
Topics: Animals; Diet; Glucokinase; Glucose; Glucose-6-Phosphatase; Glucose-6-Phosphate; Hypoglycemic Agents | 1998 |
Prevention of dexamethasone-induced insulin resistance by metformin.
Topics: Animals; Deoxyglucose; Dexamethasone; Glucose Transporter Type 1; Glucose Transporter Type 4; Hypogl | 1998 |
[Experimental study on berberin raised insulin sensitivity in insulin resistance rat models].
Topics: Animals; Berberine; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Metformin | 1997 |
The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Andros | 1999 |
Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.
Topics: Animals; Blood Glucose; Blood Pressure; Catecholamines; Chromans; Diabetes Mellitus, Type 2; Glucose | 1999 |
Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; | 1999 |
Ovarian responses to hCG stimulation: insulin resistance/hyperinsulinaemia vs. insulin deficiency.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenocorticotropic Hormone; Blood Glucose; Chorionic Gona | 1999 |
The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androstenedione; Buserelin; Case-Control Studies; Female; Folli | 1999 |
[Renaissance of metformin].
Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Metformin; Obesity | 1999 |
Pathogenesis of type 2 diabetes: implications for metformin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin | 1999 |
Metformin improves vascular function in insulin-resistant rats.
Topics: Acetylcholine; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endotheliu | 2000 |
Metformin and polycystic ovary syndrome.
Topics: Dexamethasone; Female; Glucocorticoids; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; | 2000 |
Metformin and ovarian steroidogenesis in PCOS women.
Topics: Dexamethasone; Female; Glucocorticoids; Gonadotropin-Releasing Hormone; Humans; Hypoglycemic Agents; | 2000 |
Effects of metformin on androgens and insulin concentrations in type A insulin resistance syndrome.
Topics: Acanthosis Nigricans; Adolescent; Androgens; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypo | 2000 |
Insulin sensitizers and antiandrogens in the treatment of polycystic ovary syndrome.
Topics: Androgen Antagonists; Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; | 2000 |
[Metformin for prevention of diabetes?].
Topics: Adult; Child; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resis | 2000 |
[Give them a pill?].
Topics: Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Insulin Resistance; | 2000 |
Association of metformin and pregnancy in the polycystic ovary syndrome. A report of three cases.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Poly | 2000 |
Insulin resistance and the modulation of rat cardiac K(+) currents.
Topics: Animals; Cells, Cultured; Cycloheximide; Dietary Carbohydrates; Fructose; Heart; Heart Ventricles; H | 2000 |
Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Topics: Adenosine Triphosphate; Adipose Tissue; Animals; Body Weight; Energy Intake; Energy Metabolism; Fatt | 2000 |
Improvement of insulin sensitivity after adrenalectomy in patients with pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Cl | 2000 |
Beneficial insulin-sensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat.
Topics: Animals; Blood Glucose; Body Weight; Chromans; Eating; Fluorenes; Gene Expression; Glucose Tolerance | 2000 |
Metformin treatment corrects vascular insulin resistance in hypertension.
Topics: Acetylcholine; Angiotensin II; Animals; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistan | 2000 |
Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance.
Topics: Aged; Cohort Studies; Creatinine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephrop | 2000 |
Insulin-sensitizing agents and their effect on adrenal androgens.
Topics: Adrenal Glands; Androgens; Female; Humans; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2000 |
Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study.
Topics: Abdomen; Adult; Aged; Biguanides; Biomarkers; Cardiovascular Diseases; Endothelium, Vascular; Female | 2001 |
Prevention of pancreatic cancer induction in hamsters by metformin.
Topics: Adenocarcinoma; Animals; Cell Division; Cricetinae; Dietary Fats; DNA; Female; Glucose; Hypoglycemic | 2001 |
The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Adult; Female; Glucose Tolerance Test; Gonadotropin-Rel | 2001 |
Comparison of the metabolic effects of metformin and troglitazone on fructose-induced insulin resistance in male Sprague-Dawley rats.
Topics: Animals; Chromans; Fatty Acids, Nonesterified; Fructose; Hypoglycemic Agents; Insulin Resistance; Le | 2001 |
[Effects of metformin on insulin resistance and on ovarian steroidogenesis in women with polycystic ovary syndrome].
Topics: Adult; Female; Gonadal Steroid Hormones; Humans; Insulin Resistance; Metformin; Polycystic Ovary Syn | 2001 |
Metformin and intervention in polycystic ovary syndrome. Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group.
Topics: Diabetes Mellitus, Type 2; Endocrinology; Evidence-Based Medicine; Female; Glucose Intolerance; Huma | 2001 |
Metformin, but not exercise training, increases insulin responsiveness in skeletal muscle of Sprague-Dawley rats.
Topics: Aging; Animals; Body Composition; Drinking; Eating; Glucose; Glucose Tolerance Test; Glycogen; Hypog | 2001 |
Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Endothelin-1; Endothelium, Vascular; Female; Humans; Hy | 2001 |
Metabolic alterations in HIV lipodystrophy. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
Topics: Acidosis; Anti-HIV Agents; Bone Diseases, Metabolic; Cost-Benefit Analysis; Glucose; Glucose Intoler | 2001 |
Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androstenedione; Blood Glucose; Chorionic Gonadotropin; Estradi | 2001 |
[Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome].
Topics: 17-alpha-Hydroxypregnenolone; 17-alpha-Hydroxyprogesterone; Adult; Androgens; Female; Glucose Tolera | 2001 |
Post-load hyperglycaemia-an inappropriate therapeutic target.
Topics: Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2002 |
Fowler's syndrome: cause or consequence of insulin resistance?
Topics: Adult; Electromyography; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycys | 2002 |
Metformin restores responses to insulin but not to growth hormone in Sprague-Dawley rats.
Topics: Adipose Tissue; Animals; Biological Transport; Body Composition; Exercise Test; Fatty Acids; Glucose | 2002 |
Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Weight; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Diabet | 2002 |
Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
Topics: Adolescent; Adrenal Glands; Adrenocorticotropic Hormone; Androgens; Body Composition; Female; Glucos | 2002 |
Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome.
Topics: Female; Forecasting; Humans; Insulin Resistance; Menstrual Cycle; Metformin; Polycystic Ovary Syndro | 2002 |
[Metformin has a positive effect on disorders of carbohydrate metabolism in long-term care with low doses of prednisone].
Topics: Adolescent; Adult; Female; Glucocorticoids; Glucose Intolerance; Glucose Tolerance Test; Humans; Hyp | 2002 |
Diabetes prevention.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin Resistance; Metfo | 2002 |
Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.
Topics: Animals; Diabetic Neuropathies; Guanidines; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; | 2002 |
Effects of metformin on insulin resistance after injury in the rat.
Topics: Animals; Blood Glucose; Burns; Glucose; Insulin; Insulin Resistance; Ischemia; Lactates; Liver Glyco | 1976 |
Metformin ameliorates extreme insulin resistance in a patient with anti-insulin receptor antibodies: description of insulin receptor and postreceptor effects in vivo and in vitro.
Topics: Adipose Tissue; Autoantibodies; Erythrocytes; Female; Humans; Hydrogen-Ion Concentration; Insulin; I | 1992 |
Evidence that metformin ameliorates cellular insulin-resistance by potentiating insulin-induced translocation of glucose transporters to the plasma membrane.
Topics: Adipose Tissue; Animals; Biological Transport; Blotting, Northern; Cell Membrane; Drug Synergism; El | 1991 |
Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM).
Topics: Diabetes Mellitus, Type 1; Female; Humans; Insulin Resistance; Lipids; Male; Metformin; Rheology | 1991 |
Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors.
Topics: Blood Glucose; C-Peptide; Cholesterol; Cholesterol, LDL; Fibrinogen; Humans; Hypertension; Insulin; | 1991 |
Metformin increases insulin-stimulated glucose transport in insulin-resistant human skeletal muscle.
Topics: 3-O-Methylglucose; Adult; Aged; Biological Transport; Drug Synergism; Female; Glucose; Humans; In Vi | 1991 |
Dual effect of metformin in cultured rat hepatocytes: potentiation of insulin action and prevention of insulin-induced resistance.
Topics: Animals; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Female; Glycogen; Insuli | 1990 |
Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine.
Topics: Animals; Blood Glucose; Female; Insulin; Insulin Resistance; Intestinal Mucosa; Metformin; Rats; Rat | 1989 |
[Lipoatrophic diabetes with insulin resistance controlled by metformin].
Topics: Diabetes Mellitus, Lipoatrophic; Female; Humans; Insulin Resistance; Metformin; Middle Aged | 1988 |
[Therapeutic management of the secondary failure of sulfonylurea therapy].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diet, Diabetic; Dose-Response Relationship, Drug; Drug The | 1985 |
Influence of dimethylbiguanide (Metformin) on carbohydrate metabolism in obese, non-diabetic women.
Topics: Blood Glucose; Carbohydrate Metabolism; Female; Humans; Insulin; Insulin Resistance; Insulin Secreti | 1972 |